PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kariminia, A; Chamberlain, ME; Keogh, J; Shea, A				Kariminia, A; Chamberlain, ME; Keogh, J; Shea, A			Randomised controlled trial of effect of hands and knees posturing on incidence of occiput posterior position at birth	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY	Objective To evaluate the efficacy of hands and knees position and pelvic rocking exercises on the incidence of fetal occiput posterior position at birth. Design Multicentre randomised controlled trial. Setting Seven maternity units in New South Wales, Australia, encompassing teaching hospitals and district general hospitals. Participants 2547 pregnant women at 37 weeks' gestation; 1292 randomised to the intervention group and 1255 to the control group. Intervention Hands and knees position and pelvic rocking exercises from 37 weeks' gestation until the onset of labour. Main outcome measure Incidence of fetal occiput posterior position at birth. Results 1046 women in the intervention group and 1209 women in the control group remained in the study until they went into labour. No significant difference existed between the groups for the incidence of occiput posterior position at birth: 105 (8.1%) women in the intervention group and 98 (7.8%) in the control group had a baby in a posterior position at delivery (difference in risk 0.3%, 95% confidence interval -1.8 to 2.4). The incidence of fetal transverse arrest was 3.4% (44 women) in the intervention group and 3.0% (38 women) in the control group (difference in risk 0.4, - 1 to 1.7). No differences occurred between intervention and control groups for induction of labour, use of epidural, duration of labour, mode of delivery, use of episiotomy, or Apgar score. Conclusion Hands and knees exercise with pelvic rocking from 37 weeks' gestation to the onset of labour did not reduce the incidence of persistent occiput posterior position at birth.	Hornsby Hosp, Dept Obstet & Gynaecol, Hornsby, NSW 2077, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney	Kariminia, A (corresponding author), Pub Hlth Unit, Long Bay Complex,Anzac Parade,POB 150, Matraville, NSW 2036, Australia.	karimia@chs.health.nsw.gov.au						ANDREWS CM, 1983, NURS RES, V32, P336; ANDREWS CM, 1981, J ADV NURS, V3, P53; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; BIANCUZZO M, 1991, BIRTH-ISS PERINAT C, V18, P40, DOI 10.1111/j.1523-536X.1991.tb00053.x; Cunningham FG, 1997, WILLIAMS OBSTET; Fitzpatrick M, 2001, OBSTET GYNECOL, V98, P1027, DOI 10.1016/S0029-7844(01)01600-3; Gardberg M, 1998, OBSTET GYNECOL, V91, P746, DOI 10.1016/S0029-7844(98)00074-X; HOFMEYR GJ, 2002, COCHRANE DATABASE SY, DOI UNSP CD0010163; Neri A., 1995, Clinical and Experimental Obstetrics and Gynecology, V22, P126; PEARL ML, 1993, J REPROD MED, V38, P955; Public Health Division, 2001, NEW S WAL MOTH BAB 2; PUDDICOMBE JF, 1958, INT COLL SURG, V23, P73; RICHTMULLER D, 1999, J GYNECOL OBST BIO R, V28, P41; *ROYAL N SHOR HOSP, 1997, ROYAL N SHOR HOSP 19	14	23	27	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					490	493		10.1136/bmj.37942.594456.44	http://dx.doi.org/10.1136/bmj.37942.594456.44			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14744821	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220002900019
J	Jarman, B; Aylin, P; Bottle, A				Jarman, B; Aylin, P; Bottle, A			Dr Foster's case notes - Acute stroke units and early CT scans are linked to lower in-hospital mortality rates	BRITISH MEDICAL JOURNAL			English	Article								Stroke is the third largest cause of death in the United Kingdom and other developed countries. Early diagnosis, including a brain scan, and treatment in a specialist hospital based stroke unit have been shown to be effective in improving outcomes. The NHS in England has recently introduced the target that all hospitals should ensure stroke patients are given a CT scan within 48 hours of admission and are treated in a specialist stroke unit. The minority of hospitals that do this are achieving significantly better in-hospital death rates.	Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Jarman, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011					0	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 14	2004	328	7436					369	369						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962873				2022-12-28	WOS:000189031300016
J	Fromme, JC; Banerjee, A; Huang, SJ; Verdine, GL				Fromme, JC; Banerjee, A; Huang, SJ; Verdine, GL			Structural basis for removal of adenine mispaired with 8-oxoguanine by MutY adenine DNA glycosylase	NATURE			English	Article							C-TERMINAL DOMAIN; SOMATIC G-C->T-A MUTATIONS; ESCHERICHIA-COLI MUTY; STEADY-STATE KINETICS; INHERITED VARIANTS; DUPLEX; RECOGNITION; MECHANISM; REPAIR; MYH	The genomes of aerobic organisms suffer chronic oxidation of guanine to the genotoxic product 8-oxoguanine (oxoG)(1). Replicative DNA polymerases misread oxoG residues and insert adenine instead of cytosine opposite the oxidized base. Both bases in the resulting A.oxoG mispair are mutagenic lesions, and both must undergo base-specific replacement to restore the original C.G pair. Doing so represents a formidable challenge to the DNA repair machinery, because adenine makes up roughly 25% of the bases in most genomes. The evolutionarily conserved enzyme adenine DNA glycosylase (called MutY in bacteria and hMYH in humans) initiates repair of A.oxoG to C.G by removing the inappropriately paired adenine base from the DNA backbone. A central issue concerning MutY function is the mechanism by which A.oxoG mispairs are targeted among the vast excess of A.T pairs. Here we report the use of disulphide crosslinking(2) to obtain high-resolution crystal structures of MutY-DNA lesion-recognition complexes. These structures reveal the basis for recognizing both lesions in the A.oxoG pair and for catalysing removal of the adenine base.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University; Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	verdine@chemistry.harvard.edu	Banerjee, Anirban/AAC-4286-2020	Fromme, J. Christopher/0000-0002-8837-0473; Banerjee, Anirban/0000-0002-9314-2862; banerjee, anirban/0000-0003-1494-6801	NATIONAL CANCER INSTITUTE [R01CA100742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Bernards AS, 2002, J BIOL CHEM, V277, P20960, DOI 10.1074/jbc.C200181200; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Chmiel NH, 2003, J MOL BIOL, V327, P431, DOI 10.1016/S0022-2836(03)00124-4; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Massiah MA, 2003, BIOCHEMISTRY-US, V42, P10140, DOI 10.1021/bi030105p; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Porello SL, 1996, J AM CHEM SOC, V118, P10684, DOI 10.1021/ja9602206; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178	24	261	283	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					652	656		10.1038/nature02306	http://dx.doi.org/10.1038/nature02306			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961129				2022-12-28	WOS:000188875300046
J	Oaks, JL; Gilbert, M; Virani, MZ; Watson, RT; Meteyer, CU; Rideout, BA; Shivaprasad, HL; Ahmed, S; Chaudhry, MJI; Arshad, M; Mahmood, S; Ali, A; Khan, AA				Oaks, JL; Gilbert, M; Virani, MZ; Watson, RT; Meteyer, CU; Rideout, BA; Shivaprasad, HL; Ahmed, S; Chaudhry, MJI; Arshad, M; Mahmood, S; Ali, A; Khan, AA			Diclofenac residues as the cause of vulture population decline in Pakistan	NATURE			English	Article							POLYMERASE-CHAIN-REACTION; WEST NILE VIRUS; INFECTIOUS-BRONCHITIS; CHICKENS; DIFFERENTIATION; PATHOLOGY; MORTALITY	The Oriental white-backed vulture (OWBV; Gyps bengalensis) was once one of the most common raptors in the Indian subcontinent(1). A population decline of >95%, starting in the 1990s, was first noted at Keoladeo National Park, India(2). Since then, catastrophic declines, also involving Gyps indicus and Gyps tenuirostris, have continued to be reported across the subcontinent(3). Consequently these vultures are now listed as critically endangered by BirdLife International(4). In 2000, the Peregrine Fund initiated its Asian Vulture Crisis Project with the Ornithological Society of Pakistan, establishing study sites at 16 OWBV colonies in the Kasur, Khanewal and Muzaffargarh-Layyah Districts of Pakistan to measure mortality at over 2,400 active nest sites(5). Between 2000 and 2003, high annual adult and subadult mortality (5-86%) and resulting population declines (34-95%) (ref. 5 and M. G., manuscript in preparation) were associated with renal failure and visceral gout. Here, we provide results that directly correlate residues of the anti-inflammatory drug diclofenac with renal failure. Diclofenac residues and renal disease were reproduced experimentally in OWBVs by direct oral exposure and through feeding vultures diclofenac-treated livestock. We propose that residues of veterinary diclofenac are responsible for the OWBV decline.	Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA; Peregrine Fund, Boise, ID 83709 USA; US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI 53711 USA; Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA; Univ Calif Davis, Fresno Branch, Calif Anim Hlth & Food Safety Lab Syst, Fresno, CA 93725 USA; Bahauddin Zakariya Univ, Inst Pure & Appl Biol, Div Zool, Multan, Pakistan	Washington State University; United States Department of the Interior; United States Geological Survey; Zoological Society of San Diego; University of California System; University of California Davis; Bahauddin Zakariya University	Oaks, JL (corresponding author), Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.	loaks@vetmed.wsu.edu	Arshad, Muhammad/K-7335-2019; Arshad, Muhammad/GXW-0743-2022	Arshad, Muhammad/0000-0001-5501-6956; Gilbert, Martin/0000-0002-9930-4383				Ali S., 1968, HDB BIRDS INDIA PAKI; Baert K, 2003, COMP BIOCHEM PHYS C, V134, P25, DOI 10.1016/S1532-0456(02)00184-9; BEYER W, 1996, ENV CONTAMINANTS WIL, pCH10; BirdLife International, 2001, THREAT BIRDS AS BIRD; Crespo R., 2003, DIS POULTRY, P1085; Cunningham AA, 2003, ANIM CONSERV, V6, P189, DOI 10.1017/S136794300300324X; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; Docherty D.E., 1988, Journal of Tissue Culture Methods, V11, P165, DOI 10.1007/BF01404270; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GATOME CW, 2002, HAEMATOLOGY BLOOD BI; Gilbert M, 2002, BIRD CONSERV INT, V12, P311, DOI 10.1017/S0959270902002198; HENNY CJ, 1985, J WILDLIFE MANAGE, V49, P648, DOI 10.2307/3801689; HILL E F, 1982, Environmental Toxicology and Chemistry, V1, P27, DOI 10.1897/1552-8618(1982)1[27:APOBFM]2.0.CO;2; Johnson DJ, 2001, EMERG INFECT DIS, V7, P739; KWON HM, 1993, AVIAN DIS, V37, P194, DOI 10.2307/1591474; Langelier K.M., 1993, P231; Lee MS, 2001, J VIROL METHODS, V97, P13, DOI 10.1016/S0166-0934(01)00301-9; McKellar QA, 1997, VET PARASITOL, V72, P413, DOI 10.1016/S0304-4017(97)00108-8; Mendenhall MK, 2000, J VET DIAGN INVEST, V12, P57, DOI 10.1177/104063870001200110; Mishra SK, 2002, INDIAN J ANIM SCI, V72, P283; MURRAY MD, 1993, ANNU REV PHARMACOL, V33, P434; NYS Y, 1983, CR ACAD SCI III-VIE, V296, P401; Pain DJ, 2003, CONSERV BIOL, V17, P661, DOI 10.1046/j.1523-1739.2003.01740.x; Paul-Murphy Joanne, 2001, Veterinary Clinics of North America Exotic Animal Practice, V4, P35; Prakash Vibhu, 1999, Journal of the Bombay Natural History Society, V96, P365; Steele KE, 2000, VET PATHOL, V37, P208, DOI 10.1354/vp.37-3-208; SWAYNE DE, 1994, VET PATHOL, V31, P237, DOI 10.1177/030098589403100211; Tixier C, 2003, ENVIRON SCI TECHNOL, V37, P1061, DOI 10.1021/es025834r; TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495-198835030-00004; Ziegler AF, 2002, AVIAN DIS, V46, P847, DOI 10.1637/0005-2086(2002)046[0847:NIBIPC]2.0.CO;2	30	1061	1140	19	500	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					630	633		10.1038/nature02317	http://dx.doi.org/10.1038/nature02317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14745453				2022-12-28	WOS:000188875300040
J	Bialek, W; Botstein, D				Bialek, W; Botstein, D			Introductory science and mathematics education for 21st-century biologists	SCIENCE			English	Editorial Material								Galileo wrote that "the book of nature is written in the language of mathematics"; his quantitative approach to understanding the natural world arguably marks the beginning of modern science. Nearly 400 years later, the fragmented teaching of science in our universities still leaves biology outside the quantitative and mathematical culture that has come to de. ne the physical sciences and engineering. This strikes us as particularly inopportune at a time when opportunities for quantitative thinking about biological systems are exploding. We propose that a way out of this dilemma is a unified introductory science curriculum that fully incorporates mathematics and quantitative thinking.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Botstein, D (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	botstein@princeton.edu						*BOARD LIF SCI DIV, 2003, BIO 2010 TRANSF UND; Snow C., 1959, 2 CULTURES SCI REVOL	2	144	148	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					788	790		10.1126/science.1095480	http://dx.doi.org/10.1126/science.1095480			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764865				2022-12-28	WOS:000188753800043
J	Hartwell, L				Hartwell, L			Robust interactions	SCIENCE			English	Editorial Material									Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hartwell, L (corresponding author), Univ Washington, Dept Genet, Seattle, WA 98195 USA.	lhartwel@fhcrc.org						Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; KACSER H, 1981, GENETICS, V97, P639; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484	5	37	40	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					774	775		10.1126/science.1094731	http://dx.doi.org/10.1126/science.1094731			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764857				2022-12-28	WOS:000188753800035
J	Landon, BE				Landon, BE			Career satisfaction among physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JOB-SATISFACTION; MANAGED CARE		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Landon, BE (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010803] Funding Source: NIH RePORTER; AHRQ HHS [P0-1-HS-10803] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BARNARD A, 2000, BOSTON GLOBE    0709, pA1; Barzansky B, 2003, JAMA-J AM MED ASSOC, V290, P1190, DOI 10.1001/jama.290.9.1190; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Konrad TR, 1999, MED CARE, V37, P1174, DOI 10.1097/00005650-199911000-00010; Landon BE, 2002, AM J MANAG CARE, V8, P890; LANDON BE, 1997, JAMA-J AM MED ASSOC, V289, P442; Linzer M, 2000, J GEN INTERN MED, V15, P441, DOI 10.1046/j.1525-1497.2000.05239.x; Pescosolido BA, 2001, J HEALTH SOC BEHAV, V42, P1, DOI 10.2307/3090224; Stoddard JJ, 2001, J GEN INTERN MED, V16, P675, DOI 10.1111/j.1525-1497.2001.01206.x	9	20	22	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					634	634		10.1001/jama.291.5.634	http://dx.doi.org/10.1001/jama.291.5.634			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762046				2022-12-28	WOS:000188650700032
J	Haas, JS; Kaplan, CP; Gerstenberger, EP; Kerlikowske, K				Haas, JS; Kaplan, CP; Gerstenberger, EP; Kerlikowske, K			Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results	ANNALS OF INTERNAL MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; PLUS PROGESTIN; BREAST-CANCER; UNITED-STATES; WOMEN	Background: The recent publication of clinical trial results has led to a dramatic shift in the evidence about postmenopausal hormone therapy. Objective: To examine whether the publication of clinical trial results, specifically the Heart and Estrogen/progestin Replacement Study (HERS) in 1998 and the Women's Health Initiative (WHI) in 2002, has influenced the use of hormone therapy among postmenopausal women. Design: Observational cohort (1997 to 2003). Setting: San Francisco Mammography Registry, San Francisco, California. Participants: Postmenopausal women between the ages of 50 and 74 years without a personal history of breast cancer who underwent mammography (151862 mammograms). Measurements: Self-reported current use of hormone therapy. Results: Among menopausal women who had mammography, it was estimated that 41% were currently using hormone therapy in 1997. Before the publication of HERS, the use of hormone therapy was increasing at a rate of 1% (95% Cl, 0% to 2%) per quarter. After the publication of HERS, use decreased by 1% (Cl, -3% to 0%) per quarter. In contrast, the publication of the WHI in 2002 was associated with a more substantial decline in the use of hormone therapy of 18% (Cl, -21% to -16%) per quarter. Similar associations were observed for most subgroups of women, including women older than 65 years of age; women with a previous hysterectomy; and women who described their race or ethnicity as white, African American, Latina, Chinese, or Filipina. Conclusions: The release of the HERS data was temporally associated with a modest decline in the use of hormone therapy. In contrast, the release of the principal findings from the WHI was associated with a more substantial decline in use by postmenopausal women. The reason for the differences in decline may relate to the fact that the WHI results were widely publicized or were more applicable to most postmenopausal women because the WHI study was performed in healthy women.	Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Haas, JS (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.	jhaas@partners.org		HAAS, JENNIFER/0000-0001-7227-851X	NCI NIH HHS [U01CA63740] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BallardBarbash R, 1997, AM J ROENTGENOL, V169, P1001, DOI 10.2214/ajr.169.4.9308451; BELANGER D, 1991, J CLIN ONCOL, V9, P7, DOI 10.1200/JCO.1991.9.1.7; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; KOLATA G, 2003, NY TIMES        0109, P18; LIPSITZ SR, 1994, BIOMETRICS, V50, P270, DOI 10.2307/2533218; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Swan J, 2003, CANCER, V97, P1528, DOI 10.1002/cncr.11208; Weng HH, 2001, PREV MED, V33, P668, DOI 10.1006/pmed.2001.0943	16	250	250	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					184	188		10.7326/0003-4819-140-3-200402030-00009	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757616				2022-12-28	WOS:000188704500004
J	Pal-Bhadra, M; Leibovitch, BA; Gandhi, SG; Rao, M; Bhadra, U; Birchler, JA; Elgin, SCR				Pal-Bhadra, M; Leibovitch, BA; Gandhi, SG; Rao, M; Bhadra, U; Birchler, JA; Elgin, SCR			Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery	SCIENCE			English	Article							PROTEIN-1 BINDS; GENE; METHYLATION; MELANOGASTER; REPEATS; DNA	Genes normally resident in euchromatic domains are silenced when packaged into heterochromatin, as exemplified in Drosophila melanogaster by position effect variegation (PEV). Loss-of-function mutations resulting in suppression of PEV have identified critical components of heterochromatin, including proteins HP1, HP2, and histone H3 lysine 9 methyltransferase. Here, we demonstrate that this silencing is dependent on the RNA interference machinery, using tandem mini-white arrays and white transgenes in heterochromatin to show loss of silencing as a result of mutations in piwi, aubergine, or spindle-E ( homeless), which encode RNAi components. These mutations result in reduction of H3 Lys(9) methylation and delocalization of HP1 and HP2, most dramatically in spindle-E mutants.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA; Ctr Cellular & Mol Biol, Funct Genom & Gene Silencing Grp, Hyderabad 500007, Andhra Pradesh, India	University of Missouri System; University of Missouri Columbia; Washington University (WUSTL); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Bhadra, U (corresponding author), Univ Missouri, Div Biol Sci, 117 Tucker Hall, Columbia, MO 65211 USA.	utpal@ccmb.res.in; birchlerj@missouri.edu; selgin@biology.wustl.edu		Leibovitch, Boris/0000-0001-6771-5906; Gandhi, Sumit G./0000-0002-9759-1745; Elgin, Sarah C. R./0000-0002-5176-2510	NICHD NIH HHS [HD23844] Funding Source: Medline; NIGMS NIH HHS [GM68388] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068388] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Birchler James A., 2003, P23; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Fanti L, 1998, CHROMOSOMA, V107, P286, DOI 10.1007/s004120050310; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Mette MF, 1999, EMBO J, V18, P241, DOI 10.1093/emboj/18.1.241; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Shaffer CD, 2002, P NATL ACAD SCI USA, V99, P14332, DOI 10.1073/pnas.212458899; Stapleton W, 2001, CHROMOSOMA, V110, P228, DOI 10.1007/s004120100136; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Zhao T, 2000, J BIOL CHEM, V275, P28332; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	21	538	623	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					669	672		10.1126/science.1092653	http://dx.doi.org/10.1126/science.1092653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752161	Green Submitted			2022-12-28	WOS:000188530800040
J	Zhukovsky, EA; Lee, JO; Villegas, M; Chan, C; Chu, S; Mroske, C				Zhukovsky, EA; Lee, JO; Villegas, M; Chan, C; Chu, S; Mroske, C			TNF ligands: Is TALL-1 a trimer or a virus-like cluster?	NATURE			English	Editorial Material							CRYSTAL-STRUCTURE; FAMILY-MEMBER; ACTIVATION; BAFF		Xencor, Monrovia, CA 91016 USA; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Sch Mol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Zhukovsky, EA (corresponding author), Xencor, Monrovia, CA 91016 USA.	ezhukovsky@xencor.com	Lee, Jie-Oh/C-1581-2011; Zhukovsky, Eugene/Q-3218-2019; Lee, Jie-Oh/AAG-4302-2020	Lee, Jie-Oh/0000-0001-6519-6049; Zhukovsky, Eugene/0000-0003-1822-8946				Arunkumar AI, 2002, PROTEIN SCI, V11, P1050, DOI 10.1110/ps.2270102; Kanakaraj P, 2001, CYTOKINE, V13, P25, DOI 10.1006/cyto.2000.0793; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kim HM, 2003, NAT STRUCT BIOL, V10, P342, DOI 10.1038/nsb925; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Wu JW, 1999, ACTA BIOCHIM POL, V46, P591, DOI 10.18388/abp.1999_4131	8	27	33	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 29	2004	427	6973					413	414		10.1038/427413a	http://dx.doi.org/10.1038/427413a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749821				2022-12-28	WOS:000188470500033
J	Berger, F				Berger, F			Plant sciences - Imprinting - a green variation	SCIENCE			English	Editorial Material							SEED DEVELOPMENT; DNA METHYLATION; POLYCOMB GENE; ARABIDOPSIS; MAINTENANCE; ENDOSPERM; MEDEA; GLYCOSYLASE		Ecole Normale Super Lyon, Lab RDP, UMR 5667, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON)	Berger, F (corresponding author), Ecole Normale Super Lyon, Lab RDP, UMR 5667, F-69364 Lyon 07, France.	frederic.berger@ens-lyon.fr	Berger, Frédéric/B-6947-2009	Berger, Frederic/0000-0002-3609-8260				Baroux C, 2002, ADV GENET, V46, P165; Berger F, 2003, CHROMOSOME RES, V11, P277, DOI 10.1023/A:1022844127716; Berger F, 2003, CURR OPIN PLANT BIOL, V6, P42, DOI 10.1016/S1369526602000043; Cao XF, 2000, P NATL ACAD SCI USA, V97, P4979, DOI 10.1073/pnas.97.9.4979; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; Choi YH, 2002, CELL, V110, P33, DOI 10.1016/S0092-8674(02)00807-3; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; DELAVAL K, IN PRESS CURR OPIN G, V14; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; Kinoshita T, 1999, PLANT CELL, V11, P1945, DOI 10.1105/tpc.11.10.1945; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Kinoshita T., COMMUNICATION; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Saze H, 2003, NAT GENET, V34, P65, DOI 10.1038/ng1138; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Spielman M, 2001, TRENDS GENET, V17, P705, DOI 10.1016/S0168-9525(01)02519-7; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; Xiao WY, 2003, DEV CELL, V5, P891, DOI 10.1016/S1534-5807(03)00361-7	20	15	19	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					483	485		10.1126/science.1094375	http://dx.doi.org/10.1126/science.1094375			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739448				2022-12-28	WOS:000188316400026
J	Davis, BG				Davis, BG			Biochemistry - Mimicking posttranslational modifications of proteins	SCIENCE			English	Editorial Material							GLYCOSYLATION		Univ Oxford, Dept Chem, Dyson Perrins Lab, Oxford OX1 3QY, England	University of Oxford	Davis, BG (corresponding author), Univ Oxford, Dept Chem, Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	ben.davis@chemistry.oxford.ac.uk	Davis, Benjamin G/C-5281-2011	Davis, Benjamin G/0000-0002-5056-407X	Biotechnology and Biological Sciences Research Council [BB/C510824/1, EGA17763] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Davis BG, 2000, BIOORGAN MED CHEM, V8, P1527, DOI 10.1016/S0968-0896(00)00083-3; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; GAMBLIN DP, IN PRESS ANGEW CHEM; Haselbeck A, 2003, CURR MED RES OPIN, V19, P430, DOI 10.1185/030079903125002063; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kochendoerfer GG, 2003, SCIENCE, V299, P884, DOI 10.1126/science.1079085; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Liu HT, 2003, J AM CHEM SOC, V125, P1702, DOI 10.1021/ja029433n; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Vocadlo DJ, 2003, P NATL ACAD SCI USA, V100, P9116, DOI 10.1073/pnas.1632821100; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077	16	94	103	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					480	482		10.1126/science.1093449	http://dx.doi.org/10.1126/science.1093449			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739446				2022-12-28	WOS:000188316400024
J	Stevens, J; Corper, AL; Basler, CF; Taubenberger, JK; Palese, P; Wilson, IA				Stevens, J; Corper, AL; Basler, CF; Taubenberger, JK; Palese, P; Wilson, IA			Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus	SCIENCE			English	Article							SPANISH INFLUENZA; MEMBRANE-FUSION; RECEPTOR-BINDING; PANDEMIC INFLUENZA; ORIGIN; GENE; PH; GLYCOPROTEIN; SPECIFICITY; CONFORMATION	The 1918 "Spanish" influenza pandemic represents the largest recorded outbreak of any infectious disease. The crystal structure of the uncleaved precursor of the major surface antigen of the extinct 1918 virus was determined at 3.0 angstrom resolution after reassembly of the hemagglutinin gene from viral RNA fragments preserved in 1918 formalin-fixed lung tissues. A narrow avian-like receptor-binding site, two previously unobserved histidine patches, and a less exposed surface loop at the cleavage site that activates viral membrane fusion reveal structural features primarily found in avian viruses, which may have contributed to the extraordinarily high infectivity and mortality rates observed during 1918.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Armed Forces Inst Pathol, Dept Cellular Pathol & Genet, Div Mol Pathol, Washington, DC 20306 USA	Scripps Research Institute; Scripps Research Institute; Icahn School of Medicine at Mount Sinai; United States Department of Defense	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Taubenberger, Jeffery/AAQ-1407-2021; Basler, Christopher/AAG-8346-2019	Basler, Christopher/0000-0003-4195-425X; Palese, Peter/0000-0002-0337-5823	NATIONAL CANCER INSTITUTE [R01CA055896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI058113, R37AI042266, R01AI042266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062411] Funding Source: NIH RePORTER; NCI NIH HHS [CA55896] Funding Source: Medline; NIAID NIH HHS [AI42266, AI058113, AI50619] Funding Source: Medline; NIGMS NIH HHS [P50-GM 62411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; BEKLEMISHEV AB, 1993, MOL GEN MIKROBIOL VI, V1, P24; Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; Brownlee GG, 2001, PHILOS T ROY SOC B, V356, P1871, DOI 10.1098/rstb.2001.1001; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carneiro FA, 2003, J BIOL CHEM, V278, P13789, DOI 10.1074/jbc.M210615200; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; CONNOR RJ, 1994, VIROLOGY, V205, P17, DOI 10.1006/viro.1994.1615; de Jong J C, 2003, Ned Tijdschr Geneeskd, V147, P1971; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha Y, 2002, EMBO J, V21, P865, DOI 10.1093/emboj/21.5.865; Ha Y, 2001, P NATL ACAD SCI USA, V98, P11181, DOI 10.1073/pnas.201401198; HARDY CT, 1995, VIROLOGY, V211, P302, DOI 10.1006/viro.1995.1405; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KIDO H, 1993, FEBS LETT, V322, P115, DOI 10.1016/0014-5793(93)81549-F; Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5; Reid AH, 1999, LAB INVEST, V79, P95; Reid AH, 2000, P NATL ACAD SCI USA, V97, P6785, DOI 10.1073/pnas.100140097; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Reid AH, 2002, J VIROL, V76, P10717, DOI 10.1128/JVI.76.21.10717-10723.2002; Reid AH, 2001, MICROBES INFECT, V3, P81, DOI 10.1016/S1286-4579(00)01351-4; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; ROGERS GN, 1989, VIROLOGY, V173, P317, DOI 10.1016/0042-6822(89)90249-3; Rosenthal PB, 1998, NATURE, V396, P92, DOI 10.1038/23974; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shope RE, 1936, J EXP MED, V63, P669, DOI 10.1084/jem.63.5.669; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STONE JE, 1998, THESIS U MISSOURI; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; SUZUKI Y, 1987, BIOCHIM BIOPHYS ACTA, V903, P417, DOI 10.1016/0005-2736(87)90048-4; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	38	379	451	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1866	1870		10.1126/science.1093373	http://dx.doi.org/10.1126/science.1093373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	14764887				2022-12-28	WOS:000220281600055
J	Tyson, GW; Chapman, J; Hugenholtz, P; Allen, EE; Ram, RJ; Richardson, PM; Solovyev, VV; Rubin, EM; Rokhsar, DS; Banfield, JF				Tyson, GW; Chapman, J; Hugenholtz, P; Allen, EE; Ram, RJ; Richardson, PM; Solovyev, VV; Rubin, EM; Rokhsar, DS; Banfield, JF			Community structure and metabolism through reconstruction of microbial genomes from the environment	NATURE			English	Article							IN-SITU DETECTION; MINE DRAINAGE; PHYLOGENETIC IDENTIFICATION; THIOBACILLUS-FERROOXIDANS; LEPTOSPIRILLUM; DIVERSITY; RUSTICYANIN; SEQUENCES; BACTERIA; OXIDASE	Microbial communities are vital in the functioning of all ecosystems; however, most microorganisms are uncultivated, and their roles in natural systems are unclear. Here, using random shotgun sequencing of DNA from a natural acidophilic biofilm, we report reconstruction of near-complete genomes of Leptospirillum group II and Ferroplasma type II, and partial recovery of three other genomes. This was possible because the biofilm was dominated by a small number of species populations and the frequency of genomic rearrangements and gene insertions or deletions was relatively low. Because each sequence read came from a different individual, we could determine that single-nucleotide polymorphisms are the predominant form of heterogeneity at the strain level. The Leptospirillum group II genome had remarkably few nucleotide polymorphisms, despite the existence of low-abundance variants. The Ferroplasma type II genome seems to be a composite from three ancestral strains that have undergone homologous recombination to form a large population of mosaic genomes. Analysis of the gene complement for each organism revealed the pathways for carbon and nitrogen fixation and energy generation, and provided insights into survival strategies in an extreme environment.	Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Joint Genome Inst, Walnut Creek, CA 94598 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI	Banfield, JF (corresponding author), Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA.	jill@eps.berkeley.edu	Solovyev, Victor/C-4614-2013; Tyson, Gene W/C-6558-2013; WU, TAKLON/A-2827-2010; Hugenholtz, Philip/AAD-9138-2019	Solovyev, Victor/0000-0001-8885-493X; Tyson, Gene W/0000-0001-8559-9427; Hugenholtz, Philip/0000-0001-5386-7925; Rokhsar, Daniel/0000-0002-8704-2224; Banfield, Jill/0000-0001-8203-8771				Abe T, 2003, GENOME RES, V13, P693, DOI 10.1101/gr.634603; ACUNA J, 1992, FEMS MICROBIOL LETT, V96, P37, DOI 10.1016/0378-1097(92)90453-U; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Amils R, 1998, BIOCHIMIE, V80, P911, DOI 10.1016/S0300-9084(00)88888-4; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Appia-Ayme C, 1999, APPL ENVIRON MICROB, V65, P4781; Baker BJ, 2003, FEMS MICROBIOL ECOL, V44, P139, DOI 10.1016/S0168-6496(03)00028-X; Beja O, 2002, APPL ENVIRON MICROB, V68, P335, DOI 10.1128/AEM.68.1.335-345.2002; Beja O, 2000, ENVIRON MICROBIOL, V2, P516, DOI 10.1046/j.1462-2920.2000.00133.x; BLAKE R, 1992, GEOMICROBIOL J, V10, P173, DOI 10.1080/01490459209377919; BLAKE RC, 1994, BIOCHEMISTRY-US, V33, P9220, DOI 10.1021/bi00197a025; Bond PL, 2000, APPL ENVIRON MICROB, V66, P4962, DOI 10.1128/AEM.66.11.4962-4971.2000; Bond PL, 2000, APPL ENVIRON MICROB, V66, P3842, DOI 10.1128/AEM.66.9.3842-3849.2000; Bond PL, 2001, MICROBIAL ECOL, V41, P149; Branscomb E, 2002, J BACTERIOL, V184, P6406, DOI 10.1128/JB.184.23.6406-6409.2002; Coram NJ, 2002, APPL ENVIRON MICROB, V68, P838, DOI 10.1128/AEM.68.2.838-845.2002; Dewdney AK, 2000, BIOL BULL-US, V198, P152, DOI 10.2307/1542811; Edwards KJ, 1999, APPL ENVIRON MICROB, V65, P3627; Edwards KJ, 2000, CHEM GEOL, V169, P383, DOI 10.1016/S0009-2541(00)00216-3; Fraser CM, 2002, J BACTERIOL, V184, P6403, DOI 10.1128/JB.184.23.6403-6405.2002; Hugenholtz P, 2002, GENOME BIOL, V3; Komorowski L, 2002, BIOL CHEM, V383, P1791, DOI 10.1515/BC.2002.200; Koonin EV, 1996, CURR OPIN GENET DEV, V6, P757, DOI 10.1016/S0959-437X(96)80032-3; MACALADY JL, UNPUB EXTREMOPHILES; Magurran AE, 2003, NATURE, V422, P714, DOI 10.1038/nature01547; Makarova KS, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-115; McGill BJ, 2003, NATURE, V422, P881, DOI 10.1038/nature01583; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Parro V, 2003, P NATL ACAD SCI USA, V100, P7883, DOI 10.1073/pnas.1230487100; Pitcher RS, 2002, BIOCHEM SOC T, V30, P653, DOI 10.1042/bst0300653; Poole RK, 1997, BIOSCIENCE REP, V17, P303, DOI 10.1023/A:1027336712748; Preisig O, 1996, ARCH MICROBIOL, V165, P297, DOI 10.1007/s002030050330; Rondon MR, 2000, APPL ENVIRON MICROB, V66, P2541, DOI 10.1128/AEM.66.6.2541-2547.2000; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Sandberg R, 2001, GENOME RES, V11, P1404, DOI 10.1101/gr.186401; SILVERMAN M. P., 1964, Advances in Applied Microbiology, V6, P153, DOI 10.1016/S0065-2164(08)70626-9; SINGER PC, 1970, SCIENCE, V167, P1121, DOI 10.1126/science.167.3921.1121; Spratt BG, 2001, CURR OPIN MICROBIOL, V4, P602, DOI 10.1016/S1369-5274(00)00257-5; Torsvik V, 2002, SCIENCE, V296, P1064, DOI 10.1126/science.1071698; Vulic M, 1997, P NATL ACAD SCI USA, V94, P9763, DOI 10.1073/pnas.94.18.9763; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Yamanaka T, 1995, FEMS MICROBIOL REV, V17, P401	42	1497	1615	15	571	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					37	43		10.1038/nature02340	http://dx.doi.org/10.1038/nature02340			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14961025				2022-12-28	WOS:000189363800028
J	Stafford, E				Stafford, E			Patient commentary: paying to choose	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												rosy@gothere.uk.com							0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					402	402		10.1136/bmj.328.7436.402	http://dx.doi.org/10.1136/bmj.328.7436.402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962880	Green Published			2022-12-28	WOS:000189031300033
J	De Tomaso, AW; Weissman, IL				De Tomaso, AW; Weissman, IL			Evolution of a protochordate allorecognition locus	SCIENCE			English	Article							SYSTEM		Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University	De Tomaso, AW (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	tdet@stanford.edu			NIAID NIH HHS [R01 AI041588, AI10332, AI41588] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041588] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDEN B, 1982, P NATL ACAD SCI-BIOL, V79, P2342, DOI 10.1073/pnas.79.7.2342; BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; Stoner DS, 2002, MAR ECOL PROG SER, V243, P93, DOI 10.3354/meps243093; Stoner DS, 1999, P NATL ACAD SCI USA, V96, P9148, DOI 10.1073/pnas.96.16.9148; Wu CT, 1999, CURR OPIN GENET DEV, V9, P237, DOI 10.1016/S0959-437X(99)80035-5	7	26	26	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					977	977		10.1126/science.1094952	http://dx.doi.org/10.1126/science.1094952			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963321				2022-12-28	WOS:000188918000035
J	Donev, A; Cisse, I; Sachs, D; Variano, E; Stillinger, FH; Connelly, R; Torquato, S; Chaikin, PM				Donev, A; Cisse, I; Sachs, D; Variano, E; Stillinger, FH; Connelly, R; Torquato, S; Chaikin, PM			Improving the density of jammed disordered packings using ellipsoids	SCIENCE			English	Article							RANDOM CLOSE PACKING; DYNAMICS; SPHERES	Packing problems, such as how densely objects can fill a volume, are among the most ancient and persistent problems in mathematics and science. For equal spheres, it has only recently been proved that the face-centered cubic lattice has the highest possible packing fraction phi=pi/root18approximate to0.74. It is also well known that certain random (amorphous) jammed packings have phiapproximate to0.64. Here, we show experimentally and with a new simulation algorithm that ellipsoids can randomly pack more densely-up to phi=0.68 to 0.71 for spheroids with an aspect ratio close to that of M&M's Candies-and even approach phiapproximate to0.74 for ellipsoids with other aspect ratios. We suggest that the higher density is directly related to the higher number of degrees of freedom per particle and thus the larger number of particle contacts required to mechanically stabilize the packing. We measured the number of contacts per particle Zapproximate to10 for our spheroids, as compared to Zapproximate to6 for spheres. Our results have implications for a broad range of scientific disciplines, including the properties of granular media and ceramics, glass formation, and discrete geometry.	Princeton Univ, Program Appl & Computat Math, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Mat Inst, Princeton, NJ 08544 USA; N Carolina Cent Univ, Durham, NC 27707 USA; Cornell Univ, Dept Civil & Environm Engn, Ithaca, NY 14853 USA; Cornell Univ, Dept Math, Ithaca, NY 14853 USA	Princeton University; Princeton University; Princeton University; Princeton University; University of North Carolina; North Carolina Central University; Cornell University; Cornell University	Torquato, S (corresponding author), Princeton Univ, Program Appl & Computat Math, Princeton, NJ 08544 USA.	torquato@princeton.edu						Abreu CRA, 2003, POWDER TECHNOL, V134, P167, DOI 10.1016/S0032-5910(03)00151-7; Alexander S, 1998, PHYS REP, V296, P65, DOI 10.1016/S0370-1573(97)00069-0; Allen M.P., 1993, ADV CHEM PHYS, P1, DOI [10.1002/9780470141458.ch1, DOI 10.1002/9780470141458.CH1]; Aste T, 2000, PURSUIT PERFECT PACK; BARKER GC, 1992, PHYS REV A, V45, P3435, DOI 10.1103/PhysRevA.45.3435; BERNAL JD, 1990, NATURE, V385, P910; BEZDEK A, 1991, DIMACS SERIES DISCRE, V4, P71; BUCHALTER BJ, 1992, PHYS REV A, V46, P3046, DOI 10.1103/PhysRevA.46.3046; Chaikin P, 2000, SUSSP PROC, V53, P315, DOI 10.1201/9781420033519.ch13; Coelho D, 1997, PHYS REV E, V55, P1959, DOI 10.1103/PhysRevE.55.1959; Conway JH, 1999, SPHERE PACKINGS LATT; DONEV A, IN PRESS J COMP PHYS; DONEV A, UNPUB, P74302; Edwards S. F., 1994, GRANULAR MATTER INTE, P121; Edwards SF, 1999, PHYS REV LETT, V82, P5397, DOI 10.1103/PhysRevLett.82.5397; FRENKEL D, 1983, MOL PHYS, V49, P503, DOI 10.1080/00268978300101331; HALES TC, 1998, XXXLANLGOVMATHMG9811; Kansal AR, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.041109; KNIGHT JB, 1995, PHYS REV E, V51, P3957, DOI 10.1103/PhysRevE.51.3957; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; LUBACHEVSKY BD, 1990, J STAT PHYS, V60, P561, DOI 10.1007/BF01025983; LUBACHEVSKY BD, 1991, J STAT PHYS, V64, P501, DOI 10.1007/BF01048304; Makse HA, 2002, NATURE, V415, P614, DOI 10.1038/415614a; SCOTT GD, 1969, J PHYS D APPL PHYS, V2, P863, DOI 10.1088/0022-3727/2/6/311; Sherwood JD, 1997, J PHYS A-MATH GEN, V30, pL839, DOI 10.1088/0305-4470/30/24/004; Torquato S, 2000, PHYS REV LETT, V84, P2064, DOI 10.1103/PhysRevLett.84.2064; Torquato S, 2001, J PHYS CHEM B, V105, P11849, DOI 10.1021/jp011960q; Williams SR, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051301; Zallen R., 1983, PHYS AMORPHOUS SOLID	29	921	948	9	227	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					990	993		10.1126/science.1093010	http://dx.doi.org/10.1126/science.1093010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963324				2022-12-28	WOS:000188918000039
J	Mira, MT; Alcais, A; Van Thuc, N; Moraes, MO; Di Flumeri, C; Thai, VH; Phuong, MC; Huong, NT; Ba, NN; Khoa, PX; Sarno, EN; Alter, A; Montpetit, A; Moraes, ME; Moraes, JR; Dore, C; Gallant, CJ; Lepage, P; Verner, A; van de Vosse, E; Hudson, TJ; Abel, L; Schurr, E				Mira, MT; Alcais, A; Van Thuc, N; Moraes, MO; Di Flumeri, C; Thai, VH; Phuong, MC; Huong, NT; Ba, NN; Khoa, PX; Sarno, EN; Alter, A; Montpetit, A; Moraes, ME; Moraes, JR; Dore, C; Gallant, CJ; Lepage, P; Verner, A; van de Vosse, E; Hudson, TJ; Abel, L; Schurr, E			Susceptibility to leprosy is associated with PARK2 and PACRG	NATURE			English	Article								Leprosy is caused by Mycobacterium leprae and affects about 700,000 individuals each year(1). It has long been thought that leprosy has a strong genetic component(2), and recently we mapped a leprosy susceptibility locus to chromosome 6 region q25-q26 (ref. 3). Here we investigate this region further by using a systematic association scan of the chromosomal interval most likely to harbour this leprosy susceptibility locus. In 197 Vietnamese families we found a significant association between leprosy and 17 markers located in a block of approx. 80 kilobases overlapping the 5' regulatory region shared by the Parkinson's disease gene PARK2 and the co-regulated gene PACRG. Possession of as few as two of the 17 risk alleles was highly predictive of leprosy. This was confirmed in a sample of 975 unrelated leprosy cases and controls from Brazil in whom the same alleles were strongly associated with leprosy. Variants in the regulatory region shared by PARK2 and PACRG therefore act as common risk factors for leprosy.	McGill Univ, McGill Ctr Study Host Resistance, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Univ Catolica Parana, Ctr Ciencias Biol & Saude, BR-80215901 Curitiba, Parana, Brazil; Univ Paris 05, Fac Med Necker, INSERM, U550,Lab Genet Humaine Malad Infect, F-75015 Paris, France; Hosp Dermatovenereol, Ho Chi Minh City, Vietnam; Fiocruz MS, Inst Oswaldo Cruz, Dept Trop Med, Leprosy Lab, BR-20221903 Rio De Janeiro, Brazil; McGill Univ, Montreal, PQ H3A 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; Minist Saude, Inst Nacl Canc, Lab Imunogenet, BR-20230130 Rio De Janeiro, Brazil; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands	McGill University; McGill University; McGill University; McGill University; Pontificia Universidade Catolica do Parana; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Fundacao Oswaldo Cruz; McGill University; National Cancer Institute (Inca); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Abel, L (corresponding author), Univ Paris 05, Fac Med Necker, INSERM, U550,Lab Genet Humaine Malad Infect, F-75015 Paris, France.	abel@necker.fr; erwin@igloo.epi.mcgill.ca	van de Vosse, Esther/HDO-0723-2022; Alcais, Alexandre/J-5882-2017; Mira, Marcelo T/B-5046-2010; van de Vosse, Esther/B-7285-2009; Moraes, Milton Ozório/G-9753-2011; Abel, Laurent/H-8888-2017; Peng, Bo/A-6920-2009; Moraes, Milton/AFF-1842-2022	Alcais, Alexandre/0000-0002-1012-2226; Mira, Marcelo T/0000-0002-8087-9400; van de Vosse, Esther/0000-0001-5199-3426; Moraes, Milton Ozório/0000-0003-2653-0037; Abel, Laurent/0000-0001-7016-6493; Peng, Bo/0000-0001-8225-2284; Nunes Sarno, Euzenir/0000-0003-0129-2159				Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dupuis J, 1999, GENETICS, V151, P373; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Imai Y, 2003, J BIOL CHEM, V278, P51901, DOI 10.1074/jbc.M309655200; Jacobson RR, 1999, LANCET, V353, P655, DOI 10.1016/S0140-6736(98)06322-3; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; Mira MT, 2003, NAT GENET, V33, P412, DOI 10.1038/ng1096; Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Schaid DJ, 1998, AM J HUM GENET, V63, P1492, DOI 10.1086/302094; THOMSON G, 1995, AM J HUM GENET, V57, P487; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; *WHO, 2002, WKLY EPIDEMIOL REC, V77, P1	18	358	370	0	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					636	640		10.1038/nature02326	http://dx.doi.org/10.1038/nature02326			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14737177				2022-12-28	WOS:000188875300042
J	Tian, XL; Kadaba, R; You, SA; Liu, MG; Timura, AA; Yang, L; Chen, QY; Szafranski, P; Rao, SQ; Wu, L; Housman, DE; DiCorleto, PE; Driscoll, DJ; Borrow, J; Wang, Q				Tian, XL; Kadaba, R; You, SA; Liu, MG; Timura, AA; Yang, L; Chen, QY; Szafranski, P; Rao, SQ; Wu, L; Housman, DE; DiCorleto, PE; Driscoll, DJ; Borrow, J; Wang, Q			Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome	NATURE			English	Article							BLOOD-VESSEL FORMATION; GROWTH; TWEAK; TRANSLOCATION; MECHANISMS; RECEPTOR; DOMAINS; MEMBER; BINDS; CELLS	Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network(1). Here we use human genetics as an approach to identify an angiogenic factor, VG5Q, and further define two genetic defects of VG5Q in patients with the vascular disease Klippel-Trenaunay syndrome (KTS)(2,3). One mutation is chromosomal translocation t(5;11), which increases VG5Q transcription. The second is mutation E133K identified in five KTS patients, but not in 200 matched controls. VG5Q protein acts as a potent angiogenic factor in promoting angiogenesis, and suppression of VG5Q expression inhibits vessel formation. E133K is a functional mutation that substantially enhances the angiogenic effect of VG5Q. VG5Q shows strong expression in blood vessels and is secreted as vessel formation is initiated. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that it may act in an autocrine fashion. We also demonstrate a direct interaction of VG5Q with another secreted angiogenic factor, TWEAK (also known as TNFSF12)(4,5). These results define VG5Q as an angiogenic factor, establish VG5Q as a susceptibility gene for KTS, and show that increased angiogenesis is a molecular pathogenic mechanism of KTS.	Cleveland Clin Fdn, Dept Mol Cardiol, Ctr Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Ctr Cardiovasc Genet, Cleveland, OH 44195 USA; Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44195 USA; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Mayo Clin & Mayo Fdn, Div Pediat Cardiol, Rochester, MN 55905 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Fudan University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Baylor College of Medicine; Massachusetts Institute of Technology (MIT); Mayo Clinic	Wang, Q (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Ctr Mol Genet, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	wangq2@ccf.org		Szafranski, Przemyslaw/0000-0002-3886-2971; Rao, Shaoqi/0000-0001-7809-3700	NHLBI NIH HHS [R01 HL066251, R01 HL065630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066251, R01HL065630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BASKERVILLE PA, 1985, ANN SURG, V202, P624, DOI 10.1097/00000658-198511000-00015; Berry SA, 1998, AM J MED GENET, V79, P319, DOI 10.1002/(SICI)1096-8628(19981002)79:4<319::AID-AJMG15>3.3.CO;2-A; Buschmann I, 1999, NEWS PHYSIOL SCI, V14, P121; Calvert JT, 1999, HUM MOL GENET, V8, P1279, DOI 10.1093/hmg/8.7.1279; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Fan C, 2003, J Med Genet, V40, pe29, DOI 10.1136/jmg.40.3.e29; Fan C, 2003, J BIOL CHEM, V278, P8780, DOI 10.1074/jbc.M208120200; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Guglielmi B, 2002, J BIOL CHEM, V277, P35712, DOI 10.1074/jbc.M205526200; HAPPLE R, 1993, BRIT J DERMATOL, V128, P465, DOI 10.1111/j.1365-2133.1993.tb00214.x; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; JACKSON CL, 1996, CURRENT PROTOCOLS HU; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shriver MD, 1997, AM J HUM GENET, V60, P957; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 2001, CYTOGENET CELL GENET, V95, P183, DOI 10.1159/000059343; WHELAN AJ, 1995, AM J MED GENET, V59, P492, DOI 10.1002/ajmg.1320590416; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	30	213	236	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					640	645		10.1038/nature02320	http://dx.doi.org/10.1038/nature02320			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961121	Green Accepted			2022-12-28	WOS:000188875300043
J	Wang, M; Vijayraghavan, S; Goldman-Rakic, PS				Wang, M; Vijayraghavan, S; Goldman-Rakic, PS			Selective D2 receptor actions on the functional circuitry of working memory	SCIENCE			English	Article							PREFRONTAL CORTEX; NEURONS; NUCLEUS; MODULATION; RACLOPRIDE; ACCUMBENS; AGONIST; MONKEYS; FIELDS; MICE	Prefrontal neurons engaged by working memory tasks express a sequence of phasic and tonic activations linked to a train of sensory, mnemonic, and response-related events. Here, we report that the dopamine D2 receptor selectively modulates the neural activities associated with memory-guided saccades in oculomotor delayed-response tasks yet has little or no effect on the persistent mnemonic-related activity, which is instead modulated by D1 receptors. This associates the D2 receptor with a specific component of working memory circuitry and fractionates the modulatory effects of D1 and D2 receptors on the neural machinery of a cognitive process.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA	Yale University	Wang, M (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.	min.wang@yale.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068789, P50MH044866] Funding Source: NIH RePORTER; NIMH NIH HHS [P50 MH44866, P50 MH068789] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anderson CM, 2002, AM J PSYCHIAT, V159, P1322, DOI 10.1176/appi.ajp.159.8.1322; ARNSTEN AFT, 1995, J NEUROSCI, V15, P3429; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BROOKS DJ, 1992, ANN NEUROL, V31, P184, DOI 10.1002/ana.410310209; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; FEINBERG I, 1978, SCHIZOPHRENIA BULL, V4, P636, DOI 10.1093/schbul/4.4.636; FRITH C, 1995, LANCET, V346, P615, DOI 10.1016/S0140-6736(95)91441-2; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; ILINSKY IA, 1985, J COMP NEUROL, V236, P315, DOI 10.1002/cne.902360304; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; Lidow MS, 1998, SYNAPSE, V28, P10, DOI 10.1002/(SICI)1098-2396(199801)28:1<10::AID-SYN2>3.0.CO;2-F; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; LYNCH JC, 1994, EXP BRAIN RES, V100, P181; Mehta MA, 2001, PSYCHOPHARMACOLOGY, V159, P10, DOI 10.1007/s002130100851; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; Sommer MA, 2002, SCIENCE, V296, P1480, DOI 10.1126/science.1069590; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; Tanibuchi I, 2003, J NEUROPHYSIOL, V89, P1067, DOI 10.1152/jn.00207.2002; Tran AH, 2002, P NATL ACAD SCI USA, V99, P8986, DOI 10.1073/pnas.132284599; Usiello A, 2000, NATURE, V408, P199, DOI 10.1038/35041572; Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0; WANG M, UNPUB; Williams GV, 2002, J NEUROSCI, V22, P2843, DOI 10.1523/JNEUROSCI.22-07-02843.2002; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0	30	242	249	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	2004	303	5659					853	856		10.1126/science.1091162	http://dx.doi.org/10.1126/science.1091162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764884				2022-12-28	WOS:000188753800063
J	Cyranoski, D				Cyranoski, D			Lack of infrastructure hampers virus monitoring	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 5	2004	427	6974					472	472						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14770450				2022-12-28	WOS:000188721800004
J	Dennis, C				Dennis, C			Mixed messages	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 5	2004	427	6974					473	473						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14768651				2022-12-28	WOS:000188721800005
J	Fairchild, AL; Bayer, R				Fairchild, AL; Bayer, R			Ethics and the conduct of public health surveillance	SCIENCE			English	Editorial Material									Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA	Columbia University	Fairchild, AL (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA.	alf4@columbia.edu	Fairchild, Amy/F-1811-2018	Fairchild, Amy/0000-0002-1292-7212				Ackerman T.F., 1996, ETHICS RES INVOLVING, P83; [Anonymous], INT GUID ETH REV EP; [Anonymous], 2002, COMMUNICATION   1202; BRAINARD J, 2003, CHRON HIGH ED   1031, V50, pA25; Cann Cristina I, 1984, IRB, V6, P5; Capron Alexander Morgan, 1991, Law Med Health Care, V19, P184; *CDC, 1996, CDC M PROT HUM RES S, P2; *CDC, 1999, CDC COUNC STAT TERR, P22; *CDC, 2003, AG HIV AIDS PUBL HLT; FAIRCHILD AL, IN PRESS ETHICAL ISS; GORDIS L, 1977, AM J EPIDEMIOL, V105, P163, DOI 10.1093/oxfordjournals.aje.a112372; MIDDAUGH J, 1999, COMMUNICATION   0607, P2; OBERMEYER C, 2004, COMMUNICATION   0112; *OFF PROT RES RISK, 1995, EV HUM SUBJ PROT RES, P14; Rothman David J., 1991, STRANGERS BEDSIDE HI, P63; SNIDER DE, 1997, PUBL HLTH REP, V112, P30; *WORLD BANK GROUP, 2002, PUBL HLTH SURV TOOLK	17	40	40	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					631	632		10.1126/science.1094038	http://dx.doi.org/10.1126/science.1094038			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	768EN	14752148				2022-12-28	WOS:000188530800026
J	Heeschen, C; Dimmeler, S; Fichtlscherer, S; Hamm, CW; Berger, J; Simoons, ML; Zeiher, AM				Heeschen, C; Dimmeler, S; Fichtlscherer, S; Hamm, CW; Berger, J; Simoons, ML; Zeiher, AM		CAPTURE Investigators	Prognostic value of placental growth factor in patients with acute chest pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; ACUTE CORONARY SYNDROMES; UNSTABLE ANGINA; TROPONIN-T; ELEVATED LEVELS; MORTALITY; REVASCULARIZATION; STRATIFICATION; INTERLEUKIN-6; ANGIOGENESIS	Context Experimental data suggest that placental growth factor (PIGF), a member of the vascular endothelial growth factor family, acts as a primary inflammatory instigator of atherosclerotic plaque instability and thus may be useful as a risk-predicting biomarker in patients with acute coronary syndromes (ACS). Objective To determine whether blood levels of PIGF predict risk for death or non-fatal myocardial infarction in patients with acute chest pain. Design, Setting, and Patients Measurement of PIGF levels as well as levels of markers of myocardial necrosis (troponin T [TnT]), platelet activation (soluble CD40 ligand [sCD40L]) and inflammation (high-sensitivity C-reactive protein [hsCRP]) in an inception cohort of 547 patients with angiographically validated ACS participating in the CAPTURE (c7E3 Fab Anti-Platelet Therapy in Unstable Refractory Angina) trial and in a heterogeneous cohort of 626 patients presenting with acute chest pain to an emergency department in Germany between December 1996 and March 1999. Main Outcome Measure Risk for death or non-fatal myocardial infarction after 30 days. Results Inpatients with ACS, elevated PIG F levels (>27.0 ng/L; 40.8% of patients) indicated a markedly increased risk of events at 30 days (14.8% vs 4.9%; unadjusted hazard ratio [HR], 3.34; 95% confidence interval [CI], 1.79-6.24; P<.001). In a multivariable model, elevated levels of TnT (HR, 1.83; 95% CI, 1.05-3.86; P=.03), sCD40L (HR, 2.65; 95% CI, 1.41-4.99; P=.002), and PIGF (HR, 3.03; 95% CI, 1.54-5.95; P<.001) were independent predictors, while elevated hsCRP level was not (HR, 0.98; 95% CI, 0.53-1.98; P=.94). In patients with acute chest pain, elevated levels of PIGF predicted risk (21.2% vs 5.3%) (unadjusted: HR, 4.80; 95% CI, 2.81-8.21; P<.001; adjusted: HR, 3.00; 95% Cl, 1.68-5.38; P<.001). Patients negative for all 3 markers (TnT, sCD40L, and PIGF) were at very low cardiac risk Q days: no event; 30 days: 2.1% event rate). Conclusions Plasma PIGF levels may be an independent biomarker of adverse outcome in patients with suspected ACS. A single initial measurement of plasma PIGF appears to extend the predictive and prognostic information gained from traditional inflammatory markers.	Goethe Univ Frankfurt, Dept Cardiol, D-60590 Frankfurt, Germany; Kerckhoff Heart Ctr, Bad Nauheim, Germany; Univ Hamburg, Inst Math & Comp Sci Med, Hamburg, Germany; Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands	Goethe University Frankfurt; Kerckhoff Clinic; University of Hamburg; Erasmus University Rotterdam; Erasmus MC	Heeschen, C (corresponding author), Goethe Univ Frankfurt, Dept Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	c.heeschen@em.uni-frankfurt.de	Hamm, Christian W./I-3155-2017; Guba, Markus/M-4309-2019	Hamm, Christian W./0000-0001-6763-4161; Dimmeler, Stefanie/0000-0002-1045-2436; Heeschen, Christopher/0000-0002-1158-8554				Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci L M, 2001, Ital Heart J, V2, P164; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; *CAPTURE INV, 1997, LANCET, V350, P744; COX DR, 1972, J R STAT SOC B, V34, P187; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; Hamm CW, 2000, CIRCULATION, V102, P118, DOI 10.1161/01.CIR.102.1.118; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Heeschen C, 2000, J AM COLL CARDIOL, V35, P1535, DOI 10.1016/S0735-1097(00)00581-7; Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600; Heeschen C, 2003, CIRCULATION, V107, P524, DOI 10.1161/01.CIR.0000048183.37648.1A; Khaliq A, 1999, LAB INVEST, V79, P151; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Lindmark E, 2001, JAMA-J AM MED ASSOC, V286, P2107, DOI 10.1001/jama.286.17.2107; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Liuzzo G, 1996, CIRCULATION, V94, P2373, DOI 10.1161/01.CIR.94.10.2373; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3; Pepys M B, 2001, Ital Heart J, V2, P804; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Simoons ML, 1997, LANCET, V349, P1429; Toss H, 1997, CIRCULATION, V96, P4204	30	123	151	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					435	441		10.1001/jama.291.4.435	http://dx.doi.org/10.1001/jama.291.4.435			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747500	Bronze			2022-12-28	WOS:000188426700028
J	Aguzzi, A; Polymenidou, M				Aguzzi, A; Polymenidou, M			Mammalian prion biology: One century of evolving concepts	CELL			English	Review							CREUTZFELDT-JAKOB-DISEASE; CENTRAL-NERVOUS-SYSTEM; FOLLICULAR DENDRITIC CELLS; CHRONIC WASTING DISEASE; CELLULAR PRION; PROTEIN PRP; SPONGIFORM ENCEPHALOPATHIES; INCUBATION PERIOD; SCRAPIE PATHOGENESIS; MESSENGER-RNA	Prions have been responsible for an entire century of tragic episodes. Fifty years ago, kuru decimated the population of Papua New Guinea. Then, iatrogenic transmission of prions caused more than 250 cases of Creutzfeldt-Jakob disease. More recently, transmission of bovine spongiform encephalopathy to humans caused a widespread health scare. On the other hand, the biology of prions represents a fascinating and poorly understood phenomenon, which may account for more than just diseases and may represent a fundamental mechanism of crosstalk between proteins. The two decades since Stanley Prusiner's formulation of the protein-only hypothesis have witnessed spectacular advances, and yet some of the most basic questions in prion science have remained unanswered.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008; Polymenidou, Magdalini/D-2254-2014	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Aguzzi A, 2003, J EXP MED, V198, P1, DOI 10.1084/jem.20030732; Aguzzi A, 1996, NATURE, V381, P734, DOI 10.1038/381734a0; Aguzzi A, 1996, NATURE, V383, P666, DOI 10.1038/383666a0; Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; ALPER T, 1966, BIOCHEM BIOPH RES CO, V22, P278, DOI 10.1016/0006-291X(66)90478-5; Andrews NJ, 2003, LANCET, V361, P751, DOI 10.1016/S0140-6736(03)12632-3; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Bellon A, 2003, J GEN VIROL, V84, P1921, DOI 10.1099/vir.0.18996-0; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bosque PJ, 2000, J VIROL, V74, P4377, DOI 10.1128/JVI.74.9.4377-4386.2000; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Caughey B, 2003, J VIROL, V77, P5499, DOI 10.1128/JVI.77.9.5499-5502.2003; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHANDLER RL, 1961, LANCET, V1, P1378; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; Cooper E, 2002, BRIT MED J, V324, P239; Creutzfeldt HG, 1920, Z GESAMTE NEUROL PSY, V57, P1, DOI 10.1007/BF02866081; CUILLE J., 1939, Compte Rendu de l'Academie des Sciences, V208, P1058; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; DUFFY P, 1974, NEW ENGL J MED, V290, P692; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Frigg R, 1999, J VIROL, V73, P9584, DOI 10.1128/JVI.73.11.9584-9588.1999; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; GAJDUSEK DC, 1967, SCIENCE, V155, P212; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; Glatzel M, 2003, LANCET NEUROL, V2, P757, DOI 10.1016/S1474-4422(03)00588-X; Glatzel M, 2002, LANCET, V360, P139, DOI 10.1016/S0140-6736(02)09384-4; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; Glockshuber R, 1998, FEBS LETT, V426, P291, DOI 10.1016/S0014-5793(98)00372-X; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HADLOW WJ, 1959, LANCET, V2, P289; HARMEY JH, 1995, BIOCHEM BIOPH RES CO, V210, P753, DOI 10.1006/bbrc.1995.1723; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Hutter G, 2003, BIOL CHEM, V384, P1279, DOI 10.1515/BC.2003.142; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Jakob A, 1921, Z GESAMTE NEUROL PSY, V64, P147, DOI 10.1007/BF02870932; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; Luhrs T, 2003, J MOL BIOL, V326, P1549, DOI 10.1016/S0022-2836(02)01471-7; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OESCH B, 1990, BIOCHEMISTRY-US, V29, P5848, DOI 10.1021/bi00476a029; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; PATTISON IH, 1961, J COMP PATHOL THERAP, V71, P101, DOI 10.1016/S0368-1742(61)80013-1; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; POPPER K, 1991, PHILOS SCI, P100; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Prinz M, 2003, AM J PATHOL, V162, P1103, DOI 10.1016/S0002-9440(10)63907-7; Prinz M, 2003, EMBO REP, V4, P195, DOI 10.1038/sj.embor.embor731; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P4606, DOI 10.1073/pnas.78.7.4606; PRUSINER SB, 1977, P NATL ACAD SCI USA, V74, P4656, DOI 10.1073/pnas.74.10.4656; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Revesz T, 2002, BRAIN PATHOL, V12, P343; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakudo A, 2003, BIOCHEM BIOPH RES CO, V308, P660, DOI 10.1016/S0006-291X(03)01459-1; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Schreuder BEC, 1996, NATURE, V381, P563, DOI 10.1038/381563a0; Schwartz M., 2003, COWS TURNED MAD; Scoazec JY, 2003, ANN NEUROL, V53, P546, DOI 10.1002/ana.10530; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Souan L, 2001, EUR J IMMUNOL, V31, P2338, DOI 10.1002/1521-4141(200108)31:8&lt;2338::AID-IMMU2338&gt;3.0.CO;2-V; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Valleron AJ, 2001, SCIENCE, V294, P1726, DOI 10.1126/science.1066838; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Watarai MH, 2003, J EXP MED, V198, P5, DOI 10.1084/jem.20021980; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; WILLIAMS ES, 1980, J WILDLIFE DIS, V16, P89, DOI 10.7589/0090-3558-16.1.89; Yehiely F, 2002, NEUROBIOL DIS, V10, P67, DOI 10.1006/nbdi.2002.0484; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zanusso G, 2003, NEW ENGL J MED, V348, P711, DOI 10.1056/NEJMoa022043; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	160	473	498	0	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					313	327		10.1016/S0092-8674(03)01031-6	http://dx.doi.org/10.1016/S0092-8674(03)01031-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744440	Bronze, Green Accepted			2022-12-28	WOS:000188541700019
J	Danial, NN; Korsmeyer, SJ				Danial, NN; Korsmeyer, SJ			Cell death: Critical control points	CELL			English	Review							CYTOCHROME-C RELEASE; APOPTOSIS-INDUCING FACTOR; MITOCHONDRIAL PERMEABILITY TRANSITION; BCL-2 FAMILY MEMBERS; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; STRUCTURAL BASIS; CASPASE ACTIVATION; GRANZYME-B; CHROMOSOMAL BREAKPOINT	Programmed cell death is a distinct genetic and biochemical pathway essential to metazoans. An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis. Apoptosis has proven to be tightly interwoven with other essential cell pathways. The identification of critical control points in the cell death pathway has yielded fundamental insights for basic biology, as well as provided rational targets for new therapeutics.	Harvard Univ, Howard Hughes Med Inst, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Korsmeyer, SJ (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.	stanley_korsmeyer@dfci.harvard.edu						Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; BRENNER S, 1974, GENETICS, V77, P71; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHIPUK JE, 2004, IN PRESS SCIENCE; CHOI SS, 1995, ONCOGENE, V11, P1693; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deshmukh M, 2002, J NEUROSCI, V22, P8018; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, GENETICS, V129, P79; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Gibson L, 1996, ONCOGENE, V13, P665; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicotera P, 1997, Adv Neurol, V72, P95; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Quinn L, 2003, EMBO J, V22, P3568, DOI 10.1093/emboj/cdg355; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SULSTON JE, 1976, PHILOS T ROY SOC B, V275, P287, DOI 10.1098/rstb.1976.0084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wu YC, 2000, GENE DEV, V14, P536; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	162	3774	4054	9	667	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					205	219		10.1016/S0092-8674(04)00046-7	http://dx.doi.org/10.1016/S0092-8674(04)00046-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744432	Bronze			2022-12-28	WOS:000188541700011
J	Cioli, D; Liberti, P				Cioli, D; Liberti, P			Schistosoma japonicum: modern tools for an ancient disease	LANCET			English	Editorial Material									Inst Cell Biol, I-00016 Monterotondo, Rome, Italy		Cioli, D (corresponding author), Inst Cell Biol, I-00016 Monterotondo, Rome, Italy.	dcioli@ibc.cnr.it						Bilharz T., 1852, Z WISS ZOOL ABT A, V4, P53; Christopherson JB, 1918, LANCET, V2, P325; CIOLI D, 1995, PHARMACOL THERAPEUT, V68, P35, DOI 10.1016/0163-7258(95)00026-7; DEELDER AM, 1990, LANCET, V335, P724, DOI 10.1016/0140-6736(90)90838-V; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Ruffer M A, 1910, Br Med J, V1, P16; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; WHO, 2002, WHO TECH REP SER	9	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					180	181		10.1016/S0140-6736(03)15366-4	http://dx.doi.org/10.1016/S0140-6736(03)15366-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738785				2022-12-28	WOS:000188243900002
J	Gamblin, SJ; Haire, LF; Russell, RJ; Stevens, DJ; Xiao, B; Ha, Y; Vasisht, N; Steinhauer, DA; Daniels, RS; Elliot, A; Wiley, DC; Skehel, JJ				Gamblin, SJ; Haire, LF; Russell, RJ; Stevens, DJ; Xiao, B; Ha, Y; Vasisht, N; Steinhauer, DA; Daniels, RS; Elliot, A; Wiley, DC; Skehel, JJ			The structure and receptor binding properties of the 1918 influenza hemagglutinin	SCIENCE			English	Article							VIRUS HEMAGGLUTININS; SPANISH INFLUENZA; SIALIC-ACID; A-VIRUSES; SPECIFICITY; ORIGIN; H1; EVOLUTION; VARIANTS; CELL	The 1918 influenza pandemic resulted in about 20 million deaths. This enormous impact, coupled with renewed interest in emerging infections, makes characterization of the virus involved a priority. Receptor binding, the initial event in virus infection, is a major determinant of virus transmissibility that, for influenza viruses, is mediated by the hemagglutinin ( HA) membrane glycoprotein. We have determined the crystal structures of the HA from the 1918 virus and two closely related HAs in complex with receptor analogs. They explain how the 1918 HA, while retaining receptor binding site amino acids characteristic of an avian precursor HA, is able to bind human receptors and how, as a consequence, the virus was able to spread in the human population.	Natl Inst Med Res, Ridgeway, London NW7 1AA, England; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Skehel, JJ (corresponding author), Natl Inst Med Res, Ridgeway, Mill Hill, London NW7 1AA, England.	mbrenna@nimr.mrc.ac.uk		Elliot, Alex/0000-0002-6414-3065	NIAID NIH HHS [AI-13654] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013654] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUM LG, 1990, ACTA HISTOCHEM, P35; BENNETT MA, UNPUB; CONNOR RJ, 1994, VIROLOGY, V205, P17, DOI 10.1006/viro.1994.1615; Eisen MB, 1997, VIROLOGY, V232, P19, DOI 10.1006/viro.1997.8526; Francis T, 1934, SCIENCE, V80, P457, DOI 10.1126/science.80.2081.457-a; Gambaryan AS, 1997, VIROLOGY, V232, P345, DOI 10.1006/viro.1997.8572; Ha Y, 2003, VIROLOGY, V309, P209, DOI 10.1016/S0042-6822(03)00068-0; Ha Y, 2002, EMBO J, V21, P865, DOI 10.1093/emboj/21.5.865; Ha Y, 2001, P NATL ACAD SCI USA, V98, P11181, DOI 10.1073/pnas.201401198; Ito T, 1998, J VIROL, V72, P7367, DOI 10.1128/JVI.72.9.7367-7373.1998; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999; MATROSOVICH MN, 1993, VIROLOGY, V196, P111, DOI 10.1006/viro.1993.1459; NAEVE CW, 1984, J VIROL, V51, P567, DOI 10.1128/JVI.51.2.567-569.1984; NELSON J, 1993, VIRUS RES, V29, P155, DOI 10.1016/0168-1702(93)90056-S; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; RAYMOND FL, 1983, NUCLEIC ACIDS RES, V11, P7191, DOI 10.1093/nar/11.20.7191; Reid AH, 2003, EMERG INFECT DIS, V9, P1249; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; ROGERS GN, 1989, VIROLOGY, V173, P317, DOI 10.1016/0042-6822(89)90249-3; RUSSELL R, UNPUB; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; Shope R E, 1931, J Exp Med, V54, P373, DOI 10.1084/jem.54.3.373; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Smith W, 1933, LANCET, V2, P66, DOI 10.1016/S0140-6736(00)78541-2; Webster RG, 1999, P NATL ACAD SCI USA, V96, P1164, DOI 10.1073/pnas.96.4.1164; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0	29	530	634	0	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1838	1842		10.1126/science.1093155	http://dx.doi.org/10.1126/science.1093155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	14764886				2022-12-28	WOS:000220281600047
J	Taft, A; Broom, DH; Legge, D				Taft, A; Broom, DH; Legge, D			General practitioner management of intimate partner abuse and the whole family: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOMESTIC VIOLENCE; WOMEN; HEALTH; SURVIVORS	Objective To explore management by general practitioners of victimised female patients, mate partners who abuse, and children in the family. Design Triangulated qualitative study comparing doctors' reported management with current recommendations in the literature. Participants 28 general practitioners attending continuing medical education about management of domestic violence. Results Doctors perceived partner abuse in diverse ways. Their gender, perceptions, and attitudes could all affect identification and management of this difficult problem. A few doctors practised in recommended ways, but many showed stress and aversion, difficulties in resolving the tensions involved in managing all family members, and neglect of the risks to children. Some doctors used contraindicated practices, such as breaking confidentiality and undertaking or referring for couple counselling. Doctors who were not familiar with community based agencies were reluctant to use them. A lack of expertise and support could have a negative impact on doctors themselves. Conclusions General practitioners managing partner abuse need to be more familiar with and apply the central principles of confidentiality and safety of women and children. Recommended guidelines for managing the whole family should be developed. Doctors should consider referring one partner elsewhere and avoid couple counselling; always ask about and act on the children's welfare; refer to specialist family violence agencies; and seek training, supervision, and support for the inherent stress. Medical education and administration should ensure comprehensive training and support for doctors undertaking this difficult work.	La Trobe Univ, Ctr Study Mothers & Childrens Hlth, Carlton, Vic 3053, Australia; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; La Trobe Univ, Fac Hlth Sci, Sch Publ Hlth, Bundoora, Vic 3086, Australia	La Trobe University; Australian National University; La Trobe University	Taft, A (corresponding author), La Trobe Univ, Ctr Study Mothers & Childrens Hlth, 251 Faraday St, Carlton, Vic 3053, Australia.	a.taft@latrobe.edu.au		Taft, Angela/0000-0002-6350-843X				Adams D, 1996, J Am Med Womens Assoc (1972), V51, P123; BENSING JM, 1993, MED CARE, V31, P219, DOI 10.1097/00005650-199303000-00004; BOWKER LH, 1987, WOMEN HEALTH, V12, P25, DOI 10.1300/J013v12n01_03; Brandt EN, 1997, ACAD MED, V72, pS51; EDLESON J, 1999, FUTURE CHILD, V9; Eisenstat SA, 1999, NEW ENGL J MED, V341, P886, DOI 10.1056/NEJM199909163411206; Ferris L E, 1999, Fam Med, V31, P415; Ferris LE, 1997, JAMA-J AM MED ASSOC, V278, P851, DOI 10.1001/jama.278.10.851; Gerbert B, 1999, WOMEN HEALTH, V29, P115, DOI 10.1300/J013v29n03_08; Gerbert B, 1999, ANN INTERN MED, V131, P578, DOI 10.7326/0003-4819-131-8-199910190-00005; Hegarty KL, 2002, AUST NZ J PUBL HEAL, V26, P437, DOI 10.1111/j.1467-842X.2002.tb00344.x; Hegarty KL, 2001, AUST NZ J PUBL HEAL, V25, P433, DOI 10.1111/j.1467-842X.2001.tb00288.x; JOHNSON MP, 1995, J MARRIAGE FAM, V57, P283, DOI 10.2307/353683; Mintz HA, 1997, POSTGRAD MED, V101, P219, DOI 10.3810/pgm.1997.04.205; Oriel KA, 1998, J FAM PRACTICE, V46, P493; Richardson J, 2001, BRIT J GEN PRACT, V51, P468; SASSETTI MR, 1993, PRIMARY CARE, V20, P289; Strauss A., 1990, BASICS QUALITATIVE R; Warshaw C, 1997, ACAD MED, V72, pS26; Wathen CN, 2003, JAMA-J AM MED ASSOC, V289, P589, DOI 10.1001/jama.289.5.589; Webb E, 2001, BRIT MED J, V323, P210, DOI 10.1136/bmj.323.7306.210; Yin R. K., 1994, APPL SOCIAL RES METH, V5, P171	22	53	54	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					618	621		10.1136/bmj.38014.627535.0B	http://dx.doi.org/10.1136/bmj.38014.627535.0B			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	803CB	14766719	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000220208100019
J	Fox, CS; Larson, MG; Leip, EP; Culleton, B; Wilson, PWF; Levy, D				Fox, CS; Larson, MG; Leip, EP; Culleton, B; Wilson, PWF; Levy, D			Predictors of new-onset kidney disease in a community-based population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; CORONARY HEART-DISEASE; BLOOD-PRESSURE CONTROL; 3RD NATIONAL-HEALTH; SERUM CREATININE; CARDIOVASCULAR OUTCOMES; CLINICAL EPIDEMIOLOGY; RISK-FACTORS; HYPERTENSION; PROGRESSION	Context Kidney disease is associated with an increased risk for the development of cardiovascular disease and end-stage renal disease; however, risk factors for kidney disease have not been well studied. Objective To identify predictors of the development of new-onset kidney disease. Design, Setting, and Participants A community-based, longitudinal cohort study of 2585 participants who attended both a baseline examination in 1978-1982 and a follow-up examination in 1998-2001, and who were free of kidney disease at baseline. Main Outcome Measures Kidney disease was assessed by the Modification of Diet in Renal Disease Study equation and defined by a glomerular filtration rate (GFR) in the fifth or lower percentile (less than or equal to59.25 mL/min per 1.73 m(2) in women, less than or equal to64.25 mL/min per 1.73 m(2) in men). Stepwise logistic regression was used to determine the impact of risk factors on the occurrence of new-onset kidney disease. Baseline and long-term, 12-year, averaged risk factor models were explored. Results At baseline, there were 1223 men and 1362 women, with a mean age of 43 years, who were free of preexisting kidney disease. After a mean follow-up of 18.5 years, 244 participants (9.4%) had developed kidney disease. In multivariable models, baseline age (odds ratio [OR], 2.36 per 10-year increment; 95% confidence interval [CI], 2.00-2.78), GFR (<90 mL/min per 1.73 m(2): OR, 3.01; 95% CI, 1.98-4.58; 90-119 mL/min per 1.73 m(2): OR, 1.84; 95% CI, 1.16-2.93), body mass index (OR, 1.23 per 1 SD; 95% CI, 1.08-1.41), diabetes (OR, 2.60; 95% CI, 1.44-4.70), and smoking (OR, 1.42; 95% CI, 1.06-1.91) were related to the development of kidney disease. In addition to baseline age and GFR, the long-term, averaged risk factors that were predictive of kidney disease included hypertension (OR, 1.57; 95% CI, 1.17-2.12), high-density lipoprotein cholesterol level (OR, 0.80 per 1 SD; 95% CI, 0.69-0.92), and diabetes (OR, 2.38; 95% CI, 1.45-3.92). Compared with a normal GFR (>= 120 mL/min per 1.73 m(2)), a mildly reduced GFR (<90 mL/min per 1.73 m(2)) predicted a 3-fold odds of progression to kidney disease (OR, 2.95; 95% CI, 1.94-4.49). Conclusions Established cardiovascular disease risk factors are associated with the development of new-onset kidney disease. Patients with a mildly reduced GFR should be monitored for progression to kidney disease.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Calgary, Foothills Hosp, Calgary, AB, Canada	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; University of Calgary	Fox, CS (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	caroline@fram.nhlbi.nih.gov	Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Wilson, Peter W.F./J-2455-2016	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-25195] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Bethesda, 2002, US REN DAT SYST USRD; Bleyer AJ, 2000, KIDNEY INT, V57, P2072, DOI 10.1046/j.1523-1755.2000.00056.x; Brancati FL, 1997, JAMA-J AM MED ASSOC, V278, P2069, DOI 10.1001/jama.278.23.2069; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Briganti EM, 2002, AM J KIDNEY DIS, V40, P704, DOI 10.1053/ajkd.2002.35677; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Coresh J, 2001, ARCH INTERN MED, V161, P1207, DOI 10.1001/archinte.161.9.1207; Culleton BF, 1999, ARCH INTERN MED, V159, P1785, DOI 10.1001/archinte.159.15.1785; CUPPLES LA, 1987, NIH PUBLICATION; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Iseki K, 1997, KIDNEY INT, V51, P850, DOI 10.1038/ki.1997.119; Kambham N, 2001, KIDNEY INT, V59, P1498, DOI 10.1046/j.1523-1755.2001.0590041498.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Kasiske BL, 1998, AM J KIDNEY DIS, V32, pS142, DOI 10.1053/ajkd.1998.v32.pm9820472; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523-1755.2003.00838.x; Manjunath G, 2003, J AM COLL CARDIOL, V41, P47, DOI 10.1016/S0735-1097(02)02663-3; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; MANTTARI M, 1995, HYPERTENSION, V26, P670, DOI 10.1161/01.HYP.26.4.670; Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x; Parfrey PS, 1999, J AM SOC NEPHROL, V10, P1606; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; PERRY HM, 1995, HYPERTENSION, V25, P587, DOI 10.1161/01.HYP.25.4.587; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Pinto-Sietsma SJ, 2000, ANN INTERN MED, V133, P585, DOI 10.7326/0003-4819-133-8-200010170-00008; Regalado M, 2000, AM J KIDNEY DIS, V35, P687, DOI 10.1016/S0272-6386(00)70017-5; Ruilope LM, 2001, J AM SOC NEPHROL, V12, P218, DOI 10.1681/ASN.V122218; Samuelsson O, 1997, NEPHROL DIAL TRANSPL, V12, P1908, DOI 10.1093/ndt/12.9.1908; *SAS I INC, 2000, SAS STAT US GUID VER, P1901; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tozawa M, 2002, KIDNEY INT, V62, P956, DOI 10.1046/j.1523-1755.2002.00506.x; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Young JH, 2002, J AM SOC NEPHROL, V13, P2776, DOI 10.1097/01.ASN.0000031805.09178.37	45	885	921	1	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					844	850		10.1001/jama.291.7.844	http://dx.doi.org/10.1001/jama.291.7.844			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970063	Bronze			2022-12-28	WOS:000189000400022
J	Panian, J; Wiltschko, D				Panian, J; Wiltschko, D			Ramp initiation in a thrust wedge	NATURE			English	Article							OVERTHRUST BELT; MECHANICS; TECTONICS; FORELAND; SHEETS; MOTION	Collisional mountain belts are characterized by fold and thrust belts that grow through sequential stacking of thrust sheets from the interior (hinterland) to the exterior (foreland) of the mountain belt(1-5). Each of these sheets rides on a fault that cuts up through the stratigraphic section on inclined ramps that join a flat basal fault at depth. Although this stair-step or ramp-flat geometry is well known, there is no consensus on why a particular ramp forms where it does. Perturbations in fault shape(6,7), stratigraphy(8,9), fluid pressure(10,11), folding(2,12), and surface slope(13,14) have all been suggested as possible mechanisms. Here we show that such pre-existing inhomogeneities, though feasible causes, are not required. Our computer simulations show that a broad foreland-dipping plastic strain band forms at the surface near the topographic inflection produced by the previous ramp. This strain band then migrates towards the rigid base, where the plastic strain is preferentially concentrated in a thrust ramp. Subsequent ramps develop toward the foreland in a similar fashion. Syntectonic erosion and deposition may strongly control the location of thrust ramps by enhancing or removing the surface point of initiation.	Texas A&M Univ, Dept Geol & Geophys, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Tectonophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Panian, J (corresponding author), Texas A&M Univ, Dept Geol & Geophys, College Stn, TX 77843 USA.	jpanian@neo.tamu.edu						Armstrong F. C., 1965, AAPG BULL, V49, P1847; Bally A.W., 1986, MEMORIE SOC GEOLOGIC, V35, P257; Bally A.W., 1966, B CAN PETROL GEOL, V14, P337; BOMBOLAKIS EG, 1986, J STRUCT GEOL, V8, P281, DOI 10.1016/0191-8141(86)90049-0; CELLO G, 1988, TECTONICS, V7, P261, DOI 10.1029/TC007i002p00261; CHAPPLE WM, 1978, GEOL SOC AM BULL, V89, P1189, DOI 10.1130/0016-7606(1978)89<1189:MOTFB>2.0.CO;2; Dahlstrom C. D., 1970, B CAN PETROL GEOL, V18, P332; DAVIES RK, 1990, GEOL SOC LOND SPEC P, V54, P123; DAVIS D, 1983, J GEOPHYS RES, V88, P1153, DOI 10.1029/JB088iB02p01153; DIXON JS, 1982, AAPG BULL, V66, P1560; ELLIOTT D, 1976, J GEOPHYS RES, V81, P949, DOI 10.1029/JB081i005p00949; GOFF D, 1992, J STRUCT GEOL, V14, P437, DOI 10.1016/0191-8141(92)90104-5; Goff DF, 1996, J GEOPHYS RES-SOL EA, V101, P11341, DOI 10.1029/96JB00172; Handin J, 1957, AAPG AM ASS PET GEOL, V41, P1; Hibbitt H.D., 1997, ABAQUS THEORY MANUAL; HILL KC, 1991, AAPG BULL, V75, P857; JORDAN TE, 1993, J GEOL, V101, P135, DOI 10.1086/648213; KNIPE RJ, 1985, J STRUCT GEOL, V7, P1, DOI 10.1016/0191-8141(85)90110-5; KRAIG DH, 1987, AAPG BULL, V99, P654; MAKEL G, 1993, TECTONOPHYSICS, V226, P167, DOI 10.1016/0040-1951(93)90116-2; Malvern L.E, 1969, INTRO MECH CONTINUOU, P306; MANDL G, 1981, GEOL SOC LOND SPEC P, P79; PANIAN J, 1990, J GEOPHYS RES, V86, P8607; PLATT JP, 1988, GEOL RUNDSCH, V77, P577, DOI 10.1007/BF01832399; Price R. A., 1970, GEOL ASS CAN, V6, P7; Royse Jr F., 1975, S DEEP DRILLING CENT, P41; SUPPE J., 1980, P GEOL SOC CHINA, V23, P46; WILLIAMS GD, 1985, J STRUCT GEOL, V7, P11, DOI 10.1016/0191-8141(85)90111-7; WILTSCHKO DV, 1983, AAPG BULL, V67, P1304; WILTSCHKO DV, 1982, GEOL SOC AM MEM, V158, P177	30	14	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 12	2004	427	6975					624	627		10.1038/nature02334	http://dx.doi.org/10.1038/nature02334			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961118				2022-12-28	WOS:000188875300038
J	Lees, KR; Muir, KW; Ford, I; Reid, JL; Mendelow, AD; Sandercock, PAG; Bath, PMW; Lees, KR; Ford, I; Muir, KW; Lees, KR; Bath, PMW; Chen, C; Davis, SM; Muir, KW; Phillips, SJ; Saver, J; Vanhooren, G; Forbes, C; Murray, G; Bone, I; Ford, I; Norrie, J; Kean, S; Robertson, M; Murray, H; McIlvenna, Y; Gardner, A; Bradford, A; Fenton, J; Sakhri, A; Rodger, M; Sanmuganathan, P; Milia, P; Chong, V; Teasdale, E; Muir, KW; Lees, KR; Ford, I; Davis, S; Donnan, G; Crimmins, D; Hankey, G; Vanhooren, G; Phillips, S; Shuaib, A; Bailey, P; Jaramillo, A; Lisheng, L; Li, KB; Jiang, XD; Gao, B; Jia, QS; Cai, ZL; Zhang, JP; Feng, HL; Xu, CL; Zhang, Q; Ma, C; Zhang, HY; Wang, AH; Yu, SL; Cao, YB; Wang, XH; Li, YW; Yuan, XD; Meng, LH; Li, L; Zhang, LH; He, YJ; Zhang, XJ; Ji, H; Wang, JL; Li, YH; Cenek, M; Vlachova, I; Cheung, R; Gallai, V; Parnetti, L; Chen, C; Haur, LS; Alvaro, LC; Ozdemir, G; Lees, KR; Nandi, K; Muir, KW; Barrett, J; Sangster, G; Ford, G; McLeod, MJ; Dijkhuizen, R; Grant, R; Adams, K; Wani, M; Steven, M; Srivastava, PK; Bland, R; Curless, R; Evans, M; Murphy, P; Bruce, D; Jenkinson, D; Sharma, A; Power, M; Scane, A; Bishop-Miller, J; Roffe, C; Sleight, P; Deering, A; Kalra, L; Bath, P; Fulcher, RA; Chaudhury, MD; Bath, P; Ardron, M; Lindley, R; Chadha, DK; Hussain, R; Kelly, J; Villar, T; Athulathmudali, C; Seddon, D; Dewar, RI; Watt, M; Kemp, T; Robinson, T; Sharma, J; Hudson, C; Erwin, L; Ali, MS; Forsyth, D; Farag, R; Ross, I; Tsang, P; Kafetz, K; Tyrell, P; Ghosh, SK; Patterson, J; Fricker, R; Kidwell, C; Neff, S; Saver, J; Friday, G; Mattio, T; Hwang, TL; Simon, L; Burke, J				Lees, KR; Muir, KW; Ford, I; Reid, JL; Mendelow, AD; Sandercock, PAG; Bath, PMW; Lees, KR; Ford, I; Muir, KW; Lees, KR; Bath, PMW; Chen, C; Davis, SM; Muir, KW; Phillips, SJ; Saver, J; Vanhooren, G; Forbes, C; Murray, G; Bone, I; Ford, I; Norrie, J; Kean, S; Robertson, M; Murray, H; McIlvenna, Y; Gardner, A; Bradford, A; Fenton, J; Sakhri, A; Rodger, M; Sanmuganathan, P; Milia, P; Chong, V; Teasdale, E; Muir, KW; Lees, KR; Ford, I; Davis, S; Donnan, G; Crimmins, D; Hankey, G; Vanhooren, G; Phillips, S; Shuaib, A; Bailey, P; Jaramillo, A; Lisheng, L; Li, KB; Jiang, XD; Gao, B; Jia, QS; Cai, ZL; Zhang, JP; Feng, HL; Xu, CL; Zhang, Q; Ma, C; Zhang, HY; Wang, AH; Yu, SL; Cao, YB; Wang, XH; Li, YW; Yuan, XD; Meng, LH; Li, L; Zhang, LH; He, YJ; Zhang, XJ; Ji, H; Wang, JL; Li, YH; Cenek, M; Vlachova, I; Cheung, R; Gallai, V; Parnetti, L; Chen, C; Haur, LS; Alvaro, LC; Ozdemir, G; Lees, KR; Nandi, K; Muir, KW; Barrett, J; Sangster, G; Ford, G; McLeod, MJ; Dijkhuizen, R; Grant, R; Adams, K; Wani, M; Steven, M; Srivastava, PK; Bland, R; Curless, R; Evans, M; Murphy, P; Bruce, D; Jenkinson, D; Sharma, A; Power, M; Scane, A; Bishop-Miller, J; Roffe, C; Sleight, P; Deering, A; Kalra, L; Bath, P; Fulcher, RA; Chaudhury, MD; Bath, P; Ardron, M; Lindley, R; Chadha, DK; Hussain, R; Kelly, J; Villar, T; Athulathmudali, C; Seddon, D; Dewar, RI; Watt, M; Kemp, T; Robinson, T; Sharma, J; Hudson, C; Erwin, L; Ali, MS; Forsyth, D; Farag, R; Ross, I; Tsang, P; Kafetz, K; Tyrell, P; Ghosh, SK; Patterson, J; Fricker, R; Kidwell, C; Neff, S; Saver, J; Friday, G; Mattio, T; Hwang, TL; Simon, L; Burke, J		IMAGES Study Investigators	Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial	LANCET			English	Article							ACUTE ISCHEMIC-STROKE; SULFATE; NEUROPROTECTION; GLUTAMATE	Background Magnesium is neuroprotective in animal models of stroke, and findings of small clinical pilot trials suggest potential benefit in people. We aimed to test whether intravenous magnesium sulphate, given within 12 h of stroke onset, reduces death or disability at 90 days. Methods 2589 patients were randomised within 12 h of acute stroke to receive 16 mmol MgSO4 intravenously over 15 min and then 65 mmol over 24 h, or matching placebo. Primary outcome was a global endpoint statistic expressed as the common odds ratio for death or disability at day 90. Secondary outcomes were mortality and death or disability, variously defined as Barthel score less than 95, Barthel score less than 60, and modified Rankin scale more than 1. Predefined subgroup analyses were for the primary endpoint in patients in whom treatment commenced within 6 h versus after 6 h, ischaemic versus non-ischaemic strokes, and cortical stroke syndromes versus non-cortical strokes. Intention-to-treat and efficacy analyses were done. Findings The efficacy dataset included 2386 patients. Primary outcome was not improved by magnesium (odds ratio 0.95, 95% CI 0.80-1.13, p=0.59). Mortality was slightly higher in the magnesium-treated group than in the placebo group (hazard ratio 1.18, 95% CI 0.97-1.42, p=0.098). Secondary outcomes did not show any treatment effect. Planned subgroup analyses showed benefit of magnesium in non-cortical strokes (p=0.011) whereas greater benefit had been expected in the cortical group. Interpretation Magnesium given within 12 h of acute stroke does not reduce the chances of death or disability significantly, although it may be of benefit in lacunar strokes.	Univ Glasgow, Western Infirm, Gardiner Inst, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ Melbourne, Parkville, Vic 3052, Australia; Dalhousie Univ, Halifax, NS, Canada; Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland	University of Glasgow; University of Melbourne; Dalhousie University; University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Gardiner Inst, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk	Roffe, Christine/AAT-5611-2020; Hankey, Graeme J/H-4968-2014; Davis, Stephen M/L-5260-2013; Ford, Gary/AAY-6405-2020; Murray, Heather/GQY-8016-2022; Vanhooren, Geert/H-4433-2011; Milia, Paolo/Q-8099-2018; Ford, Ian/ABE-6145-2020; Mendelow, Alexander/AAW-2878-2021; Lindley, Richard/B-8148-2013; Chen, Christopher/E-7023-2013; Ford, Gary A/A-6353-2012; DONNAN, GEOFFREY A/A-9947-2008; Muir, Keith W/A-7670-2011; Bath, Philip/F-9020-2011	Roffe, Christine/0000-0002-5259-6649; Hankey, Graeme J/0000-0002-6044-7328; Davis, Stephen M/0000-0003-0962-2300; Ford, Gary/0000-0001-8719-4968; Vanhooren, Geert/0000-0001-6818-9346; Milia, Paolo/0000-0002-7204-4104; Lindley, Richard/0000-0002-0104-5679; Chen, Christopher/0000-0002-1047-9225; Muir, Keith W/0000-0001-9535-022X; Saver, Jeffrey/0000-0001-9141-2251; Bath, Philip/0000-0003-2734-5132				[Anonymous], 2003, COCHRANE DATABASE SY; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BRADFORD APJ, 1998, CEREBROVASC DIS, V8, P86; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; CHI OZ, 1990, ARCH INT PHARMACOD T, V304, P196; COLLINS R, 1995, LANCET, V345, P669; Crowther CA, 2003, JAMA-J AM MED ASSOC, V290, P2669, DOI 10.1001/jama.290.20.2669; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gerraty RP, 2002, STROKE, V33, P2019, DOI 10.1161/01.STR.0000020841.74704.5B; Gorelick PB, 2000, LANCET, V355, P1925, DOI 10.1016/S0140-6736(00)02318-7; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; Lampl Y, 2001, CLIN NEUROPHARMACOL, V24, P11, DOI 10.1097/00002826-200101000-00003; Lees KR, 2003, LANCET NEUROL, V2, P54, DOI 10.1016/S1474-4422(03)00267-9; Lin JY, 2002, LIFE SCI, V71, P803, DOI 10.1016/S0024-3205(02)01738-1; MAHONEY F I, 1965, Md State Med J, V14, P61; Marinov MB, 1996, J NEUROSURG, V85, P117, DOI 10.3171/jns.1996.85.1.0117; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Muir KW, 1998, STROKE, V29, P918, DOI 10.1161/01.STR.29.5.918; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RANKIN J, 1957, Scott Med J, V2, P200; RANSOM BR, 1990, STROKE, V21, P52; Samsa GP, 2001, STROKE, V32, P669, DOI 10.1161/01.STR.32.3.669; Saver JL, 2002, STROKE, V33, P353; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Toni D, 2000, NEUROLOGY, V54, P684, DOI 10.1212/WNL.54.3.684; WESTER PO, 1984, ACTA NEUROL SCAND, V70, P143; Yang Y, 2000, NEUROSCI LETT, V285, P119, DOI 10.1016/S0304-3940(00)01048-X; Young FB, 2003, STROKE, V34, P2676, DOI 10.1161/01.STR.0000096210.36741.E7	30	287	315	1	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					439	445						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962524				2022-12-28	WOS:000188999500010
J	Dumestre, F; Chaudret, B; Amiens, C; Renaud, P; Fejes, P				Dumestre, F; Chaudret, B; Amiens, C; Renaud, P; Fejes, P			Superlattices of iron nanocubes synthesized from Fe[N(SiMe3)(2)](2)	SCIENCE			English	Article							MAGNETIC-PROPERTIES; NANOCRYSTAL SUPERLATTICES; COBALT NANORODS; NANOPARTICLES; SHAPE; PARTICLES	The reaction of the metal-organic precursor Fe[N(SiMe3)(2)](2) with H-2 in the presence of a long-chain acid and a long-chain amine in various proportions produces monodisperse zerovalent iron nanoparticles. These Fe particles display magnetic properties that match those of bulk iron as evidenced by magnetic and Mossbauer measurements. The nanoparticles adopt a cubic shape with edges of 7 nanometers and are incorporated into extended crystalline superlattices containing nanocubes in close proximity and with their crystallographic axes aligned. These superlattices are formed in solution, precipitate in high yield, and may be redissolved and redeposited as two-dimensional arrays.	CNRS, Chim Coordinat Lab, F-31077 Toulouse 04, France; Digital DNA Labs, Semicond Prod Sector, F-31023 Toulouse, France; Motorola Inc, Semicond Prod Sector, Digital DNA Labs, Tempe, AZ 85824 USA	Centre National de la Recherche Scientifique (CNRS); NXP Semiconductors; Freescale Semiconductor	Chaudret, B (corresponding author), CNRS, Chim Coordinat Lab, 205 Route Narbonne, F-31077 Toulouse 04, France.	chaudret@lcc-toulouse.fr						ANDERSEN RA, 1988, INORG CHEM, V27, P1782, DOI 10.1021/ic00283a022; Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; Black CT, 2000, SCIENCE, V290, P1131, DOI 10.1126/science.290.5494.1131; Cordente N, 2001, NANO LETT, V1, P565, DOI 10.1021/nl0100522; Dumestre F, 2002, ANGEW CHEM INT EDIT, V41, P4286, DOI 10.1002/1521-3773(20021115)41:22<4286::AID-ANIE4286>3.0.CO;2-M; Dumestre F, 2003, ANGEW CHEM INT EDIT, V42, P5213, DOI 10.1002/anie.200352090; EDELSTEIN AS, 1991, SCIENCE, V251, P1590, DOI 10.1126/science.251.5001.1590; Farrell D, 2003, J PHYS CHEM B, V107, P11022, DOI 10.1021/jp0351831; GRINSTAFF MW, 1993, PHYS REV B, V48, P269, DOI 10.1103/PhysRevB.48.269; Lee HK, 2003, J APPL PHYS, V93, P7047, DOI 10.1063/1.1557396; Mallinson J. C., 1996, MAGNETORESISTIVE HEA; Murray CB, 2001, IBM J RES DEV, V45, P47, DOI 10.1147/rd.451.0047; MURRAY CB, 2003, 225 AM CHEM SOC NAT; Nayral C, 2000, CHEM-EUR J, V6, P4082, DOI 10.1002/1521-3765(20001117)6:22<4082::AID-CHEM4082>3.0.CO;2-S; Park SJ, 2000, J AM CHEM SOC, V122, P8581, DOI 10.1021/ja001628c; Peng ZA, 2001, J AM CHEM SOC, V123, P1389, DOI 10.1021/ja0027766; Puntes VF, 2001, SCIENCE, V291, P2115, DOI 10.1126/science.1057553; Puntes VF, 2002, J AM CHEM SOC, V124, P12874, DOI 10.1021/ja027262g; Respaud M, 1998, PHYS REV B, V57, P2925, DOI 10.1103/PhysRevB.57.2925; Soulantica K, 2003, ANGEW CHEM INT EDIT, V42, P1945, DOI 10.1002/anie.200250484; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Suslick KS, 1996, J AM CHEM SOC, V118, P11960, DOI 10.1021/ja961807n	22	452	458	1	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					821	823		10.1126/science.1092641	http://dx.doi.org/10.1126/science.1092641			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764874				2022-12-28	WOS:000188753800052
J	Friedman, N				Friedman, N			Inferring cellular networks using probabilistic graphical models	SCIENCE			English	Review							REGULATORY NETWORKS; BAYESIAN NETWORKS; GENETIC NETWORK; EXPRESSION	High-throughput genome-wide molecular assays, which probe cellular networks from different perspectives, have become central to molecular biology. Probabilistic graphical models are useful for extracting meaningful biological insights from the resulting data sets. These models provide a concise representation of complex cellular networks by composing simpler submodels. Procedures based on well-understood principles for inferring such models from data facilitate a model-based methodology for analysis and discovery. This methodology and its capabilities are illustrated by several recent applications to gene expression data.	Hebrew Univ Jerusalem, Sch Comp Sci & Engn, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Friedman, N (corresponding author), Hebrew Univ Jerusalem, Sch Comp Sci & Engn, IL-91904 Jerusalem, Israel.	nir@cs.huji.ac.il	Friedman, Nir/H-9692-2012	Friedman, Nir/0000-0002-9678-3550				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barash Y, 2002, J COMPUT BIOL, V9, P169, DOI 10.1089/10665270252935403; Buntine WL, 1994, J ARTIF INTELL RES, V2, P159, DOI 10.1613/jair.62; Cooper GF, 1999, UNCERTAINTY IN ARTIFICIAL INTELLIGENCE, PROCEEDINGS, P116; Deng M., 2003, P 7 INT C COMP MOL B, P95; Durbin R., 1998, BIOL SEQUENCE ANAL P; Friedman N, 2000, J COMPUT BIOL, V7, P601, DOI 10.1089/106652700750050961; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Getoor L, 2001, RELATIONAL DATA MINING, P307; HARTEMINK AJ, 2001, PAC S BIOCOMPUT, V6, P422; Hartemink Alexander J, 2002, Pac Symp Biocomput, P437; HECKERMAN D, 1995, MACH LEARN, V20, P197, DOI 10.1007/BF00994016; Holmes I, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P202; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Imoto Seiya, 2002, Pac Symp Biocomput, P175; Kim Sun Yong, 2003, Briefings in Bioinformatics, V4, P228, DOI 10.1093/bib/4.3.228; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Ong Irene M, 2002, Bioinformatics, V18 Suppl 1, pS241; Pe'er D, 2001, Bioinformatics, V17 Suppl 1, pS215; Pe'er Dana, 2002, Bioinformatics, V18 Suppl 1, pS258; Pearl J., 1988, PROBABILISTIC REASON, DOI 10.1016/B978-0-08-051489-5.50008-4; Perrin BE, 2003, BIOINFORMATICS, V19, pII138, DOI 10.1093/bioinformatics/btg1071; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Segal E, 2003, BIOINFORMATICS, V19, pi273, DOI 10.1093/bioinformatics/btg1038; Segal E, 2003, BIOINFORMATICS, V19, pi264, DOI 10.1093/bioinformatics/btg1037; Segal E, 2001, Bioinformatics, V17 Suppl 1, pS243; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; SEGAL E, 2002, P 6 ANN INT C COMP M; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Spirtes P., 2000, CAUSATION PREDICTION, Vsecond; Tamada Y, 2003, BIOINFORMATICS, V19, pII227, DOI 10.1093/bioinformatics/btg1082; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Toh H, 2002, BIOINFORMATICS, V18, P287, DOI 10.1093/bioinformatics/18.2.287; Vance W, 2002, P NATL ACAD SCI USA, V99, P5816, DOI 10.1073/pnas.022049699; Yeang C.H., 2003, P 7 ANN INT C RES CO, P312	41	792	843	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					799	805		10.1126/science.1094068	http://dx.doi.org/10.1126/science.1094068			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764868				2022-12-28	WOS:000188753800046
J	Pool, JA; Lobkovsky, E; Chirik, PJ				Pool, JA; Lobkovsky, E; Chirik, PJ			Hydrogenation and cleavage of dinitrogen to ammonia with a zirconium complex	NATURE			English	Article							DIHYDROGEN; ACTIVATION; REDUCTION; MOLECULE	Molecular nitrogen is relatively inert owing to the strength of its triple bond, nonpolarity and high ionization potential. As a result, the fixation of atmospheric nitrogen to ammonia under mild conditions has remained a challenge to chemists for more than a century. Although the Haber-Bosch process produces over 100 million tons of ammonia annually(1) for the chemical industry and agriculture(2), it requires high temperature and pressure, in addition to a catalyst(3), to induce the combination of hydrogen (H-2) and nitrogen (N-2). Coordination of molecular nitrogen to transition metal complexes can activate and even rupture the strong N-N bond(4) under mild conditions, with protonation yielding ammonia in stoichiometric(5) and even catalytic yields(6). But the assembly of N-H bonds directly from H-2 and N-2 remains challenging: adding H-2 to a metal-N-2 complex results in the formation of N-2 and metal-hydrogen bonds or, in the case of one zirconium complex(7), in formation of one N-H bond and a bridging hydride. Here we extend our work on zirconium complexes containing cyclopentadienyl ligands(8,9) and show that adjustment of the ligands allows direct observation of N-H bond formation from N-2 and H-2. Subsequent warming of the complex cleaves the N-N bond at 45degreesC, and continued hydrogenation at 85degreesC results in complete fixation to ammonia.	Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Chirik, PJ (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	pc92@cornell.edu						Basch H, 1999, J AM CHEM SOC, V121, P5754, DOI 10.1021/ja984408w; Basch H, 2000, ORGANOMETALLICS, V19, P3393, DOI 10.1021/om000389z; Bielawa H, 2001, ANGEW CHEM INT EDIT, V40, P1061, DOI 10.1002/1521-3773(20010316)40:6<1061::AID-ANIE10610>3.3.CO;2-2; CHANEY AL, 1962, CLIN CHEM, V8, P130; Chirik PJ, 2002, ANGEW CHEM INT EDIT, V41, P3463, DOI 10.1002/1521-3773(20020916)41:18<3463::AID-ANIE3463>3.0.CO;2-P; CUMMINS CC, 1988, J AM CHEM SOC, V110, P8731, DOI 10.1021/ja00234a044; Fryzuk MD, 2000, COORDIN CHEM REV, V200, P379, DOI 10.1016/S0010-8545(00)00264-2; Fryzuk MD, 2003, CHEM REC, V3, P2, DOI 10.1002/tcr.10044; Fryzuk MD, 1997, SCIENCE, V275, P1445, DOI 10.1126/science.275.5305.1445; Hidai M, 1999, COORDIN CHEM REV, V185-6, P99, DOI 10.1016/S0010-8545(98)00250-1; HILLHOUSE GL, 1984, J AM CHEM SOC, V106, P5472, DOI 10.1021/ja00331a015; JANIAK C, 1995, J ORGANOMET CHEM, V501, P219, DOI 10.1016/0022-328X(95)05647-8; MANRIQUEZ JM, 1978, J AM CHEM SOC, V100, P3078, DOI 10.1021/ja00478a020; MANRIQUEZ JM, 1974, J AM CHEM SOC, V96, P6229, DOI 10.1021/ja00826a071; Pool JA, 2003, J AM CHEM SOC, V125, P2241, DOI 10.1021/ja020960g; SANNER RD, 1976, J AM CHEM SOC, V98, P8351, DOI 10.1021/ja00442a007; Schlogl R, 2003, ANGEW CHEM INT EDIT, V42, P2004, DOI 10.1002/anie.200301553; Smil V., 2001, ENRICHING THE EARTH; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326	19	449	456	11	362	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					527	530		10.1038/nature02274	http://dx.doi.org/10.1038/nature02274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	770KM	14765191				2022-12-28	WOS:000188721800037
J	Song, TRA; Helmberger, DV; Grand, SP				Song, TRA; Helmberger, DV; Grand, SP			Low-velocity zone atop the 410-km seismic discontinuity in the northwestern United States	NATURE			English	Article							TRANSITION-ZONE; UPPER-MANTLE; NORTH-AMERICA; TOPOGRAPHY; SUBDUCTION; PRECURSORS; MAGMATISM; STACKING; BENEATH; DENSITY	The seismic discontinuity at 410 km depth in the Earth's mantle is generally attributed to the phase transition of (Mg,Fe)(2)SiO4 (refs 1, 2) from the olivine to wadsleyite structure. Variation in the depth of this discontinuity is often taken as a proxy for mantle temperature owing to its response to thermal perturbations. For example, a cold anomaly would elevate the 410-km discontinuity, because of its positive Clapeyron slope, whereas a warm anomaly would depress the discontinuity. But trade-offs between seismic wave-speed heterogeneity and discontinuity topography often inhibit detailed analysis of these discontinuities, and structure often appears very complicated. Here we simultaneously model seismic refracted waves and scattered waves from the 410-km discontinuity in the western United States to constrain structure in the region. We find a low-velocity zone, with a shear-wave velocity drop of 5%, on top of the 410-km discontinuity beneath the northwestern United States, extending from southwestern Oregon to the northern Basin and Range province. This low-velocity zone has a thickness that varies from 20 to 90 km with rapid lateral variations. Its spatial extent coincides with both an anomalous composition of overlying volcanism and seismic 'receiver-function' observations observed above the region. We interpret the low-velocity zone as a compositional anomaly, possibly due to a dense partial-melt layer, which may be linked to prior subduction of the Farallon plate and back-arc extension. The existence of such a layer could be indicative of high water content in the Earth's transition zone.	CALTECH, Div Geol & Planetary Sci, Seismol Lab, Pasadena, CA 91125 USA; UT Austin, Dept Geol Sci, Austin, TX 78749 USA	California Institute of Technology; University of Texas System; University of Texas Austin	Song, TRA (corresponding author), CALTECH, Div Geol & Planetary Sci, Seismol Lab, Pasadena, CA 91125 USA.	alex@gps.caltech.edu	Grand, Stephen/B-4238-2011; Song, Teh-Ru Alex/I-7563-2012					Agee CB, 1998, PHYS EARTH PLANET IN, V107, P63, DOI 10.1016/S0031-9201(97)00124-6; Angel RJ, 2001, PHYS EARTH PLANET IN, V127, P181, DOI 10.1016/S0031-9201(01)00227-8; AWATER T, 1998, INT GEOL REV, V40, P375; Bercovici D, 2003, NATURE, V425, P39, DOI 10.1038/nature01918; Chen GQ, 2002, PHYS EARTH PLANET IN, V134, P35, DOI 10.1016/S0031-9201(02)00080-8; Dixon JE, 2002, NATURE, V420, P385, DOI 10.1038/nature01215; Dueker KG, 1997, J GEOPHYS RES-SOL EA, V102, P8313, DOI 10.1029/96JB03857; FITTON JG, 1991, J GEOPHYS RES-SOLID, V96, P13693, DOI 10.1029/91JB00372; Flanagan MP, 1998, J GEOPHYS RES-SOL EA, V103, P2673, DOI 10.1029/97JB03212; Flanagan MP, 1998, J GEOPHYS RES-SOL EA, V103, P21165, DOI 10.1029/98JB00595; GILBERT HJ, 2003, J GEOPHYS RES, V109; GRAND SP, 1984, GEOPHYS J ROY ASTR S, V76, P399, DOI 10.1111/j.1365-246X.1984.tb05053.x; Gu YJ, 2003, GEOPHYS J INT, V154, P559, DOI 10.1046/j.1365-246X.2003.01967.x; Hammond WC, 2000, J GEOPHYS RES-SOL EA, V105, P10975, DOI 10.1029/2000JB900041; HART WK, 1984, GEOL SOC AM BULL, V95, P186, DOI 10.1130/0016-7606(1984)95<186:ADAAOL>2.0.CO;2; HART WK, 1985, GEOCHIM COSMOCHIM AC, V49, P131, DOI 10.1016/0016-7037(85)90197-8; Helffrich G, 2000, REV GEOPHYS, V38, P141, DOI 10.1029/1999RG000060; KEMPTON PD, 1991, J GEOPHYS RES-SOLID, V96, P13713, DOI 10.1029/91JB00373; KENNETT BLN, 1990, PHYS EARTH PLANET IN, V59, P134, DOI 10.1016/0031-9201(90)90220-R; NOLET G, 1994, J GEOPHYS RES-SOL EA, V99, P15813, DOI 10.1029/94JB00083; Ramesh DS, 2002, GEOPHYS J INT, V150, P91, DOI 10.1046/j.1365-246X.2002.01697.x; REVENAUGH J, 1994, NATURE, V369, P474, DOI 10.1038/369474a0; RIGDEN SM, 1984, SCIENCE, V226, P1071, DOI 10.1126/science.226.4678.1071; SACKS IS, 1977, J GEOPHYS RES, V82, P2011, DOI 10.1029/JB082i014p02011; SAIKIA CK, 1994, GEOPHYS J INT, V118, P142, DOI 10.1111/j.1365-246X.1994.tb04680.x; Shearer PM, 2000, GEOPHYS MONOGR SER, V117, P115, DOI DOI 10.1029/GM117P0115; STOLPER E, 1981, J GEOPHYS RES, V86, P6261, DOI 10.1029/JB086iB07p06261; van der Lee S, 2002, EARTH PLANET SC LETT, V203, P15, DOI 10.1016/S0012-821X(02)00846-4; Vinnik L, 2003, GEOPHYS RES LETT, V30; Williams Q, 2001, ANNU REV EARTH PL SC, V29, P365, DOI 10.1146/annurev.earth.29.1.365	30	229	239	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					530	533		10.1038/nature02231	http://dx.doi.org/10.1038/nature02231			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765192				2022-12-28	WOS:000188721800038
J	Young, NS; Brown, KE				Young, NS; Brown, KE			Mechanisms of disease - Parvovirus B19	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POLYMERASE-CHAIN-REACTION; COLONY FORMATION INVITRO; CHRONIC-FATIGUE-SYNDROME; ERYTHROID LINEAGE CELLS; B19 INFECTION; APLASTIC-ANEMIA; RHEUMATOID-ARTHRITIS; BONE-MARROW; CLINICAL MANIFESTATIONS; FULMINANT-HEPATITIS		NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Young, NS (corresponding author), NHLBI, Hematol Branch, NIH, Bldg 10,Rm 7C103,9000 Rockville Pike, Bethesda, MD 20892 USA.	youngn@nhlbi.nih.gov	Dagi, Hatice Turk/AAH-1682-2019	Dagi, Hatice Turk/0000-0002-0291-4987; Brown, Kevin/0000-0002-1568-683X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002319, ZIAHL002315, Z01HL002315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abkowitz JL, 1997, J INFECT DIS, V176, P269, DOI 10.1086/517264; ADIBO AO, 1998, J ULTRAS MED, V17, P547; Alger LS, 1997, INFECT DIS CLIN N AM, V11, P55, DOI 10.1016/S0891-5520(05)70341-X; ANAND A, 1987, NEW ENGL J MED, V316, P183, DOI 10.1056/NEJM198701223160403; Anderson L.J., 1997, MONOGRAPHS VIROLOGY, V20; ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; ANDERSON MJ, 1985, J MED VIROL, V15, P163, DOI 10.1002/jmv.1890150209; ANDERSON MJ, 1984, J HYG-CAMBRIDGE, V93, P85, DOI 10.1017/S0022172400060964; ANDERSON MJ, 1987, LANCET, V1, P738; Arista S, 2003, J HEPATOL, V38, P375, DOI 10.1016/S0168-8278(02)00416-6; Azzi A, 1999, TRANSFUS MED REV, V13, P194, DOI 10.1016/S0887-7963(99)80033-9; Ballou WR, 2003, J INFECT DIS, V187, P675, DOI 10.1086/368382; BANSAL GP, 1993, J INFECT DIS, V167, P1034, DOI 10.1093/infdis/167.5.1034; Barash J, 2003, IMMUNOL LETT, V88, P109, DOI 10.1016/S0165-2478(03)00075-0; Barlow GD, 2000, J INFECTION, V40, P192, DOI 10.1016/S0163-4453(00)80018-3; Beghetti M, 2000, EUR J PEDIATR, V159, P135, DOI 10.1007/s004310050034; BELL LM, 1989, NEW ENGL J MED, V321, P485, DOI 10.1056/NEJM198908243210801; BLOOM ME, 1994, INFECT AGENT DIS, V3, P279; BLOOM ME, 2001, FIELDS VIROLOGY, P2361; BROWN KE, 1994, NEW ENGL J MED, V330, P1192, DOI 10.1056/NEJM199404283301704; BROWN KE, 1994, LANCET, V343, P895, DOI 10.1016/S0140-6736(94)90011-6; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; Brown KE, 1997, REV MED VIROL, V7, P211, DOI 10.1002/(SICI)1099-1654(199712)7:4<211::AID-RMV204>3.3.CO;2-W; Brown Kevin E., 2001, Transfusion (Bethesda), V41, P130, DOI 10.1046/j.1537-2995.2001.41010130.x; Bux J, 1998, BLOOD, V91, P181, DOI 10.1182/blood.V91.1.181.181_181_186; Cassinotti P, 1998, J MED VIROL, V56, P199, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;199::AID-JMV4&gt;3.0.CO;2-2; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P81; Chipman PR, 1996, P NATL ACAD SCI USA, V93, P7502, DOI 10.1073/pnas.93.15.7502; CHORBA T, 1986, J INFECT DIS, V154, P383, DOI 10.1093/infdis/154.3.383; COSSART YE, 1975, LANCET, V1, P72; COTMORE SF, 1984, SCIENCE, V226, P1161, DOI 10.1126/science.6095448; DEFREITAS RB, 1990, J MED VIROL, V32, P203, DOI 10.1002/jmv.1890320402; Dettmeyer R, 2003, J FORENSIC SCI, V48, P183; ERDMAN DD, 1997, MG VIROLOGY, V20, P93; FAIRLEY CK, 1995, LANCET, V346, P1335, DOI 10.1016/S0140-6736(95)92346-2; FAUQUET CM, 2001, VIRUS TAXONOMY DELUX; Ferguson PJ, 1996, ARTHRITIS RHEUM, V39, P880, DOI 10.1002/art.1780390523; FINKEL TH, 1994, LANCET, V343, P1255, DOI 10.1016/S0140-6736(94)92152-0; Forestier F, 1999, BRIT J HAEMATOL, V104, P925, DOI 10.1046/j.1365-2141.1999.01241.x; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; Gabriel SE, 1999, ARTHRITIS RHEUM, V42, P1255, DOI 10.1002/1529-0131(199906)42:6<1255::AID-ANR23>3.0.CO;2-P; Goodear M, 1998, Australas Radiol, V42, P275, DOI 10.1111/j.1440-1673.1998.tb00518.x; He ZP, 2003, J MED VIROL, V69, P59, DOI 10.1002/jmv.10248; Heegaard ED, 2002, J PEDIAT HEMATOL ONC, V24, P368, DOI 10.1097/00043426-200206000-00009; Heegaard ED, 2002, CLIN MICROBIOL REV, V15, P485, DOI 10.1128/CMR.15.3.485-505.2002; Hoang MP, 1998, HUM PATHOL, V29, P1074, DOI 10.1016/S0046-8177(98)90416-6; Jacobson SK, 1997, CLIN INFECT DIS, V24, P1048, DOI 10.1086/513627; Jordan JA, 1996, AM J OBSTET GYNECOL, V174, P37, DOI 10.1016/S0002-9378(96)70370-8; KAJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646, DOI 10.1073/pnas.88.11.4646; Kerr JR, 2002, J NEUROL NEUROSUR PS, V73, P739, DOI 10.1136/jnnp.73.6.739; KERR JR, 1995, BRIT J RHEUMATOL, V34, P809; Kerr JR, 2002, J RHEUMATOL, V29, P595; Kerr JR, 2000, ANN RHEUM DIS, V59, P672, DOI 10.1136/ard.59.9.672; Koch WC, 1998, PEDIATR INFECT DIS J, V17, P489, DOI 10.1097/00006454-199806000-00011; KOCH WC, 1990, J PEDIATR-US, V116, P355, DOI 10.1016/S0022-3476(05)82820-3; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; KURTZMAN GJ, 1988, LANCET, V2, P1159; KURTZMAN GJ, 1989, BLOOD, V74, P71; KURTZMAN GJ, 1989, J CLIN INVEST, V84, P1114, DOI 10.1172/JCI114274; LANDENBERG P, 2003, ARTHRITIS RHEUM, V48, P1393; Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608; Lehmann HW, 2003, AUTOIMMUN REV, V2, P218, DOI 10.1016/S1568-9972(03)00014-4; LEVENTHAL LJ, 1991, ARTHRITIS RHEUM, V34, P1319, DOI 10.1002/art.1780341018; Levy R, 1997, Obstet Gynecol Surv, V52, P254, DOI 10.1097/00006254-199704000-00023; Lunardi C, 1998, EUR J IMMUNOL, V28, P936, DOI 10.1002/(SICI)1521-4141(199803)28:03<936::AID-IMMU936>3.3.CO;2-O; Miller E, 1998, BRIT J OBSTET GYNAEC, V105, P174, DOI 10.1111/j.1471-0528.1998.tb10048.x; MIMORI A, 1994, RHEUMATOL INT, V14, P87, DOI 10.1007/BF00300807; MIYAMURA K, 1994, P NATL ACAD SCI USA, V91, P8507, DOI 10.1073/pnas.91.18.8507; Moffatt S, 1998, J VIROL, V72, P3018, DOI 10.1128/JVI.72.4.3018-3028.1998; MOLITOR TW, 1990, CRC HDB PARVOVIRUSES, V2, P135; Moore TL, 2000, CURR OPIN RHEUMATOL, V12, P289, DOI 10.1097/00002281-200007000-00010; MOREY AL, 1992, BRIT J OBSTET GYNAEC, V99, P566, DOI 10.1111/j.1471-0528.1992.tb13822.x; MORTIMER PP, 1983, NATURE, V302, P426, DOI 10.1038/302426a0; Muzyczka N., 2001, FIELDS VIROLOGY, P2327; Naides SJ, 1998, RHEUM DIS CLIN N AM, V24, P375, DOI 10.1016/S0889-857X(05)70014-4; Nguyen QT, 1999, J CLIN MICROBIOL, V37, P2483, DOI 10.1128/JCM.37.8.2483-2487.1999; Nguyen QT, 2002, VIROLOGY, V301, P374, DOI 10.1006/viro.2002.1585; Nigro G, 2000, CLIN INFECT DIS, V31, P65, DOI 10.1086/313929; NIGRO G, 1994, LANCET, V343, P1260, DOI 10.1016/S0140-6736(94)92154-7; NIKKARI S, 1994, ANN RHEUM DIS, V53, P106, DOI 10.1136/ard.53.2.106; Notari EP, 2001, TRANSFUSION, V41, P751, DOI 10.1046/j.1537-2995.2001.41060751.x; Osaki M, 1999, ANN HEMATOL, V78, P83, DOI 10.1007/s002770050477; OSullivan MG, 1997, J VIROL, V71, P4517, DOI 10.1128/JVI.71.6.4517-4521.1997; OSULLIVAN MG, 1994, J CLIN INVEST, V93, P1571, DOI 10.1172/JCI117136; OZAWA K, 1988, J VIROL, V62, P2884, DOI 10.1128/JVI.62.8.2884-2889.1988; OZAWA K, 1986, SCIENCE, V233, P883, DOI 10.1126/science.3738514; Pankuweit S, 2003, HUM PATHOL, V34, P497, DOI 10.1016/S0046-8177(03)00078-9; PARRISH CR, 1995, BAILLIERE CLIN HAEM, V8, P57, DOI 10.1016/S0950-3536(05)80232-X; PATTISON JR, 1981, LANCET, V1, P664; PONT J, 1992, BRIT J HAEMATOL, V80, P160, DOI 10.1111/j.1365-2141.1992.tb08894.x; POTTER CG, 1987, J CLIN INVEST, V79, P1486, DOI 10.1172/JCI112978; POWARS D, 1965, NEW ENGL J MED, V273, P700, DOI 10.1056/NEJM196509232731307; Qian XH, 2002, ARCH DIS CHILD, V87, P436, DOI 10.1136/adc.87.5.436; REID DM, 1985, LANCET, V1, P422; RODIS JF, 1990, AM J OBSTET GYNECOL, V163, P1168, DOI 10.1016/0002-9378(90)90681-V; SAARINEN UM, 1986, BLOOD, V67, P1411; SAIKAWA T, 1993, J VIROL, V67, P3004, DOI 10.1128/JVI.67.6.3004-3009.1993; SAINTMARTIN J, 1990, J PEDIATR-US, V116, P1007, DOI 10.1016/S0022-3476(05)80677-8; SAUNDERS PWG, 1986, BRIT J HAEMATOL, V63, P407, DOI 10.1111/j.1365-2141.1986.tb05572.x; Schowengerdt KO, 1997, CIRCULATION, V96, P3549; SCHWARZ TF, 1989, ZBL BAKT-INT J MED M, V271, P231; Segovia JC, 1999, J VIROL, V73, P1774, DOI 10.1128/JVI.73.3.1774-1784.1999; Serjeant BE, 2001, LANCET, V358, P1779, DOI 10.1016/S0140-6736(01)06807-6; SERJEANT GR, 1981, LANCET, V2, P595; SERKE S, 1991, BRIT J HAEMATOL, V79, P6, DOI 10.1111/j.1365-2141.1991.tb07999.x; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; SHIRONO K, 1995, BRIT J HAEMATOL, V89, P923; Skjoldebrand-Sparre K, 2000, BRIT J OBSTET GYNAEC, V107, P476, DOI 10.1111/j.1471-0528.2000.tb13265.x; Smith SB, 2002, J AM ACAD DERMATOL, V47, P749, DOI 10.1067/mjd.2002.124612; Smith-Whitley K, 2004, BLOOD, V103, P422, DOI 10.1182/blood-2003-01-0069; Soderlund M, 1997, LANCET, V349, P1063, DOI 10.1016/S0140-6736(96)09110-6; Sokal EM, 1998, LANCET, V352, P1739, DOI 10.1016/S0140-6736(98)06165-0; Speyer I, 1998, CLIN EXP RHEUMATOL, V16, P576; SRIVASTAVA A, 1990, BLOOD, V76, P1997; Takahashi Y, 1998, P NATL ACAD SCI USA, V95, P8227, DOI 10.1073/pnas.95.14.8227; Tanaka A, 1998, INTERNAL MED, V37, P708, DOI 10.2169/internalmedicine.37.708; Torok TJ, 1997, MONOGR VIROL, V20, P61; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; Valeur-Jensen AK, 1999, JAMA-J AM MED ASSOC, V281, P1099, DOI 10.1001/jama.281.12.1099; Verge J, 1928, CR SOC BIOL, V99, P312; WHITE DG, 1985, LANCET, V1, P419; Wong S, 2003, J INFECT DIS, V187, P1581, DOI 10.1086/374781; WOOLF AD, 1989, ARCH INTERN MED, V149, P1153, DOI 10.1001/archinte.149.5.1153; YAEGASHI N, 1989, J VIROL, V63, P2422, DOI 10.1128/JVI.63.6.2422-2426.1989; Zadori Z, 2001, DEV CELL, V1, P291, DOI 10.1016/S1534-5807(01)00031-4; Zerbini M, 2002, PATHOL BIOL, V50, P332, DOI 10.1016/S0369-8114(02)00308-5	126	600	658	2	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					586	597		10.1056/NEJMra030840	http://dx.doi.org/10.1056/NEJMra030840			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762186				2022-12-28	WOS:000188712800010
J	Clement, G; Ahlberg, PE; Blieck, A; Blom, H; Clack, JA; Poty, E; Thorez, J; Janvier, P				Clement, G; Ahlberg, PE; Blieck, A; Blom, H; Clack, JA; Poty, E; Thorez, J; Janvier, P			Palaeogeography - Devonian tetrapod from western Europe	NATURE			English	Editorial Material									Museum Natl Hist Nat, CNRS, UMR 5143, F-75005 Paris, France; Nat Hist Museum, London SW7 5BD, England; Uppsala Univ, Dept Evolutionary Organismal Biol, S-75236 Uppsala, Sweden; USTL Sci Terre, CNRS, UMR 8014, F-59655 Villeneuve Dascq, France; Univ Cambridge, Museum Zool, Cambridge CB2 3EJ, England; Univ Liege, Dept Geol, B-4000 Liege 1, Belgium	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Natural History Museum London; Uppsala University; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; University of Cambridge; University of Liege	Clement, G (corresponding author), Museum Natl Hist Nat, CNRS, UMR 5143, F-75005 Paris, France.	janvier@mnhn.fr	Ahlberg, Per/E-8086-2013	Ahlberg, Per/0000-0001-9054-2900				Ahlberg PE, 1998, T ROY SOC EDIN-EARTH, V89, P11, DOI 10.1017/S0263593300002340; AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; CLACK JA, 2002, GAINING GROUND; Coates Michael I., 1995, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V17, P373; Daeschler EB, 1998, NATURE, V391, P133, DOI 10.1038/34317; Jarvik Erik, 1996, Fossils and Strata, V40, P1; Lohest M., 1888, ANN SOC GEOL BELG, V15, P112; LUKSEVICS E, 2003, ICHTHYOLITH ISSUES S, V7, P1302; Thorez J., 1988, TIDE INFLUENCED SEDI, P389; Thorez J., 1977, MEDEDELINGEN RIJKS G, V28, P17; Zhu M, 2002, NATURE, V420, P760, DOI 10.1038/420760a	11	52	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					412	413		10.1038/427412a	http://dx.doi.org/10.1038/427412a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749820				2022-12-28	WOS:000188470500032
J	Heath, PGT; Balfour, G; Weisner, AM; Efstratiou, A; Lamagni, TL; Tighe, H; O'Connell, LAF; Cafferkey, M; Verlander, NQ; Nicoll, A; McCartney, AC				Heath, PGT; Balfour, G; Weisner, AM; Efstratiou, A; Lamagni, TL; Tighe, H; O'Connell, LAF; Cafferkey, M; Verlander, NQ; Nicoll, A; McCartney, AC		PHLS GBS Working Grp	Group B streptococcal disease in UK and Irish infants younger than 90 days	LANCET			English	Article								The incidence, morbidity, and. mortality of group B streptococcal disease in the UK and Republic of Ireland are largely unknown. Between Feb 1, 2000, and Feb 28, 2001, we identified cases of invasive group B streptococcal disease in infants younger than 90 days through surveillance involving paediatricians, microbiologists, and parents. 568 cases were identified, equivalent to a total incidence of 0.72 per 1000 live-births (95% CI 0.66-0.78); the incidence for early-onset disease (n = 377) was 0.48 per 1000 (0.43-0.53), and for late-onset disease (n = 191) was 0.24 per 1000 (0.21-0.28). Risk factors were identifiable for 218 (58%) cases of early-onset disease. 53 infants died (overall 9.7%). We have established the minimum current burden of group B streptococcal disease in UK and Irish infants. This information will assist in the formulation of guidelines for prevention of this disease.	St George Hosp, Sch Med, Dept Child Hlth, Vaccine Inst, London SW17 0RE, England; Hlth Protect Agcy London, Ctr Communicable Dis Surveillance, London, England; Hlth Protect Agcy London, Cent Publ Hlth Lab, London, England; Hlth Protect Agcy London, Stat Unit, London, England; Rotunda Hosp, Dublin, Ireland; Royal Coll Surgeons Ireland, Dublin 2, Ireland	St Georges University London; Health Protection Agency; Health Protection Agency; Public Health England; Health Protection Agency; Royal College of Surgeons - Ireland	Heath, PGT (corresponding author), St George Hosp, Sch Med, Dept Child Hlth, Vaccine Inst, Cranmer Terrace, London SW17 0RE, England.	pheath@sghms.ac.uk	Lamagni, Theresa/I-4115-2019	Lamagni, Theresa/0000-0002-3965-8323; Heath, Paul/0000-0002-7540-7433				*BRIT PAED SURV UN, 2001, 15 ROYAL COLL PAED C; Luck S, 2003, LANCET, V361, P1953, DOI 10.1016/S0140-6736(03)13553-2; Mayon-White R T, 1985, Antibiot Chemother (1971), V35, P17; Nicoll A, 2000, ARCH DIS CHILD-FETAL, V82, pF207; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1	5	179	187	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					292	294		10.1016/S0140-6736(03)15389-5	http://dx.doi.org/10.1016/S0140-6736(03)15389-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751704				2022-12-28	WOS:000188361400013
J	Petrou, S; Mugford, M				Petrou, S; Mugford, M			Should prenatal diagnostic testing be offered to all pregnant women on economic grounds?	LANCET			English	Editorial Material							PREFERENCES		Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of Oxford; University of East Anglia	Petrou, S (corresponding author), Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England.	stavros.petrou@perinat.ox.ac.uk	Petrou, Stavros/ABD-8323-2021	Petrou, Stavros/0000-0003-3121-6050				Drummond MF, 2015, METHODS EC EVALUATIO; Hall S, 2000, BMJ-BRIT MED J, V320, P407, DOI 10.1136/bmj.320.7232.407; Jansen SJT, 2000, MED DECIS MAKING, V20, P62, DOI 10.1177/0272989X0002000108; Kuppermann M, 2000, OBSTET GYNECOL, V96, P511, DOI 10.1016/S0029-7844(00)00969-8; MCGUIRE A, 1991, PROVIDING HLTH CARE; Petrou S, 2000, J MED SCREEN, V7, P59, DOI 10.1136/jms.7.2.59; Petrou S, 2001, HEALTH ECON, V10, P775, DOI 10.1002/hec.636	7	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					258	259		10.1016/S0140-6736(03)15416-5	http://dx.doi.org/10.1016/S0140-6736(03)15416-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766FQ	14751693				2022-12-28	WOS:000188361400002
J	Kirichok, Y; Krapivinsky, G; Clapham, DE				Kirichok, Y; Krapivinsky, G; Clapham, DE			The mitochondrial calcium uniporter is a highly selective ion channel	NATURE			English	Article							RAT-LIVER MITOCHONDRIA; CA2+; TRANSPORT; MEMBRANE; TRANSLOCATION; MICRODOMAINS; INHIBITION; APOPTOSIS; CATIONS; COMPLEX	During intracellular Ca2+ signalling mitochondria accumulate significant amounts of Ca2+ from the cytosol(1,2). Mitochondrial Ca2+ uptake controls the rate of energy production(1,3,4), shapes the amplitude and spatio- temporal patterns of intracellular Ca2+ signals(1,5-8), and is instrumental to cell death(9,10). This Ca2+ uptake is undertaken by the mitochondrial Ca2+ uniporter ( MCU) located in the organelle's inner membrane(11,12). The uniporter passes Ca2+ down the electrochemical gradient maintained across this membrane without direct coupling to ATP hydrolysis or transport of other ions(11). Carriers are characterized by turnover numbers that are typically 1,000- fold lower than ion channels, and until now it has been unclear whether the MCU is a carrier or a channel(13). By patch- clamping the inner mitochondrial membrane, we identified a previously unknown Ca2+ selective ion channel sensitive to inhibitors of mitochondrial Ca2+ uptake. Our data indicate that this unique channel binds Ca2+ with extremely high affinity ( dissociation constant less than or equal to 2 nM), enabling high Ca2+ selectivity despite relatively low cytoplasmic Ca2+ concentrations. The channel is inwardly rectifying, making it especially effective for Ca2+ uptake into energized mitochondria. Thus, we conclude that the properties of the current mediated by this novel channel are those of the MCU.	Childrens Hosp, Howard Hughes Med Inst, Dept Cardiovasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Dept Cardiovasc Res, 320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; BRAGADIN M, 1979, BIOCHEMISTRY-US, V18, P5972, DOI 10.1021/bi00593a033; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Cannon B, 1979, Methods Enzymol, V55, P65; DELUCA HF, 1961, P NATL ACAD SCI USA, V47, P1744, DOI 10.1073/pnas.47.11.1744; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; DRAHOTA Z, 1969, ARCH BIOCHEM BIOPHYS, V130, P267, DOI 10.1016/0003-9861(69)90033-2; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KOSTYUK PG, 1977, J PHYSIOL-LONDON, V270, P569, DOI 10.1113/jphysiol.1977.sp011969; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SELWYN MJ, 1970, FEBS LETT, V10, P1, DOI 10.1016/0014-5793(70)80402-1; TASHMUKH.BA, 1972, FEBS LETT, V28, P239, DOI 10.1016/0014-5793(72)80721-X; VAINIO H, 1970, EUR J BIOCHEM, V12, P387, DOI 10.1111/j.1432-1033.1970.tb00863.x; VINOGRADOV A, 1973, J BIOL CHEM, V248, P5527; YING WL, 1991, BIOCHEMISTRY-US, V30, P4949, DOI 10.1021/bi00234a016	30	987	1016	4	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					360	364		10.1038/nature02246	http://dx.doi.org/10.1038/nature02246			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737170				2022-12-28	WOS:000188266200043
J	Nguyen, JH; Holmes, NC				Nguyen, JH; Holmes, NC			Melting of iron at the physical conditions of the Earth's core	NATURE			English	Article							HIGH-PRESSURES; PHASE-TRANSITIONS; TEMPERATURES; VELOCITIES; ROTATION; CURVE	Seismological data can yield physical properties of the Earth's core, such as its size and seismic anisotropy(1-3). A well- constrained iron phase diagram, however, is essential to determine the temperatures at core boundaries and the crystal structure of the solid inner core. To date, the iron phase diagram at high pressure has been investigated experimentally through both laser- heated diamond- anvil cell and shock- compression techniques, as well as through theoretical calculations(4-17). Despite these contributions, a consensus on the melt line or the high-pressure, high- temperature phase of iron is lacking. Here we report new and re- analysed sound velocity measurements of shock- compressed iron at Earth- core conditions(15). We show that melting starts at 225 +/- 3 GPa (5,100 +/- 500 K) and is complete at 260 +/- 3 GPa ( 6,100 +/- 500 K), both on the Hugoniot curve - the locus of shock- compressed states. This new melting pressure is lower than previously reported(16), and we find no evidence for a previously reported solid - solid phase transition on the Hugoniot curve near 200 GPa ( ref. 16).	Lawrence Livermore Natl Lab, Div H, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Nguyen, JH (corresponding author), Lawrence Livermore Natl Lab, Div H, Livermore, CA 94551 USA.	nguyen29@llnl.gov						AHRENS TJ, 1990, SHOCK COMPRESSION CO; Akins JA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014806; Alfe D, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165118; Andrault D, 2000, AM MINERAL, V85, P364, DOI 10.2138/am-2000-2-315; Benuzzi-Mounaix A, 2002, PHYS PLASMAS, V9, P2466, DOI 10.1063/1.1478557; Boehler R, 1997, EARTH PLANET SC LETT, V153, P223, DOI 10.1016/S0012-821X(97)00188-X; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; BOEHLER R, 1992, EARTH PLANET SC LETT, V111, P217, DOI 10.1016/0012-821X(92)90180-4; Brown J. M., 1984, Shock Waves in Condensed Matter - 1983. Proceedings of the American Physical Society Topical Conference, P91; Brown JM, 2000, J APPL PHYS, V88, P5496, DOI 10.1063/1.1319320; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; HIXSON RS, 1989, PHYS REV LETT, V62, P637, DOI 10.1103/PhysRevLett.62.637; Laio A, 2000, SCIENCE, V287, P1027, DOI 10.1126/science.287.5455.1027; Lehmann I., 1936, PUBLICATIONS BUREAU, V14, P87; LOU SN, 2003, APPL PHYS LETT, V82, P1836; LOU SN, IN PRESS PHYS EARTH; McQueen R. G., 1984, Shock Waves in Condensed Matter - 1983. Proceedings of the American Physical Society Topical Conference, P95; MCQUEEN RG, 1982, REV SCI INSTRUM, V53, P245, DOI 10.1063/1.1136937; Nguyen J. H., 1999, SHOCK COMPRESSION CO, P81; Saxena SK, 2000, AM MINERAL, V85, P372, DOI 10.2138/am-2000-2-316; SHANER JW, 1984, MATER RES SOC S P, V22, P137; Shen GY, 1998, GEOPHYS RES LETT, V25, P373, DOI 10.1029/97GL03776; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; Su WJ, 1996, SCIENCE, V274, P1883, DOI 10.1126/science.274.5294.1883; WALLACE DC, 1980, PHYS REV B, V22, P1477, DOI 10.1103/PhysRevB.22.1477; Wasserman E, 1996, PHYS REV B, V53, P8296, DOI 10.1103/PhysRevB.53.8296; WILLIAMS Q, 1987, SCIENCE, V236, P181, DOI 10.1126/science.236.4798.181; YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473; YOO CS, 1993, PHYS REV LETT, V70, P3931, DOI 10.1103/PhysRevLett.70.3931; ZELDOVICH YB, 1967, PHYSICS SHOCK WAVES	30	250	259	0	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					339	342		10.1038/nature02248	http://dx.doi.org/10.1038/nature02248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737164				2022-12-28	WOS:000188266200037
J	Jung, JH; Min, PK; Moon, YW; Shim, WH				Jung, JH; Min, PK; Moon, YW; Shim, WH			Congestive heart failure and a swollen breast	LANCET			English	Editorial Material									Yonsei Univ, Coll Med, Yonsei Cardiovasc Ctr, Div Cardiovasc, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Shim, WH (corresponding author), Yonsei Univ, Coll Med, Yonsei Cardiovasc Ctr, Div Cardiovasc, Seoul 120752, South Korea.	whshim@yumc.yonsei.ac.kr		Min, Pil-Ki/0000-0001-7033-7651				Gould D, 1998, J INTERN MED, V243, P328; MCELLIGOTT G, 1986, BRIT MED J, V292, P446, DOI 10.1136/bmj.292.6518.446; Oraedu C O, 2001, Breast J, V7, P117, DOI 10.1046/j.1524-4741.2001.007002117.x; Pluchinotta A M, 1994, Minerva Chir, V49, P1171; STOLZ JL, 1974, JAMA-J AM MED ASSOC, V229, P682, DOI 10.1001/jama.229.6.682	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					210	210		10.1016/S0140-6736(03)15327-5	http://dx.doi.org/10.1016/S0140-6736(03)15327-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738794				2022-12-28	WOS:000188243900011
J	Maisel, WH				Maisel, WH			Medical device regulation: An introduction for the practicing physician	ANNALS OF INTERNAL MEDICINE			English	Article							ADMINISTRATION MODERNIZATION ACT; PRIMER; FDA	Patient care for the practicing physician increasingly relies on medical devices. The U.S. Food and Drug Administration is responsible for the safety and effectiveness of medical devices in the United States. in addition to playing a role in the clinical use of devices, physicians may also participate in their design, production, use, and safety by expressing their need for certain products, by providing practical input and feedback into product design, by participating in device-related research, and by reporting device-related adverse events. Physicians should understand the rules that govern the approved and unapproved use of medical devices as well as device premarket evaluation and approval processes and device postmarket surveillance.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Maisel, WH (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	wmaisel@partners.org						*AM COLL CARD, 2002, CMS FDA TAK CLOS LOO; Basile EM, 1999, FOOD DRUG LAW J, V54, P519; Birnbaum D, 1999, Clin Perform Qual Health Care, V7, P97; CUSACK B, 2003, MEDICARE WONT FULLY; *DEP HHS US FOOD D, 1997, IMPR PAT CAR REP PRO; DICKENSON JG, 2002, C ENACTS DEVICE LAW; DICKINSON JG, 1997, ANOTHER BLOODY SEASO; Donawa M E, 1999, Med Device Technol, V10, P13; Feigal DW, 2003, NEW ENGL J MED, V348, P191, DOI 10.1056/NEJMp020170; Kessler L, 1998, AM J MANAG CARE, V4, pSP129; Kimbell JJ, 1996, FOOD DRUG LAW J, V51, P339; Medicare Program, 2003, FED REGISTER, V68, P55634; *MEDTR ACT DYST TH, 2003, HUM US DEV LIST CDRH; Merrill RA, 1999, HEALTH AFFAIR, V18, P96, DOI 10.1377/hlthaff.18.2.96; Monsein LH, 1997, RADIOLOGY, V205, P1; Monsein LH, 1997, RADIOLOGY, V205, P19, DOI 10.1148/radiology.205.1.9314954; Monsein LH, 1997, RADIOLOGY, V205, P10, DOI 10.1148/radiology.205.1.9314953; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; MOSS AJ, 1991, ADV DATA, V191, P1; MUNSEY RR, 1995, FOOD DRUG LAW J, P163; Nelson DB, 2001, GASTROINTEST ENDOSC, V53, P880; ONEILL WW, 1995, NEW ENGL J MED, V333, P414, DOI 10.1056/NEJM199508173330703; Pearson M, 1999, Med Device Technol, V10, P14; PHURROUGH S, 2003, NATL COVERAGE DETERM; Pilot LR, 1998, FOOD DRUG LAW J, V53, P267; Pritchard WF, 1997, RADIOLOGY, V205, P27, DOI 10.1148/radiology.205.1.9314955; SAPIRSTEIN W, 1994, CIRCULATION, V89, P1900, DOI 10.1161/01.CIR.89.4.1900; Smith JJ, 2000, FOOD DRUG LAW J, V55, P435; Smith JJ, 1999, AM J ROENTGENOL, V173, P879, DOI 10.2214/ajr.173.4.10511140; *US DEP HHS FOOD D, 1999, MAN RISKS MED PROD U; Weinstein JW, 1999, INFECT CONT HOSP EP, V20, P543, DOI 10.1086/501675; 2000, FED REG, V65, P2296; 1998, FED REG, V63, P59217; 2001, FED REG, V66, P38786; 1999, HUMANITARIAN USE DEV; 2002, FED REG, V67, P38878; 2000, MEDICARE NEWS   0511; 1995, FED REG, V60, P63577; 2003, LOS ANGELES TIM 0614; 2002, FED REG, V67, P5943; 2003, MED PRODUCT SURVEILL, V3, P21; 2001, HLTH LAW, V61, P1	42	112	114	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					296	302		10.7326/0003-4819-140-4-200402170-00012	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970153				2022-12-28	WOS:000188970400008
J	Deluga, GA; Salge, JR; Schmidt, LD; Verykios, XE				Deluga, GA; Salge, JR; Schmidt, LD; Verykios, XE			Renewable hydrogen from ethanol by autothermal reforming	SCIENCE			English	Article							HYDROCARBONS; OXIDATION; ALCOHOLS; CATALYST	Ethanol and ethanol-water mixtures were converted directly into H-2 with similar to100% selectivity and >95% conversion by catalytic partial oxidation, with a residence time on rhodium-ceria catalysts of <10 milliseconds. Rapid vaporization and mixing with air with an automotive fuel injector were performed at temperatures sufficiently low and times sufficiently fast that homogeneous reactions producing carbon, acetaldehyde, ethylene, and total combustion products can be minimized. This process has great potential for low-cost H-2 generation in fuel cells for small portable applications where liquid fuel storage is essential and where systems must be small, simple, and robust.	Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Univ Patras, Dept Chem Engn, GR-26500 Patras, Greece	University of Minnesota System; University of Minnesota Twin Cities; University of Patras	Schmidt, LD (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	schmidt@cems.umn.edu						Brown LF, 2001, INT J HYDROGEN ENERG, V26, P381, DOI 10.1016/S0360-3199(00)00092-6; Cavallaro S, 2000, ENERG FUEL, V14, P1195, DOI 10.1021/ef0000779; Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009; Fatsikostas AN, 2001, CHEM COMMUN, P851, DOI 10.1039/b101455m; Fatsikostas AN, 2002, CATAL TODAY, V75, P145, DOI 10.1016/S0920-5861(02)00057-3; Garcia L, 2000, APPL CATAL A-GEN, V201, P225, DOI 10.1016/S0926-860X(00)00440-3; Huber GW, 2003, SCIENCE, V300, P2075, DOI 10.1126/science.1085597; Krummenacher JJ, 2003, J CATAL, V215, P332, DOI 10.1016/S0021-9517(03)00011-3; Lamy C, 2001, J APPL ELECTROCHEM, V31, P799, DOI 10.1023/A:1017587310150; Liguras DK, 2003, APPL CATAL B-ENVIRON, V43, P345, DOI 10.1016/S0926-3373(02)00327-2; LIGURAS DK, IN PRESS INT J HYDRO; LIGURAS DK, IN PRESS J POWER SOU; Rostrup-Nielsen JR, 2001, PHYS CHEM CHEM PHYS, V3, P283, DOI 10.1039/b004660o; Wang M.Q., 2002, ENERGY BALANCE CORN; WHEELER C, IN PRESS J CATAL	16	851	889	7	415	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					993	997		10.1126/science.1093045	http://dx.doi.org/10.1126/science.1093045			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	773JJ	14963325				2022-12-28	WOS:000188918000040
J	Carr, A; Workman, C; Carey, D; Rogers, G; Martin, A; Baker, D; Wand, H; Law, M; Samaras, K; Emery, S; Cooper, DA				Carr, A; Workman, C; Carey, D; Rogers, G; Martin, A; Baker, D; Wand, H; Law, M; Samaras, K; Emery, S; Cooper, DA		Rosey Investigators	No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial	LANCET			English	Article							ACTIVATED RECEPTOR-GAMMA; ADIPOSE-TISSUE; ANTIRETROVIRAL THERAPY; INSULIN SENSITIVITY; INFECTED PATIENTS; CASE-DEFINITION; OPEN-LABEL; LIPODYSTROPHY; EXPRESSION; DIFFERENTIATION	Background Lipodystrophy commonly complicates antiretroviral therapy of HIV-1 infection. Thiazolidinediones such as rosiglitazone promote subcutaneous fat growth in type 2 diabetics and adults with congenital lipodystrophy, and can prevent HIV-1 protease inhibitor toxicity to adipocytes in vitro. We postulated that rosiglitazone would improve HIV lipoatrophy. Methods 108 HIV-1-infected lipoatrophic adults on antiretroviral therapy were randomised to rosiglitazone 4 mg twice daily (n=53) or matching placebo (n=55) for 48 weeks. The study had 80% power to detect a 0.5 kg difference in changes in limb fat (using dual-energy X-ray absorptiometry) between groups at week 48 by intention-to-treat analysis, and a 0.7 kg difference within each protease inhibitor stratum. Findings Limb fat increased by 0.14 kg in the rosiglitazone group and 0.18 kg in the placebo group (mean difference -0.04 kg [95%Cl-0.29 to 0.21]; p=0.74 by t test), with three participants (one on rosiglitazone and two controls), lost to follow-up. Rosiglitazone had no significant benefit on any other measure of lipodystrophy, despite large relative increases in plasma adiponectin (4.2 mmol/L [102%]; p<0.0001) and in three markers of insulin sensitivity (p=0.01 to 0.02). Six participants ceased study drug in each group, four participants (three on rosiglitazone and one control) for related adverse events. The main adverse effects, which seem to be almost unique to this population, were asymptomatic hypertriglyceridaemia (mean relative increase 0.9 mmol/L at week 48; p=0.04) and hypercholesterolaemia (1.5 mmol/L; p=0.001). Interpretation Rosiglitazone for 48 weeks did not improve lipoatrophy in HIV-1-infected adults receiving antiretroviral therapy. Use of less toxic antiretroviral treatment is necessary to prevent lipoatrophy.	St Vincents Hosp, Sydney, NSW 2010, Australia; AIDS Res Initiat, Sydney, NSW, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ Adelaide, Dept Gen Practice, Adelaide, SA 5005, Australia; 407 Doctors, Sydney, NSW, Australia; Garvan Inst Med Res, Sydney, NSW, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute; University of Adelaide; Garvan Institute of Medical Research	Carr, A (corresponding author), St Vincents Hosp, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au	Emery, Sean/J-3825-2017; Emery, Sean/O-9122-2019	Emery, Sean/0000-0001-6072-8309; Emery, Sean/0000-0001-6072-8309; Martin, Allison/0000-0001-6065-1188; Rogers, Gary D./0000-0003-4655-0131; Law, Matthew/0000-0002-3540-8837				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Calmy A, 2003, AIDS, V17, P770, DOI 10.1097/00002030-200303280-00022; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151; Carr A, 2003, JAIDS-J ACQ IMM DEF, V33, P571, DOI 10.1097/00126334-200308150-00004; Carr A, 2001, AIDS, V15, P1811, DOI 10.1097/00002030-200109280-00010; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chaput E, 2000, BIOCHEM BIOPH RES CO, V271, P445, DOI 10.1006/bbrc.2000.2647; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; DUBE MP, 2003, ANTIVIR THER, V7, P18; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Gelato MC, 2002, JAIDS-J ACQ IMM DEF, V31, P163, DOI 10.1097/00126334-200210010-00006; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Hadigan C, 2003, ANTIVIR THER, V8, pL12; Iwata M, 2001, DIABETES, V50, P1083, DOI 10.2337/diabetes.50.5.1083; John M, 2003, JAIDS-J ACQ IMM DEF, V33, P29, DOI 10.1097/00126334-200305010-00005; Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005; MARTIN A, IN PRESS ANTIVIRAL T; Miserez AR, 2002, AIDS, V16, P1587, DOI 10.1097/00002030-200208160-00003; Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004; Nugent C, 2001, MOL ENDOCRINOL, V15, P1729, DOI 10.1210/me.15.10.1729; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009; SHLAY J, 2003, ANTIVIR THER, V8, P12; STASZEWSKI S, 2002, 14 INT AIDS C BARC S; Sutinen J, 2003, ANTIVIR THER, V8, P199; Takamura T, 2001, EUR J PHARMACOL, V422, P23, DOI 10.1016/S0014-2999(01)01053-6; Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117, DOI 10.1097/00042560-200202010-00002; Walli R, 2000, RES EXP MED, V199, P253, DOI 10.1007/s004330050123; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; Zhang Y, 2002, BBA-MOL CELL BIOL L, V1584, P115, DOI 10.1016/S1388-1981(02)00298-6	36	185	188	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					429	438		10.1016/S0140-6736(04)15489-5	http://dx.doi.org/10.1016/S0140-6736(04)15489-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962523				2022-12-28	WOS:000188999500009
J	Helmerhorst, FM; Perquin, DAM; Donker, D; Keirse, MJNC				Helmerhorst, FM; Perquin, DAM; Donker, D; Keirse, MJNC			Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies	BRITISH MEDICAL JOURNAL			English	Review							IN-VITRO FERTILIZATION; DUTCH UNIVERSITY HOSPITALS; INVITRO FERTILIZATION; UNEXPLAINED INFERTILITY; MULTIPLE GESTATIONS; NEONATAL OUTCOMES; MATCHED CONTROL; PREGNANCIES; REPRODUCTION; IVF	Objective To compare the perinatal outcome of singleton and main pregnancies between natural and assisted conceptions. Design Systematic review of controlled studies published 1985-2002. Studies reviewed 25 studies were included of which 17 had matched and 8 had non-matched controls. Main outcome measures Very preterm birth, preterm birth, very low birth weights low birth weight, small for gestational age, caesarean section, admission to neonatal intensive care unit; and perinatal mortality. Results For singletons, studies with matched controls indicated a relative risk of 3.27 (95% confidence interval 2.03 to 5.28) for very preterm (< 32 weeks) and 2.04 (1.80 to 2.32) for preterm (< 37 weeks) birth in pregnancies after assisted conception. Relative risks were 3.00 (2.07 to 4.36) for very low birth weight (< 1500 g), 1.70 (1.50 to 1.92) for low birth weight (< 2500 g) 1.40 (1.15 to 1.71) for small for gestational age, 1.54 (1.44 to 1.66) for caesarean section, 1.27 (1.16 to 1.40) for admission to a neonatal intensive care unit, and 1.68 (1.11 to 2.55) for perinatal mortality Results of the non-matched studies were similar. In matched studies of twin gestations, relative risks were 0.95 (0.78 to 1.15) for very preterm birth, 1.07 (1.02 to 1.13) for preterm birth, 0.89 (0.74 to 1.07) for very low birth weight, 1.03 (0.99 to 1.08) for low birth weight, 1.27 (0.97 to 1.65) for small for gestational age, 1.21 (1.11 to 1.32) for caesarean section, 1.05 (1.01 to 1.09) for admission to a neonatal intensive care unit, and 0.58 (0.44 to 0.77) for perinatal mortality. The non-matched studies mostly showed similar trends. Conclusions Singleton pregnancies from assisted reproduction have a significantly worse perinatal outcome than non-assisted singleton pregnancies, but this is less so for twin pregnancies. In twin pregnancies, perinatal mortality is about 40% lower after assisted compared with natural conception.	Leiden Univ, Med Ctr, Dept Obstet Gynaecol & Reprod Med, NL-2300 AK Leiden, Netherlands; Flinders Univ S Australia, Dept Obstet Gynaecol & Reprod Med, Adelaide, SA, Australia; Flinders Med Ctr, Adelaide, SA, Australia	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Flinders University South Australia; Flinders Medical Centre	Helmerhorst, FM (corresponding author), Leiden Univ, Med Ctr, Dept Obstet Gynaecol & Reprod Med, NL-2300 AK Leiden, Netherlands.	f.m.helmerhorst@lumc.nl						Addor V, 1998, FERTIL STERIL, V69, P210, DOI 10.1016/S0015-0282(97)00468-8; Agustsson T, 1997, ACTA OBSTET GYN SCAN, V76, P45, DOI 10.3109/00016349709047783; Bernasko J, 1997, OBSTET GYNECOL, V89, P368, DOI 10.1016/S0029-7844(96)00527-3; Chow JS, 2001, J ULTRAS MED, V20, P757, DOI 10.7863/jum.2001.20.7.757; Daniel Y, 2000, FERTIL STERIL, V74, P683, DOI 10.1016/S0015-0282(00)01491-6; Dhont M, 1999, AM J OBSTET GYNECOL, V181, P688, DOI 10.1016/S0002-9378(99)70514-4; Dhont M, 1997, J ASSIST REPROD GEN, V14, P575, DOI 10.1023/A:1022576500894; DSouza SW, 1997, ARCH DIS CHILD-FETAL, V76, pF70, DOI 10.1136/fn.76.2.F70; Fitzsimmons BP, 1998, AM J OBSTET GYNECOL, V179, P1162, DOI 10.1016/S0002-9378(98)70125-5; FRYDMAN R, 1986, AM J OBSTET GYNECOL, V154, P550, DOI 10.1016/0002-9378(86)90600-9; Isaksson R, 2002, HUM REPROD, V17, P1755, DOI 10.1093/humrep/17.7.1755; Keirse MJNC, 1995, SOZ PRAVENTIV MED, V40, P343, DOI 10.1007/BF01325415; KEIRSE MJNC, 1978, BRIT J OBSTET GYNAEC, V85, P81, DOI 10.1111/j.1471-0528.1978.tb10457.x; Keirse MJNC, 2000, EUR J OBSTET GYN R B, V92, P21, DOI 10.1016/S0301-2115(00)00454-1; Koivurova S, 2002, HUM REPROD, V17, P1391, DOI 10.1093/humrep/17.5.1391; Koudstaal J, 2000, HUM REPROD, V15, P935, DOI 10.1093/humrep/15.4.935; Koudstaal J, 2000, HUM REPROD, V15, P1819, DOI 10.1093/humrep/15.8.1819; Lambalk CB, 2001, FERTIL STERIL, V75, P731, DOI 10.1016/S0015-0282(01)01679-X; LANCASTER PAL, 1985, BRIT MED J, V291, P1160; Maman E, 1998, FERTIL STERIL, V70, P240, DOI 10.1016/S0015-0282(98)00160-5; Minakami H, 1998, HUM REPROD, V13, P2005, DOI 10.1093/humrep/13.7.2005; Moise J, 1998, HUM REPROD, V13, P1702, DOI 10.1093/humrep/13.6.1702; Nuojua-Huttunen S, 1999, HUM REPROD, V14, P2110, DOI 10.1093/humrep/14.8.2110; Nygren KG, 2001, HUM REPROD, V16, P384; OLIVENNES F, 1993, HUM REPROD, V8, P1297, DOI 10.1093/oxfordjournals.humrep.a138245; Olivennes F, 1996, FERTIL STERIL, V66, P105, DOI 10.1016/S0015-0282(16)58395-2; Pandian Z, 2001, HUM REPROD, V16, P2593, DOI 10.1093/humrep/16.12.2593; PETERSEN K, 1995, ACTA OBSTET GYN SCAN, V74, P129, DOI 10.3109/00016349509008921; Reubinoff BE, 1997, FERTIL STERIL, V67, P1077, DOI 10.1016/S0015-0282(97)81442-2; TALLO CP, 1995, J PEDIATR-US, V127, P794, DOI 10.1016/S0022-3476(95)70175-3; TAN SL, 1992, AM J OBSTET GYNECOL, V167, P778, DOI 10.1016/S0002-9378(11)91589-0; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; VERLAENEN H, 1995, OBSTET GYNECOL, V86, P906, DOI 10.1016/0029-7844(95)00322-I	33	802	824	0	42	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					261	264B		10.1136/bmj.37957.560278.EE	http://dx.doi.org/10.1136/bmj.37957.560278.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14742347	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000188786000021
J	Salomon, JA; Tandon, A; Murray, CJL				Salomon, JA; Tandon, A; Murray, CJL		World Hlth Survey Pilot Study Coll	Comparability of self rated health: cross sectional multi-country survey using anchoring vignettes	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; LIMITATIONS; MORBIDITY	Objective To examine differences in expectations for health using "anchoring vignettes," which describe fixed levels of health on dimensions such as mobility. Design Cross sectional survey of adults living in the community. Setting China, Myanmar, Sri Lanka, Pakistan, Turkey, and United Arab Emirates. Participants 3012 men and women aged 18 years and older (self ratings); subsample of 406 (vignette ratings). Main outcome measures Self rated mobility levels and ratings of hypothetical vignettes using the same questions and response categories. Results Consistent rankings of vignettes are evidence that vignettes are understood in similar ways in different settings, and internal consistency of orderings on two mobility questions indicates good comprehension. Variation in vignette ratings across age groups suggests that expectations for mobility decline with age. Comparison of responses to two different mobility questions supports the assumption that individual ratings of hypothetical vignettes relate to expectations for health in similar ways as self assessments. Conclusions Anchoring vignettes could provide a powerful tool for understanding and adjusting for the influence of different health expectations on self ratings of health. Incorporating anchoring vignettes in surveys can improve the comparability of self reported measures.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Cambridge, MA 02138 USA; Harvard Univ, Global Hlth Iniat, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Salomon, JA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, 9 Bow St, Cambridge, MA 02138 USA.	jsalomon@hsph.harvard.edu	Salomon, Joshua A/D-3898-2009; Salomon, Joshua/S-1929-2019	Salomon, Joshua A/0000-0003-3929-5515; Salomon, Joshua/0000-0003-3929-5515	NIA NIH HHS [P01 AG17625] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Carr AJ, 2001, BMJ-BRIT MED J, V322, P1240, DOI 10.1136/bmj.322.7296.1240; Fischer D, 1999, JAMA-J AM MED ASSOC, V282, P1157, DOI 10.1001/jama.282.12.1157; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; Garratt AN, 2002, BMJ-BRIT MED J, V324, P1417, DOI 10.1136/bmj.324.7351.1417; Goldie J, 2002, MED EDUC, V36, P489, DOI 10.1046/j.1365-2923.2002.01176.x; GROUT W, 2000, J HLTH EC, V19, P103; Herskovits MJ, 1950, SOUTHWEST J ANTHROP, V6, P32, DOI 10.1086/soutjanth.6.1.3628688; Hughes R, 2002, J ADV NURS, V37, P382, DOI 10.1046/j.1365-2648.2002.02100.x; Kelly WF, 2002, CHEST, V121, P957, DOI 10.1378/chest.121.3.957; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; King G, 2003, AM POLIT SCI REV, V97, P567, DOI 10.1017/S0003055403000881; KING G, 2004, IN PRESS AM POLIT SC, V98; Koedoot CG, 2002, J CLIN ONCOL, V20, P3658, DOI 10.1200/JCO.2002.12.012; Mathers C., 1998, MEASURING PROGR IS L, P125; Montague J. A., 1951, INTRO PROJECTIVE TEC; Murray, 2002, SUMMARY MEASURES POP, P205; MURRAY CJL, 1992, POPUL DEV REV, V18, P481, DOI 10.2307/1973655; Rossi P. H., 1982, MEASURING SOCIAL JUD; Sadana R, 2002, SUMMARY MEASURES POP; Sen A, 2002, BRIT MED J, V324, P860, DOI 10.1136/bmj.324.7342.860; Shibuya K, 2002, BRIT MED J, V324, P16, DOI 10.1136/bmj.324.7328.16; TANDON A, 2003, HLTH SYSTEMS PERFORM, P727; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; WALSTER E, 1966, J PERS SOC PSYCHOL, V3, P73, DOI 10.1037/h0022733; Wolfe R, 2002, J ROY STAT SOC C-APP, V51, P245, DOI 10.1111/1467-9876.00267; World Health Organization, WORLD HLTH SURV	27	230	236	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	2004	328	7434					258	261		10.1136/bmj.37963.691632.44	http://dx.doi.org/10.1136/bmj.37963.691632.44			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14742348	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000188786000020
J	Scotland, RW; Sanderson, MJ				Scotland, RW; Sanderson, MJ			The significance of few versus many in the tree of life	SCIENCE			English	Article							DIVERSIFICATION RATES		Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA	University of Oxford; University of California System; University of California Davis	Scotland, RW (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	robert.scotland@plants.ox.ac.uk						Cardillo M, 2003, J EVOLUTION BIOL, V16, P282, DOI 10.1046/j.1420-9101.2003.00513.x; Magallon S, 2001, EVOLUTION, V55, P1762, DOI 10.1111/j.0014-3820.2001.tb00826.x; NEE S, 1992, P NATL ACAD SCI USA, V89, P8322, DOI 10.1073/pnas.89.17.8322; Sims HJ, 2003, EVOLUTION, V57, P460, DOI 10.1111/j.0014-3820.2003.tb01538.x; Willis JC, 1922, NATURE, V109, P177, DOI 10.1038/109177a0; [No title captured]	6	54	56	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	2004	303	5658					643	643		10.1126/science.1091483	http://dx.doi.org/10.1126/science.1091483			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752153				2022-12-28	WOS:000188530800031
J	Yoo, AS; Bais, C; Greenwald, I				Yoo, AS; Bais, C; Greenwald, I			Crosstalk between the EGFR and LIN-12/Notch pathways in C-elegans vulval development	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; NOTCH; INDUCTION; RECEPTOR; PROTEIN	The Caenorhabditis elegans vulva is an important paradigm for cell-cell interactions in animal development. The fates of six vulval precursor cells are patterned through the action of the epidermal growth factor receptor - mitogen-activated protein kinase (EGFR-MAPK) inductive signaling pathway, which specifies the 1degrees fate, and the LIN-12/Notch lateral signaling pathway, which specifies the 2degrees fate. Here, we provide evidence that the inductive signal is spatially graded and initially activates the EGFR-MAPK pathway in the prospective 2degrees cells. Subsequently, this effect is counteracted by the expression of multiple new negative regulators of the EGFR-MAPK pathway, under direct transcriptional control of the LIN-12-mediated lateral signal.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Greenwald, I (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, 701 W 168th St,Room 720, New York, NY 10032 USA.	greenwald@cancercenter.columbia.edu		Yoo, Andrew/0000-0002-0304-3247	NATIONAL CANCER INSTITUTE [R01CA095389] Funding Source: NIH RePORTER; NCI NIH HHS [CA095389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Chen N, UNPUB; Christensen S, 1996, DEVELOPMENT, V122, P1373; GARRIGA G, COMMUNICATION; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Greenwald Iva, 1997, Cold Spring Harbor Monograph Series, V33, P519; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; KOGA M, 1995, DEVELOPMENT, V121, P2655; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Liu J, 1999, GENETICS, V153, P1257; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rebeiz M, 2002, P NATL ACAD SCI USA, V99, P9888, DOI 10.1073/pnas.152320899; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116	24	198	223	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					663	666		10.1126/science.1091639	http://dx.doi.org/10.1126/science.1091639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752159				2022-12-28	WOS:000188530800038
J	Hancock, EW				Hancock, EW			A clearer view of effusive-constrictive pericarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Hancock, EW (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.							Venditti FJ, 1997, NEW ENGL J MED, V336, P1812, DOI 10.1056/NEJM199706193362508	1	43	44	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					435	437		10.1056/NEJMp038199	http://dx.doi.org/10.1056/NEJMp038199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749449				2022-12-28	WOS:000188463900003
J	Edwards, R				Edwards, R			The problem of tobacco smoking	BRITISH MEDICAL JOURNAL			English	Review							MORTALITY		Univ Manchester, Sch Med, Evidence Epidemiol Hlth Unit, Manchester M13 9PL, Lancs, England	University of Manchester	Edwards, R (corresponding author), Univ Manchester, Sch Med, Evidence Epidemiol Hlth Unit, Manchester M13 9PL, Lancs, England.		Edwards, Richard/O-4771-2017	Edwards, Richard/0000-0003-2264-9823				DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; JHA P, 1999, TOBACCO CONTROL DEV; *TOB ADV GROUP ROY, 2000, NIC ADD BRIT; U. S. Department of Health and Human Services, 1990, DHHS PUBL; Wilson K, 2000, ARCH INTERN MED, V160, P939, DOI 10.1001/archinte.160.7.939; World Bank, 1999, CURB EP GOV EC TOB C	6	176	184	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	2004	328	7433					217	219		10.1136/bmj.328.7433.217	http://dx.doi.org/10.1136/bmj.328.7433.217			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739193	Green Published			2022-12-28	WOS:000188652200023
J	Bonifacino, JS; Glick, BS				Bonifacino, JS; Glick, BS			The mechanisms of vesicle budding and fusion	CELL			English	Review							TO-GOLGI TRANSPORT; INTRACELLULAR PROTEIN-TRANSPORT; PLASMA-MEMBRANE ATPASE; COPII-COATED VESICLES; AMINO-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SNARE PROTEINS	Genetic and biochemical analyses of the secretory pathway have produced a detailed picture of the molecular mechanisms involved in selective cargo transport between organelles. This transport occurs by means of vesicular intermediates that bud from a donor compartment and fuse with an acceptor compartment. Vesicle budding and cargo selection are mediated by protein coats, while vesicle targeting and fusion depend on a machinery that includes the SNARE proteins. Precise regulation of these two aspects of vesicular transport ensures efficient cargo transfer while preserving organelle identity.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Chicago	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antonny B, 2003, EMBO REP, V4, P419, DOI 10.1038/sj.embor.embor812; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Balch William E., 2004, Cell, VS116, pS17, DOI 10.1016/S0092-8674(03)00970-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; De Matteis MA, 2002, CURR OPIN CELL BIOL, V14, P434, DOI 10.1016/S0955-0674(02)00357-5; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; Dietrich LEP, 2003, BBA-MOL CELL RES, V1641, P111, DOI 10.1016/S0167-4889(03)00094-6; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; Elazar Z, 2003, BBA-MOL CELL RES, V1641, P145, DOI 10.1016/S0167-4889(03)00086-7; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; GIMENO RE, 1995, J CELL BIOL, V131, P325, DOI 10.1083/jcb.131.2.325; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Huang MD, 2001, J CELL BIOL, V155, P937, DOI 10.1083/jcb.200106039; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Joglekar AP, 2003, J BIOL CHEM, V278, P14121, DOI 10.1074/jbc.M300659200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kurihara T, 2000, MOL BIOL CELL, V11, P983, DOI 10.1091/mbc.11.3.983; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lederkremer GZ, 2001, P NATL ACAD SCI USA, V98, P10704, DOI 10.1073/pnas.191359398; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Palfrey HC, 2003, CURR BIOL, V13, pR397, DOI 10.1016/S0960-9822(03)00320-8; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Payne WE, 2000, YEAST, V16, P979; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Powers J, 2002, MOL BIOL CELL, V13, P880, DOI 10.1091/mbc.01-10-0499; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rein U, 2002, J CELL BIOL, V157, P395, DOI 10.1083/jcb.200112092; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saito-Nakano Y, 2000, GENES CELLS, V5, P1039, DOI 10.1046/j.1365-2443.2000.00391.x; Schekman Randy, 2004, Cell, VS116, pS13, DOI 10.1016/S0092-8674(03)00972-3; Segev N, 2001, SCI STKE, pre11, DOI DOI 10.1126/STKE.2001.100.RE11; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stephens DJ, 2000, J CELL SCI, V113, P2177; Supek F, 2002, J CELL BIOL, V158, P1029, DOI 10.1083/jcb.200207053; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Szule JA, 2003, BBA-MOL CELL RES, V1641, P121, DOI 10.1016/S0167-4889(03)00095-8; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; Whyte JRC, 2002, J CELL SCI, V115, P2627; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4	128	1229	1276	8	273	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					153	166		10.1016/S0092-8674(03)01079-1	http://dx.doi.org/10.1016/S0092-8674(03)01079-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744428	Bronze			2022-12-28	WOS:000188541700007
J	Emerson, JJ; Kaessmann, H; Betran, E; Long, MY				Emerson, JJ; Kaessmann, H; Betran, E; Long, MY			Extensive gene traffic on the mammalian X chromosome	SCIENCE			English	Article							HUMAN Y-CHROMOSOME; HUMAN GENOME; SEX-CHROMOSOMES; EVOLUTION; EXPRESSION; INACTIVATION; DROSOPHILA; SEQUENCE; TESTIS; IDENTIFICATION	Mammalian sex chromosomes have undergone profound changes since evolving from ancestral autosomes. By examining retroposed genes in the human and mouse genomes, we demonstrate that, during evolution, the mammalian X chromosome has generated and recruited a disproportionately high number of functional retroposed genes, whereas the autosomes experienced lower gene turnover. Most autosomal copies originating from X-linked genes exhibited testis-biased expression. Such export is incompatible with mutational bias and is likely driven by natural selection to attain male germline function. However, the excess recruitment is consistent with a combination of both natural selection and mutational bias.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Univ Lausanne, BEP, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Texas, Dept Biol, Arlington, TX 76019 USA	University of Chicago; University of Lausanne; University of Texas System; University of Texas Arlington	Long, MY (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57th St, Chicago, IL 60637 USA.	mlong@uchicago.edu	Emerson, J.J./D-8955-2011; Kaessmann, Henrik/B-4989-2013	Kaessmann, Henrik/0000-0001-7563-839X; Betran, Esther/0000-0002-4742-7963; Emerson, James/0000-0001-9474-0891	NIGMS NIH HHS [GM-065429-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Betran E, 2002, GENOME RES, V12, P1854, DOI 10.1101/gr.6049; Betran E, 2002, MOL BIOL EVOL, V19, P654, DOI 10.1093/oxfordjournals.molbev.a004124; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; Courseaux A, 2001, SCIENCE, V291, P1293, DOI 10.1126/science.1057284; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Dass B, 2001, J BIOL CHEM, V276, P8044, DOI 10.1074/jbc.M009091200; Elliott DJ, 2000, HUM MOL GENET, V9, P2117, DOI 10.1093/hmg/9.14.2117; Fujii T, 2002, EMBO REP, V3, P367, DOI 10.1093/embo-reports/kvf073; Graves JAM, 2002, CYTOGENET GENOME RES, V96, P161, DOI 10.1159/000063022; Gu ZL, 2000, GENE, V259, P81, DOI 10.1016/S0378-1119(00)00434-0; Harrison PM, 2002, GENOME RES, V12, P272, DOI 10.1101/gr.207102; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lahn BT, 2001, NAT REV GENET, V2, P207, DOI 10.1038/35056058; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANGLEY CH, 1988, GENET RES, V52, P223, DOI 10.1017/S0016672300027695; Lercher MJ, 2003, MOL BIOL EVOL, V20, P1113, DOI 10.1093/molbev/msg131; Lewin B., 2000, GENES; MCCARREY JR, 1994, BIOSCIENCE, V44, P20, DOI 10.2307/1312402; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; Ranz JM, 2003, SCIENCE, V300, P1742, DOI 10.1126/science.1085881; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; Strichman-Almashanu LZ, 2003, GENOME RES, V13, P800, DOI 10.1101/gr.893803; TAIRA M, 1990, J BIOL CHEM, V265, P16491; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WICHMAN HA, 1992, GENETICA, V86, P287, DOI 10.1007/BF00133727; Wu CI, 2003, TRENDS GENET, V19, P243, DOI 10.1016/S0168-9525(03)00058-1; Zhang ZL, 2002, GENOME RES, V12, P1466, DOI 10.1101/gr.331902	35	308	314	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					537	540		10.1126/science.1090042	http://dx.doi.org/10.1126/science.1090042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739461				2022-12-28	WOS:000188316400042
J	Lai, CW; Zoch, J; Gossard, AC; Chemla, DS				Lai, CW; Zoch, J; Gossard, AC; Chemla, DS			Phase diagram of degenerate exciton systems	SCIENCE			English	Article							BOSE-EINSTEIN CONDENSATION; COUPLED QUANTUM-WELLS; NOBEL LECTURE; PHOTOLUMINESCENCE; DIMENSIONS; STATES; TRAPS	Degenerate exciton systems have been produced in quasi-two-dimensional confined areas in semiconductor coupled quantum well structures. We observed contractions of clouds containing tens of thousands of excitons within areas as small as (10 mum)(2) near 10 kelvin. The spatial and energy distributions of optically active excitons were determined by measuring photoluminescence as a function of temperature and laser excitation and were used as thermodynamic quantities to construct the phase diagram of the exciton system, which demonstrates the existence of distinct phases. Understanding the formation mechanisms of these degenerate exciton systems can open new opportunities for the realization of Bose-Einstein condensation in the solid state.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Santa Barbara	Lai, CW (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	celai@lbl.gov	Lai, Chih Wei/E-4945-2010	Lai, Chih Wei/0000-0003-3571-4671				ADACHI S, 1994, GAAS RELATED MAT BUL, pR19; BAGNATO V, 1991, PHYS REV A, V44, P7439, DOI 10.1103/PhysRevA.44.7439; Bebb H. B., 1972, SEMICONDUCT SEMIMET, P181, DOI [10.1016/S0080-8784(08)62345-5, DOI 10.1016/S0080-8784(08)62345-5]; Butov LV, 2002, NATURE, V417, P47, DOI 10.1038/417047a; Butov LV, 1999, PHYS REV B, V59, P1625, DOI 10.1103/PhysRevB.59.1625; Butov LV, 2002, NATURE, V418, P751, DOI 10.1038/nature00943; BUTOV LV, CONDMAT0308117, P43001; Cornell EA, 2002, REV MOD PHYS, V74, P875, DOI 10.1142/S0217979202014681; DIGNAM MJ, COMMUNICATION; DIGNAM MM, 1991, PHYS REV B, V43, P4084, DOI 10.1103/PhysRevB.43.4084; FELDMANN J, 1987, PHYS REV LETT, V59, P2337, DOI 10.1103/PhysRevLett.59.2337; FUKUZAWA T, 1990, PHYS REV LETT, V64, P3066, DOI 10.1103/PhysRevLett.64.3066; HOHENBERG PC, 1967, PHYS REV, V158, P383, DOI 10.1103/PhysRev.158.383; Ivanov AL, 2002, EUROPHYS LETT, V59, P586, DOI 10.1209/epl/i2002-00144-3; Ivanov AL, 1999, PHYS REV B, V59, P5032, DOI 10.1103/PhysRevB.59.5032; JEFFRIES CD, 1983, ELECT HOLE DROPLETS, pR37; KELDYSH LV, 1965, FIZ TVERD TELA+, V6, P2219; KELDYSH LV, 1995, BOSE EINSTEIN CONDEN, P246; KELDYSH LV, 1968, ZH EKSP TEOR FIZ, V27, P521; Ketterle W, 2002, REV MOD PHYS, V74, P1131, DOI [10.1103/RevModPhys.74.1131, 10.1142/S0217979202014668]; Ketterle W, 1996, PHYS REV A, V54, P656, DOI 10.1103/PhysRevA.54.656; KLINGSHIRN CF, 1997, SEMICONDUCTOR OPTICS, P306; Perakis IE, 2002, NATURE, V417, P33, DOI 10.1038/417033a; Popov V. N., 1983, Functional integrals in quantum field theory and statistical physics, DOI 10.1007/BF01028373; RAPAPORT R, CONDMAT0308150, P45409; Reinholz H, 2002, SOLID STATE COMMUN, V123, P489, DOI 10.1016/S0038-1098(02)00423-4; Rice TM, 1978, SOLID STATE PHYS, V32, P1; Snoke D, 2002, NATURE, V418, P754, DOI 10.1038/nature00940; ZHU XJ, 1995, PHYS REV LETT, V74, P1633, DOI 10.1103/PhysRevLett.74.1633	29	47	50	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					503	506		10.1126/science.1092691	http://dx.doi.org/10.1126/science.1092691			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739453				2022-12-28	WOS:000188316400032
J	de Nadal, E; Zapater, M; Alepuz, PM; Sumoy, L; Mas, G; Posas, F				de Nadal, E; Zapater, M; Alepuz, PM; Sumoy, L; Mas, G; Posas, F			The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes	NATURE			English	Article							OSMOTIC-STRESS; KINASE HOG1; YEAST; TRANSCRIPTION; ACETYLATION; OSMOSTRESS	Regulation of gene expression by mitogen- activated protein kinases ( MAPKs) is essential for proper cell adaptation to extracellular stimuli. Exposure of yeast cells to high osmolarity results in rapid activation of the MAPK Hog1, which coordinates the transcriptional programme required for cell survival on osmostress(1). The mechanisms by which Hog1 and MAPKs in general regulate gene expression are not completely understood, although Hog1 can modify some transcription factors(2). Here we propose that Hog1 induces gene expression by a mechanism that involves recruiting a specific histone deacetylase complex to the promoters of genes regulated by osmostress. Cells lacking the Rpd3 - Sin3 histone deacetylase complex are sensitive to high osmolarity and show compromised expression of osmostress genes. Hog1 interacts physically with Rpd3 in vivo and in vitro and, on stress, targets the deacetylase to specific osmostress-responsive genes. Binding of the Rpd3 - Sin3 complex to specific promoters leads to histone deacetylation, entry of RNA polymerase II and induction of gene expression. Together, our data indicate that targeting of the Rpd3 histone deacetylase to osmo-responsive promoters by the MAPK Hog1 is required to induce gene expression on stress.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, E-08003 Barcelona, Spain; CRG, E-08003 Barcelona, Spain	Pompeu Fabra University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG)	Posas, F (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, E-08003 Barcelona, Spain.	francesc.posas@upf.edu	Posas, Francesc/K-1364-2013; de Nadal, Eulàlia/J-8178-2014; Sumoy, Lauro/AGZ-3186-2022; Alepuz, Paula/F-7849-2016; Sumoy, Lauro/K-1680-2013	Posas, Francesc/0000-0002-4164-7076; de Nadal, Eulàlia/0000-0003-0039-5607; Sumoy, Lauro/0000-0003-0005-4618; Alepuz, Paula/0000-0003-1472-2373; Sumoy, Lauro/0000-0003-0005-4618				Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790	16	242	250	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					370	374		10.1038/nature02258	http://dx.doi.org/10.1038/nature02258			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737171				2022-12-28	WOS:000188266200045
J	Epstein, AM; Lee, TH; Hamel, MB				Epstein, AM; Lee, TH; Hamel, MB			Paying physicians for high-quality care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICARE BENEFICIARIES; OF-CARE; CONTRACT						Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				*AG HEALTHC RES QU, 2001, ANN REP NAT CAHPS BE; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; GULLAND A, 2003, BMJ-BRIT MED J, V326, P519; Institute of Medicine, 2001, CROSSING QUALITY CHA; Institute of Medicine, 2002, LEAD EX COORD GOV RO; Jencks S, 2003, NEW ENGL J MED, V348, P2251, DOI 10.1056/NEJMe030056; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Marshall M, 2002, BRIT J GEN PRACT, V52, P531; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; *NAT COMM QUAL ASS, 2002, STAT HLTH CAR QUAL 2; PEAR R, 2002, NY TIMES        1031, pA21; Peterson ED, 1998, J AM COLL CARDIOL, V32, P993, DOI 10.1016/S0735-1097(98)00332-5; Rosenthal MB, 2002, HEALTH AFFAIR, V21, P197, DOI 10.1377/hlthaff.21.4.197; Schoenbaum S C, 1989, HMO Pract, V3, P161; Shekelle P, 2003, BRIT MED J, V326, P457, DOI 10.1136/bmj.326.7387.457; Steinberg EP, 2003, NEW ENGL J MED, V348, P2681, DOI 10.1056/NEJMe030085; STODDARD J, 2002, PHYS MORE LIKELY FAC; Wang SJ, 2003, AM J MED, V114, P397, DOI 10.1016/S0002-9343(03)00057-3; Zaslavsky AM, 2000, MED CARE, V38, P981, DOI 10.1097/00005650-200010000-00002	24	213	216	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					406	410		10.1056/NEJMsb035374	http://dx.doi.org/10.1056/NEJMsb035374			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765EU	14736934				2022-12-28	WOS:000188254800015
J	Ane, JM; Kiss, GB; Riely, BK; Penmetsa, RV; Oldroyd, GED; Ayax, C; Levy, J; Debelle, F; Baek, JM; Kalo, P; Rosenberg, C; Roe, BA; Long, SR; Denarie, J; Cook, DR				Ane, JM; Kiss, GB; Riely, BK; Penmetsa, RV; Oldroyd, GED; Ayax, C; Levy, J; Debelle, F; Baek, JM; Kalo, P; Rosenberg, C; Roe, BA; Long, SR; Denarie, J; Cook, DR			Medicago truncatula DMI1 required for bacterial and fungal symbioses in legumes	SCIENCE			English	Article							NOD FACTOR TRANSDUCTION; RECEPTOR KINASE GENE; MEDICAGO-TRUNCATULA; NODULATION; RECOGNITION	Legumes form symbiotic associations with both mycorrhizal fungi and nitrogen-fixing soil bacteria called rhizobia. Several of the plant genes required for transduction of rhizobial signals, the Nod factors, are also necessary for mycorrhizal symbiosis. Here, we describe the cloning and characterization of one such gene from the legume Medicago truncatula. The DMI1 ( does not make infections) gene encodes a novel protein with low global similarity to a ligand-gated cation channel domain of archaea. The protein is highly conserved in angiosperms and ancestral to land plants. We suggest that DMI1 represents an ancient plant-specific innovation, potentially enabling mycorrhizal associations.	Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; INRA, CNRS, UMR215, Lab Interact Plantes Microorganismes, F-31326 Castanet Tolosan, France; Hungarian Acad Sci, Biol Res Ctr, Inst Genet, H-6701 Szeged, Hungary; Agr Biotechnol Ctr, Inst Genet, H-2100 Godollo, Hungary; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Calif Davis, Coll Agr & Environm Sci, Gen Facil, Davis, CA 95616 USA; Univ Oklahoma, Adv Ctr Genome Technol, Norman, OK 73019 USA	University of California System; University of California Davis; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Stanford University; University of California System; University of California Davis; University of Oklahoma System; University of Oklahoma - Norman	Cook, DR (corresponding author), Univ Calif Davis, Dept Plant Pathol, 1 Shields Ave, Davis, CA 95616 USA.	drcook@ucdavis.edu	Ané, Jean-Michel/G-5921-2010; levy, julien G./I-9904-2019; Oldroyd, Giles/ABD-8143-2021; Oldroyd, Giles/ABA-7501-2020; Kalo, Peter/A-3919-2012	Ané, Jean-Michel/0000-0002-3128-9439; levy, julien G./0000-0002-1422-2195; Oldroyd, Giles/0000-0002-5245-6355; Kalo, Peter/0000-0002-0404-8904				Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Ane JM, 2002, MOL PLANT MICROBE IN, V15, P1108, DOI 10.1094/MPMI.2002.15.11.1108; Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Boisson-Dernier A, 2001, MOL PLANT MICROBE IN, V14, P695, DOI 10.1094/MPMI.2001.14.6.695; Bornberg-Bauer E, 1998, NUCLEIC ACIDS RES, V26, P2740, DOI 10.1093/nar/26.11.2740; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; CHOI HK, IN PRESS GENETICS; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; Doyle JJ, 1998, TRENDS PLANT SCI, V3, P473, DOI 10.1016/S1360-1385(98)01340-5; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Geurts R, 2002, PLANT CELL, V14, pS239, DOI 10.1105/tpc.002451; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Levy J, 2004, SCIENCE, V303, P1361, DOI 10.1126/science.1093038; Limpens E, 2003, SCIENCE, V302, P630, DOI 10.1126/science.1090074; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Oldroyd GED, 2003, PLANT PHYSIOL, V131, P1027, DOI 10.1104/pp.102.010710; Parniske M, 2003, NATURE, V425, P569, DOI 10.1038/425569a; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Wais RJ, 2000, P NATL ACAD SCI USA, V97, P13407, DOI 10.1073/pnas.230439797	23	371	397	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1364	1367		10.1126/science.1092986	http://dx.doi.org/10.1126/science.1092986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14963334				2022-12-28	WOS:000189238600050
J	Margolis, PA; Lannon, CM; Stuart, JM; Fried, BJ; Keyes-Elstein, L; Moore, DE				Margolis, PA; Lannon, CM; Stuart, JM; Fried, BJ; Keyes-Elstein, L; Moore, DE			Practice based education to improve delivery systems for prevention in primary care: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY; SERVICES; CANCER; INTERVENTIONS	Objective To examine the effectiveness of an intervention that combined continuing medical education with process improvement methods to implement "office systems" to improve the delivery of preventive care to children. Design Randomised trial in primary care practices. Setting Private paediatric and family practices in two areas of North Carolina. Participants Random sample of 44 practices allocated to intervention and control groups. Intervention Practice based continuing medical education in which project staff coached practice staff in reviewing performance and identifying, testing, and implementing new care processes (such as chart screening) to improve delivery of preventive care. Main outcome measure Change over time in the proportion of children aged 24-30 months who received age appropriate care for four preventive services (immunisations, and screening for tuberculosis, anaemia, and lead). Results The proportion of children per practice with age appropriate delivery of all four preventive services changed, after a one year period of implementation, from 7% to 34% in intervention practices and from 9% to 10% in control practices. After adjustment for baseline differences in the groups, the change in die prevalence of all four services between the beginning and the end of the study was 4.6-fold greater. (95% confidence interval 1.6 to 13.2) in intervention practices. Thirty months after baseline, the proportion of children who were up to date with preventive services was higher in intervention than in control practices; results for screening for tuberculosis (54% v 32% lead (68% v 30%), and anaemia (79% v 71%) were statistically significant (P < 0.05). Conclusion Continuing education combined with process improvement methods is effective in increasing rates of delivery of preventive care to children.	Univ N Carolina, N Carolina Ctr Childrens Healthcare Improvement, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Hlth Policy & Adm, Chapel Hill, NC USA; Rho Inc, Chapel Hill, NC 27514 USA; Vanderbilt Univ, Sch Med, Div Continuing Med Educ, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Rho; Vanderbilt University	Margolis, PA (corresponding author), Univ N Carolina, N Carolina Ctr Childrens Healthcare Improvement, 730 Airport Rd,Ste 104,CB 7226, Chapel Hill, NC 27599 USA.	Peter_Margolis@med.unc.edu			AHRQ HHS [R01-HS08509] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008509] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		American Academy of Pediatrics, 2000, PEDIATRICS, V105, P645; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Bordley WC, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e41; Carey TS, 1996, J COMMUN HEALTH, V21, P315, DOI 10.1007/BF01702785; *CDC, 2001, MMWR-MORBID MORTAL W, V50, P637; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; DEMING EW, 1977, OUT CRISIS, P330; Dietrich AJ, 1998, ARCH FAM MED, V7, P320, DOI 10.1001/archfami.7.4.320; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; Goodwin MA, 2001, AM J PREV MED, V21, P20, DOI 10.1016/S0749-3797(01)00310-5; Hulscher MEJL, 1999, AM J PUBLIC HEALTH, V89, P737, DOI 10.2105/AJPH.89.5.737; KISH L, 1965, SURVEY SAMPLING, P148; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Leininger LS, 1996, ARCH FAM MED, V5, P108, DOI 10.1001/archfami.5.2.108; Mazmanian PE, 2002, JAMA-J AM MED ASSOC, V288, P1057, DOI 10.1001/jama.288.9.1057; *NAT PARTN IMM, N CAR IMM RAT; NORMAN EH, 1994, PEDIATRICS, V94, P59; Solberg L I, 2000, Eff Clin Pract, V3, P105; Solberg L I, 2000, Eff Clin Pract, V3, P153; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Szilagyi PG, 2000, JAMA-J AM MED ASSOC, V284, P1820, DOI 10.1001/jama.284.14.1820; *US DEP HHS PHS, 1998, PUBL APPIP; *US PREV SERV TASK, 2002, GUID CLIN PREV SERV; VONESH EF, 1997, LINEAR NONLINEAR MOD, P381	24	99	100	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					388	392B		10.1136/bmj.38009.706319.47	http://dx.doi.org/10.1136/bmj.38009.706319.47			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14766718	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000189031300026
J	Keeley, EC; Grines, CL				Keeley, EC; Grines, CL			Primary coronary intervention for acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SITE CARDIAC-SURGERY; PRIMARY ANGIOPLASTY; THROMBOLYTIC THERAPY; RANDOMIZED-TRIAL; EARLY REVASCULARIZATION; IMMEDIATE THROMBOLYSIS; REPERFUSION; TIME; MANAGEMENT; MORTALITY		Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA; William Beaumont Hosp, Dept Internal Med, Royal Oak, MI 48073 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Beaumont Health	Keeley, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ellen.keeley@utsouthwestern.edu						ANDERSON JL, 1993, CIRCULATION, V87, P1829, DOI 10.1161/01.CIR.87.6.1829; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Becker Richard C., 1999, American Journal of Cardiology, V83, p3E; Berger AK, 2000, J AM COLL CARDIOL, V36, P366, DOI 10.1016/S0735-1097(00)00723-3; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Brodie BR, 1998, J AM COLL CARDIOL, V32, P1312, DOI 10.1016/S0735-1097(98)00395-7; Brodie BR, 2001, AM J CARDIOL, V88, P1085, DOI 10.1016/S0002-9149(01)02039-2; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Corti R, 2003, J AM COLL CARDIOL, V41, p7S, DOI 10.1016/S0735-1097(02)02833-4; Dalby M, 2003, CIRCULATION, V108, P1809, DOI 10.1161/01.CIR.0000091088.63921.8C; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Gibson CM, 2003, J AM COLL CARDIOL, V42, P7, DOI 10.1016/S0735-1097(03)00506-0; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grzybowski M, 2003, JAMA-J AM MED ASSOC, V290, P1891, DOI 10.1001/jama.290.14.1891; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; Hochman JS, 2001, JAMA-J AM MED ASSOC, V285, P190, DOI 10.1001/jama.285.2.190; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Singh M, 2002, J AM COLL CARDIOL, V39, P1881, DOI 10.1016/S0735-1097(02)01901-0; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2000, AM J CARDIOL, V85, P1292, DOI 10.1016/S0002-9149(00)00758-X; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; Thiemann DR, 2000, CIRCULATION, V101, P2239, DOI 10.1161/01.CIR.101.19.2239; Topol EJ, 1998, CIRCULATION, V97, P211, DOI 10.1161/01.CIR.97.2.211; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993	35	40	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					736	739		10.1001/jama.291.6.736	http://dx.doi.org/10.1001/jama.291.6.736			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871919				2022-12-28	WOS:000188819200029
J	Aguzzi, A; Glatzel, M				Aguzzi, A; Glatzel, M			vCJD tissue distribution and transmission by transfusion - a worst-case scenario coming true?	LANCET			English	Editorial Material							PRION PROTEIN; AGENT; PATHOGENESIS; DISEASES; SCRAPIE; BSE; PRP		Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Glatzel, Markus/G-3356-2011; Glatzel, Markus/V-8844-2019; Aguzzi, Adriano/A-3351-2008	Glatzel, Markus/0000-0002-7720-8817; Glatzel, Markus/0000-0002-7720-8817; Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Beekes M, 2000, NEUROSCI LETT, V278, P181, DOI 10.1016/S0304-3940(99)00934-9; Collins SJ, 2004, LANCET, V363, P51, DOI 10.1016/S0140-6736(03)15171-9; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; FRASER H, 1982, NATURE, V295, P149, DOI 10.1038/295149a0; Glatzel M, 2003, LANCET NEUROL, V2, P757, DOI 10.1016/S1474-4422(03)00588-X; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; KIMBERLIN RH, 1982, J ROY SOC MED, V75, P618; Terry LA, 2003, VET REC, V152, P387, DOI 10.1136/vr.152.13.387; Watarai MH, 2003, J EXP MED, V198, P5, DOI 10.1084/jem.20021980; Wells GAH, 1998, VET REC, V142, P103, DOI 10.1136/vr.142.5.103	14	25	26	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					411	412		10.1016/S0140-6736(04)15520-7	http://dx.doi.org/10.1016/S0140-6736(04)15520-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962516				2022-12-28	WOS:000188999500003
J	Cluett, ER; Pickering, RM; Getliffe, K; Saunders, NJS				Cluett, ER; Pickering, RM; Getliffe, K; Saunders, NJS			Randomised controlled trial of labouring in water compared with standard of augmentation for management of dystocia in first stage of labour	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVE MANAGEMENT; IMMERSION; BIRTH	Objectives To evaluate the impact of labouring in water during first stage of labour on rates of epidural analgesia and operative delivery in nulliparous women with dystocia. Design Randomised controlled trial. Setting University teaching hospital in southern England. Participants 99 nulliparous women with dystocia (cervical dilation rate <1 cm/hour in active labour) at low risk of complications. Interventions Immersion in water in birth pool or standard augmentation for dystocia (amniotomy and intravenous oxytocin). Main outcome measures Primary: epidural analgesia and operative delivery rates. Secondary: augmentation rates with amniotomy and oxytocin, length of labour, maternal and neonatal morbidity including infections, maternal pain score, and maternal satisfaction with care. Results Women randomised to immersion in water had a lower rate of epidural analgesia than women allocated to augmentation (47% v 66%, relative risk 0.71 (95% confidence interval 0.49 to 1.01), number needed to treat for benefit (NNT) 5). They showed no difference in rates of operative delivery (49% v 50%, 0.98 (0.65 to 1.47), NNT 98), but significantly fewer received augmentation (71% v 96%,0.74 (0.59 to 0.88), NNT 4) or any form of obstetric intervention (amniotomy, oxytocin, epidural, or operative delivery) (80% v 98%, 0.81 (0.67 to 0.92), NNT 5). More neonates of women in the water group were admitted to the neonatal unit (6 v 0, P=0.013), but there was no difference in Apgar score, infection rates, or umbilical cord pH. Conclusions Labouring in water under midwifery care may be an option for slow progress in labour, reducing the need for obstetric Intervention and offering an alternative pain management strategy.	Univ Southampton, Southampton SO17 1BJ, Hants, England; Southampton Gen Hosp, Hlth Care Res Unit 805, Med Stat Grp, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Trust Management Unit, Southampton, Hants, England	University of Southampton; University of Southampton; University of Southampton	Cluett, ER (corresponding author), Univ Southampton, NIghtingale Bldg 67, Southampton SO17 1BJ, Hants, England.	ecl@soton.ac.uk		Cluett, Elizabeth/0000-0002-8707-5042				Aird IA, 1997, AUST NZ J OBSTET GYN, V37, P137, DOI 10.1111/j.1479-828X.1997.tb02240.x; ALDERDICE F, 1995, BRIT MED J, V310, P837, DOI 10.1136/bmj.310.6983.837; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Blanch G, 1998, BRIT J OBSTET GYNAEC, V105, P117, DOI 10.1111/j.1471-0528.1998.tb09362.x; BROWNRIDGE P, 1995, EUR J OBSTET GYN R B, V59, pS9, DOI 10.1016/0028-2243(95)02058-Z; Cammu H, 1996, BRIT J OBSTET GYNAEC, V103, P313, DOI 10.1111/j.1471-0528.1996.tb09734.x; CAMMU H, 1994, ACTA OBSTET GYN SCAN, V73, P468, DOI 10.3109/00016349409013433; Cluett ER, 2001, MIDWIFERY, V17, P35, DOI 10.1054/midw.2000.0233; *DEP HLTH, 1997, STAT B, V28, P1; DEPUNZIO C, 1994, J PSYCHOSOM OBST GYN, V15, P205, DOI 10.3109/01674829409025647; Eckert K, 2001, BIRTH-ISS PERINAT C, V28, P84, DOI 10.1046/j.1523-536X.2001.00084.x; Garland D., 1994, BRIT J MIDWIFERY, V2, P113; Gilbert RE, 1999, BRIT MED J, V319, P483, DOI 10.1136/bmj.319.7208.483; Green JM, 1998, GREAT EXPECTATIONS P; HODNETT ED, 2003, COCHRANE LIB; Impey L, 1999, BRIT J OBSTET GYNAEC, V106, P183, DOI 10.1111/j.1471-0528.1999.tb08229.x; Johanson R, 2002, BRIT MED J, V324, P892, DOI 10.1136/bmj.324.7342.892; KWAST BE, 1994, LANCET, V343, P1399; Lavender T, 1999, MIDWIFERY, V15, P40, DOI 10.1016/S0266-6138(99)90036-0; NIKODEM VC, 2003, COCHRANE LIB; Ohlsson G, 2001, ACTA OBSTET GYN SCAN, V80, P311, DOI 10.1034/j.1600-0412.2001.080004311.x; Otigbah CM, 2000, EUR J OBSTET GYN R B, V91, P15, DOI 10.1016/S0301-2115(99)00238-9; Rush J, 1996, BIRTH-ISS PERINAT C, V23, P136, DOI 10.1111/j.1523-536X.1996.tb00474.x; Sadler LC, 2000, BRIT J OBSTET GYNAEC, V107, P909, DOI 10.1111/j.1471-0528.2000.tb11091.x; SCHORN MN, 1993, J NURSE-MIDWIFERY, V38, P336, DOI 10.1016/0091-2182(93)90014-8	25	73	75	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					314	318		10.1136/bmj.37963.606412.EE	http://dx.doi.org/10.1136/bmj.37963.606412.EE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14744822	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188926900017
J	Gatrad, AR; Sheikh, A				Gatrad, AR; Sheikh, A			10-minute consultation - Persistent crying in babies	BRITISH MEDICAL JOURNAL			English	Article									Manor Hosp, Walsall NHS Trust, Walsall WS2 2PS, W Midlands, England; Univ Edinburgh, Dept Community Hlth Serv, GP Sect, Edinburgh EH10 5PF, Midlothian, Scotland	University of Edinburgh	Gatrad, AR (corresponding author), Manor Hosp, Walsall NHS Trust, Walsall WS2 2PS, W Midlands, England.	drgatrad@hotmail.com	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				Garrison MM, 2000, PEDIATRICS, V106, P184; *HLTH PROM ENGL, 2000, BIRTH FIVE, P22; KILGOUR S, 2003, CLINICAL EVIDENCE, P385; Lucassen PLBJ, 1998, BMJ-BRIT MED J, V316, P1563, DOI 10.1136/bmj.316.7144.1563; Morris S, 2001, ARCH DIS CHILD, V84, P15, DOI 10.1136/adc.84.1.15; Wade S, 2001, BMJ-BRIT MED J, V323, P437, DOI 10.1136/bmj.323.7310.437	6	2	2	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2004	328	7435					330	330		10.1136/bmj.328.7435.330	http://dx.doi.org/10.1136/bmj.328.7435.330			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764497	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000188926900025
J	Bush, MB; Silman, MR; Urrego, DH				Bush, MB; Silman, MR; Urrego, DH			48,000 years of climate and forest change in a biodiversity hot spot	SCIENCE			English	Article							PRECIPITATION; RECORDS; HISTORY; ANDES	A continuous 48,000-year-long paleoecological record from Neotropical lower montane forest reveals a consistent forest presence and an ice-age cooling of similar to5degrees to 9degreesC. After 30,000 years of compositional stability, a steady turnover of species marks the 8000-year-long transition from ice-age to Holocene conditions. Although the changes were directional, the rates of community change were no different during this transitional period than in the preceding 30,000-year period of community stability. The warming rate of about 1degreesC per millennium during the Pleistocene-Holocene transition was an order of magnitude less than the projected changes for the 21st century.	Florida Inst Technol, Melbourne, FL 32901 USA; Wake Forest Univ, Dept Biol, Winston Salem, NC 27109 USA	Florida Institute of Technology; Wake Forest University	Bush, MB (corresponding author), Florida Inst Technol, 150 W Univ Blvd, Melbourne, FL 32901 USA.	mbush@fit.edu; silmanmr@wfu.org	Urrego, Dunia/A-6545-2010	Urrego, Dunia H./0000-0001-7938-5529; Bush, Mark/0000-0001-6894-8613				Baker PA, 2001, NATURE, V409, P698, DOI 10.1038/35055524; Baker PA, 2001, SCIENCE, V291, P640, DOI 10.1126/science.291.5504.640; Bush MB, 2000, QUATERNARY RES, V54, P132, DOI 10.1006/qres.2000.2138; Bush MB, 2002, J PALEOLIMNOL, V27, P341, DOI 10.1023/A:1016059415848; Cavelier J, 1997, J HYDROL, V193, P83, DOI 10.1016/S0022-1694(96)03151-4; Clark JS, 2003, NATURE, V423, P635, DOI 10.1038/nature01632; Clark JS, 2001, AM NAT, V157, P537, DOI 10.1086/319934; Colinvaux P., 1999, AMAZON POLLEN MANUAL; Colinvaux PA, 1997, QUATERNARY RES, V48, P69, DOI 10.1006/qres.1997.1908; GRABANDT RAJ, 1985, THESIS U AMSTERDAM; HANSEN BCS, 1995, QUATERNARY RES, V44, P216, DOI 10.1006/qres.1995.1066; Hooghiemstra H, 1995, BIODIVERSITY AND CONSERVATION OF NEOTROPICAL MONTANE FORESTS, P35; Hubbell Stephen P., 2001, V32, pi; *INT PAN CLIM CHAN, 2001, IPCC SUMM POL CLIM C; Iversen J, 1989, J BIOGEOGR; Mayle FE, 2000, SCIENCE, V290, P2291, DOI 10.1126/science.290.5500.2291; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Paduano GM, 2003, PALAEOGEOGR PALAEOCL, V194, P259, DOI 10.1016/S0031-0182(03)00281-5; Pounds JA, 1999, NATURE, V398, P611, DOI 10.1038/19297; Sandweiss DH, 1999, SCIENCE, V283, P499, DOI 10.1126/science.283.5401.499; Silverman B., 1986, DENSITY ESTIMATION S, V175; Thompson LG, 2002, SCIENCE, V298, P589, DOI 10.1126/science.1073198; Weng CY, 2004, J TROP ECOL, V20, P113, DOI 10.1017/S0266467403001068	23	225	232	2	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					827	829		10.1126/science.1090795	http://dx.doi.org/10.1126/science.1090795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764876				2022-12-28	WOS:000188753800054
J	Savina, MR; Davis, AM; Tripa, CE; Pellin, MJ; Gallino, R; Lewis, RS; Amari, S				Savina, MR; Davis, AM; Tripa, CE; Pellin, MJ; Gallino, R; Lewis, RS; Amari, S			Extinct technetium in silicon carbide stardust grains: Implications for stellar nucleosynthesis	SCIENCE			English	Article							GIANT BRANCH STARS; S-PROCESS; ISOTOPIC COMPOSITION; MURCHISON METEORITE; NEUTRON-CAPTURE; CROSS-SECTIONS; CHONDRITES; MOLYBDENUM; ZIRCONIUM; STRONTIUM	The isotopic composition of ruthenium (Ru) in individual presolar silicon carbide (SiC) stardust grains bears the signature of s-process nucleosynthesis in asymptotic giant branch stars, plus an anomaly in Ru-99 that is explained by the in situ decay of technetium isotope Tc-99 in the grains. This finding, coupled with the observation of Tc spectral lines in certain stars, shows that the majority of presolar SiC grains come from low-mass asymptotic giant branch stars, and that the amount of Tc-99 produced in such stars is insufficient to have left a detectable Ru-99 anomaly in early solar system materials.	Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Univ Turin, Dipartimento Fis Gen, I-10125 Turin, Italy; Ist Nazl Fis Nucl, Sez Torino, I-10125 Turin, Italy; Washington Univ, Space Sci Lab, St Louis, MO 63130 USA; Washington Univ, Dept Phys, St Louis, MO 63130 USA	United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago; University of Chicago; University of Turin; Istituto Nazionale di Fisica Nucleare (INFN); Washington University (WUSTL); Washington University (WUSTL)	Savina, MR (corresponding author), Argonne Natl Lab, Div Mat Sci, 9700 S Cass Ave, Argonne, IL 60439 USA.	msavina@anl.gov	Pellin, Michael J/B-5897-2008	Pellin, Michael J/0000-0002-8149-9768; Davis, Andrew/0000-0001-7955-6236; Savina, Michael/0000-0002-3077-618X				AMARI S, 1995, METEORITICS, V30, P679, DOI 10.1111/j.1945-5100.1995.tb01165.x; AMARI S, 1994, GEOCHIM COSMOCHIM AC, V58, P459, DOI 10.1016/0016-7037(94)90477-4; Arlandini C, 1999, ASTROPHYS J, V525, P886, DOI 10.1086/307938; Bao ZY, 2000, ATOM DATA NUCL DATA, V76, P70, DOI 10.1006/adnd.2000.0838; Becker H, 2003, CHEM GEOL, V196, P43, DOI 10.1016/S0009-2541(02)00406-0; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; CHEN JH, 2003, LUNAR PLANET SCI, V34, P1789; FEGLEY B, 1993, METEORITICS, V28, P346; Gallino R, 1998, ASTROPHYS J, V497, P388, DOI 10.1086/305437; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; HOPPE P, 1996, ASTROPHYSICAL IMPLIC, P27; HUTCHEON ID, 1987, GEOCHIM COSMOCHIM AC, V51, P3175, DOI 10.1016/0016-7037(87)90126-8; KASHIV Y, COMMUNICATION; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; LITTLE SJ, 1987, ASTRON J, V94, P981, DOI 10.1086/114532; Lugaro M, 2003, ASTROPHYS J, V593, P486, DOI 10.1086/376442; MA Z, 1995, REV SCI INSTRUM, V66, P3168, DOI 10.1063/1.1145546; MERRILL PW, 1952, ASTROPHYS J, V116, P21; MEYER BS, 1994, ANNU REV ASTRON ASTR, V32, P153; Nicolussi GK, 1998, PHYS REV LETT, V81, P3583, DOI 10.1103/PhysRevLett.81.3583; Nicolussi GK, 1997, SCIENCE, V277, P1281, DOI 10.1126/science.277.5330.1281; Nicolussi GK, 1998, GEOCHIM COSMOCHIM AC, V62, P1093, DOI 10.1016/S0016-7037(98)00038-6; POTHS H, 1987, GEOCHIM COSMOCHIM AC, V51, P1143, DOI 10.1016/0016-7037(87)90207-9; Savina MR, 2003, GEOCHIM COSMOCHIM AC, V67, P3201, DOI 10.1016/S0016-7037(03)00083-8; Savina MR, 2003, GEOCHIM COSMOCHIM AC, V67, P3215, DOI [10.1016/S0016-7037(03)00082-6, 10.1016/S0016-7037(00)00082-6]; SMITH VV, 1986, ASTROPHYS J, V311, P843, DOI 10.1086/164823; TAKAHASHI K, 1987, ATOM DATA NUCL DATA, V36, P375, DOI 10.1016/0092-640X(87)90010-6; VOSS F, 1994, PHYS REV C, V50, P2582, DOI 10.1103/PhysRevC.50.2582; WASSERBURG GJ, 1994, ASTROPHYS J, V424, P412, DOI 10.1086/173899; WILLIAMSON JH, 1968, CAN J PHYS, V46, P1845, DOI 10.1139/p68-523; Zinner E, 1998, METEORIT PLANET SCI, V33, P549, DOI 10.1111/j.1945-5100.1998.tb01664.x	31	68	69	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	2004	303	5658					649	652		10.1126/science.3030649	http://dx.doi.org/10.1126/science.3030649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752154	Green Published			2022-12-28	WOS:000188530800033
J	Kokoszka, JE; Waymire, KG; Levy, SE; Sligh, JE; Cal, JY; Jones, DP; MacGregor, GR; Wallace, DC				Kokoszka, JE; Waymire, KG; Levy, SE; Sligh, JE; Cal, JY; Jones, DP; MacGregor, GR; Wallace, DC			The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore	NATURE			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; OXIDATIVE STRESS; CYCLOSPORINE-A; APOPTOSIS; HEPATOCYTES; EXPRESSION; GENES; ADP; AGE	A sudden increase in permeability of the inner mitochondrial membrane, the so-called mitochondrial permeability transition, is a common feature of apoptosis and is mediated by the mitochondrial permeability transition pore (mtPTP). It is thought that the mtPTP is a protein complex formed by the voltage-dependent anion channel, members of the pro- and antiapoptotic BAX-BCL2 protein family, cyclophilin D, and the adenine nucleotide (ADP/ATP) translocators (ANTs)(1,2). The latter exchange mitochondrial ATP for cytosolic ADP and have been implicated in cell death. To investigate the role of the ANTs in the mtPTP, we genetically inactivated the two isoforms of ANT(3-5) in mouse liver and analysed mtPTP activation in isolated mitochondria and the induction of cell death in hepatocytes. Mitochondria lacking ANT could still be induced to undergo permeability transition, resulting in release of cytochrome c. However, more Ca2+ than usual was required to activate the mtPTP, and the pore could no longer be regulated by ANT ligands. Moreover, hepatocytes without ANT remained competent to respond to various initiators of cell death. Therefore, ANTs are non-essential structural components of the mtPTP, although they do contribute to its regulation.	Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Emory University; Emory University; Emory University	Wallace, DC (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.	dwallace@uci.edu		Levy, Shawn/0000-0002-1369-5740	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036437, U01HD045913] Funding Source: NIH RePORTER; NICHD NIH HHS [U01 HD045913-01, R01 HD036437-04, R01 HD036437-02, R01 HD036437-03, R01 HD036437-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Ellison JW, 1996, GENOMICS, V36, P369, DOI 10.1006/geno.1996.0478; Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; LEIST M, 1994, J IMMUNOL, V153, P1778; Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	20	851	881	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					461	465		10.1038/nature02229	http://dx.doi.org/10.1038/nature02229			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749836	Green Accepted			2022-12-28	WOS:000188470500048
J	Krinner, G; Mangerud, J; Jakobsson, M; Crucifix, M; Ritz, C; Svendsen, JI				Krinner, G; Mangerud, J; Jakobsson, M; Crucifix, M; Ritz, C; Svendsen, JI			Enhanced ice sheet growth in Eurasia owing to adjacent ice-dammed lakes	NATURE			English	Article							SPATIAL VARIABILITY; CLIMATE	Large proglacial lakes cool regional summer climate because of their large heat capacity, and have been shown to modify precipitation through mesoscale atmospheric feedbacks, as in the case of Lake Agassiz(1). Several large ice-dammed lakes, with a combined area twice that of the Caspian Sea, were formed in northern Eurasia about 90,000 years ago, during the last glacial period when an ice sheet centred over the Barents and Kara seas(2) blocked the large northbound Russian rivers(3). Here we present high-resolution simulations with an atmospheric general circulation model that explicitly simulates the surface mass balance of the ice sheet. We show that the main influence of the Eurasian proglacial lakes was a significant reduction of ice sheet melting at the southern margin of the Barents - Kara ice sheet through strong regional summer cooling over large parts of Russia. In our simulations, the summer melt reduction clearly outweighs lake-induced decreases in moisture and hence snowfall, such as has been reported earlier for Lake Agassiz1. We conclude that the summer cooling mechanism from proglacial lakes accelerated ice sheet growth and delayed ice sheet decay in Eurasia and probably also in North America.	UJF, CNRS, LGGE, F-38402 St Martin Dheres, France; Univ Bergen, Dept Earth Sci, N-5007 Bergen, Norway; Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; Ctr Coastal & Ocean Mapping, Joint Hydrog Ctr, Chase Ocean Engn Lab, Durham, NH 03824 USA; Catholic Univ Louvain, Inst Astron & Geophys G Lemaitre, B-1348 Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Bergen; Bjerknes Centre for Climate Research; Universite Catholique Louvain	Krinner, G (corresponding author), UJF, CNRS, LGGE, BP 96, F-38402 St Martin Dheres, France.	krinner@ujf-grenoble.fr	Krinner, Gerhard/A-6450-2011; Krinner, Gerhard/AAB-8837-2022; Jakobsson, Martin/F-6214-2010	Krinner, Gerhard/0000-0002-2959-5920; Krinner, Gerhard/0000-0002-2959-5920; Jakobsson, Martin/0000-0002-9033-3559; Ritz, Catherine/0000-0003-0785-8571				BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; Charbit S, 2002, QUATERNARY SCI REV, V21, P243, DOI 10.1016/S0277-3791(01)00093-2; Clarke G, 2003, SCIENCE, V301, P922, DOI 10.1126/science.1085921; CROWLEY TJ, 1995, GLOBAL BIOGEOCHEM CY, V9, P377, DOI 10.1029/95GB01107; Crucifix M, 2002, CLIM DYNAM, V19, P43, DOI 10.1007/s00382-001-0208-6; deNoblet NI, 1996, GEOPHYS RES LETT, V23, P3191, DOI 10.1029/96GL03004; Gallimore RG, 1996, NATURE, V381, P503, DOI 10.1038/381503a0; Genthon C, 2001, J GEOPHYS RES-ATMOS, V106, P20653, DOI 10.1029/2001JD900136; Hostetler SW, 2000, NATURE, V405, P334, DOI 10.1038/35012581; Khodri M, 2001, NATURE, V410, P570, DOI 10.1038/35069044; Krinner G, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002597; Krinner G, 2003, EARTH PLANET SC LETT, V216, P525, DOI 10.1016/S0012-821X(03)00550-8; Krinner G, 1997, J GEOPHYS RES-ATMOS, V102, P13731, DOI 10.1029/96JD03356; LEGATES DR, 1990, INT J CLIMATOL, V10, P111, DOI 10.1002/joc.3370100202; LEGATES DR, 1990, THEOR APPL CLIMATOL, V41, P11, DOI 10.1007/BF00866198; Lundqvist J., 1992, GEOLOGICAL SURVEY FI, V15, P43; Mangerud J, 2001, GLOBAL PLANET CHANGE, V31, P321, DOI 10.1016/S0921-8181(01)00127-8; Mangerud J, 2001, J QUATERNARY SCI, V16, P773, DOI 10.1002/jqs.661; MANGERUD J, IN PRESS QUAT SCI RE; Marshall SJ, 2000, CAN J EARTH SCI, V37, P769, DOI [10.1139/cjes-37-5-769, 10.1139/e99-113]; NELSON FE, 1987, ARCTIC ALPINE RES, V19, P279, DOI 10.2307/1551363; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Siegert MJ, 2001, GLOBAL PLANET CHANGE, V31, P367, DOI 10.1016/S0921-8181(01)00130-8; SVENDSEN JI, IN PRESS QUAT SCI RE; TELLER JT, 2003, QUATERNARY PERIOD US, pCH3; Thompson SL, 1997, J CLIMATE, V10, P871, DOI 10.1175/1520-0442(1997)010<0871:GAAMBF>2.0.CO;2	27	67	68	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					429	432		10.1038/nature02233	http://dx.doi.org/10.1038/nature02233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749827				2022-12-28	WOS:000188470500039
J	Audetat, A; Keppler, H				Audetat, A; Keppler, H			Viscosity of fluids in subduction zones	SCIENCE			English	Article							COMPLETE MISCIBILITY; MANTLE METASOMATISM; SILICATE MELTS; OCEANIC-CRUST; MINERALS; H2O	The viscosities of aqueous fluids with 10 to 80 weight percent dissolved silicates have been measured at 600degrees to 950degreesC and 1.0 to 2.0 gigapascals by in situ observation of falling spheres in the diamond anvil cell. The viscosities at 800degreesC range from 10(-4) to 10(0.5) pascal seconds. The combination of low viscosities with a favorable wetting angle makes silicate-rich fluid an efficient agent for material transport at low-volume fractions. Our results therefore suggest that there may be a direct relationship between the position of the volcanic front and the onset of complete miscibility between water and silicate melt in the subducting slab.	Univ Tubingen, Inst Geowissensch, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen	Audetat, A (corresponding author), Univ Tubingen, Inst Geowissensch, D-72074 Tubingen, Germany.	andreas.audetat@uni-tuebingen.de		Audetat, Andreas/0000-0002-6176-4122				Adam J, 1997, EUR J MINERAL, V9, P569; BASSETT WA, 1993, REV SCI INSTRUM, V64, P2340, DOI 10.1063/1.1143931; Bureau H, 1999, EARTH PLANET SC LETT, V165, P187, DOI 10.1016/S0012-821X(98)00266-0; Dingwell D.B., 1987, MAGMATIC PROCESSES P, V1, P423; Doremus RH., 1994, GLASS SCI, V2nd ed; GILL JB, 1980, OROGENIC ANDESITES P; Hermann J, 2001, EARTH PLANET SC LETT, V188, P149, DOI 10.1016/S0012-821X(01)00321-1; KUSHIRO I, 1978, EARTH PLANET SC LETT, V41, P87, DOI 10.1016/0012-821X(78)90044-4; LANGE RA, 1994, REV MINERAL, V30, P331; Newton RC, 2002, GEOCHIM COSMOCHIM AC, V66, P4165, DOI 10.1016/S0016-7037(02)00998-5; Ono S, 2002, EARTH PLANET SC LETT, V203, P895, DOI 10.1016/S0012-821X(02)00920-2; Prouteau G, 2001, NATURE, V410, P197, DOI 10.1038/35065583; RAPP RP, 1995, J PETROL, V36, P891, DOI 10.1093/petrology/36.4.891; Romano C, 2001, CHEM GEOL, V174, P115, DOI 10.1016/S0009-2541(00)00311-9; SCHNEIDER ME, 1986, GEOCHIM COSMOCHIM AC, V50, P711, DOI 10.1016/0016-7037(86)90347-9; Scholze H., 1988, GLAS NATUR STRUKTUR; Schulze F, 1996, AM MINERAL, V81, P1155; SHAW HR, 1972, AM J SCI, V272, P870, DOI 10.2475/ajs.272.9.870; Shen AH, 1997, NATURE, V385, P710, DOI 10.1038/385710a0; SHEN AH, 1992, HIGH PRESSURE RES AP, P61; TATSUMI Y, 1986, GEOPHYS RES LETT, V13, P717, DOI 10.1029/GL013i008p00717; Tatsumi Y., 1995, SUBDUCTION ZONE MAGM; Turner SP, 2000, PHILOS T ROY SOC A, V358, P1443, DOI 10.1098/rsta.2000.0598; WANNAMAKER BJ, 1991, PHYS CHEM MINER, V18, P26; Watson EB., 1990, CONTINENTAL MANTLE, P111	25	97	107	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					513	516		10.1126/science.1092282	http://dx.doi.org/10.1126/science.1092282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739456				2022-12-28	WOS:000188316400035
J	De Libero, G				De Libero, G			Immunology - The Robin Hood of antigen presentation	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; MOLECULES; SAPOSINS; ANGSTROM; CD1		Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland	University of Basel	De Libero, G (corresponding author), Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland.	gennaro.delibero@unibas.ch	De Libero, Gennaro/P-2694-2017	De Libero, Gennaro/0000-0003-0853-7868				Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353; Neyrolles O, 2001, J IMMUNOL, V166, P447, DOI 10.4049/jimmunol.166.1.447; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; Speir JA, 1999, IMMUNITY, V10, P51, DOI 10.1016/S1074-7613(00)80006-0; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	12	10	10	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					485	+		10.1126/science.1093953	http://dx.doi.org/10.1126/science.1093953			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739449				2022-12-28	WOS:000188316400027
J	Kadonaga, JT				Kadonaga, JT			Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors	CELL			English	Review							HUMAN GLUCOCORTICOID RECEPTOR; MAJOR LATE PROMOTER; WHOLE-CELL EXTRACT; NUCLEAR FACTOR-I; NF-KAPPA-B; GENE-EXPRESSION; CHROMATIN-STRUCTURE; ACTIVATOR PROTEIN; ENHANCER-BINDING; MAMMALIAN-CELLS	In eukaryotes, transcription of the diverse array of tens of thousands of protein-coding genes is carried out by RNA polymerase II. The control of this process is predominantly mediated by a network of thousands of sequence-specific DNA binding transcription factors that interpret the genetic regulatory information, such as in transcriptional enhancers and promoters, and transmit the appropriate response to the RNA polymerase II transcriptional machinery. This review will describe some early advances in the discovery and characterization of the sequence-specific DNA binding transcription factors as well as some of the properties of these regulatory proteins.	Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA.	jkadonaga@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058272] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41249, GM46995, GM58272] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Blau J, 1996, MOL CELL BIOL, V16, P2044; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; Calhoun VC, 2002, P NATL ACAD SCI USA, V99, P9243, DOI 10.1073/pnas.142291299; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Glass CK, 2000, GENE DEV, V14, P121; Goldberg M.L., 1979, THESIS STANFORD U ST; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Goodman RH, 2000, GENE DEV, V14, P1553; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVINDAN MV, 1985, NUCLEIC ACIDS RES, V13, P8293, DOI 10.1093/nar/13.23.8293; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; HANDA H, 1981, J BIOL CHEM, V256, P478; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; Kuhn EJ, 2003, CURR OPIN CELL BIOL, V15, P259, DOI 10.1016/S0955-0674(03)00039-5; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PAYVAR F, 1981, P NATL ACAD SCI-BIOL, V78, P6628, DOI 10.1073/pnas.78.11.6628; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRUHL K, 1981, P NATL ACAD SCI-BIOL, V78, P4461, DOI 10.1073/pnas.78.7.4461; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WASYLYK B, 1980, NATURE, V285, P366; WEIL PA, 1979, CELL, V18, P469; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WOLFFE A, 1992, CHROMATIN STRUCTURE; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU GJ, 1978, P NATL ACAD SCI USA, V75, P2175, DOI 10.1073/pnas.75.5.2175; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	135	264	338	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					247	257		10.1016/S0092-8674(03)01078-X	http://dx.doi.org/10.1016/S0092-8674(03)01078-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744435	Bronze			2022-12-28	WOS:000188541700014
J	Federman, DD				Federman, DD			Three facets of sexual differentiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University	Federman, DD (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.								0	8	11	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					323	324		10.1056/NEJMp038175	http://dx.doi.org/10.1056/NEJMp038175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736921				2022-12-28	WOS:000188254800001
J	Dewar, H; Tanaka, K; Nasmyth, K; Tanaka, TU				Dewar, H; Tanaka, K; Nasmyth, K; Tanaka, TU			Tension between two kinetochores suffices for their bi-orientation on the mitotic spindle	NATURE			English	Article							DNA TOPOISOMERASE-II; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; AURORA-B; MICROTUBULE ATTACHMENT; PRECOCIOUS SEPARATION; PROTEIN-KINASE; MITOSIS; INCENP	The movement of sister chromatids to opposite spindle poles during anaphase depends on the prior capture of sister kinetochores by microtubules with opposing orientations (amphitelic attachment or bi-orientation)(1). In addition to proteins necessary for the kinetochore-microtubule attachment, bi-orientation requires the Ipl1 (Aurora B in animal cells) protein kinase(2-7) and tethering of sister chromatids by cohesin(8,9). Syntelic attachments, in which sister kinetochores attach to microtubules with the same orientation, must be either 'avoided' or 'corrected'. Avoidance might be facilitated by the juxtaposition of sister kinetochores such that they face in opposite directions; kinetochore geometry is therefore deemed important. Error correction, by contrast, is thought to stem from the stabilization of kinetochore-spindle pole connections by tension in microtubules, kinetochores, or the surrounding chromatin arising from amphitelic but not syntelic attachment(10,11). The tension model predicts that any type of connection between two kinetochores suffices for efficient bi-orientation. Here we show that the two kinetochores of engineered, unreplicated dicentric chromosomes in Saccharomyces cerevisiae bi-orient efficiently, implying that sister kinetochore geometry is dispensable for bi-orientation. We also show that Ipl1 facilitates bi-orientation by promoting the turnover of kinetochore-spindle pole connections in a tension-dependent manner.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Dundee; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Tanaka, TU (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	t.tanaka@dundee.ac.uk	Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Nasmyth, Kim/0000-0001-7030-4403; Tanaka, Kozo/0000-0001-6086-2858; Tanaka, Tomoyuki/0000-0002-9886-5947				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Thrower DA, 2001, MOL BIOL CELL, V12, P2800, DOI 10.1091/mbc.12.9.2800; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Vagnarelli P, 2004, EMBO REP, V5, P167, DOI 10.1038/sj.embor.7400077; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601	31	151	154	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					93	97		10.1038/nature02328	http://dx.doi.org/10.1038/nature02328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14961024				2022-12-28	WOS:000189363800042
J	Koranda, FC				Koranda, FC			Use of multinucleated giant cells to diagnose a viral eruption	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Kansas, Med Ctr, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Koranda, FC (corresponding author), Univ Kansas, Med Ctr, Kansas City, KS 66160 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					E6	E6		10.1056/ENEJMicm010775	http://dx.doi.org/10.1056/ENEJMicm010775			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960757				2022-12-28	WOS:000188869500012
J	Song, YM; Sung, JH; Lawlor, DA; Smith, GD; Shin, YS; Ebrahim, S				Song, YM; Sung, JH; Lawlor, DA; Smith, GD; Shin, YS; Ebrahim, S			Blood pressure, haemorrhagic stroke, and ischaemic stroke: the Korean national prospective occupational cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; CHOLESTEROL		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Family Med, Seoul, South Korea; Kangweon Natl Univ, Coll Med, Dept Prevent Med, Chunchon, Kangwon Do, South Korea; Seoul Natl Univ, Coll Med, Dept Hlth Policy & Management, Seoul, South Korea	University of Bristol; Sungkyunkwan University (SKKU); Samsung Medical Center; Kangwon National University; Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU)	Ebrahim, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	shah.ebrahim@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Lawlor, Debbie A/0000-0002-6793-2262				Lawlor DA, 2002, LANCET, V360, P1818, DOI 10.1016/S0140-6736(02)11769-7; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; McCarron P, 2001, BMJ-BRIT MED J, V322, P885, DOI 10.1136/bmj.322.7291.885; Rodgers A, 1998, LANCET, V352, P1801; Song YM, 2000, AM J EPIDEMIOL, V151, P739, DOI 10.1093/oxfordjournals.aje.a010272	5	38	41	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					324	325		10.1136/bmj.328.7435.324	http://dx.doi.org/10.1136/bmj.328.7435.324			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764495	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188926900022
J	Hardy, J; Francis, KP; DeBoer, M; Chu, P; Gibbs, K; Contag, CH				Hardy, J; Francis, KP; DeBoer, M; Chu, P; Gibbs, K; Contag, CH			Extracellular replication of Listeria monocytogenes in the murine gall bladder	SCIENCE			English	Article							INFECTIONS	The bacterium Listeria monocytogenes can cause a life-threatening systemic illness in humans. Despite decades of progress in animal models of listeriosis, much remains unknown about the processes of infection and colonization. Here, we report that L. monocytogenes can replicate in the murine gall bladder and provide evidence that its replication there is extracellular and intraluminal. In vivo bioluminescence imaging was employed to determine the location of the infection over time in live animals, revealing strong signals from the gall bladder over a period of several days, in diseased as well as asymptomatic animals. The data suggest that L. monocytogenes may be carried in the human gall bladder.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Xenogen Corp, Alameda, CA 94501 USA	Stanford University; Stanford University; Stanford University	Contag, CH (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.	ccontag@cmgm.stanford.edu	Hamblin, Mike/AAB-2511-2022; Hardy, Jonathan/AAO-9306-2020; Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Gibbs, Karine/0000-0002-1246-6401; Contag, Christopher/0000-0002-1011-8278	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037543] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD37543] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRIONES V, 1992, AM J VET RES, V53, P191; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Contag CH, 1995, MOL MICROBIOL, V18, P593, DOI 10.1111/j.1365-2958.1995.mmi_18040593.x; Crum Nancy F, 2002, Curr Gastroenterol Rep, V4, P287, DOI 10.1007/s11894-002-0078-z; Dramsi S, 2002, J CELL BIOL, V156, P943, DOI 10.1083/jcb.200202121; Dussurget O, 2002, MOL MICROBIOL, V45, P1095, DOI 10.1046/j.1365-2958.2002.03080.x; Francis KP, 2000, INFECT IMMUN, V68, P3594, DOI 10.1128/IAI.68.6.3594-3600.2000; Francis KP, 2001, INFECT IMMUN, V69, P3350, DOI 10.1128/IAI.69.5.3350-3358.2001; GORDON S, 1986, J INFECT DIS, V154, P918, DOI 10.1093/infdis/154.5.918; HARDY JG, UNPUB; Lauer P, 2002, J BACTERIOL, V184, P4177, DOI 10.1128/JB.184.15.4177-4186.2002; Lecuit M, 2001, SCIENCE, V292, P1722, DOI 10.1126/science.1059852; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; Rice BW, 2001, J BIOMED OPT, V6, P432, DOI 10.1117/1.1413210; Smith GA, 1997, TRENDS MICROBIOL, V5, P272, DOI 10.1016/S0966-842X(97)01048-2	16	185	201	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					851	853		10.1126/science.1092712	http://dx.doi.org/10.1126/science.1092712			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764883				2022-12-28	WOS:000188753800062
J	Zimdahl, H; Nyakatura, G; Brandt, P; Schulz, H; Hummel, O; Fartmann, B; Brett, D; Droege, M; Monti, J; Lee, YA; Sun, YY; Zhao, SY; Winter, EE; Ponting, CP; Chen, Y; Kasprzyk, A; Birney, E; Ganten, D; Hubner, N				Zimdahl, H; Nyakatura, G; Brandt, P; Schulz, H; Hummel, O; Fartmann, B; Brett, D; Droege, M; Monti, J; Lee, YA; Sun, YY; Zhao, SY; Winter, EE; Ponting, CP; Chen, Y; Kasprzyk, A; Birney, E; Ganten, D; Hubner, N			A SNP map of the rat genome generated from cDNA sequences	SCIENCE			English	Article									Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; MWG, D-85560 Ebersberg, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Inst Genom Res, Rockville, MD 20850 USA; Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford OX1 3QX, England; European Bioinformat Inst, EMBL, Cambridge CB10 1SD, England	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; J. Craig Venter Institute; University of Oxford; European Molecular Biology Laboratory (EMBL)	Hubner, N (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	nhuebner@mdc-berlin.de	Ponting, Chris/AAV-2621-2021	Ponting, Chris/0000-0003-0202-7816; Birney, Ewan/0000-0001-8314-8497				Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252	5	44	46	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					807	807		10.1126/science.1092427	http://dx.doi.org/10.1126/science.1092427			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764869				2022-12-28	WOS:000188753800047
J	Rost, S; Fregin, A; Ivaskevicius, V; Conzelmann, E; Hortnagel, K; Pelz, HJ; Lappegard, K; Seifried, E; Scharrer, I; Tuddenham, EGD; Muller, CR; Strom, TM; Oldenburg, J				Rost, S; Fregin, A; Ivaskevicius, V; Conzelmann, E; Hortnagel, K; Pelz, HJ; Lappegard, K; Seifried, E; Scharrer, I; Tuddenham, EGD; Muller, CR; Strom, TM; Oldenburg, J			Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2	NATURE			English	Article							VITAMIN-K 2,3-EPOXIDE; GAMMA-GLUTAMYL CARBOXYLASE; ENDOPLASMIC-RETICULUM; EPOXIDE-REDUCTASE; RAT-LIVER; IDENTIFICATION; PROTHROMBIN; METABOLISM; COMPLEX; LOCUS	Coumarin derivatives such as warfarin represent the therapy of choice for the long-term treatment and prevention of thromboembolic events. Coumarins target blood coagulation by inhibiting the vitamin K epoxide reductase multiprotein complex (VKOR)(1). This complex recycles vitamin K 2,3-epoxide to vitamin K hydroquinone, a cofactor that is essential for the post-translational gamma-carboxylation of several blood coagulation factors(2,3). Despite extensive efforts, the components of the VKOR complex have not been identified(4-8). The complex has been proposed to be involved in two heritable human diseases: combined deficiency of vitamin-K-dependent clotting factors type 2 (VKCFD2; Online Mendelian Inheritance in Man (OMIM) 607473), and resistance to coumarin-type anticoagulant drugs (warfarin resistance, WR; OMIM 122700). Here we identify, by using linkage information from three species, the gene vitamin K epoxide reductase complex subunit 1 (VKORC1), which encodes a small transmembrane protein of the endoplasmic reticulum. VKORC1 contains missense mutations in both human disorders and in a warfarin-resistant rat strain. Overexpression of wildtype VKORC1, but not VKORC1 carrying the VKCFD2 mutation, leads to a marked increase in VKOR activity, which is sensitive to warfarin inhibition.	Univ Wurzburg, Biozentrum, Dept Human Genet, D-97074 Wurzburg, Germany; GSF, Natl Res Ctr, Inst Human Genet, D-85764 Munich, Germany; Univ Frankfurt, DRK Blood Donor Serv, Inst Transfus Med & Immune Haematol, D-60526 Frankfurt, Germany; Univ Wurzburg, Biozentrum, Dept Physiol Chem 2, D-97074 Wurzburg, Germany; Fed Biol Res Ctr Agr & Forestry, Inst Nematol & Vertebrate Res, D-48161 Munster, Germany; Nordland Hosp, Dept Med, N-8092 Bodo, Norway; Univ Frankfurt, Ctr Internal Med, D-60528 Frankfurt, Germany; Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, London W12 0NN, England; Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-81675 Munich, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Goethe University Frankfurt; University of Wurzburg; Goethe University Frankfurt; Imperial College London; Technical University of Munich	Oldenburg, J (corresponding author), Univ Wurzburg, Biozentrum, Dept Human Genet, D-97074 Wurzburg, Germany.	joldenburg@bsdhessen.de	Oldenburg, Johannes/ABB-7817-2020; Scharrer, Inge/N-2999-2013; Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909; Oldenburg, Johannes/0000-0002-1585-4100				Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Begent LA, 2001, J PHARM PHARMACOL, V53, P481, DOI 10.1211/0022357011775776; Cain D, 1997, J BIOL CHEM, V272, P29068, DOI 10.1074/jbc.272.46.29068; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; FASCO MJ, 1983, J BIOL CHEM, V258, P4372; Fregin A, 2002, BLOOD, V100, P3229, DOI 10.1182/blood-2002-03-0698; GREAVES JH, 1967, NATURE, V215, P877, DOI 10.1038/215877a0; Hortnagel K, 2003, HUM MOL GENET, V12, P321, DOI 10.1093/hmg/ddg026; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kohn MH, 1999, MAMM GENOME, V10, P696, DOI 10.1007/s003359901073; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; MARTIN AD, 1979, LAB ANIM, V13, P209, DOI 10.1258/002367779780937852; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; Oldenburg J, 2000, THROMB HAEMOSTASIS, V84, P937; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Romero EE, 1998, EXP CELL RES, V243, P334, DOI 10.1006/excr.1998.4151; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Suttie J W, 1987, Adv Exp Med Biol, V214, P3; THIJSSEN HH, 2001, ADV VERTEBRATE PEST, P181; WALLACE ME, 1976, J HYG-CAMBRIDGE, V76, P173, DOI 10.1017/S0022172400055078; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje	23	888	965	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					537	541		10.1038/nature02214	http://dx.doi.org/10.1038/nature02214			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765194				2022-12-28	WOS:000188721800040
J	Iglehart, JK				Iglehart, JK			The mental health maze and the call for transformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRESIDENTS; MEDICAID; POLICIES; PARITY											Alegria M, 2003, HEALTH AFFAIR, V22, P51, DOI 10.1377/hlthaff.22.5.51; APPELBAUM PS, 2003, HLTH AFF MILLWOOD, V22, P1110; BARRY CL, 2003, HLTH AFF MILLWOOD, V222, P127; *BAZ CTR MENT HLTH, 2002, DIST SYST STAT STAT; CUNNINGHAM R, 2003, MENTAL HLTH COMMISSI; *DHHS, 2003, DHHS PUBL; Feldman S, 2003, PSYCHIAT SERV, V54, P1482, DOI 10.1176/appi.ps.54.11.1482; Frank RG, 2003, HEALTH AFFAIR, V22, P101, DOI 10.1377/hlthaff.22.1.101; Frank RG, 2000, HANDB ECON, V17, P893; Frank RG, 2001, NEW ENGL J MED, V345, P1701, DOI 10.1056/NEJM200112063452311; Gitterman DP, 2001, HEALTH AFFAIR, V20, P68, DOI 10.1377/hlthaff.20.4.68; Goin MK, 2003, PSYCHIAT SERV, V54, P1480, DOI 10.1176/appi.ps.54.11.1480; Goldman HH, 2003, HEALTH AFFAIR, V22, P65, DOI 10.1377/hlthaff.22.5.65; Goldman W, 1998, HEALTH AFFAIR, V17, P40, DOI 10.1377/hlthaff.17.2.40; Hennessy KD, 2001, HEALTH AFFAIR, V20, P58, DOI 10.1377/hlthaff.20.4.58; Hogan MF, 2003, PSYCHIAT SERV, V54, P1467, DOI 10.1176/appi.ps.54.11.1467; KOYANAGI C, 1991, INCHING FORWARD REPO; Mechanic D, 2003, HEALTH AFFAIR, V22, P8, DOI 10.1377/hlthaff.22.5.8; *MENT HLTH FUND CO, 2003, STAT MENT HLTH CAR C; *PRES NEW FREED CO, 2003, MAJ FED PROGR SUPP F; *PUBL HLTH SERV, 2001, NAT STRAT SUIC PREV; Public Health Service, 1999, MENT HLTH REP SURG G; Rowland D, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.5.73; 1999, MMWR MORB MORTAL WKL, V48, P1053; 1978, REPORT PRESIDENT PRE; 2002, FED REG, V67, P22337	26	16	17	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					507	514		10.1056/NEJMhpr032740	http://dx.doi.org/10.1056/NEJMhpr032740			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	767QJ	14749461				2022-12-28	WOS:000188463900016
J	Meunier, PJ; Roux, C; Seeman, E; Ortolani, S; Badurski, JE; Spector, TD; Cannata, J; Balogh, A; Lemmel, EM; Pors-Nielsen, S; Rizzoli, R; Genant, HK; Reginster, JY; Graham, J; Ng, KW; Prince, R; Prins, J; Seeman, E; Wark, J; Reginster, JY; Devogelaer, JP; Kaufman, JM; Raeman, F; Ziekenhuis, JP; Walravens, M; Pors-Nielsen, S; Beck-Nielsen, H; Charles, P; Sorensen, OH; Meunier, PJ; Aquino, JP; Benhamou, C; Blotman, F; Bonidan, O; Bourgeois, P; Dehais, J; Fardellone, P; Kahan, A; Kuntz, JL; Marcelli, C; Prost, A; Vellas, B; Weryha, G; Lemmel, EM; Felsenberg, D; Hensen, J; Kruse, HP; Schmidt, W; Semler, J; Stucki, G; Phenekos, C; Balogh, A; De Chatel, R; Ortolani, S; Adami, S; Bianchi, G; Brandi, ML; Cucinotta, D; Fiore, C; Gennari, C; Isaia, G; Luisetto, G; Passariello, R; Passeri, M; Rovetta, G; Tessari, L; Badurski, JE; Hoszowski, K; Lorenc, RS; Sawicki, A; Diez, A; Cannata, JB; Curiel, MD; Rapado, A; Gijon, J; Torrijos, A; Padrino, JM; Varela, AR; Bonjour, JP; Rizzoli, R; Spector, TD; Clements, M; Doyle, DV; Ryan, P; Smith, IG; Smith, R				Meunier, PJ; Roux, C; Seeman, E; Ortolani, S; Badurski, JE; Spector, TD; Cannata, J; Balogh, A; Lemmel, EM; Pors-Nielsen, S; Rizzoli, R; Genant, HK; Reginster, JY; Graham, J; Ng, KW; Prince, R; Prins, J; Seeman, E; Wark, J; Reginster, JY; Devogelaer, JP; Kaufman, JM; Raeman, F; Ziekenhuis, JP; Walravens, M; Pors-Nielsen, S; Beck-Nielsen, H; Charles, P; Sorensen, OH; Meunier, PJ; Aquino, JP; Benhamou, C; Blotman, F; Bonidan, O; Bourgeois, P; Dehais, J; Fardellone, P; Kahan, A; Kuntz, JL; Marcelli, C; Prost, A; Vellas, B; Weryha, G; Lemmel, EM; Felsenberg, D; Hensen, J; Kruse, HP; Schmidt, W; Semler, J; Stucki, G; Phenekos, C; Balogh, A; De Chatel, R; Ortolani, S; Adami, S; Bianchi, G; Brandi, ML; Cucinotta, D; Fiore, C; Gennari, C; Isaia, G; Luisetto, G; Passariello, R; Passeri, M; Rovetta, G; Tessari, L; Badurski, JE; Hoszowski, K; Lorenc, RS; Sawicki, A; Diez, A; Cannata, JB; Curiel, MD; Rapado, A; Gijon, J; Torrijos, A; Padrino, JM; Varela, AR; Bonjour, JP; Rizzoli, R; Spector, TD; Clements, M; Doyle, DV; Ryan, P; Smith, IG; Smith, R			The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAINTAINING BONE-FORMATION; PARATHYROID-HORMONE; RANDOMIZED-TRIAL; MINERAL DENSITY; ALENDRONATE; RESORPTION; PREVALENT; ESTROGEN; QUALITY; 2-YEAR	BACKGROUND: Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that dissociates bone remodeling by increasing bone formation and decreasing bone resorption, has been shown to reduce the risk of vertebral fractures and to increase bone mineral density. METHODS: To evaluate the efficacy of strontium ranelate in preventing vertebral fractures in a phase 3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium ranelate per day or placebo for three years. We gave calcium and vitamin D supplements to both groups before and during the study. Vertebral radiographs were obtained annually, and measurements of bone mineral density were performed every six months. RESULTS: New vertebral fractures occurred in fewer patients in the strontium ranelate group than in the placebo group, with a risk reduction of 49 percent in the first year of treatment and 41 percent during the three-year study period (relative risk, 0.59; 95 percent confidence interval, 0.48 to 0.73). Strontium ranelate increased bone mineral density at month 36 by 14.4 percent at the lumbar spine and 8.3 percent at the femoral neck (P<0.001 for both comparisons). There were no significant differences between the groups in the incidence of serious adverse events. CONCLUSIONS: Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures.	Hop Edouard Herriot, Dept Rheumatol & Bone Dis, F-69437 Lyon 03, France; Univ Paris 05, Cochin Hosp, Dept Rheumatol, Paris, France; Univ Melbourne, Austin Hosp, Endocrine Unit, Melbourne, Vic, Australia; Ist Auxol Italiano, Ctr Metab Bone Dis, Milan, Italy; Ctr Osteoporosis & Osteoarticular Dis, Bialystok, Poland; St Thomas Hosp, Dept Rheumatol, London, England; Univ Oviedo, Hosp Cent Asturias, Mineral & Bone Dept, E-33080 Oviedo, Spain; Univ Debrecen, Med & Hlth Sci Ctr, Dept Obstet & Gynecol, Debrecen, Hungary; Max Grundig Klin, Buhl, Germany; Hillerod Hosp, Dept Clin Physiol, Hillerod, Denmark; Univ Hosp, Dept Internal Med, Div Bone Dis, Geneva, Switzerland; Univ Calif San Francisco, Osteoporosis & Arthrit Grp, San Francisco, CA 94143 USA; Univ Liege, WHO, Collaborating Ctr Publ Hlth Aspects Osteoarticula, Dept Epidemiol & Publ Hlth, Liege, Belgium	CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; IRCCS Istituto Auxologico Italiano; Guy's & St Thomas' NHS Foundation Trust; Central University Hospital Asturias; University of Oviedo; University of Debrecen; University of Copenhagen; University of Geneva; University of California System; University of California San Francisco; University of Liege; World Health Organization	Meunier, PJ (corresponding author), Hop Edouard Herriot, Dept Rheumatol & Bone Dis, Pavillon F, F-69437 Lyon 03, France.	pierre.meunier@laennec.univ-lyon1.fr	Prins, Johannes B/M-5884-2013; Spector, Tim D/F-6533-2012; Seeman, Ego/AAC-3656-2019; Cannata-Andía, Jorge B L/L-2260-2013; Marcelli, Christian/O-2218-2015	Prins, Johannes B/0000-0001-9497-927X; Seeman, Ego/0000-0002-9692-048X; Cannata-Andía, Jorge B L/0000-0001-6543-9960; 				Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Boivin G, 1996, J BONE MINER RES, V11, P1302; Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756-3282(00)00376-8; Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756-3282(01)00484-7; Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756-3282(96)00080-4; Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668; Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756-3282(01)00419-7; Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS6; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; Genant HK, 1996, J BONE MINER RES, V11, P984; GRYNPAS MD, 1990, BONE, V11, P313, DOI 10.1016/8756-3282(90)90086-E; KOTOWICZ MA, 1994, J BONE MINER RES, V9, P599; Lindsay R, 2001, JAMA-J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055; MARIE PJ, 1993, J BONE MINER RES, V8, P607; MARIE PJ, 1985, MINER ELECTROL METAB, V11, P5; Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; Nielsen SP, 1999, J CLIN DENSITOM, V2, P371, DOI 10.1016/S1094-6950(06)60402-2; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; Reginster JY, 2002, OSTEOPOROSIS INT, V13, P925, DOI 10.1007/s001980200129; Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140-6736(02)08706-8; Slosman DO, 1999, J CLIN DENSITOM, V2, P37, DOI 10.1385/JCD:2:1:37; WU CY, 1995, OSTEOPOROSIS INT, V5, P354, DOI 10.1007/BF01622258	31	1140	1240	3	124	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					459	468		10.1056/NEJMoa022436	http://dx.doi.org/10.1056/NEJMoa022436			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749454	Green Published			2022-12-28	WOS:000188463900008
J	Michel, P; Quenon, JL; de Sarasqueta, AM; Scemama, O				Michel, P; Quenon, JL; de Sarasqueta, AM; Scemama, O			Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE SURVEY; INFECTIONS; COMPLICATIONS; RELIABILITY; MORBIDITY; QUALITY	Objectives To compare the effectiveness, reliability, and acceptability of estimating rates of adverse events and rates of preventable adverse events using three methods: cross sectional (data gathered in one day), prospective (data gathered during hospital stay), and retrospective (review of medical records). Design Independent assessment of three methods applied to one sample. Setting 37 wards in seven hospitals (three public, four private) in southwestern France. Participants 778 patients: medical (n = 278), surgical (n = 263), and obstetric (n = 237). Main outcome measures ne main outcome measures were the proportion of cases (patients with at least one adverse event) identified by each method compared with a reference list of cases confirmed by ward staff and the proportion of preventable cases (patients with at least one preventable adverse event). Secondary outcome measures were inter-rater reliability of screening and identification, perceived workload, and face validity of results. Results The prospective and retrospective methods identified similar numbers of medical and surgical cases (70% and 66% of the total, respectively) but the prospective method identified more preventable cases (64% and 40%, respectively), had good reliability for identification (kappa = 0.83), represented an acceptable workload, and had higher face validity. The cross sectional method showed a large number of false positives and identified none of the most serious adverse events. None of the methods was appropriate for obstetrics. Conclusion The prospective method of data collection may be more appropriate for epidemiological studies that aim to convince clinical teams that their errors contribute significantly to adverse events, to study organisational and human factors, and to assess the impact of risk reduction programmes.	Hosp Xavier Amozan, Comite Coordinat Evaluat Clin & Qual Aquitaine, F-33604 Pessac, France	CHU Bordeaux	Michel, P (corresponding author), Hosp Xavier Amozan, Comite Coordinat Evaluat Clin & Qual Aquitaine, F-33604 Pessac, France.	philippe.michel@ccecqa.asso.fr	michel, philippe/J-9443-2017	michel, philippe/0000-0001-8455-8332				Astagneau P, 2000, J HOSP INFECT, V46, P186, DOI 10.1053/jhin.2000.0833; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; Davis P, 2001, NEW ZEAL MED J, V114, P203; Emmerson AM, 1996, J HOSP INFECT, V32, P175, DOI 10.1016/S0195-6701(96)90144-9; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; GLENISTER HM, 1993, J HOSP INFECT, V23, P229, DOI 10.1016/0195-6701(93)90028-X; Grohskopf LA, 2002, J PEDIATR-US, V140, P432, DOI 10.1067/mpd.2002.122499; Healey MA, 2002, ARCH SURG-CHICAGO, V137, P611, DOI 10.1001/archsurg.137.5.611; Mantel GD, 1998, BRIT J OBSTET GYNAEC, V105, P985, DOI 10.1111/j.1471-0528.1998.tb10262.x; *MIN EMPL SOL, 2000, STATISS 2000 REG FRA; Neale G, 2003, QUAL SAF HEALTH CARE, V12, P2, DOI 10.1136/qhc.12.1.2; Pouyanne P, 2000, BRIT MED J, V320, P1036, DOI 10.1136/bmj.320.7241.1036; Schioler T, 2001, Ugeskr Laeger, V163, P5370; Thomas EJ, 2002, ANN INTERN MED, V136, P812, DOI 10.7326/0003-4819-136-11-200206040-00009; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089; Weingart SN, 2000, BRIT MED J, V320, P774, DOI 10.1136/bmj.320.7237.774; Weingart SN, 2002, HEALTH SERV RES, V37, P483, DOI 10.1111/1475-6773.033; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x	21	234	244	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	2004	328	7433					199	202A		10.1136/bmj.328.7433.199	http://dx.doi.org/10.1136/bmj.328.7433.199			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739187	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000188652200014
J	Dawkins, MS; Donnelly, CA; Jones, TA				Dawkins, MS; Donnelly, CA; Jones, TA			Chicken welfare is influenced more by housing conditions than by stocking density	NATURE			English	Article							FOOT-PAD DERMATITIS; BROILER-CHICKENS; LEG WEAKNESS; PERFORMANCE; PREVALENCE; BEHAVIOR	Intensive broiler ( meat) chicken production now exceeds 800 million birds each year in the United Kingdom and 2 x 10(10) birds worldwide(1), but it attracts accusations of poor welfare(2,3). The European Union is currently adopting standards for broilers aimed at a chief welfare concern - namely, overcrowding - by limiting maximum ' stocking density' ( bird weight per unit area). It is not clear, however, whether this will genuinely improve bird welfare because evidence is contradictory(4-10). Here we report on broiler welfare in relation to the European Union proposals through a large- scale study ( 2.7 million birds) with the unprecedented cooperation of ten major broiler producers in an experimental manipulation of stocking density under a range of commercial conditions. Producer companies stocked birds to five different final densities, but otherwise followed company practice, which we recorded in addition to temperature, humidity, litter and air quality. We assessed welfare through mortality, physiology, behaviour and health, with an emphasis on leg health and walking ability. Our results show that differences among producers in the environment that they provide for chickens have more impact on welfare than has stocking density itself.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Dawkins, MS (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	marian.dawkins@zoo.ox.ac.uk		Donnelly, Christl/0000-0002-0195-2463				BAGSHAW CS, 2001, BROILER WELFARE REV; Bradshaw RH, 2002, AVIAN POULT BIOL REV, V13, P45, DOI 10.3184/147020602783698421; BROOM DM, 1986, BRIT VET J, V142, P524, DOI 10.1016/0007-1935(86)90109-0; COCKREM JF, 1994, BRIT POULTRY SCI, V35, P433, DOI 10.1080/00071669408417708; DAWKINS MS, 2001, COPING CHALLENGE WEL, P63; Dehnhard M, 2003, GEN COMP ENDOCR, V131, P345, DOI 10.1016/S0016-6480(03)00033-9; Ekstrand C, 1998, BRIT POULTRY SCI, V39, P318, DOI 10.1080/00071669888845; Farm Animal Welfare Council, 1992, REP WELF BROIL CHICK; Feddes JJR, 2002, POULTRY SCI, V81, P774, DOI 10.1093/ps/81.6.774; Gordon S. H., 2001, British Poultry Science, V42, pS118; GRASHORN M, 1991, ARCH GEFLUGELKD, V55, P84; Hall AL, 2001, ANIM WELFARE, V10, P23; Heier BT, 2002, PREV VET MED, V53, P147, DOI 10.1016/S0167-5877(01)00266-5; KEMP C, 2002, ROSS BROILER MANAGEM, V36; KESTIN SC, 1992, VET REC, V131, P190, DOI 10.1136/vr.131.9.190; Kestin SC, 2001, VET REC, V148, P195, DOI 10.1136/vr.148.7.195; Kristensen HH, 2000, WORLD POULTRY SCI J, V56, P235, DOI 10.1079/WPS20000018; Martrenchar A, 2002, PREV VET MED, V52, P213, DOI 10.1016/S0167-5877(01)00259-8; McLean JA, 2002, ANIM WELFARE, V11, P55; Mendl M, 2001, NATURE, V410, P31, DOI 10.1038/35065194; Reiter K, 1998, ARCH GEFLUGELKD, V62, P145; *ROYAL SOC PREV CR, 1995, RSPCS WELF STAND CHI; Scientific Committee on Animal Health and Animal Welfare, 2000, WELF CHICK KEPT MEAT; Sorensen P, 2000, POULTRY SCI, V79, P864, DOI 10.1093/ps/79.6.864; STEVENSON P, 1995, WELFARE BROILER CHIC; Webster J., 1994, ANIMAL WELFARE COOL; Weeks CA, 2000, APPL ANIM BEHAV SCI, V67, P111, DOI 10.1016/S0168-1591(99)00102-1; Whitehead CC, 2002, WORLD POULTRY SCI J, V58, P349, DOI 10.1079/WPS20020027	28	400	430	5	222	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					342	344		10.1038/nature02226	http://dx.doi.org/10.1038/nature02226			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737165				2022-12-28	WOS:000188266200038
J	Levy, J; Bres, C; Geurts, R; Chalhoub, B; Kulikova, O; Duc, G; Journet, EP; Ane, JM; Lauber, E; Bisseling, T; Denarie, J; Rosenberg, C; Debelle, F				Levy, J; Bres, C; Geurts, R; Chalhoub, B; Kulikova, O; Duc, G; Journet, EP; Ane, JM; Lauber, E; Bisseling, T; Denarie, J; Rosenberg, C; Debelle, F			A putative Ca2+ and calmodulin-dependent protein kinase required for bacterial and fungal symbioses	SCIENCE			English	Article							NOD FACTOR TRANSDUCTION; MEDICAGO-TRUNCATULA; CALCIUM SPIKING; NODULATION; GENE; RESPONSES; MUTANTS; SIGNAL; RECOGNITION; PERCEPTION	Legumes can enter into symbiotic relationships with both nitrogen-fixing bacteria ( rhizobia) and mycorrhizal fungi. Nodulation by rhizobia results from a signal transduction pathway induced in legume roots by rhizobial Nod factors. DMI3, a Medicago truncatula gene that acts immediately downstream of calcium spiking in this signaling pathway and is required for both nodulation and mycorrhizal infection, has high sequence similarity to genes encoding calcium and calmodulin-dependent protein kinases (CCaMKs). This indicates that calcium spiking is likely an essential component of the signaling cascade leading to nodule development and mycorrhizal infection, and sheds light on the biological role of plant CCaMKs.	INRA, CNRS, Lab Interact Plantes Micoorganismes, F-31326 Castanet Tolosan, France; Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands; INRA, Unite Rech Gen Vegetale, F-91057 Evry, France; INRA, Unite Rech Genet & Ecophysiol Legumineuses, F-21065 Dijon, France	INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Wageningen University & Research; INRAE; INRAE	Debelle, F (corresponding author), INRA, CNRS, Lab Interact Plantes Micoorganismes, BP27, F-31326 Castanet Tolosan, France.	debelle@toulouse.inra.fr	Bres, Cecile/F-8305-2013; Bisseling, Ton/A-2421-2013; Journet, Etienne-Pascal/AAE-1573-2022; levy, julien G./I-9904-2019; Journet, Etienne-Pascal/C-5878-2018; Ané, Jean-Michel/G-5921-2010; Lauber, Emmanuelle/ABB-3077-2021	Bres, Cecile/0000-0001-6460-4637; Journet, Etienne-Pascal/0000-0003-1704-2998; levy, julien G./0000-0002-1422-2195; Journet, Etienne-Pascal/0000-0003-1704-2998; Ané, Jean-Michel/0000-0002-3128-9439; Lauber, Emmanuelle/0000-0001-5933-4476				Ane JM, 2002, MOL PLANT MICROBE IN, V15, P1108, DOI 10.1094/MPMI.2002.15.11.1108; Brundrett MC, 2002, NEW PHYTOL, V154, P275, DOI 10.1046/j.1469-8137.2002.00397.x; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DUC G, 1989, PLANT SCI, V60, P215, DOI 10.1016/0168-9452(89)90169-6; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Geurts R, 2002, PLANT CELL, V14, pS239, DOI 10.1105/tpc.002451; GianinazziPearson V, 1996, PLANT CELL, V8, P1871, DOI 10.1105/tpc.8.10.1871; Harrison MJ, 1999, ANNU REV PLANT PHYS, V50, P361, DOI 10.1146/annurev.arplant.50.1.361; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; Limpens E, 2003, SCIENCE, V302, P630, DOI 10.1126/science.1090074; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Oldroyd GED, 2001, PLANT J, V28, P191, DOI 10.1046/j.1365-313X.2001.01149.x; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; Poovaiah BW, 1999, PLANTA, V209, P161, DOI 10.1007/s004250050618; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Sathyanarayanan PV, 2002, EUR J BIOCHEM, V269, P2457, DOI 10.1046/j.1432-1033.2002.02904.x; Sathyanarayanan PV, 2001, J BIOL CHEM, V276, P32940, DOI 10.1074/jbc.M009648200; Schneider A, 2002, THEOR APPL GENET, V104, P1312, DOI 10.1007/s00122-002-0896-2; Shaw SL, 2003, PLANT PHYSIOL, V131, P976, DOI 10.1104/pp.005546; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Wais RJ, 2000, P NATL ACAD SCI USA, V97, P13407, DOI 10.1073/pnas.230439797; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097; Wang WY, 1999, J BIOL CHEM, V274, P12001, DOI 10.1074/jbc.274.17.12001; Yang TB, 2003, TRENDS PLANT SCI, V8, P505, DOI 10.1016/j.tplants.2003.09.004	28	533	573	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1361	1364		10.1126/science.1093038	http://dx.doi.org/10.1126/science.1093038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14963335				2022-12-28	WOS:000189238600049
J	Haninger, K; Thompson, KM				Haninger, K; Thompson, KM			Content and ratings of teen-rated video games	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AGGRESSIVE-BEHAVIOR; VIOLENCE	Context Children's exposure to violence, blood, sexual themes, profanity, substances, and gambling in the media remains a source of public health concern. However, content in video games played by older children and adolescents has not been quantified or compared with the rating information provided to consumers by the Entertainment Software Rating Board (ESRB). Objectives To quantify and characterize the content in video games rated T (for "Teen") and to measure the agreement between the content observed in game play and the ESRB-assigned content descriptors displayed on the game box. Design and Setting We created a database of all 396 T-rated video game titles released on the major video game consoles in the United States by April 1, 2001, to identify the distribution of games by genre and to characterize the distribution of ESRB-assigned content descriptors. We randomly sampled 80 video game titles (which included 81 games because 1 title included 2 separate games), played each game for at least 1 hour, quantitatively assessed the content, and compared the content we observed with the content descriptors assigned by the ESRB. Main Outcome Measures Depictions of violence, blood, sexual themes, gambling, and alcohol, tobacco, or other drugs; whether injuring or killing characters is rewarded or is required to advance in the game; characterization of gender associated with sexual themes; and use of profanity in dialogue, lyrics, or gestures. Results Analysis of all content descriptors assigned to the 396 T-rated video game titles showed 373 (94%) received content descriptors for violence, 102 (26%) for blood, 60 (15%) for sexual themes, 57 (14%) for profanity, 26 (7%) for comic mischief, 6 (2%) for substances, and none for gambling. In the random sample of 81 games we played, we found that 79 (98%) involved intentional violence for an average of 36% of game play, 73 (90%) rewarded or required the player to injure characters, 56 (69%) rewarded or required the player to kill, 34 (42%) depicted blood, 22 (27%) depicted sexual themes, 22 (27%) contained profanity, 12 (15%) depicted substances, and 1 (1%) involved gambling. Our observations of 81 games match the ESRB content descriptors for violence in 77 games (95%), for blood in 22 (27%), for sexual themes in 16 (20%), for profanity in 14 (17%), and for substances in 1 (1%). Games were significantly more likely to depict females partially nude or engaged in sexual behaviors than males. Overall, we identified 51 observations of content that could warrant a content descriptor in 39 games (48%) in which the ESRB had not assigned a content descriptor. We found that the ESRB assigned 7 content descriptors for 7 games (9%) in which we did not observe the content indicated within 1 hour of game play. Conclusions Content analysis suggests a significant amount of content in T-rated video games that might surprise adolescent players and their parents given the presence of this content in games without ESRB content descriptors. Physicians and parents should be aware that popular T-rated video games may be a source of exposure to a wide range of unexpected content.	Harvard Univ, Sch Publ Hlth, Kids Risk Project, Boston, MA 02115 USA; Childrens Hosp, Ctr Media & Child Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital	Thompson, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Kids Risk Project, 677 Huntington Ave, Boston, MA 02115 USA.	kimt@hsph.harvard.edu		Thompson, Kimberly/0000-0002-0849-9147				Anderson CA, 2001, PSYCHOL SCI, V12, P353, DOI 10.1111/1467-9280.00366; Cantor J, 1998, ANN AM ACAD POLIT SS, V557, P54, DOI 10.1177/0002716298557000005; Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647; *INT DIG SOFTW ASS, 2003, ESS FACTS COMP VID G; Johnson JG, 2002, SCIENCE, V295, P2468, DOI 10.1126/science.1062929; Roberts D. F., 1999, KIDS MEDIA NEW MILLE; SHELOV S, 1995, PEDIATRICS, V95, P949; Thompson KM, 2001, JAMA-J AM MED ASSOC, V286, P591, DOI 10.1001/jama.286.5.591; Woodard E. H., 2000, MEDIA HOME 5 ANN SUR	9	111	112	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					856	865		10.1001/jama.291.7.856	http://dx.doi.org/10.1001/jama.291.7.856			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970065	Bronze			2022-12-28	WOS:000189000400024
J	McNeil, JG; Johnston, MI; Birx, DL; Tramont, EC				McNeil, JG; Johnston, MI; Birx, DL; Tramont, EC			Policy rebuttal - HIV vaccine trial justified	SCIENCE			English	Editorial Material							RECOMBINANT CANARYPOX; IMMUNODEFICIENCY; RESPONSES; GP120		NIAID, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	McNeil, JG (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jomcneil@mail.nih.gov						Andersson S, 1996, J INFECT DIS, V174, P977, DOI 10.1093/infdis/174.5.977; Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620; Clements-Mann ML, 1998, J INFECT DIS, V177, P1230, DOI 10.1086/515288; Cohen J, 2002, SCIENCE, V295, P1616, DOI 10.1126/science.295.5560.1616; FRANCHINI G, 1995, AIDS RES HUM RETROV, V11, P909, DOI 10.1089/aid.1995.11.909; Gorse GJ, 2001, VACCINE, V19, P1806, DOI 10.1016/S0264-410X(00)00378-9; Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002; Ratto-Kim S, 2003, JAIDS-J ACQ IMM DEF, V32, P9, DOI 10.1097/00126334-200301010-00003; Sabbaj S, 2000, AIDS, V14, P1365, DOI 10.1097/00002030-200007070-00009; Safrit JT, 2004, JAIDS-J ACQ IMM DEF, V35, P169, DOI 10.1097/00126334-200402010-00012; *WHO UNAIDS CDC, 2002, CONS REP; 2002, NIAID NEWS      0225	12	26	29	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					961	961		10.1126/science.1096161	http://dx.doi.org/10.1126/science.1096161			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963313				2022-12-28	WOS:000188918000027
J	Rasmussen, S; Chen, LH; Deamer, D; Krakauer, DC; Packard, NH; Stadler, PF; Bedau, MA				Rasmussen, S; Chen, LH; Deamer, D; Krakauer, DC; Packard, NH; Stadler, PF; Bedau, MA			Transitions from nonliving to living matter	SCIENCE			English	Editorial Material							LIFE		Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Argonne Natl Lab, Argonne, IL 60439 USA; Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA; Santa Fe Inst, Santa Fe, NM 87506 USA; Protolife Srl, Venice, Italy; Univ Leipzig, Leipzig, Germany; Reed Coll, Portland, OR 97202 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of California System; University of California Santa Cruz; The Santa Fe Institute; Leipzig University; Reed College - Oregon	Rasmussen, S (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	steen@lanl.gov	Stadler, Peter F. F/L-7857-2015	Stadler, Peter F. F/0000-0002-5016-5191				Bedau MA, 2000, ARTIF LIFE, V6, P363, DOI 10.1162/106454600300103683; Eckardt LH, 2002, NATURE, V420, P286, DOI 10.1038/420286a; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Luisi PL, 2004, ORIGINS LIFE EVOL B, V34, P1, DOI 10.1023/B:ORIG.0000009999.54565.63; Pohorille A, 2002, TRENDS BIOTECHNOL, V20, P123, DOI 10.1016/S0167-7799(02)01909-1; Rasmussen S, 2003, ARTIF LIFE, V9, P269, DOI 10.1162/106454603322392479; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176	8	202	215	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					963	965		10.1126/science.1093669	http://dx.doi.org/10.1126/science.1093669			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963315				2022-12-28	WOS:000188918000029
J	Westover, KD; Bushnell, DA; Kornberg, RD				Westover, KD; Bushnell, DA; Kornberg, RD			Structural basis of transcription: Separation of RNA from DNA by RNA polymerase II	SCIENCE			English	Article							ELONGATION COMPLEX; RESOLUTION; STABILITY; HYBRID	The structure of an RNA polymerase II-transcribing complex has been determined in the posttranslocation state, with a vacancy at the growing end of the RNA-DNA hybrid helix. At the opposite end of the hybrid helix, the RNA separates from the template DNA. This separation of nucleic acid strands is brought about by interaction with a set of proteins loops in a strand/loop network. Formation of the network must occur in the transition from abortive initiation to promoter escape.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu	Westover, Ken/AAZ-1795-2020	Westover, Ken/0000-0003-3653-5923	NIGMS NIH HHS [GM49985] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; BUSHNELL DA, 2004, SCIENCE, V303; CHRISTOPHER JA, 1998, SPOCK; DeLano W.L, PYMOL MOL GRAPHICS S; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Krapp S, 1998, NAT STRUCT BIOL, V5, P110, DOI 10.1038/nsb0298-110; Kuznedelov K, 2002, EMBO J, V21, P1369, DOI 10.1093/emboj/21.6.1369; TINTUT Y, 1995, GENE DEV, V9, P2305, DOI 10.1101/gad.9.18.2305; WESTOVER KD, UNPUB	12	208	214	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1014	1016		10.1126/science.1090839	http://dx.doi.org/10.1126/science.1090839			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963331				2022-12-28	WOS:000188918000046
J	Cullen, T				Cullen, T			The chronicity of chronic disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												theresa.cullen@ihs.gov							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					671	672		10.1001/jama.291.6.671	http://dx.doi.org/10.1001/jama.291.6.671			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871900				2022-12-28	WOS:000188819200001
J	Palazzo, AF; Eng, CH; Schlaepfer, DD; Marcantonio, EE; Gundersen, GG				Palazzo, AF; Eng, CH; Schlaepfer, DD; Marcantonio, EE; Gundersen, GG			Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling	SCIENCE			English	Article							FOCAL ADHESION KINASE; DETYROSINATED GLU MICROTUBULES; TRANSFORMATION	Microtubule (MT) stabilization is regulated by the small guanosine triphosphate (GTP)-binding protein Rho and its effector, mammalian homolog of Diaphanous (mDia), in migrating cells, but factors responsible for localized stabilization at the leading edge are unknown. We report that integrin-mediated activation of focal adhesion kinase (FAK) at the leading edge is required for MT stabilization by the Rho-mDia signaling pathway in mouse fibroblasts. MT stabilization also involved FAK-regulated localization of a lipid raft marker, ganglioside G(M1), to the leading edge. The integrin-FAK signaling pathway may facilitate Rho-mDia signaling through G(M1), or through a specialized membrane domain containing G(M1), to stabilize MTs in the leading edge of migrating cells.	Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92307 USA	Columbia University; Columbia University; Columbia University; Scripps Research Institute	Gundersen, GG (corresponding author), Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.	ggg1@columbia.edu	Palazzo, Alexander/B-1270-2013	Palazzo, Alexander/0000-0002-9700-1995	NCI NIH HHS [CA87038] Funding Source: Medline; NIGMS NIH HHS [GM 68695, GM 62939, GM 44585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044585, R01GM062939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; ILLC D, 1995, NATURE, V377, P539; Infante AS, 2000, J CELL SCI, V113, P3907; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056	24	348	356	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					836	839		10.1126/science.1091325	http://dx.doi.org/10.1126/science.1091325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764879				2022-12-28	WOS:000188753800057
J	Chae, HK; Siberio-Perez, DY; Kim, J; Go, Y; Eddaoudi, M; Matzger, AJ; O'Keeffe, M; Yaghi, OM				Chae, HK; Siberio-Perez, DY; Kim, J; Go, Y; Eddaoudi, M; Matzger, AJ; O'Keeffe, M; Yaghi, OM			A route to high surface area, porosity and inclusion of large molecules in crystals	NATURE			English	Article							METAL-ORGANIC FRAMEWORK; DESIGN; STORAGE	One of the outstanding challenges in the field of porous materials is the design and synthesis of chemical structures with exceptionally high surface areas(1). Such materials are of critical importance to many applications involving catalysis, separation and gas storage. The claim for the highest surface area of a disordered structure is for carbon, at 2,030 m(2) g(-1) (ref. 2). Until recently, the largest surface area of an ordered structure was that of zeolite Y, recorded at 904 m(2) g(-1) (ref. 3). But with the introduction of metal-organic framework materials, this has been exceeded, with values up to 3,000 m(2) g(-1) (refs 4-7). Despite this, no method of determining the upper limit in surface area for a material has yet been found. Here we present a general strategy that has allowed us to realize a structure having by far the highest surface area reported to date. We report the design, synthesis and properties of crystalline Zn4O(1,3,5-benzenetribenzoate)(2), a new metal-organic framework with a surface area estimated at 4,500 m(2) g(-1). This framework, which we name MOF-177, combines this exceptional level of surface area with an ordered structure that has extra-large pores capable of binding polycyclic organic guest molecules-attributes not previously combined in one material.	Univ Michigan, Dept Chem, Mat Design & Discovery Grp, Ann Arbor, MI 48109 USA; Arizona State Univ, Dept Chem, Tempe, AZ 85287 USA; Hankuk Univ Foreign Studies, Dept Chem, Seoul, South Korea	University of Michigan System; University of Michigan; Arizona State University; Arizona State University-Tempe; Hankuk University Foreign Studies	Matzger, AJ (corresponding author), Univ Michigan, Dept Chem, Mat Design & Discovery Grp, Ann Arbor, MI 48109 USA.	matzger@umich.edu; mokeeffe@asu.edu; oyaghi@umich.edu	Eddaoudi, Mohamed/D-2298-2009; Yaghi, Omar M/C-6749-2013; Matzger, Adam J/G-7497-2016	Eddaoudi, Mohamed/0000-0003-1916-9837; Matzger, Adam J/0000-0002-4926-2752; Yaghi, Omar/0000-0002-5611-3325				Chae HK, 2003, ANGEW CHEM INT EDIT, V42, P3907, DOI 10.1002/anie.200351546; Chen BL, 2001, SCIENCE, V291, P1021, DOI 10.1126/science.1056598; CHESTER AW, 2000, Patent No. 6136291; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; De Vos D. E., 2001, STUD SURF SCI CATAL, V137, P957; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Friedrichs OD, 2003, ACTA CRYSTALLOGR A, V59, P22, DOI 10.1107/S0108767302018494; Kahr B, 2001, CHEM REV, V101, P893, DOI 10.1021/cr980088n; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; Nijkamp MG, 2001, APPL PHYS A-MATER, V72, P619, DOI 10.1007/s003390100847; Noro S, 2002, J AM CHEM SOC, V124, P2568, DOI 10.1021/ja0113192; Sato K, 2001, J CATAL, V200, P288, DOI 10.1006/jcat.2001.3184; Seki K, 2001, CHEM LETT, P332, DOI 10.1246/cl.2001.332; Yaghi OM, 2003, NATURE, V423, P705, DOI 10.1038/nature01650	15	2364	2557	72	2233	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					523	527		10.1038/nature02311	http://dx.doi.org/10.1038/nature02311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765190	Green Published			2022-12-28	WOS:000188721800036
J	Li, T; Chang, CY; Jin, DY; Lin, PJ; Khvorova, A; Stafford, DW				Li, T; Chang, CY; Jin, DY; Lin, PJ; Khvorova, A; Stafford, DW			Identification of the gene for vitamin K epoxide reductase	NATURE			English	Article							DEPENDENT PROTEINS; WARFARIN; TARGET; EMBRYOPATHY; CARBOXYLASE; EXPRESSION; RESISTANCE; LOCUS; MICE	Vitamin K epoxide reductase (VKOR) is the target of warfarin, the most widely prescribed anticoagulant for thromboembolic disorders. Although estimated to prevent twenty strokes per induced bleeding episode(1), warfarin is under-used because of the difficulty of controlling dosage and the fear of inducing bleeding. Although identified in 1974 (ref. 2), the enzyme has yet to be purified or its gene identified. A positional cloning approach has become possible after the mapping of warfarin resistance to rat chromosome 1 (ref. 3) and of vitamin K-dependent protein deficiencies to the syntenic region of human chromosome 16 (ref. 4). Localization of VKOR to 190 genes within human chromosome 16p12-q21 narrowed the search to 13 genes encoding candidate transmembrane proteins, and we used short interfering RNA (siRNA) pools against individual genes to test their ability to inhibit VKOR activity in human cells. Here, we report the identification of the gene for VKOR based on specific inhibition of VKOR activity by a single siRNA pool. We confirmed that MGC11276 messenger RNA encodes VKOR through its expression in insect cells and sensitivity to warfarin. The expressed enzyme is 163 amino acids long, with at least one transmembrane domain. Identification of the VKOR gene extends our understanding of blood clotting, and should facilitate development of new anticoagulant drugs.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Dharmacon Inc, Lafayette, CO 80026 USA	University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	dws@email.unc.edu						BARR M, 1976, TERATOLOGY, V14, P129, DOI 10.1002/tera.1420140203; Bohley P, 1996, BIOL CHEM, V377, P425; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; DICE JF, 1975, P NATL ACAD SCI USA, V72, P3893, DOI 10.1073/pnas.72.10.3893; Fregin A, 2002, BLOOD, V100, P3229, DOI 10.1182/blood-2002-03-0698; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harborth J, 2001, J CELL SCI, V114, P4557; Holen T, 2003, NUCLEIC ACIDS RES, V31, P2401, DOI 10.1093/nar/gkg338; Horton JD, 1999, AM FAM PHYSICIAN, V59, P635; HOWE AM, 1992, TERATOLOGY, V46, P379, DOI 10.1002/tera.1420460408; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; KHOVOROVA A, 2003, CELL, V115, P1; Kohn MH, 2000, BLOOD, V96, P1996, DOI 10.1182/blood.V96.5.1996.h8001996_1996_1998; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Lin PJ, 2002, J BIOL CHEM, V277, P28584, DOI 10.1074/jbc.M202292200; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Scaringe SA, 2000, METHOD ENZYMOL, V317, P3; STEVENSON RE, 1980, JAMA-J AM MED ASSOC, V243, P1549, DOI 10.1001/jama.243.15.1549; THIJSSEN HHW, 1994, BIOCHEM J, V297, P277, DOI 10.1042/bj2970277; Tsaioun KI, 1999, NUTR REV, V57, P231, DOI 10.1111/j.1753-4887.1999.tb06950.x; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; ZIMMERMA.A, 1974, BIOCHEM PHARMACOL, V23, P1033, DOI 10.1016/0006-2952(74)90002-1	30	537	575	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					541	544		10.1038/nature02254	http://dx.doi.org/10.1038/nature02254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765195				2022-12-28	WOS:000188721800041
J	LaRoche, SM; Helmers, SL				LaRoche, SM; Helmers, SL			The new antiepileptic drugs - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NEWLY-DIAGNOSED EPILEPSY; TONIC-CLONIC SEIZURES; BONE-MINERAL DENSITY; ANTICONVULSANT DRUGS; DOUBLE-BLIND; ELDERLY-PATIENTS; CARBAMAZEPINE; LAMOTRIGINE; VALPROATE; THERAPY	In the past decade, 8 new antiepileptic drugs have been approved for use in the United States, offering many new treatment options to patients with epilepsy. With expanding use of these newer agents, primary care clinicians are challenged with understanding the roles that each new agent plays in the treatment of patients with epilepsy as well as possible interactions with other pharmacological therapies. Each new medication provides a unique profile of pharmacokinetics, adverse effects, and mechanisms of action, making an appreciation of how these agents are best utilized even more difficult. Despite well-performed trials evaluating the safety and efficacy of specific antiepileptic drugs, the lack of head-to-head comparisons among them makes it difficult to endorse a single therapeutic regimen. Limited studies have compared the new antiepileptic drugs with more traditional medications and found similar efficacy but improved tolerability of the newer agents. There remains no well-established guidelines for choosing a particular antiepileptic drug or for choosing a newer agent over a traditional one. However, careful consideration of seizure type, patient comorbidities, and specific medication toxicities aids in prescribing the most appropriate medication. This article aims to familiarize the general practitioner with the appropriate roles and effective uses of the new antiepileptic drugs in specific clinical scenarios.	Atlanta VA Med Ctr, Atlanta, GA USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; Emory University	LaRoche, SM (corresponding author), Emory Clin, Bldg A,1365 Clifton Rd, Atlanta, GA 30322 USA.	suzette_LaRoche@emoryhealthcare.org						Asconape JJ, 2002, SEMIN NEUROL, V22, P27, DOI 10.1055/s-2002-33046; BACK DJ, 1980, CONTRACEPTION, V22, P495, DOI 10.1016/0010-7824(80)90102-X; Betts T, 2000, SEIZURE-EUR J EPILEP, V9, P80, DOI 10.1053/seiz.2000.0380; Biton V, 1999, NEUROLOGY, V52, P1330, DOI 10.1212/WNL.52.7.1330; Bourgeois BFD, 2001, TREATMENT EPILEPSY, P843; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Canger R, 1999, EPILEPSIA, V40, P1231, DOI 10.1111/j.1528-1157.1999.tb00851.x; Crawford P, 2002, CNS DRUGS, V16, P263, DOI 10.2165/00023210-200216040-00005; DANSKY LV, 1987, ANN NEUROL, V21, P176, DOI 10.1002/ana.410210210; DANSKY LV, 1992, NEUROLOGY, V42, P32; DINESEN H, 1984, ACTA NEUROL SCAND, V70, P65; DREIFUSS FE, 1987, NEUROLOGY, V37, P379, DOI 10.1212/WNL.37.3.379; Fattore C, 1999, EPILEPSIA, V40, P783, DOI 10.1111/j.1528-1157.1999.tb00779.x; Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37; Fisher RS, 2001, NEUROLOGY, V56, P743, DOI 10.1212/WNL.56.6.743; FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224; GILLIAM FG, 2001, TREATMENT EPILEPSY, P933; Guberman AH, 1999, EPILEPSIA, V40, P985, DOI 10.1111/j.1528-1157.1999.tb00807.x; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HOLDRICH T, 1992, EPILEPSIA S1, V32, P96; HOLMES L, 2002, AM J OBSTET GYNECOL, V187, P5137; Holmes LB, 2001, NEW ENGL J MED, V344, P1132, DOI 10.1056/NEJM200104123441504; Karceski S, 2001, EPILEPSY BEHAV, V2, pA1, DOI 10.1006/ebeh.2001.0283; Lamy C, 2003, NEUROLOGY, V60, P400, DOI 10.1212/WNL.60.3.400; Lee S, 2003, EPILEPSIA, V44, P339, DOI 10.1046/j.1528-1157.2003.27402.x; LINDHOUT D, 1984, LANCET, V2, P396; LOISEAU J, 1990, ANN NEUROL, V27, P232, DOI 10.1002/ana.410270304; Martin R, 2001, EPILEPSIA, V42, P764, DOI 10.1046/j.1528-1157.2001.33300.x; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MATTSON RH, 1986, JAMA-J AM MED ASSOC, V256, P238, DOI 10.1001/jama.256.2.238; *MED EC CO, 2002, PHYS DESK REF; Ojemann LM, 2001, EPILEPSY BEHAV, V2, P579, DOI 10.1006/ebeh.2001.0285; Pack AM, 2001, CNS DRUGS, V15, P633, DOI 10.2165/00023210-200115080-00006; Radtke RA, 2001, EPILEPSIA, V42, P24, DOI 10.1046/j.1528-1157.2001.0420s4024.x; RADULOVIC LL, 1994, EPILEPSIA, V35, P155, DOI 10.1111/j.1528-1157.1994.tb02926.x; Ramsay R. E., 1994, Epilepsia, V35, P91; Rosenfeld WE, 1997, EPILEPSIA, V38, P324, DOI 10.1111/j.1528-1157.1997.tb01124.x; Samren EB, 1997, EPILEPSIA, V38, P981, DOI 10.1111/j.1528-1157.1997.tb01480.x; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; SHORVON SD, 1996, EPILEPSIA S2, V37, P18; Steiner TJ, 1999, EPILEPSIA, V40, P601, DOI 10.1111/j.1528-1157.1999.tb05562.x; Tennis P, 2002, EPILEPSIA, V43, P1161, DOI 10.1046/j.1528-1157.2002.45901.x; TOMITA S, 1991, J STEROID BIOCHEM, V39, P479, DOI 10.1016/0960-0760(91)90241-V; VALIMAKI MJ, 1994, J BONE MINER RES, V9, P631; WASSERSTEIN AG, 1995, EPILEPSIA S3, V36, P153; Willmore LJ, 2000, DRUG AGING, V17, P441, DOI 10.2165/00002512-200017060-00002; Wong ICK, 2000, DRUG SAFETY, V23, P35, DOI 10.2165/00002018-200023010-00003; YERBY MS, 1992, NEUROLOGY, V42, P132	51	62	64	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					615	620		10.1001/jama.291.5.615	http://dx.doi.org/10.1001/jama.291.5.615			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762041	Bronze			2022-12-28	WOS:000188650700027
J	Kodish, E; Eder, M; Noll, RB; Ruccione, K; Lange, B; Angiolillo, A; Pentz, R; Zyzanski, S; Siminoff, LA; Drotar, D				Kodish, E; Eder, M; Noll, RB; Ruccione, K; Lange, B; Angiolillo, A; Pentz, R; Zyzanski, S; Siminoff, LA; Drotar, D			Communication of randomization in childhood leukemia trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMED-CONSENT; CLINICAL-TRIALS; THERAPEUTIC MISCONCEPTION; CANCER; PARENTS; QUALITY; EQUIPOISE; ETHICS	Context Most children diagnosed as having leukemia become research subjects in randomized clinical trials (RCTs), but little is known about how randomization is explained to or understood by parents. Objective To investigate physicians' explanation and parental understanding of randomization in childhood leukemia RCTs. Design and Setting A multisite study of the informed consent communication process for RCTs of childhood leukemia. Consecutive cases were recruited from pediatric oncology inpatient wards at 6 US children's hospitals associated with major academic medical centers from July 1, 1999, until December 31, 2001. The informed consent conferences were observed and audiotaped, and the information obtained was coded and analyzed. Parents were interviewed shortly after the conference to ascertain their understanding. Participants Parents and members of the healthcare team who participated in 137 informed consent conferences for children with newly diagnosed acute leukemia. Main Outcome Measures Observed explanations of randomization and parental understanding of randomization after the consent conference. Results Randomization was explained by physicians in 83% of cases and a consent document was presented during the conference in 95% of cases. Interviews after the conference demonstrated that 68 (50%) of 137 parents did not understand randomization. Parents of racial minority and lower socioeconomic status were less likely to understand randomization (P<.001 for each). Discussion of specific clinical trial details and the presence of a nurse during the conference were associated with understanding. Eighty-four percent of children were enrolled in a leukemia trial. Conclusions Despite oral and written explanation, half of the parents in this study did not understand randomization for childhood leukemia trials. To make informed consent more effective, future research must seek to improve communication during this critical interchange.	Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Dept Pediat, Rainbow Ctr Pediat Eth, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Family Med, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH USA; Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; Winship Canc Inst, Atlanta, GA USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cincinnati Children's Hospital Medical Center; Children's Hospital Los Angeles; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Children's National Health System	Kodish, E (corresponding author), Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Dept Pediat, Rainbow Ctr Pediat Eth, 11100 Euclid Ave,RBC 680, Cleveland, OH 44106 USA.	edk4@po.cwru.edu	Siminoff, Laura A/H-6277-2012		NATIONAL CANCER INSTITUTE [R01CA083267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advisory Committee on Human Radiation Experiments, 1995, FIN REP; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Berg J, 2001, INFORMED CONSENT; Dresser R, 2002, SOC PHILOS POLICY, V19, P271, DOI 10.1017/S0265052502192119; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; Flores G, 2000, J PEDIATR-US, V136, P14, DOI 10.1016/S0022-3476(00)90043-X; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; Hockenberry MJ, 2002, J PEDIAT HEMATOL ONC, V24, P35, DOI 10.1097/00043426-200201000-00010; Hollingshead AA., 1957, 2 FACTOR INDEX SOCIA; Horng Sam, 2003, IRB, V25, P11, DOI 10.2307/3564408; Jenkins VA, 1999, EUR J CANCER, V35, P1187, DOI 10.1016/S0959-8049(99)00116-1; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; Kodish E, 2003, J PEDIATR-US, V142, P89, DOI 10.1067/mpd.2003.64; Kodish ED, 1998, CANCER-AM CANCER SOC, V82, P2467; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lavori PW, 1999, CONTROL CLIN TRIALS, V20, P187, DOI 10.1016/S0197-2456(98)00064-6; Lee Stephanie J, 2002, Hematology Am Soc Hematol Educ Program, P464, DOI 10.1182/asheducation-2002.1.464; Levi RB, 2000, J PEDIAT HEMATOL ONC, V22, P3, DOI 10.1097/00043426-200001000-00002; Marquis D, 1999, NEW ENGL J MED, V341, P691, DOI 10.1056/NEJM199908263410912; McGrath Pam, 2002, Oncol Nurs Forum, V29, P988, DOI 10.1188/02.ONF.988-996; Miller FG, 2003, HASTINGS CENT REP, V33, P19, DOI 10.2307/3528434; MURPHY SB, 1995, MED PEDIATR ONCOL, V24, P279, DOI 10.1002/mpo.2950240502; Padberg R M, 1990, Oncol Nurs Forum, V17, P65; PUI C, 1999, CHILDHOOD LEUKEMIAS, P297; Roter D.L., 1992, DOCTORS TALKING PATI; ROTER DL, 1977, HEALTH EDUC QUART, V5, P281, DOI 10.1177/109019817700500402; Ruccione K, 1991, J Pediatr Oncol Nurs, V8, P112, DOI 10.1177/104345429100800304; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMINOFF LA, 1991, SOC SCI MED, V32, P813, DOI 10.1016/0277-9536(91)90307-X; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013; Truog RD, 2001, AM J KIDNEY DIS, V38, P901, DOI 10.1053/ajkd.2001.27855; Wiley FM, 1999, CANCER PRACT, V7, P248, DOI 10.1046/j.1523-5394.1999.75010.x; 1983, FED REG, V48, P9814	39	168	169	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					470	475		10.1001/jama.291.4.470	http://dx.doi.org/10.1001/jama.291.4.470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747504	Bronze			2022-12-28	WOS:000188426700032
J	Davies, P; Nwokoro, C; Leigh, M				Davies, P; Nwokoro, C; Leigh, M			Vaccinations against influenza and pneumococcus in children with diabetes: telephone questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Bedford Hosp NHS Trust, Dept Paediat, Bedford MK42 9DJ, England		Davies, P (corresponding author), Bedford Hosp NHS Trust, Dept Paediat, Bedford MK42 9DJ, England.	daviespatrick@hotmail.com	Nwokoro, Chinedu/A-1516-2013	Nwokoro, Chinedu/0000-0002-0355-7803				[Anonymous], IMM INF DIS; BOUTER KP, 1991, DIABETES RES CLIN PR, V12, P61, DOI 10.1016/0168-8227(91)90131-V; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; *PARK WAICHM, FREE CAS EV INFL VAC; FLU VACCINE REACTION	5	11	13	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	2004	328	7433					203	203		10.1136/bmj.328.7433.203	http://dx.doi.org/10.1136/bmj.328.7433.203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739188	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000188652200015
J	Peppercorn, JM; Weeks, JC; Cook, EF; Joffe, S				Peppercorn, JM; Weeks, JC; Cook, EF; Joffe, S			Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review	LANCET			English	Review							CELL LUNG-CANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; LONG-TERM SURVIVAL; ADJUVANT CHEMOTHERAPY; TREATMENT PROTOCOLS; RANDOMIZED TRIALS; HODGKINS-DISEASE; MULTIPLE-MYELOMA; SELECTION BIAS; BREAST-CANCER	Background Many oncologists believe that patients with cancer who enrol in clinical trials have better outcomes than those who do not enrol. We aimed to assess the empirical evidence that such a trial effect exists. Methods We developed a conceptual framework for comparison of trial and non-trial patients. We then did a comprehensive literature search to identify studies that compared outcomes between these groups. We critically evaluated these studies to assess whether they provide valid and generalisable support for a trial effect. Findings We identified 26 comparisons, from 24 published articles, of outcomes among cancer patients enrolled and not enrolled in clinical trials. 21 comparisons used retrospective cohort designs. 14 comparisons provided some evidence that patients enrolled in trials have improved outcomes. However, strategies to control for potential confounding factors were inconsistent and frequently inadequate. Only eight comparisons restricted non-trial patients to those meeting trial eligibility criteria. Of these, three noted better outcomes in trial patients than in non-trial patients. Children with cancer, patients with haematological malignant disease, and patients treated before 1986 were disproportionately represented in positive studies. Interpretation Despite widespread belief that enrolment in clinical trials leads to improved outcomes in patients with cancer, there are insufficient data to conclude that such a trial effect exists. Until such data are available, patients with cancer should be encouraged to enrol in clinical trials on the basis of trials' unquestioned role in improving treatment for future patients.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Joffe, S (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	steven_joffe@dfci.harvard.edu	Peppercorn, Jeffrey/GPX-3100-2022; Joffe, Steven/H-3941-2019	Joffe, Steven/0000-0002-0667-7384	NATIONAL CANCER INSTITUTE [K01CA096872] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA96872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTMAN K, 1985, J CLIN ONCOL, V3, P1142, DOI 10.1200/JCO.1985.3.8.1142; ANTMAN K, 1988, NEW ENGL J MED, V319, P46, DOI 10.1056/NEJM198807073190109; Bailes J, 2000, J CLIN ONCOL, V18, P705, DOI 10.1200/JCO.2000.18.4.705; BERTELSEN K, 1991, BRIT J CANCER, V64, P1172, DOI 10.1038/bjc.1991.485; BOROS L, 1985, CANCER, V56, P2161, DOI 10.1002/1097-0142(19851101)56:9<2161::AID-CNCR2820560904>3.0.CO;2-M; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Burgers JA, 2002, BRIT J CANCER, V87, P562, DOI 10.1038/sj.bjc.6600433; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; Chen CI, 2000, LEUKEMIA LYMPHOMA, V38, P327, DOI 10.3109/10428190009087023; *CHILDR ONC GROUP, AB CANC CLIN TRIALS; Cottin V, 1999, ANN ONCOL, V10, P809, DOI 10.1023/A:1008399831512; Dahlberg M, 1999, ANN SURG, V229, P493, DOI 10.1097/00000658-199904000-00007; DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO;2-T; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Dowling AJ, 2000, J UROLOGY, V163, P1481, DOI 10.1016/S0022-5347(05)67647-1; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; FEUER EJ, 1994, J CLIN ONCOL, V12, P368, DOI 10.1200/JCO.1994.12.2.368; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GELBER RD, 1988, JNCI-J NATL CANCER I, V80, P886, DOI 10.1093/jnci/80.12.886; Greil R, 1999, EUR J CANCER, V35, P698, DOI 10.1016/S0959-8049(99)00025-8; Hillner BE, 2000, J CLIN ONCOL, V18, P2327, DOI 10.1200/JCO.2000.18.11.2327; HJORTH M, 1992, BRIT J HAEMATOL, V80, P55, DOI 10.1111/j.1365-2141.1992.tb06400.x; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; KARJALAINEN S, 1989, BMJ-BRIT MED J, V299, P1069, DOI 10.1136/bmj.299.6707.1069; Lantos JD, 1999, J PEDIATR-US, V134, P130, DOI 10.1016/S0022-3476(99)70400-2; Lara PN, 2001, J CLIN ONCOL, V19, P1728, DOI 10.1200/JCO.2001.19.6.1728; LENNOX EL, 1979, BRIT MED J, V2, P567, DOI 10.1136/bmj.2.6190.567; LEVENTHAL H, 1991, PREV MED, V20, P132, DOI 10.1016/0091-7435(91)90014-U; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; Marubini E, 1996, LANCET, V347, P1000, DOI 10.1016/S0140-6736(96)90145-2; Mayers C, 2001, CANCER, V91, P2246, DOI 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.3.CO;2-W; MEADOWS AT, 1983, CANCER INVEST, V1, P49, DOI 10.3109/07357908309040932; MERZ B, 1988, JAMA-J AM MED ASSOC, V260, P1337; MRC Working Group on Leukaemia, 1971, BMJ-BRIT MED J, V4, P7; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; POISSON R, 1994, NEW ENGL J MED, V330, P1460; Rahman ZU, 1997, J CLIN ONCOL, V15, P3171, DOI 10.1200/JCO.1997.15.10.3171; Roy P, 2000, EUR J CANCER, V36, P384, DOI 10.1016/S0959-8049(99)00267-1; SCHEA RA, 1995, RADIOLOGY, V197, P859, DOI 10.1148/radiology.197.3.7480770; Schmoor C, 1996, STAT MED, V15, P263, DOI 10.1002/(SICI)1097-0258(19960215)15:3<263::AID-SIM165>3.0.CO;2-K; Stiller CA, 1999, BRIT J CANCER, V79, P658, DOI 10.1038/sj.bjc.6690104; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; STILLER CA, 1994, ARCH DIS CHILD, V70, P219, DOI 10.1136/adc.70.3.219; STILLER CA, 1989, ARCH DIS CHILD, V64, P657, DOI 10.1136/adc.64.5.657; Stiller CA, 1999, ARCH DIS CHILD, V81, P202, DOI 10.1136/adc.81.3.202; Taylor J, 1998, J CLIN ONCOL, V16, P1628; *TROUT REV GROUP, DO OUTC PAT TREAT RA; WAGNER HP, 1995, MED PEDIATR ONCOL, V24, P281, DOI 10.1002/mpo.2950240503; WARD LC, 1992, BRIT J CANCER, V66, P943, DOI 10.1038/bjc.1992.390; WINGER MJ, 1989, ANN NEUROL, V26, P531, DOI 10.1002/ana.410260406; ZELEN M, 2000, CANC MED, P298	52	283	287	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					263	270		10.1016/S0140-6736(03)15383-4	http://dx.doi.org/10.1016/S0140-6736(03)15383-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751698				2022-12-28	WOS:000188361400007
J	See, C; Elliott, D				See, C; Elliott, D			Pneumatosis intestinalis and portal venous gas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Madigan Army Med Ctr, Tacoma, WA 98431 USA	Madigan Army Medical Center	See, C (corresponding author), Madigan Army Med Ctr, Tacoma, WA 98431 USA.								0	12	13	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					E3	E3		10.1056/ENEJMicm020289	http://dx.doi.org/10.1056/ENEJMicm020289			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736943				2022-12-28	WOS:000188254800012
J	Deyo, RA; Nachemson, A; Mirza, SK				Deyo, RA; Nachemson, A; Mirza, SK			Spinal-fusion surgery - The case for restraint	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW-BACK-PAIN; PEDICLE SCREW INSTRUMENTATION; DEGENERATIVE LUMBAR SPONDYLOLISTHESIS; 3 SURGICAL TECHNIQUES; POSTEROLATERAL LUMBAR; WORKERS-COMPENSATION; CERVICAL DISKECTOMY; INTERNAL-FIXATION; CONTROLLED TRIAL; FOLLOW-UP		Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Orthoped Surg, Seattle, WA 98195 USA; Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA; Univ Gothenburg, Dept Orthoped Surg, Gothenburg, Sweden	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Gothenburg	Deyo, RA (corresponding author), 146 N Canal St,Suite 300, Seattle, WA 98103 USA.				NIAMS NIH HHS [P60 AR48093, 5K23 AR48979] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR048979, P60AR048093] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angevine PD, 2003, SPINE, V28, P931, DOI 10.1097/00007632-200305010-00016; BERNHARDT M, 1992, CLIN ORTHOP RELAT R, P109; Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632-200212010-00005; BONO C, 2003, ANN M INT SOC STUD L; Brox JI, 2003, SPINE, V28, P1913; Carragee E J, 2000, Curr Rev Pain, V4, P301; Christensen FB, 2002, SPINE, V27, P1269, DOI 10.1097/00007632-200206150-00006; Ciol MA, 1996, J AM GERIATR SOC, V44, P285, DOI 10.1111/j.1532-5415.1996.tb00915.x; de Kleuver M, 2003, EUR SPINE J, V12, P108, DOI 10.1007/s00586-002-0500-0; DeBerard MS, 2001, SPINE, V26, P738; DEYO RA, 1993, SPINE, V18, P1463; Dowd GC, 1999, J NEUROSURG, V90, P8, DOI 10.3171/spi.1999.90.1.0008; EKMAN P, 2003, ANN M NORD SPIN DEF; Fischgrund JS, 1997, SPINE, V22, P2807, DOI 10.1097/00007632-199712150-00003; Fouyas IP, 2002, SPINE, V27, P736, DOI 10.1097/00007632-200204010-00011; France JC, 1999, SPINE, V24, P553, DOI 10.1097/00007632-199903150-00010; FRANKLIN GM, 1994, SPINE, V19, P1897, DOI 10.1097/00007632-199409000-00005; Fritzell P, 2001, SPINE, V26, P2521, DOI 10.1097/00007632-200112010-00002; Fritzell P, 2002, SPINE, V27, P1131, DOI 10.1097/00007632-200206010-00002; Fritzell P, 2003, EUR SPINE J, V12, P178, DOI 10.1007/s00586-002-0493-8; Gibson JNA, 1999, SPINE, V24, P1820, DOI 10.1097/00007632-199909010-00012; GROB D, 1995, J BONE JOINT SURG AM, V77A, P1036, DOI 10.2106/00004623-199507000-00009; HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002; Horng S, 2002, NEW ENGL J MED, V347, P137, DOI 10.1056/NEJMsb021025; Katz JN, 1997, SPINE, V22, P1123, DOI 10.1097/00007632-199705150-00012; Katz JN, 1995, SPINE, V20, pS78, DOI 10.1097/00007632-199512151-00002; Kuntz KM, 2000, SPINE, V25, P1132, DOI 10.1097/00007632-200005010-00015; Malter AD, 1998, SPINE, V23, P814, DOI 10.1097/00007632-199804010-00015; MARTIN BI, 2003, ANN M W REG EP NETW; MCGUIRE RA, 1993, SPINE, V18, P1662, DOI 10.1097/00007632-199309000-00015; *MEND ASS INC, 2002, ORTHOPEDIC NETWORK N, V13, P7; Moller H, 2000, SPINE, V25, P1711, DOI 10.1097/00007632-200007010-00016; Moller H, 2000, SPINE, V25, P1716, DOI 10.1097/00007632-200007010-00017; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Myers MA, 1997, SPINE, V22, P1325, DOI 10.1097/00007632-199706150-00009; NACHEMSON A, 1989, SPINE, V14, P555, DOI 10.1097/00007632-198906000-00001; RICHARDSON WJ, 1993, CURRENT OPIN ORTHOPE, V4, P155; Savolainen S, 1998, NEUROSURGERY, V43, P51, DOI 10.1097/00006123-199807000-00032; Thomsen K, 1997, SPINE, V22, P2813, DOI 10.1097/00007632-199712150-00004; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907; ZDEBLICK TA, 1993, SPINE, V18, P983, DOI 10.1097/00007632-199306150-00006	41	402	427	0	16	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					722	726		10.1056/NEJMsb031771	http://dx.doi.org/10.1056/NEJMsb031771			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960750				2022-12-28	WOS:000188869500015
J	Moyle, G; Sutinen, J				Moyle, G; Sutinen, J			Managing HIV lipoatrophy	LANCET			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; INSULIN-RESISTANCE; PROTEASE INHIBITORS; PREADIPOCYTE DIFFERENTIATION; LIPODYSTROPHY SYNDROME; INFECTED PATIENTS; ADIPOSE-TISSUE; ROSIGLITAZONE; SUBSTITUTION; ABACAVIR		Chelsea & Westminster Hosp, London, England; Univ Helsinki, Cent Hosp, Div Diabet, Helsinki, Finland; Univ Helsinki, Cent Hosp, Div Infect Dis, Helsinki, Finland	Imperial College London; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Moyle, G (corresponding author), Chelsea & Westminster Hosp, London, England.	gm@moyleg.demon.co.uk						Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; Calmy A, 2003, AIDS, V17, P770, DOI 10.1097/00002030-200303280-00022; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Engelson ES, 2002, J ACQ IMMUN DEF SYND, V30, P379, DOI 10.1097/01.QAI.0000020501.93209.1C; Fliers E, 2003, LANCET, V362, P1758, DOI 10.1016/S0140-6736(03)14858-1; Gelato MC, 2002, JAIDS-J ACQ IMM DEF, V31, P163, DOI 10.1097/00126334-200210010-00006; Hadigan C, 2003, ANTIVIR THER, V8, pL12; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; John M, 2003, JAIDS-J ACQ IMM DEF, V33, P29, DOI 10.1097/00126334-200305010-00005; Kannisto K, 2003, AIDS, V17, P1753, DOI 10.1097/00002030-200308150-00004; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V38, P1008, DOI 10.1053/jhep.2003.50420; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Sutinen J, 2003, ANTIVIR THER, V8, P199; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007	23	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					412	414		10.1016/S0140-6736(04)15521-9	http://dx.doi.org/10.1016/S0140-6736(04)15521-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962517				2022-12-28	WOS:000188999500004
J	Cuomo, S				Cuomo, S			The sinews of war: Ancient catapults	SCIENCE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Cr Hist Sci, London SW7 2AZ, England	Imperial College London	Cuomo, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Cr Hist Sci, London SW7 2AZ, England.	s.cuomo@imperial.ac.uk	Cuomo, Salvatore/Q-1365-2016	Cuomo, Salvatore/0000-0003-4128-2588				BAATZ D, 1994, BAUTEN KATAPULTE ROM; DIODORUS S, 1954, LIB HIST; FRONTINUS, 1925, STRATAGEMS; Garlan Yvon., 1974, RECHERCHES POLIORCET; HERO ALEXANDRIA, BELOPOIETICS; Marsden E.W., 1969, GREEK ROMAN ARTILLER; Marsden EW., 1971, GREEK ROMAN ARTILLER; PHILO, BELOPOIETICS; PLUTARCH, 1927, SAYINGS KINGS COMMAN, V3	9	3	3	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	2004	303	5659					771	772		10.1126/science.1091066	http://dx.doi.org/10.1126/science.1091066			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764855	Green Published			2022-12-28	WOS:000188753800033
J	Whiting, P; Rutjes, AWS; Reitsma, JB; Glas, AS; Bossuyt, PMM; Kleijnen, J				Whiting, P; Rutjes, AWS; Reitsma, JB; Glas, AS; Bossuyt, PMM; Kleijnen, J			Sources of variation and bias in studies of diagnostic accuracy - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Article							FACTORS AFFECTING SENSITIVITY; BRONCHIAL BRUSH SPECIMENS; CLINICAL HISTORY; VERIFICATION BIAS; SPECTRUM BIAS; EXERCISE ELECTROCARDIOGRAPHY; SELECTION BIAS; GOLD STANDARD; BAYES THEOREM; META-ANALYSIS	Background: Studies of diagnostic accuracy are subject to different sources of bias and variation than studies that evaluate the effectiveness of an intervention. Little is known about the effects of these sources of bias and variation. Purpose: To summarize the evidence on factors that can lead to bias or variation in the results of diagnostic accuracy studies. Data Sources: MEDLINE, EMBASE, and BIOSIS, and the methodologic databases of the Centre for Reviews and Dissemination and the Cochrane Collaboration. Methodologic experts in diagnostic tests were contacted. Study Selection: Studies that investigated the effects of bias and variation on measures of test performance were eligible for inclusion, which was assessed by one reviewer and checked by a second reviewer. Discrepancies were resolved through discussion. Data Extraction: Data extraction was conducted by one reviewer and checked by a second reviewer. Data Synthesis: The best-documented effects of bias and variation were found for demographic features, disease prevalence and severity, partial verification bias, clinical review bias, and observer and instrument variation. For other sources, such as distorted selection of participants, absent or inappropriate reference standard, differential verification bias, and review bias, the amount of evidence was limited. Evidence was lacking for other features, including incorporation bias, treatment paradox, arbitrary choice of threshold value, and dropouts. Conclusions: Many issues in the design and conduct of diagnostic accuracy studies can lead to bias or variation; however, the empirical evidence about the size and effect of these issues is limited.	Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England; Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands	University of York - UK; University of Amsterdam	Whiting, P (corresponding author), Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England.	pfw2@york.ac.uk	Bossuyt, Patrick M/AAR-1183-2021; Rutjes, Anne/L-8750-2017; Bossuyt, Patrick M./B-4557-2016	Bossuyt, Patrick M/0000-0003-4427-0128; Rutjes, Anne/0000-0001-9782-779X; Bossuyt, Patrick M./0000-0003-4427-0128; Whiting, Penny/0000-0003-1138-5682				ARANA GW, 1990, BIOL PSYCHIAT, V28, P733, DOI 10.1016/0006-3223(90)90460-J; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BERBAUM KS, 1988, RADIOLOGY, V168, P507, DOI 10.1148/radiology.168.2.3393672; BERBAUM KS, 1989, AM J ROENTGENOL, V153, P1221, DOI 10.2214/ajr.153.6.1221; Bossuyt PM, 2003, CLIN CHEM, V49, P7, DOI 10.1373/49.1.7; Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P18, DOI 10.1136/jnnp.64.1.18; BOYKO EJ, 1988, J GEN INTERN MED, V3, P476, DOI 10.1007/BF02595925; Cecil MP, 1996, J CLIN EPIDEMIOL, V49, P735, DOI 10.1016/0895-4356(96)00014-5; CICCONE G, 1992, EUR J CANCER, V28A, P1054, DOI 10.1016/0959-8049(92)90455-B; COHEN MB, 1987, ARCH PATHOL LAB MED, V111, P518; Corley DE, 1997, CHEST, V112, P458, DOI 10.1378/chest.112.2.458; CUARON A, 1980, J NUCL MED, V21, P1; Curtin F, 1997, J CLIN EPIDEMIOL, V50, P837, DOI 10.1016/S0895-4356(97)00063-2; DENEEF P, 1987, MED DECIS MAKING, V7, P92, DOI 10.1177/0272989X8700700205; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; DETRANO R, 1989, J AM COLL CARDIOL, V14, P1501, DOI 10.1016/0735-1097(89)90388-4; DETRANO R, 1989, PROG CARDIOVASC DIS, V32, P173, DOI 10.1016/0033-0620(89)90025-X; DETRANO R, 1988, ARCH INTERN MED, V148, P1289, DOI 10.1001/archinte.148.6.1289; DIAMOND GA, 1992, MED DECIS MAKING, V12, P22, DOI 10.1177/0272989X9201200105; DIAMOND GA, 1991, MED DECIS MAKING, V11, P48, DOI 10.1177/0272989X9101100109; DOUBILET P, 1981, AM J ROENTGENOL, V137, P1055, DOI 10.2214/ajr.137.5.1055; Egglin TKP, 1996, JAMA-J AM MED ASSOC, V276, P1752, DOI 10.1001/jama.276.21.1752; ELDEVIK OP, 1982, RADIOLOGY, V145, P85, DOI 10.1148/radiology.145.1.7122902; Elmore JG, 1997, JAMA-J AM MED ASSOC, V277, P49, DOI 10.1001/jama.277.1.49; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Froelicher VF, 1998, ANN INTERN MED, V128, P965, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00001; GOOD BC, 1990, AM J ROENTGENOL, V154, P709, DOI 10.2214/ajr.154.4.2107662; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Lijmer JG, 1996, ULTRASOUND MED BIOL, V22, P391, DOI 10.1016/0301-5629(96)00036-1; Melbye Hasse, 1993, Scandinavian Journal of Primary Health Care, V11, P241, DOI 10.3109/02813439308994838; Miller TD, 1998, J AM COLL CARDIOL, V31, p167A, DOI 10.1016/S0735-1097(97)84439-7; Mol BWJ, 1999, OBSTET GYNECOL, V94, P864, DOI 10.1016/S0029-7844(99)00496-2; Moons KGM, 1997, EPIDEMIOLOGY, V8, P12, DOI 10.1097/00001648-199701000-00002; MORISE AP, 1995, AM HEART J, V130, P741, DOI 10.1016/0002-8703(95)90072-1; MORISE AP, 1994, CIRCULATION, V90, P273; OConnor PW, 1996, NEUROLOGY, V47, P140, DOI 10.1212/WNL.47.1.140; PANZER RJ, 1987, MED DECIS MAKING, V7, P115, DOI 10.1177/0272989X8700700209; PHELPS CE, 1995, MED DECIS MAKING, V15, P44, DOI 10.1177/0272989X9501500108; PHILBRICK JT, 1982, JAMA-J AM MED ASSOC, V248, P2467, DOI 10.1001/jama.248.19.2467; POTCHEN EJ, 1979, INVEST RADIOL, V14, P404; Raab SS, 2000, AM J CLIN PATHOL, V114, P78, DOI 10.1309/4099-QALD-NVGF-TM4G; RAAB SS, 1995, AM J CLIN PATHOL, V103, P588; Ransohoff D F, 1982, Med Decis Making, V2, P139, DOI 10.1177/0272989X8200200205; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Roger VL, 1997, CIRCULATION, V95, P405; Ronco G, 1996, CYTOPATHOLOGY, V7, P151, DOI 10.1046/j.1365-2303.1996.39382393.x; ROZANSKI A, 1983, NEW ENGL J MED, V309, P518, DOI 10.1056/NEJM198309013090902; Santana-Boado C, 1998, J NUCL MED, V39, P751; SCHREIBER MH, 1963, JAMA-J AM MED ASSOC, V185, P137; STEIN PD, 1993, CHEST, V104, P1461, DOI 10.1378/chest.104.5.1461; Steinbauer JR, 1998, ANN INTERN MED, V129, P353, DOI 10.7326/0003-4819-129-5-199809010-00002; TAUBE A, 1990, ACTA ONCOL, V29, P971, DOI 10.3109/02841869009091785; THIBODEAU LA, 1981, BIOMETRICS, V37, P801, DOI 10.2307/2530161; VANDERSCHOUW YT, 1995, J CLIN EPIDEMIOL, V48, P417, DOI 10.1016/0895-4356(94)00144-F; VANRIJKOM HM, 1995, CARIES RES, V29, P364, DOI 10.1159/000262094; WHITING PJ, IN PRESS HLTH TECHNO; ZHOU XH, 1994, STAT MED, V13, P1737, DOI 10.1002/sim.4780131705	61	600	611	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					189	202		10.7326/0003-4819-140-3-200402030-00010	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00010			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757617				2022-12-28	WOS:000188704500005
J	Hasegawa, K; Martin, F; Huang, GM; Tumas, D; Diehl, L; Chan, AC				Hasegawa, K; Martin, F; Huang, GM; Tumas, D; Diehl, L; Chan, AC			PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells	SCIENCE			English	Article							PROTEIN-KINASE P50(CSK); TRANSGENIC MICE; PTP-PEST; B-CELLS; RECEPTOR; MEMORY; THYMOCYTES; EXPRESSION; ANTIGEN; ASSOCIATION	Protein tyrosine kinases and phosphatases cooperate to regulate normal immune cell function. We examined the role of PEST domain - enriched tyrosine phosphatase ( PEP) in regulating T cell antigen - receptor function during thymocyte development and peripheral T cell differentiation. Although normal naive T cell functions were retained in pep-deficient mice, effector/memory T cells demonstrated enhanced activation of Lck. In turn, this resulted in increased expansion and function of the effector/memory T cell pool, which was also associated with spontaneous development of germinal centers and elevated serum antibody levels. These results revealed a central role for PEP in negatively regulating specific aspects of T cell development and function.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Chan, AC (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way, San Francisco, CA 94080 USA.	acc@gene.com						Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; Azzam HS, 2001, J IMMUNOL, V166, P5464, DOI 10.4049/jimmunol.166.9.5464; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Hu H, 2001, NAT IMMUNOL, V2, P705, DOI 10.1038/90643; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Luzina IG, 2001, J LEUKOCYTE BIOL, V70, P578; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; SHI YF, 1991, J IMMUNOL, V146, P3340	26	302	313	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					685	689		10.1126/science.1092138	http://dx.doi.org/10.1126/science.1092138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752163				2022-12-28	WOS:000188530800045
J	Di Toro, G; Goldsby, DL; Tullis, TE				Di Toro, G; Goldsby, DL; Tullis, TE			Friction falls towards zero in quartz rock as slip velocity approaches seismic rates	NATURE			English	Article							SAN-ANDREAS FAULT; HEAT-FLOW; STRESS; EARTHQUAKES; MECHANICS; STRENGTH; SURFACE; MODELS; STATE	An important unsolved problem in earthquake mechanics is to determine the resistance to slip on faults in the Earth's crust during earthquakes(1). Knowledge of coseismic slip resistance is critical for understanding the magnitude of shear-stress reduction and hence the near-fault acceleration that can occur during earthquakes, which affects the amount of damage that earthquakes are capable of causing. In particular, a long-unresolved problem is the apparently low strength of major faults(2-6), which may be caused by low coseismic frictional resistance(3). The frictional properties of rocks at slip velocities up to 3 mm s(-1) and for slip displacements characteristic of large earthquakes have been recently simulated under laboratory conditions(7). Here we report data on quartz rocks that indicate an extraordinary progressive decrease in frictional resistance with increasing slip velocity above 1 mm s(-1). This reduction extrapolates to zero friction at seismic slip rates of similar to1m s(-1), and appears to be due to the formation of a thin layer of silica gel on the fault surface: it may explain the low strength of major faults during earthquakes.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Univ Padua, Dipartimento Geol Paleontol & Geofis, I-35137 Padua, Italy	Brown University; University of Padua	Tullis, TE (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.	Terry_Tullis@brown.edu		Goldsby, David/0000-0002-9004-0086				[Anonymous], 1991, APPL FLUID RHEOLOGY; ARCHARD JF, 1958, WEAR, V2, P438; Beeler NM, 1996, B SEISMOL SOC AM, V86, P1130; Brodsky EE, 2001, J GEOPHYS RES-SOL EA, V106, P16357, DOI 10.1029/2001JB000430; BRUNE JN, 1969, J GEOPHYS RES, V74, P3821, DOI 10.1029/JB074i015p03821; BRUNE JN, 1993, TECTONOPHYSICS, V218, P59, DOI 10.1016/0040-1951(93)90259-M; BYERLEE J, 1978, PURE APPL GEOPHYS, V116, P615, DOI 10.1007/BF00876528; Deer W. A., 1992, INTRO ROCK FORMING M; DIETERICH JH, 1978, PURE APPL GEOPHYS, V116, P790, DOI 10.1007/BF00876539; Dieterich JH, 1996, TECTONOPHYSICS, V256, P219, DOI 10.1016/0040-1951(95)00165-4; Goldsby DL, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015240; HICKMAN SH, 1991, REV GEOPHYS, V29, P759, DOI 10.1002/rog.1991.29.s2.759; KANAMORI H, 1994, ANNU REV EARTH PL SC, V22, P207, DOI 10.1146/annurev.ea.22.050194.001231; Killick AM, 1998, TECTONOPHYSICS, V284, P247, DOI 10.1016/S0040-1951(97)00181-9; KNAUTH LP, 1994, SILICA PHYS BEHAV GE, P233; LACHENBRUCH AH, 1980, J GEOPHYS RES, V85, P6249; Mair K, 2000, PURE APPL GEOPHYS, V157, P1847, DOI 10.1007/PL00001064; MCKENZIE D, 1972, GEOPHYS J ROY ASTR S, V29, P65, DOI 10.1111/j.1365-246X.1972.tb06152.x; Melosh HJ, 1996, NATURE, V379, P601, DOI 10.1038/379601a0; MOUNT VS, 1987, GEOLOGY, V15, P1143, DOI 10.1130/0091-7613(1987)15<1143:SOSNTS>2.0.CO;2; PERRIN G, 1995, J MECH PHYS SOLIDS, V43, P1461, DOI 10.1016/0022-5096(95)00036-I; POWER WL, 1989, J STRUCT GEOL, V11, P879, DOI 10.1016/0191-8141(89)90105-3; Rice J., 1992, FAULT MECH TRANSPORT, P475, DOI DOI 10.1016/S0074-6142(08)62835-1; SPRAY JG, 1987, J STRUCT GEOL, V9, P49, DOI 10.1016/0191-8141(87)90043-5; SPRAY JG, 1993, J GEOPHYS RES-SOL EA, V98, P8053, DOI 10.1029/93JB00020; TITONE B, 2001, EOS, V82; Tsutsumi A, 1997, GEOPHYS RES LETT, V24, P699, DOI 10.1029/97GL00503; TULLIS TE, 1986, PURE APPL GEOPHYS, V124, P383, DOI 10.1007/BF00877209; YUNG RA, 1990, J GEOPHYS RES-SOLID, V95, P15589, DOI 10.1029/JB095iB10p15589; ZOBACK MD, 1987, SCIENCE, V238, P1105, DOI 10.1126/science.238.4830.1105	30	408	411	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					436	439		10.1038/nature02249	http://dx.doi.org/10.1038/nature02249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749829				2022-12-28	WOS:000188470500041
J	Williams, JV; Harris, PA; Tollefson, SJ; Halburnt-Rush, LL; Pingsterhaus, JM; Edwards, KM; Wright, PF; Crowe, JE				Williams, JV; Harris, PA; Tollefson, SJ; Halburnt-Rush, LL; Pingsterhaus, JM; Edwards, KM; Wright, PF; Crowe, JE			Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; SYNCYTIAL VIRUS; YOUNG-CHILDREN; INFECTIONS; RHINOVIRUS; ADENOVIRUS; INFLUENZA; ASSAY	BACKGROUND: We sought to determine the role of human metapneumovirus in lower respiratory tract illness in previously healthy infants and children. METHODS: We tested nasal-wash specimens, obtained over a 25-year period from otherwise healthy children presenting with acute respiratory tract illness, for human metapneumovirus. RESULTS: A viral cause other than human metapneumovirus was determined for 279 of 687 visits for acute lower respiratory tract illness (41 percent) by 463 children in a population of 2009 infants and children prospectively seen from 1976 to 2001. There were 408 visits for lower respiratory tract illness by 321 children for which no cause was identified. Of these 321 children, specimens from 248 were available. Forty-nine of these 248 specimens (20 percent) contained human metapneumovirus RNA or viable virus. Thus, 20 percent of all previously virus-negative lower respiratory tract illnesses were attributable to human metapneumovirus, which means that 12 percent of all lower respiratory tract illnesses in this cohort were most likely due to this virus. The mean age of human metapneumovirus-infected children was 11.6 months, the male:female ratio was 1.8:1, 78 percent of illnesses occurred between December and April, and the hospitalization rate was 2 percent. The virus was associated with bronchiolitis in 59 percent of cases, pneumonia in 8 percent, croup in 18 percent, and an exacerbation of asthma in 14 percent. We also detected human metapneumovirus in 15 percent of samples from 261 patients with upper respiratory tract infection but in only 1 of 86 samples from asymptomatic children. CONCLUSIONS: Human metapneumovirus infection is a leading cause of respiratory tract infection in the first years of life, with a spectrum of disease similar to that of respiratory syncytial virus.	Vanderbilt Univ, Med Ctr, Dept Pediat, Div Infect Dis, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Div Infect Dis, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Div Infect Dis, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Div Infect Dis, D-7235 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	james.crowe@vanderbilt.edu	Crowe, James/B-5549-2009; Williams, John/F-6962-2010; Williams, John/ABE-3227-2020	Crowe, James/0000-0002-0049-1079; Williams, John/0000-0001-8377-5175; Williams, John/0000-0001-8377-5175	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI054790] Funding Source: NIH RePORTER; NIAID NIH HHS [R03 AI054790] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319; EDWARDS KM, 1985, PEDIATRICS, V76, P420; Esper F, 2003, PEDIATRICS, V111, P1407, DOI 10.1542/peds.111.6.1407; Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901; Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fisher RG, 1997, PEDIATRICS, V99, pE71, DOI 10.1542/peds.99.2.e7; Freymuth F, 1997, CLIN DIAGN VIROL, V8, P31, DOI 10.1016/S0928-0197(97)00060-3; Freymuth F, 2003, PEDIATR INFECT DIS J, V22, P92, DOI 10.1097/00006454-200301000-00024; GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4; Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289; HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; Jartti T, 2002, LANCET, V360, P1393, DOI 10.1016/S0140-6736(02)11391-2; Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001; Mackay IM, 2003, J CLIN MICROBIOL, V41, P100, DOI 10.1128/JCM.41.1.100-105.2003; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; Nissen MD, 2002, MED J AUSTRALIA, V176, P188, DOI 10.5694/j.1326-5377.2002.tb04354.x; Osterhaus A, 2003, LANCET, V361, P890, DOI 10.1016/S0140-6736(03)12785-7; Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; Reed G, 1997, J INFECT DIS, V175, P807, DOI 10.1086/513975; Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Wright PF, 2000, J INFECT DIS, V182, P1331, DOI 10.1086/315859	25	640	685	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					443	450		10.1056/NEJMoa025472	http://dx.doi.org/10.1056/NEJMoa025472			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749452	Green Accepted			2022-12-28	WOS:000188463900006
J	Lucock, M				Lucock, M			Is folic acid the ultimate functional food component for disease prevention?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MATERNAL RISK-FACTORS; PLASMA HOMOCYSTEINE; METHIONINE SYNTHASE; FOLATE METABOLISM; VASCULAR-DISEASE; COMMON MUTATION; SUSCEPTIBILITY; FORTIFICATION; POLYMORPHISMS		Univ Newcastle, Sch Appl Sci, Ourimbah, NSW 2258, Australia	University of Newcastle	Lucock, M (corresponding author), Univ Newcastle, Sch Appl Sci, Brush Rd, Ourimbah, NSW 2258, Australia.	Mark.Lucock@newcastle.edu						[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Choumenkovitch SF, 2002, J NUTR, V132, P2792, DOI 10.1093/jn/132.9.2792; Fenech M, 2002, FOOD CHEM TOXICOL, V40, P1113, DOI 10.1016/S0278-6915(02)00028-5; Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Hobbs CA, 2000, AM J HUM GENET, V67, P623, DOI 10.1086/303055; James SJ, 1999, AM J CLIN NUTR, V70, P495; KANG SS, 1991, AM J HUM GENET, V48, P536; Kelly P, 1997, AM J CLIN NUTR, V65, P1790, DOI 10.1093/ajcn/65.6.1790; Lewis CJ, 1999, AM J CLIN NUTR, V70, P198; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; LUCOCK MD, 1995, FOOD CHEM, V53, P329, DOI 10.1016/0308-8146(95)93941-J; LUCOCK MD, 1989, BIOCHEM MED METAB B, V42, P30, DOI 10.1016/0885-4505(89)90038-8; LUCOCK MD, 2001, FOLATE HUMAN DEV, P263; Ma J, 1997, CANCER RES, V57, P1098; MATTHEWS RG, 1980, BIOCHEMISTRY-US, V19, P2040, DOI 10.1021/bi00551a005; Mills JL, 1999, AM J MED GENET, V86, P71, DOI 10.1002/(SICI)1096-8628(19990903)86:1<71::AID-AJMG14>3.3.CO;2-P; RAO KN, 1994, INDIAN J BIOCHEM BIO, V31, P184; ROSS J, 1984, BIOCHEMISTRY-US, V23, P1796, DOI 10.1021/bi00303a033; Schorah CJ, 1998, EUR J CLIN NUTR, V52, P407, DOI 10.1038/sj.ejcn.1600576; Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810; SKIBOLA CF, 1999, BLOOD, V99, P3788; Slattery ML, 1999, CANCER EPIDEM BIOMAR, V8, P513; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879; Yates Z, 2002, HAEMATOLOGICA, V87, P751; 1996, FED REG, V61, P8781	29	131	141	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					211	214		10.1136/bmj.328.7433.211	http://dx.doi.org/10.1136/bmj.328.7433.211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739191	Green Submitted, Green Published			2022-12-28	WOS:000188652200021
J	Bartel, DP				Bartel, DP			MicroRNAs: Genomics, biogenesis, mechanism, and function	CELL			English	Review							DOUBLE-STRANDED-RNA; SHORT INTERFERING RNA; GERM-LINE DEVELOPMENT; SMALL TEMPORAL RNAS; C-ELEGANS; MESSENGER-RNA; CAENORHABDITIS-ELEGANS; NUCLEAR EXPORT; REGULATORY RNA; PAZ DOMAIN	MicroRNAs (miRNAs) are endogenous similar to22 nt RNAs that can play important regulatory roles in animals and plants by targeting mRNAs; for cleavage or translational repression. Although they escaped notice until relatively recently, miRNAs comprise one of the more abundant classes of gene regulatory molecules in multicellular organisms and likely influence the output of many protein-coding genes.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Bartel, DP (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dbartel@wi.mit.edu	Young, Richard A/F-6495-2012; ravegnini, gloria/K-1330-2016; Calin, George/E-9390-2011	Young, Richard A/0000-0001-8855-8647; ravegnini, gloria/0000-0002-7774-402X; 				Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; AUKERMAN MJ, 2003, PLANT CELL, V10, P10; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bashirullah A, 2003, DEV BIOL, V259, P1, DOI 10.1016/S0012-1606(03)00063-0; Basyuk E, 2003, NUCLEIC ACIDS RES, V31, P6593, DOI 10.1093/nar/gkg855; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Bollman KM, 2003, DEVELOPMENT, V130, P1493, DOI 10.1242/dev.00362; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; CHEN X, 2003, MICRORNA TRANSLATION, DOI DOI 10.1126/SCIENCE.1088060; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dostie J, 2003, RNA, V9, P631; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; Enright AJ, 2004, GENOME BIOL, V5; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hipfner DR, 2002, GENETICS, V161, P1527; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kawasaki H, 2003, NATURE, V426, P100, DOI 10.1038/nature02141; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; MENEELY PM, 1979, GENETICS, V92, P99; Mette MF, 2002, PLANT PHYSIOL, V130, P6, DOI 10.1104/pp.007047; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; OHLER U, 2004, IN PRESS RNA; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Papp I, 2003, PLANT PHYSIOL, V132, P1382, DOI 10.1104/pp.103.021980; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pickford AS, 2002, ADV GENET, V46, P277; Pusch O, 2003, NUCLEIC ACIDS RES, V31, P6444, DOI 10.1093/nar/gkg876; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Schauer SE, 2002, TRENDS PLANT SCI, V7, P487, DOI 10.1016/S1360-1385(02)02355-5; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Vance V, 2001, SCIENCE, V292, P2277, DOI 10.1126/science.1061334; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; Xie ZX, 2003, CURR BIOL, V13, P784, DOI 10.1016/S0960-9822(03)00281-1; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yan Kelley S, 2003, Nature, V426, P468, DOI 10.1038/nature02129; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	132	28055	30609	97	2678	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					281	297		10.1016/S0092-8674(04)00045-5	http://dx.doi.org/10.1016/S0092-8674(04)00045-5			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744438	Bronze			2022-12-28	WOS:000188541700017
J	MacLaughlin, DT; Donahoe, PK				MacLaughlin, DT; Donahoe, PK			Mechanisms of disease: Sex determination and differentiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MULLERIAN-INHIBITING SUBSTANCE; CONGENITAL ADRENAL-HYPERPLASIA; STEROIDOGENIC FACTOR-I; MIXED GONADAL-DYSGENESIS; HUMAN ANDROGEN RECEPTOR; PRIMORDIAL GERM-CELLS; HUMAN Y-CHROMOSOME; TRUE HERMAPHRODITISM; X-CHROMOSOME; 21-HYDROXYLASE DEFICIENCY		Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pediat Surg Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	MacLaughlin, DT (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA.	maclaughlin@helix.mgh.harvard.edu; donahoe.patricia@mgh.harvard.edu			NCI NIH HHS [CA 17393] Funding Source: Medline; NICHD NIH HHS [HD 32112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; [Anonymous], 2002, SCI MED ASPECTS HUMA; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Barbara PD, 2002, DEVELOPMENT, V129, P551; Belville C, 1999, AM J MED GENET, V89, P218, DOI 10.1002/(SICI)1096-8628(19991229)89:4<218::AID-AJMG6>3.0.CO;2-E; BERKOVITZ GD, 1992, HUM GENET, V88, P411, DOI 10.1007/BF00215675; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; COHENHAGUENAUER O, 1987, CYTOGENET CELL GENET, V44, P2, DOI 10.1159/000132332; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; Di Cerbo A, 2002, J CLIN ENDOCR METAB, V87, P898, DOI 10.1210/jc.87.2.898; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONAHOE PK, 1978, J PEDIATR SURG, V13, P293, DOI 10.1016/S0022-3468(78)80403-5; DONAHOE PK, 1980, J PEDIATR SURG, V15, P486, DOI 10.1016/S0022-3468(80)80759-7; DONAHOE PK, 1979, J PEDIATR SURG, V14, P287, DOI 10.1016/S0022-3468(79)80486-8; DONAHOE PK, 1997, J PEDIATR SURG, V12, P1045; DONAHOE PK, 1986, PEDIATR SURG, V2, P1363; EVANS EP, 1990, GENET RES, V56, P15, DOI 10.1017/S0016672300028834; Goodman FR, 2001, CLIN GENET, V59, P1, DOI 10.1034/j.1399-0004.2001.590101.x; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Haqq CM, 1998, PHYSIOL REV, V78, P1; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HUTSON JM, 1987, PEDIATR SURG INT, V2, P191; Imperato-McGinley J, 2002, MOL CELL ENDOCRINOL, V198, P51, DOI 10.1016/S0303-7207(02)00368-4; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Koshimizu U, 1996, DEVELOPMENT, V122, P1235; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LABOSKY PA, 1994, DEVELOPMENT, V120, P3197; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; Lee MM, 1997, NEW ENGL J MED, V336, P1480, DOI 10.1056/NEJM199705223362102; LeersSucheta S, 1997, J BIOL CHEM, V272, P7960, DOI 10.1074/jbc.272.12.7960; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; MacLaughlin DT, 2001, ENDOCRINOLOGY, V142, P2167, DOI 10.1210/en.142.6.2167; Matova N, 2001, DEV BIOL, V231, P291, DOI 10.1006/dbio.2000.0120; MATSUMOTO A, 1996, SPERMATOGENESIS, P359; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; MCLAREN A, 1990, CELL DIFFER DEV, V31, P185, DOI 10.1016/0922-3371(90)90131-F; McLaren A, 2001, CELL STRUCT FUNCT, V26, P119, DOI 10.1247/csf.26.119; Mehlmann LM, 2002, SCIENCE, V297, P1343, DOI 10.1126/science.1073978; Merke Deborah P., 2002, Annals of Internal Medicine, V136, P320; Miller C, 1998, NAT GENET, V20, P228, DOI 10.1038/3027; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MORISSETTE J, 1995, CYTOGENET CELL GENET, V69, P59, DOI 10.1159/000133938; MORNET E, 1989, J BIOL CHEM, V264, P20961; Mroz K, 1999, DEV BIOL, V207, P229, DOI 10.1006/dbio.1998.9160; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; New MI, 2001, PEDIATRICS, V107, P804, DOI 10.1542/peds.107.4.804; NIHOULFEKETE C, 1984, J PEDIATR SURG, V19, P50, DOI 10.1016/S0022-3468(84)80015-9; Ottolenghi C, 2000, GENOMICS, V64, P170, DOI 10.1006/geno.2000.6121; Parker KL, 1999, CELL MOL LIFE SCI, V55, P831, DOI 10.1007/s000180050337; Parker KL, 1995, VITAM HORM, V51, P339, DOI 10.1016/S0083-6729(08)61044-4; Parker KL, 1999, ANNU REV PHYSIOL, V61, P417, DOI 10.1146/annurev.physiol.61.1.417; Peltoketo H, 1999, J MOL ENDOCRINOL, V23, P1, DOI 10.1677/jme.0.0230001; Prasad SV, 2000, CELLS TISSUES ORGANS, V166, P148, DOI 10.1159/000016730; PUCHOLT V, 1980, J MED GENET, V17, P447, DOI 10.1136/jmg.17.6.447; REY R, 1994, J CLIN ENDOCR METAB, V79, P960, DOI 10.1210/jc.79.4.960; ROBBOY SJ, 1982, HUM PATHOL, V13, P700, DOI 10.1016/S0046-8177(82)80292-X; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; SANYANUSIN P, 1995, HUM MOL GENET, V4, P2183, DOI 10.1093/hmg/4.11.2183; Schnitzer JJ, 2001, ENDOCRIN METAB CLIN, V30, P137, DOI 10.1016/S0889-8529(08)70023-9; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Shamblott MJ, 1999, P NATL ACAD SCI USA, V96, P1162; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Speiser PW, 2001, ENDOCRIN METAB CLIN, V30, P31, DOI 10.1016/S0889-8529(08)70018-5; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stocco DM, 2001, MOL ENDOCRINOL, V15, P1245, DOI 10.1210/me.15.8.1245; TAKETO M, 1995, GENOMICS, V25, P565, DOI 10.1016/0888-7543(95)80059-U; TALERMAN A, 1985, ANN PATHOL, V5, P145; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; Telvi L, 1999, PEDIATRICS, V104, P304, DOI 10.1542/peds.104.2.304; Torres M, 1995, DEVELOPMENT, V121, P4057; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; VISSER JA, 1995, BIOCHEM BIOPH RES CO, V215, P1029, DOI 10.1006/bbrc.1995.2567; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; WHITE PC, 1985, ANN NY ACAD SCI, V458, P277, DOI 10.1111/j.1749-6632.1985.tb14613.x; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	88	182	205	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					367	378		10.1056/NEJMra022784	http://dx.doi.org/10.1056/NEJMra022784			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736929				2022-12-28	WOS:000188254800009
J	Schapira, AHV; Olanow, CW				Schapira, AHV; Olanow, CW			Neuroprotection in Parkinson disease - Mysteries, myths, and misconceptions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRIATAL DOPAMINE TRANSPORTER; AMINO-ACID DECARBOXYLASE; IN-VIVO; AUTORECEPTOR ACTIVATION; SUBSTANTIA-NIGRA; CHRONIC LEVODOPA; CONTROLLED-TRIAL; BINDING-SITES; RAT STRIATUM; PROGRESSION	Parkinson disease is an age-related neurodegenerative disease that affects approximately 1. million persons in the United States. Current therapies provide effective control of symptoms, particularly in the early stages of the disease, but most patients develop motor complications with long-term treatment, and features develop such as postural instability, failing, and dementia that are not adequately controlled with existing medications. Accordingly, neuroprotective therapy that might slow, stop, or reverse disease progression is urgently needed. While many agents appear to be promising based on laboratory studies, selecting clinical end points for clinical trials that are not confounded by symptomatic effects of the study intervention has been difficult. More recently, neuroimaging end points have been used as. biomarkers of disease progression, but again there are concerns that they may be influenced by regulatory effects of the drugs used. We review clinical trials aimed at detecting neuroprotection in Parkinson disease and address the controversies surrounding the interpretation of these studies.	UCL Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England; Inst Neurol, London WC1N 3BG, England; Mt Sinai Sch Med, Dept Neurol, New York, NY USA	University of London; University College London; UCL Medical School; University of London; University College London; Icahn School of Medicine at Mount Sinai	Schapira, AHV (corresponding author), UCL Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, Rowland Hill St, London NW3 2PF, England.	warren.olanow@mssm.edu	Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				Agid Y, 2002, LANCET, V360, P575, DOI 10.1016/S0140-6736(02)09733-7; Ahlskog JE, 2003, NEUROLOGY, V60, P381, DOI 10.1212/01.WNL.0000044047.58984.2F; Albin RL, 2003, NEUROLOGY, V60, P390, DOI 10.1212/01.WNL.0000052681.28286.52; ALLARD P, 1990, PSYCHOPHARMACOLOGY, V102, P291, DOI 10.1007/BF02244092; Batchelor M, 1998, J NEUROSCI, V18, P10304; Cumming P, 1997, J CEREBR BLOOD F MET, V17, P1254, DOI 10.1097/00004647-199711000-00014; Ekesbo A, 1999, NEUROLOGY, V52, P120, DOI 10.1212/WNL.52.1.120; Fahn S, 2002, MOVEMENT DISORD, V17, pS13; GNANALINGHAM KK, 1994, BRAIN RES, V640, P185, DOI 10.1016/0006-8993(94)91872-4; GOETZ CG, 2002, MOV DISORD S4, V17, pS1; Gordon I, 1996, EUR J PHARMACOL, V298, P27, DOI 10.1016/0014-2999(95)00770-9; Guttman M, 2001, NEUROLOGY, V56, P1559, DOI 10.1212/WNL.56.11.1559; HADJICONSTANTINOU M, 1993, J NEUROCHEM, V60, P2175, DOI 10.1111/j.1471-4159.1993.tb03503.x; Harrington KA, 1996, MOL BRAIN RES, V36, P157, DOI 10.1016/0169-328X(95)00278-Z; IKAWA K, 1993, EUR J PHARMACOL, V250, P261, DOI 10.1016/0014-2999(93)90390-4; Innis RB, 1999, MOVEMENT DISORD, V14, P436, DOI 10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J; Joyce JN, 1997, MOVEMENT DISORD, V12, P885, DOI 10.1002/mds.870120609; KREISS DS, 1995, EUR J PHARMACOL, V277, P209, DOI 10.1016/0014-2999(95)00069-W; Le WD, 2001, DRUG AGING, V18, P389, DOI 10.2165/00002512-200118060-00001; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS10; Little KY, 1996, BRAIN RES, V742, P313, DOI 10.1016/S0006-8993(96)01033-5; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; Marek K, 2001, NEUROLOGY, V57, P2089, DOI 10.1212/WNL.57.11.2089; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; MEIERGERD SM, 1993, J NEUROCHEM, V61, P764; MELAMED E, 1983, NEUROLOGY, V33, P950, DOI 10.1212/WNL.33.7.950; Moody CA, 1996, NEUROSCI LETT, V217, P55; Morrish PK, 1998, J NEUROL NEUROSUR PS, V64, P314, DOI 10.1136/jnnp.64.3.314; Murer MG, 1998, ANN NEUROL, V43, P561, DOI 10.1002/ana.410430504; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Nurmi E, 2000, ANN NEUROL, V47, P804, DOI 10.1002/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F; Nurmi E, 2000, J CEREBR BLOOD F MET, V20, P1604, DOI 10.1097/00004647-200011000-00010; Olanow C. W., 2003, ANN NEUROL S3, V53; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Olanow CW, 1998, ANN NEUROL, V44, pS167; Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; Parkinson Study Group, 2000, JAMA, V284, P1931; PATE BD, 1993, ANN NEUROL, V34, P331, DOI 10.1002/ana.410340306; Pirker W, 2002, MOVEMENT DISORD, V17, P45, DOI 10.1002/mds.1265; Pothos EN, 1998, J NEUROSCI, V18, P5575; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Rioux L, 1997, MOVEMENT DISORD, V12, P148, DOI 10.1002/mds.870120204; Schapira AHV, 2002, NEUROLOGY, V58, pS9, DOI 10.1212/WNL.58.suppl_1.S9; Schapira AHV, 2003, ANN NEUROL, V53, pS149, DOI 10.1002/ana.10514; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937; SNOW BJ, 1993, ANN NEUROL, V34, P324, DOI 10.1002/ana.410340304; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; TISSARI AH, 1993, J NEUROCHEM, V61, P231, DOI 10.1111/j.1471-4159.1993.tb03559.x; Torstenson R, 1997, ANN NEUROL, V41, P334, DOI 10.1002/ana.410410308; UHL GR, 1994, ANN NEUROL, V35, P494, DOI 10.1002/ana.410350421; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; Whone AL, 2003, ANN NEUROL, V54, P93, DOI 10.1002/ana.10609; Wooten GF, 2003, NEUROLOGY, V60, P360, DOI 10.1212/WNL.60.3.360; ZHU MY, 1993, EUR J PHARMACOL, V238, P157, DOI 10.1016/0014-2999(93)90843-7	58	211	222	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					358	364		10.1001/jama.291.3.358	http://dx.doi.org/10.1001/jama.291.3.358			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734599				2022-12-28	WOS:000188243100036
J	Bassotti, G; Chistolini, F; Sietchiping-Nzepa, F; de Roberto, G; Morelli, A; Chiarioni, G				Bassotti, G; Chistolini, F; Sietchiping-Nzepa, F; de Roberto, G; Morelli, A; Chiarioni, G			Biofeedback for pelvic floor dysfunction in constipation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VISUAL BIOFEEDBACK; RANDOMIZED-TRIAL; THERAPY; ENCOPRESIS		Univ Perugia, Dept Clin & Expt Med, Gastroenterol & Hepatol Sect, I-06100 Perugia, Italy; Azienda Osped, Valeggio sul Mincio Hosp, Gastrointestinal Rehabil Div, Valeggio Sul Mincio, VR, Italy; Univ Verona, Valeggio Sul Mincio, VR, Italy	University of Perugia; University of Verona	Bassotti, G (corresponding author), Str Cimitero 2-A, I-06131 Perugia, Italy.	gabassot@tin.it	Chiarioni, Giuseppe/C-1876-2016; de Roberto, giuseppe/AAQ-4818-2020	Chiarioni, Giuseppe/0000-0002-9183-4750; 				[Anonymous], 1999, GASTROENTEROLOGY, V116, P732, DOI 10.1016/S0016-5085(99)70195-2; Azpiroz F, 2002, AM J GASTROENTEROL, V97, P232; Bassotti G, 1997, QJM-INT J MED, V90, P545, DOI 10.1093/qjmed/90.8.545; Battaglia E, 2004, DIS COLON RECTUM, V47, P90, DOI 10.1007/s10350-003-0010-0; BLEIJENBERG G, 1994, AM J GASTROENTEROL, V89, P1021; BLEIJENBERG G, 1987, DIS COLON RECTUM, V30, P108, DOI 10.1007/BF02554946; Brazzelli M, 2001, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002240; Chiarioni G, 2002, AM J GASTROENTEROL, V97, P109; CHIARIONI G, IN PRESS DIS COLON R; COX DJ, 1994, BIOFEEDBACK SELF-REG, V19, P41, DOI 10.1007/BF01720669; D'Hoore A, 2003, Colorectal Dis, V5, P280, DOI 10.1046/j.1463-1318.2003.00497.x; DROSSMAN DA, 2000, ROME II FUNCTIONAL G; Gilliland R, 1997, BRIT J SURG, V84, P1123, DOI 10.1046/j.1365-2168.1997.02746.x; Glia A, 1997, DIS COLON RECTUM, V40, P889, DOI 10.1007/BF02051194; Heymen S, 2003, DIS COLON RECTUM, V46, P1208, DOI 10.1007/s10350-004-6717-8; Heymen S, 1999, DIS COLON RECTUM, V42, P1388, DOI 10.1007/BF02235034; KAWIMBE BM, 1991, GUT, V32, P1175, DOI 10.1136/gut.32.10.1175; KOUTSOMANIS D, 1995, GUT, V37, P95, DOI 10.1136/gut.37.1.95; LOENINGBAUCKE V, 1990, J PEDIATR-US, V116, P214, DOI 10.1016/S0022-3476(05)82877-X; Mason HJ, 2002, AM J GASTROENTEROL, V97, P3154; Nolan T, 1998, ARCH DIS CHILD, V79, P131, DOI 10.1136/adc.79.2.131; Rao SSC, 1997, DIGEST DIS SCI, V42, P2197, DOI 10.1023/A:1018846113210; Sunic-Omejc M, 2002, COLLEGIUM ANTROPOL, V26, P93; Thompson WG, 1999, GUT, V45, P43; vanderPlas RN, 1996, LANCET, V348, P776, DOI 10.1016/S0140-6736(96)03206-0; WALD A, 1987, J PEDIATR GASTR NUTR, V6, P554, DOI 10.1097/00005176-198707000-00011; Wang J, 2003, WORLD J GASTROENTERO, V9, P2109, DOI 10.3748/wjg.v9.i9.2109; Whitehead WE, 2000, ROME 2 FUNCTIONAL GA, V2nd, P483; Whitehead WEHS, 2002, SCHUSTER ATLAS GASTR, V2nd, P381	29	49	54	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					393	396		10.1136/bmj.328.7436.393	http://dx.doi.org/10.1136/bmj.328.7436.393			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962877	Green Published			2022-12-28	WOS:000189031300027
J	Schulpher, M; Bryan, S; Fry, P; de Winter, P; Payne, H; Emberton, M				Schulpher, M; Bryan, S; Fry, P; de Winter, P; Payne, H; Emberton, M			Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To establish which attributes of conservative treatments for prostate cancer are most important to men. Design Discrete choice experiment. Setting Two London hospitals. Participants 129 men with non-metastatic prostate cancer, mean age 70 years; 69 of 118 (58%) with T stage 1 or 2 cancer at diagnosis. Main outcome measures Men's preferences for, and trade-offs between, the attributes of diarrhoea, hot flushes, ability to maintain an erection, breast swelling or tenderness, physical energy, sex drive, life expectancy, and out of pocket expenses. Results The men's responses to changes in attributes were all statistically significant. When asked to assume a starting life expectancy of five years, the men were willing to make trade-offs between life expectancy and side effects. On average, they were most willing to give up life expectancy to avoid limitations in physical energy (mean three months) and least willing to trade life expectancy to avoid hot flushes (mean 0.6 months to move from a moderate to mild level or from mild to none). Conclusions Men with prostate cancer are willing to participate in a relatively complex exercise that weighs up the advantages and disadvantages of various conservative treatments for their condition. They were willing to trade off some life expectancy to be relieved of the burden of troublesome side effects such as limitations in physical energy.	Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Univ Birmingham, Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England; UCL Royal Free & Univ Coll Med Sch, Inst Urol, London W1P 7PN, England; Middlesex Hosp, Meyerstein Inst Oncol, London W1T 3AA, England	University of York - UK; University of Birmingham; University of London; University College London; UCL Medical School; University of London; University College London	Schulpher, M (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	mjs23@york.ac.uk		Sculpher, Mark/0000-0003-3746-9913				Adolfsson J, 1999, EUR UROL, V36, P3, DOI 10.1159/000052336; Blackard C E, 1973, Urology, V1, P553, DOI 10.1016/0090-4295(73)90515-3; Bryan S, 1998, HEALTH ECON, V7, P595, DOI 10.1002/(SICI)1099-1050(1998110)7:7<595::AID-HEC381>3.3.CO;2-5; Bryan S, 2000, HEALTH ECON, V9, P385; Bryan S, 2002, APPL ECON, V34, P561, DOI 10.1080/00036840110103733; Iversen P, 1998, UROLOGY, V51, P389, DOI 10.1016/S0090-4295(98)00004-1; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Ryan M, 2000, BMJ-BRIT MED J, V320, P1530, DOI 10.1136/bmj.320.7248.1530	9	96	96	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					382	384A		10.1136/bmj.37872.497234.44	http://dx.doi.org/10.1136/bmj.37872.497234.44			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14751919				2022-12-28	WOS:000189031300020
J	Walley, T; Folino-Gallo, P; Schwabe, U; van Ganse, E				Walley, T; Folino-Gallo, P; Schwabe, U; van Ganse, E		EuroMedStat Grp	Variations and increase in use of statins across Europe: data from administrative databases	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England; CNR, IRPPS, I-00198 Rome, Italy; Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany; Univ Lyon, Unite Pharmacoepidemiol, Lyon, France	University of Liverpool; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerche sulla Popolazione e le Politiche Sociali (IRPPS-CNR); Ruprecht Karls University Heidelberg	Walley, T (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England.	twalley@liv.ac.uk	VAN GANSE, Eric/D-5876-2015	VAN GANSE, Eric/0000-0002-7463-9187				*EUR MED STAT GROU, IN PRESS EUR J PUBLI; Larsen J, 2000, BRIT J CLIN PHARMACO, V49, P463, DOI 10.1046/j.1365-2125.2000.00192.x; Majeed A, 2000, J PUBLIC HEALTH MED, V22, P275, DOI 10.1093/pubmed/22.3.275; SUDLOW C, 2003, CLIN EVIDENCE, P166; WORLD HEALTH ORGANIZATION (WHO) REGIONAL OFFICE FOR EUROPE, 2003, EUR HLTH ALL DAT	5	100	104	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 14	2004	328	7436					385	386		10.1136/bmj.328.7436.385	http://dx.doi.org/10.1136/bmj.328.7436.385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962875	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000189031300024
J	Engel, MS; Grimaldi, DA				Engel, MS; Grimaldi, DA			New light shed on the oldest insect	NATURE			English	Article							LAND ANIMALS; PHYLOGENY; RHYNIE	Insects are the most diverse lineage of all life in numbers of species, and ecologically they dominate terrestrial ecosystems. However, how and when this immense radiation of animals originated is unclear. Only a few fossils provide insight into the earliest stages of insect evolution, and among them are specimens in chert from Rhynie, Scotland's Old Red Sandstone (Pragian; about 396-407 million years ago(1)), which is only slightly younger than formations harbouring the earliest terrestrial faunas. The most well-known animal from Rhynie is the springtail Rhyniella praecursor (Entognatha; Collembola), long considered to be the oldest hexapod(2,3). For true insects (Ectognatha), the oldest records are two apparent wingless insects from later in the Devonian period of North America(4,5). Here we show, however, that a fragmentary fossil from Rhynie, Rhyniognatha hirsti, is not only the earliest true insect but may be relatively derived within basal Ectognatha. In fact, Rhyniognatha has derived characters shared with winged insects, suggesting that the origin of wings may have been earlier than previously believed. Regardless, Rhyniognatha indicates that insects originated in the Silurian period and were members of some of the earliest terrestrial faunas.	Univ Kansas, Museum Nat Hist, Div Entomol, Lawrence, KS 66045 USA; Univ Kansas, Dept Ecol & Evolutionary Biol, Lawrence, KS 66045 USA; Amer Museum Nat Hist, Div Invertebrate Zool, New York, NY 10024 USA	University of Kansas; University of Kansas; American Museum of Natural History (AMNH)	Engel, MS (corresponding author), Univ Kansas, Museum Nat Hist, Div Entomol, Snow Hall,1460 Jayhawk Blvd, Lawrence, KS 66045 USA.	msengel@ku.edu	Engel, Michael S/C-5461-2012	Engel, Michael S/0000-0003-3067-077X				ALEGO TJ, 2001, PLANTS INVADE LAND, P213; [Anonymous], 1992, TREATISE INVERTEBRAT; BERNER RA, 1989, AM J SCI, V289, P333, DOI 10.2475/ajs.289.4.333; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; Dudley R., 2000, BIOMECHANICS INSECT; EDWARDS D, 1995, NATURE, V377, P329, DOI 10.1038/377329a0; Gaunt MW, 2002, MOL BIOL EVOL, V19, P748, DOI 10.1093/oxfordjournals.molbev.a004133; Gensel P. G., 1984, PLANT LIFE DEVONIAN; Grimaldi D, 2001, J PALEONTOL, V75, P1152, DOI 10.1666/0022-3360(2001)075<1152:IEHFHT>2.0.CO;2; Groning, 1996, ANN SOC GEOL BELG, V117, P47; Hasenfuss I, 2002, J ZOOL SYST EVOL RES, V40, P65, DOI 10.1046/j.1439-0469.2002.00180.x; Hennig W., 1981, INSECT PHYLOGENY; HIRST STANLEY, 1926, GEOL MAG [LONDON], V63, P69; JERAM AJ, 1990, SCIENCE, V250, P658, DOI 10.1126/science.250.4981.658; Kristensen N.P., 1991, P125; KUHNE WG, 1985, ENTOMOL GEN, V11, P91; Kukalova-Peck J., 1991, INSECTS AUSTR, VI, P141; Labandeira CC, 1997, ANNU REV ECOL SYST, V28, P153, DOI 10.1146/annurev.ecolsys.28.1.153; LABANDEIRA CC, 1988, SCIENCE, V242, P913, DOI 10.1126/science.242.4880.913; NOVACEK MJ, 1992, SYST BIOL, V41, P58, DOI 10.2307/2992506; Rasnitsyn AP, 2002, HIST INSECTS, DOI [10.1007/0-306-47577-4, DOI 10.1007/0-306-47577-4]; RICE CM, 1995, J GEOL SOC LONDON, V152, P229, DOI 10.1144/gsjgs.152.2.0229; Scourfield DJ, 1940, NATURE, V145, P799, DOI 10.1038/145799a0; SHEAR WA, 1984, SCIENCE, V224, P492, DOI 10.1126/science.224.4648.492; Staniczek AH, 2000, ZOOL ANZ, V239, P147; TILLYARD R. J., 1928, TRANS ENT SOC LONDON, V76, P65; von Lieven AF, 2000, ZOOL ANZ, V239, P139; Wellman CH, 2003, NATURE, V425, P282, DOI 10.1038/nature01884; WHALLEY P, 1981, NATURE, V291, P317, DOI 10.1038/291317a0; Wheeler WC, 2001, CLADISTICS, V17, P113, DOI [10.1111/j.1096-0031.2001.tb00115.x, 10.1006/clad.2000.0147]	30	206	227	2	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					627	630		10.1038/nature02291	http://dx.doi.org/10.1038/nature02291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961119				2022-12-28	WOS:000188875300039
J	Osyczka, A; Moser, CC; Daldal, F; Dutton, PL				Osyczka, A; Moser, CC; Daldal, F; Dutton, PL			Reversible redox energy coupling in electron transfer chains	NATURE			English	Article							CYTOCHROME BC(1) COMPLEX; IRON-SULFUR PROTEIN; UBIQUINOL OXIDATION; BC1 COMPLEX; RHODOBACTER-CAPSULATUS; DOMAIN MOVEMENT; UBIHYDROQUINONE OXIDATION; 2-ELECTRON TRANSFER; INHIBITOR BINDING; CRYSTAL-STRUCTURE	Reversibility is a common theme in respiratory and photosynthetic systems that couple electron transfer with a transmembrane proton gradient driving ATP production. This includes the intensely studied cytochrome bc(1), which catalyses electron transfer between quinone and cytochrome c. To understand how efficient reversible energy coupling works, here we have progressively inactivated individual cofactors comprising cytochrome bc(1). We have resolved millisecond reversibility in all electron-tunnelling steps and coupled proton exchanges, including charge-separating hydroquinone-quinone catalysis at the Q(o) site, which shows that redox equilibria are relevant on a catalytic timescale. Such rapid reversibility renders popular models based on a semiquinone in Q(o) site catalysis prone to short-circuit failure. Two mechanisms allow reversible function and safely relegate short-circuits to long-distance electron tunnelling on a timescale of seconds: conformational gating of semiquinone for both forward and reverse electron transfer, or concerted two-electron quinone redox chemistry that avoids the semiquinone intermediate altogether.	Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Jagiellonian Univ, Fac Biotechnol, Krakow, Poland	University of Pennsylvania; University of Pennsylvania; Jagiellonian University	Dutton, PL (corresponding author), Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.	dutton@mail.med.upenn.edu	Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568; Osyczka, Artur/0000-0002-1637-2365				ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1972, BIOCHIM BIOPHYS ACTA, V256, P199, DOI 10.1016/0005-2728(72)90053-9; Berry EA, 1999, BIOCHEM SOC T, V27, P565, DOI 10.1042/bst0270565; Boman P, 1999, J AM CHEM SOC, V121, P1558, DOI 10.1021/ja9831251; Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; CHANCE B, 1961, J BIOL CHEM, V236, P1562; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; Dutton PL, 2000, COENZYME Q OXIDATION, P65, DOI [10.1201/9781420036701.sec1b, DOI 10.1201/9781420036701.SEC1B]; Elbehti A, 2000, J BACTERIOL, V182, P3602, DOI 10.1128/JB.182.12.3602-3606.2000; Gileadi E, 2002, J ELECTROANAL CHEM, V532, P181, DOI 10.1016/S0022-0728(02)00766-0; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; Greaves MD, 1999, J AM CHEM SOC, V121, P266, DOI 10.1021/ja982451d; Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Klishin SS, 2002, BBA-BIOENERGETICS, V1553, P177, DOI 10.1016/S0005-2728(01)00250-X; KRAMER DM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P72, DOI 10.1016/0005-2728(93)90006-2; Lambert C, 2003, CHEMPHYSCHEM, V4, P877, DOI 10.1002/cphc.200300726; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; Nicholls D., 2002, BIOENERGETICS, V3; Osyczka A, 2001, BIOCHEMISTRY-US, V40, P14547, DOI 10.1021/bi011630w; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; RICH PR, 1982, FARADAY DISCUSS, V74, P349, DOI 10.1039/dc9827400349; ROBERTSON DE, 1986, J BIOL CHEM, V261, P584; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; Yu CA, 2002, BBA-BIOENERGETICS, V1555, P65, DOI 10.1016/S0005-2728(02)00256-6; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zusman LD, 1997, J PHYS CHEM A, V101, P4136, DOI 10.1021/jp970123e	49	213	221	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					607	612		10.1038/nature02242	http://dx.doi.org/10.1038/nature02242			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961113				2022-12-28	WOS:000188875300033
J	Holmberg, L; Anderson, H				Holmberg, L; Anderson, H		HABITS Steering Data Monitoring Co	HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped	LANCET			English	Article							WOMEN	In the 1990s, two randomised clinical trials started in Scandinavia addressing whether hormone replacement therapy (HRT) is safe for women with previous breast cancer. We report the findings of the safety analysis in HABITS (hormonal replacement therapy after breast cancer-is it safe?), an open randomised clinical trial with allocation to either HRT or best treatment without hormones. The main endpoint was any new breast cancer event. All analyses were done according to intention-to-treat. Until September, 2003, 434 women were randomised; 345 had at least one follow-up report. After a median follow-up of 2.1 years, 26 women in the HRT group and seven in the non-HRT group had a new breast-cancer event. All women with an event in the HRT group and two of those in the non-HRT group were exposed to HRT and most women had their event when on treatment. We decided that these findings indicated an unacceptable risk for women exposed to HRT in the HABITS trial, and the trial was terminated on Dec 17, 2003.	Univ Hosp, Reg Oncol Ctr, SE-75185 Uppsala, Sweden; Lund Univ, Dept Canc Epidemiol, Lund, Sweden	Uppsala University; Uppsala University Hospital; Lund University	Holmberg, L (corresponding author), Univ Hosp, Reg Oncol Ctr, SE-75185 Uppsala, Sweden.	lars.holmberg@lul.se						Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Col NF, 2001, J CLIN ONCOL, V19, P2357, DOI 10.1200/JCO.2001.19.8.2357; O'Meara ES, 2001, JNCI-J NATL CANCER I, V93, P754, DOI 10.1093/jnci/93.10.754	5	344	356	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	2004	363	9407					453	455		10.1016/S0140-6736(04)15493-7	http://dx.doi.org/10.1016/S0140-6736(04)15493-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962527				2022-12-28	WOS:000188999500013
J	Mumby, PJ; Edwards, AJ; Arias-Gonzalez, JE; Lindeman, KC; Blackwell, PG; Gall, A; Gorczynska, MI; Harborne, AR; Pescod, CL; Renken, H; Wabnitz, CCC; Llewellyn, G				Mumby, PJ; Edwards, AJ; Arias-Gonzalez, JE; Lindeman, KC; Blackwell, PG; Gall, A; Gorczynska, MI; Harborne, AR; Pescod, CL; Renken, H; Wabnitz, CCC; Llewellyn, G			Mangroves enhance the biomass of coral reef fish communities in the Caribbean	NATURE			English	Article							SEAGRASS BEDS; HABITATS; BAY	Mangrove forests are one of the world's most threatened tropical ecosystems with global loss exceeding 35% (ref. 1). Juvenile coral reef fish often inhabit mangroves(2-5), but the importance of these nurseries to reef fish population dynamics has not been quantified. Indeed, mangroves might be expected to have negligible influence on reef fish communities: juvenile fish can inhabit alternative habitats and fish populations may be regulated by other limiting factors such as larval supply or fishing(6). Here we show that mangroves are unexpectedly important, serving as an intermediate nursery habitat that may increase the survivorship of young fish. Mangroves in the Caribbean strongly influence the community structure of fish on neighbouring coral reefs. In addition, the biomass of several commercially important species is more than doubled when adult habitat is connected to mangroves. The largest herbivorous fish in the Atlantic, Scarus guacamaia, has a functional dependency on mangroves and has suffered local extinction after mangrove removal. Current rates of mangrove deforestation are likely to have severe deleterious consequences for the ecosystem function, fisheries productivity and resilience of reefs. Conservation efforts should protect connected corridors of mangroves, seagrass beds and coral reefs.	Univ Exeter, Sch Biol & Chem Sci, Marine Spatial Ecol Lab, Exeter EX4 4PS, Devon, England; Newcastle Univ, Sch Biol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; CINVESTAV, Unidad Merida, Dept Recursos Mar, Lab Ecol Ecosistemas Arrecifes Coralinos, Merida 97310, Yucatan, Mexico; Environm Def, Caribbean Field Off, Miami, FL 33186 USA; Univ Sheffield, Dept Probabil & Stat, Sheffield S3 7RH, S Yorkshire, England; Univ British Columbia, Lower Mall Res Stn, Fisheries Ctr, Vancouver, BC V6T 1Z4, Canada; WWF US, Conservat Sci Program, Washington, DC 20037 USA	University of Exeter; Newcastle University - UK; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; University of Sheffield; University of British Columbia; World Wildlife Fund	Mumby, PJ (corresponding author), Univ Exeter, Sch Biol & Chem Sci, Marine Spatial Ecol Lab, Prince Wales Rd, Exeter EX4 4PS, Devon, England.	p.j.mumby@exeter.ac.uk	Mumby, Peter/F-9914-2010; Blackwell, Paul/F-2885-2017; Edwards, Alasdair J/C-9558-2009; Harborne, Alastair R/F-6155-2013	Mumby, Peter/0000-0002-6297-9053; Blackwell, Paul/0000-0002-3141-4914; Edwards, Alasdair J/0000-0002-2979-7389; Harborne, Alastair R/0000-0002-6818-8615; Wabnitz, Colette C.C./0000-0002-5076-9163; Lindeman, Ken/0000-0003-4098-4158; Arias-Gonzalez, Jesus Ernesto/0000-0003-4601-710X				Bohnsack J., 1988, NMFSSEFC215 NAT OC A; Caley MJ, 1996, ANNU REV ECOL SYST, V27, P477, DOI 10.1146/annurev.ecolsys.27.1.477; Chapman MR, 2000, ENVIRON BIOL FISH, V57, P11, DOI 10.1023/A:1004545724503; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; CLARO R, 1993, CUBA AVICENNIA, V10, P60; GREENE LE, 1989, B MAR SCI, V44, P899; Gunderson LH, 2000, ANNU REV ECOL SYST, V31, P425, DOI 10.1146/annurev.ecolsys.31.1.425; IUCN [International Union for Conservation of Nature], 2002, IUCN RED LIST THREAT; Knowlton N, 2001, P NATL ACAD SCI USA, V98, P5419, DOI 10.1073/pnas.091092998; Laegdsgaard P, 2001, J EXP MAR BIOL ECOL, V257, P229, DOI 10.1016/S0022-0981(00)00331-2; Ley JA, 1999, ESTUAR COAST SHELF S, V48, P701, DOI 10.1006/ecss.1998.0459; Manly BFJ, 1992, DESIGN ANAL RES STUD; MCNEILL SE, 1994, BIODIVERS CONSERV, V3, P586, DOI 10.1007/BF00114203; Nagelkerken I, 2002, MAR ECOL PROG SER, V244, P299, DOI 10.3354/meps244299; Nagelkerken I, 2000, MAR ECOL PROG SER, V202, P175, DOI 10.3354/meps202175; Nagelkerken I, 2001, MAR ECOL PROG SER, V214, P225, DOI 10.3354/meps214225; Ogden John C., 1997, P288; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Purdy EG, 2003, INT J EARTH SCI, V92, P532, DOI 10.1007/s00531-003-0324-0; RANDALL JOHN E., 1967, STUD TROP OCEANOGR INST MAR SCI UNIV MIAMI, V5, P665; ROOKER JR, 1991, B MAR SCI, V49, P684; SERAFY JE, B MAR SCI; Sullivan-Sealey K., 1999, SETTING GEOGRAPHIC P; Valiela I, 2001, BIOSCIENCE, V51, P807, DOI 10.1641/0006-3568(2001)051[0807:MFOOTW]2.0.CO;2	24	739	777	13	596	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					533	536		10.1038/nature02286	http://dx.doi.org/10.1038/nature02286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765193	Green Accepted			2022-12-28	WOS:000188721800039
J	Kuo, IFW; Mundy, CJ				Kuo, IFW; Mundy, CJ			An ab initio molecular dynamics study of the aqueous liquid-vapor interface	SCIENCE			English	Article							WATER; SPECTROSCOPY; SIMULATION; SURFACE; SPECTRUM; PHYSICS; VOLUME	We present an ab initio molecular dynamics simulation of the aqueous liquid-vapor interface. Having successfully stabilized a region of bulk water in the center of a water slab, we were able to reproduce and further quantify the experimentally observed abundance of surface "acceptor-only" (19%) and "single-donor" (66%) moieties as well as substantial surface relaxation approaching the liquid-vapor interface. Examination of the orientational dynamics points to a faster relaxation in the interfacial region. Furthermore, the average value of the dipole decreases and the average value of the highest occupied molecular orbital for each water molecule increases approaching the liquid-vapor interface. Our results support the idea that the surface contains, on average, far more reactive states than the bulk.	Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Mundy, CJ (corresponding author), Lawrence Livermore Natl Lab, Livermore, CA 94550 USA.	mundy2@llnl.gov		Kuo, I-Feng W./0000-0002-5258-1041; Mundy, Christopher/0000-0003-1378-5241				Ball P, 2003, NATURE, V423, P25, DOI 10.1038/423025a; BENJAMIN I, 1994, PHYS REV LETT, V73, P2083, DOI 10.1103/PhysRevLett.73.2083; Berghold G, 2000, PHYS REV B, V61, P10040, DOI 10.1103/PhysRevB.61.10040; DU Q, 1993, PHYS REV LETT, V70, P2313, DOI 10.1103/PhysRevLett.70.2313; GERSTEIN M, 1995, J MOL BIOL, V249, P955, DOI 10.1006/jmbi.1995.0351; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Hunt P, 2003, CHEM PHYS LETT, V376, P68, DOI 10.1016/S0009-2614(03)00954-0; HUTTER J, 1999, CPMD V 3 6 5; Jang MS, 2002, SCIENCE, V298, P814, DOI 10.1126/science.1075798; Jensen TR, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.086101; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; Lippert G, 1997, MOL PHYS, V92, P477, DOI 10.1080/00268979709482119; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; Luzar A, 1996, PHYS REV LETT, V76, P928, DOI 10.1103/PhysRevLett.76.928; Luzar A, 1996, NATURE, V379, P55, DOI 10.1038/379055a0; Marx D., 2000, NIC SERIES, P329; Modig K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.075502; Myneni S, 2002, J PHYS-CONDENS MAT, V14, pL213, DOI 10.1088/0953-8984/14/8/106; Raymond EA, 2003, J PHYS CHEM B, V107, P546, DOI 10.1021/jp021366w; Silvestrelli PL, 1997, CHEM PHYS LETT, V277, P478, DOI 10.1016/S0009-2614(97)00930-5; Silvestrelli PL, 1999, PHYS REV LETT, V82, P3308, DOI 10.1103/PhysRevLett.82.3308; Sprik M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957; Steitz R, 2003, LANGMUIR, V19, P2409, DOI 10.1021/la026731p; Vassilev P, 2001, J CHEM PHYS, V115, P9815, DOI 10.1063/1.1413515; Wilson KR, 2002, J CHEM PHYS, V117, P7738, DOI 10.1063/1.1508364; Wilson KR, 2002, J PHYS-CONDENS MAT, V14, pL221, DOI 10.1088/0953-8984/14/8/107; Wilson KR, 2001, J PHYS CHEM B, V105, P3346, DOI 10.1021/jp010132u; WILSON MA, 1987, J PHYS CHEM-US, V91, P4873, DOI 10.1021/j100303a002; Yaminsky V, 2003, LANGMUIR, V19, P1970, DOI 10.1021/la026122h	30	326	330	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					658	660		10.1126/science.1092787	http://dx.doi.org/10.1126/science.1092787			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752157				2022-12-28	WOS:000188530800036
J	Brockington, I				Brockington, I			Postpartum psychiatric disorders	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; MOTHER-INFANT INTERACTION; POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; POSTNATAL DEPRESSION SCALE; GROUP INTERVENTION; PSYCHOLOGICAL TREATMENT; PUERPERAL PSYCHOSIS; MATERNAL DEPRESSION; CHILD-RELATIONSHIP	This review summarises the psychiatry of the puerperium, in the light of publications during the past 5 years. A wide variety of disorders are seen. Recognition of disorders of the mother-infant relationship is important, because these have pernicious long-term effects but generally respond to treatment. Psychoses complicate about one in 1000 deliveries. The most common is related to manic depression, in which neuroleptic drugs should be used with caution. Post-traumatic stress disorder, obsessions of child harm, and a range of anxiety disorders all require specific psychological treatments. Postpartum depression necessitates thorough exploration. Cessation of breastfeeding is not necessary, because most antidepressant drugs seem not to affect the infant. Controlled trials have shown the benefit of involving the child's father in therapy and of interventions promoting interaction between mother and infant. Owing to its complexity, multidisciplinary specialist teams have an important place in postpartum psychiatry.	Univ Birmingham, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Brockington, I (corresponding author), Lower Brockington Farm, Bromyard HR7 4TE, England.	i.f.brockington@bham.ac.uk						Affonso DD, 2000, J PSYCHOSOM RES, V49, P207, DOI 10.1016/S0022-3999(00)00176-8; AINSWORTH MD, 1972, MERRILL-PALMER Q BEH, V18, P123; Appleby L, 1997, BRIT MED J, V314, P932, DOI 10.1136/bmj.314.7085.932; Appleby L, 1998, BRIT J PSYCHIAT, V173, P209, DOI 10.1192/bjp.173.3.209; Armstrong KL, 1999, J PAEDIATR CHILD H, V35, P237, DOI 10.1046/j.1440-1754.1999.00348.x; Ayers S, 2001, BIRTH-ISS PERINAT C, V28, P111, DOI 10.1046/j.1523-536X.2001.00111.x; Baker D, 1997, SOC SCI MED, V45, P1325, DOI 10.1016/S0277-9536(97)00059-2; Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004; Bloch M, 2000, AM J PSYCHIAT, V157, P924, DOI 10.1176/appi.ajp.157.6.924; Blum LD, 2003, NEW ENGL J MED, V348, P1294, DOI 10.1056/NEJM200303273481319; BROCKINGTON I, 1998, ARCH WOMEN MENT HLTH, V1, P3; BROCKINGTON IF, 1984, BRIT J PSYCHIAT, V145, P316, DOI 10.1192/bjp.145.3.316; Brockington IF., 1999, INFANT OBSERV, V2, P116, DOI [10.1080/13698039908400552, DOI 10.1080/13698039908400552]; Brockington IF., 2001, ARCH WOMEN MENT HLTH, V3, P133, DOI [10.1007/s007370170010, DOI 10.1007/S007370170010]; Brouwers EPM, 2001, J PSYCHOSOM RES, V51, P659, DOI 10.1016/S0022-3999(01)00245-8; Brugha TS, 2000, PSYCHOL MED, V30, P1273, DOI 10.1017/S0033291799002937; Buttolph M, 1990, OBSESSIVE COMPULSIVE, V2nd, P89; BUTTON JH, 1972, ARCH GEN PSYCHIAT, V27, P235; Bydlowski M, 1978, PERSPECT PSYCHIAT, V4, P321; Chabrol H, 2002, ENCEPHALE, V28, P65; CHAPMAN AH, 1959, ARCH GEN PSYCHIAT, V1, P12; Chen CH, 2000, J PSYCHOSOM RES, V49, P395, DOI 10.1016/S0022-3999(00)00180-X; Cooper PJ, 2003, BRIT J PSYCHIAT, V182, P412, DOI 10.1192/bjp.182.5.412; Cooper PJ, 2002, BRIT J PSYCHIAT, V180, P76, DOI 10.1192/bjp.180.1.76; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; COX JL, 1993, BRIT J PSYCHIAT, V163, P27, DOI 10.1192/bjp.163.1.27; Creedy DK, 2000, BIRTH-ISS PERINAT C, V27, P104, DOI 10.1046/j.1523-536x.2000.00104.x; Czarnocka J, 2000, BRIT J CLIN PSYCHOL, V39, P35, DOI 10.1348/014466500163095; DAVID HP, 1981, FAM PLANN PERSPECT, V13, P88, DOI 10.2307/2134703; De Armond M, 1954, DIS NERV SYST, V15, P26; DECASTELNAU PB, 1861, ANN MED-PSYCHOL, V7, P553; Dennis CL, 2003, CAN J PSYCHIAT, V48, P115, DOI 10.1177/070674370304800209; Eberhard-Gran M, 2001, ACTA PSYCHIAT SCAND, V104, P243, DOI 10.1034/j.1600-0447.2001.00187.x; Elliott SA, 2000, BRIT J CLIN PSYCHOL, V39, P223, DOI 10.1348/014466500163248; Epperson N, 2001, AM J PSYCHIAT, V158, P1631, DOI 10.1176/appi.ajp.158.10.1631; ESQUIROL JED, 1965, MENTAL MALADIES TREA, P125; Field T, 1996, INFANT BEHAV DEV, V19, P107, DOI 10.1016/S0163-6383(96)90048-X; Filer ADJ, 1996, PSYCHOPATHOLOGY, V29, P135, DOI 10.1159/000284982; Fisch R Z, 1997, J Obstet Gynaecol Res, V23, P547; FLEMING AS, 1992, J CHILD PSYCHOL PSYC, V33, P685, DOI 10.1111/j.1469-7610.1992.tb00905.x; Forman DN, 2000, BRIT J OBSTET GYNAEC, V107, P1210; Gissler M, 1996, BRIT MED J, V313, P1431, DOI 10.1136/bmj.313.7070.1431; Godfroid I O, 1996, Rev Med Brux, V17, P22; GORDON R E, 1957, J Med Soc N J, V54, P569; GORDON RE, 1960, OBSTET GYNECOL, V15, P433; Gottvall K, 2002, BJOG-INT J OBSTET GY, V109, P254, DOI 10.1111/j.1471-0528.2002.01200.x; Gregoire AJP, 1996, LANCET, V347, P930, DOI 10.1016/S0140-6736(96)91414-2; Gurel SA, 2000, EUR J OBSTET GYN R B, V91, P21; Hayes BA, 2001, BIRTH-ISS PERINAT C, V28, P28, DOI 10.1046/j.1523-536x.2001.00028.x; Hertzberg T, 1999, J PSYCHOSOM OBST GYN, V20, P59, DOI 10.3109/01674829909075578; Hipwell AE, 1996, BRIT J PSYCHIAT, V169, P655, DOI 10.1192/bjp.169.5.655; HOCK E, 1989, CHILD DEV, V60, P793, DOI 10.1111/j.1467-8624.1989.tb03510.x; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; Honey KL, 2002, BRIT J CLIN PSYCHOL, V41, P405, DOI 10.1348/014466502760387515; Jennings KD, 1999, J AFFECT DISORDERS, V54, P21; Jones H W, 2001, J Psychosoc Nurs Ment Health Serv, V39, P23; Jones I, 1999, MOL PSYCHIATR, V4, pS26; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; Kit L K, 1997, J Obstet Gynaecol Res, V23, P85; KLOMPENHOUWER JL, 1992, THESIS U ROTTERDAM; KUBICKA L, 1995, ACTA PSYCHIAT SCAND, V91, P361, DOI 10.1111/j.1600-0447.1995.tb09795.x; Kumar RC, 1997, BRIT J PSYCHIAT, V171, P175, DOI 10.1192/bjp.171.2.175; Lappin J, 2001, BRIT MED J, V323, P1367, DOI 10.1136/bmj.323.7325.1367a; LAVECCHIA C, 1994, ACTA PSYCHIAT SCAND, V90, P53; Lavender T, 1998, BIRTH-ISS PERINAT C, V25, P215, DOI 10.1046/j.1523-536X.1998.00215.x; Lawrie TA, 1998, BRIT J OBSTET GYNAEC, V105, P1082, DOI 10.1111/j.1471-0528.1998.tb09940.x; Lee D. T. S., 2000, Hong Kong Medical Journal, V6, P349; Lee DTS, 2001, J AFFECT DISORDERS, V63, P233, DOI 10.1016/S0165-0327(00)00193-2; Lyons S., 1998, J REPROD INFANT PSYC, V16, P91, DOI DOI 10.1080/02646839808404562; MacArthur C, 2002, LANCET, V359, P378, DOI 10.1016/S0140-6736(02)07596-7; MAIN TF, 1958, LANCET, V2, P845; Maina G, 2001, Epidemiol Psichiatr Soc, V10, P90; MANASSIS K, 1994, J AM ACAD CHILD PSY, V33, P1106, DOI 10.1097/00004583-199410000-00006; MATHESON I, 1985, LANCET, V2, P1124; Matthey S, 2003, J AFFECT DISORDERS, V74, P139, DOI 10.1016/S0165-0327(02)00012-5; McIvor RJ, 1996, J AFFECT DISORDERS, V40, P131; Menage J., 1993, J REPROD INFANT PSYC, V11, P221, DOI [DOI 10.1080/02646839308403222, 10.1080/02646839308403222]; Misri S, 2000, CAN J PSYCHIAT, V45, P554, DOI 10.1177/070674370004500607; MOLL L, 1920, WIEN KLIN WSCHR, V33, P160; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Murray L, 1996, J CHILD PSYCHOL PSYC, V37, P927, DOI 10.1111/j.1469-7610.1996.tb01490.x; Murray L, 2003, BRIT J PSYCHIAT, V182, P420, DOI 10.1192/bjp.182.5.420; Myhrman A, 1996, BRIT J PSYCHIAT, V169, P637, DOI 10.1192/bjp.169.5.637; Nagata M, 2000, ACTA PSYCHIAT SCAND, V101, P209, DOI 10.1034/j.1600-0447.2000.101003209.x; Nahas VL, 1999, J NURSE-MIDWIFERY, V44, P65, DOI 10.1016/S0091-2182(98)00083-4; Najman JM, 2000, SOC PSYCH PSYCH EPID, V35, P19, DOI 10.1007/s001270050004; O'Hara MW, 2000, ARCH GEN PSYCHIAT, V57, P1039, DOI 10.1001/archpsyc.57.11.1039; OATES M, 2001, WHY MOTHERS DIE, P165; Oates M, 1988, MOTHERHOOD MENTAL IL, P133; Onozawa K, 2001, J AFFECT DISORDERS, V63, P201, DOI 10.1016/S0165-0327(00)00198-1; Oppenheim H, 1919, Z GESAMTE NEUROL PSY, V45, P1, DOI 10.1007/BF02871723; Pantlen A, 2001, ZBL GYNAKOL, V123, P42, DOI 10.1055/s-2001-12025; Pound A, 1988, BRIT J PSYCHOTHERAPY, V4, P240, DOI DOI 10.1111/j.1752-0118.1988.tb01026.x; PRICE DK, 1989, BRIT J PSYCHIAT, V155, P849, DOI 10.1192/bjp.155.6.849; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; Reed P, 1999, J AFFECT DISORDERS, V54, P255, DOI 10.1016/S0165-0327(99)00012-9; Reid M, 2002, BJOG-INT J OBSTET GY, V109, P1164; Righetti-Veltema M, 2002, J AFFECT DISORDERS, V70, P291, DOI 10.1016/S0165-0327(01)00367-6; Ryding EL, 1998, BIRTH-ISS PERINAT C, V25, P246, DOI 10.1046/j.1523-536X.1998.00246.x; RYDING EL, 1993, ACTA OBSTET GYN SCAN, V72, P280, DOI 10.3109/00016349309068038; SALARIYA EM, 1984, J ADV NURS, V9, P589, DOI 10.1111/j.1365-2648.1984.tb00415.x; Sevringhaus EL, 1933, AM J OBSTET GYNECOL, V25, P361, DOI 10.1016/S0002-9378(33)90240-9; SICHEL DA, 1993, J CLIN PSYCHIAT, V54, P156; Small R, 2000, BRIT MED J, V321, P1043, DOI 10.1136/bmj.321.7268.1043; Soet JE, 2003, BIRTH-ISS PERINAT C, V30, P36, DOI 10.1046/j.1523-536X.2003.00215.x; Spigset O, 1998, CNS DRUGS, V9, P111, DOI 10.2165/00023210-199809020-00004; STEWART DE, 1991, BRIT J PSYCHIAT, V158, P393, DOI 10.1192/bjp.158.3.393; Stuart S, 1998, J NERV MENT DIS, V186, P420, DOI 10.1097/00005053-199807000-00006; Stuchbery M, 1998, SOC PSYCH PSYCH EPID, V33, P483, DOI 10.1007/s001270050083; SVEDWILLIAMS AE, 1992, AUST NZ J PSYCHIAT, V26, P631, DOI 10.3109/00048679209072099; TARDIEU A, 1860, ANN HYG PUBLIQUE MED, V13, P361, DOI DOI 10.3917/EP.039.0174; Terp IM, 1998, BRIT J PSYCHIAT, V172, P521, DOI 10.1192/bjp.172.6.521; Treloar SA, 1999, PSYCHOL MED, V29, P645, DOI 10.1017/S0033291799008387; TRONICK E, 1978, J AM ACAD CHILD PSY, V17, P1, DOI 10.1016/S0002-7138(09)62273-1; Weightman H, 1998, PSYCHOPATHOLOGY, V31, P246, DOI 10.1159/000029046; Wendland-Carro J, 1999, CHILD DEV, V70, P713, DOI 10.1111/1467-8624.00051; Wenzel A, 2003, Arch Womens Ment Health, V6, P43, DOI 10.1007/s00737-002-0154-2; Wickberg B, 1996, J AFFECT DISORDERS, V39, P209, DOI 10.1016/0165-0327(96)00034-1; Wijma K, 1997, J ANXIETY DISORD, V11, P587, DOI 10.1016/S0887-6185(97)00041-8; Williams KE, 1997, J CLIN PSYCHIAT, V58, P330, DOI 10.4088/JCP.v58n0709; Wisner KL, 1999, J CLIN PSYCHIAT, V60, P176, DOI 10.4088/JCP.v60n0305; Wisner KL, 2001, J CLIN PSYCHIAT, V62, P82, DOI 10.4088/JCP.v62n0202; Wisner KL, 2002, NEW ENGL J MED, V347, P194, DOI 10.1056/NEJMcp011542; WOLMAN WL, 1993, AM J OBSTET GYNECOL, V168, P1388, DOI 10.1016/S0002-9378(11)90770-4; WOODWARD J, 1963, 300 YEARS PSYCHIAT, P338; Yapp P, 2000, ANN PHARMACOTHER, V34, P1269, DOI 10.1345/aph.10120; Yonkers KA, 2001, AM J PSYCHIAT, V158, P1856, DOI 10.1176/appi.ajp.158.11.1856; Zlotnick C, 2001, AM J PSYCHIAT, V158, P638, DOI 10.1176/appi.ajp.158.4.638	129	330	343	6	93	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					303	310		10.1016/S0140-6736(03)15390-1	http://dx.doi.org/10.1016/S0140-6736(03)15390-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766FQ	14751705				2022-12-28	WOS:000188361400023
J	Racki, G; Koeberl, C				Racki, G; Koeberl, C			Comment on "Impact ejecta layer from the mid-Devonian: Possible connection to global mass extinctions"	SCIENCE			English	Editorial Material									Silesian Univ, Dept Earth Sci, PL-41200 Sosnowiec, Poland; Univ Vienna, Dept Geol Sci, A-1090 Vienna, Austria	University of Silesia in Katowice; University of Vienna	Racki, G (corresponding author), Silesian Univ, Dept Earth Sci, PL-41200 Sosnowiec, Poland.	racki@us.edu.pl; christian.koeberl@univie.ac.at	/A-5467-2010	/0000-0003-4609-8341				Ellwood BB, 2003, SCIENCE, V300, P1734, DOI 10.1126/science.1081544; Hallam A., 1997, MASS EXTINCTIONS THE; House MR, 2002, PALAEOGEOGR PALAEOCL, V181, P5, DOI 10.1016/S0031-0182(01)00471-0; McGhee GR, 2001, PALAEOGEOGR PALAEOCL, V176, P47, DOI 10.1016/S0031-0182(01)00325-X; Renne PR, 2002, EARTH PLANET SC LETT, V201, P247, DOI 10.1016/S0012-821X(02)00690-8; Sandberg CA, 2002, GEOL SOC AM SPEC PAP, V356, P473; SCHONE R, 1997, GOTTINGER ARB GEOL P, V70, P1; Sepkoski J.J., 1996, GLOBAL EVENT STRATIG, P35, DOI [10.1007/978-3-642-79634-0_4, DOI 10.1007/978-3-642-79634-0_4]; UYSAL SD, 2001, EARTH PLANET SC LETT, V192, P218; Walliser O.H., 1996, GLOBAL EVENTS EVENT, P225, DOI [10.1007/978-3-642-79634-0_11, DOI 10.1007/978-3-642-79634-0_11]	10	9	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					471	471		10.1126/science.1090332	http://dx.doi.org/10.1126/science.1090332			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739442				2022-12-28	WOS:000188316400019
J	Reiner, WG; Gearhart, JP				Reiner, WG; Gearhart, JP			Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENDER IDENTITY; DIETHYLSTILBESTROL DES; ANDROGENS; REASSIGNMENT; EXPERIENCE; BEHAVIOR; EXPOSURE; REVERSAL; CHILDREN; PENIS	BACKGROUND: Cloacal exstrophy is a rare, complex defect of the entire pelvis and its contents that occurs during embryogenesis and is associated with severe phallic inadequacy or phallic absence in genetic males. For about 25 years, neonatal assignment to female sex has been advocated for affected males to overcome the issue of phallic inadequacy, but data on outcome remain sparse. METHODS: We assessed all 16 genetic males in our cloacal-exstrophy clinic at the ages of 5 to 16 years. Fourteen underwent neonatal assignment to female sex socially, legally, and surgically; the parents of the remaining two refused to do so. Detailed questionnaires extensively evaluated the development of sexual role and identity, as defined by the subjects' persistent declarations of their sex. RESULTS: Eight of the 14 subjects assigned to female sex declared themselves male during the course of this study, whereas the 2 raised as males remained male. Subjects could be grouped according to their stated sexual identity. Five subjects were living as females; three were living with unclear sexual identity, although two of the three had declared themselves male; and eight were living as males, six of whom had reassigned themselves to male sex. All 16 subjects had moderate-to-marked interests and attitudes that were considered typical of males. Follow-up ranged from 34 to 98 months. CONCLUSIONS: Routine neonatal assignment of genetic males to female sex because of severe phallic inadequacy can result in unpredictable sexual identification. Clinical interventions in such children should be reexamined in the light of these findings.	Johns Hopkins Med Inst, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Reiner, WG (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Urol, WP 3150,920 SL Young Blvd, Oklahoma City, OK 73104 USA.				NIMH NIH HHS [K08 MH001777-05, K08 MH001777-04, 5 K08MH01777-02, K08 MH001777] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001777] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BATES JE, 1973, CHILD DEV, V44, P591; Berenbaum SA, 1997, PSYCHONEUROENDOCRINO, V22, P505, DOI 10.1016/S0306-4530(97)00049-8; Berenbaum SA, 2003, J CLIN ENDOCR METAB, V88, P1102, DOI 10.1210/jc.2002-020782; Berenbaum SA, 2000, J CLIN ENDOCR METAB, V85, P727, DOI 10.1210/jc.85.2.727; Bin-Abbas B, 1999, J PEDIATR-US, V134, P579, DOI 10.1016/S0022-3476(99)70244-1; Birnbacher R, 1999, J PEDIATR ENDOCR MET, V12, P687; Bradley SJ, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e9; Diamond M, 1997, ARCH PEDIAT ADOL MED, V151, P298, DOI 10.1001/archpedi.1997.02170400084015; Glassberg KI, 1999, J UROLOGY, V161, P1308, DOI 10.1016/S0022-5347(01)61676-8; GRELLERT EA, 1982, ARCH SEX BEHAV, V11, P451, DOI 10.1007/BF01542472; Grumbach M., 2003, WILLIAMS TXB ENDOCRI, V10th ed, P842; Hendren WH, 1997, J UROLOGY, V157, P1469, DOI 10.1016/S0022-5347(01)65026-2; IMPERATOMCGINLEY J, 1979, NEW ENGL J MED, V300, P1233, DOI 10.1056/NEJM197905313002201; KLEIN AR, 1980, J ABNORM CHILD PSYCH, V8, P201, DOI 10.1007/BF00919064; LISH JD, 1992, ARCH SEX BEHAV, V21, P423, DOI 10.1007/BF01542268; LISH JD, 1991, J AM ACAD CHILD PSY, V30, P29, DOI 10.1097/00004583-199101000-00005; Lund DP, 2001, J PEDIATR SURG, V36, P68, DOI 10.1053/jpsu.2001.20009; Mathews R, 1998, J UROLOGY, V160, P2452, DOI 10.1016/S0022-5347(01)62209-2; Mathews RI, 1999, BJU INT, V84, P99; Mayer A, 1998, NEUROGENETICS, V1, P281, DOI 10.1007/s100480050042; Meyer-Bahlburg HFL, 1994, J PSYCHOL HUM SEX, V6, P19, DOI DOI 10.1300/J056v06n01_01; MEYERBAHLBURG HFL, 1984, ARCH SEX BEHAV, V13, P479, DOI 10.1007/BF01541431; MEYERBAHLBURG HFL, 1994, J ABNORM CHILD PSYCH, V22, P643, DOI 10.1007/BF02171993; MONEY J, 1955, B JOHNS HOPKINS HOSP, V97, P301; MONEY J, 1975, ARCH SEX BEHAV, V4, P65, DOI 10.1007/BF01541887; Money J, 1994, SEX ERRORS BODY RELA, p[1, 60, 108]; Money J, 1972, MAN WOMAN BOY GIRL D, P311; Phoenix C. H., 1968, P33; Reiner WG, 1996, J AM ACAD CHILD PSY, V35, P799, DOI 10.1097/00004583-199606000-00020; Schober JM, 2002, J UROLOGY, V167, P300, DOI 10.1016/S0022-5347(05)65455-9; SKOOG SJ, 1989, J UROLOGY, V141, P589, DOI 10.1016/S0022-5347(17)40903-7; TANK ES, 1970, AM J SURG, V119, P95, DOI 10.1016/0002-9610(70)90018-8; Wilson JD, 1999, ENDOCR REV, V20, P726, DOI 10.1210/er.20.5.726; Xu J, 2002, HUM MOL GENET, V11, P1409, DOI 10.1093/hmg/11.12.1409	34	194	197	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					333	341		10.1056/NEJMoa022236	http://dx.doi.org/10.1056/NEJMoa022236			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736925	Green Accepted			2022-12-28	WOS:000188254800005
J	Koivunen, P; Uhari, M; Luotonen, J; Kristo, A; Raski, R; Pokka, T; Alho, OP				Koivunen, P; Uhari, M; Luotonen, J; Kristo, A; Raski, R; Pokka, T; Alho, OP			Adenoidectomy versus chemoprophylaxis and placebo for recurrent acute otitis media in children aged under 2 years: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TYMPANOSTOMY TUBES; EFFICACY; EFFUSION; TONSILLECTOMY; PREVENTION; INSERTION; INFANTS; LIFE	Objective To evaluate the efficacy of adenoidectomy compared with long term chemoprophylaxis and placebo in die prevention of recurrent acute otitis media in children aged between 10 months and 2 years. Design Randomised, double blind, controlled trial. Setting Oulu University Hospital, a tertiary centre in Finland. Participants 180 children aged 10 months to 2 years with recurrent acute otitis media. Intervention Adenoidectomy, sulfafurazole (sulphisoxazole) 50 mg/kg body weight, given once a day for six months or placebo. Follow up lasted for two years, during which time all symptoms and episodes of acute otitis media were recorded. Main outcome measures Intervention failure (two episodes in two months or three in six months or persistent effusion) during follow up, number of episodes of acute otitis media, number of visits to a doctor because of any infection, and antibiotic prescriptions. Number of prescriptions, and days with symptoms of respiratory infection. Results Compared with placebo, interventions failed during both the first six months and the rest of the follow up period of 24 months, similarly in the adenoidectomy and chemoprophylaxis groups (at six months the differences in risk were 10% (95% confidence interval -9% to 29%) and 18% (- 2% to 38%), respectively). No significant differences were observed between the groups in the numbers of episodes of acute otitis media, visits to a doctor, antibiotic prescriptions, and days with symptoms of respiratory infection. Conclusions Adenoidectomy, as the first surgical treatment of children aged 10 to 24 months with recurrent acute otitis media, is not effective in preventing further episodes. It cannot be recommended as the primary method of prophylaxis.	Univ Oulu, FIN-90014 Oulu, Finland	University of Oulu	Koivunen, P (corresponding author), Univ Oulu, POB 5000, FIN-90014 Oulu, Finland.	petri.koivunen@ppshp.fi						ALHO OP, 1991, INT J PEDIATR OTORHI, V21, P7, DOI 10.1016/0165-5876(91)90054-F; Alho OP, 1997, ACTA OTO-LARYNGOL, P8; Alho OP, 1996, J FAM PRACTICE, V43, P258; ALHO OP, 1999, OTORHINOLARYNGOL NOV, V8, P123; ALHO OP, 1997, ACTA OTOLARYNGOL STO, V529, P89; Bluestone CD, 1998, PEDIATR INFECT DIS J, V17, P1090, DOI 10.1097/00006454-199811000-00040; Brown RA, 1994, MED STAT PERSONAL CO; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; Coyte PC, 2001, NEW ENGL J MED, V344, P1188, DOI 10.1056/NEJM200104193441602; Gardner M. J., 1989, STAT CONFIDENCE; GATES GA, 1987, NEW ENGL J MED, V317, P1444, DOI 10.1056/NEJM198712033172305; Lanphear BP, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.3.e1; MANDEL EM, 1992, PEDIATR INFECT DIS J, V11, P270, DOI 10.1097/00006454-199204000-00003; Mattila PS, 2003, ARCH OTOLARYNGOL, V129, P163, DOI 10.1001/archotol.129.2.163; MAW AR, 1986, LANCET, V1, P1399; Paradise JL, 1999, JAMA-J AM MED ASSOC, V282, P945, DOI 10.1001/jama.282.10.945; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; SADE J, 1991, ANN OTO RHINOL LARYN, V100, P226, DOI 10.1177/000348949110000311; SIPILA M, 1987, ACTA OTO-LARYNGOL, V104, P138, DOI 10.3109/00016488709109059; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344	21	40	42	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					487	490		10.1136/bmj.37972.678345.0D	http://dx.doi.org/10.1136/bmj.37972.678345.0D			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14769785	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220002900018
J	Toelle, BG; Ng, K; Belousova, E; Salome, CM; Peat, JK; Marks, GB				Toelle, BG; Ng, K; Belousova, E; Salome, CM; Peat, JK; Marks, GB			Prevalence of asthma and allergy in schoolchildren in Belmont, Australia: three cross sectional surveys over 20 years	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN		Univ Sydney, Woolcock Inst Med Res, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney	Toelle, BG (corresponding author), Univ Sydney, Woolcock Inst Med Res, Box M77,Missenden Rd PO, Camperdown, NSW 2050, Australia.	bgt@woolcock.org.au	Marks, Guy B./F-5058-2013; Toelle, Brett G/B-1531-2008	Marks, Guy B./0000-0002-8976-8053; Toelle, Brett G/0000-0002-7375-0019				BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; DRANE JW, 1991, AM J EPIDEMIOL, V134, P908, DOI 10.1093/oxfordjournals.aje.a116165; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591	5	103	107	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 14	2004	328	7436					386	387		10.1136/bmj.328.7436.386	http://dx.doi.org/10.1136/bmj.328.7436.386			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962876	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000189031300025
J	Menon, KVN; Shah, V; Kamath, PS				Menon, KVN; Shah, V; Kamath, PS			Current concepts - The Budd-Chiari syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEPATIC VEIN-THROMBOSIS; LIVER-TRANSPLANTATION; PORTOSYSTEMIC SHUNT; ANTIPHOSPHOLIPID SYNDROME; POLYCYTHEMIA-VERA; MEDICAL PROGRESS; ANGIOPLASTY; THROMBOPHILIA; OBSTRUCTION; EXPERIENCE		Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med, Adv Liver Dis Study Grp, Rochester, MN 55905 USA	Mayo Clinic	Kamath, PS (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med, Adv Liver Dis Study Grp, 200 1st St SW, Rochester, MN 55905 USA.	patrick@mayo.edu						Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164; BLUM U, 1995, RADIOLOGY, V197, P805, DOI 10.1148/radiology.197.3.7480760; BOLONDI L, 1991, GASTROENTEROLOGY, V100, P1324; Cazals-Hatem D, 2003, HEPATOLOGY, V37, P510, DOI 10.1053/jhep.2003.50076; Denninger MH, 2000, HEPATOLOGY, V31, P587, DOI 10.1002/hep.510310307; Espinosa G, 2001, MEDICINE, V80, P345, DOI 10.1097/00005792-200111000-00001; Fisher NC, 1999, GUT, V44, P568, DOI 10.1136/gut.44.4.568; FRANK JW, 1994, MAYO CLIN PROC, V69, P877, DOI 10.1016/S0025-6196(12)61791-1; Ganguli SC, 1998, HEPATOLOGY, V27, P1157, DOI 10.1002/hep.510270434; Girolami A, 1996, BLOOD COAGUL FIBRIN, V7, P590, DOI 10.1097/00001721-199609000-00003; HADENGUE A, 1994, GASTROENTEROLOGY, V106, P1042, DOI 10.1016/0016-5085(94)90765-X; Hemming AW, 1996, AM J SURG, V171, P176, DOI 10.1016/S0002-9610(99)80095-6; HENDERSON JM, 1990, AM J SURG, V159, P41, DOI 10.1016/S0002-9610(05)80605-1; Hirshberg B, 2000, J HEPATOL, V32, P574, DOI 10.1016/S0168-8278(00)80218-4; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; LUDWIG J, 1990, MAYO CLIN PROC, V65, P51, DOI 10.1016/S0025-6196(12)62109-0; Mahmoud AEA, 1996, QJM-MON J ASSOC PHYS, V89, P37, DOI 10.1093/oxfordjournals.qjmed.a030135; McCuskey RS, 2000, LIVER, V20, P3, DOI 10.1034/j.1600-0676.2000.020001003.x; MCCUSKEY RS, 1993, SEMIN LIVER DIS, V13, P1, DOI 10.1055/s-2007-1007333; Melear JM, 2002, TRANSPLANTATION, V74, P1090, DOI 10.1097/00007890-200210270-00006; Min A D, 1997, Liver Transpl Surg, V3, P423, DOI 10.1002/lt.500030410; MITCHELL MC, 1982, MEDICINE, V61, P199, DOI 10.1097/00005792-198207000-00001; Mohanty D, 2001, HEPATOLOGY, V34, P666, DOI 10.1053/jhep.2001.27948; Najean Y, 1997, SEMIN HEMATOL, V34, P6; Noone TC, 2000, JMRI-J MAGN RESON IM, V11, P44, DOI 10.1002/(SICI)1522-2586(200001)11:1<44::AID-JMRI6>3.3.CO;2-F; Orloff MJ, 2000, ANN SURG, V232, P340, DOI 10.1097/00000658-200009000-00006; PAGLIUCA A, 1990, Q J MED, V76, P981; PANIS Y, 1994, SURGERY, V115, P276; Perello A, 2002, HEPATOLOGY, V35, P132, DOI 10.1053/jhep.2002.30274; Pisani-Ceretti A, 1998, WORLD J SURG, V22, P48, DOI 10.1007/s002689900348; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Raju GS, 1996, AM J GASTROENTEROL, V91, P1262; RINGE B, 1995, HEPATOLOGY, V21, P1337, DOI 10.1016/0270-9139(95)90055-1; Ruckert JC, 1999, HEPATO-GASTROENTEROL, V46, P867; Ryu RK, 1999, J VASC INTERV RADIOL, V10, P799, DOI 10.1016/S1051-0443(99)70118-1; SCHATTENFROH N, 1993, TRANSPLANT INT, V6, P354, DOI 10.1007/BF00335976; Slakey DP, 2001, ANN SURG, V233, P522, DOI 10.1097/00000658-200104000-00007; Srinivasan P, 2002, TRANSPLANTATION, V73, P973, DOI 10.1097/00007890-200203270-00026; Tang TJ, 2001, J HEPATOL, V35, P338, DOI 10.1016/S0168-8278(01)00131-3; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; TERASAKI M, 1994, EUR SURG RES, V26, P19, DOI 10.1159/000129314; VALLA D, 1986, GASTROENTEROLOGY, V90, P807, DOI 10.1016/0016-5085(86)90855-3; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329; Walker ID, 2000, J CLIN PATHOL, V53, P573, DOI 10.1136/jcp.53.8.573; WOLF M, 1991, BLOOD COAGUL FIBRIN, V2, P705, DOI 10.1097/00001721-199112000-00003; Yang XL, 1996, J AM COLL CARDIOL, V28, P1720, DOI 10.1016/S0735-1097(96)00385-3; Zeitoun G, 1999, HEPATOLOGY, V30, P84, DOI 10.1002/hep.510300125	47	311	341	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					578	585		10.1056/NEJMra020282	http://dx.doi.org/10.1056/NEJMra020282			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762185				2022-12-28	WOS:000188712800009
J	van Rood, JJ				van Rood, JJ			Weighing HLA matching against the equitable distribution of kidney allografts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Europdonor Fdn, Leiden, Netherlands		van Rood, JJ (corresponding author), Europdonor Fdn, Leiden, Netherlands.								0	3	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					535	536		10.1056/NEJMp030011	http://dx.doi.org/10.1056/NEJMp030011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762177				2022-12-28	WOS:000188712800001
J	Mak, W; Nesterova, TB; de Napoles, M; Appanah, R; Yamanaka, S; Otte, AP; Brockdorff, N				Mak, W; Nesterova, TB; de Napoles, M; Appanah, R; Yamanaka, S; Otte, AP; Brockdorff, N			Reactivation of the paternal X chromosome in early mouse embryos	SCIENCE			English	Article							LINKED GENES; HISTONE H3; INACTIVATION; MAINTENANCE; METHYLATION; PLURIPOTENCY; EXPRESSION; NANOG; CELL	It is generally accepted that paternally imprinted X inactivation occurs exclusively in extraembryonic lineages of mouse embryos, whereas cells of the embryo proper, derived from the inner cell mass (ICM), undergo only random X inactivation. Here we show that imprinted X inactivation, in fact, occurs in all cells of early embryos and that the paternal X is then selectively reactivated in cells allocated to the ICM. This contrasts with more differentiated cell types where X inactivation is highly stable and generally irreversible. Our observations illustrate that an important component of genome plasticity in early development is the capacity to reverse heritable gene silencing decisions.	Hammersmith Hosp, ICSM, MRC, Clin Sci Ctr,X Inactivat Grp, London W12 0NN, England; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Lab Anim Mol Technol, Nara 6300192, Japan; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands	Imperial College London; Nara Institute of Science & Technology; University of Amsterdam	Brockdorff, N (corresponding author), Hammersmith Hosp, ICSM, MRC, Clin Sci Ctr,X Inactivat Grp, London W12 0NN, England.	neil.brockdorff@csc.mrc.ac.uk	Mak, Winifred/AAN-1971-2021	Nesterova, Tatyana/0000-0001-7740-4386; Brockdorff, Neil/0000-0003-4838-2653				BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GARDNER RL, 1971, NATURE, V231, P385, DOI 10.1038/231385a0; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; LATHAM KE, 1995, DEV GENET, V17, P212, DOI 10.1002/dvg.1020170306; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; Nesterova TB, 2001, DEV BIOL, V235, P343, DOI 10.1006/dbio.2001.0295; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P10469, DOI 10.1073/pnas.89.21.10469; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; TAKAGI N, 1978, CYTOGENET CELL GENET, V20, P240, DOI 10.1159/000130856; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	19	403	415	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					666	669		10.1126/science.1092674	http://dx.doi.org/10.1126/science.1092674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752160				2022-12-28	WOS:000188530800039
J	Torres, A; Ewig, S				Torres, A; Ewig, S			Diagnosing ventilator-associated pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANTIBIOTIC-THERAPY		Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Inst Clin Pneumol & Cirurg Torac, Resp Intens Care Unit, Barcelona, Spain; Augusta Kranken Anstalt, Klin Pneumol Beatmungsmed & Infektiol, Bochum, Germany	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Torres, A (corresponding author), Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Inst Clin Pneumol & Cirurg Torac, Resp Intens Care Unit, Barcelona, Spain.		Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167				Chastre J, 2003, JAMA-J AM MED ASSOC, V290, P2588, DOI 10.1001/jama.290.19.2588; Fabregas N, 1999, THORAX, V54, P867, DOI 10.1136/thx.54.10.867; Singh N, 2000, AM J RESP CRIT CARE, V162, P505, DOI 10.1164/ajrccm.162.2.9909095	3	46	52	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					433	435		10.1056/NEJMp038219	http://dx.doi.org/10.1056/NEJMp038219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749448				2022-12-28	WOS:000188463900002
J	Harrison, TW; Oborne, J; Newton, S; Tattersfield, AE				Harrison, TW; Oborne, J; Newton, S; Tattersfield, AE			Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial	LANCET			English	Article							SELF-MANAGEMENT PLAN; CREDIT CARD ASTHMA; BUDESONIDE; SALMETEROL	Background Asthma self-management plans that include doubling the dose of inhaled corticosteroid when the condition deteriorates improve asthma control. Whether doubling the dose of corticosteroid in isolation is effective is unknown. We undertook a randomised controlled trial to investigate the effects of doubling the dose of inhaled corticosteriods when asthma deteriorates. Methods 390 individuals with asthma who were at risk of an exacerbation monitored their morning peak flow and asthma symptoms for up to 12 months. When peak flow or symptoms started to deteriorate, participants added an active or placebo corticosteroid inhaler to their usual corticosteroid for 14 days to produce a doubling or no change in dose. The primary outcome was the number of individuals starting oral prednisolone in each group. Findings During 12 months, 207 (53%) started their study inhaler and 46 (12%) started prednisolone-22 (11%) of 192 and 24 (12%) of 198 in the active and placebo groups, respectively. The risk ratio for starting prednisolone was therefore 0.95 (95% Cl 0.55-1.64, p = 0.8). Interpretation We recorded little evidence to support the widely recommended intervention of doubling the dose of inhaled corticosteroid when asthma control starts to deteriorate.	City Hosp Nottingham, David Evans Res Ctr, Resp Med Unit, Div Resp Med, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Harrison, TW (corresponding author), City Hosp Nottingham, David Evans Res Ctr, Resp Med Unit, Div Resp Med, Hucknall Rd, Nottingham NG5 1PB, England.	tharris2@ncht.trent.nhs.uk						BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; DSOUZA W, 1994, EUR RESPIR J, V7, P1260, DOI 10.1183/09031936.94.07071260; DSouza W, 1996, J ALLERGY CLIN IMMUN, V97, P1085, DOI 10.1016/S0091-6749(96)70262-2; Foresi A, 2000, CHEST, V117, P440, DOI 10.1378/chest.117.2.440; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Hoskins G, 1996, BRIT J GEN PRACT, V46, P169; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; Lahdensuo A, 1996, BRIT MED J, V312, P748; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Phillips K, 1999, J ROY COLL PHYS LOND, V33, P425; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; [No title captured]	15	171	175	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					271	275		10.1016/S0140-6736(03)15384-6	http://dx.doi.org/10.1016/S0140-6736(03)15384-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751699				2022-12-28	WOS:000188361400008
J	Poupon, R; Poupon, RE				Poupon, R; Poupon, RE			Retrovirus infection as a trigger for primary biliary cirrhosis?	LANCET			English	Editorial Material							MAMMARY-TUMOR VIRUS; BREAST-CANCER; IMMUNE-SYSTEM; IDENTIFICATION		Hop St Antoine, Assistance Publ Hop Paris, Serv Hepatol, F-75571 Paris 12, France; Fac Med Necker Enfants Malad, INSERM, U370, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Poupon, R (corresponding author), Hop St Antoine, Assistance Publ Hop Paris, Serv Hepatol, F-75571 Paris 12, France.	raoul.poupon@sat.ap-hop-paris.fr						Czarneski J, 2003, IMMUNOL RES, V27, P469, DOI 10.1385/IR:27:2-3:469; Etkind P, 2000, CLIN CANCER RES, V6, P1273; Jude BA, 2003, NAT IMMUNOL, V4, P573, DOI 10.1038/ni926; Liu BR, 2001, CANCER RES, V61, P1754; Otten LA, 2002, TRENDS MICROBIOL, V10, P303, DOI 10.1016/S0966-842X(02)02385-5; Poupon R.E., 1996, HEPATOLOGY TXB LIVER, Vthird, P1329; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; Shimoda S, 1998, J CLIN INVEST, V102, P1831, DOI 10.1172/JCI4213; VANDEWATER J, 1993, J CLIN INVEST, V91, P2653, DOI 10.1172/JCI116504; Xu LZ, 2003, P NATL ACAD SCI USA, V100, P8454, DOI 10.1073/pnas.1433063100	10	18	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					260	261		10.1016/S0140-6736(03)15418-9	http://dx.doi.org/10.1016/S0140-6736(03)15418-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751695				2022-12-28	WOS:000188361400004
J	Kadokura, H; Tian, HP; Zander, T; Bardwell, JCA; Beckwith, J				Kadokura, H; Tian, HP; Zander, T; Bardwell, JCA; Beckwith, J			Snapshots of DsbA in action: Detection of proteins in the process of oxidative folding	SCIENCE			English	Article							DISULFIDE-BOND-FORMATION; ESCHERICHIA-COLI; FORMATION INVIVO; RESPIRATORY-CHAIN; LIVING CELLS; THIOREDOXIN; CYSTEINES; SITE; IDENTIFICATION; ISOMERASE	DsbA, a thioredoxin superfamily member, introduces disulfide bonds into newly translocated proteins. This process is thought to occur via formation of mixed disulfide complexes between DsbA and its substrates. However, these complexes are difficult to detect, probably because of their short-lived nature. Here we show that it is possible to detect such covalent intermediates in vivo by a mutation in DsbA that alters cis proline-151. Further, this mutant allowed us to identify substrates of DsbA. Alteration of the cis proline, highly conserved among thioredoxin superfamily members, may be useful for the detection of substrates and intermediate complexes in other systems.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.	jbeckwith@hms.harvard.edu	Kadokura, Hiroshi/AAE-1645-2019	Kadokura, Hiroshi/0000-0001-7308-7141	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041883, R01GM057039] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57039, GM41883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Charbonnier JB, 1999, PROTEIN SCI, V8, P96; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; Guddat LW, 1997, PROTEIN SCI, V6, P1148, DOI 10.1002/pro.5560060603; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KADOKURA H, UNPUB; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; ORTENBERG R, UNPUB; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Richarme G, 1998, BIOCHEM BIOPH RES CO, V252, P156, DOI 10.1006/bbrc.1998.9591; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Vinci F, 2002, PROTEIN SCI, V11, P1600, DOI 10.1110/ps.4960102; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	30	180	183	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					534	537		10.1126/science.1091724	http://dx.doi.org/10.1126/science.1091724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739460				2022-12-28	WOS:000188316400041
J	Smartt, SJ; Maund, JR; Hendry, MA; Tout, CA; Gilmore, GF; Mattila, S; Benn, CR				Smartt, SJ; Maund, JR; Hendry, MA; Tout, CA; Gilmore, GF; Mattila, S; Benn, CR			Detection of a red supergiant progenitor star of a type II - Plateau supernova	SCIENCE			English	Article							MASSIVE STARS; GALAXIES; WFPC2; CALIBRATION; PHOTOMETRY; DISTANCES; EVOLUTION; PHYSICS; NGC-628; 2001DU	We present the discovery of a red supergiant star that exploded as supernova 2003gd in the nearby spiral galaxy M74. The Hubble Space Telescope (HST) and the Gemini Telescope imaged this galaxy 6 to 9 months before the supernova explosion, and subsequent HST images confirm the positional coincidence of the supernova with a single resolved star that is a red supergiant of 8(-2)(+4) solar masses. This confirms both stellar evolution models and supernova theories predicting that cool red supergiants are the immediate progenitor stars of type II-plateau supernovae.	Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; AlbaNova Univ Ctr, Stockholm Observ, SE-10691 Stockholm, Sweden; Isaac Newton Grp Telescopes, E-38700 Santa Cruz De La Palma, Spain	University of Cambridge; Stockholm University; Isaac Newton Group of Telescopes	Smartt, SJ (corresponding author), Univ Cambridge, Inst Astron, Madingley Rd, Cambridge CB3 0HA, England.	sjs@ast.cam.ac.uk	Tout, Christopher/AAE-6975-2021	Maund, Justyn/0000-0003-0733-7215; Tout, Christopher/0000-0002-1556-9449; Mattila, Seppo/0000-0001-7497-2994				ALDERING G, 1994, ASTRON J, V107, P662, DOI 10.1086/116886; ARNETT D, 1996, SUPERMOVAE NUCLEOSYN; BELLEY J, 1992, ASTROPHYS J SUPPL S, V78, P61, DOI 10.1086/191621; CARDELLI JA, 1989, ASTROPHYS J, V345, P245, DOI 10.1086/167900; Dolphin AE, 2000, PUBL ASTRON SOC PAC, V112, P1397, DOI 10.1086/316631; Drilling J.S., 2000, ALLENS ASTROPHYSICAL, P381; ELIAS JH, 1985, ASTROPHYS J SUPPL S, V57, P91, DOI 10.1086/190997; EVANS R, 2003, 8150 INT ASTR; Ferguson AMN, 1998, ASTRON J, V116, P673, DOI 10.1086/300456; Freedman WL, 2001, ASTROPHYS J, V553, P47, DOI 10.1086/320638; GARNAVICH P, 2003, 8150 INT ASTR; Hamuy M, 2003, ASTROPHYS J, V582, P905, DOI 10.1086/344689; Hamuy M, 2002, ASTROPHYS J, V566, pL63, DOI 10.1086/339676; HAMUY M, ASTROPH0309122; Heger A, 2003, ASTROPHYS J, V591, P288, DOI 10.1086/375341; Heger A, 2000, ASTROPHYS J, V544, P1016, DOI 10.1086/317239; HENDEN A, 2002, 1242 GAMM RAY BURST; Hendry MJ, UNPUB; HOLTZMAN JA, 1995, PUBL ASTRON SOC PAC, V107, P1065, DOI 10.1086/133664; HOOK RN, 2004, SPACE TELESCOPE EURO, P16; KOTAK R, 2003, 8152 INT ASTR; Leonard DC, 2003, ASTROPHYS J, V594, P247, DOI 10.1086/376831; Maund JR, 2004, NATURE, V427, P129, DOI 10.1038/nature02161; Meynet G, 2000, ASTRON ASTROPHYS, V361, P101; MEYNET G, 1994, ASTRON ASTROPHYS SUP, V103, P97; POLS OR, 1995, MON NOT R ASTRON SOC, V274, P964, DOI 10.1093/mnras/274.3.964; ROZANSKI R, 1994, MON NOT R ASTRON SOC, V271, P530, DOI 10.1093/mnras/271.3.530; Sharina ME, 1996, ASTRON ASTROPHYS SUP, V119, P499, DOI 10.1051/aas:1996262; Smartt SJ, 2003, MON NOT R ASTRON SOC, V343, P735, DOI 10.1046/j.1365-8711.2003.06718.x; Smartt SJ, 2002, ASTROPHYS J, V572, pL147, DOI 10.1086/341747; Smartt SJ, 2002, ASTROPHYS J, V565, P1089, DOI 10.1086/324690; SMARTT SJ, 2003, 8152 INT ASTR; Sohn YJ, 1996, ASTRON J, V111, P2280, DOI 10.1086/117962; Theureau G, 1998, ASTRON ASTROPHYS SUP, V130, P333, DOI 10.1051/aas:1998416; Tonry JL, 2000, ASTROPHYS J, V530, P625, DOI 10.1086/308409; TULLY RB, 1988, CATALOGUE NEARBY GAL; Van Dyk SD, 2003, PUBL ASTRON SOC PAC, V115, P1289, DOI 10.1086/378308; Van Dyk SD, 2003, PUBL ASTRON SOC PAC, V115, P448, DOI 10.1086/374299; WALBORN NR, 1989, ASTRON ASTROPHYS, V219, P229; WHITE GL, 1987, NATURE, V327, P36, DOI 10.1038/327036a0; WOOSLEY SE, 1986, ANNU REV ASTRON ASTR, V24, P205, DOI 10.1146/annurev.aa.24.090186.001225	42	152	152	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					499	503		10.1126/science.1092967	http://dx.doi.org/10.1126/science.1092967			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739452				2022-12-28	WOS:000188316400031
J	Cummings, DAT; Irizarry, RA; Huang, NE; Endy, TP; Nisalak, A; Ungchusak, K; Burke, DS				Cummings, DAT; Irizarry, RA; Huang, NE; Endy, TP; Nisalak, A; Ungchusak, K; Burke, DS			Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand	NATURE			English	Article							TIME-SERIES ANALYSIS; PARENTERAL INFECTION; AEDES-AEGYPTI; DISEASE; TEMPERATURE; DYNAMICS; VIRUSES; PREY	Dengue fever is a mosquito- borne virus that infects 50 - 100 million people each year(1). Of these infections, 200,000 - 500,000 occur as the severe, life- threatening form of the disease, dengue haemorrhagic fever ( DHF)(2). Large, unanticipated epidemics of DHF often overwhelm health systems(3). An understanding of the spatial - temporal pattern of DHF incidence would aid the allocation of resources to combat these epidemics. Here we examine the spatial - temporal dynamics of DHF incidence in a data set describing 850,000 infections occurring in 72 provinces of Thailand during the period 1983 to 1997. We use the method of empirical mode decomposition(4) to show the existence of a spatial - temporal travelling wave in the incidence of DHF. We observe this wave in a three- year periodic component of variance, which is thought to reflect host pathogen population dynamics(5,6). The wave emanates from Bangkok, the largest city in Thailand, moving radially at a speed of 148 km per month. This finding provides an important starting point for detecting and characterizing the key processes that contribute to the spatial - temporal dynamics of DHF in Thailand.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Geog & Environm Engn, Baltimore, MD 21218 USA; NASA, Goddard Space Flight Ctr, Lab Hydrospher Proc, Oceans & Ice Branch, Greenbelt, MD 20771 USA; USA, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA; Armed Forces Res Inst Med Sci, Dept Virol, Bangkok 10400, Thailand; Minist Publ Hlth, Bur Epidemiol, Nonthaburi, Thailand	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Ministry of Public Health - Thailand	Burke, DS (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	dburke@jhsph.edu		/0000-0002-5704-8094				ANDERSON RM, 1984, J HYG-CAMBRIDGE, V93, P587, DOI 10.1017/S0022172400065177; Bacon P., 1985, POPULATION DYNAMICS; Bjornstad ON, 2002, SCIENCE, V298, P1020, DOI 10.1126/science.1075182; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Bjornstad ON, 2001, ENVIRON ECOL STAT, V8, P53, DOI 10.1023/A:1009601932481; Chareonsook O, 1999, EPIDEMIOL INFECT, V122, P161, DOI 10.1017/S0950268898001617; Coulson T, 2001, SCIENCE, V292, P1528, DOI 10.1126/science.292.5521.1528; de Roos AM, 1998, THEOR POPUL BIOL, V53, P108, DOI 10.1006/tpbi.1997.1345; DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; Ferguson N, 1999, P NATL ACAD SCI USA, V96, P790, DOI 10.1073/pnas.96.2.790; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; Gubler D. J., 1998, Annals Academy of Medicine Singapore, V27, P227; GUBLER DJ, 1977, J MED ENTOMOL, V13, P469, DOI 10.1093/jmedent/13.4-5.469; GUBLER DJ, 1979, B WORLD HEALTH ORGAN, V57, P931; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Hay SI, 2000, P NATL ACAD SCI USA, V97, P9335, DOI 10.1073/pnas.97.16.9335; Huang NE, 1998, P ROY SOC A-MATH PHY, V454, P903, DOI 10.1098/rspa.1998.0193; Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462; MOLLISON D, 1986, PHILOS T R SOC B, V314, P675, DOI 10.1098/rstb.1986.0080; Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191; ROSEN L, 1985, AM J TROP MED HYG, V34, P603, DOI 10.4269/ajtmh.1985.34.603; Sherratt JA, 2001, ECOL LETT, V4, P30, DOI 10.1046/j.1461-0248.2001.00193.x; Tun-Lin W, 2000, MED VET ENTOMOL, V14, P31, DOI 10.1046/j.1365-2915.2000.00207.x; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143	24	363	374	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					344	347		10.1038/nature02225	http://dx.doi.org/10.1038/nature02225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737166				2022-12-28	WOS:000188266200039
J	Bronner-Fraser, M				Bronner-Fraser, M			Making sense of the sensory lineage	SCIENCE			English	Editorial Material							CELLS		CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Bronner-Fraser, M (corresponding author), CALTECH, Pasadena, CA 91125 USA.	mbronner@caltech.edu		Bronner, Marianne/0000-0003-4274-1862				Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Lahav R, 1998, P NATL ACAD SCI USA, V95, P14214, DOI 10.1073/pnas.95.24.14214; Le Douarin NM, 1999, NEURAL CREST, V2; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Shah NM, 1997, P NATL ACAD SCI USA, V94, P11369, DOI 10.1073/pnas.94.21.11369	10	14	14	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					966	968		10.1126/science.1094732	http://dx.doi.org/10.1126/science.1094732			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963317				2022-12-28	WOS:000188918000031
J	Bushnell, DA; Westover, KD; Davis, RE; Kornberg, RD				Bushnell, DA; Westover, KD; Davis, RE; Kornberg, RD			Structural basis of transcription: An RNA polymerase II-TFIIB cocrystal at 4.5 angstroms	SCIENCE			English	Article							START SITE SELECTION; N-TERMINAL REGION; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; ZINC RIBBON; SACCHAROMYCES-CEREVISIAE; PROTEIN INTERACTIONS; ANGSTROM RESOLUTION; ELONGATION COMPLEX; INITIATION COMPLEX	The structure of the general transcription factor IIB (TFIIB) in a complex with RNA polymerase II reveals three features crucial for transcription initiation: an N-terminal zinc ribbon domain of TFIIB that contacts the "dock" domain of the polymerase, near the path of RNA exit from a transcribing enzyme; a "finger" domain of TFIIB that is inserted into the polymerase active center; and a C-terminal domain, whose interaction with both the polymerase and with a TATA box-binding protein (TBP)-promoter DNA complex orients the DNA for unwinding and transcription. TFIIB stabilizes an early initiation complex, containing an incomplete RNA-DNA hybrid region. It may interact with the template strand, which sets the location of the transcription start site, and may interfere with RNA exit, which leads to abortive initiation or promoter escape. The trajectory of promoter DNA determined by the C-terminal domain of TFIIB traverses sites of interaction with TFIIE, TFIIF, and TFIIH, serving to de. ne their roles in the transcription initiation process.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu	Westover, Ken/AAZ-1795-2020	Westover, Ken/0000-0003-3653-5923	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM49985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bhargava P, 1999, J BIOL CHEM, V274, P26550, DOI 10.1074/jbc.274.37.26550; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; Chen HT, 2000, PROTEIN SCI, V9, P1743, DOI 10.1110/ps.9.9.1743; Chen HT, 2003, MOL CELL, V12, P437, DOI 10.1016/S1097-2765(03)00306-X; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Chung WH, 2003, MOL CELL, V12, P1003, DOI 10.1016/S1097-2765(03)00387-3; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Fairley JA, 2002, MOL CELL BIOL, V22, P6697, DOI 10.1128/MCB.22.19.6697-6705.2002; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PINTO I, 1994, J BIOL CHEM, V269, P30569; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WESTOVER KD, 2004, SCIENCE, V303; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; Zhang DY, 2002, NUCLEIC ACIDS RES, V30, P3078, DOI 10.1093/nar/gkf422; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	47	255	272	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					983	988		10.1126/science.1090838	http://dx.doi.org/10.1126/science.1090838			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963322				2022-12-28	WOS:000188918000037
J	Check, E				Check, E			Retraction signals end of cell-biology debate	NATURE			English	News Item																		Chan SK, 2004, CELL, V116, P481, DOI 10.1016/S0092-8674(04)00122-9; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1	2	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					574	574		10.1038/427574a	http://dx.doi.org/10.1038/427574a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961082	Bronze			2022-12-28	WOS:000188875300004
J	Liu, AS; Jones, R; Liao, L; Samara-Rubio, D; Rubin, D; Cohen, O; Nicolaescu, R; Paniccia, M				Liu, AS; Jones, R; Liao, L; Samara-Rubio, D; Rubin, D; Cohen, O; Nicolaescu, R; Paniccia, M			A high-speed silicon optical modulator based on a metal-oxide-semiconductor capacitor	NATURE			English	Article							WAVE-GUIDES; SOI; INTERFEROMETERS; FABRICATION; WAVELENGTH; VOLTAGE	Silicon has long been the optimal material for electronics, but it is only relatively recently that it has been considered as a material option for photonics(1). One of the key limitations for using silicon as a photonic material has been the relatively low speed of silicon optical modulators compared to those fabricated from III-V semiconductor compounds(2-6) and/or electro-optic materials such as lithium niobate(7-9). To date, the fastest silicon-waveguide-based optical modulator that has been demonstrated experimentally has a modulation frequency of only similar to20 MHz (refs 10, 11), although it has been predicted theoretically that a similar to1-GHz modulation frequency might be achievable in some device structures(12,13). Here we describe an approach based on a metal-oxide-semiconductor (MOS) capacitor structure embedded in a silicon waveguide that can produce high-speed optical phase modulation: we demonstrate an all-silicon optical modulator with a modulation bandwidth exceeding 1 GHz. As this technology is compatible with conventional complementary MOS (CMOS) processing, monolithic integration of the silicon modulator with advanced electronics on a single silicon substrate becomes possible.	Intel Corp, Santa Clara, CA 95054 USA; Intel Corp, IL-91031 Jerusalem, Israel	Intel Corporation; Intel Corporation	Liu, AS (corresponding author), Intel Corp, 2200 Miss Coll Blvd,CHP3-109, Santa Clara, CA 95054 USA.	ansheng.liu@intel.com						Ahmed SS, 2001, J VAC SCI TECHNOL B, V19, P800, DOI 10.1116/1.1364698; BANK RE, 1983, IEEE T ELECTRON DEV, V30, P1031, DOI 10.1109/T-ED.1983.21257; CITES JS, 1992, J LIGHTWAVE TECHNOL, V12, P1167; Cutolo A, 1997, J LIGHTWAVE TECHNOL, V15, P505, DOI 10.1109/50.557567; Dainesi P, 2000, IEEE PHOTONIC TECH L, V12, P660, DOI 10.1109/68.849076; DAVARI B, 1995, P IEEE, V83, P595, DOI 10.1109/5.371968; Fetterman M, 1996, IEEE PHOTONIC TECH L, V8, P69, DOI 10.1109/68.475781; FUJIWARA T, 1990, IEEE PHOTONIC TECH L, V2, P260, DOI 10.1109/68.53255; Howerton MM, 2000, IEEE PHOTONIC TECH L, V12, P792, DOI 10.1109/68.853502; Ido T, 1996, J LIGHTWAVE TECHNOL, V14, P2026, DOI 10.1109/50.536970; Irace A, 2003, ELECTRON LETT, V39, P232, DOI 10.1049/el:20030136; Leclerc O, 1998, ELECTRON LETT, V34, P1011, DOI 10.1049/el:19980745; Liao L, 2000, J ELECTRON MATER, V29, P1380, DOI 10.1007/s11664-000-0122-4; Liao L., 1997, LOW LOSS POLYSILICON; Png CE, 2003, PROC SPIE, V4997, P190, DOI 10.1117/12.476666; Sciuto A, 2003, J LIGHTWAVE TECHNOL, V21, P228, DOI 10.1109/JLT.2003.808608; Soref R. A., 1987, PROC SPIE, V704, P32; SOREF RA, 1986, IEEE J QUANTUM ELECT, V22, P873, DOI 10.1109/JQE.1986.1073057; SOREF RA, 1987, IEEE J QUANTUM ELECT, V23, P123, DOI 10.1109/JQE.1987.1073206; SOREF RA, 1993, P IEEE, V81, P1687, DOI 10.1109/5.248958; SUDBO AS, 1993, IEEE PHOTONIC TECH L, V5, P342, DOI 10.1109/68.205632; Sze S., 1981, PHYS SEMICONDUCTOR D, V2nd ed., P85; TANG CK, 1995, ELECTRON LETT, V31, P451, DOI 10.1049/el:19950328; Wooten EL, 2000, IEEE J SEL TOP QUANT, V6, P69, DOI 10.1109/2944.826874; ZUCKER JE, 1990, IEEE PHOTONIC TECH L, V2, P32, DOI 10.1109/68.47033	25	1281	1378	24	561	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					615	618		10.1038/nature02310	http://dx.doi.org/10.1038/nature02310			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961115				2022-12-28	WOS:000188875300035
J	Mauroy, B; Filoche, M; Weibel, ER; Sapoval, B				Mauroy, B; Filoche, M; Weibel, ER; Sapoval, B			An optimal bronchial tree may be dangerous	NATURE			English	Article							MODEL	The geometry and dimensions of branched structures such as blood vessels or airways are important factors in determining the efficiency of physiological processes. It has been shown that fractal trees can be space filling(1) and can ensure minimal dissipation(2-4). The bronchial tree of most mammalian lungs is a good example of an efficient distribution system with an approximate fractal structure(5,6). Here we present a study of the compatibility between physical optimization and physiological robustness in the design of the human bronchial tree. We show that this physical optimization is critical in the sense that small variations in the geometry can induce very large variations in the net air flux. Maximum physical efficiency therefore cannot be a sufficient criterion for the physiological design of bronchial trees. Rather, the design of bronchial trees must be provided with a safety factor and the capacity for regulating airway calibre. Paradoxically, our results suggest that bronchial malfunction related to asthma is a necessary consequence of the optimized efficiency of the tree structure.	Ecole Normale Super, Ctr Math & Leurs Applicat, F-94235 Cachan, France; Ecole Polytech, CNRS, Phys Mat Condensee Lab, F-91128 Palaiseau, France; Univ Bern, Dept Anat, CH-3000 Bern, Switzerland	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; University of Bern	Sapoval, B (corresponding author), Ecole Normale Super, Ctr Math & Leurs Applicat, F-94235 Cachan, France.	Bernard.Sapoval@polytechnique.fr	Weibel, Ewald R./K-3814-2019	FILOCHE, Marcel/0000-0001-8637-3016				Bejan A., 2000, SHAPE STRUCTURE ENG; Brown J., 2000, SCALING BIOL; Hess W, 1914, ARCH ANAT PHYSL, P1; Hoppeler H, 2003, MED SCI SPORT EXER, V35, P95, DOI 10.1097/00005768-200301000-00016; Kitaoka H, 1999, J APPL PHYSIOL, V87, P2207, DOI 10.1152/jappl.1999.87.6.2207; Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT, P480; Mauroy B, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.148101; Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207; NELSON TR, 1988, IEEE T MED IMAGING, V7, P321, DOI 10.1109/42.14515; Que CL, 2001, J APPL PHYSIOL, V91, P1131, DOI 10.1152/jappl.2001.91.3.1131; Sapoval B, 2002, P NATL ACAD SCI USA, V99, P10411, DOI 10.1073/pnas.122352499; Sapoval B., 1997, UNIVERSALITES FRACTA; Weibel E R., 1984, PATHWAY OXYGEN; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; Weibel ER, 2000, SYMMORPHOSIS; WEIBEL ER, 1997, LUNG SCI FDN, V1, P1061; WEST BJ, 1986, J APPL PHYSIOL, V60, P1089, DOI 10.1152/jappl.1986.60.3.1089; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003	19	195	204	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					633	636		10.1038/nature02287	http://dx.doi.org/10.1038/nature02287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961120				2022-12-28	WOS:000188875300041
J	Teichman, JMH				Teichman, JMH			Acute renal colic from ureteral calculus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SHOCK-WAVE LITHOTRIPSY; URIC-ACID NEPHROLITHIASIS; HOLMIUM-YAG LITHOTRIPSY; ACUTE FLANK PAIN; HELICAL COMPUTERIZED-TOMOGRAPHY; URINARY-TRACT CALCULI; KIDNEY-STONES; NATURAL-HISTORY; FAMILY HISTORY; UNITED-STATES		Univ British Columbia, Div Urol, Vancouver, BC V5Z 1M9, Canada; St Pauls Hosp, Urol Sect, Vancouver, BC V6Z 1Y6, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Teichman, JMH (corresponding author), Univ British Columbia, Div Urol, Vancouver, BC V5Z 1M9, Canada.		Teichman, Joel/CAJ-0452-2022					ALAKULJU K, 1985, ANN CHIR GYNAECOL FE, V74, P284; ANDRENSANDBERG A, 1983, SCAND J UROL NEPHROL, V17, P81, DOI 10.3109/00365598309179787; Bird VG, 2002, J UROLOGY, V167, P1597, DOI 10.1016/S0022-5347(05)65161-0; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; Bove P, 1999, J UROLOGY, V162, P685, DOI 10.1097/00005392-199909010-00013; Brater D. Craig, 1999, American Journal of Medicine, V107, p65S; BURNS JR, 1984, J UROLOGY, V131, P708, DOI 10.1016/S0022-5347(17)50591-1; CASS AS, 1995, J UROLOGY, V153, P588, DOI 10.1016/S0022-5347(01)67654-7; Chandhoke PS, 2002, J UROLOGY, V168, P937, DOI 10.1016/S0022-5347(05)64546-6; Cordell WH, 1996, ANN EMERG MED, V28, P151, DOI 10.1016/S0196-0644(96)70055-0; CORDELL WH, 1994, ANN EMERG MED, V23, P262, DOI 10.1016/S0196-0644(94)70038-9; Curhan GC, 1997, J AM SOC NEPHROL, V8, P1568; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; ELSHERIF AE, 1995, J UROLOGY, V153, P1395, DOI 10.1016/S0022-5347(01)67411-1; Erturk E, 1997, J ENDOUROL, V11, P315, DOI 10.1089/end.1997.11.315; Gillis JC, 1997, DRUGS, V53, P139, DOI 10.2165/00003495-199753010-00012; Goldfarb DS, 1999, AM FAM PHYSICIAN, V60, P2269; Graber SF, 2003, J UROLOGY, V169, P54, DOI 10.1016/S0022-5347(05)64033-5; GUTMAN AB, 1968, AM J MED, V45, P756, DOI 10.1016/0002-9343(68)90209-X; HUBNER WA, 1993, EUR UROL, V24, P172; Irving SO, 2000, BJU INT, V85, P637, DOI 10.1046/j.1464-410x.2000.00563.x; Joseph P, 2002, J UROLOGY, V167, P1968, DOI 10.1016/S0022-5347(05)65064-1; KELLEHER JP, 1991, BRIT J UROL, V67, P125, DOI 10.1111/j.1464-410X.1991.tb15092.x; Kober A, 2003, J UROLOGY, V170, P741, DOI 10.1097/01.ju.0000080570.83834.ad; Kuo RL, 1999, J UROLOGY, V162, P1913, DOI 10.1016/S0022-5347(05)68067-6; Laerum E, 1996, EUR UROL, V30, P358; Lam JS, 2002, J UROLOGY, V167, P1972, DOI 10.1016/S0022-5347(05)65065-3; Larkin GL, 1999, AM J EMERG MED, V17, P6, DOI 10.1016/S0735-6757(99)90003-7; LEE YH, 1992, J UROLOGY, V147, P16, DOI 10.1016/S0022-5347(17)37121-5; LJUNGHALL S, 1985, BRIT J UROL, V57, P370, DOI 10.1111/j.1464-410X.1985.tb06290.x; Lopes T, 2001, BJU INT, V87, P322, DOI 10.1046/j.1464-410x.2001.00068.x; Lotan Y, 2002, J UROLOGY, V167, P1621, DOI 10.1016/S0022-5347(05)65166-X; Low RK, 1997, UROL CLIN N AM, V24, P135, DOI 10.1016/S0094-0143(05)70359-1; Miller OF, 1998, UROLOGY, V52, P982, DOI 10.1016/S0090-4295(98)00368-9; Miller OF, 1999, J UROLOGY, V162, P688, DOI 10.1097/00005392-199909010-00014; MORSE RM, 1991, J UROLOGY, V145, P263, DOI 10.1016/S0022-5347(17)38310-6; Pak CYC, 2003, J UROLOGY, V169, P465, DOI 10.1016/S0022-5347(05)63934-1; PAK CYC, 1986, KIDNEY INT, V30, P422, DOI 10.1038/ki.1986.201; Parks JH, 2002, J UROLOGY, V167, P1607, DOI 10.1016/S0022-5347(05)65163-4; Parks JH, 2001, J UROLOGY, V166, P2057, DOI 10.1016/S0022-5347(05)65505-X; Pearle MS, 2001, J UROLOGY, V166, P1255, DOI 10.1016/S0022-5347(05)65748-5; Pearle MS, 1998, J UROLOGY, V160, P1260, DOI 10.1016/S0022-5347(01)62511-4; Roberts WW, 1998, J UROLOGY, V159, P723, DOI 10.1016/S0022-5347(01)63711-X; Sakhaee K, 2002, KIDNEY INT, V62, P971, DOI 10.1046/j.1523-1755.2002.00508.x; SARMINA I, 1987, J UROLOGY, V138, P14, DOI 10.1016/S0022-5347(17)42971-5; Segura JW, 1997, J UROLOGY, V158, P1915, DOI 10.1016/S0022-5347(01)64173-9; Seltzer MA, 1996, J UROLOGY, V156, P907, DOI 10.1016/S0022-5347(01)65659-3; Shokeir AA, 2000, UROLOGY, V55, P344, DOI 10.1016/S0090-4295(99)00475-6; SIERAKOWSKI R, 1978, INVEST UROL, V15, P438; Sofer M, 2002, J UROLOGY, V167, P31, DOI 10.1016/S0022-5347(05)65376-1; SOUCIE JM, 1994, KIDNEY INT, V46, P893, DOI 10.1038/ki.1994.347; Streem SB, 1996, J UROLOGY, V155, P1186, DOI 10.1016/S0022-5347(01)66208-6; Teichman JMH, 1997, J UROLOGY, V158, P1357, DOI 10.1016/S0022-5347(01)64214-9; Teichman JMH, 1998, J UROLOGY, V159, P17, DOI 10.1016/S0022-5347(01)63998-3; Teichman JMH, 2000, J UROLOGY, V164, P1259, DOI 10.1016/S0022-5347(05)67151-0; Tramer MR, 1998, ACTA ANAESTH SCAND, V42, P71; UENO A, 1977, Urology, V10, P544, DOI 10.1016/0090-4295(77)90097-8; van Drongelen J, 1998, UROLOGY, V52, P384, DOI 10.1016/S0090-4295(98)00201-5; Vassar GJ, 1999, J ENDOUROL, V13, P181, DOI 10.1089/end.1999.13.181; VAUGHAN ED, 1971, J UROLOGY, V106, P27, DOI 10.1016/S0022-5347(17)61219-9; Vieweg J, 1998, J UROLOGY, V160, P679, DOI 10.1016/S0022-5347(01)62754-X; VIEWEG J, 1992, J UROLOGY, V148, P1007, DOI 10.1016/S0022-5347(17)36801-5; Yagisawa T, 1999, J UROLOGY, V161, P1449, DOI 10.1016/S0022-5347(05)68922-7; YU TF, 1967, ANN INTERN MED, V67, P1133, DOI 10.7326/0003-4819-67-6-1133; Zabihi N, 2001, LANCET, V358, P437, DOI 10.1016/S0140-6736(01)05668-9	65	245	254	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					684	693		10.1056/NEJMcp030813	http://dx.doi.org/10.1056/NEJMcp030813			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960744				2022-12-28	WOS:000188869500009
J	Everaers, R; Sukumaran, SK; Grest, GS; Svaneborg, C; Sivasubramanian, A; Kremer, K				Everaers, R; Sukumaran, SK; Grest, GS; Svaneborg, C; Sivasubramanian, A; Kremer, K			Rheology and microscopic topology of entangled polymeric liquids	SCIENCE			English	Article							STATISTICAL MECHANICS; CHAIN DIMENSIONS; MOLECULAR-WEIGHT; MELTS; REPTATION; LENGTH; SIMULATIONS; MODEL; DYNAMICS; SYSTEMS	The viscoelastic properties of high molecular weight polymeric liquids are dominated by topological constraints on a molecular scale. In a manner similar to that of entangled ropes, polymer chains can slide past but not through each other. Tube models of polymer dynamics and rheology are based on the idea that entanglements con. ne a chain to small fluctuations around a primitive path that follows the coarse-grained chain contour. Here we provide a microscopic foundation for these highly successful phenomenological models. We analyze the topological state of polymeric liquids in terms of primitive paths and obtain parameter-free, quantitative predictions for the plateau modulus, which agree with experiment for all major classes of synthetic polymers.	Max Planck Inst Polymer Res, D-55128 Mainz, Germany; Max Planck Inst Phys Komplexer Syst, D-01187 Dresden, Germany; Sandia Natl Labs, Albuquerque, NM 87185 USA	Max Planck Society; Max Planck Society; United States Department of Energy (DOE); Sandia National Laboratories	Everaers, R (corresponding author), Max Planck Inst Polymer Res, Ackermannweg 10, D-55128 Mainz, Germany.	everaers@mpipks-dresden.mpg.de	Kremer, Kurt/G-5652-2011; Everaers, Ralf/K-2228-2013	Kremer, Kurt/0000-0003-1842-9369; Everaers, Ralf/0000-0002-6843-2753; Svaneborg, Carsten/0000-0003-4301-3365				Abrams CF, 2003, MACROMOLECULES, V36, P260, DOI 10.1021/ma0213495; Ahlrichs P, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.040501; Auhl R, 2003, J CHEM PHYS, V119, P12718, DOI 10.1063/1.1628670; Boal D. H., 2002, MECH CELL; COLBY R, 1991, MACROMOLECULES, V24, P3783; COLBY RH, 1987, MACROMOLECULES, V20, P2226, DOI 10.1021/ma00175a030; COLBY RH, 1992, MACROMOLECULES, V25, P996, DOI 10.1021/ma00028a076; DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789; Doi M, 2003, PHILOS T R SOC A, V361, P641, DOI 10.1098/rsta.2002.1168; Doi M., 1988, THEORY POLYM DYNAMIC; EDWARDS SF, 1967, P PHYS SOC LOND, V91, P513, DOI 10.1088/0370-1328/91/3/301; EDWARDS SF, 1967, P PHYS SOC LOND, V92, P9, DOI 10.1088/0370-1328/92/1/303; EDWARDS SF, 1977, BRIT POLYM J, V9, P140, DOI 10.1002/pi.4980090209; Everaers R, 1996, PHYS REV E, V53, pR37, DOI 10.1103/PhysRevE.53.R37; Fetters LJ, 1999, MACROMOLECULES, V32, P6847, DOI 10.1021/ma990620o; FETTERS LJ, 1994, MACROMOLECULES, V27, P4639, DOI 10.1021/ma00095a001; Fetters LJ, 1999, J POLYM SCI POL PHYS, V37, P1023, DOI 10.1002/(SICI)1099-0488(19990515)37:10<1023::AID-POLB7>3.0.CO;2-T; GRAESSLEY WW, 1981, POLYMER, V22, P1329, DOI 10.1016/0032-3861(81)90231-7; Inoue T, 2002, MACROMOLECULES, V35, P9169, DOI 10.1021/ma020849v; IWATA K, 1989, J CHEM PHYS, V90, P4567, DOI 10.1063/1.456617; Iwata K, 2002, POLYMER, V43, P6595, DOI 10.1016/S0032-3861(02)00525-6; KAS J, 1994, NATURE, V368, P226, DOI 10.1038/368226a0; KREMER K, 1990, J CHEM PHYS, V92, P5057, DOI 10.1063/1.458541; LEON S, UNPUB; Masubuchi Y, 2001, J CHEM PHYS, V115, P4387, DOI 10.1063/1.1389858; Matsumiya Y, 1998, MACROMOLECULES, V31, P7973, DOI 10.1021/ma980465y; McLeish TCB, 2002, ADV PHYS, V51, P1379, DOI 10.1080/00018730210153216; MCLEISH TCB, 2002, ADV PHYS, V5, P1527; Michalke W, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.012801; Morse DC, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.031502; Padding JT, 2002, J CHEM PHYS, V117, P925, DOI 10.1063/1.1481859; Putz M, 2000, EUROPHYS LETT, V49, P735, DOI 10.1209/epl/i2000-00212-8; PUTZ M, UNPUB; Schieber JD, 2003, J RHEOL, V47, P213, DOI 10.1122/1.1530155; Schleger P, 1998, PHYS REV LETT, V81, P124, DOI 10.1103/PhysRevLett.81.124; Treloar L. R. G., 1975, PHYS TODAY, DOI DOI 10.1063/1.3060678; Van Krevelen D.W., 1990, PROPERTIES POLYM, Vthird	37	584	587	10	295	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					823	826		10.1126/science.1091215	http://dx.doi.org/10.1126/science.1091215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764875				2022-12-28	WOS:000188753800053
J	Helveg, S; Lopez-Cartes, C; Sehested, J; Hansen, PL; Clausen, BS; Rostrup-Nielsen, JR; Abild-Pedersen, F; Norskov, JK				Helveg, S; Lopez-Cartes, C; Sehested, J; Hansen, PL; Clausen, BS; Rostrup-Nielsen, JR; Abild-Pedersen, F; Norskov, JK			Atomic-scale imaging of carbon nanofibre growth	NATURE			English	Article							NANOTUBES; NICKEL; CATALYSTS; DECOMPOSITION; FORMALISM	The synthesis of carbon nanotubes with predefined structure and functionality plays a central role in the field of nanotechnology(1,2), whereas the inhibition of carbon growth is needed to prevent a breakdown of industrial catalysts for hydrogen and synthesis gas production(3). The growth of carbon nanotubes and nanofibres has therefore been widely studied(4-10). Recent advances in in situ techniques now open up the possibility of studying gas - solid interactions at the atomic level(11-12). Here we present time-resolved, high-resolution in situ transmission electron microscope observations of the formation of carbon nanofibres from methane decomposition over supported nickel nanocrystals. Carbon nanofibres are observed to develop through a reaction-induced reshaping of the nickel nanocrystals. Specifically, the nucleation and growth of graphene layers are found to be assisted by a dynamic formation and restructuring of mono-atomic step edges at the nickel surface. Density-functional theory calculations indicate that the observations are consistent with a growth mechanism involving surface diffusion of carbon and nickel atoms. The finding that metallic step edges act as spatio-temporal dynamic growth sites may be important for understanding other types of catalytic reactions and nanomaterial syntheses.	Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark; Tech Univ Denmark, Dept Phys, Ctr Atom Scale Mat Phys, DK-2800 Kgs Lyngby, Denmark	Haldor Topsoe; Technical University of Denmark	Helveg, S (corresponding author), Haldor Topsoe Res Labs, Nymollevej 55, DK-2800 Kgs Lyngby, Denmark.	sth@topsoe.dk	Cartes, Carlos López/I-4589-2017; Helveg, Stig/AAD-8603-2021; Cartes, Carlos López/M-3110-2019; Norskov, Jens K/D-2539-2017; Helveg, Stig/O-7513-2018; Abild-Pedersen, Frank/C-3248-2014	Cartes, Carlos López/0000-0002-6556-3117; Helveg, Stig/0000-0002-0328-8295; Cartes, Carlos López/0000-0002-6556-3117; Norskov, Jens K/0000-0002-4427-7728; Abild-Pedersen, Frank/0000-0002-1911-074X				Ajayan PM, 1999, CHEM REV, V99, P1787, DOI 10.1021/cr970102g; ALSTRUP I, 1988, J CATAL, V109, P241, DOI 10.1016/0021-9517(88)90207-2; ASKELAND DR, 1989, SCI ENG MAT, pCH5; BAKER RTK, 1972, J CATAL, V26, P51, DOI 10.1016/0021-9517(72)90032-2; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Bengaard HS, 2002, J CATAL, V209, P365, DOI 10.1006/jcat.2002.3579; Boskovic BO, 2002, NAT MATER, V1, P165, DOI 10.1038/nmat755; Charlier JC, 2001, TOP APPL PHYS, V80, P55; Clausen BS, 1998, ADV CATAL, V42, P315, DOI 10.1016/S0360-0564(08)60630-6; Da Silva JLF, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.066104; De Jong KP, 2000, CATAL REV, V42, P481, DOI 10.1081/CR-100101954; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; Hammer B, 1999, PHYS REV B, V59, P7413, DOI 10.1103/PhysRevB.59.7413; Hansen PL, 2002, SCIENCE, V295, P2053, DOI 10.1126/science.1069325; JONES RO, 1989, REV MOD PHYS, V61, P689, DOI 10.1103/RevModPhys.61.689; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0; Norskov JK, 2002, J CATAL, V209, P275, DOI 10.1006/jcat.2002.3615; ROSEI R, 1983, PHYS REV B, V28, P1161, DOI 10.1103/PhysRevB.28.1161; Rostrup-Nielsen J R, 1977, J CATAL, V48, P155, DOI DOI 10.1016/0021-9517(77)90087-2; Rostrup-Nielsen JR, 2002, ADV CATAL, V47, P65, DOI 10.1016/S0360-0564(02)47006-X; ROSTRUPNIELSEN JR, 1972, J CATAL, V27, P343, DOI 10.1016/0021-9517(72)90170-4; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Topsoe H., 2000, STUD SURF SCI CAT, V130, P1, DOI [10.1016/s0167-2991(00)80942-8, DOI 10.1016/S0167-2991(00)80942-8]; TRIMM DL, 1977, CATAL REV, V16, P155, DOI 10.1080/03602457708079636; VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892	26	1197	1219	17	654	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					426	429		10.1038/nature02278	http://dx.doi.org/10.1038/nature02278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749826				2022-12-28	WOS:000188470500038
J	Johnston, KP; Shah, PS				Johnston, KP; Shah, PS			Materials science - Making nanoscale materials with supercritical fluids	SCIENCE			English	Editorial Material							CARBON-DIOXIDE; DEPOSITION; NANOWIRES		Univ Texas, Texas Mat Inst, Dept Chem Engn, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnston, KP (corresponding author), Univ Texas, Texas Mat Inst, Dept Chem Engn, Austin, TX 78712 USA.	kpj@che.utexas.edu						Blackburn JM, 2001, SCIENCE, V294, P141, DOI 10.1126/science.1064148; DESIMONE JM, 1994, SCIENCE, V265, P356, DOI 10.1126/science.265.5170.356; Fukushima Y, 1999, J PHYS CHEM B, V103, P3062, DOI 10.1021/jp984649q; Holmes JD, 2000, SCIENCE, V287, P1471, DOI 10.1126/science.287.5457.1471; Liu H, 2002, LANGMUIR, V18, P6066, DOI 10.1021/la0257945; Pai RA, 2004, SCIENCE, V303, P507, DOI 10.1126/science.1092627; Pham JQ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.175503; Ryan KM, 2003, J AM CHEM SOC, V125, P6284, DOI 10.1021/ja0345064; Shah PS, 2003, NANO LETT, V3, P1671, DOI 10.1021/nl034793+	9	173	178	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					482	483		10.1126/science.1093951	http://dx.doi.org/10.1126/science.1093951			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739447				2022-12-28	WOS:000188316400025
J	Solomon, S				Solomon, S			The hole truth - What's news (and what's not) about the ozone hole.	NATURE			English	Editorial Material							CFC-11		NOAA, Aeron Lab, Boulder, CO 80305 USA	National Oceanic Atmospheric Admin (NOAA) - USA	Solomon, S (corresponding author), NOAA, Aeron Lab, Boulder, CO 80305 USA.							Allen DR, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017117; CAGIN S, 1993, EARTH SKY; FARMAN JC, 1985, NATURE, V315, P207, DOI 10.1038/315207a0; McCulloch A, 2001, ATMOS ENVIRON, V35, P4387, DOI 10.1016/S1352-2310(01)00249-7; Montzka SA, 1999, NATURE, V398, P690, DOI 10.1038/19499; Prinn RG, 2000, J GEOPHYS RES-ATMOS, V105, P17751, DOI 10.1029/2000JD900141; REVKIN AC, 2003, NY TIMES        1110; SOLOMON S, 1986, NATURE, V321, P755, DOI 10.1038/321755a0; TABAZADEH A, 1993, SCIENCE, V260, P1082, DOI 10.1126/science.260.5111.1082; Walker SJ, 2000, J GEOPHYS RES-OCEANS, V105, P14285, DOI 10.1029/1999JC900273; *WORLD MET ORG, 1991, 25 WORLD MET ORG; *WORLD MET ORG, 1998, 25 WORLD MET ORG	12	35	37	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					289	291		10.1038/427289a	http://dx.doi.org/10.1038/427289a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737143				2022-12-28	WOS:000188266200017
J	Rowan, K; Harrison, D; Brady, A; Black, N				Rowan, K; Harrison, D; Brady, A; Black, N			Hospitals' star ratings and clinical outcomes: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Intens Care Natl Audit & Res Ctr, London WC1H 9HR, England	University of London; London School of Hygiene & Tropical Medicine; Intensive Care National Audit & Research Centre	Black, N (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	nick.black@lshtm.ac.uk	Harrison, David A/O-4355-2018	Harrison, David A/0000-0002-9002-9098; Brady, Tony/0000-0003-4751-7616				[Anonymous], NHS PERF RAT AC TRUS; Black N, 2003, QUAL SAF HEALTH CARE, V12, P348, DOI 10.1136/qhc.12.5.348; GILL K, 2003, ANN R COLL SURG EN S, V85, pS244; ROWAN K, 2000, HLTH CARE UK     SPR, P42; ROWAN KM, 1993, THESIS U OXFORD OXFO	5	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2004	328	7445					924	925		10.1136/bmj.38007.694745.F7	http://dx.doi.org/10.1136/bmj.38007.694745.F7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	14742352	Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000220994400017
J	Plowe, CV; Kublin, PG; Dzinjalamala, FK; Kamwendo, DS; Mukadam, RAG; Chimpeni, P; Molyneux, ME; Taylor, TE				Plowe, CV; Kublin, PG; Dzinjalamala, FK; Kamwendo, DS; Mukadam, RAG; Chimpeni, P; Molyneux, ME; Taylor, TE			Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study	BRITISH MEDICAL JOURNAL			English	Article							PLASMODIUM-FALCIPARUM; DIHYDROFOLATE-REDUCTASE; DIHYDROPTEROATE SYNTHASE; DRUG-RESISTANCE; AFRICA; CHLOROQUINE; MUTATIONS; THERAPY; FAILURE; POLICY	Objective To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993. Design Prospective open label drug efficacy study. Setting Health centre in large peri-urban township adjacent to Blantyre, Malawi. Participants People presenting to a health centre with uncomplicated Plasmodium falciparum malaria. Main outcome measures Therapeutic efficacy and parasitological resistance to standard sulfadoxine-pyrimediamine treatment at 14 days and 28 days of follow up. Results Therapeutic efficacy remained stable, with adequate clinical response rates of 80% or higher throughout the five years of the study. Analysis of follow up to 28 days showed modest but significant trends towards diminishing clinical and parasitological efficacy over time within the study period. Conclusion Contrary to expectations, sulfadoxine-pyrimethamine has retained good efficacy after 10 years as the first line antimalarial drug in Malawi. African countries with very low chloroquine efficacy, high sulfadoxine-pyrimethamine efficacy, and no other immediately available alternatives may benefit from interim use of sulfadoxine-pyrimethamine while awaiting implementation of combination antimalarial treatments.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21044 USA; Univ Malawi, Coll Med, Blantyre Malaria Project, Blantyre, Malawi; Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; Michigan State Univ, Coll Osteopath Med, Lansing, MI USA	University System of Maryland; University of Maryland Baltimore; University of Malawi; University of Malawi; Michigan State University; Michigan State University College of Osteopathic Medicine	Plowe, CV (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, 685 W Baltimore St,HSFI-480, Baltimore, MD 21044 USA.	cplowe@medicine.umaryland.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040539, R01AI044824] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI-40539, R01-AI-44824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bloland PB, 2000, B WORLD HEALTH ORGAN, V78, P1378; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Bloland PB, 2003, AM J TROP MED HYG, V68, P125, DOI 10.4269/ajtmh.2003.68.125; Bredenkamp BLF, 2001, SAMJ S AFR MED J, V91, P970; Cortese JF, 1998, MOL BIOCHEM PARASIT, V94, P205, DOI 10.1016/S0166-6851(98)00075-9; Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; Plowe CV, 2001, AM J TROP MED HYG, V64, P242, DOI 10.4269/ajtmh.2001.64.242; Plowe CV, 1998, DRUG RESIST UPDATE, V1, P389, DOI 10.1016/S1368-7646(98)80014-9; Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0; Sirawaraporn W, 1997, P NATL ACAD SCI USA, V94, P1124, DOI 10.1073/pnas.94.4.1124; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; *WHO DIV CONTR TRO, 1996, ASS THER EFF ANT DRU; World Health Organization (WHO), 1973, WHO TECHN REP SER, V529	16	70	70	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2004	328	7439					545	+		10.1136/bmj.37977.653750.EE	http://dx.doi.org/10.1136/bmj.37977.653750.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	14757706	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000220091800016
J	King, M; Smith, G; Bartlett, A				King, M; Smith, G; Bartlett, A			Treatments of homosexuality in Britain since the 1950s - an oral history: the experience of professionals	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To investigate the experiences of professionals who administered and evaluated treatments for homosexuality in Britain since the 1950s. Design A nationwide study based on qualitative interviews. Participants 30 health professionals who developed and practised treatments for homosexuality Results A range of treatments were developed to make homosexuals into heterosexuals, the most common of which were behavioural interventions. Treatments were based on little evidence of effectiveness and were open to the criticism that legal or social pressures coerced patients. Treatments did not become mainstream within British mental health services. With hindsight, professionals realised that they had not appreciated the influence of social context on sexual behaviour. Most now regarded same sex attraction as compatible with psychological health, although a small minority considered that the option to try to become heterosexual should still be available to patients who desire it. Conclusions Social and political assumptions sometimes lie at the heart of what we regard as mental pathology and serve as a warning for future practice.	UCL Royal Free & Univ Coll Sch Med, Dept Mental Hlth Sci, London NW3 2PF, England; St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England	University of London; University College London; St Georges University London	King, M (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Mental Hlth Sci, Royal Free Campus, London NW3 2PF, England.	m.king@rfc.ucl.ac.uk	bartlett, annie/I-6651-2013; King, Michael B/D-7477-2011	bartlett, annie/0000-0002-5498-7141; King, Michael B/0000-0003-4715-7171				King M, 1999, BRIT J PSYCHIAT, V175, P106, DOI 10.1192/bjp.175.2.106; Smith G, 2004, BMJ-BRIT MED J, V328, P427, DOI 10.1136/bmj.37984.442419.EE; Weeks J., 1990, COMING OUT HOMOSEXUA; Wolpe J., 1958, PSYCHOTHERAPY RECIPR	4	33	33	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					429	432		10.1136/bmj.37984.496725.EE	http://dx.doi.org/10.1136/bmj.37984.496725.EE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14751921	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000189161000015
J	Thomas, SL; Wheeler, JG; Hall, AJ				Thomas, SL; Wheeler, JG; Hall, AJ			Case-control study of the effect of mechanical trauma on the risk of herpes zoster	BRITISH MEDICAL JOURNAL			English	Article							VARICELLA-ZOSTER; VIRUS		Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England	University of London; London School of Hygiene & Tropical Medicine; University of Cambridge	Thomas, SL (corresponding author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.	sara.thomas@lshtm.ac.uk						ARVIN AM, 1992, J INFECT DIS, V166, pS35, DOI 10.1093/infdis/166.Supplement_1.S35; BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291; Juel-Jensen B E, 1970, J R Coll Gen Pract, V20, P323; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; Thomas SL, 2002, LANCET, V360, P678, DOI 10.1016/S0140-6736(02)09837-9	5	52	55	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					439	440		10.1136/bmj.37991.511829.F7	http://dx.doi.org/10.1136/bmj.37991.511829.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14742350	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000189161000020
J	Campbell, DE; Lynn, J; Louis, TA; Shugarman, LR				Campbell, DE; Lynn, J; Louis, TA; Shugarman, LR			Medicare program expenditures associated with hospice use	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL COMORBIDITY INDEX; COST SAVINGS; LAST YEAR; PROPENSITY SCORES; CARE; LIFE; END; PATTERNS; SERVICES; FAILURE	Background: Hospice providers contend that enrollment reduces the cost of the Medicare programs, but estimates of effects are dated, methodologically limited, and focused on persons with cancer. Objective: To estimate the effects of hospice care on Medicare program payments during the last year of life from 1996 to 1999 within cohorts defined by age and diagnosis. Design: Retrospective cohort. Setting: Deceased Medicare enrollees. Participants: Elderly Medicare fee-for-service beneficiaries who received 36 months of continuous Part A and B coverage before death during 1996 to 1999 (n = 245 326). Age- and condition-specific (cancer or noncancer and principal condition) cohorts were defined. Measurements: Medicare expenditures in the last year of life, as a total figure and by service type. The cost effects of hospice were estimated by using linear regression within the cohorts for hospice enrollees compared with nonenrollees after adjustment for propensity to use hospice, gender, race, enrollment in Medicaid, urban setting, duration of illness, comorbid conditions, low use of Medicare, nursing home residence, and year of death. Results: Adjusted mean expenditures were 4.0% higher overall among hospice enrollees than among nonenrollees. Adjusted mean expenditures were 1% lower for hospice enrollees with cancer than for patients with cancer who did not use hospice. Savings were highest (7% to 17%) among enrollees with lung cancer and other very aggressive types of cancer diagnosed in the last year of life. Expenditures for hospice enrollees without cancer were 11% higher than for nonenrollees, ranging from 20% to 44% for patients with dementia and 0% to 16% for those with chronic heart failure or failure of most other organ systems. Hospice-related savings decreased and relative costs increased with age. Conclusion: Hospice enrollment correlates with reduced Medicare expenditures among younger decedents with cancer but increased expenditures among decedents without cancer and those older than 84 years of age. Future studies should assess the effects of hospice on quality and on expenditures from all payment sources.	Washington Home Ctr Palliat Care Studies, Washington, DC 20016 USA; Med Outcomes Res & Evaluat Serv, Thetford, VT USA; RAND Corp, Santa Monica, CA 90407 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	RAND Corporation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lynn, J (corresponding author), Washington Home Ctr Palliat Care Studies, 4200 Wisconsin Ave,4th Floor, Washington, DC 20016 USA.	jlynn@rand.org						[Anonymous], 1999, DEATH FORETOLD PROPH; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Banaszak-Holl J, 1996, Hosp J, V11, P1, DOI 10.1300/J011v11n03_01; BRANCH LG, 1995, GERONTOLOGIST, V35, P349, DOI 10.1093/geront/35.3.349; BROOKS CH, 1984, MED CARE, V22, P691, DOI 10.1097/00005650-198408000-00002; Byock I, 2000, CA-CANCER J CLIN, V50, P123, DOI 10.3322/canjclin.50.2.123; Christakis N A, 1998, Hosp J, V13, P71; *COMM STAT PARTN I, 2001, HOSP CAR 1, P11; Connor S R, 1996, HMO Pract, V10, P20; Covinsky KE, 2003, J AM GERIATR SOC, V51, P492, DOI 10.1046/j.1532-5415.2003.51157.x; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Field MJ, 1997, APPROACHING DEATH IM; FOLEY DM, 2001, IMPROVING PALLIATIVE; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; GAGE B, 2000, SYNTHESIS ANAL MEDIC; GAGE B, 2003, MEDICARES HOSPICE BE; *GEN ACC OFF, 2000, GAOHEHS00182; Ghelfi Linda M., 1997, RURAL DEV PERSPECTIV, V12, P32; HARRINGTON C, 1993, GERONTOLOGIST, V33, P790, DOI 10.1093/geront/33.6.790; HOGAN C, 2000, MEDPAC PUBLICATION; HOYERT DL, 1999, DEATHS FINAL DATA 19, V47; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; KANE RL, 1984, LANCET, V1, P890; KANE RL, 2001, HDB AGING SOCIAL SCI; KIDDER D, 1992, HEALTH SERV RES, V27, P195; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; Levinsky NG, 1999, J AM GERIATR SOC, V47, P553, DOI 10.1111/j.1532-5415.1999.tb02569.x; Levinsky NG, 2001, JAMA-J AM MED ASSOC, V286, P1349, DOI 10.1001/jama.286.11.1349; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 1996, Duquesne Law Rev, V35, P311; Lynn J, 2000, J AM GERIATR SOC, V48, pS91, DOI 10.1111/j.1532-5415.2000.tb03147.x; Lynn J, 1998, Hosp J, V13, P151; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; *MED PAYM ADV COMM, 2002, REP C ASS MED BEN; Medicare Payment Advisory Commission, 2002, REP C MED BEN ACC HO; MILLER GW, 2002, DELIVERING QUALITY C; MILLER SC, 2000, SYNTHESIS ANAL MEDIC; MOON M, 2003, MEDICARE END LIFE CA; MOR V, 1985, HEALTH SERV RES, V20, P407; *NAT HOSP ORG, 1995, AN COST SAV MED HOS; *NAT HOSP PALL CAR, 2001, HOSP HOSP PARTN PALL; *NAT PACE ASS, 2000, PACE PROF PROGR ALL; REIS LA, 2000, SEER STAT REV 1973 1; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Somogyi-Zalud E, 2000, J AM GERIATR SOC, V48, pS140, DOI 10.1111/j.1532-5415.2000.tb03123.x; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; WHITE AJ, 2000, EVALUATION PROGRAM A	60	102	104	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					269	277		10.7326/0003-4819-140-4-200402170-00009	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970150				2022-12-28	WOS:000188970400005
J	Costescu, RM; Cahill, DG; Fabreguette, FH; Sechrist, ZA; George, SM				Costescu, RM; Cahill, DG; Fabreguette, FH; Sechrist, ZA; George, SM			Ultra-low thermal conductivity in W/Al2O3 nanolaminates	SCIENCE			English	Article							YTTRIA-STABILIZED ZIRCONIA; SURFACE-CHEMISTRY; DEPOSITION; FILMS; RESISTANCE; TRANSPORT; DENSE	Atomic layer deposition and magnetron sputter deposition were used to synthesize thin-film multilayers of W/Al2O3. With individual layers only a few nanometers thick, the high interface density produced a strong impediment to heat transfer, giving rise to a thermal conductivity of similar to0.6 watts per meter per kelvin. This result suggests that high densities of interfaces between dissimilar materials may provide a route for the production of thermal barriers with ultra-low thermal conductivity.	Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA; Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Colorado System; University of Colorado Boulder	Cahill, DG (corresponding author), Univ Illinois, Dept Mat Sci & Engn, 1304 W Green St, Urbana, IL 61801 USA.	d-cahill@uiuc.edu	George, Steven M/O-2163-2013; Costescu, Ruxandra/AAC-4526-2022; Cahill, David G./B-3495-2014	George, Steven M/0000-0003-0253-9184; Costescu, Ruxandra/0000-0002-4703-7818; 				Cahill DG, 2003, J APPL PHYS, V93, P793, DOI 10.1063/1.1524305; Cahill DG, 2002, J HEAT TRANS-T ASME, V124, P223, DOI 10.1115/1.1454111; Costescu RM, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.054302; DILLON AC, 1995, SURF SCI, V322, P230, DOI 10.1016/0039-6028(95)90033-0; Feldman A, 1999, HIGH TEMP-HIGH PRESS, V31, P293, DOI 10.1068/htrt171; Goodson KE, 1996, J HEAT TRANS-T ASME, V118, P279, DOI 10.1115/1.2825842; HASSELMAN DPH, 1987, AM CERAM SOC BULL, V66, P799; Huxtable ST, 2002, APPL PHYS LETT, V80, P1737, DOI 10.1063/1.1455693; Klaus JW, 2000, THIN SOLID FILMS, V360, P145, DOI 10.1016/S0040-6090(99)01076-7; LEE SM, 1995, PHYS REV B, V52, P253, DOI 10.1103/PhysRevB.52.253; Nan CW, 1997, J APPL PHYS, V81, P6692, DOI 10.1063/1.365209; PADDOCK CA, 1986, J APPL PHYS, V60, P285, DOI 10.1063/1.337642; Padture NP, 2002, SCIENCE, V296, P280, DOI 10.1126/science.1068609; Schlichting KW, 2001, J MATER SCI, V36, P3003, DOI 10.1023/A:1017970924312; Soyez G, 2000, APPL PHYS LETT, V77, P1155, DOI 10.1063/1.1289803; STONER RJ, 1993, PHYS REV B, V48, P16373, DOI 10.1103/PhysRevB.48.16373; SWARTZ ET, 1989, REV MOD PHYS, V61, P605, DOI 10.1103/RevModPhys.61.605; Young D. A., 1986, Phonon Scattering in Condensed Matter V. Proceedings of the Fifth International Conference, P49	18	307	331	5	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					989	990		10.1126/science.1093711	http://dx.doi.org/10.1126/science.1093711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963323				2022-12-28	WOS:000188918000038
J	Lipson, SJ				Lipson, SJ			Spinal-fusion surgery - Advances and concerns	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02115 USA; Harvard Vanguard Med Associates, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard Vanguard Medical Associates	Lipson, SJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02115 USA.								0	52	53	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					643	644		10.1056/NEJMp038162	http://dx.doi.org/10.1056/NEJMp038162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960739				2022-12-28	WOS:000188869500003
J	Pascual, A; Huang, KL; Neveu, J; Preat, T				Pascual, A; Huang, KL; Neveu, J; Preat, T			Brain asymmetry and long-term memory	NATURE			English	Editorial Material							DROSOPHILA		CNRS, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Pascual, A (corresponding author), Hosp Univ Virgen del Rocio, Lab Invest Biomed, Seville 41013, Spain.	preat@iaf.cnrs-gif.fr	Pascual, Alberto P/E-9609-2015; IBIS, NEURONAL/O-9910-2015; Pascual, Alberto/L-2014-2019	Pascual, Alberto P/0000-0001-5459-6207; Pascual, Alberto/0000-0001-5459-6207; Preat, Thomas/0000-0001-9976-1763				Bradshaw JL., 1993, EVOLUTION LATERAL AS; Concha ML, 2001, J ANAT, V199, P63, DOI 10.1046/j.1469-7580.2001.19910063.x; GALABURDA AM, 1991, CIBA F SYMP, V162, P219; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; Heisenberg M., 1994, FORTSCH ZOOL, V39, P30; Hobert O, 2002, NAT REV NEUROSCI, V3, P629, DOI 10.1038/nrn897; NASSEL DR, 1982, CELL TISSUE RES, V226, P355; Pascual A, 2001, SCIENCE, V294, P1115, DOI 10.1126/science.1064200; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033	10	133	138	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					605	606		10.1038/427605a	http://dx.doi.org/10.1038/427605a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961111				2022-12-28	WOS:000188875300031
J	Robertson, RP				Robertson, RP			Medical progress: Islet transplantation as a treatment for diabetes - A work in progress	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							UPPER ABDOMINAL EXENTERATION; INDUCED INSULIN-SECRETION; LONG-TERM SURVIVAL; QUALITY-OF-LIFE; PANCREATIC-ISLETS; IMMUNOSUPPRESSIVE DRUGS; METABOLIC FUNCTION; INDUCED INHIBITION; GLUCOSE-TOLERANCE; PORCINE ISLETS		Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	rpr@pnri.org	Roberston, R Paul/AAX-5613-2021		PHS HHS [R01 39994] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alejandro R, 1997, DIABETES, V46, P1983, DOI 10.2337/diabetes.46.12.1983; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Ault A, 2003, LANCET, V361, P2054; BALLINGER WF, 1972, SURGERY, V72, P175; BARROU B, 1995, TRANSPL P, V27, P303; BILLAUDEL B, 1982, J ENDOCRINOL, V95, P315, DOI 10.1677/joe.0.0950315; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Bosi E, 2001, DIABETES, V50, P2464, DOI 10.2337/diabetes.50.11.2464; BRENDEL MD, 1994, CELL TRANSPLANT, V3, P427, DOI 10.1177/096368979400300510; Brunicardi FC, 1996, DIABETES, V45, P385, DOI 10.2337/diab.45.4.385; Carlsson PO, 2002, J CLIN ENDOCR METAB, V87, P5418, DOI 10.1210/jc.2002-020728; CARROLL PB, 1995, TRANSPLANTATION, V59, P875, DOI 10.1097/00007890-199503270-00013; CHANDRASEKAR B, 1988, BIOCHEM PHARMACOL, V37, P3609, DOI 10.1016/0006-2952(88)90391-7; Contreras JL, 2000, TRANSPLANTATION, V69, P195, DOI 10.1097/00007890-200001270-00001; DAGOGOJACK S, 1994, DIABETES, V43, P1426, DOI 10.2337/diabetes.43.12.1426; Davani B, 2000, J BIOL CHEM, V275, P34841, DOI 10.1074/jbc.C000600200; DAVIS M, 1994, AM J MED, V97, P535, DOI 10.1016/0002-9343(94)90349-2; de la Tour DD, 2001, MOL ENDOCRINOL, V15, P476; DRAZNIN B, 1988, BIOCHEM PHARMACOL, V37, P3941, DOI 10.1016/0006-2952(88)90077-9; FABIAN MC, 1993, TRANSPLANTATION, V56, P1137, DOI 10.1097/00007890-199311000-00017; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; Fioretto P, 1998, NEW ENGL J MED, V339, P69, DOI 10.1056/NEJM199807093390202; Fiorina P, 2003, DIABETES CARE, V26, P1129, DOI 10.2337/diacare.26.4.1129; Fiorina P, 2001, DIABETES, V50, P496, DOI 10.2337/diabetes.50.3.496; Gaber AO, 2001, TRANSPLANTATION, V72, P1730, DOI 10.1097/00007890-200112150-00005; GILLISON SL, 1989, DIABETES, V38, P465, DOI 10.2337/diabetes.38.4.465; GILLISON SL, 1991, TRANSPLANTATION, V52, P890, DOI 10.1097/00007890-199111000-00026; GOLD G, 1988, DIABETES, V37, P160, DOI 10.2337/diabetes.37.2.160; GORES PF, 1993, AM J SURG, V166, P538, DOI 10.1016/S0002-9610(05)81149-3; GORES PF, 1993, LANCET, V341, P19, DOI 10.1016/0140-6736(93)92484-B; GROSS CR, 1993, TRANSPL P, V25, P1293; Gruessner Angelika C, 2002, Clin Transpl, P41; Gupta V, 1997, DIABETES, V46, P28, DOI 10.2337/diabetes.46.1.28; Hering BJ, 2002, TRANSPLANTATION, V74, P1813, DOI 10.1097/01.TP.0000038292.24519.C3; Hirshberg B, 2003, DIABETES CARE, V26, P3288, DOI 10.2337/diacare.26.12.3288; Hirshberg B, 2002, J CLIN ENDOCR METAB, V87, P5424, DOI 10.1210/jc.2002-020684; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; ISHIZUKA J, 1993, TRANSPLANTATION, V56, P1486, DOI 10.1097/00007890-199312000-00039; Jaeger C, 1997, DIABETES, V46, P1907, DOI 10.2337/diabetes.46.11.1907; Jukema JW, 2002, DIABETES CARE, V25, P906, DOI 10.2337/diacare.25.5.906; Kairaitis LK, 1999, MED J AUSTRALIA, V170, P368, DOI 10.5694/j.1326-5377.1999.tb139168.x; Kendall DM, 1997, DIABETES, V46, P23, DOI 10.2337/diabetes.46.1.23; KENDALL DM, 1990, NEW ENGL J MED, V322, P898, DOI 10.1056/NEJM199003293221305; Kenyon NS, 1999, DIABETES, V48, P1473, DOI 10.2337/diabetes.48.7.1473; Kenyon NS, 1999, P NATL ACAD SCI USA, V96, P8132, DOI 10.1073/pnas.96.14.8132; Keymeulen B, 1998, DIABETOLOGIA, V41, P452, DOI 10.1007/s001250050929; Kin T, 2003, AM J TRANSPLANT, V3, P281, DOI 10.1034/j.1600-6143.2003.00049.x; KURODA Y, 1988, TRANSPLANTATION, V46, P457; Lakey JRT, 2002, TRANSPLANTATION, V74, P1809, DOI 10.1097/01.TP.0000038314.77538.55; LANZA RP, 1991, P NATL ACAD SCI USA, V88, P11100, DOI 10.1073/pnas.88.24.11100; LARGIADER F, 1980, TRANSPLANTATION, V29, P76, DOI 10.1097/00007890-198001000-00017; Larsen JL, 2002, TRANSPLANTATION, V73, P936, DOI 10.1097/00007890-200203270-00019; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Lumelsky N, 2001, SCIENCE, V293, P428; Luzi L, 1996, J CLIN INVEST, V97, P2611, DOI 10.1172/JCI118710; Luzi L, 2001, DIABETES, V50, P277, DOI 10.2337/diabetes.50.2.277; Markmann JF, 2003, ANN SURG, V237, P741, DOI 10.1097/00000658-200306000-00001; Markmann JF, 2003, TRANSPLANTATION, V75, P1423, DOI 10.1097/01.TP.0000061119.32575.F4; Matsumoto S, 2002, TRANSPLANTATION, V74, P1414, DOI 10.1097/00007890-200211270-00013; Meredith M, 1997, BIOCHEM PHARMACOL, V53, P1873, DOI 10.1016/S0006-2952(97)00057-9; MILDE FK, 1992, DIABETES CARE, V15, P1459, DOI 10.2337/diacare.15.11.1459; Morrison H., 1937, B HIST MED, V5, P259; NAJARIAN JS, 1980, ANN SURG, V192, P526, DOI 10.1097/00000658-198010000-00011; Navarro X, 1997, ANN NEUROL, V42, P727, DOI 10.1002/ana.410420509; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; NIELSEN JH, 1986, DIABETES, V35, P1049, DOI 10.2337/diabetes.35.9.1049; Oberholzer J, 2000, TRANSPLANTATION, V69, P1115, DOI 10.1097/00007890-200003270-00016; Oetjen E, 2003, MOL PHARMACOL, V63, P1289, DOI 10.1124/mol.63.6.1289; Oetjen E, 2003, N-S ARCH PHARMACOL, V367, P227, DOI 10.1007/s00210-003-0694-7; Paty BW, 2002, DIABETES, V51, P3428, DOI 10.2337/diabetes.51.12.3428; Paty BW, 2002, TRANSPLANTATION, V73, P353, DOI 10.1097/00007890-200202150-00007; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; PIEHLMEIER W, 1991, Diabetologia, V34, pS150, DOI 10.1007/BF00587644; PYZDROWSKI KL, 1992, NEW ENGL J MED, V327, P220, DOI 10.1056/NEJM199207233270402; Rajagopal J, 2003, SCIENCE, V299, P363; Redmon JB, 1996, J CLIN INVEST, V98, P2786, DOI 10.1172/JCI119105; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RICORDI C, 1991, TRANSPLANTATION, V52, P519, DOI 10.1097/00007890-199109000-00026; ROBERTSON RP, 1992, NEW ENGL J MED, V327, P1861; ROBERTSON RP, 1987, TRANSPLANT P, V19, P2354; Robertson RP, 2002, TRANSPLANTATION, V73, P736; Robertson RP, 2001, DIABETES, V50, P47, DOI 10.2337/diabetes.50.1.47; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; ROBERTSON RP, 2003, CURR OPIN ENDOCRINOL, V10, P128; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; SAMOLS E, 1988, J CLIN INVEST, V82, P350, DOI 10.1172/JCI113593; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SCHARP DW, 1991, TRANSPLANTATION, V51, P76, DOI 10.1097/00007890-199101000-00012; Secchi A, 1997, DIABETOLOGIA, V40, P225, DOI 10.1007/s001250050667; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shapiro James, 2002, CMAJ, V167, P1398; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; Soria B, 2001, DIABETOLOGIA, V44, P407, DOI 10.1007/s001250051636; STRASSER S, 1992, METABOLISM, V41, P64, DOI 10.1016/0026-0495(92)90192-D; Sun YL, 1996, J CLIN INVEST, V98, P1417, DOI 10.1172/JCI118929; SUTHERLAND D E R, 1980, Diabetes, V29, P31; Sutherland DER, 2001, ANN SURG, V233, P463, DOI 10.1097/00000658-200104000-00003; Thomas JM, 2001, DIABETES, V50, P1227, DOI 10.2337/diabetes.50.6.1227; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; WAHOFF DC, 1995, ANN SURG, V222, P562; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89, DOI 10.1007/BF00400857; WARNOCK GL, 1991, DIABETOLOGIA, V34, P55, DOI 10.1007/BF00404026; Williams PW., 1894, BMJ-BRIT MED J, Vi, P1303; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	105	320	335	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					694	705		10.1056/NEJMra032425	http://dx.doi.org/10.1056/NEJMra032425			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960745				2022-12-28	WOS:000188869500010
J	Bingley, PJ; Williams, AJK; Norcross, AJ; Unsworth, DJ; Lock, RJ; Ness, AR; Jones, RW				Bingley, PJ; Williams, AJK; Norcross, AJ; Unsworth, DJ; Lock, RJ; Ness, AR; Jones, RW		Avon Longitudinal Study Parents Ch	Undiagnosed coeliac disease at age seven: population based prospective birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN		Univ Bristol, Southmead Hosp, Div Med, Bristol BS10 5NB, Avon, England; Southmead Gen Hosp, N Bristol NHS Trust, Dept Immunol, Bristol BS10 5NB, Avon, England; Univ Bristol, Div Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England	Southmead Hospital; University of Bristol; North Bristol NHS Trust; Southmead Hospital; University of Bristol	Bingley, PJ (corresponding author), Univ Bristol, Southmead Hosp, Div Med, Bristol BS10 5NB, Avon, England.	polly.bingley@bristol.ac.uk	Williams, Alistair/E-7647-2013; Ness, Andy R/M-7612-2013	Ness, Andy R/0000-0003-3548-9523; Williams, Alistair/0000-0002-3615-3899				Bazzigaluppi E, 1999, J AUTOIMMUN, V12, P51, DOI 10.1006/jaut.1998.0253; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Hawkes ND, 2000, EUR J GASTROEN HEPAT, V12, P345, DOI 10.1097/00042737-200012030-00013; Maki M, 2003, NEW ENGL J MED, V348, P2517, DOI 10.1056/NEJMoa021687; West J, 2003, GUT, V52, P960, DOI 10.1136/gut.52.7.960	5	189	195	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2004	328	7435					322	323		10.1136/bmj.328.7435.322	http://dx.doi.org/10.1136/bmj.328.7435.322			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764493	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000188926900020
J	Goldstein, LB				Goldstein, LB			Neuroprotective therapy for acute ischaemic stroke: down, but not out	LANCET			English	Editorial Material							INTRAVENOUS MAGNESIUM-SULFATE; DOUBLE-BLIND; TRIAL; RECOMMENDATIONS		Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Durham, NC 27710 USA	Duke University	Goldstein, LB (corresponding author), Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Durham, NC 27710 USA.	golds004@mc.duke.edu						Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Baird AE, 1997, ANN NEUROL, V41, P581, DOI 10.1002/ana.410410506; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Ginsberg MD, 1997, CEREBROVASC DIS, V7, P7, DOI 10.1159/000108237; Goldstein LB, 2000, DRUG SAFETY, V22, P13, DOI 10.2165/00002018-200022010-00002; Goldstein LB, 1999, STROKE, V30, P1165, DOI 10.1161/01.STR.30.6.1165; Lampl Y, 2001, CLIN NEUROPHARMACOL, V24, P11, DOI 10.1097/00002826-200101000-00003; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Muir KW, 1998, STROKE, V29, P918, DOI 10.1161/01.STR.29.5.918; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; MUIR KW, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001244; Muir KW, 2000, J STROKE CEREBROVASC, V9, P257; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136	18	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					414	415		10.1016/S0140-6736(04)15522-0	http://dx.doi.org/10.1016/S0140-6736(04)15522-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962518				2022-12-28	WOS:000188999500005
J	Hsu, KF; Loo, S; Guo, F; Chen, W; Dyck, JS; Uher, C; Hogan, T; Polychroniadis, EK; Kanatzidis, MG				Hsu, KF; Loo, S; Guo, F; Chen, W; Dyck, JS; Uher, C; Hogan, T; Polychroniadis, EK; Kanatzidis, MG			Cubic AgPbmSbTe2+m: Bulk thermoelectric materials with high figure of merit	SCIENCE			English	Article							SUPERLATTICE STRUCTURES; THERMAL-CONDUCTIVITY; CLATHRATE	The conversion of heat to electricity by thermoelectric devices may play a key role in the future for energy production and utilization. However, in order to meet that role, more efficient thermoelectric materials are needed that are suitable for high-temperature applications. We show that the material system AgPbm SbTe2+m may be suitable for this purpose. With m=10 and 18 and doped appropriately, n-type semiconductors can be produced that exhibit a high thermoelectric figure of merit material ZT(max) of similar to2.2 at 800 kelvin. In the temperature range 600 to 900 kelvin, the AgPbm SbTe2+m material is expected to outperform all reported bulk thermoelectrics, thereby earmarking it as a material system for potential use in efficient thermoelectric power generation from heat sources.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; Aristotle Univ Thessaloniki, Dept Phys, Thessaloniki 54124, Greece	Michigan State University; University of Michigan System; University of Michigan; Aristotle University of Thessaloniki	Kanatzidis, MG (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.	kanatzid@cem.msu.edu	Guo, Fu/F-1627-2010; Uher, Ctirad/M-9966-2014					Beyer H, 2002, APPL PHYS LETT, V80, P1216, DOI 10.1063/1.1448388; BILC D, UNPUB; Chung DY, 2000, SCIENCE, V287, P1024, DOI 10.1126/science.287.5455.1024; Chung DY, 1997, CHEM MATER, V9, P3060, DOI 10.1021/cm970397e; GENZEL L, 1953, Z PHYS, V135, P177, DOI 10.1007/BF01333342; Harman TC, 1996, J ELECTRON MATER, V25, P1121, DOI 10.1007/BF02659913; Harman TC, 2002, SCIENCE, V297, P2229, DOI 10.1126/science.1072886; Kanatzidis MG, 2001, SEMICONDUCT SEMIMET, V69, P51; Latturner S, 2000, J SOLID STATE CHEM, V151, P61, DOI 10.1006/jssc.2000.8622; LOO S, UNPUB; Nolas GS, 2001, SEMICONDUCT SEMIMET, V69, P255; Poon SJ, 2001, SEMICONDUCT SEMIMET, V70, P37; Ravich Y. I., 1970, SEMICONDUCTING LEAD, P323; Sales BC, 1999, J SOLID STATE CHEM, V146, P528, DOI 10.1006/jssc.1999.8354; Sales BC, 1996, SCIENCE, V272, P1325, DOI 10.1126/science.272.5266.1325; Terasaki I, 2001, JPN J APPL PHYS 2, V40, pL65, DOI 10.1143/JJAP.40.L65; Tritt TM, 2001, SEMICONDUCT SEMIMET, V70, P179; Uher C, 2001, SEMICONDUCT SEMIMET, V69, P139; Venkatasubramanian R, 2001, NATURE, V413, P597, DOI 10.1038/35098012; Venkatasubramanian R, 1997, J CRYST GROWTH, V170, P817, DOI 10.1016/S0022-0248(96)00656-2	20	2547	2639	20	984	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					818	821		10.1126/science.1092963	http://dx.doi.org/10.1126/science.1092963			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764873				2022-12-28	WOS:000188753800051
J	Radisky, DC; Bissell, MJ				Radisky, DC; Bissell, MJ			Respect thy neighbor!	SCIENCE			English	Editorial Material							ROUS-SARCOMA VIRUS; GROWTH-FACTOR-BETA; INHIBITOR; PROMOTES; CANCER; CELLS		Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Radisky, DC (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.	mjbissell@lbl.gov	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784				Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; Farrell RJ, 2002, LANCET, V359, P331, DOI 10.1016/S0140-6736(02)07499-8; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wirtzfeld DA, 2001, ANN SURG ONCOL, V8, P319, DOI 10.1245/aso.2001.8.4.319	17	91	95	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					775	777		10.1126/science.1094412	http://dx.doi.org/10.1126/science.1094412			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764858				2022-12-28	WOS:000188753800036
J	Funato, Y; Makino, J; Hut, P; Kokubo, E; Kinoshita, D				Funato, Y; Makino, J; Hut, P; Kokubo, E; Kinoshita, D			The formation of Kuiper-belt binaries through exchange reactions	NATURE			English	Article							SINGLE-STAR SCATTERING; CROSS-SECTIONS; PLANETESIMALS; EVOLUTION; OBJECTS; ORIGIN	Recent observations(1-8) have revealed that an unexpectedly high fraction-a few per cent-of the trans-Neptunian objects (TNOs) that inhabit the Kuiper belt are binaries. The components have roughly equal masses, with very eccentric orbits that are wider than a hundred times the radius of the primary. Standard theories of binary asteroid formation tend to produce close binaries with circular orbits, so two models have been proposed(9,10) to explain the unique characteristics of the TNOs. Both models, however, require extreme assumptions regarding the size distribution of the TNOs. Here we report a mechanism that is capable of producing binary TNOs with the observed properties during the early stages of their formation and growth. The only required assumption is that the TNOs were initially formed through gravitational instabilities(11) in the protoplanetary dust disk. The basis of the mechanism is an exchange reaction in which a binary whose primary component is much more massive than the secondary interacts with a third body, whose mass is comparable to that of the primary. The low-mass secondary component is ejected and replaced by the third body in a wide but eccentric orbit.	Univ Tokyo, Meguro Ku, Tokyo 153, Japan; Univ Tokyo, Dept Astron, Bunkyo Ku, Tokyo 113, Japan; Inst Adv Study, Princeton, NJ 08540 USA; Natl Astron Observ, Mitaka, Tokyo 180, Japan; Natl Cent Univ, Chungli 32054, Taiwan	University of Tokyo; University of Tokyo; Institute for Advanced Study - USA; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); National Central University	Funato, Y (corresponding author), Univ Tokyo, Meguro Ku, Tokyo 153, Japan.	funato@chianti.c.u-tokyo.ac.jp	Makino, Junichiro/K-5260-2019; Makino, Junichiro/A-9525-2014	Makino, Junichiro/0000-0002-0411-4297				Burns JA, 2002, SCIENCE, V297, P942, DOI 10.1126/science.1072078; DURDA DD, 2001, B AM ASTRON SOC, V33, P1134; DURDA DD, 2003, LUNAR PLANET SCI, V34; FABIAN AC, 1975, MNRAS, V172, P15; GOLDREIC.P, 1973, ASTROPHYS J, V183, P1051, DOI 10.1086/152291; HEGGIE DC, 1975, MON NOT R ASTRON SOC, V173, P729, DOI 10.1093/mnras/173.3.729; HEGGIE DC, 2003, GRAVITATIONAL MILLIO, pCH23; HUT P, 1984, ASTROPHYS J SUPPL S, V55, P301, DOI 10.1086/190957; HUT P, 1985, ASTROPHYS J, V298, P502, DOI 10.1086/163636; KENYON SJ, 1998, ASTRON J, V115, P2125; Kokubo E, 2000, ICARUS, V148, P419, DOI 10.1006/icar.2000.6496; Makino J, 1998, NEW ASTRON, V3, P411, DOI 10.1016/S1384-1076(98)00021-9; Margot JL, 2002, NATURE, V416, P694, DOI 10.1038/416694a; McMillan SLW, 1996, ASTROPHYS J, V467, P348, DOI 10.1086/177610; MERLINE WJ, 2003, ASTEROIDS, V3, P273; NOLL K, 2003, 8143 IAU; NOLL K, 2002, 8034 IAU; Noll KS, 2002, ASTRON J, V124, P3424, DOI 10.1086/344762; NOLL KS, 2003, DPS 35 M; SCHALLER EL, 2003, DPS 35 M; Spitzer L., 1987, ANNU REV ASTRON ASTR; Veillet C, 2002, NATURE, V416, P711, DOI 10.1038/416711a; Weidenschilling SJ, 2002, ICARUS, V160, P212, DOI 10.1006/icar.2002.6952; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225	27	73	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 5	2004	427	6974					518	520		10.1038/nature02323	http://dx.doi.org/10.1038/nature02323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765188	Green Submitted			2022-12-28	WOS:000188721800034
J	Frank, E				Frank, E			Physician health and patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN PHYSICIANS; UNITED-STATES; US PHYSICIANS; PREVENTION; MORTALITY; BEHAVIORS		Emory Univ, Sch Med, Atlanta, GA 30322 USA	Emory University	Frank, E (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.			Frank, Erica/0000-0001-7159-5417				Frank E, 1998, ARCH INTERN MED, V158, P342, DOI 10.1001/archinte.158.4.342; Frank E, 2000, ARCH FAM MED, V9, P359, DOI 10.1001/archfami.9.4.359; Frank E, 2000, AM J PREV MED, V19, P155, DOI 10.1016/S0749-3797(00)00201-4; Frank E, 2000, ARCH FAM MED, V9, P287, DOI 10.1001/archfami.9.3.287; FRANK E, IN PRESS RES Q EXERC; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; WILLIAMS SV, 1971, J CHRON DIS, V24, P393, DOI 10.1016/0021-9681(71)90139-1	9	113	115	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					637	637		10.1001/jama.291.5.637	http://dx.doi.org/10.1001/jama.291.5.637			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762049				2022-12-28	WOS:000188650700035
J	Sternberg, PW				Sternberg, PW			A pattern of precision	SCIENCE			English	Editorial Material							CAENORHABDITIS-ELEGANS; C-ELEGANS; VULVAR INDUCTION; PRECURSOR CELLS; INHIBITION; FATES		CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	pws@caltech.edu		Sternberg, Paul/0000-0002-7699-0173				Ambros V, 1999, DEVELOPMENT, V126, P1947; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KOGA M, 1995, DEVELOPMENT, V121, P2655; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; Wang MQ, 1999, DEV BIOL, V212, P12, DOI 10.1006/dbio.1999.9357; Yoo AS, 2004, SCIENCE, V303, P663, DOI 10.1126/science.1091639	12	9	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	2004	303	5658					637	638		10.1126/science.1094409	http://dx.doi.org/10.1126/science.1094409			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752152				2022-12-28	WOS:000188530800030
J	Acheson, DWK; Fiore, AE				Acheson, DWK; Fiore, AE			Preventing foodborne disease - What clinicians can do	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA; Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr Infect Dis, Atlanta, GA USA	US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA	Acheson, DWK (corresponding author), US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA.		Fiore, Anthony/AAO-8956-2020						0	18	18	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					437	440		10.1056/NEJMp038213	http://dx.doi.org/10.1056/NEJMp038213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749450				2022-12-28	WOS:000188463900004
J	Dubrulle, J; Pourquie, O				Dubrulle, J; Pourquie, O			fgf8 mRNA decay establishes a gradient that couples axial elongation to patterning in the vertebrate embryo	NATURE			English	Article							SIGNALING CONTROLS; GENE; SEGMENTATION; REGIONS	Formation and patterning of the vertebrate embryo occur in a head-to-tail sequence. This progressive mode of body formation from the posterior end of the embryo requires a strict temporal coordination of tissue differentiation - a process involving fibroblast growth factor (FGF) signalling. Here we show that transcription of fgf8 messenger RNA is restricted to the growing posterior tip of the embryo. fgf8 mRNA is progressively degraded in the newly formed tissues, resulting in the formation of an mRNA gradient in the posterior part of the embryo. This fgf8 mRNA gradient is translated into a gradient of FGF8 protein, which correlates with graded phosphorylation of the kinase Akt, a downstream effector of FGF signalling. Such a mechanism provides an efficient means to monitor the timing of FGF signalling, coupling the differentiation of embryonic tissues to the posterior elongation of the embryo. In addition, this mechanism provides a novel model for morphogen gradient formation.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Pourquie, O (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	olp@stowers-institute.org	Pourquié, Olivier/CAJ-5443-2022	Pourquié, Olivier/0000-0001-5189-1227				Bertrand N, 2000, DEVELOPMENT, V127, P4837; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; CATALA M, 1995, MECH DEVELOP, V51, P51, DOI 10.1016/0925-4773(95)00350-A; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Davis Gregory K., 1999, Trends in Cell Biology, V9, pM68, DOI 10.1016/S0962-8924(99)01663-3; Diez del Corral R, 2002, DEVELOPMENT, V129, P1681; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; HYMAN RW, 1970, J MOL BIOL, V50, P421, DOI 10.1016/0022-2836(70)90202-0; Kulesa PM, 2002, SCIENCE, V298, P991, DOI 10.1126/science.1075544; Mathis L, 2001, NAT CELL BIOL, V3, P559, DOI 10.1038/35078535; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Sawada A, 2001, DEVELOPMENT, V128, P4873; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; STERN CD, 1988, DEVELOPMENT, V104, P231; Vasiliauskas D, 2001, CELL, V106, P133, DOI 10.1016/S0092-8674(01)00442-1	21	312	322	3	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					419	422		10.1038/nature02216	http://dx.doi.org/10.1038/nature02216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749824				2022-12-28	WOS:000188470500036
J	Staalsoe, T; Shulman, CE; Bulmer, JN; Kawuondo, K; Marsh, K; Hviid, L				Staalsoe, T; Shulman, CE; Bulmer, JN; Kawuondo, K; Marsh, K; Hviid, L			Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria	LANCET			English	Article							CHONDROITIN SULFATE-A; SUB-SAHARAN AFRICA; RED-CELL SURFACE; INFECTED ERYTHROCYTES; PLACENTAL INFECTION; BIRTH-WEIGHT; VAR GENE; ANTIBODIES; ADHESION; WOMEN	Background Pregnancy-associated malaria caused by Plasmodium falciparum adherence to chondroitin sulfate A in the placental intervillous space is a major cause of low birthweight and maternal anaemia in areas of endemic P falciparum transmission. Adhesion-blocking antibodies that specifically recognise parasite-encoded variant surface antigens (VSA) are associated with resistance to pregnancy-associated malaria. We looked for a possible relation between VSA-specific antibody concentrations, placental infection, and protection from low birthweight and maternal anaemia. Methods We used flow cytometry to measure VSA-specific IgG concentrations in plasma samples taken during child birth from 477 Kenyan women selected from a cohort of 910 women on the basis of HIV-1 status, gravidity, and placental histology. We measured VSA expressed by one placental P falciparum isolate and two isolates selected or not selected for chondroitin sulfate A adhesiveness in-vitro. Findings Concentrations of plasma IgG specific for VSA, expressed by chondroitin sulfate A-adhering parasites (VSA in pregnancy-associated malaria or vsa-pam), increased with gravidity and were associated with placental histological findings. Women with chronic pregnancy-associated malaria and low or absent VSA-PAM-specific IgG had lower haemoglobin values (reduced by 17 g/L; 95% CI 8.1-25.2) and delivered smaller babies (birthweight reduced by 0.26 kg; 0.10-0.55) than did corresponding women with high VSA-PAM-specific IgG. No such relation was shown for concentrations of IgG with specificity for non-pregnancy-associated malaria VSA. Interpretation VSA-PAM-specific IgG protects against low birthweight and maternal anaemia. Our data indicate an important mechanism of clinical protection against malaria and raise hope for the clinical effectiveness of a potential VSA-based vaccine against pregnancy-associated malaria.	Univ Copenhagen Hosp, Rigshosp, Ctr Med Parasitol, Dept Infect Dis, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Clin Microbiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Med Microbiol & Immunol, Copenhagen, Denmark; London Sch Hyg & Trop Med, London WC1, England; Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya; Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute; Newcastle University - UK	Hviid, L (corresponding author), Rigshosp, Dept Infect Dis M7641, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	lhcmp@rh.dk	Hviid, Lars/G-3705-2012	Hviid, Lars/0000-0002-1698-4927; Staalso, Trine/0000-0002-7259-9425; Shulman, Caroline/0000-0002-7744-2101				Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Beeson JG, 2002, TRENDS PARASITOL, V18, P145, DOI 10.1016/S1471-4922(01)02228-0; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x; Duffy PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GARNER P, 2003, COCHRANE LIB; Guyatt HL, 2001, T ROY SOC TROP MED H, V95, P569, DOI 10.1016/S0035-9203(01)90082-3; Guyatt HL, 2001, AM J TROP MED HYG, V64, P36, DOI 10.4269/ajtmh.2001.64.36; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; NGUYENDINH P, 1988, LANCET, V2, P751; O'Neil-Dunne I, 2001, INFECT IMMUN, V69, P7487, DOI 10.1128/IAI.69.12.7487-7492.2001; Ofori MF, 2003, INFECT IMMUN, V71, P1584, DOI 10.1128/IAI.71.3.1584-1586.2003; Ofori MF, 2002, INFECT IMMUN, V70, P2982, DOI 10.1128/IAI.70.6.2982-2988.2002; Okoko BJ, 2003, ACTA TROP, V87, P193, DOI 10.1016/S0001-706X(03)00097-4; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; Rowe JA, 2002, J INFECT DIS, V185, P1207, DOI 10.1086/339684; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Salanti A, 2002, MOL BIOCHEM PARASIT, V122, P111, DOI 10.1016/S0166-6851(02)00080-4; Shulman CE, 2001, TROP MED INT HEALTH, V6, P770, DOI 10.1046/j.1365-3156.2001.00786.x; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; YAMADA M, 1989, AM J TROP MED HYG, V41, P161, DOI 10.4269/ajtmh.1989.41.161	29	222	224	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					283	289		10.1016/S0140-6736(03)15386-X	http://dx.doi.org/10.1016/S0140-6736(03)15386-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751701				2022-12-28	WOS:000188361400010
J	Cech, TR				Cech, TR			Beginning to understand the end of the chromosome	CELL			English	Review							TELOMERASE-REVERSE-TRANSCRIPTASE; SACCHAROMYCES-CEREVISIAE TELOMERASE; TETRAHYMENA-TELOMERASE; CATALYTIC SUBUNIT; RNA COMPONENT; FISSION YEAST; TUMOR-CELLS; PROTEIN; SENESCENCE; LENGTH	In their 1985 Cell paper, Greider and Blackburn announced the discovery of an enzyme that extended the DNA at chromosome telomeres in the ciliate, Tetrahymena. Since then, there has been an explosion of knowledge about both the RNA and protein subunits of this unusual ribonucleoprotein enzyme in organisms ranging from the ciliates to yeast to humans. The regulation of telomerase is now understood to take place both at the level of synthesis of the enzyme and via the state of its substrate, the telomere itself. The roles of telomerase in both cellular immortality and cancer are vibrant areas of current research.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Cech, TR (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.	thomas.cech@colorado.edu						Aigner S, 2003, BIOCHEMISTRY-US, V42, P5736, DOI 10.1021/bi034121y; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 2003, MOL BIOL CELL, V14, P4794, DOI 10.1091/mbc.E03-07-0474; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; CECH TR, 1994, SCIENCE, V266, P387, DOI 10.1126/science.7939679; Chen JL, 2003, GENE DEV, V17, P2747, DOI 10.1101/gad.1140303; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chen JL, 2002, NUCLEIC ACIDS RES, V30, P592, DOI 10.1093/nar/30.2.592; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrezuelo F, 2002, MOL CELL BIOL, V22, P6046, DOI 10.1128/MCB.22.17.6046-6055.2002; Friedman KL, 2003, MOL BIOL CELL, V14, P1, DOI 10.1091/mbc.E02-06-0327; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hall S.S., 2003, MERCHANTS IMMORTALIT; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jacob NK, 2003, MOL CELL, V11, P1021, DOI 10.1016/S1097-2765(03)00131-X; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lendvay TS, 1996, GENETICS, V144, P1399; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Livengood AJ, 2002, MOL CELL BIOL, V22, P2366, DOI 10.1128/MCB.22.7.2366-2374.2002; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Ly H, 2003, GENE DEV, V17, P1078, DOI 10.1101/gad.1060803; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2002, P NATL ACAD SCI USA, V99, P6585, DOI 10.1073/pnas.102024699; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Ray A, 1999, MOL CELL BIOL, V19, P31; Reichenbach P, 2003, CURR BIOL, V13, P568, DOI 10.1016/S0960-9822(03)00173-8; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Sadaie M, 2003, GENE DEV, V17, P2271, DOI 10.1101/gad.1112103; Seto AG, 2002, GENE DEV, V16, P2800, DOI 10.1101/gad.1029302; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Stellwagen AE, 2003, GENE DEV, V17, P1; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Szutorisz H, 2003, CANCER RES, V63, P689; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Teixeira MT, 2002, EMBO REP, V3, P652, DOI 10.1093/embo-reports/kvf133; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Ulaner GA, 1998, CANCER RES, V58, P4168; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Wright WE, 1996, DEV GENET, V18, P173; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	73	347	356	2	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					273	279		10.1016/S0092-8674(04)00038-8	http://dx.doi.org/10.1016/S0092-8674(04)00038-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744437	Bronze, Green Published			2022-12-28	WOS:000188541700016
J	Pawson, T				Pawson, T			Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems	CELL			English	Review							GROWTH-FACTOR-RECEPTOR; PROTEIN-PROTEIN INTERACTIONS; PHOSPHOLIPASE-C-GAMMA; AVIAN-SARCOMA VIRUS; ALDRICH-SYNDROME PROTEIN; ABL TYROSINE KINASE; PDGF BETA-RECEPTOR; POLO-BOX DOMAIN; SRC SH2 DOMAIN; HIGH-AFFINITY	Over the last two decades, a new and unifying concept of cellular organization has emerged in which modular protein-protein interactions provide an underlying framework through which signaling pathways are assembled and controlled. In this scheme, posttranslational modifications such as phosphorylation commonly exert their biological effects by regulating molecular interactions, exemplified by the ability of phosphotyrosine sites to bind selectively to SH2 domains. Although these interactions are rather simple in isolation, they can nonetheless be exploited to generate complex cellular systems. Here, I discuss experiments that have led to this view of dynamic cellular behavior and identify some current and future areas of interest in cell signaling.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Bradshaw JM, 2000, J MOL BIOL, V299, P521; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ECKHART W, 1979, CELL, V18, P925, DOI 10.1016/0092-8674(79)90205-8; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Irazoqui JE, 2003, NAT CELL BIOL, V5, P1062, DOI 10.1038/ncb1068; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; Kessels HWHG, 2002, P NATL ACAD SCI USA, V99, P8524, DOI 10.1073/pnas.142224499; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LAI MMC, 1973, P NATL ACAD SCI USA, V70, P2266, DOI 10.1073/pnas.70.8.2266; LAROSE L, 1993, ONCOGENE, V8, P2493; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; PAWSON T, 1988, ONCOGENE, V3, P491; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2001, J CELL SCI, V114, P2255; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shelly M, 2003, DEV CELL, V5, P475, DOI 10.1016/j.devcel.2003.08.001; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; USHIRO H, 1980, J BIOL CHEM, V255, P8363; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Walhout AJM, 2002, CURR BIOL, V12, P1952, DOI 10.1016/S0960-9822(02)01279-4; Wasteson A., 1983, NATURE, V304, P35; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178; ZARRINPAR A, 2003, SCI STKE, V178, pRE8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	145	625	646	0	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					191	203		10.1016/S0092-8674(03)01077-8	http://dx.doi.org/10.1016/S0092-8674(03)01077-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744431	Bronze			2022-12-28	WOS:000188541700010
J	Dhar, AD; Werchniak, AE; Li, Y; Brennick, JB; Goldsmith, CS; Kline, R; Damon, I; Klaus, SN				Dhar, AD; Werchniak, AE; Li, Y; Brennick, JB; Goldsmith, CS; Kline, R; Damon, I; Klaus, SN			Brief report: Tanapox infection in a college student	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS; DISEASE		Dartmouth Hitchcock Med Ctr, Dept Med, Dermatol Sect, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Med, Dermatol Sect, Hanover, NH USA; Dartmouth Coll Sch Med, Dept Pathol, Hanover, NH USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Dartmouth College; Dartmouth College; Dartmouth College; Centers for Disease Control & Prevention - USA	Klaus, SN (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, Dermatol Sect, 1 Med Ctr Dr, Lebanon, NH 03756 USA.							Baxby D, 1997, J Med Microbiol, V46, P17; Baxby D., 1997, J MED MICROBIOL, V46, P28; Croitoru Anca G, 2002, Skinmed, V1, P156, DOI 10.1111/j.1540-9740.2002.01778.x; Diven DG, 2001, J AM ACAD DERMATOL, V44, P1, DOI 10.1067/mjd.2001.109302; DOWNIE AW, 1972, J HYG-CAMB, V70, P23, DOI 10.1017/S0022172400022051; DOWNIE AW, 1971, BRIT MED J, V1, P363, DOI 10.1136/bmj.1.5745.363; JEZEK Z, 1985, B WORLD HEALTH ORGAN, V63, P1027; KNIGHT JC, 1989, VIROLOGY, V172, P116, DOI 10.1016/0042-6822(89)90113-X; Stich A, 2002, T ROY SOC TROP MED H, V96, P178, DOI 10.1016/S0035-9203(02)90295-6	9	44	45	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					361	366		10.1056/NEJMoa031467	http://dx.doi.org/10.1056/NEJMoa031467			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736928	Bronze			2022-12-28	WOS:000188254800008
J	Ilani, S; Martin, J; Teitelbaum, E; Smet, JH; Mahalu, D; Umansky, V; Yacoby, A				Ilani, S; Martin, J; Teitelbaum, E; Smet, JH; Mahalu, D; Umansky, V; Yacoby, A			The microscopic nature of localization in the quantum Hall effect	NATURE			English	Article							METAL-INSULATOR-TRANSITION; 2-DIMENSIONAL ELECTRON-SYSTEM; TRANSPORT; STATES; FLUCTUATIONS; BEHAVIOR; DENSITY; REGIME	The quantum Hall effect arises from the interplay between localized and extended states that form when electrons, confined to two dimensions, are subject to a perpendicular magnetic field(1). The effect involves exact quantization of all the electronic transport properties owing to particle localization. In the conventional theory of the quantum Hall effect, strong- field localization is associated with a single- particle drift motion of electrons along contours of constant disorder potential(2). Transport experiments that probe the extended states in the transition regions between quantum Hall phases have been used to test both the theory and its implications for quantum Hall phase transitions. Although several experiments(3-9) on highly disordered samples have affirmed the validity of the single- particle picture, other experiments(10-12) and some recent theories(13-15) have found deviations from the predicted universal behaviour. Here we use a scanning single- electron transistor to probe the individual localized states, which we find to be strikingly different from the predictions of single- particle theory. The states are mainly determined by Coulomb interactions, and appear only when quantization of kinetic energy limits the screening ability of electrons. We conclude that the quantum Hall effect has a greater diversity of regimes and phase transitions than predicted by the single-particle framework. Our experiments suggest a unified picture of localization in which the single- particle model is valid only in the limit of strong disorder.	Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Weizmann Institute of Science; Max Planck Society	Ilani, S (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.	shahal.ilani@cornell.edu	ILANI, SHAHAL/K-1377-2012; Martin, Jens/H-9029-2013; Umansky, Vladimir/P-1334-2019	ILANI, SHAHAL/0000-0001-8589-7723; Umansky, Vladimir/0000-0001-5727-2064				Balaban NQ, 1998, PHYS REV LETT, V81, P4967, DOI 10.1103/PhysRevLett.81.4967; CHKLOVSKII DB, 1993, PHYS REV B, V48, P18060, DOI 10.1103/PhysRevB.48.18060; Cobden DH, 1999, PHYS REV LETT, V82, P4695, DOI 10.1103/PhysRevLett.82.4695; COOPER NR, 1993, PHYS REV B, V48, P4530, DOI 10.1103/PhysRevB.48.4530; EFROS AL, 1993, PHYS REV B, V47, P2233, DOI 10.1103/PhysRevB.47.2233; EFROS AL, 1988, SOLID STATE COMMUN, V67, P1019, DOI 10.1016/0038-1098(88)91177-5; ENGEL L, 1990, SURF SCI, V229, P13, DOI 10.1016/0039-6028(90)90820-X; ENGEL LW, 1993, PHYS REV LETT, V71, P2638, DOI 10.1103/PhysRevLett.71.2638; HOHLS F, 2002, PHYS REV LETT, V89, P1; HOHLS F, 2002, PHYS REV LETT, V88, P1; HUCKESTEIN B, 1995, REV MOD PHYS, V67, P357, DOI 10.1103/RevModPhys.67.357; Ilani S, 2000, PHYS REV LETT, V84, P3133, DOI 10.1103/PhysRevLett.84.3133; Ilani S, 2001, SCIENCE, V292, P1354, DOI 10.1126/science.1058645; KOCH S, 1991, PHYS REV LETT, V67, P883, DOI 10.1103/PhysRevLett.67.883; Kukushkin IV, 1996, PHYS REV B, V53, P13260, DOI 10.1103/PhysRevB.53.R13260; Prange R. E., 1990, QUANTUM HALL EFFECT; Ruzin IM, 1996, PHYS REV B, V53, P1558, DOI 10.1103/PhysRevB.53.1558; Shahar D, 1998, SOLID STATE COMMUN, V107, P19, DOI 10.1016/S0038-1098(98)00157-4; SHASHKIN AA, 1994, PHYS REV LETT, V73, P3141, DOI 10.1103/PhysRevLett.73.3141; WEI HP, 1992, PHYS REV B, V45, P3926, DOI 10.1103/PhysRevB.45.3926; WEI HP, 1988, PHYS REV LETT, V61, P1294, DOI 10.1103/PhysRevLett.61.1294; Yacoby A, 1999, SOLID STATE COMMUN, V111, P1, DOI 10.1016/S0038-1098(99)00139-8; Yoo MJ, 1997, SCIENCE, V276, P579, DOI 10.1126/science.276.5312.579; Zhitenev NB, 2000, NATURE, V404, P473, DOI 10.1038/35006591	24	161	161	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					328	332		10.1038/nature02230	http://dx.doi.org/10.1038/nature02230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737162	Green Submitted			2022-12-28	WOS:000188266200034
J	Velicer, CM; Heckbert, SR; Lampe, JW; Potter, JD; Robertson, CA; Taplin, SH				Velicer, CM; Heckbert, SR; Lampe, JW; Potter, JD; Robertson, CA; Taplin, SH			Antibiotic use in relation to the risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METABOLISM; VEGETABLES; ESTROGENS; INFECTIONS; EXPRESSION	Context Use of antibiotics may be associated with risk of breast cancer through effects on immune function, inflammation, and. metabolism of <LF>estrogen and phytochemicals; however, clinical data on the association between antibiotic use and risk of. breast cancer are sparse. Objective To examine the association between use of antibiotics and risk of breast cancer. Design, Setting, and Participants Case-control Study among 2266,women older than 19 years with primary, invasive breast cancer (cases) enrolled in a large, non-profit health plan for at least 1 year between January 1, 1993, and June 30, 2001, and 7953 randomly selected female health plan members (controls), frequency-matched to cases on age and length of enrollment. Cases were ascertained from the Surveillance, Epidemiology, and End Results cancer registry. Antibiotic use was ascertained from computerized pharmacy records. Main Outcome Measure Association between extent of antibiotic use and risk of breast cancer. Results Increasing cumulative-days of antibiotic. use were associated with increased risk of incident breast cancer, adjusted for age and length of enrollment. For categories of increasing use (0, 1-50, 51-100, 101-500, 501-1000, and greater than or equal to1001 days), odds ratios (95% confidence intervals) for breast <LF>cancer were 1.00 (reference), 1.45 (1.24-1.69), 1.53 (1.28-1.83), 1.68 (1.42-2.00), 2.14 (1.60-2.88),and 2.07 (1.48-2.89) (P<.001 for trend). Increased risk was observed in all antibiotic classes studied and in a subanalysis having breast cancer fatality as the outcome. Among women with the highest levels of tetracycline or macrolide use, risk of breast cancer was not elevated in those using these antibiotics exclusively for acne or rosacea (indications that could be risk factors for breast cancer due to altered hormone levels), compared with those using them exclusively for respiratory tract infections, adjusted for age and length. of enrollment (odds ratio, 0.91; 95% confidence interval, 0.44-1.87). Conclusions Use of antibiotics is associated with increased risk of incident and fatal breast cancer. It cannot be determined from this study whether antibiotic use is causally related to breast cancer, or whether indication for used overall weakened immune function, or other factors are pertinent underlying exposures. Although further studies are needed, these findings reinforce the need for prudent long-term use of antibiotics.	Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Dept Family Med, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Grp Hlth Cooperat Puget Sound, Dept Pharm, Seattle, WA 98121 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; NCI, Appl Res Program, Bethesda, MD 20892 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; Group Health Cooperative; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Heckbert, SR (corresponding author), Univ Washington, Dept Epidemiol, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.	heckbert@u.washington.edu		Potter, John/0000-0001-5439-1500	NATIONAL CANCER INSTITUTE [U01CA063731, T32CA009168] Funding Source: NIH RePORTER; NCI NIH HHS [UO1CA63731, T32CA09168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1976, J CLIN ENDOCR METAB, V43, P497, DOI 10.1210/jcem-43-3-497; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; *AM CANC SOC, 2001, BREAST CANC FACTS FI; Attur MG, 1999, J IMMUNOL, V162, P3160; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Coogan PF, 1999, PREV MED, V29, P72, DOI 10.1006/pmed.1999.0518; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Gonzales R, 2001, ANN INTERN MED, V134, P490, DOI 10.7326/0003-4819-134-6-200103200-00015; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Kilkkinen A, 2002, AM J EPIDEMIOL, V155, P472, DOI 10.1093/aje/155.5.472; Knekt P, 2000, BRIT J CANCER, V82, P1107, DOI 10.1054/bjoc.1999.1047; Lampe JW, 1999, AM J CLIN NUTR, V70, p475S, DOI 10.1093/ajcn/70.3.475s; Reed MJ, 2001, CLIN ENDOCRINOL, V54, P563, DOI 10.1046/j.1365-2265.2001.01276.x; Rowland I, 1999, BIOCHEM SOC T, V27, P304, DOI 10.1042/bst0270304; SAUNDERS KW, 2000, PHARMACOEPIDEM DR S, P247; SETCHELL KDR, 1981, LANCET, V2, P4; Shapiro TA, 1998, CANCER EPIDEM BIOMAR, V7, P1091; Shu XO, 2001, CANCER EPIDEM BIOMAR, V10, P483; Taplin SH, 1997, CANCER EPIDEM BIOMAR, V6, P625; Thompson LU, 1998, BAILLIERE CLIN ENDOC, V12, P691, DOI 10.1016/S0950-351X(98)80011-6; TIKKANEN MJ, 1973, BMJ-BRIT MED J, V2, P369, DOI 10.1136/bmj.2.5862.369; Velicer CM, 2003, CANCER CAUSE CONTROL, V14, P739, DOI 10.1023/A:1026323424792; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733	24	213	220	2	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					827	835		10.1001/jama.291.7.827	http://dx.doi.org/10.1001/jama.291.7.827			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970061	Bronze			2022-12-28	WOS:000189000400020
J	Wong, TY; Klein, R; Sharrett, AR; Duncan, BB; Couper, DJ; Klein, BEK; Hubbard, LD; Nieto, FJ				Wong, TY; Klein, R; Sharrett, AR; Duncan, BB; Couper, DJ; Klein, BEK; Hubbard, LD; Nieto, FJ		Atherosclerosis Risk Communities S	Retinal arteriolar diameter and risk for hypertension	ANNALS OF INTERNAL MEDICINE			English	Article							ATHEROSCLEROSIS RISK; MICROVASCULAR ABNORMALITIES; BLOOD-PRESSURE; MICROCIRCULATION	Background: Narrowing of the small arterioles has been hypothesized to contribute to the pathogenesis of hypertension, but prospective clinical data are lacking. Objective: To examine the relation of retinal arteriolar narrowing to incident hypertension in healthy middle-aged persons. Design: Prospective cohort study. Setting: The population-based Atherosclerosis Risk in Communities Study, conducted in 4 U.S. communities. Participants: 5628 persons 49 to 73 years of age without preexisting hypertension. Measurements: Diameters of retinal vessels were measured from digitized retinal photographs. A summary arteriole-to-venule ratio was computed as an indicator of generalized arteriolar narrowing; a lower ratio indicated greater narrowing. Areas of focal arteriolar narrowing were defined from photographs by using a standard protocol. Incident hypertension, defined as systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure of 90 mm Hg or higher, or use of anti hypertensive medication, was identified from the cohort. Results: After 3 years of follow-up, 811 (14.4%) persons had developed hypertension. The incidence of hypertension was higher in persons with lower arteriole-to-venule ratios (incidence of 8.9%, 12.3%, 13.7%, 14.3%, and 22.3%, comparing decreasing quintiles of the ratio) and in persons with focal arteriolar narrowing than in those without focal arteriolar narrowing (25.1% vs. 13.0%). After the authors controlled for the average systolic and diastolic blood pressures over the preceding 6 years, body mass index, waist-to-hip ratio, and other risk factors, the odds of developing hypertension were approximately 60% higher in persons with lower arteriole-to-venule ratios (odds ratio, 1.62 [95% Cl, 1.21 to 2.18] comparing lowest to highest quintile; P = 0.006 for trend) and focal arteriolar narrowing (odds ratio, 1.61 [CI, 1.27 to 2.04]; P < 0.001). Conclusions: smaller retinal arteriolar diameters are independently associated with incident hypertension, which suggests that arteriolar narrowing may be linked to the occurrence and development of hypertension.	Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia; Natl Univ Singapore, Singapore Eye Res Inst, Singapore, Singapore; Univ Wisconsin, Madison, WI USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil; Univ N Carolina, Chapel Hill, NC USA	Centre for Eye Research Australia; University of Melbourne; National University of Singapore; Singapore National Eye Center; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Universidade Federal do Rio Grande do Sul; University of North Carolina; University of North Carolina Chapel Hill	Wong, TY (corresponding author), Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.	ophwty@nus.edu.sg	Duncan, Bruce B/L-4140-2016; Wong, Tien Yin/AAC-9724-2020	Duncan, Bruce B/0000-0002-7491-2630; Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235	NEI NIH HHS [EYO13939] Funding Source: Medline; NHLBI NIH HHS [N01-HC-35126, N01-HC-55022, N01-HC-55016, N01-HC-55015, N01-HC-35125, N01-HC-55020, N01-HC-55019, N01-HC-55018, N01-HC-55021] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC035125, N01HC055015, N01HC055016, N01HC055019, N01HC055020, N01HC035126, N01HC055018, N01HC055022, N01HC055021] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY013939] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BAUMBACH GL, 1989, HYPERTENSION, V13, P968, DOI 10.1161/01.HYP.13.6.968; Burchfiel CM, 1997, ARTERIOSCL THROM VAS, V17, P760, DOI 10.1161/01.ATV.17.4.760; Chobanian AV, 2001, NEW ENGL J MED, V345, P534, DOI 10.1056/NEJM200108163450709; DEVEREUX RB, 1990, ANN INTERN MED, V112, P157, DOI 10.7326/0003-4819-112-3-157; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0; *JOINT NAT COMM PR, 1997, NIH PUBL; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; Levy BI, 2001, CIRCULATION, V104, P735, DOI 10.1161/hc3101.091158; MULVANY MJ, 1991, HYPERTENSION, V18, P52, DOI 10.1161/01.HYP.18.3_Suppl.I52; *NAT HEART LUNG BL, 1988, ATH RISK COMM STUDY; NORRELUND H, 1994, HYPERTENSION, V24, P301, DOI 10.1161/01.HYP.24.3.301; Papastathopoulos KI, 1999, BRIT J OPHTHALMOL, V83, P285, DOI 10.1136/bjo.83.3.285; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; Pries AR, 1999, HYPERTENSION, V33, P153, DOI 10.1161/01.HYP.33.1.153; RIZZONI D, 1994, AM J HYPERTENS, V7, P193, DOI 10.1093/ajh/7.2.193; Sharrett AR, 1999, AM J EPIDEMIOL, V150, P263; THYBO NK, 1995, HYPERTENSION, V25, P474, DOI 10.1161/01.HYP.25.4.474; VICAUT E, 1992, J HYPERTENS, V10, pS59, DOI 10.1097/00004872-199207005-00009; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X	22	248	255	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					248	255		10.7326/0003-4819-140-4-200402170-00006	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970147				2022-12-28	WOS:000188970400002
J	Klejnot, J; Lin, CT				Klejnot, J; Lin, CT			A CONSTANS experience brought to light	SCIENCE			English	Editorial Material							ARABIDOPSIS PHOTORECEPTORS; FLOWERING TIME		Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Klejnot, J (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	clin@mcdb.ucla.edu						Garner WW, 1919, J AGRIC RES, V18, P0553; Goldman BD, 2001, J BIOL RHYTHM, V16, P283, DOI 10.1177/074873001129001980; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Hayama R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549; Lin CT, 2000, PLANT PHYSIOL, V123, P39, DOI 10.1104/pp.123.1.39; Mas P, 2003, NATURE, V426, P567, DOI 10.1038/nature02163; Mockler T, 2003, P NATL ACAD SCI USA, V100, P2140, DOI 10.1073/pnas.0437826100; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sharrock RA, 2002, PLANT PHYSIOL, V130, P442, DOI 10.1104/pp.005389; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	15	4	8	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					965	966		10.1126/science.1094734	http://dx.doi.org/10.1126/science.1094734			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963316				2022-12-28	WOS:000188918000030
J	Chlebowski, RT; Col, N				Chlebowski, RT; Col, N			Menopausal hormone therapy after breast cancer	LANCET			English	Editorial Material							ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN		Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA; Brigham & Womens Hlth Hosp, Boston, MA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Brigham & Women's Hospital	Chlebowski, RT (corresponding author), Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA.	rchlebow@whi.org	Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X				ANDERSON GL, 2003, JAMA-J AM MED ASSOC, V230, P1739; Armstrong K, 2000, NEW ENGL J MED, V342, P564, DOI 10.1056/NEJM200002243420807; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Chlebowski RT, 2003, SEMIN ONCOL, V30, P776, DOI 10.1053/j.seminoncol.2003.08.021; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; HOLMBERG I, 1997, HABITS HORMONAL REPL; Kim HJ, 2002, AM J NEPHROL, V22, P532, DOI 10.1159/000065292; MacLennan A, 2002, CLIMACTERIC, V5, P313, DOI 10.1080/713605308; O'Meara ES, 2001, JNCI-J NATL CANCER I, V93, P754, DOI 10.1093/jnci/93.10.754; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; *WRIT GROUP WOM HL, 2002, JAMA-J AM MED ASSOC, V255, P3243	12	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					410	411		10.1016/S0140-6736(04)15519-0	http://dx.doi.org/10.1016/S0140-6736(04)15519-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962515	Green Published			2022-12-28	WOS:000188999500002
J	Herzog, C; Sales, N; Etchegaray, N; Charbonnier, A; Freire, S; Dormont, D; Deslys, JP; Lasmezas, CI				Herzog, C; Sales, N; Etchegaray, N; Charbonnier, A; Freire, S; Dormont, D; Deslys, JP; Lasmezas, CI			Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection	LANCET			English	Article							CREUTZFELDT-JAKOB-DISEASE; RESISTANT PRION PROTEIN; VARIANT CJD; BSE AGENT; TRANSMISSION; MICE; SCRAPIE; HEALTH; BLOOD; PATHOGENESIS	Background The disease-associated form of prion protein (Prp(res)) has been noted in lymphoreticular tissues in patients with variant Creutzfeldt-Jakob disease (vCJD). Thus, the disease could be transmitted iatrogenically by surgery or use of blood products. We aimed to assess transmissibility of the bovine spongiform encephalopathy (BSE) agent to primates by the intravenous route and study its tissue distribution compared with infection by the oral route. Methods Cynomolgus macaques were infected either intravenously or orally with brain homogenates from first-passage animals with BSE. They were clinically monitored for occurrence of neurological signs and killed humanely at the terminal stage of the disease. Brain, lymphoreticular tissues, digestive tract, and peripheral nerves were obtained and analysed by sandwich ELISA and immunohistochemistry for quantitative and qualitative assessment of their Prp(res) content. Findings Incubation periods after intravenous transmission of BSE were much shorter than after oral infection. We noted that Prp(res) was present in lymphoreticular tissues such as spleen and tonsils and in the entire gut from the duodenum to the rectum. In the gut, PrPres was present in Peyer's patches and in the enteric nervous system and nerve fibres of intestinal mucosa. Furthermore, Prp(res) was found in locomotor peripheral nerves and the autonomic nervous system. Amount of PrPres ranged from 0.02% to more than 10% of that recorded in brain. Distribution of Prp(res) was similar in animals infected by the intravenous or oral route. Interpretation Our findings suggest that the possible risk of vCJD linked to endoscopic procedures might be currently underestimated. Human iatrogenic vCJD cases infected intravenously raise the same public-health concerns as primary cases and need the same precautionary measures with respect to blood and tissue donations and surgical procedures.	Commissariat Energie Atom, Dept Rech Med, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Lasmezas, CI (corresponding author), Commissariat Energie Atom, Dept Rech Med, BP6, F-92265 Fontenay Aux Roses, France.	lasmezas@cea.fr						BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Bruce ME, 2001, LANCET, V358, P208, DOI 10.1016/S0140-6736(01)05411-3; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Cervenakova L, 2003, TRANSFUSION, V43, P1687, DOI 10.1046/j.0041-1132.2003.00586.x; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Deslys JP, 2001, NATURE, V409, P476, DOI 10.1038/35054134; Giaccone G, 2000, BRAIN PATHOL, V10, P31, DOI 10.1111/j.1750-3639.2000.tb00240.x; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; Head MW, 2004, AM J PATHOL, V164, P143, DOI 10.1016/S0002-9440(10)63105-7; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; Ironside JW, 2003, J THROMB HAEMOST, V1, P1479, DOI 10.1046/j.1538-7836.2003.00268.x; KIMBERLIN RH, 1979, J COMP PATHOL, V89, P551, DOI 10.1016/0021-9975(79)90046-X; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Maignien T, 1999, J GEN VIROL, V80, P3035, DOI 10.1099/0022-1317-80-11-3035; Schulz-Schaeffer WJ, 2000, AM J PATHOL, V156, P51, DOI 10.1016/S0002-9440(10)64705-0; Thomzig A, 2003, EMBO REP, V4, P530, DOI 10.1038/sj.embor.embor827; van Duijn CM, 1998, LANCET, V351, P1081, DOI 10.1016/S0140-6736(97)09468-3; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	23	114	118	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					422	428		10.1016/S0140-6736(04)15487-1	http://dx.doi.org/10.1016/S0140-6736(04)15487-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962521				2022-12-28	WOS:000188999500008
J	Michie, S; Johnston, M				Michie, S; Johnston, M			Changing clinical behaviour by making guidelines specific	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE		UCL, Dept Psychol, Ctr Outcomes Res & Effectiveness, London WC1E 7HB, England; Univ Aberdeen, Kings Coll, Sch Psychol, Aberdeen AB24 2UB, Scotland	University of London; University College London; University of Aberdeen	Michie, S (corresponding author), UCL, Dept Psychol, Ctr Outcomes Res & Effectiveness, London WC1E 7HB, England.	s.michie@ucl.ac.uk	Michie, Susan/A-1745-2010; Greiver, Michelle/N-8764-2015; Johnston, Marie/C-5245-2008	Michie, Susan/0000-0003-0063-6378; Greiver, Michelle/0000-0001-8957-0285; 				Cone JD, 1997, BEHAV RES THER, V35, P259, DOI 10.1016/S0005-7967(96)00101-5; Eccles M, 2001, LANCET, V357, P1406, DOI 10.1016/S0140-6736(00)04564-5; ECCLES M, IN PRESS QUAL SAF HL; Gollwitzer PM, 1999, AM PSYCHOL, V54, P493, DOI 10.1037//0003-066X.54.7.493; Grady KE, 1997, PREV MED, V26, P791, DOI 10.1006/pmed.1997.0219; GRIMSHAW JM, 2001, MED CARE S2, V39, P2, DOI DOI 10.1097/00005650-200108002-00002; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Kanfer F. H., 1969, BEHAVIOR THERAPY APP, P417; KAZDIN AE, 2001, BEHAV MODIFICATION A; Ley P., 1988, COMMUNICATING PATIEN; Ley P, 1997, CAMBRIDGE HDB PSYCHO, P331; *NAT I CLIN EXC, CG3 CHRON HEART FAIL; *NAT I CLIN EXC, CG2 INF CONTR PREV H; *NAT I CLIN EXC, CG4 HEAD INJ TRIAG A; National Institute for Clinical Excellence, 2002, SCHIZ COR INT TREATM	16	183	188	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2004	328	7435					343	345		10.1136/bmj.328.7435.343	http://dx.doi.org/10.1136/bmj.328.7435.343			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764503	Green Submitted, Green Published			2022-12-28	WOS:000188926900031
J	Nowak, MA; Sigmund, K				Nowak, MA; Sigmund, K			Evolutionary dynamics of biological games	SCIENCE			English	Review							POPULATION BIOLOGY; PRISONERS-DILEMMA; COOPERATION; COMPETITION; STRATEGIES; DISPERSAL; STABILITY; ADAPTATION; FITNESS; MODELS	Darwinian dynamics based on mutation and selection form the core of mathematical models for adaptation and coevolution of biological populations. The evolutionary outcome is often not a fitness-maximizing equilibrium but can include oscillations and chaos. For studying frequency-dependent selection, game-theoretic arguments are more appropriate than optimization algorithms. Replicator and adaptive dynamics describe short- and long-term evolution in phenotype space and have found applications ranging from animal behavior and ecology to speciation, macroevolution, and human language. Evolutionary game theory is an essential component of a mathematical and computational approach to biology.	Harvard Univ, Dept Organism & Evolutionary Biol, Dept Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA; Univ Vienna, Fac Math, A-1090 Vienna, Austria; Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria	Harvard University; University of Vienna; International Institute for Applied Systems Analysis (IIASA)	Nowak, MA (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Dept Math, Program Evolutionary Dynam, 1 Brattle Sq, Cambridge, MA 02138 USA.	martin_nowak@harvard.edu	Nowak, Martin A/A-6977-2008; Allen, John A/B-5510-2008					Abrams PA, 1997, EVOL ECOL, V11, P1, DOI 10.1023/A:1018445517101; ANDERSON R M, 1991; [Anonymous], 1998, THEORY LEARNING GAME; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Binmore K. G., 1994, GAME THEORY SOCIAL C; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; Burger R, 2002, AM NAT, V160, P661, DOI 10.1086/342813; CHRISTIANSEN FB, 1991, AM NAT, V138, P37, DOI 10.1086/285203; Cressman R, 2003, ECON LEARN SOC EVOL, P1; DIECKMANN U, 1995, J THEOR BIOL, V176, P91, DOI 10.1006/jtbi.1995.0179; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Dieckmann U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751; Dieckmann U., 2000, GEOMETRY ECOLOGICAL; Doebeli M, 1997, EVOLUTION, V51, P1730, DOI 10.1111/j.1558-5646.1997.tb05097.x; Durrett R, 1999, SIAM REV, V41, P677, DOI 10.1137/S0036144599354707; Eshel I, 1996, J MATH BIOL, V34, P485; ESHEL I, 1983, J THEOR BIOL, V103, P99, DOI 10.1016/0022-5193(83)90201-1; Falster DS, 2003, TRENDS ECOL EVOL, V18, P337, DOI 10.1016/S0169-5347(03)00061-2; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Ferriere R, 1996, AM NAT, V147, P692, DOI 10.1086/285875; Frank, 1998, FDN SOCIAL EVOLUTION; Frauenfelder H, 1997, PHYSICA D, V107, pR5, DOI 10.1016/S0167-2789(97)80614-8; Fudenberg D., 1991, GAME THEORY; Gintis H., 2000, GAME THEORY EVOLVING; Giraldeau L.A., 1998, GAME THEORY ANIMAL B; GODFRAY HCJ, 1995, NATURE, V376, P133, DOI 10.1038/376133a0; Gyllenberg M, 2002, J MATH BIOL, V45, P79, DOI 10.1007/s002850200151; Haig D., 2002, GENOMIC IMPRINTING K; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hammerstein P, 1996, J MATH BIOL, V34, P511; HARDY ICW, 2002, MOTHER KNOWS BEST SO; Hauert C, 2002, SCIENCE, V296, P1129, DOI 10.1126/science.1070582; HEINSOHN R, 1995, SCIENCE, V269, P1260, DOI 10.1126/science.7652573; Hendry AP, 2000, SCIENCE, V290, P516, DOI 10.1126/science.290.5491.516; Henrich J, 2001, AM ECON REV, V91, P7378; Hofbauer J, 2003, B AM MATH SOC, V40, P479, DOI 10.1090/S0273-0979-03-00988-1; Hofbauer J., 1990, APPL MATH LETT, V3, P75, DOI [10.1016/0893-9659(90)90051-C, DOI 10.1016/0893-9659(90)90051-C, DOI 10.1016/0893-9659(90)90051-C)]; Hofbauer J, 1998, EVOLUTIONARY GAMES P; Houston AI, 1999, MODELS ADAPTIVE BEHA; IWASA Y, 1995, NATURE, V377, P420, DOI 10.1038/377420a0; JOHNSTONE RA, 2002, ENCY EVOLUTION, P1059; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; Krakauer DC, 2000, NATURE, V403, P501, DOI 10.1038/35000654; Levin BR, 1999, SCIENCE, V283, P806, DOI 10.1126/science.283.5403.806; Levin SA, 1997, SCIENCE, V275, P334, DOI 10.1126/science.275.5298.334; Matessi C, 2001, SELECTION, V2, P41, DOI DOI 10.1556/SELECT.2.2001.1-2.4); May R.M., 1973, STABILITY COMPLEXITY; Maynard Smith J., 1982, pi; Metz J. A. J., 1996, STOCHASTIC SPATIAL S, P183; METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K; Mock D. W., 1997, EVOLUTION SIBLING RI; Mylius SD, 2001, J THEOR BIOL, V211, P297, DOI 10.1006/jtbi.2001.2349; Nee S, 2000, PHILOS T R SOC B, V355, P1607, DOI 10.1098/rstb.2000.0722; NOWAK M, 1990, J THEOR BIOL, V142, P237, DOI 10.1016/S0022-5193(05)80224-3; NOWAK M, 1989, J THEOR BIOL, V137, P21, DOI 10.1016/S0022-5193(89)80146-8; NOWAK M, 1990, ACTA APPL MATH, V20, P247, DOI 10.1007/BF00049570; Nowak MA, 2000, SCIENCE, V289, P1773, DOI 10.1126/science.289.5485.1773; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; Nowak MA, 2002, NATURE, V417, P611, DOI 10.1038/nature00771; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Page KM, 2002, J THEOR BIOL, V219, P93, DOI 10.1006/yjtbi.3112; Parvinen K, 1999, B MATH BIOL, V61, P531, DOI 10.1006/bulm.1999.0100; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Sasaki A, 2002, P ROY SOC B-BIOL SCI, V269, P761, DOI 10.1098/rspb.2001.1837; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; SLATKIN M, 1979, GENETICS, V93, P755; SMITH JM, 1973, NATURE, V246, P15, DOI 10.1038/246015a0; Sober E., 1998, OTHERS EVOLUTION PSY; Sugden R, 1986, EC RIGHTS COOPERATIO; TAYLOR PD, 1978, MATH BIOSCI, V40, P145, DOI 10.1016/0025-5564(78)90077-9; TAYLOR PD, 1989, THEOR POPUL BIOL, V36, P125, DOI 10.1016/0040-5809(89)90025-7; Trivers R., 1983, Q REV BIOL, V58, P62, DOI [10.1086/413059, DOI 10.1086/413059]; Turner PE, 1999, NATURE, V398, P441, DOI 10.1038/18913; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; Velicer GJ, 2003, NATURE, V425, P75, DOI 10.1038/nature01908; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850; Weibull Jorgen W., EVOLUTIONARY GAME TH; Wright S., 1969, THEORY GENE FREQUENC, V2, P520; [No title captured]	81	724	765	18	345	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					793	799		10.1126/science.1093411	http://dx.doi.org/10.1126/science.1093411			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764867	Green Submitted			2022-12-28	WOS:000188753800045
J	Roberts, JP; Wolfe, RA; Bragg-Gresham, JL; Rush, SH; Wynn, JJ; Distant, DA; Ashby, VB; Held, PJ; Port, FK				Roberts, JP; Wolfe, RA; Bragg-Gresham, JL; Rush, SH; Wynn, JJ; Distant, DA; Ashby, VB; Held, PJ; Port, FK			The effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CADAVERIC RENAL-TRANSPLANTATION; RACIAL-DIFFERENCES; UNITED-STATES; ACCESS; IMPACT; RACE; GENDER; DONOR; SEX	Background: HLA typing and the time a patient has spent on the waiting list are the primary criteria used to allocate cadaveric kidneys for transplantation in the United States. Candidates with no HLA-A, B, and DR mismatches are given top priority, followed by candidates with the fewest mismatches at the HLA-B and DR loci; this policy contributes to a higher transplantation rate among whites than nonwhites. We hypothesized that changing this allocation policy would affect graft survival and the racial balance among transplant recipients. Methods: We estimated the relative rates of kidney transplantation according to race resulting from the current allocation policy and racial differences in HLA antigen profiles, using a Cox model for the time from placement on the waiting list to transplantation. Another model, also adjusted for HLA-B and DR antigen profiles, estimated the relative rates of kidney transplantation that would result if the distribution of these antigen profiles were identical among the racial and ethnic groups. We also investigated the effect of HLA matching on the risk of graft failure, using a Cox model for the time from the first transplantation to graft failure. The results of the two analyses were used to estimate the change in the racial balance of transplantation and graft-failure rates that would result from the elimination of HLA-B matching or HLA-B and DR matching as a means of assigning priority. Results: Eliminating the HLA-B matching as a priority while maintaining HLA-DR matching as a priority would decrease the number of transplantations among whites by 4.0 percent (166 fewer transplantations over a one-year period), whereas it would increase the number among nonwhites by 6.3 percent and increase the rate of graft loss by 2.0 percent. Conclusions: Removing HLA-B matching as a priority for the allocation of cadaveric kidneys could reduce the existing racial imbalance by increasing the number of transplantations among nonwhites, with only a small increase in the rate of graft loss.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Renal Res & Educ Assoc, Ann Arbor, MI USA; Med Coll Georgia, Augusta, GA 30912 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA	University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University System of Georgia; Augusta University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Roberts, JP (corresponding author), Univ Calif San Francisco, Rm M896, San Francisco, CA 94143 USA.	robertsj@surgery.ucsf.edu		Wynn, James/0000-0001-5879-3400	PHS HHS [231-00-0116] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; ASHBY VB, 2001, AM J TRANSPLANTAT S1, V1, P357; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; BEATTY PG, 1995, TRANSPLANTATION, V60, P778, DOI 10.1097/00007890-199510270-00003; Bloembergen WE, 1997, AM J KIDNEY DIS, V30, P733, DOI 10.1016/S0272-6386(97)90076-7; Cecka J M, 2000, Clin Transpl, P1; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1994, NEW ENGL J MED, V331, P765, DOI 10.1056/NEJM199409223311203; *HLTH RES SERV ADM, 2002, 2001 ANN REP US ORG; HOSMER DW, 1999, APPL SURVIVAL ANAL R, P202; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Narva A, 1996, BLOOD PURIFICAT, V14, P293, DOI 10.1159/000170276; OJO A, 1993, AM J KIDNEY DIS, V22, P835, DOI 10.1016/S0272-6386(12)70343-8; Schnitzler MA, 1999, NEW ENGL J MED, V341, P1440, DOI 10.1056/NEJM199911043411906; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; Takemoto SK, 2000, NEW ENGL J MED, V343, P1078, DOI 10.1056/NEJM200010123431504; *UN NETW ORG SHAR, 2002, OPTN UNOS POL 3 5 OR; Webb R L, 1990, Clin Transpl, P75; Wolfe RA, 2000, AM J KIDNEY DIS, V36, P1025, DOI 10.1053/ajkd.2000.19106	22	117	118	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					545	551		10.1056/NEJMoa025056	http://dx.doi.org/10.1056/NEJMoa025056			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762181				2022-12-28	WOS:000188712800005
J	Xie, LL; Miller, LM; Chatterjee, C; Averin, O; Kelleher, NL; van der Donk, WA				Xie, LL; Miller, LM; Chatterjee, C; Averin, O; Kelleher, NL; van der Donk, WA			Lacticin 481: In vitro reconstitution of lantibiotic synthetase activity	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; LACTOCOCCUS-LACTIS; NISIN BIOSYNTHESIS; EXPRESSION SYSTEM; GENE; PEPTIDE; LOCALIZATION; CONSTRUCTION; BACTERIOCIN; SEQUENCE	The lantibiotic lacticin 481 is synthesized on ribosomes as a prepeptide (LctA) and posttranslationally modified to its mature form. These modi. cations include dehydration of serines and threonines, followed by intramolecular addition of cysteines to the unsaturated amino acids, which generates cyclic thioethers. This process breaks eight chemical bonds and forms six newbonds and is catalyzed by one enzyme, LctM. We have characterized the in vitro activity of LctM, which completely processed a series of LctA mutants, displaying a permissive substrate specificity that holds promise for antibiotic engineering.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.	vddonk@uiuc.edu	van der Donk, Wilfred/K-2961-2015	van der Donk, Wilfred/0000-0002-5467-7071	NIGMS NIH HHS [GM 067725, GM58822] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058822, R01GM067725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIERBAUM G, 1994, APPL ENVIRON MICROB, V60, P4332, DOI 10.1128/AEM.60.12.4332-4338.1994; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Chen P, 1998, APPL ENVIRON MICROB, V64, P2335; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; Kleinnijenhuis AJ, 2003, ANAL CHEM, V75, P3219, DOI 10.1021/ac0263770; Koponen O, 2002, MICROBIOL-SGM, V148, P3561, DOI 10.1099/00221287-148-11-3561; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; Kuipers OP, 1996, ANTON LEEUW INT J G, V69, P161, DOI 10.1007/BF00399421; Li YM, 1996, SCIENCE, V274, P1188, DOI 10.1126/science.274.5290.1188; LIU W, 1992, J BIOL CHEM, V267, P25078; McLafferty FW, 1999, SCIENCE, V284, P1289, DOI 10.1126/science.284.5418.1289; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Okeley NM, 2003, BIOCHEMISTRY-US, V42, P13613, DOI 10.1021/bi0354942; PIARD JC, 1993, J BIOL CHEM, V268, P16361; REIS M, 1994, APPL ENVIRON MICROB, V60, P2876, DOI 10.1128/AEM.60.8.2876-2883.1994; Rince A, 1997, APPL ENVIRON MICROB, V63, P4252; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; Siezen RJ, 1996, ANTON LEEUW INT J G, V69, P171, DOI 10.1007/BF00399422; Szekat C, 2003, APPL ENVIRON MICROB, V69, P3777, DOI 10.1128/AEM.69.7.3777-3783.2003; vandenHooven HW, 1996, FEBS LETT, V391, P317, DOI 10.1016/0014-5793(96)00771-5; VANDERMEER JR, 1994, J BIOL CHEM, V269, P3555; XIE L, 2003, THESIS U ILLINOIS UR	25	200	211	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					679	681		10.1126/science.1092600	http://dx.doi.org/10.1126/science.1092600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752162				2022-12-28	WOS:000188530800043
J	Mizukami, T; Wallis, SR; Yamamoto, J				Mizukami, T; Wallis, SR; Yamamoto, J			Natural examples of olivine lattice preferred orientation patterns with a flow normal a-axis maximum	NATURE			English	Article							SAMBAGAWA METAMORPHIC BELT; UPPER MANTLE ANISOTROPY; SEISMIC ANISOTROPY; JAPAN; PERIDOTITES; SHEAR; ZONE; EVOLUTION; PETROLOGY; BENEATH	Tectonic plate motion is thought to cause solid-state plastic flow within the underlying upper mantle and accordingly lead to the development of a lattice preferred orientation of the constituent olivine crystals(1-3). The mechanical anisotropy that results from such preferred orientation typically produces a direction of maximum seismic wave velocity parallel to the plate motion direction(4,5). This has been explained by the existence of an olivine preferred orientation with an 'a-axis' maximum parallel to the induced mantle flow direction(3,5,6-8). In subduction zones, however, the olivine a axes have been inferred to be arranged roughly perpendicular to plate motion(9-13), which has usually been ascribed to localized complex mantle flow patterns(10-13). Recent experimental work(14) suggests an alternative explanation: under conditions of high water activity, a 'B-type' olivine preferred orientation may form, with the a-axis maximum perpendicular to the flow direction. Natural examples of such B-type preferred orientation are, however, almost entirely unknown. Here we document widespread B-type olivine preferred orientation patterns from a subduction-type metamorphic belt in southwest Japan and show that these patterns developed in the presence of water. Our discovery implies that mantle flow above subduction zones may be much simpler than has generally been thought.	Kyoto Univ, Dept Geol & Mineral, Sakyo Ku, Kyoto 6068501, Japan; Nagoya Univ, Grad Sch Environm Studies, Dept Earth & Planetary Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Earthquake Chem Lab, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Nagoya University; University of Tokyo	Mizukami, T (corresponding author), Kyoto Univ, Dept Geol & Mineral, Sakyo Ku, Kyoto 6068501, Japan.	mizukami@kueps.kyoto-u.ac.jp	Wallis, Simon/M-1272-2019; Yamamoto, Junji/F-8821-2012	Wallis, Simon/0000-0002-7875-5740				ANDO M, 1983, J GEOPHYS RES, V88, P5850, DOI 10.1029/JB088iB07p05850; BANNO S, 1989, EVOLUTION METAMORPHI, P519; BOUDIER F, 1995, J PETROL, V36, P777, DOI 10.1093/petrology/36.3.777; CARTER NL, 1970, GEOL SOC AM BULL, V81, P2181, DOI 10.1130/0016-7606(1970)81[2181:HTFODA]2.0.CO;2; CHRISTENSEN NI, 1984, GEOPHYS J ROY ASTR S, V76, P89, DOI 10.1111/j.1365-246X.1984.tb05025.x; Enami M, 2004, J METAMORPH GEOL, V22, P1, DOI 10.1111/j.1525-1314.2003.00492.x; FOUTH MJ, 1996, J GEOPHYS RES, V101, P15897; FRANCIS TJG, 1969, NATURE, V221, P162, DOI 10.1038/221162b0; HARLEY SL, 1982, NATURE, V300, P697, DOI 10.1038/300697a0; HESS HH, 1964, NATURE, V203, P629, DOI 10.1038/203629a0; HIRAI H, 1987, EARTH PLANET SC LETT, V85, P311, DOI 10.1016/0012-821X(87)90041-0; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; MERCIER JCC, 1975, J PETROL, V16, P454; MORI T, 1973, CONTRIB MINERAL PETR, V41, P301, DOI 10.1007/BF00372169; Nicolas A., 1987, COMPOSITION STRUCTUR, V16, P111, DOI [10.1029/GD016p0111, DOI 10.1029/GD016P0111]; PESELNICK L, 1974, J GEOPHYS RES, V79, P1175, DOI 10.1029/JB079i008p01175; RAITT RW, 1969, J GEOPHYS RES, V74, P3095, DOI 10.1029/JB074i012p03095; ROSSMAN GR, 1988, REV MINERAL, V18, P193; SHIH XR, 1991, J GEOPHYS RES-SOLID, V96, P12069, DOI 10.1029/91JB01201; Smith GP, 2001, SCIENCE, V292, P713, DOI 10.1126/science.1058763; TAKASU A, 1990, TECTONOPHYSICS, V185, P111, DOI 10.1016/0040-1951(90)90408-Z; Wallis S, 1998, J METAMORPH GEOL, V16, P83, DOI 10.1111/j.1525-1314.1998.00072.x; YANG XP, 1995, J GEOPHYS RES-SOL EA, V100, P18165, DOI 10.1029/95JB01425; YOSHINO G, 1961, J SCI HIROSHIMA U C, V3, P343; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	25	120	126	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 29	2004	427	6973					432	436		10.1038/nature02179	http://dx.doi.org/10.1038/nature02179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749828				2022-12-28	WOS:000188470500040
J	Khorasanizadeh, S				Khorasanizadeh, S			The nucleosome: From genomic organization to genomic regulation	CELL			English	Review							CHROMATIN-REMODELING COMPLEX; HIGHER-ORDER STRUCTURE; INACTIVE X-CHROMOSOME; HISTONE H3; CRYSTAL-STRUCTURE; CORE PARTICLE; STRUCTURAL BASIS; ANGSTROM RESOLUTION; DNA METHYLATION; TRANSCRIPTIONAL ACTIVATION	Electron micrographs first confirmed that the eukaryotic genome is organized into repeating disk-shaped nucleosomal units composed of histories and their associated DNA. Those images made clear the function of the nucleosome in packaging and condensing the genome. Today, nucleosomes are recognized as highly dynamic units through which the eukaryotic genome can be regulated with epigenetically heritable consequences. This review focuses on the conserved protein structures that mobilize and remodel nucleosomes and specifically mark and recognize their histone and DNA components. These events directly impact DNA transcription, replication, recombination, and repair.	Univ Virginia, Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Khorasanizadeh, S (corresponding author), Univ Virginia, Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	khorasan@virginia.edu						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Ahmad K, 2001, J CELL BIOL, V153, P101, DOI 10.1083/jcb.153.1.101; Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X; [Anonymous], 2001, WATER AIR SOIL POLLU, DOI DOI 10.1023/A:1017531532576; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Asturias FJ, 2002, P NATL ACAD SCI USA, V99, P13477, DOI 10.1073/pnas.162504299; BAKAYEV VV, 1977, CELL, V11, P619, DOI 10.1016/0092-8674(77)90079-4; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Cui Y, 2000, P NATL ACAD SCI USA, V97, P127, DOI 10.1073/pnas.97.1.127; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dou YL, 2002, J CELL BIOL, V158, P1161, DOI 10.1083/jcb.200202131; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Fazzio TG, 2003, MOL CELL, V12, P1333, DOI 10.1016/S1097-2765(03)00436-2; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Flaus A, 2003, BIOPOLYMERS, V68, P563, DOI 10.1002/bip.10323; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Grune T, 2003, MOL CELL, V12, P449, DOI 10.1016/S1097-2765(03)00273-9; Guarente L, 2000, GENE DEV, V14, P1021; Harp JM, 1996, ACTA CRYSTALLOGR D, V52, P283, DOI 10.1107/S0907444995009139; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Marmorstein R, 2001, STRUCTURE, V9, P1127, DOI 10.1016/S0969-2126(01)00690-6; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; MIZUGUCHI G, 2003, IN PRESS SCIENCE, DOI DOI 10.1126/SC2ENCE.1090701; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; OLINS AL, 1974, SCIENCE, V183, P330, DOI 10.1126/science.183.4122.330; Olins DE, 2003, NAT REV MOL CELL BIO, V4, P809, DOI 10.1038/nrm1225; OUDET P, 1975, CELL, V4, P281, DOI 10.1016/0092-8674(75)90149-X; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Ramachandran A, 2003, J BIOL CHEM, V278, P48590, DOI 10.1074/jbc.M309033200; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rydberg B, 1998, J MOL BIOL, V284, P71, DOI 10.1006/jmbi.1998.2150; Schnitzler GR, 2001, MOL CELL BIOL, V21, P8504, DOI 10.1128/MCB.21.24.8504-8511.2001; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; Smith CL, 2003, NAT STRUCT BIOL, V10, P141, DOI 10.1038/nsb888; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; van Holde K.E., 1988, CHROMATIN; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Zhang KL, 2002, ANAL BIOCHEM, V306, P259, DOI 10.1006/abio.2002.5719; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521	99	496	513	0	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					259	272		10.1016/S0092-8674(04)00044-3	http://dx.doi.org/10.1016/S0092-8674(04)00044-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744436	Bronze			2022-12-28	WOS:000188541700015
J	Wagner, U; Gais, S; Haider, H; Verleger, R; Born, J				Wagner, U; Gais, S; Haider, H; Verleger, R; Born, J			Sleep inspires insight	NATURE			English	Article							EYE-MOVEMENT SLEEP; REM-SLEEP; MEMORY; HIPPOCAMPUS; AWARENESS; SYSTEMS; SKILLS; DREAMS	Insight denotes a mental restructuring that leads to a sudden gain of explicit knowledge allowing qualitatively changed behaviour(1,2). Anecdotal reports on scientific discovery suggest that pivotal insights can be gained through sleep(3). Sleep consolidates recent memories(4-6) and, concomitantly, could allow insight by changing their representational structure. Here we show a facilitating role of sleep in a process of insight. Subjects performed a cognitive task requiring the learning of stimulus - response sequences, in which they improved gradually by increasing response speed across task blocks. However, they could also improve abruptly after gaining insight into a hidden abstract rule underlying all sequences. Initial training establishing a task representation was followed by 8 h of nocturnal sleep, nocturnal wakefulness, or daytime wakefulness. At subsequent retesting, more than twice as many subjects gained insight into the hidden rule after sleep as after wakefulness, regardless of time of day. Sleep did not enhance insight in the absence of initial training. A characteristic antecedent of sleep- related insight was revealed in a slowing of reaction times across sleep. We conclude that sleep, by restructuring new memory representations, facilitates extraction of explicit knowledge and insightful behaviour.	Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany; Univ Cologne, Inst Psychol, D-50931 Cologne, Germany; Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany	University of Lubeck; University of Cologne; University of Lubeck	Wagner, U (corresponding author), Univ Lubeck, Dept Neuroendocrinol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	wagner@kfg.uni-luebeck.de; born@kfg.uni-luebeck.de	Born, Jan/K-2596-2016	Born, Jan/0000-0002-1847-6248				Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; CARTWRIGHT RD, 1974, J ABNORM PSYCHOL, V83, P451, DOI 10.1037/h0036811; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; DURSO FT, 1994, PSYCHOL SCI, V5, P94, DOI 10.1111/j.1467-9280.1994.tb00637.x; EPSTEIN R, 1984, NATURE, V308, P61, DOI 10.1038/308061a0; Fischer S, 2002, P NATL ACAD SCI USA, V99, P11987, DOI 10.1073/pnas.182178199; FISHBEIN W, 1971, PHYSIOL BEHAV, V6, P279, DOI 10.1016/0031-9384(71)90155-7; Frensch PA, 2002, ATTENTION IMPLICIT L, P335; Gais S, 2000, NAT NEUROSCI, V3, P1335, DOI 10.1038/81881; HORNE JA, 1988, SLEEP, V11, P528, DOI 10.1093/sleep/11.6.528; Jimenez L, 1996, J EXP PSYCHOL LEARN, V22, P948, DOI 10.1037/0278-7393.22.4.948; Kohler W., 1947, GESTALT PSYCHOL INTR; Luo J, 2003, HIPPOCAMPUS, V13, P316, DOI 10.1002/hipo.10069; Maquet P, 2000, NAT NEUROSCI, V3, P831, DOI 10.1038/77744; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; Mazzarello P, 2000, NATURE, V408, P523, DOI 10.1038/35046170; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; McIntosh AR, 2003, J NEUROSCI, V23, P6520; McNaughton, 2003, SLEEP BRAIN PLASTICI, P225, DOI DOI 10.1093/ACPROF:OSO/9780198574002.003.0013; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; Plihal W, 1997, J COGNITIVE NEUROSCI, V9, P534, DOI 10.1162/jocn.1997.9.4.534; Rechtschaffen A, 1968, NIH PUBL, V204; Rose M, 2002, NEURON, V36, P1221, DOI 10.1016/S0896-6273(02)01105-4; SMITH C, 1995, BEHAV BRAIN RES, V69, P137, DOI 10.1016/0166-4328(95)00024-N; Sternberg R. J, 1995, NATURE INSIGHT; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Thurstone L. L., 1941, PSYCHOMETRIC MONOGR, V2, P94; Wagner U, 2001, LEARN MEMORY, V8, P112, DOI 10.1101/lm.36801; Walker MP, 2002, COGNITIVE BRAIN RES, V14, P317, DOI 10.1016/S0926-6410(02)00134-9; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517	30	559	571	5	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					352	355		10.1038/nature02223	http://dx.doi.org/10.1038/nature02223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	765KE	14737168				2022-12-28	WOS:000188266200041
J	Silva, GA; Czeisler, C; Niece, KL; Beniash, E; Harrington, DA; Kessler, JA; Stupp, SI				Silva, GA; Czeisler, C; Niece, KL; Beniash, E; Harrington, DA; Kessler, JA; Stupp, SI			Selective differentiation of neural progenitor cells by high-epitope density nanofibers	SCIENCE			English	Article							POLY(DL-LACTIC-CO-GLYCOLIC ACID) FOAMS; PEPTIDE-AMPHIPHILE NANOFIBERS; COLLAGEN-GAG MATRIX; SPINAL-CORD INJURY; STEM-CELLS; IN-VITRO; INJECTABLE ALGINATE; HIPPOCAMPAL-NEURONS; GENE-THERAPY; GROWTH	Neural progenitor cells were encapsulated in vitro within a three-dimensional network of nanofibers formed by self-assembly of peptide amphiphile molecules. The self-assembly is triggered by mixing cell suspensions in media with dilute aqueous solutions of the molecules, and cells survive the growth of the nanofibers around them. These nanofibers were designed to present to cells the neurite-promoting laminin epitope IKVAV at nearly van der Waals density. Relative to laminin or soluble peptide, the artificial nanofiber scaffold induced very rapid differentiation of cells into neurons, while discouraging the development of astrocytes. This rapid selective differentiation is linked to the amplification of bioactive epitope presentation to cells by the nanofibers.	Northwestern Univ, Inst Bioengn & Nanosci Adv Med, Chicago, IL 60611 USA; Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA; Northwestern Univ, Dept Mat Sci & Engn, Chicago, IL 60611 USA; Northwestern Univ, Dept Chem, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University	Stupp, SI (corresponding author), Northwestern Univ, Inst Bioengn & Nanosci Adv Med, Chicago, IL 60611 USA.	gsilva@ucsd.edu; s-stupp@northwestern.edu	Stupp, Samuel/B-6737-2009; Stupp, Samuel/AGV-1942-2022	Harrington, Daniel/0000-0003-2505-0349; Czeisler, Catherine/0000-0001-7895-6449	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020778, R01NS020013, R01NS034758] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20778, NS34758, NS20013] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; ATALA A, 1993, J UROLOGY, V150, P745, DOI 10.1016/S0022-5347(17)35603-3; Butler CE, 1999, BRIT J PLAST SURG, V52, P127, DOI 10.1054/bjps.1997.3047; Canaple L, 2002, J BIOMAT SCI-POLYM E, V13, P783, DOI 10.1163/156856202760197410; Chamberlain LJ, 2000, J NEUROSCI RES, V60, P666, DOI 10.1002/(SICI)1097-4547(20000601)60:5<666::AID-JNR12>3.0.CO;2-0; Chang JC, 2001, BIOSENS BIOELECTRON, V16, P527, DOI 10.1016/S0956-5663(01)00166-X; Chang SCN, 2001, J BIOMED MATER RES, V55, P503, DOI 10.1002/1097-4636(20010615)55:4<503::AID-JBM1043>3.0.CO;2-S; Chen ZJ, 2002, MOL CELL NEUROSCI, V20, P125, DOI 10.1006/mcne.2002.1102; Cornish T, 2002, MOL CELL NEUROSCI, V20, P140, DOI 10.1006/mcne.2002.1101; Costa S, 2002, GLIA, V37, P105, DOI 10.1002/glia.10015; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999; Hortelano G, 1996, BLOOD, V87, P5095, DOI 10.1182/blood.V87.12.5095.bloodjournal87125095; Hsu WC, 2000, INVEST OPHTH VIS SCI, V41, P2404; Kam L, 2001, BIOMATERIALS, V22, P1049, DOI 10.1016/S0142-9612(00)00352-5; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lauer L, 2002, BIOMATERIALS, V23, P3123, DOI 10.1016/S0142-9612(02)00056-X; Lavik Erin, 2002, Methods Mol Biol, V198, P89; Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142-9612(00)00047-8; Marler JJ, 2000, PLAST RECONSTR SURG, V105, P2049, DOI 10.1097/00006534-200005000-00020; Matsuzawa M, 1996, INT J DEV NEUROSCI, V14, P283, DOI 10.1016/0736-5748(96)00014-7; Mehler MF, 1999, ARCH NEUROL-CHICAGO, V56, P780, DOI 10.1001/archneur.56.7.780; MIKOS AG, 1994, BIOMATERIALS, V15, P55, DOI 10.1016/0142-9612(94)90197-X; Mooney DJ, 1996, BIOMATERIALS, V17, P1417, DOI 10.1016/0142-9612(96)87284-X; Nehrer S, 1997, J BIOMED MATER RES, V38, P95; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Orgill DP, 1998, PLAST RECONSTR SURG, V102, P423, DOI 10.1097/00006534-199808000-00020; Parmar M, 2002, MOL CELL NEUROSCI, V21, P645, DOI 10.1006/mcne.2002.1204; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Powell SK, 2000, J NEUROSCI RES, V61, P302, DOI 10.1002/1097-4547(20000801)61:3<302::AID-JNR8>3.0.CO;2-G; Rabchevsky AG, 2001, ARCH NEUROL-CHICAGO, V58, P721, DOI 10.1001/archneur.58.5.721; Rowley JA, 2002, J BIOMED MATER RES, V60, P217, DOI 10.1002/jbm.1287; Storch Alexander, 2002, Curr Opin Investig Drugs, V3, P774; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Thiebaud P, 2002, BIOSENS BIOELECTRON, V17, P87, DOI 10.1016/S0956-5663(01)00279-2; WALD HL, 1993, BIOMATERIALS, V14, P270, DOI 10.1016/0142-9612(93)90117-K; Wheeler BC, 1999, J BIOMECH ENG-T ASME, V121, P73, DOI 10.1115/1.2798045; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Xu WM, 2001, FASEB J, V15, P213, DOI 10.1096/fj.01-0590fje; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899; Yeung CK, 2001, NEUROSCI LETT, V301, P147, DOI 10.1016/S0304-3940(01)01628-7; Zhu G, 2000, J NEUROSCI RES, V59, P312, DOI 10.1002/(SICI)1097-4547(20000201)59:3<312::AID-JNR4>3.0.CO;2-A	46	1780	1889	5	568	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1352	1355		10.1126/science.1093783	http://dx.doi.org/10.1126/science.1093783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14739465				2022-12-28	WOS:000189238600046
J	Valverde, F; Mouradov, A; Soppe, W; Ravenscroft, D; Samach, A; Coupland, G				Valverde, F; Mouradov, A; Soppe, W; Ravenscroft, D; Samach, A; Coupland, G			Photoreceptor regulation of CONSTANS protein in photoperiodic flowering	SCIENCE			English	Article							ARABIDOPSIS PHOTORECEPTORS; FLORAL INDUCTION; CIRCADIAN CLOCK; PHYTOCHROME-A; TIME; LIGHT; GENES; EXPRESSION; PLANTS; ROLES	Many plants flower in response to seasonal fluctuations in day length. The CONSTANS (CO) gene of Arabidopsis promotes flowering in long days. Flowering is induced when CO messenger RNA expression coincides with the exposure of plants to light. However, how this promotes CO activity is unknown. We show that light stabilizes nuclear CO protein in the evening, whereas in the morning or in darkness the protein is degraded by the proteasome. Photoreceptors regulate CO stability and act antagonistically to generate daily rhythms in CO abundance. This layer of regulation refines the circadian rhythm in CO messenger RNA and is central to the mechanism by which day length controls flowering.	Max Planck Inst Plant Breeding, D-50829 Cologne, Germany; Hebrew Univ Jerusalem, Robert H Smith Inst Plant Sci & Genet Agr, IL-76100 Rehovot, Israel	Max Planck Society; Hebrew University of Jerusalem	Coupland, G (corresponding author), Max Planck Inst Plant Breeding, Carl Von Linne Weg 10, D-50829 Cologne, Germany.	coupland@mpiz-koeln.mpg.de	Coupland, George/AAP-8609-2020; Valverde, Federico/K-1248-2014; Rosa, Bruce/F-6393-2010	Coupland, George/0000-0001-6988-4172; Valverde, Federico/0000-0001-8063-0974; Mouradov, Aidyn/0000-0003-2945-3751				BROWN JAM, 1971, PLANT PHYSIOL, V47, P393, DOI 10.1104/pp.47.3.393; Cerdan PD, 2003, NATURE, V423, P881, DOI 10.1038/nature01636; El-Assal SED, 2001, NAT GENET, V29, P435, DOI 10.1038/ng767; Garner WW, 1919, J AGRIC RES, V18, P0553; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Halliday KJ, 2003, PLANT J, V33, P875, DOI 10.1046/j.1365-313X.2003.01674.x; Hayama R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549; Hayama R, 2003, CURR OPIN PLANT BIOL, V6, P13, DOI 10.1016/S1369-5266(02)00011-0; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Mockler T, 2003, P NATL ACAD SCI USA, V100, P2140, DOI 10.1073/pnas.0437826100; Mockler TC, 1999, DEVELOPMENT, V126, P2073; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Robson F, 2001, PLANT J, V28, P619, DOI 10.1046/j.1365-313x.2001.01163.x; Roden LC, 2002, P NATL ACAD SCI USA, V99, P13313, DOI 10.1073/pnas.192365599; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Tepperman JM, 2001, P NATL ACAD SCI USA, V98, P9437, DOI 10.1073/pnas.161300998; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	23	873	960	4	260	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1003	1006		10.1126/science.1091761	http://dx.doi.org/10.1126/science.1091761			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963328	Green Published			2022-12-28	WOS:000188918000043
J	Wegmann-Burns, M; Gugger, M; Goldblum, D				Wegmann-Burns, M; Gugger, M; Goldblum, D			Hypertensive retinopathy	LANCET			English	Article									Univ Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland; Univ Bern, Dept Pathol, CH-3010 Bern, Switzerland	University of Bern; University of Bern	Wegmann-Burns, M (corresponding author), Univ Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.		Goldblum, David/G-8559-2014	Goldblum, David/0000-0002-2119-1710					0	5	5	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	2004	363	9407					456	456		10.1016/S0140-6736(04)15494-9	http://dx.doi.org/10.1016/S0140-6736(04)15494-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962528	Bronze			2022-12-28	WOS:000188999500014
J	Kim, J; Dong, HL; Seabaugh, J; Newell, SW; Eberl, DD				Kim, J; Dong, HL; Seabaugh, J; Newell, SW; Eberl, DD			Role of microbes in the smectite-to-illite reaction	SCIENCE			English	Article							SOLE ELECTRON-ACCEPTOR; STRUCTURAL FE(III); SP-NOV; REDUCTION; GROWTH; NONTRONITES; CONVERSION; BENTONITES; MINERALS; ROCKS	Temperature, pressure, and time have been thought to control the smectite-to-illite (S-I) reaction, an important diagenetic process used for petroleum exploration. We demonstrated that microorganisms can promote the S-I reaction by dissolving smectite through reduction of structural Fe(III) at room temperature and 1 atmosphere within 14 days. This reaction typically requires conditions of 300degrees to 350degreesC, 100 megapascals, and 4 to 5 months in the absence of microbial activity. These results challenge the conventional concept of the S-I reaction and of reaction kinetic models.	USN, Res Lab, Seafloor Sci Branch, Stennis Space Ctr, MS 39529 USA; Miami Univ, Dept Geol, Oxford, OH 45056 USA; US Geol Survey, Boulder, CO 80303 USA	United States Department of Defense; United States Navy; Naval Research Laboratory; University System of Ohio; Miami University; United States Department of the Interior; United States Geological Survey	Kim, J (corresponding author), USN, Res Lab, Seafloor Sci Branch, Stennis Space Ctr, MS 39529 USA.	jkim@nrlssc.navy.mil	Kim, Jinwook/AAO-7501-2020					BETHKE CM, 1986, CLAY CLAY MINER, V34, P136, DOI 10.1346/CCMN.1986.0340204; BOONE DR, 1995, INT J SYST BACTERIOL, V45, P441, DOI 10.1099/00207713-45-3-441; Brown KM, 2001, EARTH PLANET SC LETT, V194, P97, DOI 10.1016/S0012-821X(01)00546-5; BRUCE CH, 1984, AAPG BULL, V68, P673; BUCKLEY HA, 1978, MINERAL MAG, V42, P373, DOI 10.1180/minmag.1978.042.323.08; Dong HL, 1997, AM MINERAL, V82, P379; Dong HL, 2003, ENVIRON SCI TECHNOL, V37, P1268, DOI 10.1021/es020919d; Eberl DD, 1998, CLAY CLAY MINER, V46, P89, DOI 10.1346/CCMN.1998.0460110; Eberl DD, 1998, AM J SCI, V298, P499, DOI 10.2475/ajs.298.6.499; EBERL DD, 1996, 96171 USGS; ESLINGER E, 1979, CLAY CLAY MINER, V27, P327, DOI 10.1346/CCMN.1979.0270503; FREED RL, 1989, AAPG BULL, V73, P1223; GAUDETT E, 1966, CLAYS CLAY MINER, V13, P33; Kashefi K, 2002, APPL ENVIRON MICROB, V68, P1735, DOI 10.1128/AEM.68.4.1735-1742.2002; Keeling JL, 2000, CLAY CLAY MINER, V48, P537, DOI 10.1346/CCMN.2000.0480506; Kostka JE, 2002, APPL ENVIRON MICROB, V68, P6256, DOI 10.1128/AEM.68.12.6256-6262.2002; Kostka JE, 1996, CLAY CLAY MINER, V44, P522, DOI 10.1346/CCMN.1996.0440411; Lovley DR, 2000, ENVIRONMENTAL MICROBE-METAL INTERACTIONS, P3; Masuda H, 2001, CLAY CLAY MINER, V49, P109, DOI 10.1346/CCMN.2001.0490201; MYERS CR, 1988, SCIENCE, V240, P1319, DOI 10.1126/science.240.4857.1319; Pevear DR, 1999, P NATL ACAD SCI USA, V96, P3440, DOI 10.1073/pnas.96.7.3440; POLLASTRO RM, 1993, CLAY CLAY MINER, V41, P119, DOI 10.1346/CCMN.1993.0410202; Reed DW, 2002, APPL ENVIRON MICROB, V68, P3759, DOI 10.1128/AEM.68.8.3759-3770.2002; RUSSELL JD, 1979, CLAY CLAY MINER, V27, P63, DOI 10.1346/CCMN.1979.0270108; WARSHAW CM, 1957, THESIS PENNSYLVANIA; Weaver C.E., 1973, CHEM CLAY MINERALS	26	217	237	4	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	2004	303	5659					830	832		10.1126/science.1093245	http://dx.doi.org/10.1126/science.1093245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764877				2022-12-28	WOS:000188753800055
J	Mello, MM; Studdert, DM; Brennan, TA				Mello, MM; Studdert, DM; Brennan, TA			The pharmaceutical industry versus Medicaid - Limits on state initiatives to control prescription-drug costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							US HEALTH-CARE; LESSONS; MARKET		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St,PBB4, Boston, MA 02115 USA.	tabrennan@partners.org	Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270				BERNASEK C, 2002, FLORIDAS MEDICAID PR; BERNASEK C, 2003, CASE STUDY MICHIGANS; BRUEN B, 2002, STATES STRIVE LIMIT; CARRIER P, 2003, PORTLAND PRESS  0521, pA1; Huskamp HA, 2003, HEALTH AFFAIR, V22, P149, DOI 10.1377/hlthaff.22.3.149; Iglehart JK, 2003, NEW ENGL J MED, V348, P2140, DOI 10.1056/NEJMhpr035376; IGLEHART JK, 2003, NEW ENGL J MED, V349, P100; *KAIS COMM MED UN, 2002, MED PRESCR DRUG BEN; Kanavos P, 2003, HEALTH AFFAIR, V22, P16, DOI 10.1377/hlthaff.22.3.16; KLEIN R, 2003, BOSTON GLOBE    0612, pA1; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; Maynard A, 2003, HEALTH AFFAIR, V22, P31, DOI 10.1377/hlthaff.22.3.31; Morgan SG, 2003, HEALTH AFFAIR, V22, P49, DOI 10.1377/hlthaff.22.3.49; *NAT C STAT LEG, STAT PHARM ASS PROGR; *NAT GOV ASS NAT A, 2002, FISC SURV STAT; SCHNEIDER A, 2002, MEDICAID PURCHASING; SMITH DG, 2002, COMMUNICATION   0918; STURGES P, 2003, BNA HLTH LAW REP, V12, P796; Towse A, 2003, HEALTH AFFAIR, V22, P42, DOI 10.1377/hlthaff.22.3.42; 2002, BNA HLTH LAW REP, V11, P896	20	23	24	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					608	613		10.1056/NEJMlim035683	http://dx.doi.org/10.1056/NEJMlim035683			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762190				2022-12-28	WOS:000188712800015
J	Starace, DM; Bezanilla, F				Starace, DM; Bezanilla, F			A proton pore in a potassium channel voltage sensor reveals a focused electric field	NATURE			English	Article							SHAKER K+ CHANNEL; S4 SEGMENT; CHARGE MOVEMENT; GATING CHARGE; ION CHANNELS; INACTIVATION; FLUCTUATIONS; MUTAGENESIS; EXPRESSION; RESIDUES	Voltage-dependent potassium channels are essential for the generation of nerve impulses(1). Voltage sensitivity is conferred by charged residues located mainly in the fourth transmembrane segment (S4) of each of the four identical subunits that make up the channel. These charged segments relocate when the potential difference across the membrane changes(2,3), controlling the ability of the pore to conduct ions. In the crystal structure of the Aeropyrum pernix potassium channel KvAP(4), the S4 and part of the third (S3B) transmembrane alpha-helices are connected by a hairpin turn in an arrangement termed the 'voltage-sensor paddle'. This structure was proposed to move through the lipid bilayer during channel activation, transporting positive charges across a large fraction of the membrane(5). Here we show that replacing the first S4 arginine by histidine in the Shaker potassium channel creates a proton pore when the cell is hyperpolarized. Formation of this pore does not support the paddle model, as protons would not have access to a lipid-buried histidine. We conclude that, at hyperpolarized potentials, water and protons from the internal and external solutions must be separated by a narrow barrier in the channel protein that focuses the electric field to a small voltage-sensitive region.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bezanilla, F (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	Fbezanil@ucla.edu						Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Asamoah OK, 2003, NEURON, V37, P85, DOI 10.1016/S0896-6273(02)01126-1; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Cherny VV, 2003, J GEN PHYSIOL, V121, P615, DOI 10.1085/jgp.200308813; CONTI F, 1980, J PHYSIOL-LONDON, V308, P217, DOI 10.1113/jphysiol.1980.sp013469; ECOURSEY TE, 2003, PHYSIOL REV, V83, P475; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Islas LD, 2001, J GEN PHYSIOL, V117, P69, DOI 10.1085/jgp.117.1.69; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; LEE Y. W., 1960, STAT THEORY COMMUNIC; Olcese R, 1997, J GEN PHYSIOL, V110, P579, DOI 10.1085/jgp.110.5.579; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; Schumaker MF, 2000, BIOPHYS J, V79, P2840, DOI 10.1016/S0006-3495(00)76522-2; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Starace DM, 2001, J GEN PHYSIOL, V117, P469, DOI 10.1085/jgp.117.5.469; Stefani E, 1998, METHOD ENZYMOL, V293, P300; STEVENS CF, 1972, BIOPHYS J, V12, P1028, DOI 10.1016/S0006-3495(72)86141-1; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448	30	315	324	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					548	553		10.1038/nature02270	http://dx.doi.org/10.1038/nature02270			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765197				2022-12-28	WOS:000188721800043
J	Miller, FG; Emanuel, EJ; Rosenstein, DL; Straus, SE				Miller, FG; Emanuel, EJ; Rosenstein, DL; Straus, SE			Ethical issues concerning research in complementary and alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIAL; PLACEBO-CONTROLLED TRIALS; LOW-BACK-PAIN; HYPERICUM-PERFORATUM; UNITED-STATES; FOLLOW-UP; DEPRESSION; ACUPUNCTURE; DISORDER; THERAPY	The use of complementary and alternative medicine (CAM) has grown dramatically in recent years, as has research on the safety and efficacy of CAM treatments. Minimal attention, however, has been devoted to the ethical issues relating to research on CAM. We argue that public health and safety demand rigorous research evaluating CAM therapies, research on CAM should adhere to the same ethical requirements for all clinical research, and randomized, placebo-controlled clinical trials should be used for assessing the efficacy of CAM treatments whenever feasible and ethically justifiable. in addition, we explore the legitimacy of providing CAM and conventional therapies that have been demonstrated to be effective only by virtue of the placebo effect.	NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; NIH, Dept Clin Bioeth, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; NIMH, Off Clin Director, NIH, Bethesda, MD 20892 USA; NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Straus, SE (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, Bldg 31,Room 2B11, Bethesda, MD 20892 USA.	sstraus@nih.gov						Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Bonne O, 2003, J CLIN PSYCHIAT, V64, P282, DOI 10.4088/JCP.v64n0309; BOOZANG KM, 2000, CONN L REV, V32, P567; BRODY H, 2000, PLACEBO RESPONSE, P143; Calvert EL, 2002, GASTROENTEROLOGY, V123, P1778, DOI 10.1053/gast.2002.37071; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; De Smet PAGM, 2002, NEW ENGL J MED, V347, P2046, DOI 10.1056/NEJMra020398; *DEP HLTH HUM SERV, ELUC UND MECH PLAC E; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Ernst E, 2001, CLIN PHARMACOL THER, V70, P497, DOI 10.1067/mcp.2001.120249; Fabrega H, 2002, PERSPECT BIOL MED, V45, P395, DOI 10.1353/pbm.2002.0044; Hrobjartsson A, 2002, J CLIN EPIDEMIOL, V55, P430, DOI 10.1016/S0895-4356(01)00496-6; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Insel TR, 2003, JAMA-J AM MED ASSOC, V289, P3167, DOI 10.1001/jama.289.23.3167; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Kienle GS, 1997, J CLIN EPIDEMIOL, V50, P1311, DOI 10.1016/S0895-4356(97)00203-5; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Levin JS, 1997, MED CARE, V35, P1079, DOI 10.1097/00005650-199711000-00001; Marshall E, 2000, SCIENCE, V290, P437, DOI 10.1126/science.290.5491.437; MILLS S, 2002, CLIN RES COMPLEMENTA, P211; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Ni HY, 2002, MED CARE, V40, P353, DOI 10.1097/00005650-200204000-00011; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Smith C, 2002, BIRTH-ISS PERINAT C, V29, P1, DOI 10.1046/j.1523-536X.2002.00149.x; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Thorne S, 2002, J ALTERN COMPLEM MED, V8, P907, DOI 10.1089/10755530260511900; Walach H, 2001, J ALTERN COMPLEM MED, V7, P213, DOI 10.1089/107555301300328070; Whiskey E, 2001, INT CLIN PSYCHOPHARM, V16, P239, DOI 10.1097/00004850-200109000-00001	33	82	83	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					599	604		10.1001/jama.291.5.599	http://dx.doi.org/10.1001/jama.291.5.599			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	769LC	14762039				2022-12-28	WOS:000188650700025
J	van Dis, J				van Dis, J			Residency training and pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTETRICS; GYNECOLOGY; POLICIES		Univ Hawaii, Honolulu, HI 96822 USA	University of Hawaii System	van Dis, J (corresponding author), Univ Hawaii, Honolulu, HI 96822 USA.							*AM MED ASS, WOM RES SPEC 2002; *ASS AM MED COLL, 2002, WOM US AC MED STAT 2; Davis JL, 2001, OBSTET GYNECOL, V98, P1093, DOI 10.1016/S0029-7844(01)01605-2; ESKENAZI L, 1995, PLAST RECONSTR SURG, V95, P330, DOI 10.1097/00006534-199502000-00013; Finch SJ, 2003, ACAD MED, V78, P418, DOI 10.1097/00001888-200304000-00021; Gabbe SG, 2003, OBSTET GYNECOL, V102, P948, DOI 10.1016/S0029-7844(03)00856-1; Harris D L, 1990, J Am Med Womens Assoc (1972), V45, P127; Harris DL, 1990, J AM MED WOMEN ASSOC, V45, P131; KLEVAN JL, 1990, AM J DIS CHILD, V144, P767, DOI 10.1001/archpedi.1990.02150310035021; MANASTER BJ, 1995, ACAD RADIOL, V2, P804, DOI 10.1016/S1076-6332(05)80492-1; PHELAN ST, 1992, ACAD MED, V67, P408, DOI 10.1097/00001888-199206000-00014	11	10	10	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					636	636		10.1001/jama.291.5.636	http://dx.doi.org/10.1001/jama.291.5.636			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762048				2022-12-28	WOS:000188650700034
J	Chen, J; Muntner, P; Hamm, LL; Jones, DW; Batuman, V; Fonseca, V; Whelton, PK; He, J				Chen, J; Muntner, P; Hamm, LL; Jones, DW; Batuman, V; Fonseca, V; Whelton, PK; He, J			The metabolic syndrome and chronic kidney disease in US adults	ANNALS OF INTERNAL MEDICINE			English	Article							INSULIN-RESISTANCE SYNDROME; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR-DISEASE; RENAL-DISEASE; SERUM CREATININE; BLOOD-PRESSURE; RISK; PROGRESSION; MORTALITY; PREVALENCE	Background: The metabolic syndrome is a common risk factor for cardiovascular disease. Objective: To examine the association between the metabolic syndrome and risk for chronic kidney disease and microalbuminuria. Design: Cross-sectional study. Setting: The Third National Health and Nutrition Examination Survey. Patients: Participants 20 years of age or older were studied in the chronic kidney disease (n = 6217) and microalbuminuria (n 6125) analyses. Measurements: The metabolic syndrome was defined as the presence of 3 or more of the following risk factors: elevated blood pressure, low high-density lipoprotein cholesterol level, high triglyceride level, elevated glucose level, and abdominal obesity. Chronic kidney disease was defined as a glomerular filtration rate less than 60 mL/min per 1.73 m(2), and microalbuminuria was defined as a urinary albumin-creatinine ratio of 30 to 300 mg/g. Results: The multivariate-adjusted odds ratios of chronic kidney disease and microalbuminuria in participants with the metabolic syndrome compared with participants without the metabolic syndrome were 2.60 (95% Cl, 1.68 to 4.03) and 1.89 (Cl, 1.34 to 2.67), respectively. Compared with participants with 0 or 1 component of the metabolic syndrome, participants with 2, 3, 4, and 5 components of chronic kidney disease had multivariate-adjusted odds ratios of 2.21 (Cl, 1.16 to 4.24), 3.38 (Cl, 1.48 to 7.69), 4.23 (Cl, 2.06 to 8.63), and 5.85 (Cl, 3.11 to 11.0), respectively. The corresponding multivariate-adjusted odds ratios of microalbuminuria for participants with 3, 4, and 5 components were 1.62 (Cl, 1.10 to 2.38), 2.45 (Cl, 1.55 to 3.85), and 3.19 (Cl, 1.96 to 5.19), respectively. Conclusions: These findings suggest that the metabolic syndrome might be an important factor in the cause of chronic kidney disease.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA; Univ Mississippi, Sch Med, Jackson, MS 39216 USA	Tulane University; Tulane University; University of Mississippi	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL18, New Orleans, LA 70112 USA.	jhe@tulane.edu	He, Jiang/AAF-5303-2020	He, Jiang/0000-0002-8286-9652; Batuman, Vecihi/0000-0002-1800-9009	NICHD NIH HHS [K12 HD43451] Funding Source: Medline; NIDDK NIH HHS [U01 DK60963] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK060963] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, VITAL HLTH STAT, P1; Chen J, 2003, J AM SOC NEPHROL, V14, P469, DOI 10.1097/01.ASN.0000046029.53933.09; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Culleton BF, 1999, KIDNEY INT, V56, P2214, DOI 10.1046/j.1523-1755.1999.00773.x; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; Hall JE, 1999, ANN NY ACAD SCI, V892, P91, DOI 10.1111/j.1749-6632.1999.tb07788.x; HE J, 1999, INT HDB HYPERTENSION; Hoehner CM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015762.92814.85; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260; Iseki K, 1997, KIDNEY INT, pS169; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Kopple JD, 2000, KIDNEY INT, V57, P1688, DOI 10.1046/j.1523-1755.2000.00014.x; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; National Institutes of Health,, 2001, NIH PUBL; Nelson RG, 1996, NEW ENGL J MED, V335, P1636, DOI 10.1056/NEJM199611283352203; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; *US REN DAT SYST, 2002, USRDS 2002 ANN DAT R; Whelton PK, 1996, J HUM HYPERTENS, V10, P683	29	1016	1078	0	44	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					167	174		10.7326/0003-4819-140-3-200402030-00007	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757614				2022-12-28	WOS:000188704500002
J	Yazdanpanah, Y; Sissoko, D; Egger, M; Mouton, Y; Zwahlen, M; Chene, G				Yazdanpanah, Y; Sissoko, D; Egger, M; Mouton, Y; Zwahlen, M; Chene, G			Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; 2 NUCLEOSIDE ANALOGS; DOUBLE-BLIND TRIAL; NAIVE PATIENTS; SYSTEMATIC REVIEWS; HIV-1 INFECTION; PLUS ZIDOVUDINE; HEALTH-CARE; NEVIRAPINE; INDINAVIR	Objective To compare the clinical efficacy of triple antiretroviral regimens based on protease inhibitors and non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) in adults positive for antibodies to HIV-1. Design Systematic review and meta-analysis using indirect comparisons of clinical trials comparing three drug regimens based on two nucleoside reverse transcriptase inhibitors (NRTIs) and either a protease inhibitor or air NNRTI with two drug regimens (two NRTIs). Participants had no previous exposure to protease inhibitors or NNRTIs. Data sources Medline, the Cochrane controlled trials register, Aidstrials, Aidsdrugs, conference proceedings, and trial registers. Main outcome measure Progression to AIDS or death. Results 14 trials, totalling 6785 patients, were identified. Most patients had been exposed to an NRTI and had advanced immunodeficiency at baseline; 1096 Progressed to AIDS or died. Seven trials assessed protease inhibitors based triple regimens and seven assessed NNRTI based triple regimens (nevirapine or delavirdine). Triple therapy was more effective than dual therapy. The effect was pronounced for protease inhibitor based regimens (odds ratio 0.49, 95% confidence interval 0.41 to 0.58) but non-significant for NNRTI based regimens (0.90, 0.71 to 1.15). Indirect comparison of the two regimens gave an odds ratio of 0.54 (0.49 to 0.73) in favour of protease inhibitor based treatments. Increases in CD4 cell counts were smaller and suppression of viral replication less with NNRTI based regimens. Conclusions Indirect evidence shows that protease inhibitor based triple regimens are superior to regimens based on the NNRTIs nevirapine and delavirdine in patients with advanced immunodeficiency who have been exposed to NRTIs. Large trials with clinical end points are required.	Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, Fac Med Lille, F-59208 Tourcoing, France; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; INSERM, U593, Bordeaux, France	University of Bristol; University of Bern; Institut National de la Sante et de la Recherche Medicale (Inserm)	Yazdanpanah, Y (corresponding author), Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, Fac Med Lille, BP 619, F-59208 Tourcoing, France.	yyazdan@yahoo.com	chene, genevieve/H-8665-2014; Sissoko, Daouda/L-9193-2013	chene, genevieve/0000-0002-8368-6460; Sissoko, Daouda/0000-0002-8890-7170; Egger, Matthias/0000-0001-7462-5132				Albrecht MA, 2001, NEW ENGL J MED, V345, P398, DOI 10.1056/NEJM200108093450602; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Cozzi-Lepri A, 2002, J INFECT DIS, V185, P1062, DOI 10.1086/339821; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Floridia M, 1999, J ACQ IMMUN DEF SYND, V20, P11, DOI 10.1097/00042560-199901010-00002; Friedland GH, 1999, J ACQ IMMUN DEF SYND, V21, P281, DOI 10.1097/00126334-199908010-00005; Garcia F, 1999, AIDS, V13, P2377, DOI 10.1097/00002030-199912030-00009; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, J ACQ IMMUN DEF SYND, V19, P339, DOI 10.1097/00042560-199812010-00004; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Lefebvre C, 2001, SYSTEMATIC REV HLTH, P69; Matthews GV, 2002, AIDS, V16, P53, DOI 10.1097/00002030-200201040-00008; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MOYLE G, 1999, 39 INT C ANT AG CHEM; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Phillips AN, 2001, AIDS, V15, P2385, DOI 10.1097/00002030-200112070-00006; Podzamczer D, 2002, ANTIVIR THER, V7, P81; REEN S, 1998, 12 WORLD AIDS C GEN; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Stellbrink HJ, 2000, CLIN DRUG INVEST, V20, P295, DOI 10.2165/00044011-200020050-00001; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; SUREAU P, 1993, JAMA-J AM MED ASSOC, V269, P460; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Trotta MP, 2003, AIDS, V17, P1099, DOI 10.1097/00002030-200305020-00026; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; VANLETH F, 2003, 10 C RETR OPP INF BO; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	42	55	55	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	2004	328	7434					249	253		10.1136/bmj.37995.435787.A6	http://dx.doi.org/10.1136/bmj.37995.435787.A6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14742351	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000188786000014
J	Rendulic, S; Jagtap, P; Rosinus, A; Eppinger, M; Baar, C; Lanz, C; Keller, H; Lambert, C; Evans, KJ; Goesmann, A; Meyer, F; Sockett, RE; Schuster, SC				Rendulic, S; Jagtap, P; Rosinus, A; Eppinger, M; Baar, C; Lanz, C; Keller, H; Lambert, C; Evans, KJ; Goesmann, A; Meyer, F; Sockett, RE; Schuster, SC			A predator unmasked: Life cycle of Bdellovibrio bacteriovorus from a genomic perspective	SCIENCE			English	Article							ESCHERICHIA-COLI; PENETRATION; MEMBRANE; CELLS; 109J	Predatory bacteria remain molecularly enigmatic, despite their presence in many microbial communities. Here we report the complete genome of Bdellovibrio bacteriovorus HD100, a predatory Gram-negative bacterium that invades and consumes other Gram-negative bacteria. Its surprisingly large genome shows no evidence of recent gene transfer from its prey. A plethora of paralogous gene families coding for enzymes, such as hydrolases and transporters, are used throughout the life cycle of B. bacteriovorus for prey entry, prey killing, and the uptake of complex molecules.	Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; Univ Nottingham, Inst Genet, Nottingham NG7 2UH, England; Univ Bielefeld, Ctr Biotechnol, D-33594 Bielefeld, Germany	Max Planck Society; University of Nottingham; University of Bielefeld	Schuster, SC (corresponding author), Max Planck Inst Dev Biol, D-72076 Tubingen, Germany.	stephan.schuster@tuebingen.mpg.de	Lambert, Carey/AAY-9270-2020	Lambert, Carey/0000-0002-1844-457X; Meyer, Folker/0000-0003-1112-2284; Goesmann, Alexander/0000-0002-7086-2568; Jagtap, Pratik/0000-0003-0984-0973				Amiri H, 2003, J MOL EVOL, V56, P137, DOI 10.1007/s00239-002-2387-0; Barel G, 2001, ARCH MICROBIOL, V176, P211, DOI 10.1007/s002030100312; BURNHAM JC, 1968, J BACTERIOL, V96, P1366, DOI 10.1128/JB.96.4.1366-1381.1968; FACKRELL HB, 1973, CAN J MICROBIOL, V19, P659, DOI 10.1139/m73-107; Hasegawa H, 2003, FEMS MICROBIOL LETT, V223, P41, DOI 10.1016/S0378-1097(03)00327-6; Kachlany SC, 2000, J BACTERIOL, V182, P6169, DOI 10.1128/JB.182.21.6169-6176.2000; LENZ RW, 1978, ARCH MICROBIOL, V119, P245, DOI 10.1007/BF00405402; Martin MO, 2002, J MOL MICROB BIOTECH, V4, P467; Mattick JS, 2002, ANNU REV MICROBIOL, V56, P289, DOI 10.1146/annurev.micro.56.012302.160938; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; RITTENBERG SC, 1982, EXPT MICROBIAL ECOLO; RUBY EG, 1986, J BACTERIOL, V167, P1066, DOI 10.1128/jb.167.3.1066-1070.1986; SAIER MH, 1994, FEBS LETT, V337, P14, DOI 10.1016/0014-5793(94)80620-9; Schwudke D, 2003, J BIOL CHEM, V278, P27502, DOI 10.1074/jbc.M303012200; Shilo M, 1969, Curr Top Microbiol Immunol, V50, P174; STOLP H, 1963, ANTON VAN LEE J M S, V29, P217, DOI 10.1007/BF02046064; THOMASHOW LS, 1985, J BACTERIOL, V163, P1038, DOI 10.1128/JB.163.3.1038-1046.1985; THOMASHOW MF, 1978, J BACTERIOL, V135, P998, DOI 10.1128/JB.135.3.998-1007.1978; TUDOR JJ, 1990, J BACTERIOL, V172, P2421, DOI 10.1128/jb.172.5.2421-2426.1990; VARON M, 1980, ADV AQUATIC MICROBIO, V2	20	254	550	5	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					689	692		10.1126/science.1093027	http://dx.doi.org/10.1126/science.1093027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752164				2022-12-28	WOS:000188530800046
J	Craig, AS; Schaffner, W				Craig, AS; Schaffner, W			Prevention of hepatitis A with the hepatitis A vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COST-EFFECTIVENESS; UNITED-STATES; FOLLOW-UP; CHILDHOOD VACCINATION; VIRUS-INFECTIONS; B VACCINE; IMMUNOGENICITY; SAFETY; BOOSTER; OUTBREAK		Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Tennessee Dept Hlth, Communicable & Environm Dis Serv Sect, Nashville, TN USA	Vanderbilt University; Tennessee Department Health	Schaffner, W (corresponding author), Vanderbilt Univ, Sch Med, Dept Prevent Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	william.schaffner@vanderbilt.edu						Allard R, 2001, J EPIDEMIOL COMMUN H, V55, P251, DOI 10.1136/jech.55.4.251; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2004, VACCINES-BASEL; Arguedas MR, 2002, AM J GASTROENTEROL, V97, P721, DOI 10.1111/j.1572-0241.2002.05554.x; Armstrong GL, 2002, PEDIATRICS, V109, P839, DOI 10.1542/peds.109.5.839; Arslan M, 2001, TRANSPLANTATION, V72, P272, DOI 10.1097/00007890-200107270-00019; Ashur Y, 1999, VACCINE, V17, P2290, DOI 10.1016/S0264-410X(98)00480-0; Averhoff F, 2001, JAMA-J AM MED ASSOC, V286, P2968, DOI 10.1001/jama.286.23.2968; AVERHOFF F, 1996, 36 INT C ANT AG CHEM; Battegay M, 1998, NEW ENGL J MED, V338, P1771; Bell BP, 1998, J INFECT DIS, V178, P1579, DOI 10.1086/314518; BIALEK SR, IN PRESS AM J PUBLIC; Bower WA, 2000, J INFECT DIS, V182, P12, DOI 10.1086/315701; *CDCP, 2000, 57 CDC; *CDCP, 2002, DIS BURD VIR HEP A B; CLEMENS R, 1995, J INFECT DIS, V171, pS44, DOI 10.1093/infdis/171.Supplement_1.S44; Connor BA, 2003, BIODRUGS, V17, P19, DOI 10.2165/00063030-200317001-00005; Craig AS, 1998, CLIN INFECT DIS, V27, P531, DOI 10.1086/514700; Cuthbert JA, 2001, CLIN MICROBIOL REV, V14, P642; DAGAN R, 2002, 40 ANN M INF DIS SOC, P189; Diaz-Mitoma F, 1999, PEDIATR INFECT DIS J, V18, P109, DOI 10.1097/00006454-199902000-00006; Fiore AE, 2003, PEDIATR INFECT DIS J, V22, P354; HOKE CH, 1992, VACCINE, V10, pS75, DOI 10.1016/0264-410X(92)90550-4; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Jacobs RJ, 2003, PEDIATR INFECT DIS J, V22, P904, DOI 10.1097/01.inf.0000091295.53969.6a; Jacobs RJ, 2002, AM J GASTROENTEROL, V97, P427; Keeffe EB, 1998, HEPATOLOGY, V27, P881, DOI 10.1002/hep.510270336; Koff RS, 1999, NEW ENGL J MED, V340, P644, DOI 10.1056/NEJM199902253400810; Landry P, 2000, VACCINE, V19, P399, DOI 10.1016/S0264-410X(00)00188-2; LEDNAR WM, 1985, AM J EPIDEMIOL, V122, P226, DOI 10.1093/oxfordjournals.aje.a114093; Lee SD, 1997, J MED VIROL, V52, P215, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;215::AID-JMV16&gt;3.0.CO;2-J; MCMAHON BJ, 1995, J INFECT DIS, V171, P676, DOI 10.1093/infdis/171.3.676; McMahon BJ, 1996, ARCH PEDIAT ADOL MED, V150, P733, DOI 10.1001/archpedi.1996.02170320079014; MOSLEY JW, 1968, AM J EPIDEMIOL, V87, P539, DOI 10.1093/oxfordjournals.aje.a120845; Neilsen GA, 1997, J INFECT DIS, V176, P1064, DOI 10.1086/516512; Niu MT, 1998, CLIN INFECT DIS, V26, P1475, DOI 10.1086/517673; Piazza M, 1999, VACCINE, V17, P585, DOI 10.1016/S0264-410X(98)00237-0; Sagliocca L, 1999, LANCET, V353, P2078; Sagliocca L, 1999, LANCET, V353, P1136, DOI 10.1016/S0140-6736(98)08139-2; STOKES J, 1945, JAMA-J AM MED ASSOC, V127, P144, DOI 10.1001/jama.1945.02860030016004; Tsai IJ, 2000, VACCINE, V19, P437, DOI 10.1016/S0264-410X(00)00205-X; Van Damme P, 2003, LANCET, V362, P1065, DOI 10.1016/S0140-6736(03)14418-2; Van Herck K, 2001, J MED VIROL, V63, P1, DOI 10.1002/1096-9071(200101)63:1&lt;1::AID-JMV1000&gt;3.0.CO;2-U; VANDAMME P, 1994, J MED VIROL, V44, P446, DOI 10.1002/jmv.1890440425; Vento S, 2000, J Viral Hepat, V7 Suppl 1, P7, DOI 10.1046/j.1365-2893.2000.00019.x; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; Werzberger A, 2002, VACCINE, V20, P1699, DOI 10.1016/S0264-410X(02)00042-7; Werzberger A, 1998, NEW ENGL J MED, V338, P1160, DOI 10.1056/NEJM199804163381615; Wiedermann G, 1998, ACTA TROP, V69, P121, DOI 10.1016/S0001-706X(97)00120-4; Willner IR, 1998, ANN INTERN MED, V128, P111, DOI 10.7326/0003-4819-128-2-199801150-00006; Wolters B, 2003, VACCINE, V21, P3623, DOI 10.1016/S0264-410X(03)00399-2	51	70	74	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					476	481		10.1056/NEJMcp031540	http://dx.doi.org/10.1056/NEJMcp031540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749456				2022-12-28	WOS:000188463900010
J	Kruit, MC; van Buchem, MA; Hofman, PAM; Bakkers, JTN; Terwindt, GM; Ferrari, MD; Launer, LJ				Kruit, MC; van Buchem, MA; Hofman, PAM; Bakkers, JTN; Terwindt, GM; Ferrari, MD; Launer, LJ			Migraine as a risk factor for subclinical brain lesions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; WHITE-MATTER; CARDIOVASCULAR HEALTH; ARTERIAL TERRITORIES; CLINICAL-FEATURES; ISCHEMIC STROKE; ELDERLY-PEOPLE; YOUNG-WOMEN; PREVALENCE; INFARCTS	Context Clinical series have suggested an increased prevalence of cerebral infarction and white matter lesions (WMLs) in migraine patients. It is not known whether these lesions are prevalent in the general migraine population. Objectives To compare the prevalence of brain infarcts and WMLs in migraine cases and controls from the general population and to identify migraine characteristics associated with these lesions. Design Cross-sectional, prevalence study of population-based sample of Dutch adults aged 30 to 60 years. Participants Randomly selected patients with migraine with aura (n=161), patients with migraine without aura (n=134), and controls (n=140), who were frequency matched to cases for age, sex, and place of residence. Nearly 50% of the cases had not been previously diagnosed by a physician. Main Outcome Measures Brain magnetic resonance images were evaluated for infarcts, by location and vascular supply territory, and for periventricular WMLs (PVWMLs) and deep WMLs (DWMLs). The odds ratios (ORs) and 95% confidence intervals (CIs) of these brain lesions compared with controls were examined by migraine subtype (with or without aura) and monthly attack frequency (<1 attack, &GE;1 attack), controlling for cardiovascular risk factors and use of vasoconstrictor migraine agents. All participants underwent a standard neurological examination. Results No participants reported a history of stroke or transient ischemic attack or had relevant abnormalities at standard neurological examination. We found no significant difference between patients with migraine and controls in overall infarct prevalence (8.1% vs 5.0%). However, in the cerebellar region of the posterior circulation territory, patients with migraine had a higher prevalence of infarct than controls (5.4% vs 0.7%; P=.02; adjusted OR, 7.1; 95% CI, 0.9-55). The adjusted OR for posterior infarct varied by migraine subtype and attack frequency. The adjusted OR was 13.7 (95% CI, 1.7-112) for patients with migraine with aura compared with controls. In patients with migraine with a frequency of attacks of 1 or more per month, the adjusted OR was 9.3 (95% CI, 1.1-76). The highest risk was in patients with migraine with aura with 1 attack or more per month (OR, 15.8; 95% CI, 1.8-140). Among women, the risk for high DWML load (top 20th percentile of the distribution of DWML load vs lower 80th percentile) was increased in patients with migraine compared with controls (OR, 2.1; 95% Cl, 1.0-4.1); this risk increased with attack frequency (highest in those with &GE;1 attack per month: OR, 2.6; 95% CI, 1.2-5.7) but was similar in patients with migraine with or without aura. In men, controls and patients with migraine did not differ in the prevalence of DWMLs. There was no association between severity of PVWMLs and migraine, irrespective of sex or migraine frequency or subtype. Conclusions. These population-based findings suggest that some patients with migraine with and without aura are at increased risk for subclinical lesions in certain brain areas.	Leiden Univ, Med Ctr, Dept Radiol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2333 ZA Leiden, Netherlands; Acad Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; Slingeland Hosp, Dept Radiol, Doetinchem, Netherlands; NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University; Maastricht University Medical Centre (MUMC); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Kruit, MC (corresponding author), Leiden Univ, Med Ctr, Dept Radiol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	m.c.kruit@lumc.nl	Ferrari, Michel D./ABE-3758-2021; Launer, Lenore J/A-8218-2010; van Buchem, Mark/AAC-9843-2022; Kruit, Mark C/K-2431-2012	Ferrari, Michel D./0000-0001-9691-9449; van Buchem, Mark/0000-0003-1881-1998; Kruit, Mark C/0000-0002-4319-834X; Dichgans, Martin/0000-0002-0654-387X	NATIONAL INSTITUTE ON AGING [Z01AG007270, ZIAAG007270] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexander JA, 1996, AM J NEURORADIOL, V17, P1507; Anzola GP, 1999, NEUROLOGY, V52, P1622, DOI 10.1212/WNL.52.8.1622; Bednarczyk EM, 1998, NEUROLOGY, V50, P1736, DOI 10.1212/WNL.50.6.1736; Bernick C, 2001, NEUROLOGY, V57, P1222, DOI 10.1212/WNL.57.7.1222; Boer JMA, 1998, ATHEROSCLEROSIS, V136, P395, DOI 10.1016/S0021-9150(97)00231-1; BOGOUSSLAVSKY J, 1993, NEUROLOGY, V43, P1528, DOI 10.1212/WNL.43.8.1528; Bokura H, 1998, J NEUROL, V245, P116, DOI 10.1007/s004150050189; BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012; CAPLAN LR, 1991, NEUROLOGY, V41, P55, DOI 10.1212/WNL.41.1.55; CAPLAN LR, 1996, POSTERIOR CIRCULATIO, P555; Carolei A, 1996, LANCET, V347, P1503, DOI 10.1016/S0140-6736(96)90669-8; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Crassard I, 2001, CEPHALALGIA, V21, P630, DOI 10.1046/j.1468-2982.2001.00205.x; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; DEBENEDITTIS G, 1995, HEADACHE, V35, P264; del Rio MS, 1999, CEPHALALGIA, V19, P701, DOI 10.1046/j.1468-2982.1999.019008701.x; Donaghy M, 2002, J NEUROL NEUROSUR PS, V73, P747, DOI 10.1136/jnnp.73.6.747; Dreier JP, 2002, BRAIN, V125, P102, DOI 10.1093/brain/awf007; Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103; Eggers AE, 2001, MED HYPOTHESES, V56, P360, DOI 10.1054/mehy.2000.1214; FAZEKAS F, 1992, HEADACHE, V32, P287, DOI 10.1111/j.1526-4610.1992.hed3206287.x; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Fujita S, 2002, ACTA NEUROL SCAND, V105, P445, DOI 10.1034/j.1600-0404.2002.01208.x; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; GOADSBY PJ, 1997, HEADACHE, P5; Goldberg MP, 2003, STROKE, V34, P330, DOI 10.1161/01.STR.0000054048.22626.B9; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HoekstravanDalen RAH, 1996, J NEUROL, V243, P511, DOI 10.1007/BF00886872; Launer LJ, 1999, NEUROLOGY, V53, P537, DOI 10.1212/WNL.53.3.537; Longstreth WT, 1996, STROKE, V27, P1274, DOI 10.1161/01.STR.27.8.1274; Merikangas KR, 1997, ARCH NEUROL-CHICAGO, V54, P362, DOI 10.1001/archneur.1997.00550160012009; Milhaud D, 2001, NEUROLOGY, V57, P1805, DOI 10.1212/WNL.57.10.1805; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PAVESE N, 1994, CEPHALALGIA, V14, P342, DOI 10.1046/j.1468-2982.1994.1405342.x; PESSIN MS, 1987, ANN NEUROL, V21, P290, DOI 10.1002/ana.410210311; Price T R, 1993, Ann Epidemiol, V3, P504; Sacco RL, 1997, NEUROLOGY S4, V49, P39; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; SPENCE JD, 1984, CAN MED ASSOC J, V131, P1457; Tatu L, 1998, NEUROLOGY, V50, P1699, DOI 10.1212/WNL.50.6.1699; Tatu L, 1996, NEUROLOGY, V47, P1125, DOI 10.1212/WNL.47.5.1125; Tietjen GE, 2001, NEUROLOGY, V57, P334, DOI 10.1212/WNL.57.2.334; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; Tzourio C, 2001, NEUROLOGY, V56, P1273, DOI 10.1212/WNL.56.10.1273; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Wilmshurst P, 2001, CLIN SCI, V100, P215, DOI 10.1042/CS20000231	47	660	693	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					427	434		10.1001/jama.291.4.427	http://dx.doi.org/10.1001/jama.291.4.427			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747499	Bronze			2022-12-28	WOS:000188426700027
J	Garrel, D				Garrel, D			Burn scars: a new cause of vitamin D deficiency?	LANCET			English	Editorial Material							BONE MASS		Hop Hotel Dieu, Burn Ctr, Montreal, PQ H2W 1T8, Canada	Universite de Montreal	Garrel, D (corresponding author), Hop Hotel Dieu, Burn Ctr, Montreal, PQ H2W 1T8, Canada.	dominique.garrel@umontreal.ca						*AM BURN ASS, 2002, NAT BURN REP 2002 RE; Bernier J, 1998, CRIT CARE MED, V26, P452, DOI 10.1097/00003246-199803000-00014; Docio S, 1998, J BONE MINER RES, V13, P544, DOI 10.1359/jbmr.1998.13.4.544; Edelman LS, 2003, J SURG RES, V114, P172, DOI 10.1016/S0022-4804(03)00275-0; EVANS EB, 2002, TOTAL BURN CARE, P593; HOLICK MF, 1999, MODERN NUTR HLTH DIS, P329; Klein GL, 2002, J TRAUMA, V52, P346, DOI 10.1097/00005373-200202000-00022; KLEIN GL, 1995, BONE, V17, P455, DOI 10.1016/8756-3282(95)00279-1; KLEIN GL, 1995, J PEDIATR-US, V126, P252, DOI 10.1016/S0022-3476(95)70553-8; KLEIN GL, 1993, J BONE MINER RES, V8, P337; Lehtonen-Veromaa MKM, 2002, AM J CLIN NUTR, V76, P1446, DOI 10.1093/ajcn/76.6.1446; Mayes T, 2003, J BURN CARE REHABIL, V24, P279, DOI 10.1097/01.BCR.0000085844.84144.E0; PANDIT SK, 1993, BURNS, V19, P227, DOI 10.1016/0305-4179(93)90154-Z; Sahota O, 2001, AGE AGEING, V30, P467, DOI 10.1093/ageing/30.6.467; SCHIELE HP, 1972, RADIOLOGY, V104, P13, DOI 10.1148/104.1.13; St-Pierre DMM, 1998, ARCH PHYS MED REHAB, V79, P155, DOI 10.1016/S0003-9993(98)90292-1	16	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					259	260		10.1016/S0140-6736(03)15417-7	http://dx.doi.org/10.1016/S0140-6736(03)15417-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751694				2022-12-28	WOS:000188361400003
J	Lane, R; McLellan, F; Santangelo, J				Lane, R; McLellan, F; Santangelo, J			"Personal account": a new feature from the patient's perspective	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England; Lancet, New York, NY USA		Lane, R (corresponding author), Lancet, London NW1 7BY, England.	richard.lane@lancet.com		McLellan, Faith/0000-0003-0744-1450					0	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					262	262		10.1016/S0140-6736(03)15420-7	http://dx.doi.org/10.1016/S0140-6736(03)15420-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751697				2022-12-28	WOS:000188361400006
J	Cooper, BG; Goller, F				Cooper, BG; Goller, F			Multimodal signals: Enhancement and constraint of song motor patterns by visual display	SCIENCE			English	Article							WINGBEAT; BIRDSONG	Many birds perform visual signals during their learned songs, but little is known about the interrelationship between visual and vocal displays. We show here that male brown-headed cowbirds (Molothrus ater) synchronize the most elaborate wing movements of their display with atypically long silent periods in their song, potentially avoiding adverse biomechanical effects on sound production. Furthermore, expiratory effort for song is significantly reduced when cowbirds perform their wing display. These results show a close integration between vocal and visual displays and suggest that constraints and synergistic interactions between the motor patterns of multimodal signals influence the evolution of birdsong.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Cooper, BG (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	cooper@biology.utah.edu			NIDCD NIH HHS [DC04390, DC05722] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC005722, R01DC004390] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALLAN SE, 1994, J NEUROBIOL, V25, P1154, DOI 10.1002/neu.480250910; Beckers GJL, 2003, P NATL ACAD SCI USA, V100, P7372, DOI 10.1073/pnas.1232227100; Boggs DF, 1997, J EXP BIOL, V200, P1403; Boggs DF, 1997, J EXP BIOL, V200, P1413; Bradbury Jack W., 1998, pi; Dantzker MS, 1999, J EXP BIOL, V202, P2893; DUFTY AM, 1985, Z TIERPSYCHOL, V69, P177; EENS M, 1990, BIRD STUDY, V37, P48, DOI 10.1080/00063659009477038; Funk GD, 1997, J EXP BIOL, V200, P915; Fusani L, 1997, BEHAVIOUR, V134, P321, DOI 10.1163/156853997X00566; Goller F, 2001, P ROY SOC B-BIOL SCI, V268, P2301, DOI 10.1098/rspb.2001.1805; Hauser, 1996, EVOL COMMUN; HAVENWILEY R, 1975, SCIENCE, V190, P482; Hoese WJ, 2000, J EXP BIOL, V203, P1845; Price JJ, 2002, EVOLUTION, V56, P1514; Suthers RA, 2002, P NATL ACAD SCI USA, V99, P5680, DOI 10.1073/pnas.042103199; Suthers RA, 1999, PHILOS T ROY SOC B, V354, P927, DOI 10.1098/rstb.1999.0444; Suthers RA, 1997, CURR ORNITHOL, V14, P235; WEST MJ, 1986, J COMP PSYCHOL, V100, P296, DOI 10.1037/0735-7036.100.3.296; Wild JM, 1998, J NEUROBIOL, V36, P441, DOI 10.1002/(SICI)1097-4695(19980905)36:3<441::AID-NEU11>3.0.CO;2-E; Williams H, 2001, J EXP BIOL, V204, P3497	21	76	76	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					544	546		10.1126/science.1091099	http://dx.doi.org/10.1126/science.1091099			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739462				2022-12-28	WOS:000188316400044
J	Tanabe, K; Sakihama, N; Kaneko, A				Tanabe, K; Sakihama, N; Kaneko, A			Stable SNPs in malaria antigen genes in isolated populations	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; NATURAL-SELECTION		Osaka Inst Technol, Osaka 5358585, Japan; Karolinska Hosp, S-17276 Stockholm, Sweden; Tokyo Womens Med Univ, Tokyo 1628666, Japan	Osaka Institute of Technology; Karolinska Institutet; Karolinska University Hospital; Tokyo Women's Medical University	Tanabe, K (corresponding author), Osaka Inst Technol, Osaka 5358585, Japan.	kztanabe@ge.oit.ac.jp		, Akira/0000-0003-2411-3352				BOWDEN DK, 1982, MED J AUSTRALIA, V2, P561, DOI 10.5694/j.1326-5377.1982.tb132573.x; Escalante AA, 1998, GENETICS, V149, P189; HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2; Maitland K, 2000, PARASITOLOGY, V120, P335, DOI 10.1017/S0031182099005612; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	6	34	36	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					493	493		10.1126/science.1092077	http://dx.doi.org/10.1126/science.1092077			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739451				2022-12-28	WOS:000188316400029
J	Wahlstrom, E; Vestergaard, EK; Schaub, R; Ronnau, A; Vestergaard, M; Laegsgaard, E; Stensgaard, I; Besenbacher, F				Wahlstrom, E; Vestergaard, EK; Schaub, R; Ronnau, A; Vestergaard, M; Laegsgaard, E; Stensgaard, I; Besenbacher, F			Electron transfer-induced dynamics of oxygen molecules on the TiO2(110) surface	SCIENCE			English	Article							GOLD CATALYSTS; VACANCIES; TIO2; H2O	Diffusion of oxygen molecules on transition metal oxide surfaces plays a vital role for the understanding of catalysis and photocatalysis on these materials. By means of time-resolved scanning tunneling microscopy, we provide evidence for a charge transfer-induced diffusion mechanism for O-2 molecules adsorbed on a rutile TiO2(110) surface. The O-2 hopping rate depended on the number of surface donors (oxygen vacancies), which determines the density of conduction band electrons. These results may have implications for the understanding of oxidation processes on metal oxides in general.	Aarhus Univ, Ctr Atom Scale Mat Phys, Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Besenbacher, F (corresponding author), Aarhus Univ, Ctr Atom Scale Mat Phys, Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark.	fbe@phys.au.dk	Schaub, Renald/O-7418-2019; Schaub, Renald/B-1283-2014; Besenbacher, Flemming/A-9623-2010; Wahlström, Erik/B-6696-2009	Schaub, Renald/0000-0002-1712-3336; Schaub, Renald/0000-0002-1712-3336; Wahlström, Erik/0000-0003-1905-5880				Ashcroft N.W., 1976, SOLID STATE PHYS; Besenbacher F, 1996, REP PROG PHYS, V59, P1737, DOI 10.1088/0034-4885/59/12/004; Campbell CT, 2002, SCIENCE, V298, P811, DOI 10.1126/science.1075094; Diebold U, 2003, SURF SCI REP, V48, P53, DOI 10.1016/S0167-5729(02)00100-0; Ehrlich G., 1966, J CHEM PHYS, V44, P1036; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Haruta M, 2002, CATTECH, V6, P102, DOI 10.1023/A:1020181423055; Henderson MA, 1998, SURF SCI, V400, P203, DOI 10.1016/S0039-6028(97)00863-7; Henry CR, 1998, SURF SCI REP, V31, P235; Kasemo B, 1999, Adv Dent Res, V13, P8; KURTZ RL, 1989, SURF SCI, V218, P178, DOI 10.1016/0039-6028(89)90626-2; Laegsgaard E, 2001, REV SCI INSTRUM, V72, P3537, DOI 10.1063/1.1389497; LINSEBIGLER AL, 1995, CHEM REV, V95, P735, DOI 10.1021/cr00035a013; Sanchez A, 1999, J PHYS CHEM A, V103, P9573, DOI 10.1021/jp9935992; Schaub R, 2003, SCIENCE, V299, P377, DOI 10.1126/science.1078962; Schaub R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.266104; Schubert MM, 2001, J CATAL, V197, P113, DOI 10.1006/jcat.2000.3069; Serpone N., 1989, PHOTOCATALYSIS FUNDA; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Yagi E, 1996, PHYS REV B, V54, P7945, DOI 10.1103/PhysRevB.54.7945; Yamakata A, 2003, J MOL CATAL A-CHEM, V199, P85, DOI 10.1016/S1381-1169(03)00021-9	21	157	161	4	180	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					511	513		10.1126/science.1093425	http://dx.doi.org/10.1126/science.1093425			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739455				2022-12-28	WOS:000188316400034
J	Hughes, RAC				Hughes, RAC			Treatment of Guillain-Barre syndrome with corticosteroids: lack of benefit?	LANCET			English	Editorial Material							EXPERIMENTAL ALLERGIC NEURITIS; METHYLPREDNISOLONE; TRIAL		Guys Kings & St Thomas Sch Med, Dept Clin Neurosci, London SE1 1UL, England	University of London; King's College London	Hughes, RAC (corresponding author), Guys Kings & St Thomas Sch Med, Dept Clin Neurosci, London SE1 1UL, England.	richard.a.hughes@kcl.ac.uk						DONAGHY M, 1994, J NEUROL NEUROSUR PS, V57, P778, DOI 10.1136/jnnp.57.7.778; Hughes RAC, 2003, NEUROLOGY, V61, P736, DOI 10.1212/WNL.61.6.736; HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2; HUGHES RAC, 1993, LANCET, V341, P586; Hughes RAC, 2003, COCHRANE LIB; KING RHM, 1985, EXP NEUROL, V87, P9, DOI 10.1016/0014-4886(85)90129-3; RAPHAEL JC, 2003, COCHRANE LIB; Rich MM, 1998, ANN NEUROL, V43, P171, DOI 10.1002/ana.410430207; WATTS PM, 1989, EXP NEUROL, V103, P101, DOI 10.1016/0014-4886(89)90191-X	9	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					181	182		10.1016/S0140-6736(03)15367-6	http://dx.doi.org/10.1016/S0140-6736(03)15367-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738786				2022-12-28	WOS:000188243900003
J	Marre, M; Lievre, M; Chatellier, G; Mann, JFE; Passa, P; Menard, J				Marre, M; Lievre, M; Chatellier, G; Mann, JFE; Passa, P; Menard, J		DIABHYCAR Study Investigators	Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING ENZYME-INHIBITION; BLOOD-PRESSURE REDUCTION; MICROALBUMINURIA; NEPHROPATHY; HYPERTENSION; PROTEINURIA; ENALAPRIL; MELLITUS; EVENTS; RISK	Objective To investigate whether a low dose of the angiotensin converting enzyme (ACE) inhibitor ramipril lowers cardiovascular and renal events in patients with type 2 diabetes who have microalbuminuria or proteinuria. Design Randomised, double blind, parallel group trial comparing ramipril (1.25 mg/day) with placebo (on top of usual treatment) for cardiovascular and renal outcomes for at least three years. Setting Multicentre, primary care study conducted mostly by general practitioners in 16 European and north African countries. Participants 4912 patients with type 2 diabetes aged > 50 years who use oral antidiabetic drugs and have persistent microalbuminuria or proteinuria (urinary albumin excretion greater than or equal to 20 mg/l in two consecutive samples), and serum creatinine less than or equal to 150 mumol/l. Main outcome measures The primary outcome measure was the combined incidence of cardiovascular death, non-fatal myocardial infarction, stroke, heart failure leading to hospital admission, and end stage renal failure. Results Participants were followed for 3 to 6 (median 4) years. There were 362 primary events among the 2443 participants taking ramipril (37.8 per 1000 patient years) and 377 events among the 2469 participants taking placebo (38.8 per 1000 patient years; hazard ratio 1.03 (95% confidence interval 0.89 to 1.20, P=0.65)). None of the components of the primary outcome was reduced. Ramipril lowered systolic and diastolic blood pressures (by 2.43 and 1.06 mm Hg respectively after two years) and favoured regression from microalbuminuria (20-200 mg/l) or proteinuria (> 200 mg/l) to normal level (< 20 mgA) or microalbuminuria (P < 0.07) in 1868 participants who completed the study. Conclusions Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin. The cardiovascular benefits of a daily higher dose (10 mg) ramipril observed elsewhere are not found with an eightfold lower daily dose.	Grp Hosp Bichat Claude Bernard, Assistance Publ Hop Paris, F-75877 Paris 18, France; Fac Med Laennec, Serv Pharmacol Clin, F-69376 Lyon, France; Dept Sante Publ Informat & Stat Med, F-75270 Paris 06, France; Univ Munich, Schwabing Gen Hosp, D-80804 Munich, Germany; Hop St Louis, Assistance Publ Hop Paris, Serv Diabetol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; University of Munich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Marre, M (corresponding author), Hop Bichat Claude Bernard, Serv Endocrinol Diabetol Nutr, 46 Rue Henri Huchard, F-75877 Paris 18, France.	michel.marre@bch.ap-hop-paris.fr	Mann, Johannes/AAI-8803-2020; Alhenc-Gelas, Francois/F-9511-2017	Marre, Michel/0000-0002-3071-1837				Bojestig M, 2001, DIABETES CARE, V24, P919, DOI 10.2337/diacare.24.5.919; BOSH J, 2002, BMJ-BRIT MED J, V324, P699; CHAN JCN, 1992, BRIT MED J, V305, P981, DOI 10.1136/bmj.305.6860.981; CHOBANIAN AV, 1995, HYPERTENSION, V25, P1306, DOI 10.1161/01.HYP.25.6.1306; Gerstein HC, 2000, LANCET, V355, P253; Jarrett R J, 1984, Diabet Med, V1, P17; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LIEVRE M, 1995, HYPERTENSION, V25, P92, DOI 10.1161/01.HYP.25.1.92; Lievre M, 2000, CONTROL CLIN TRIALS, V21, P383, DOI 10.1016/S0197-2456(00)00060-X; Lonn EM, 2001, CIRCULATION, V103, P919; Maillard MP, 2002, CLIN PHARMACOL THER, V71, P68, DOI 10.1067/mcp.2002.121425; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARRE M, 1991, J CARDIOVASC PHARM, V18, pS165, DOI 10.1097/00005344-199100182-00038; Marre M, 2000, DIABETES CARE, V23, pB40; MARRE M, 1991, J CARDIOVASC PHAR S2, V18, P165; Mogensen CE, 1999, DIABETOLOGIA, V42, P263, DOI 10.1007/s001250051151; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; O'Hare JP, 2000, DIABETES CARE, V23, P1823, DOI 10.2337/diacare.23.12.1823; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; Sleight P, 2001, LANCET, V358, P2130, DOI 10.1016/S0140-6736(01)07186-0; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; TREVISAN R, 1995, AM J HYPERTENS, V8, P876, DOI 10.1016/0895-7061(95)00162-I; Yusuf S, 2000, NEW ENGL J MED, V342, P145	24	205	213	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					495	499		10.1136/bmj.37970.629537.0D	http://dx.doi.org/10.1136/bmj.37970.629537.0D			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14960504	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000220002900024
J	Booth, CM; Boone, RH; Tomlinson, G; Detsky, AS				Booth, CM; Boone, RH; Tomlinson, G; Detsky, AS			Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY PREDICTION; CARDIOPULMONARY-RESUSCITATION; INTEROBSERVER AGREEMENT; PROGNOSTIC-SIGNIFICANCE; EVOKED-POTENTIALS; NONTRAUMATIC COMA; ANOXIC COMA; CONSCIOUSNESS; RECOVERY; SCORE	Context Most survivors of cardiac arrest are comatose after resuscitation, and meaningful neurological recovery occurs in a small proportion of cases. Treatment can be lengthy, expensive, and often difficult for families and caregivers. Physical examination is potentially useful in this clinical scenario, and the information obtained may help physicians and families make accurate decisions about treatment and/or withdrawal of care. Objective To determine the precision and accuracy of the clinical examination in predicting poor outcome in post-cardiac arrest coma. Data Sources and Study Selection We searched MEDLINE for English-language articles (1966-2003) using the terms coma, cardiac arrest, prognosis, physical examination, sensitivity and specificity, and observer variation. Other sources came from bibliographies of retrieved articles and physical examination textbooks. Studies were included if they assessed the precision and accuracy of the clinical examination in prognosis of post-cardiac arrest coma in adults. Eleven studies, involving 1914 patients, met our inclusion criteria. Data Extraction Two authors independently reviewed each study to determine eligibility, abstract data, and classify methodological quality Using predetermined criteria. Disagreement was resolved by consensus. Data Synthesis Summary likelihood ratios (LRs) were calculated from random effects models. Five clinical signs were found to strongly predict death or poor neurological outcome: absent corneal reflexes at 24 hours (LR, 12.9; 95% confidence interval [CI], 2.0-68.7), absent pupillary response at 24 hours (LR, 10.2; 95% CI, 1.8-48.6), absent withdrawal response to pain at 24 hours (LR, 4.7; 95% CI, 2.2-9.8), no motor response at 24 hours (LR, 4.9; 95% CI, 1.6-13.0), and no motor response at 72 hours (LR, 9.2; 95% CI, 2.1-49.4). The proportion of individuals' dying or having a poor neurological outcome was calculated by pooling the outcome data from the 11 studies (n=1914) and used as an estimate of the pretest probability of poor outcome. The random effects estimate of poor outcome was 77% (95% CI, 72%-80%). The highest LR increases the pretest probability of 77% to a posttest probability of 97% (95% CI, 87%-100%). No clinical findings were found to have LRs that strongly predicted good neurological outcome. Conclusions Simple physical examination maneuvers strongly predict death or poor outcome in comatose survivors of cardiac arrest. The most useful signs occur at 24 hours after cardiac arrest, and earlier prognosis should not be made by clinical examination alone. These data provide prognostic information, rather than treatment recommendations, which must be made on an individual basis incorporating many other variables.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, Suite 427,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	allan.detsky@uhn.on.ca	Tomlinson, George A/L-5432-2016	Tomlinson, George A/0000-0002-9328-6399				ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Berek K, 1997, J NEUROL, V244, P556, DOI 10.1007/s004150050143; BERTINI G, 1989, CRIT CARE MED, V17, P627, DOI 10.1097/00003246-198907000-00006; BORN JD, 1987, NEUROSURGERY, V20, P513, DOI 10.1227/00006123-198704000-00001; BRAAKMAN R, 1977, CLIN NEUROL NEUROSUR, V80, P104; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EDGREN E, 1987, CRIT CARE MED, V15, P820, DOI 10.1097/00003246-198709000-00004; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; ELHEFF SM, 1996, CARDIAC ARREST SCI P, P910; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; Haerer A, 1992, DEJONGS NEUROLOGIC E DEJONGS NEUROLOGIC E; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HUNG TP, 1995, J NEUROL NEUROSUR PS, V58, P75, DOI 10.1136/jnnp.58.1.75; KANO T, 1992, RESUSCITATION, V23, P235, DOI 10.1016/0300-9572(92)90007-Y; KENTSCH M, 1990, INTENS CARE MED, V16, P378, DOI 10.1007/BF01735175; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MINDERHOUD JM, 1982, CLIN NEUROL NEUROSUR, V84, P15, DOI 10.1016/0303-8467(82)90106-8; *MRC BIOST UN, 2003, WINBUGS COMP PROGR V; MULLIE A, 1988, LANCET, V1, P137; Pifferi S, 1998, INTENS CARE MED, V24, P535, DOI 10.1007/s001340050609; PLUM F, 1972, DIAGNOSIS STUPOR COM; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Safar P, 2002, CRIT CARE MED, V30, pS140, DOI 10.1097/00003246-200204001-00004; SASSER H, 1999, THESIS U PITTSBURGH; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; SNYDER BD, 1980, NEUROLOGY, V30, P1292, DOI 10.1212/WNL.30.12.1292; SNYDER BD, 1981, NEUROLOGY, V31, P1092, DOI 10.1212/WNL.31.9.1092; SNYDER BD, 1980, NEUROLOGY, V30, P52, DOI 10.1212/WNL.30.1.52; SNYDER BD, 1977, NEUROLOGY, V27, P807, DOI 10.1212/WNL.27.9.807; STEENHANSEN JE, 1988, CRIT CARE MED, V16, P69, DOI 10.1097/00003246-198801000-00016; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Thompson RJ, 1998, AM J CARDIOL, V81, P17, DOI 10.1016/S0002-9149(97)00798-4; VANDENBERGE JH, 1979, J NEUROL NEUROSUR PS, V42, P1163, DOI 10.1136/jnnp.42.12.1163; VANGIJN J, 1977, J NEUROL NEUROSUR PS, V40, P787, DOI 10.1136/jnnp.40.8.787; WIDJIKS EF, 1994, ANN NEUROL, V35, P239; WILLOUGHBY JO, 1974, BMJ-BRIT MED J, V3, P437, DOI 10.1136/bmj.3.5928.437; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zingler VC, 2003, EUR NEUROL, V49, P79, DOI 10.1159/000068503	59	371	379	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					870	879		10.1001/jama.291.7.870	http://dx.doi.org/10.1001/jama.291.7.870			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970067				2022-12-28	WOS:000189000400026
J	Poloniecki, J; Sismanidis, C; Bland, M; Jones, P				Poloniecki, J; Sismanidis, C; Bland, M; Jones, P			Retrospective cohort study of false alarm rates associated with a series of heart operations: the case for hospital mortality monitoring groups	BRITISH MEDICAL JOURNAL			English	Article								Objective To examine the efficacy of different methods of detecting a high death rate and determining whether an increase in deaths after heart transplantation could be explained by chance. Design Retrospective analysis of deaths after heart transplantation. Seven methods were used: mortality above national average, mortality excessively above national average, test of moving average mortality, test of number of consecutive deaths, sequential probability ratio test (SPRT), cusum with v-mask, and CRAM chart. The national average mortality was not available, and a rate of 15% was used instead as the benchmark. Setting Regional cardiothoracic unit. Participants All 371 patients who received a heart transplant in the programme, 1986-2000. Main outcome measures 30 day survival after transplantation. Results All methods provided evidence that the 30 day mortality had been high at some stage. The probability that the finding was a false positive depended on which test was used. At the end of the series the average mortality, sequential probability ratio, and cusum tests indicated a level of deaths higher than the benchmark while the remaining four tests yielded negative results. Conclusions If the decision to test for outlying mortality is made retrospectively, in the light of the data, it is not possible to determine the false positive rate. Prospective on-site mortality monitoring with the CRAM chart is recommended as this method can quantify the death rate and identify periods when an audit of cases is indicated, even when data from other hospitals are not available. A hospital mortality monitoring group can routinely monitor all deaths in the hospital, by specialty, using hospital episode statistics (HES) data and appropriate statistical methods.	St George Hosp, Sch Med, London SW17 0RE, England; St Georges Healthcare NHS Trust, London SW17 0QT, England	St Georges University London; St Georges University London	Poloniecki, J (corresponding author), St George Hosp, Sch Med, London SW17 0RE, England.	j.poloniecki@sghms.ac.uk						Anyanwu AC, 1999, EUR J CARDIO-THORAC, V16, P424, DOI 10.1016/S1010-7940(99)00238-9; BARNARD GA, 1959, J ROY STAT SOC B, V21, P239; BASSEVILLE M, 1993, DETECTION ABRUPT CHA; BOOTH J, 2000, SUNDAY TELEGRAP 1015; *BRIT TRANSPL SOC, 1998, STAND ORG TISS TRANS; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; Poloniecki J, 1998, BRIT MED J, V316, P1697, DOI 10.1136/bmj.316.7146.1697; Poloniecki J, 1998, BRIT MED J, V316, P1734, DOI 10.1136/bmj.316.7146.1734; *STAT OFF, 2003, DEATH CERT INV ENGL; Wald A., 1947, SEQUENTIAL ANAL	10	40	40	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 14	2004	328	7436					375	379		10.1136/bmj.37956.520567.44	http://dx.doi.org/10.1136/bmj.37956.520567.44			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14751918	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000189031300018
J	Kennedy, S; Wang, D; Ruvkun, G				Kennedy, S; Wang, D; Ruvkun, G			A conserved siRNA-degrading RNase negatively regulates RNA interference in C-elegans	NATURE			English	Article							CAENORHABDITIS-ELEGANS; MESSENGER-RNA; GENETIC INTERFERENCE; ESCHERICHIA-COLI; PROTEIN; INDUCTION; INTERACTS; PATHWAY; DOMAIN; RDE-1	In many organisms, introducing double-stranded RNA (dsRNA) causes the degradation of messenger RNA that is homologous to the trigger dsRNA-a process known as RNA interference. The dsRNA is cleaved into short interfering RNAs (siRNAs), which hybridize to homologous mRNAs and induce their degradation(1). dsRNAs vary in their ability to trigger RNA interference: many mRNA-targeting dsRNAs show weak phenotypes, and nearly all mRNAs of the Caenorhabditis elegans nervous system are refractory to RNA interference(2-4). C. elegans eri-1 was identified in a genetic screen for mutants with enhanced sensitivity to dsRNAs. Here we show that eri-1 encodes an evolutionarily conserved protein with domains homologous to nucleic-acid-binding and exonuclease proteins. After exposure to dsRNA or siRNAs, animals with eri-1 mutations accumulate more siRNAs than do wild-type animals. C. elegans ERI-1 and its human orthologue degrade siRNAs in vitro. In the nematode worm, ERI-1 is predominantly cytoplasmic and is expressed most highly in the gonad and a subset of neurons, suggesting that ERI-1 siRNase activity suppresses RNA interference more intensely in these tissues. Thus, ERI-1 is a negative regulator that may normally function to limit the duration, cell-type specificity or endogenous functions of RNA interference.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ruvkun, G (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@molbio.mgh.harvard.edu		Kennedy, Scott/0000-0002-7974-8155				Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Dominski Z, 2003, MOL CELL, V12, P295, DOI 10.1016/S1097-2765(03)00278-8; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P4372, DOI 10.1073/pnas.96.8.4372; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	21	445	484	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					645	649		10.1038/nature02302	http://dx.doi.org/10.1038/nature02302			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961122				2022-12-28	WOS:000188875300044
J	Fleming, PJ; Blair, PS; Sidebotham, P; Hayler, T				Fleming, PJ; Blair, PS; Sidebotham, P; Hayler, T			Investigating sudden unexpected deaths in infancy and childhood and caring for bereaved families: an integrated multiagency approach	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MURDER; CARE; SIDS		Univ Bristol, Inst Child Hlth, United Bristol Healthcare NHS Trust Educ Ctr, Bristol BS2 8AE, Avon, England; Community Child Hlth, Dept Community Paediat, Bristol BS2 8EF, Avon, England; Avon & Somerset Constabulary Criminal Invest Dept, Bristol BS20 8QJ, Avon, England	University of Bristol	Fleming, PJ (corresponding author), Univ Bristol, Inst Child Hlth, United Bristol Healthcare NHS Trust Educ Ctr, Bristol BS2 8AE, Avon, England.	peter.fleming@bris.ac.uk	Fleming, Peter J/A-9081-2010; Sidebotham, Peter D/E-3011-2010; Fleming, Peter/O-3231-2019; Blair, Peter S/C-1213-2009	Fleming, Peter J/0000-0003-2521-5764; Sidebotham, Peter D/0000-0003-4891-6926; Fleming, Peter/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087				American Academy of Pediatrics. Committee on Child Abuse and Neglect, 2001, Pediatrics, V107, P437; Arnestad M, 2002, FORENSIC SCI INT, V125, P262, DOI 10.1016/S0379-0738(02)00009-9; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; Blair PS, 1999, BRIT MED J, V319, P1457, DOI 10.1136/bmj.319.7223.1457; BYARD RW, 1994, SUDDEN DEATH INFANCY; Creighton S.J., 1995, CHILD ABUSE REV, V4, P318, DOI [10.1002/car.229, DOI 10.1002/CAR.229]; Dent A, 1996, ARCH DIS CHILD, V74, P522, DOI 10.1136/adc.74.6.522; *DEP HLTH, 2002, SAF CHILDR ILLN FABR; *DEP HLTH, 1999, WORK SAF CHILDR; Durfee M., 1995, CHILD ABUSE REV, V4, P377; Dyer C, 2002, BRIT MED J, V325, P1321; Dyer Clare, 2003, BMJ, V327, P10, DOI 10.1136/bmj.327.7405.10-a; *FDN STUD INF DEAT, 2001, SUDD UN DEATHS INF S; Fleming P., 2000, SUDDEN UNEXPECTED DE; GILBERT RE, 1992, ARCH DIS CHILD, V67, P272; HOBBS CJ, 1995, CHILD ABUSE REV, V4, P329; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; Kemp JS, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e41; Krous H. F., 1995, P81; Leach CEA, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.4.e43; Meadow R, 2002, BRIT MED J, V324, P41, DOI 10.1136/bmj.324.7328.41; Mitchell E, 2000, AM J FOREN MED PATH, V21, P395, DOI 10.1097/00000433-200012000-00020; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; Morentin B, 2000, ARCH DIS CHILD, V82, P456, DOI 10.1136/adc.82.6.456; REDER P, 1998, CHILD ABUSE REV, V7, P280; Rognum T. O., 1995, SUDDEN INFANT DEATH, P289; *SECR STAT HOM DEP, 2003, DEATH CERT INV ENGL; SIDEBOTHAM P, 2002, SUDDEN UNEXPECTED DE; Stanton J, 2001, ARCH DIS CHILD, V85, P454, DOI 10.1136/adc.85.6.454; WALKINS SJ, 2000, BMJ-BRIT MED J, V320, P2; Ward Platt Martin, 2000, Archives of Disease in Childhood, V82, P98; WIGGLESWORTH JS, 1987, J CLIN PATHOL, V40, P1481, DOI 10.1136/jcp.40.12.1481; WILLINGER M, 1991, Pediatric Pathology, V11, P677; *WORK PART ROYAL C, 2002, FABR IND ILLN CAR RE	34	49	50	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					331	334A		10.1136/bmj.328.7435.331	http://dx.doi.org/10.1136/bmj.328.7435.331			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764498	Green Published, Green Submitted			2022-12-28	WOS:000188926900026
J	Rovers, MM; Schilder, AGM; Zielhuis, GA; Rosenfeld, RM				Rovers, MM; Schilder, AGM; Zielhuis, GA; Rosenfeld, RM			Otitis media	LANCET			English	Review							PNEUMOCOCCAL CONJUGATE VACCINE; RESISTANT STREPTOCOCCUS-PNEUMONIAE; TYMPANOSTOMY TUBES; MIDDLE-EAR; GLUE EAR; DOUBLE-BLIND; RISK-FACTORS; ANTIMICROBIAL PROPHYLAXIS; RESPIRATORY-INFECTIONS; INCREASING PREVALENCE	Otitis media (OM) continues to be one of the most common childhood infections and is a major cause of morbidity in children. The pathogenesis of OM is multifactorial, involving the adaptive and native immune system, Eustachian-tube dysfunction, viral and bacterial load, and genetic and environmental factors. Initial observation seems to be suitable for many children with OM, but only if appropriate follow-up can be assured. In children younger than 2 years with a certain diagnosis of acute OM, antibiotics are advised. Surgical candidacy depends on associated symptoms, the child's developmental risk, and the anticipated chance of timely spontaneous resolution of the effusion. The recommended approach for surgery is to start with tympanostomy tube placement, eventually followed by adenoidectomy. The ideal intervention for OM, however, does not yet exist, and an urgent need remains to explore new and creative options based on modern insights into the pathophysiology of OM.	Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr, Wilhelmina Childrens Hosp Utrecht, Dept Paediat, Utrecht, Netherlands; Univ Med Ctr, Wilhelmina Childrens Hosp Utrecht, Dept Otorhinolaryngol, Utrecht, Netherlands; Univ Med Ctr, Dept Epidemiol & Biostat, Nijmegen, Netherlands; Long Isl Coll Hosp, Dept Otolaryngol, Brooklyn, NY 11201 USA; SUNY Downstate Med Ctr, Brooklyn, NY USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Long Island College Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Rovers, MM (corresponding author), Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, POB 85060, NL-3508 AB Utrecht, Netherlands.	MROVERS@umcutrecht.nl	Rovers, Maroeska/F-2969-2014; Zielhuis, Gerhard A./H-8123-2014; Kneissl, Sibylle Maria/ABD-8091-2021	Rovers, Maroeska/0000-0002-3095-170X; Kneissl, Sibylle Maria/0000-0001-9588-4715; Schilder, Anne/0000-0002-5496-4580				ALHO OP, 1995, ARCH OTOLARYNGOL, V121, P432; Alsarraf R, 1999, ARCH OTOLARYNGOL, V125, P12, DOI 10.1001/archotol.125.1.12; Anteunis LJC, 1999, AUDIOLOGY, V38, P75; AROLA M, 1990, PEDIATRICS, V86, P848; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Bennett KE, 1998, J EPIDEMIOL COMMUN H, V52, P786, DOI 10.1136/jech.52.12.786; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Bluestone CD, 1996, PEDIATR INFECT DIS J, V15, P281, DOI 10.1097/00006454-199604000-00002; Bluestone CD, 2002, ANN OTO RHINOL LARYN, V111, P8, DOI 10.1177/00034894021110S304; Bluestone CD, 2000, PEDIATR INFECT DIS J, V19, pS37, DOI 10.1097/00006454-200005001-00007; BLUESTONE CD, 1993, PEDIATR INFECT DIS J, V12, P75, DOI 10.1097/00006454-199301000-00015; Bluestone CD, 1999, EVIDENCE BASED OTITI, P85; Bluestone CD., 1999, EVIDENCE BASED OTITI, P137; BONATI M, 1992, CLIN TRIAL META-ANAL, V28, P39; Bondy J, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e72; Brodsky L, 2001, INT J PEDIATR OTORHI, V58, P59, DOI 10.1016/S0165-5876(00)00467-5; Brody R, 1999, OTOLARYNG HEAD NECK, V121, P681, DOI 10.1053/hn.1999.v121.a101041; Brookhouser PE, 1998, PEDIATR INFECT DIS J, V17, P544, DOI 10.1097/00006454-199806000-00033; BUTLER CC, 2002, COCHRANE LIB; Casselbrant M., 1999, EVIDENCE BASED OTITI, P117; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; Casselbrant ML, 2000, LARYNGOSCOPE, V110, P773, DOI 10.1097/00005537-200005000-00007; Casselbrant ML, 1999, JAMA-J AM MED ASSOC, V282, P2125, DOI 10.1001/jama.282.22.2125; Cates C, 1999, BRIT MED J, V318, P715, DOI 10.1136/bmj.318.7185.715; Chalmers D., 1989, OTITIS MEDIA EFFUSIO; CHONMAITREE T, 1994, J INFECT DIS, V169, P1265, DOI 10.1093/infdis/169.6.1265; CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X; Chonmaitree T, 1996, ANN OTO RHINOL LARYN, V105, P968; Chonmaitree T, 2000, PEDIATR INFECT DIS J, V19, pS24, DOI 10.1097/00006454-200005001-00005; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; Coyte PC, 2001, JAMA-J AM MED ASSOC, V286, P2128, DOI 10.1001/jama.286.17.2128; Dagan R, 2001, J INFECT DIS, V183, P880, DOI 10.1086/319250; Damoiseaux RAMJ, 1998, BRIT J GEN PRACT, V48, P1861; Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350; DENEELING AJ, 1996, 36 INT C ANT AG CHEM; Dewey C, 2000, INT J PEDIATR OTORHI, V55, P33, DOI 10.1016/S0165-5876(00)00377-3; DiFranza JR, 1996, PEDIATRICS, V97, P560; Engel J, 1999, INT J PEDIATR OTORHI, V48, P239, DOI 10.1016/S0165-5876(99)00037-3; Englund JA, 2000, VACCINE, V19, pS116, DOI 10.1016/S0264-410X(00)00289-9; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Faden H, 1998, PEDIATR INFECT DIS J, V17, P1105, DOI 10.1097/00006454-199812000-00002; FIELLAUNIKOLAJSEN M, 1983, ANN OTO RHINOL LARYN, V92, P172, DOI 10.1177/000348948309200215; Fireman B, 2003, PEDIATR INFECT DIS J, V22, P10, DOI 10.1097/00006454-200301000-00006; FLYNN CA, 2002, COCHRANE LIB; Freid V M, 1998, Vital Health Stat 13, P1; FRIA TJ, 1985, ARCH OTOLARYNGOL, V111, P10; GATES GA, 1987, NEW ENGL J MED, V317, P1444, DOI 10.1056/NEJM198712033172305; Gates GA, 1996, OTOLARYNG HEAD NECK, V114, P525, DOI 10.1016/S0194-5998(96)70243-7; GEBHART DE, 1981, LARYNGOSCOPE, V91, P849; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Ghaffar F, 2002, CLIN INFECT DIS, V34, P1301, DOI 10.1086/340054; Giebink GS, 1999, MICROB DRUG RESIST, V5, P57, DOI 10.1089/mdr.1999.5.57; Giebink GS, 2001, NEW ENGL J MED, V345, P1177, DOI 10.1056/NEJMra010462; GLASZIOU PP, 2002, COCHRANE LIB; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; GONZALEZ C, 1986, LARYNGOSCOPE, V96, P1330; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; Halsey NA, 1997, PEDIATRICS, V99, P289, DOI 10.1542/peds.99.2.289; Hatakka K, 2001, BMJ-BRIT MED J, V322, P1327, DOI 10.1136/bmj.322.7298.1327; Heikkinen T, 2000, ACTA PAEDIATR, V89, P1316, DOI 10.1080/080352500300002499; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; Joki-Erkkila VP, 1998, EPIDEMIOL INFECT, V121, P529, DOI 10.1017/S0950268898001575; Joki-Erkkila VP, 2002, ARCH OTOLARYNGOL, V128, P17, DOI 10.1001/archotol.128.1.17; KALM O, 1994, INT J PEDIATR OTORHI, V30, P151, DOI 10.1016/0165-5876(94)90198-8; KALM O, 1991, ARCH OTOLARYNGOL, V117, P1296; Kelly K M, 1993, Int J Pediatr Otorhinolaryngol, V25, P279; Kubba H, 2000, CLIN OTOLARYNGOL, V25, P181, DOI 10.1046/j.1365-2273.2000.00350.x; KURONO Y, 1991, ANN OTO RHINOL LARYN, V100, P455, DOI 10.1177/000348949110000605; Kvaerner KJ, 1997, ANN OTO RHINOL LARYN, V106, P624, DOI 10.1177/000348949710600802; Lanphear BP, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.3.e1; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; Lim DJ, 2000, VACCINE, V19, pS17, DOI 10.1016/S0264-410X(00)00273-5; LIM DJ, 1994, HDB MUCOSAL IMMUNOLO, P599; Little P, 1997, BRIT MED J, V315, P350; LITTLE P, 2001, BMJ-BRIT MED J, V322, P356; Mandel EM, 2002, PEDIATRICS, V110, P1071, DOI 10.1542/peds.110.6.1071; MANDEL EM, 1992, PEDIATR INFECT DIS J, V11, P270, DOI 10.1097/00006454-199204000-00003; MANDEL EM, 1989, ARCH OTOLARYNGOL, V115, P1217; MARCHANT CD, 1984, J PEDIATR-US, V104, P826, DOI 10.1016/S0022-3476(84)80475-8; Marchisio P, 2002, CLIN INFECT DIS, V35, P168, DOI 10.1086/341028; MARCY M, 2001, AHRQ PUBLICATION; MAW AR, 1983, BRIT MED J, V287, P1586, DOI 10.1136/bmj.287.6405.1586; MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756; Maw R, 1999, LANCET, V353, P960, DOI 10.1016/S0140-6736(98)05295-7; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; *NEW YORK REG OT P, 2002, PUBL STAT NEW YORK D, V4894; NIEMELA M, 1994, PEDIATR INFECT DIS J, V13, P765, DOI 10.1097/00006454-199409000-00002; *NZ HLTH TECHN ASS, 1998, 3 NZ HLTH TECHN ASS, P1; Ogra PL, 2002, ANN OTO RHINOL LARYN, V111, P62, DOI 10.1177/00034894021110S309; ONEILL P, 2002, CLIN EVID, V7, P236; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; Paradise JL, 2001, NEW ENGL J MED, V344, P1179, DOI 10.1056/NEJM200104193441601; Paradise JL, 1999, JAMA-J AM MED ASSOC, V282, P945, DOI 10.1001/jama.282.10.945; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; Patel JA, 1996, RECENT ADVANCES IN OTITIS MEDIA, P178; Pelton SI, 2002, PEDIATRICS, V110, P805, DOI 10.1542/peds.110.4.805; Pignataro O, 1996, INT J PEDIATR OTORHI, V35, P231, DOI 10.1016/0165-5876(95)01315-6; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; PRELLNER K, 1985, INT J PEDIATR OTORHI, V9, P219, DOI 10.1016/S0165-5876(85)80037-9; Reidpath DD, 1999, BRIT MED J, V318, P1177; Roos K, 2001, BRIT MED J, V322, P210, DOI 10.1136/bmj.322.7280.210; Rosenfeld J, 2000, AMYOTROPH LATERAL SC, V1, P1, DOI 10.1080/14660820050515638; Rosenfeld RM, 2000, VACCINE, V19, pS134, DOI 10.1016/S0264-410X(00)00292-9; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; Rosenfeld RM, 2000, ARCH OTOLARYNGOL, V126, P585, DOI 10.1001/archotol.126.5.585; Rosenfeld RM, 2003, EVIDENCE BASED OTITI, V2nd, P227; Rosenfeld RM, 2003, EVIDENCE BASED OTITI, P180; Rovers M, 2002, AM J EPIDEMIOL, V155, P958, DOI 10.1093/aje/155.10.958; Rovers MM, 1999, EUR J PEDIATR, V158, P1; Rovers MM, 1998, CLIN OTOLARYNGOL, V23, P543, DOI 10.1046/j.1365-2273.1998.2360543.x; Rovers MM, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e42; Ruohola A, 2000, J ALLERGY CLIN IMMUN, V106, P467, DOI 10.1067/mai.2000.108912; SANDERS LAM, 1995, PEDIATR RES, V37, P812, DOI 10.1203/00006450-199506000-00023; SENTURIA BH, 1980, ANN OTO RHINOL LARYN, V89, P3; STENFORS LE, 1993, ACTA OTO-LARYNGOL, V113, P191, DOI 10.3109/00016489309135791; Stewart MG, 1999, OTOLARYNG HEAD NECK, V120, P340, DOI 10.1016/S0194-5998(99)70272-X; STOOL SE, 1994, AHCPR PUBLICATION; STRAETEMANS M, 2002, COCHRANE LIB; Takata GS, 2002, AHRQ PUBLICATION, V02-E026; Tapiainen T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e19; Tasker A, 2002, LANCET, V359, P493, DOI 10.1016/S0140-6736(02)07665-1; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; TOS M, 1984, AM J OTOL, V5, P459; Tsuboi Y, 2001, RECENT ADVANCES IN OTITIS MEDIA, PROCEEDINGS, P275; *U YORK, 1992, EFF HLTH CARE, V1, P1; Uhari M, 1996, BRIT MED J, V313, P1180, DOI 10.1136/bmj.313.7066.1180; Uhari M, 1998, PEDIATRICS, V102, P879, DOI 10.1542/peds.102.4.879; Uhari M, 1996, CLIN INFECT DIS, V22, P1079, DOI 10.1093/clinids/22.6.1079; Ukkonen P, 2000, LANCET, V356, P1398, DOI 10.1016/S0140-6736(00)02843-9; van Kempen MJP, 2000, INT ARCH ALLERGY IMM, V122, P8, DOI 10.1159/000024354; Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004; Veenhoven R, 2003, LANCET, V361, P2189, DOI 10.1016/S0140-6736(03)13772-5; Vernon-Feagans L, 1999, EVIDENCE BASED OTITI, P353; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; Williamson Ian, 2002, Clin Evid, P469; Winther B, 2002, PEDIATRICS, V109, P826, DOI 10.1542/peds.109.5.826	141	385	402	2	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					465	473		10.1016/S0140-6736(04)15495-0	http://dx.doi.org/10.1016/S0140-6736(04)15495-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962529				2022-12-28	WOS:000188999500023
J	del Pozo, MA; Alderson, NB; Kiosses, WB; Chiang, HH; Anderson, RGW; Schwartz, MA				del Pozo, MA; Alderson, NB; Kiosses, WB; Chiang, HH; Anderson, RGW; Schwartz, MA			Integrins regulate Rac targeting by internalization of membrane domains	SCIENCE			English	Article							LIPID RAFTS; CHOLESTEROL; LOCALIZATION	Translocation of the small GTP-binding protein Rac1 to the cell plasma membrane is essential for activating downstream effectors and requires integrin-mediated adhesion of cells to extracellular matrix. We report that active Rac1 binds preferentially to low-density, cholesterol-rich membranes, and specificity is determined at least in part by membrane lipids. Cell detachment triggered internalization of plasma membrane cholesterol and lipid raft markers. Preventing internalization maintained Rac1 membrane targeting and effector activation in nonadherent cells. Regulation of lipid rafts by integrin signals may regulate the location of membrane domains such as lipid rafts and thereby control domain-specific signaling events in anchorage-dependent cells.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Ctr Nacl Invest Cardiovasc, Madrid, Spain; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Mellon Prostate Canc Res, Inst & Cardiovasc Res Ctr, Charlottesville, VA 22908 USA	Scripps Research Institute; Scripps Research Institute; Centro Nacional de Investigaciones Cardiovasculares (CNIC); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Virginia; University of Virginia	del Pozo, MA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mdelpozo@scripps.edu	del Pozo, Miguel Angel/L-2861-2014	del Pozo, Miguel Angel/0000-0001-9077-391X; schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016, R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, GM52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Dietrich C, 2002, BIOPHYS J, V82, P274, DOI 10.1016/S0006-3495(02)75393-9; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Grimmer S, 2002, J CELL SCI, V115, P2953; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Kumanogoh H, 2001, NEUROSCI RES, V39, P189, DOI 10.1016/S0168-0102(00)00211-X; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Radhakrishnan A, 2000, P NATL ACAD SCI USA, V97, P12422, DOI 10.1073/pnas.220418097; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052	22	436	441	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					839	842		10.1126/science.1092571	http://dx.doi.org/10.1126/science.1092571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764880				2022-12-28	WOS:000188753800058
J	May, RM				May, RM			Uses and abuses of mathematics in biology	SCIENCE			English	Editorial Material								In the physical sciences, mathematical theory and experimental investigation have always marched together. Mathematics has been less intrusive in the life sciences, possibly because they have until recently been largely descriptive, lacking the invariance principles and fundamental natural constants of physics. Increasingly in recent decades, however, mathematics has become pervasive in biology, taking many different forms: statistics in experimental design; pattern seeking in bioinformatics; models in evolution, ecology, and epidemiology; and much else. I offer an opinionated overview of such uses-and abuses.	Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England	University of Oxford	May, RM (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.							ANDERSON R M, 1991; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; Farmelo G., 2002, IT MUST BE BEAUTIFUL, P212; FISHER DA, 1958, GENETICAL THEORY NAT; Gleick J., 1988, CHAOS MAKING NEW SCI; Goldenfeld N, 1999, SCIENCE, V284, P87, DOI 10.1126/science.284.5411.87; Hardy GH, 1908, SCIENCE, V28, P49, DOI 10.1126/science.28.706.49; Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343; MacArthur R.H., 1972, pvii; Nowak MA., 2000, VIRUS DYNAMICS MATH	10	262	269	1	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					790	793		10.1126/science.1094442	http://dx.doi.org/10.1126/science.1094442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764866				2022-12-28	WOS:000188753800044
J	Domene, HM; Bengolea, SV; Martinez, AS; Ropelato, MG; Pennisi, P; Scaglia, P; Heinrich, JJ; Jasper, HG				Domene, HM; Bengolea, SV; Martinez, AS; Ropelato, MG; Pennisi, P; Scaglia, P; Heinrich, JJ; Jasper, HG			Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1st Joint Symposium on Growth Hormone-Insulin-Like Growth Factor	OCT 05-09, 2002	BOSTON, MA				BINDING-PROTEIN COMPLEX; WEIGHT HEIGHT VELOCITY; I IGF-I; POSTNATAL-GROWTH; FASTING GLUCOSE; HORMONE; SERUM; GH; SENSITIVITY; SOMATOMEDIN	The growth-promoting actions of growth hormone were originally hypothesized to be mediated through a circulating liver-generated sulfation factor that later came to be known as insulin-like growth factor I (IGF-I).(1) This growth factor is produced in almost every tissue in the body.(2) In the cartilage growth plate, growth hormone-induced IGF-I-3 acts locally through autocrine paracrine mechanisms.(4) Some 80 to 85 percent of IGF-I circulates as a 150-kD ternary complex that includes the ligand itself, IGF-binding protein 3, and an acid-labile subunit.(5) The acid- labile subunit is a glycoprotein found almost exclusively in the circulation and produced in the liver under growth hormone stimulation.(6,7) This subunit stabilizes the IGF-IGF-binding protein 3 complex, reduces the passage of IGF-I to the extravascular compartment, and extends its half-life.(8) Recently, the role of circulating IGF-I in growth has been challenged by the finding that specific disruption of the hepatic igf1 gene in mice, the main source of circulating IGF-I,(9,10) or the inactivation of the gene encoding the acid-labile subunit protein (igfals) in mice(11) has a minor effect on growth, despite causing a profound reduction in the serum IGF-I level. In this report, we describe a 17-year-old boy who had a delayed onset of puberty, slow pubertal progress, and yet minimal slowing of his linear growth in association with an inactivation of the IGFALS gene.	Ricardo Gutierrez Childrens Hosp, Div Endocrinol, Endocrinol Res Ctr, RA-1425 Buenos Aires, DF, Argentina; JA Fernandez Hosp, Div Pediat, Buenos Aires, DF, Argentina	Hospital de Ninos Doctor Ricardo Gutierrez; Instituto Nacional de Saude Dr. Ricardo Jorge; University of Buenos Aires; University of Buenos Aires	Domene, HM (corresponding author), Ricardo Gutierrez Childrens Hosp, Div Endocrinol, Endocrinol Res Ctr CEDIE, Gallo 1330, RA-1425 Buenos Aires, DF, Argentina.	hdomene@cedie.org.ar		Pennisi, Patricia/0000-0001-5179-7353; Jasper, Hector/0000-0002-3451-8647; Scaglia, Paula/0000-0002-8568-6034				BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; Blum W F, 1992, Acta Paediatr Suppl, V383, P125; Boisclair YR, 2001, J ENDOCRINOL, V170, P63, DOI 10.1677/joe.0.1700063; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P5176, DOI 10.1210/jc.86.11.5176; Butler AA, 2001, ENDOCRINOLOGY, V142, P1685, DOI 10.1210/en.142.5.1685; Chapman IM, 1998, J CLIN ENDOCR METAB, V83, P2836, DOI 10.1210/jc.83.8.2836; DERCOLE AJ, 1980, DEV BIOL, V75, P315, DOI 10.1016/0012-1606(80)90166-9; Fisker S, 1996, EUR J CLIN INVEST, V26, P779, DOI 10.1046/j.1365-2362.1996.2010558.x; GOJI K, 1992, PEDIATR RES, V31, P535, DOI 10.1203/00006450-199205000-00027; Greulich WW., 1959, CALIF MED, V91, P53; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; Janosi JBM, 1999, J BIOL CHEM, V274, P23328, DOI 10.1074/jbc.274.33.23328; Khosravi MJ, 1997, J CLIN ENDOCR METAB, V82, P3944, DOI 10.1210/jc.82.12.3944; KOWARSKI AA, 1978, J CLIN ENDOCR METAB, V47, P461, DOI 10.1210/jcem-47-2-461; Labarta JI, 1997, CLIN ENDOCRINOL, V47, P657, DOI 10.1046/j.1365-2265.1997.2581078.x; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Le Roith D, 2001, TRENDS ENDOCRIN MET, V12, P48; Legro RS, 1998, J CLIN ENDOCR METAB, V83, P2694, DOI 10.1210/jc.83.8.2694; Lejarraga H., 1987, ARCH ARGENT PEDIATR, V85, P209; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LOWE T, 1990, NUCLEIC ACIDS RES, V18, P1757, DOI 10.1093/nar/18.7.1757; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Martinez AS, 2000, J CLIN ENDOCR METAB, V85, P4168, DOI 10.1210/jc.85.11.4168; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Moses AC, 1996, DIABETES, V45, P91, DOI 10.2337/diabetes.45.1.91; *NAT CTR BIOT INF, GENB; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Ropelato MG, 1996, J PEDIATR ENDOCR MET, V9, P41; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; SALMON WD, 1957, J LAB CLIN MED, V49, P825; Silfen ME, 2001, J CLIN ENDOCR METAB, V86, P2863, DOI 10.1210/jc.86.6.2863; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Sjogren K, 2001, DIABETES, V50, P1539, DOI 10.2337/diabetes.50.7.1539; Suwanichkul A, 2000, ENDOCRINOLOGY, V141, P833, DOI 10.1210/en.141.2.833; Takahashi Y, 1996, NEW ENGL J MED, V334, P1207; TANNER JM, 1975, J CLIN ENDOCR METAB, V41, P788, DOI 10.1210/jcem-41-4-788; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TANNER JM, 1978, TXB PEDIAT, P249; Uejima H, 2001, NAT GENET, V28, P97; Ueki I, 2000, P NATL ACAD SCI USA, V97, P6868, DOI 10.1073/pnas.120172697; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Woods KA, 1999, ACTA PAEDIATR, V88, P158, DOI 10.1111/j.1651-2227.1999.tb14376.x; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110	50	170	181	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					570	577		10.1056/NEJMoa013100	http://dx.doi.org/10.1056/NEJMoa013100			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	770FP	14762184	Bronze			2022-12-28	WOS:000188712800008
J	Halliday, AN				Halliday, AN			Mixing, volatile loss and compositional change during impact-driven accretion of the Earth	NATURE			English	Article							TERRESTRIAL MAGMA OCEAN; EARLY CORE FORMATION; HF-W CHRONOMETRY; ELEMENT DEPLETION; GIANT IMPACT; MOON; ORIGIN; AGE; MANTLE; MODEL	The degree to which efficient mixing of new material or losses of earlier accreted material to space characterize the growth of Earth-like planets is poorly constrained and probably changed with time. These processes can be studied by parallel modelling of data from different radiogenic isotope systems. The tungsten isotope composition of the silicate Earth yields a model timescale for accretion that is faster than current estimates based on terrestrial lead and xenon isotope data and strontium, tungsten and lead data for lunar samples. A probable explanation for this is that impacting core material did not always mix efficiently with the silicate portions of the Earth before being added to the Earth's core. Furthermore, tungsten and strontium isotope compositions of lunar samples provide evidence that the Moon-forming impacting protoplanet Theia was probably more like Mars, with a volatile-rich, oxidized mantle. Impact-driven erosion was probably a significant contributor to the variations in moderately volatile element abundance and oxidation found among the terrestrial planets.	ETH Zentrum, NO, Dept Earth Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Halliday, AN (corresponding author), ETH Zentrum, NO, Dept Earth Sci, Sonneggstr 5, CH-8092 Zurich, Switzerland.	halliday@erdw.ethz.ch						ALLEGRE CJ, 1995, GEOCHIM COSMOCHIM AC, V59, P1445, DOI 10.1016/0016-7037(95)00054-4; ALLEGRE CJ, 1989, EARTH PLANET SC LETT, V96, P61, DOI 10.1016/0012-821X(89)90124-6; ALLEGRE CJ, 1988, CHEM GEOL, V70, P211, DOI 10.1016/0009-2541(88)90094-0; AZBEL IY, 1993, GEOCHIM COSMOCHIM AC, V57, P2889, DOI 10.1016/0016-7037(93)90396-E; Benz W., 1990, ORIGIN EARTH, P61; CAMERON AGW, 1991, ICARUS, V92, P204, DOI 10.1016/0019-1035(91)90046-V; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; CARLSON RW, 1988, EARTH PLANET SC LETT, V90, P119, DOI 10.1016/0012-821X(88)90095-7; CARLSON RW, 2000, ORIGIN EARTH MOON, P25; DAVIES GF, 1984, J GEOPHYS RES, V89, P6017, DOI 10.1029/JB089iB07p06017; Davies GF, 1999, EARTH PLANET SC LETT, V166, P149, DOI 10.1016/S0012-821X(99)00007-2; Doe B R, 1979, GEOCHEMISTRY HYDROTH, P22; Galer S.J.G., 1996, EARTH PROCESSES READ, P75; GALER SJG, 1991, TERR ABSTR, V3, P485; Halliday AN, 2000, EARTH PLANET SC LETT, V176, P17, DOI 10.1016/S0012-821X(99)00317-9; Halliday AN, 2001, EARTH PLANET SC LETT, V192, P545, DOI 10.1016/S0012-821X(01)00479-4; HANAN BB, 1987, EARTH PLANET SC LETT, V84, P15, DOI 10.1016/0012-821X(87)90171-3; Hayashi C., 1985, PROTOSTARS PLANETS, VII, P1100; HUMAYUN M, 1995, GEOCHIM COSMOCHIM AC, V59, P2131, DOI 10.1016/0016-7037(95)00132-8; Jacobsen SB, 1996, EARTH PROCESSES READ, P47; Jones J. H., 2000, ORIGIN EARTH MOON, P197, DOI DOI 10.1016/0016-7037(83)90024-8.; Kamber BS, 1999, J GEOPHYS RES-SOL EA, V104, P25479, DOI 10.1029/1999JB900258; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; Kramers JD, 1997, CHEM GEOL, V139, P75, DOI 10.1016/S0009-2541(97)00027-2; Kwon S.T., 1989, CARBONATITES GENESIS, P360; Lee DC, 1997, SCIENCE, V278, P1098, DOI 10.1126/science.278.5340.1098; Lee DC, 1997, NATURE, V388, P854, DOI 10.1038/42206; LEE DC, 1995, NATURE, V378, P771, DOI 10.1038/378771a0; Lee DC, 2002, EARTH PLANET SC LETT, V198, P267, DOI 10.1016/S0012-821X(02)00533-2; Leya I, 2000, EARTH PLANET SC LETT, V175, P1, DOI 10.1016/S0012-821X(99)00295-2; LIEW TC, 1991, GEOL RUNDSCH, V80, P279, DOI 10.1007/BF01829366; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; Murphy DT, 2003, J PETROL, V44, P39, DOI 10.1093/petrology/44.1.39; Newsom H. E, 1990, ORIGIN EARTH, P273; Newsom H. E., 1995, GLOBAL EARTH PHYS HD, V1, P159, DOI DOI 10.1029/RF001P0159; Ozima M, 1999, J GEOPHYS RES-SOL EA, V104, P25493, DOI 10.1029/1999JB900257; PATTERSON C, 1956, GEOCHIM COSMOCHIM AC, V10, P230, DOI 10.1016/0016-7037(56)90036-9; Porcelli D, 2001, EARTH PLANET SC LETT, V193, P237, DOI 10.1016/S0012-821X(01)00493-9; Righter K, 1999, EARTH PLANET SC LETT, V171, P383, DOI 10.1016/S0012-821X(99)00156-9; Rubie DC, 2003, EARTH PLANET SC LETT, V205, P239, DOI 10.1016/S0012-821X(02)01044-0; SASAKI S, 1986, J GEOPHYS RES-SOLID, V91, P9231, DOI 10.1029/JB091iB09p09231; Schoenberg R, 2002, GEOCHIM COSMOCHIM AC, V66, P3151, DOI 10.1016/S0016-7037(02)00911-0; Stevenson DJ., 1990, ORIGIN EARTH, P231; TAYLOR SR, 1990, ORIGIN EARTH, P00029; Tera F, 1973, LUNAR SCIENCE, V4, P723; Wetherill G. W, 1986, ORIGIN MOON, P519; Wiechert U, 2001, SCIENCE, V294, P345, DOI 10.1126/science.1063037; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995; Yoshino T, 2003, NATURE, V422, P154, DOI 10.1038/nature01459; ZARTMAN RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1327, DOI 10.1016/0016-7037(88)90204-9	50	159	159	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 5	2004	427	6974					505	509		10.1038/nature02275	http://dx.doi.org/10.1038/nature02275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765187				2022-12-28	WOS:000188721800032
J	Howard, AA; Arnsten, JH; Gourevitch, MN				Howard, AA; Arnsten, JH; Gourevitch, MN			Effect of alcohol consumption on diabetes mellitus - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; IMPAIRED FASTING GLUCOSE; FREE FATTY-ACID; LIFE-STYLE; DRINKING PATTERNS; RISK-FACTORS; INSULIN; MEN; TOLERANCE	Background: Both diabetes mellitus and alcohol consumption are prevalent in the United States, yet physicians are poorly informed about how alcohol use affects risk for or management of diabetes. Purpose: To conduct a systematic review assessing the effect of alcohol use on the incidence, management, and complications of diabetes mellitus in adults. Data Sources: English-language studies in persons 19 years of age or older that were identified by searching the MEDLINE database from 1966 to the third week of August 2003 and the reference lists of key articles. Study Selection: Two independent assessors reviewed 974 retrieved citations to identify all experimental, cohort, or case-control studies that assessed the effect of alcohol use on diabetes risk, control, self-management, adverse drug events, or complications. Data Extraction: Two independent reviewers extracted data and evaluated study quality on the basis of established criteria. Data Synthesis: Thirty-two studies that met inclusion criteria were reviewed. Compared with no alcohol use, moderate consumption (one to 3 drinks/d) is associated with a 33% to 56% lower incidence of diabetes and a 34% to 55% lower incidence of diabetes-related coronary heart disease. Compared with moderate consumption, heavy consumption (>3 drinks/d) may be associated with up to a 43% increased incidence of diabetes. Moderate alcohol consumption does not acutely impair glycemic control in persons with diabetes. Conclusions: Moderate alcohol consumption is associated with a decreased incidence of diabetes mellitus and a decreased incidence of heart disease in persons with diabetes. Further studies are needed to assess the long-term effects of alcohol consumption on glycemic control and noncardiac complications in persons with diabetes.	Montefiore Med Ctr, AIDS Res Program, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Howard, AA (corresponding author), Montefiore Med Ctr, AIDS Res Program, 111 E 210th St, Bronx, NY 10467 USA.	ahoward@montefiore.org		Gourevitch, Marc/0000-0001-6865-2126				Ajani UA, 2000, ARCH INTERN MED, V160, P1025, DOI 10.1001/archinte.160.7.1025; Ajani UA, 2000, CIRCULATION, V102, P500; Burge MR, 1999, DIABETES CARE, V22, P2037, DOI 10.2337/diacare.22.12.2037; CHRISTIANSEN C, 1993, EUR J CLIN NUTR, V47, P648; CHRISTIANSEN C, 1994, BRIT J NUTR, V71, P449, DOI 10.1079/BJN19940151; Conigrave KM, 2001, DIABETES, V50, P2390, DOI 10.2337/diabetes.50.10.2390; *CTR PROT WORK RIG, 2002, D102 CPWR, P1; de Vegt F, 2002, DIABETES RES CLIN PR, V57, P53, DOI 10.1016/S0168-8227(02)00013-X; DIAMOND I, 1994, WESTERN J MED, V161, P279; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; Foot EA, 1997, DIABETES RES CLIN PR, V38, P41, DOI 10.1016/S0168-8227(97)00082-X; Fujimoto Wilfred Y., 2000, American Journal of Medicine, V108, p9S; Gavin JR, 1997, DIABETES CARE, V20, P1183; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HODGE AM, 1993, AM J EPIDEMIOL, V137, P178, DOI 10.1093/oxfordjournals.aje.a116658; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; Howard AA, 2002, AIDS, V16, P2175, DOI 10.1097/00002030-200211080-00010; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; HULLEY SB, 1981, CIRCULATION, V64, P57; Kao WHL, 2001, AM J EPIDEMIOL, V154, P748, DOI 10.1093/aje/154.8.748; Kiechl S, 1996, BRIT MED J, V313, P1040; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOIVISTO VA, 1993, DIABETES CARE, V16, P1612, DOI 10.2337/diacare.16.12.1612; LAO B, 1994, ARZNEIMITTEL-FORSCH, V44-1, P727; Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050; Lu WQ, 2003, METABOLISM, V52, P129, DOI 10.1053/meta.2003.50020; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MCMONAGLE J, 1975, METABOLISM, V24, P625, DOI 10.1016/0026-0495(75)90142-0; MONTERROSA AE, 1995, DIABETES CARE, V18, P448, DOI 10.2337/diacare.18.4.448; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1962; Nakanishi N, 2003, DIABETES CARE, V26, P48, DOI 10.2337/diacare.26.1.48; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; REWERS M, 1995, DIABETES AM, P179; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RUBIN R, 1994, ALCOHOL CLIN EXP RES, V18, P105, DOI 10.1111/j.1530-0277.1994.tb00888.x; SHAPER AG, 1988, LANCET, V2, P1267; Solomon CG, 2000, CIRCULATION, V102, P494; *SUBST AB MENT HLT, 2002, RES 2001 NAT HOUS SU, V1; Sugimori H, 1998, J Med Syst, V22, P27, DOI 10.1023/A:1022650305109; Tanasescu M, 2001, J AM COLL CARDIOL, V38, P1836, DOI 10.1016/S0735-1097(01)01655-2; Tsumura K, 1999, DIABETES CARE, V22, P1432, DOI 10.2337/diacare.22.9.1432; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Valmadrid CT, 1999, JAMA-J AM MED ASSOC, V282, P239, DOI 10.1001/jama.282.3.239; WALSH CH, 1974, DIABETES, V23, P440, DOI 10.2337/diab.23.5.440; Wannamethee SG, 2003, ARCH INTERN MED, V163, P1329, DOI 10.1001/archinte.163.11.1329; Wannamethee SG, 2002, J EPIDEMIOL COMMUN H, V56, P542, DOI 10.1136/jech.56.7.542; Watanabe M, 2002, DIABETES RES CLIN PR, V57, P191, DOI 10.1016/S0168-8227(02)00083-9; Wei M, 2000, DIABETES CARE, V23, P18, DOI 10.2337/diacare.23.1.18; YOUNG RJ, 1984, BRIT MED J, V288, P1035, DOI 10.1136/bmj.288.6423.1035; 2003, PHYSICIANS DESK REFE	53	343	361	5	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					211	219		10.7326/0003-4819-140-6-200403160-00011	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757619				2022-12-28	WOS:000188704500007
J	Rapaport, E				Rapaport, E			Update in cardiology	ANNALS OF INTERNAL MEDICINE			English	Article									San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rapaport, E (corresponding author), San Francisco Gen Hosp, Div Cardiol, Room 5G1,1001 Potrero St, San Francisco, CA 94110 USA.	erapapor@sfghdean.ucsf.edu						Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					203	210		10.7326/0003-4819-140-3-200402030-00011	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757618				2022-12-28	WOS:000188704500006
J	Chaimanee, Y; Suteethorn, V; Jintasakul, P; Vidthayanon, C; Marandat, B; Jaeger, JJ				Chaimanee, Y; Suteethorn, V; Jintasakul, P; Vidthayanon, C; Marandat, B; Jaeger, JJ			A new orang-utan relative from the Late Miocene of Thailand	NATURE			English	Article							MIDDLE MIOCENE; ANKARAPITHECUS-METEAI; BODY-WEIGHT; GREAT APE; PAKISTAN; NEOGENE; SHAPE	The fossil record of the living great apes is poor. New fossils from undocumented areas, particularly the equatorial forested habitats of extant hominoids, are therefore crucial for understanding their origins and evolution(1). Two main competing hypotheses have been proposed for orang-utan origins: dental similarities(2,3) support an origin from Lufengpithecus, a South Chinese(4) and Thai Middle Miocene hominoid(2); facial and palatal similarities(5) support an origin from Sivapithecus, a Miocene hominoid from the Siwaliks of Indo-Pakistan(4,6). However, materials other than teeth and faces do not support these hypotheses(7,8). Here we describe the lower jaw of a new hominoid from the Late Miocene of Thailand, Khoratpithecus piriyai gen. et sp. nov., which shares unique derived characters with orang-utans and supports a hypothesis of closer relationships with orang-utans than other known Miocene hominoids. It can therefore be considered as the closest known relative of orang-utans. Ancestors of this great ape were therefore evolving in Thailand under tropical conditions similar to those of today, in contrast with Southern China and Pakistan, where temperate(9) or more seasonal(10) climates appeared during the Late Miocene.	Dept Mineral Resources, Geol Survey Div, Paleontol Sect, Bangkok 10400, Thailand; Rajabhat Inst Nakorn Ratchasima, Nakhon Ratchasima 30000, Thailand; Dept Fisheries, Museum & Aquarium Div, Bangkok 10900, Thailand; Univ Montpellier 2, CNRS, ISEM, F-34095 Montpellier, France	Department of Mineral Resources - Thailand; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Chaimanee, Y (corresponding author), Dept Mineral Resources, Geol Survey Div, Paleontol Sect, Bangkok 10400, Thailand.	yaowalak@dmr.go.th		chaimanee, yaowalak/0000-0002-8432-3880				ALPAGUT B, 1990, J HUM EVOL, V19, P397, DOI 10.1016/0047-2484(90)90052-D; Alpagut B, 1996, NATURE, V382, P349, DOI 10.1038/382349a0; BADGLEY C, 1988, NATL GEOGR RES, V4, P178; Barry JC, 2002, PALEOBIOLOGY, V28, P1, DOI 10.1666/0094-8373(2002)28[1:FAECIT]2.0.CO;2; Begun DR, 2002, CAM S BIO EVOL ANTHR, V33, P339; Begun DR, 1998, AM J PHYS ANTHROPOL, V105, P279, DOI 10.1002/(SICI)1096-8644(199803)105:3<279::AID-AJPA2>3.0.CO;2-N; Brown B., 1989, THESIS KENT STATE U; Brown Barbara, 1997, P153; Chaimanee Y, 2003, NATURE, V422, P61, DOI 10.1038/nature01449; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; DAEGLING DJ, 1993, AM J PHYS ANTHROPOL, V91, P505, DOI 10.1002/ajpa.1330910407; Daegling DJ, 2000, J HUM EVOL, V39, P107, DOI 10.1006/jhev.2000.0402; de Bonis L, 1977, Geobios Lyon, V10, P849, DOI 10.1016/S0016-6995(77)80081-8; GINGERICH PD, 1982, AM J PHYS ANTHROPOL, V58, P81, DOI 10.1002/ajpa.1330580110; Harrison T, 2002, J HUM EVOL, V43, P207, DOI 10.1006/jhev.2002.0570; Hooijer D. A., 1948, ZOOL MEDEDEEL LEYDEN, V29, P175; Kelley J, 2002, CAM S BIO EVOL ANTHR, V33, P369; Legendre S., 1989, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V16, P1; MCCROSSIN ML, 1993, P NATL ACAD SCI USA, V90, P1962, DOI 10.1073/pnas.90.5.1962; MORGAN ME, 1994, NATURE, V367, P162, DOI 10.1038/367162a0; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; PILBEAM DR, 1980, POSTILLA, V181, P1; Schwartz Jeffrey H., 1997, P363; Ward S, 1999, SCIENCE, V285, P1382, DOI 10.1126/science.285.5432.1382; Ward Steve, 1997, P269	27	65	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					439	441		10.1038/nature02245	http://dx.doi.org/10.1038/nature02245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749830				2022-12-28	WOS:000188470500042
J	Zafeiriou, DI; Pavlou, E				Zafeiriou, DI; Pavlou, E			Hypoglossal-nerve palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Aristotle Univ Thessaloniki, Thessaloniki 54642, Greece	Aristotle University of Thessaloniki	Zafeiriou, DI (corresponding author), Aristotle Univ Thessaloniki, Thessaloniki 54642, Greece.		Zafeiriou, Dimitrios I/N-2641-2013; Pavlou, Evangelos/AAL-2061-2020	Zafeiriou, Dimitrios I/0000-0003-2187-9299; PAVLOU, EVANGELOS/0000-0002-2636-9768					0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					E4	E4		10.1056/ENEJMicm020058	http://dx.doi.org/10.1056/ENEJMicm020058			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749468				2022-12-28	WOS:000188463900013
J	Harris, RA; Washington, AE; Nease, RF; Kuppermann, M				Harris, RA; Washington, AE; Nease, RF; Kuppermann, M			Cost utility of prenatal diagnosis and the risk-based threshold	LANCET			English	Article							AGE-SPECIFIC RATES; CHORIONIC VILLUS; DOWN-SYNDROME; CHROMOSOME-ABNORMALITIES; REPRODUCTIVE-BEHAVIOR; ECONOMIC-EVALUATION; AMNIOCENTESIS; PREGNANCY; WOMEN; PREFERENCES	Background Prenatal testing guidelines recommend offering amniocentesis or chorionic villus sampling to women aged 35 years or older, or who have been found by screening to be at a similarly high risk of giving birth to an infant with Down's syndrome or another chromosomal abnormality. This threshold was chosen, in part, because 35 was the approximate age at which amniocentesis was cost beneficial when testing guidelines were developed in the USA in the 1970s. We aimed to assess the economic validity of thresholds based on age or risk for offering invasive prenatal diagnosis. Methods We did a cost-utility analysis of chorionic villus sampling and amniocentesis versus no invasive testing using data from randomised trials, case registries, and a utility assessment of 534 diverse pregnant women aged 16-47 years. Findings In the USA, compared with no diagnostic testing, amniocentesis costs less than US$15 000 per quality-adjusted life year gained for women of all ages and risk levels. The results do not depend on maternal age or risk of Down's syndrome-affected birth. The cost-utility ratio for any individual woman depends on her preferences for reassurance about the chromosomal status of her fetus, and, to a lesser extent, for miscarriage. Interpretation Prenatal diagnostic testing can be cost effective at any age or risk level. Current guidelines should be changed to offer testing to all pregnant women, not just those whose risk of carrying an affected fetus exceeds a specified threshold.	Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Effectiveness Res Ctr, San Francisco, CA 94143 USA; Washington Univ, Med Sch & Express Scripts, Dept Internal Med, Div Gen Med Sci,Lab Med Decis Sci, St Louis, MO USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL)	Kuppermann, M (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 3333 Calif St,Suite 335, San Francisco, CA 94143 USA.	kuppermannm@obgyn.ucsf.edu			AHRQ HHS [U01 HS07373] Funding Source: Medline; NHGRI NIH HHS [R01 HG01255] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001255] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		American College of Obstetricians and Gynecologists, 2001, Obstet Gynecol, V97, P1; Beazoglou T, 1998, PRENATAL DIAG, V18, P1241, DOI 10.1002/(SICI)1097-0223(199812)18:12<1241::AID-PD440>3.0.CO;2-M; BRANDENBURG H, 1992, CLIN GENET, V42, P149; BRANDENBURG H, 1992, PRENATAL DIAG, V12, P1031, DOI 10.1002/pd.1970121208; CONLEY R, 1975, PREVENTION GENETIC D; Dick PT, 1996, CAN MED ASSOC J, V154, P465; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Fryback DG, 1997, MED DECIS MAKING, V17, P276, DOI 10.1177/0272989X9701700303; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GRANT A, 1991, LANCET, V337, P1491; HADDOW JE, 1994, NEW ENGL J MED, V330, P1114, DOI 10.1056/NEJM199404213301603; HAGARD S, 1976, BRIT MED J, V1, P753, DOI 10.1136/bmj.1.6012.753; Hahn B., 1992, ANN EXPENSES SOURCES; Hahnemann JM, 1997, PRENATAL DIAG, V17, P801, DOI 10.1002/(SICI)1097-0223(199709)17:9<801::AID-PD153>3.0.CO;2-E; Harris RA, 2001, GENET TEST, V5, P23, DOI 10.1089/109065701750168644; *HEALTHC CONS AM, 1995, PHYS FEE COD GUID; HENSHAW SK, 1995, FAM PLANN PERSPECT, V27, P54, DOI 10.2307/2135905; Hook E B, 1977, Birth Defects Orig Artic Ser, V13, P123; HOOK EB, 1989, AM J HUM GENET, V45, P855; HOOK EB, 1989, AM J HUM GENET, V45, P474; HOOK EB, 1988, AM J HUM GENET, V42, P797; HOOK EB, 1983, AM J HUM GENET, V35, P110; HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034; KULIEV AM, 1993, PRENATAL DIAG, V13, P197, DOI 10.1002/pd.1970130307; Kuppermann M, 2000, OBSTET GYNECOL, V96, P511, DOI 10.1016/S0029-7844(00)00969-8; Kuppermann M, 1999, PRENATAL DIAG, V19, P711, DOI 10.1002/(SICI)1097-0223(199908)19:8<711::AID-PD614>3.0.CO;2-V; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LIPPMAN A, 1992, PRENATAL DIAG, V12, P385, DOI 10.1002/pd.1970120508; LUBS HA, 1972, ANTENATAL DIAGNOSIS, P17; *NAT I CHILD HLTH, 1979, ANT DIAGN REP CONS D; PAUKER SP, 1994, NEW ENGL J MED, V330, P1151, DOI 10.1056/NEJM199404213301610; Petrou S, 2001, HEALTH ECON, V10, P775, DOI 10.1002/hec.636; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; Seror V, 1998, HEALTH POLICY, V43, P83, DOI 10.1016/S0168-8510(97)00084-5; Shackley P, 1996, PRENATAL DIAG, V16, P389, DOI 10.1002/(SICI)1097-0223(199605)16:5<389::AID-PD870>3.0.CO;2-U; SICHERMAN N, 1995, FETAL DIAGN THER, V10, P157, DOI 10.1159/000264226; SIMPSON JL, 1987, JAMA-J AM MED ASSOC, V258, P2555, DOI 10.1001/jama.258.18.2555; TABOR A, 1986, LANCET, V1, P1287; Torrance G W, 1972, Health Serv Res, V7, P118; US Bureau of the Census, 1995, STAT ABSTR US; *US DEP HHS, 1995, NAT LIM CLIN LAB; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VINCENT VA, 1991, SOUTHERN MED J, V84, P1210, DOI 10.1097/00007611-199110000-00012; WAITZMAN NJ, 1994, INQUIRY-J HEALTH CAR, V31, P188	44	89	92	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					276	282		10.1016/S0140-6736(03)15385-8	http://dx.doi.org/10.1016/S0140-6736(03)15385-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766FQ	14751700				2022-12-28	WOS:000188361400009
J	Jung, D; Alt, FW				Jung, D; Alt, FW			Unraveling V(D)J recombination: Insights into gene regulation	CELL			English	Review							SITE-SPECIFIC RECOMBINATION; VARIABLE-REGION GENES; DOUBLE-STRAND BREAKS; PRE-B-CELLS; IMMUNOGLOBULIN GENE; ALLELIC EXCLUSION; RAG2 PROTEINS; HISTONE ACETYLATION; ELEMENTS 5'; DNA	V(D)J recombination assembles antigen receptor genes from component gene segments. We review findings that have shaped our current understanding of this remarkable mechanism, with a focus on two major reports-the first detailed comparison of germline and rearranged antigen receptor loci and the discovery of the recombination activating gene-1.	Harvard Univ, Howard Hughes Med Inst, Childrens Hosp, CBR Inst Biomed Res Inc,Med Sch, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute	Alt, FW (corresponding author), Harvard Univ, Howard Hughes Med Inst, Childrens Hosp, CBR Inst Biomed Res Inc,Med Sch, Boston, MA 02115 USA.	alt@rascal.med.harvard.edu						Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; ALT FW, 1980, CELL, V21, P1, DOI 10.1016/0092-8674(80)90109-9; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; Barreto V, 2001, EUR J IMMUNOL, V31, P3763, DOI 10.1002/1521-4141(200112)31:12<3763::AID-IMMU3763>3.0.CO;2-Y; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2000, NATURE, V405, P583, DOI 10.1038/35014635; Bassing CH, 2004, CELL CYCLE, V3, P149; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; BLACKWELL TK, 1984, CELL, V37, P105; BRACK C, 1978, CELL, V15, P1, DOI 10.1016/0092-8674(78)90078-8; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; Casellas R, 2002, CELL, V110, P575, DOI 10.1016/S0092-8674(02)00911-X; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chowdhury D, 2003, IMMUNITY, V18, P229, DOI 10.1016/S1074-7613(03)00030-X; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Clatworthy AE, 2003, MOL CELL, V12, P489, DOI 10.1016/S1097-2765(03)00305-8; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Desiderio S, 2000, CURR TOP MICROBIOL, V245, P31; DREYER WJ, 1965, P NATL ACAD SCI USA, V54, P864, DOI 10.1073/pnas.54.3.864; Dudley DD, 2003, J EXP MED, V198, P1439, DOI 10.1084/jem.20030627; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Feeney AJ, 2000, IMMUNOL REV, V175, P59, DOI 10.1111/j.1600-065X.2000.imr017508.x; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hesslein DGT, 2003, GENE DEV, V17, P37, DOI 10.1101/gad.1031403; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jones JM, 2002, EMBO J, V21, P4162, DOI 10.1093/emboj/cdf394; Jung D, 2003, IMMUNITY, V18, P65, DOI 10.1016/S1074-7613(02)00507-1; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khor B, 2002, CURR OPIN IMMUNOL, V14, P230, DOI 10.1016/S0952-7915(02)00326-6; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Krangel MS, 2003, NAT IMMUNOL, V4, P624, DOI 10.1038/ni0703-624; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; LAUZURICA P, 1994, J EXP MED, V179, P1913, DOI 10.1084/jem.179.6.1913; LEWIS S, 1984, NATURE, V308, P425, DOI 10.1038/308425a0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; Lieber M R, 1994, Semin Immunol, V6, P143, DOI 10.1006/smim.1994.1020; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Martensson IL, 2002, SEMIN IMMUNOL, V14, P335, DOI 10.1016/S1044-5323(02)00066-0; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; Messier TL, 2003, EMBO J, V22, P1381, DOI 10.1093/emboj/cdg137; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; MILSTEIN C, 1974, NATURE, V252, P354, DOI 10.1038/252354a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Monroe RJ, 1999, P NATL ACAD SCI USA, V96, P12713, DOI 10.1073/pnas.96.22.12713; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; Nagaoka H, 2000, CURR OPIN IMMUNOL, V12, P187, DOI 10.1016/S0952-7915(99)00070-9; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Olaru A, 2003, J IMMUNOL, V171, P3605, DOI 10.4049/jimmunol.171.7.3605; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; RITCHIE KA, 1984, NATURE, V312, P517, DOI 10.1038/312517a0; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Roth DB, 2003, NAT REV IMMUNOL, V3, P656, DOI 10.1038/nri1152; RUSCONI S, 1985, NATURE, V314, P330, DOI 10.1038/314330a0; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHILLING J, 1980, NATURE, V283, P35, DOI 10.1038/283035a0; Schlissel MS, 2002, CELL, V109, P1, DOI 10.1016/S0092-8674(02)00694-3; SEIDMAN JG, 1978, P NATL ACAD SCI USA, V75, P3881, DOI 10.1073/pnas.75.8.3881; SEIDMAN JG, 1979, NATURE, V280, P370, DOI 10.1038/280370a0; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Sikes ML, 2002, P NATL ACAD SCI USA, V99, P12309, DOI 10.1073/pnas.182166699; Sleckman BP, 2000, P NATL ACAD SCI USA, V97, P7975, DOI 10.1073/pnas.130190597; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; SWANSON PC, 2003, J BIOL CHEM, DOI DOI 10.1074/JBC.M31100200; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; Tillman RE, 2003, J IMMUNOL, V170, P5, DOI 10.4049/jimmunol.170.1.5; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tsai CL, 2003, EMBO J, V22, P1922, DOI 10.1093/emboj/cdg185; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; VALBUENA O, 1978, NATURE, V276, P780, DOI 10.1038/276780a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WEIGERT M, 1978, NATURE, V276, P785, DOI 10.1038/276785a0; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287; Yu W, 1999, SCIENCE, V285, P1080, DOI 10.1126/science.285.5430.1080; Yurchenko V, 2003, GENE DEV, V17, P581, DOI 10.1101/gad.1058103	117	252	290	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					299	311		10.1016/S0092-8674(04)00039-X	http://dx.doi.org/10.1016/S0092-8674(04)00039-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744439	Bronze			2022-12-28	WOS:000188541700018
J	Sherr, CJ				Sherr, CJ			Principles of tumor suppression	CELL			English	Review							BETA-CATENIN; RB/E2F PATHWAY; HUMAN HOMOLOG; GENE-PRODUCT; INK4A LOCUS; DNA-DAMAGE; STEM-CELLS; P53 GENE; CANCER; MUTATIONS	Molecular genetic studies of familial cancer syndromes identified and defined the recessive nature of tumor suppressor genes and resolved the paradox of why tumors arising in such families exhibited an autosomally dominant pattern of inheritance. Subsequent characterization of tumor suppressor proteins revealed their widespread involvement in sporadic cancers and pinpointed key mechanisms that protect animals against tumor development. We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis. Their study has become a center-piece of contemporary cancer research.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital	Sherr, CJ (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, Dept Genet & Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	sherr@stjude.org	高, 雨莉/HGU-8187-2022; Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRANCKE U, 1976, MED PEDIATR ONCOL, V2, P379, DOI 10.1002/mpo.2950020404; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grady WM, 1999, CANCER RES, V59, P320; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Knudson A. G., 1973, ADV CANCER RES, V17, P317; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NOEL B, 1976, CLIN GENET, V9, P593; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Schutte M, 1996, CANCER RES, V56, P2527; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shih IM, 2000, CANCER RES, V60, P1671; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	105	711	736	2	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					235	246		10.1016/S0092-8674(03)01075-4	http://dx.doi.org/10.1016/S0092-8674(03)01075-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744434	Bronze			2022-12-28	WOS:000188541700013
J	Gibbons, DL; Vaney, MC; Roussel, A; Vigouroux, A; Reilly, B; Lepault, J; Kielian, M; Rey, FA				Gibbons, DL; Vaney, MC; Roussel, A; Vigouroux, A; Reilly, B; Lepault, J; Kielian, M; Rey, FA			Conformational change and protein protein interactions of the fusion protein of Semliki Forest virus	NATURE			English	Article							MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; PORE FORMATION; CYTOPLASMIC TAIL; HEMIFUSION; CRYSTALLOGRAPHY; GLYCOPROTEIN; ACTIVATION; PATHWAY; ENTRY	Fusion of biological membranes is mediated by specific lipid- interacting proteins that induce the formation and expansion of an initial fusion pore. Here we report the crystal structure of the ectodomain of the Semliki Forest virus fusion glycoprotein E1 in its low- pH- induced trimeric form. E1 adopts a folded- back conformation that, in the final post- fusion form of the full- length protein, would bring the fusion peptide loop and the transmembrane anchor to the same end of a stable protein rod. The observed conformation of the fusion peptide loop is compatible with interactions only with the outer leaflet of the lipid bilayer. Crystal contacts between fusion peptide loops of adjacent E1 trimers, together with electron microscopy observations, suggest that in an early step of membrane fusion, an intermediate assembly of five trimers creates two opposing nipple- like deformations in the viral and target membranes, leading to formation of the fusion pore.	INRA, CNRS, UMR 2472 1157, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Yeshiva University; Albert Einstein College of Medicine	Kielian, M (corresponding author), INRA, CNRS, UMR 2472 1157, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	kielian@aecom.yu.edu; rey@vms.cnrs-gif.fr	Lepault, Jean/AAN-8859-2020; Rey, Felix/B-6497-2012	Kielian, Margaret/0000-0002-7395-4791; Rey, Felix/0000-0002-9953-7988				Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Bagai S, 1996, J CELL BIOL, V135, P73, DOI 10.1083/jcb.135.1.73; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; BRESSANELLI S, IN PRESS EMBO J; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Gaudin Y, 2000, J CELL BIOL, V150, P601, DOI 10.1083/jcb.150.3.601; Gibbons DL, 2003, CELL, V114, P573, DOI 10.1016/S0092-8674(03)00683-4; Gibbons DL, 2002, J VIROL, V76, P1194, DOI 10.1128/JVI.76.3.1194-1205.2002; GIBBONS DL, IN PRESS J VIROL; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Januszeski MM, 1997, J VIROL, V71, P3613, DOI 10.1128/JVI.71.5.3613-3619.1997; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kielian M, 2000, Subcell Biochem, V34, P409; KLIMJACK MR, 1994, J VIROL, V68, P6940, DOI 10.1128/JVI.68.11.6940-6946.1994; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Markosyan RM, 2001, BIOPHYS J, V80, P812, DOI 10.1016/S0006-3495(01)76060-2; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; Melikyan GB, 2000, J VIROL, V74, P447, DOI 10.1128/JVI.74.1.447-455.2000; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SCHLESINGER S, 2001, FIELDS VIROLOGY, P895; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Zhang W, 2002, J VIROL, V76, P11645, DOI 10.1128/JVI.76.22.11645-11658.2002; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0	42	292	302	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					320	325		10.1038/nature02239	http://dx.doi.org/10.1038/nature02239			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737160				2022-12-28	WOS:000188266200032
J	Kowalski, RG; Claassen, J; Kreiter, KT; Bates, JE; Ostapkovich, ND; Connolly, ES; Mayer, SA				Kowalski, RG; Claassen, J; Kreiter, KT; Bates, JE; Ostapkovich, ND; Connolly, ES; Mayer, SA			Initial misdiagnosis and outcome after subarachnoid hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DELAYED DIAGNOSIS; INTRACRANIAL ANEURYSMS; HEADACHE; DEATH; MANAGEMENT; EMERGENCY; PITFALLS; CARE	Context Mortality and morbidity can be reduced if aneurysmal subarachnoid hemorrhage (SAH) is treated urgently. Objective To determine the association of initial misdiagnosis and outcome after SAH. Design, Setting, and Participants Inception cohort of 482 SAH patients admitted to a tertiary care urban hospital between August 1996 and August 2001. Main Outcome Measures Misdiagnosis was defined as failure to correctly diagnose SAH at a patient's initial contact with a medical professional. Functional outcome was assessed at 3 and 12 months with the modified Rankin Scale; quality of life (QOL), with the Sickness Impact Profile. Results Fifty-six patients (12%) were initially misdiagnosed, including 42 of 221 (19%) of those with normal mental status at first contact. Migraine or tension headache (36%) was the most common incorrect diagnosis, and failure to obtain a computed tomography (CT) scan was the most common diagnostic error (73%). Neurologic complications occurred in 22 patients (39%) before they were correctly diagnosed, including 12 patients (21%) who experienced rebleeding. Normal mental status, small SAH volume, and right-sided aneurysm location were independently associated with misdiagnosis. Among patients with normal mental status at first contact, misdiagnosis was associated with worse QOL at 3 months and an increased risk of death or severe disability at 12 months. Conclusions In this study, misdiagnosis of SAH occurred in 12% of patients and was associated with a smaller hemorrhage and normal mental status. Among individuals who initially present in good condition, misdiagnosis is associated with increased mortality and morbidity. A low threshold for CT scanning of patients with mild symptoms that are suggestive of SAH may reduce the frequency of misdiagnosis.	Columbia Univ Coll Phys & Surg, Inst Neurol, Div Stroke & Crit Care Neuro, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA	Columbia University; Columbia University	Mayer, SA (corresponding author), Columbia Univ Coll Phys & Surg, Inst Neurol, Div Stroke & Crit Care Neuro, 710 W 168th St,Unit 39, New York, NY 10032 USA.	sam14@columbia.edu	Claassen, Jan/AAA-5451-2020					ADAMS HP, 1980, JAMA-J AM MED ASSOC, V244, P794, DOI 10.1001/jama.244.8.794; BARTON CW, 1994, HEADACHE, V34, P91, DOI 10.1111/j.1526-4610.1994.hed3402091.x; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; CHAN BSH, 1991, MED J AUSTRALIA, V154, P509, DOI 10.5694/j.1326-5377.1991.tb119442.x; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Damiano AM, 1996, SICKNESS IMPACT PROF; Edlow JA, 2000, NEW ENGL J MED, V342, P29, DOI 10.1056/NEJM200001063420106; Fridriksson S, 2001, ACTA NEUROL SCAND, V103, P238; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; KARCZ A, 1993, ANN EMERG MED, V22, P553, DOI 10.1016/S0196-0644(05)81941-9; KASSELL NF, 1985, STROKE, V16, P587, DOI 10.1161/01.STR.16.4.587; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Mayer PL, 1996, STROKE, V27, P1558, DOI 10.1161/01.STR.27.9.1558; MAYER SA, 2000, MERRITTS TXB NEUROLO, P260; Morgenstern LB, 1998, ANN EMERG MED, V32, P297; NeilDwyer G, 1997, J ROY COLL PHYS LOND, V31, P49; Ostapkovich N, 2001, ANN NEUROL, V50, pS78; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; SCHIEVINK WI, 1988, SURG NEUROL, V29, P367, DOI 10.1016/0090-3019(88)90045-6; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; VANGIJN J, 1985, J NEUROSURG, V63, P355, DOI 10.3171/jns.1985.63.3.0355; Vannemreddy P, 2001, SOUTHERN MED J, V94, P1108, DOI 10.1097/00007611-200111000-00014; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365	25	179	192	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					866	869		10.1001/jama.291.7.866	http://dx.doi.org/10.1001/jama.291.7.866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970066	Bronze			2022-12-28	WOS:000189000400025
J	Johnston, SC; O'Meara, ES; Manolio, TA; Lefkowitz, D; O'Leary, DH; Goldstein, S; Carlson, MC; Fried, LP; Longstreth, WT				Johnston, SC; O'Meara, ES; Manolio, TA; Lefkowitz, D; O'Leary, DH; Goldstein, S; Carlson, MC; Fried, LP; Longstreth, WT			Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article							MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL IMPROVEMENT; CEREBRAL INFARCTION; DIABETES-MELLITUS; BRAIN INFARCTION; ELDERLY-PEOPLE; OLDER-ADULTS; MRI FINDINGS; RISK-FACTORS	Background: Whether carotid artery disease is a cause of cognitive impairment in persons who have not had stroke is unknown. If this is the case, diminished performance on the Modified Mini-Mental State Examination should be more common in persons with left carotid artery disease than in those with right carotid artery disease. Objective: To determine whether left carotid artery disease is associated with cognitive impairment. Design: Cross-sectional and cohort study. Setting: Four U.S. communities participating in the Cardiovascular Health Study. Patients: 4006 right-handed men and women 65 years of age or older without history of stroke, transient ischemic attack, or carotid endarterectomy. Measurements: internal carotid artery stenosis and intimamedia thickness of the common carotid artery were assessed by using duplex ultrasonography. Cognitive impairment was defined as a score less than 80 on the Modified Mini-Mental State Examination, and cognitive decline was defined as an average decrease of more than 1 point annually in Modified Mini-Mental State Examination score during up to 5 years of follow-up. Multivariate logistic regression models were used to estimate the risk for cognitive impairment and decline associated with left internal carotid artery stenosis and intima-media thickness, after adjustment for measures of right-sided disease and risk factors for vascular disease. Results: After adjustment for right-sided stenosis, high-grade (greater than or equal to75% narrowing of diameter) stenosis of the left internal carotid artery (32 patients) was associated with cognitive impairment (odds ratio, 6.7 [95% CI, 2.4 to 18.1] compared with no stenosis) and cognitive decline (odds ratio, 2.6 [CI, 1.1 to 6.3]). Intimamedia thickness of the left common carotid artery was associated with cognitive impairment and decline in univariate analysis, but this effect did not persist after adjustment. Conclusions: Cognitive impairment and decline are associated with asymptomatic high-grade stenosis of the left internal carotid artery. The persistence of the association after adjustment for right-sided stenosis indicates that the association is not due to underlying vascular risk factors or atherosclerosis in general.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Washington, Seattle, WA 98195 USA; NHLBI, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA; Wake Forest Univ, Winston Salem, NC 27109 USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Wake Forest University; Tufts Medical Center; Tufts University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnston, SC (corresponding author), Univ Calif San Francisco, Dept Neurol, Box 0114,505 Parnassus Ave,M-798, San Francisco, CA 94143 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC085084, N01HC035129, N01HC085080, N01HC015103, N01HC085081, N01HC085083, N01HC085079, N01HC085082, N01HC085085] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85086, N01-HC-85085, N01-HC-85084, N01-HC-85083, N01-HC-85082, N01-HC-85081, N01-HC-85080, N01-HC-85079, N01-HC-15103, N01-HC-35129] Funding Source: Medline; NINDS NIH HHS [NS02254] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROTT T, 1994, STROKE, V25, P1122, DOI 10.1161/01.STR.25.6.1122; BRYAN RN, 1994, AM J NEURORADIOL, V15, P1625; Caplan D., 1987, NEUROLINGUISTICS LIN; CASEY JE, 1989, J CLIN EXP NEUROPSYC, V11, P461, DOI 10.1080/01688638908400906; Cerhan JR, 1998, GERONTOLOGY, V44, P95, DOI 10.1159/000021991; de Groot JC, 2001, NEUROLOGY, V56, P1539, DOI 10.1212/WNL.56.11.1539; De la Torre JC, 2000, ANN NY ACAD SCI, V903, P424, DOI 10.1111/j.1749-6632.2000.tb06394.x; DICK JPR, 1984, J NEUROL NEUROSUR PS, V47, P496, DOI 10.1136/jnnp.47.5.496; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FINEEDELSTEIN JS, 1994, NEUROLOGY, V44, P1046, DOI 10.1212/WNL.44.6.1046; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; GRACE J, 1995, ARCH NEUROL-CHICAGO, V52, P477, DOI 10.1001/archneur.1995.00540290067019; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; GREIFFENSTEIN MF, 1988, CORTEX, V24, P223, DOI 10.1016/S0010-9452(88)80031-5; Harrington F, 2000, HYPERTENSION, V36, P1079, DOI 10.1161/01.HYP.36.6.1079; HEMMINGSEN R, 1982, ACTA NEUROL SCAND, V66, P145, DOI 10.1111/j.1600-0404.1982.tb04512.x; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; JACOBS LA, 1983, SURGERY, V93, P683; KELLY MP, 1980, ARCH NEUROL-CHICAGO, V37, P743, DOI 10.1001/archneur.1980.00500610023002; KING GD, 1977, J CLIN PSYCHOL, V33, P215, DOI 10.1002/1097-4679(197701)33:1+<215::AID-JCLP2270330149>3.0.CO;2-D; Knopman D, 2001, NEUROLOGY, V56, P42, DOI 10.1212/WNL.56.1.42; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P1217, DOI 10.1001/archneur.55.9.1217; Luchsinger JA, 2001, AM J EPIDEMIOL, V154, P635, DOI 10.1093/aje/154.7.635; Manolio TA, 1999, ARTERIOSCL THROM VAS, V19, P356, DOI 10.1161/01.ATV.19.2.356; MATARAZZO R G, 1979, Journal of Clinical Neuropsychology, V1, P97, DOI 10.1080/01688637908414445; Melzer D, 1997, BRIT MED J, V315, P462, DOI 10.1136/bmj.315.7106.462; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; Neter J., 1996, APPL LINEAR STAT MOD; NORRIS JW, 1992, STROKE, V23, P483, DOI 10.1161/01.STR.23.4.483; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; PARKER JC, 1983, J CLIN NEUROPSYCHOL, V5, P345, DOI 10.1080/01688638308401182; Pettigrew LC, 2000, NEUROLOGY, V55, P30, DOI 10.1212/WNL.55.1.30; Price T R, 1993, Ann Epidemiol, V3, P504; Price TR, 1997, STROKE, V28, P1158, DOI 10.1161/01.STR.28.6.1158; Pullicino PM, 2001, NEUROLOGY, V57, P1945, DOI 10.1212/WNL.57.11.1945; Rao R, 2001, EUR NEUROL, V46, P63, DOI 10.1159/000050765; Rockwood K, 1997, ARCH NEUROL-CHICAGO, V54, P33, DOI 10.1001/archneur.1997.00550130019010; Rockwood K, 2000, NEUROLOGY, V54, P447, DOI 10.1212/WNL.54.2.447; SIRKKA A, 1992, ACTA NEUROL SCAND, V85, P58; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Smith A., 1982, SYMBOL DIGIT MODALIT; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TIMSIT SG, 1992, STROKE, V23, P486, DOI 10.1161/01.STR.23.4.486; VANDENBURG W, 1985, PSYCHOL MED, V15, P341, DOI 10.1017/S003329170002362X; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	57	227	250	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					237	247		10.7326/0003-4819-140-4-200402170-00005	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970146				2022-12-28	WOS:000188970400001
J	Peter, R; Mishra, V; Fraser, WD				Peter, R; Mishra, V; Fraser, WD			Lesson of the week - Severe hypocalcaemia after being given intravenous bisphosphonate	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SYMPTOMATIC HYPOCALCEMIA; ZOLEDRONIC ACID; PAMIDRONATE; HYPERCALCEMIA; BONE; HYPOPARATHYROIDISM; MALIGNANCY; DISEASE		Royal Liverpool Univ Hosp, Dept Clin Chem, Liverpool L69 3GA, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Fraser, WD (corresponding author), Royal Liverpool Univ Hosp, Dept Clin Chem, Liverpool L69 3GA, Merseyside, England.	w.d.fraser@liv.ac.uk						Comlekci A, 1998, INTERNAL MED, V37, P396, DOI 10.2169/internalmedicine.37.396; FRASER WD, 1991, BONE MINER, V12, P113, DOI 10.1016/0169-6009(91)90040-7; HARINCK HIJ, 1987, AM J MED, V82, P1133, DOI 10.1016/0002-9343(87)90215-4; Machado CE, 1996, CLIN NEPHROL, V45, P175; Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558; McIntyre E, 1996, J PALLIATIVE CARE, V12, P46, DOI 10.1177/082585979601200109; Mishra A, 2001, ENDOCRINE, V14, P159, DOI 10.1385/ENDO:14:2:159; Rosen LS, 2001, CANCER J, V7, P377; Sims E C, 1998, Clin Oncol (R Coll Radiol), V10, P407, DOI 10.1016/S0936-6555(98)80045-9; Vinholes J, 1996, BRIT J CANCER, V73, P1089, DOI 10.1038/bjc.1996.210	10	67	69	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					335	336		10.1136/bmj.328.7435.335	http://dx.doi.org/10.1136/bmj.328.7435.335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764499	Green Published			2022-12-28	WOS:000188926900027
J	West, R				West, R			ABC of smoking cessation - Assessment of dependence and motivation to stop smoking	BRITISH MEDICAL JOURNAL			English	Review									UCL, Canc Res UK Hlth Behav Unit, London WC1E 6BT, England	University of London; University College London	West, R (corresponding author), UCL, Canc Res UK Hlth Behav Unit, London WC1E 6BT, England.		West, Robert/B-5414-2009; West, Robert/B-5414-2009	West, Robert/0000-0002-0291-5760; West, Robert/0000-0001-6398-0921				KOZLOWSKI LT, 1994, DRUG ALCOHOL DEPEN, V34, P211, DOI 10.1016/0376-8716(94)90158-9; *NAT I CLIN EXC, 2002, 38 NRT NICE; Sutton S, 2001, ADDICTION, V96, P175, DOI 10.1046/j.1360-0443.2001.96117513.x	3	73	78	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2004	328	7435					338	339		10.1136/bmj.328.7435.338	http://dx.doi.org/10.1136/bmj.328.7435.338			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764501	Green Published			2022-12-28	WOS:000188926900029
J	Donnelly, CA				Donnelly, CA			Bovine spongiform encephalopathy in the United States - An epidemiologist's view	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CATTLE		Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England	Imperial College London	Donnelly, CA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.			Donnelly, Christl/0000-0002-0195-2463				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ANDERSON RM, 1997, NATURE, V384, P302; *DEFRA, 2003, BSE HOM; *DEP HLTH, 2004, MONTHL CREUTZF JAK D; Ferguson NM, 2003, P ROY SOC B-BIOL SCI, V270, P1579, DOI 10.1098/rspb.2003.2484	5	5	5	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					539	542		10.1056/NEJMp038005	http://dx.doi.org/10.1056/NEJMp038005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762179				2022-12-28	WOS:000188712800003
J	Freedman, SD; Blanco, PG; Zaman, MM; Shea, JC; Ollero, M; Hopper, IK; Weed, DA; Gelrud, A; Regan, MM; Laposata, M; Alvarez, JG; O'Sullivan, BP				Freedman, SD; Blanco, PG; Zaman, MM; Shea, JC; Ollero, M; Hopper, IK; Weed, DA; Gelrud, A; Regan, MM; Laposata, M; Alvarez, JG; O'Sullivan, BP			Association of cystic fibrosis with abnormalities in fatty acid metabolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOCOSAHEXAENOIC ACID; ADIPOSE-TISSUE; CFTR(-/-) MICE; ION-TRANSPORT; GENE; INFLAMMATION; PANCREATITIS; MUTATIONS; DISEASE; CELLS	Background: Patients with cystic fibrosis have altered levels of plasma fatty acids. We previously demonstrated that arachidonic acid levels are increased and docosahexaenoic acid levels are decreased in affected tissues from cystic fibrosis-knockout mice. In this study we determined whether humans with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have a similar fatty acid defect in tissues expressing CFTR. Methods: Fatty acids from nasal- and rectal-biopsy specimens, nasal epithelial scrapings, and plasma were analyzed from 38 subjects with cystic fibrosis and compared with results in 13 obligate heterozygotes, 24 healthy controls, 11 subjects with inflammatory bowel disease, 9 subjects with upper respiratory tract infection, and 16 subjects with asthma. Results: The ratio of arachidonic to docosahexaenoic acid was increased in mucosal and submucosal nasal-biopsy specimens (P<0.001) and rectal-biopsy specimens (P=0.009) from subjects with cystic fibrosis and pancreatic sufficiency and subjects with cystic fibrosis and pancreatic insufficiency, as compared with values in healthy control subjects. In nasal tissue, this change reflected an increase in arachidonic acid levels and a decrease in docosahexaenoic acid levels. In cells from nasal mucosa, the ratio of arachidonic to docosahexaenoic acid was increased in subjects with cystic fibrosis (P<0.001), as compared with healthy controls, with values in obligate heterozygotes intermediate between these two groups (P<0.001). The ratio was not increased in subjects with inflammatory bowel disease. Subjects with asthma and those with upper respiratory tract infection had values intermediate between those in subjects with cystic fibrosis and those in healthy control subjects. Conclusions: These data indicate that alterations in fatty acids similar to those in cystic fibrosis-knockout mice are present in CFTR-expressing tissue from subjects with cystic fibrosis.	Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Div Lab Med, Boston, MA 02114 USA; Hosp San Rafael, Ctr Infertilidad Masculina Androgen, Inst Infertilidad Masculina, La Coruna, Spain; Univ Massachusetts, Sch Med, UMass Mem Hlth Care, Dept Pediat, Worcester, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester	Freedman, SD (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Dana 552,330 Brookline Ave, Boston, MA 02215 USA.	sfreedma@caregroup.harvard.edu	Alvarez, Juan/GSD-7155-2022; Ollero, Mario/AAJ-3545-2020; Ollero, Mario/Q-6147-2018	Ollero, Mario/0000-0003-3590-706X	NCRR NIH HHS [RR 01032] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alasnier C, 2002, J NUTR BIOCHEM, V13, P337, DOI 10.1016/S0955-2863(02)00176-6; ALVAREZ JG, 1995, MOL REPROD DEV, V42, P334, DOI 10.1002/mrd.1080420311; BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BIGGEMANN B, 1988, SCAND J GASTROENTERO, V23, P135, DOI 10.3109/00365528809090234; Borowitz D, 2002, J PEDIATR GASTR NUTR, V35, P246, DOI 10.1097/00005176-200209000-00004; CARLSTEDTDUKE J, 1986, P NATL ACAD SCI USA, V83, P9202, DOI 10.1073/pnas.83.23.9202; CHRISTOPHE AB, 1994, LIPIDS, V29, P569, DOI 10.1007/BF02536629; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; Durno C, 2002, GASTROENTEROLOGY, V123, P1857, DOI 10.1053/gast.2002.37042; Farrell PM, 1996, PEDIATRICS, V97, P524; FARRELL PM, 1985, PEDIATR RES, V19, P104, DOI 10.1203/00006450-198501000-00028; Freedman SD, 2002, J APPL PHYSIOL, V92, P2169, DOI 10.1152/japplphysiol.00927.2001; Freedman SD, 1999, P NATL ACAD SCI USA, V96, P13995, DOI 10.1073/pnas.96.24.13995; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; GOLDSTEIN JL, 1988, AM J PHYSIOL, V254, pC719, DOI 10.1152/ajpcell.1988.254.5.C719; Helge JW, 2001, J APPL PHYSIOL, V90, P670, DOI 10.1063/1.1380406; Hollander M., 1999, NONPARAMETRIC STAT M, P202; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; HUBBARD VS, 1977, LANCET, V2, P1302; Kammouni W, 1997, INFECT IMMUN, V65, P5176, DOI 10.1128/IAI.65.12.5176-5183.1997; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KUO PT, 1962, J PEDIATR-US, V60, P394, DOI 10.1016/S0022-3476(62)80065-1; KUTTY KM, 1979, CLIN BIOCHEM, V12, P98, DOI 10.1016/S0009-9120(79)80074-0; LAPOSATA M, 1995, AM J CLIN PATHOL, V104, P172; LLOYDSTILL JD, 1981, AM J CLIN NUTR, V34, P1; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Noah TL, 1997, J INFECT DIS, V175, P638, DOI 10.1093/infdis/175.3.638; Rosenstein BJ, 1998, J PEDIATR-US, V132, P589, DOI 10.1016/S0022-3476(98)70344-0; Roulet M, 1997, EUR J PEDIATR, V156, P952, DOI 10.1007/s004310050750; RUBIN D, 1992, J LIPID RES, V33, P1431; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Strandvik B, 2001, J PEDIATR-US, V139, P650, DOI 10.1067/mpd.2001.118890; Tabary O, 1998, AM J PATHOL, V153, P921, DOI 10.1016/S0002-9440(10)65633-7; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; Tzetis M, 2001, HUM GENET, V108, P216, DOI 10.1007/s004390100467; VEEZE HJ, 1991, GASTROENTEROLOGY, V101, P398, DOI 10.1016/0016-5085(91)90017-F; Wang XJ, 2000, JAMA-J AM MED ASSOC, V284, P1814, DOI 10.1001/jama.284.14.1814; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607	44	299	308	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					560	569		10.1056/NEJMoa021218	http://dx.doi.org/10.1056/NEJMoa021218			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762183	Bronze			2022-12-28	WOS:000188712800007
J	Reinhard, J; Srinivasan, MV; Zhang, SW				Reinhard, J; Srinivasan, MV; Zhang, SW			Olfaction: Scent-triggered navigation in honeybees	NATURE			English	Editorial Material									Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	Australian National University	Reinhard, J (corresponding author), Australian Natl Univ, Res Sch Biol Sci, GPO Box 475, Canberra, ACT 2601, Australia.	reinhard@rsbs.anu.du.au	Srinivasan, Mandyam V/G-5571-2010; Zhang, Shaowu/C-9139-2009	Zhang, Shaowu/0000-0002-3551-5587; Muthukumarasamy, Srinivasan/0000-0002-2948-6206				Dyer FC, 2002, ANNU REV ENTOMOL, V47, P917, DOI 10.1146/annurev.ento.47.091201.145306; FREE JB, 1969, NATURE, V222, P778, DOI 10.1038/222778a0; Gould James L., 1993, P18; Jakobsen HB, 1995, J CHEM ECOL, V21, P1635, DOI 10.1007/BF02033666; Ribbands C. R., 1954, Proceedings of the Royal Entomological Society of London (A), V29, P141; Tautz J, 2003, J COMP PHYSIOL A, V189, P293, DOI 10.1007/s00359-003-0402-6; von Frisch K, 1969, DANCE LANGUAGE ORIEN; WEHNER R, 1981, HDB SENSORY PHYSL, P288	8	118	125	3	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 29	2004	427	6973					411	411		10.1038/427411a	http://dx.doi.org/10.1038/427411a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749818	Bronze			2022-12-28	WOS:000188470500030
J	Gupta, R; Irwin, A; Raviglione, MC; Kim, JY				Gupta, R; Irwin, A; Raviglione, MC; Kim, JY			Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis	LANCET			English	Article							HIV; HEALTH	The UN has launched an initiative to place 3 million people in developing countries on antiretroviral AIDS treatment by end 2005 (the 3 by 5 target). Lessons for HIV/AIDS treatment scale-up emerge from recent experience with multidrug-resistant tuberculosis. Expansion of treatment for multidrug-resistant tuberculosis through the multipartner mechanism known as the Green Light Committee (GLC) has enabled gains in areas relevant to 3 by 5, including policy development, drug procurement, rational use of drugs, and the strengthening of health systems. The successes of the GLC and the obstacles it has encountered provide insights for building sustainable HIV/AIDS treatment programmes.	WHO, Off Director Gen, CH-1211 Geneva, Switzerland; WHO, Evidence Informat & Policy Cluster, CH-1211 Geneva, Switzerland; WHO, Div Stop TB, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization; World Health Organization	Gupta, R (corresponding author), WHO, Off Director Gen, 20 Ave Appia, CH-1211 Geneva, Switzerland.	guptara@who.int		RAVIGLIONE, Mario/0000-0002-9331-2067; Gupta, Rajesh/0000-0002-3307-6541				ARNADOTTIR T, 2001, GUIDELINES ESTABLISH; Cullinan T, 2001, LANCET, V357, P1124, DOI 10.1016/S0140-6736(00)04268-9; Enarson D.A., 2000, MANAGEMENT TUBERCULO; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Flament-Saillour M, 1999, AM J RESP CRIT CARE, V160, P587, DOI 10.1164/ajrccm.160.2.9901012; FREEMAN P, 1999, PAN AM HLTH ORG REVO; Geerligs WA, 2000, INT J TUBERC LUNG D, V4, P758; Gupta R, 2003, INT J TUBERC LUNG D, V7, P410; Gupta R, 2002, INT J TUBERC LUNG D, V6, P651; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Gupta R, 2001, INT J TUBERC LUNG D, V5, P1078; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Kim JY, 2003, TUBERCULOSIS, V83, P59, DOI 10.1016/S1472-9792(02)00078-1; Lee JW, 2003, LANCET, V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; MUKHERJEE J, 2003, ACCESS ANTIRETROVIRA; Mukherjee JS, 2003, BMJ-BRIT MED J, V327, P1104, DOI 10.1136/bmj.327.7423.1104; Narita M, 2001, CHEST, V120, P343, DOI 10.1378/chest.120.2.343; OKERO A, 2003, SCALING ANTIRETROVIR; [Organization WH World Health Organization Joint United Nations Programme on HIV/AIDS], 2003, TREAT 3 MILL 2005 MA; Park SK, 1998, INT J TUBERC LUNG D, V2, P877; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; RABKIN M, 2003, SAVING MOTHERS SAVIN; RIEDMAN MA, 2003, LANCET, V361, P341; Riekstina V, 2003, INT J TUBERC LUNG D, V7, P903; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; *U CAP TOWN DEP PU, 2003, ANT THER PRIM HLTH C; Viskum K, 1997, INT J TUBERC LUNG D, V1, P299; WHO, 1997, GUID MAN DRUG RES TU; *WHO, PREQ PROJ; *WHO, 2003, UNPUB M STOP TB WORK; WHO, 1997, TREATM TUB GUID NAT, V2; *WHO, WHO SAYS FAIL DEL AI; World Health Organization, 2002, SCAL ANT THER RES LT; World Health Organization, 2003, SCAL ANT THER RES LT; ZIMMERMAN R, 2003, WALL STREET J   0605	37	20	20	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					320	324		10.1016/S0140-6736(03)15394-9	http://dx.doi.org/10.1016/S0140-6736(03)15394-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751708				2022-12-28	WOS:000188361400026
J	Harding, EJ; Paul, ES; Mendl, M				Harding, EJ; Paul, ES; Mendl, M			Animal behavior - Cognitive bias and affective state	NATURE			English	Editorial Material							DEPRESSION; INDICATOR; ANXIETY; REWARD		Univ Bristol, Ctr Behav Biol, Dept Vet Clin Sci, Langford BS40 5DU, England	University of Bristol	Harding, EJ (corresponding author), Univ Bristol, Ctr Behav Biol, Dept Vet Clin Sci, Langford House, Langford BS40 5DU, England.	mike.mendl@bris.ac.uk	Mendl, Michael T/D-7220-2016	Mendl, Michael T/0000-0002-5302-1871				Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9; DAWKINS MS, 2001, COPING CHALLENGE WEL, P63; EYSENCK MW, 1991, J ABNORM PSYCHOL, V100, P144, DOI 10.1037/0021-843X.100.2.144; Fernandes C, 1996, PHARMACOL BIOCHEM BE, V54, P31, DOI 10.1016/0091-3057(95)02171-X; Gotlib IH, 1998, BEHAV THER, V29, P603, DOI 10.1016/S0005-7894(98)80020-8; MacLeod AK, 1996, J ABNORM PSYCHOL, V105, P286, DOI 10.1037/0021-843X.105.2.286; Nielsen BL, 1999, APPL ANIM BEHAV SCI, V63, P79, DOI 10.1016/S0168-1591(99)00003-9; Spruijt BM, 2001, APPL ANIM BEHAV SCI, V72, P145, DOI 10.1016/S0168-1591(00)00204-5; Willner P, 1997, PSYCHOPHARMACOLOGY, V134, P319, DOI 10.1007/s002130050456; WRIGHT WF, 1992, ORGAN BEHAV HUM DEC, V52, P276, DOI 10.1016/0749-5978(92)90039-A; Zurita A, 2000, BEHAV BRAIN RES, V117, P163, DOI 10.1016/S0166-4328(00)00302-8	11	493	498	3	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					312	312		10.1038/427312a	http://dx.doi.org/10.1038/427312a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	765KE	14737158				2022-12-28	WOS:000188266200030
J	Modis, Y; Ogata, S; Clements, D; Harrison, SC				Modis, Y; Ogata, S; Clements, D; Harrison, SC			Structure of the dengue virus envelope protein after membrane fusion	NATURE			English	Article							BORNE ENCEPHALITIS-VIRUS; SEMLIKI-FOREST-VIRUS; INFLUENZA HEMAGGLUTININ; CONFORMATIONAL-CHANGE; GLYCOPROTEIN; DOMAIN; HEMIFUSION; PEPTIDE; BINDING; ENTRY	Dengue virus enters a host cell when the viral envelope glycoprotein, E, binds to a receptor and responds by conformational rearrangement to the reduced pH of an endosome. The conformational change induces fusion of viral and host- cell membranes. A three- dimensional structure of the soluble E ectodomain ( sE) in its trimeric, postfusion state reveals striking differences from the dimeric, prefusion form. The elongated trimer bears three ` fusion loops' at one end, to insert into the host- cell membrane. Their structure allows us to model directly how these fusion loops interact with a lipid bilayer. The protein folds back on itself, directing its carboxy terminus towards the fusion loops. We propose a fusion mechanism driven by essentially irreversible conformational changes in E and facilitated by fusion- loop insertion into the outer bilayer leaflet. Specific features of the folded- back structure suggest strategies for inhibiting flavivirus entry.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Hawaii Biotech Inc, Aiea, HI 96701 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Harrison, SC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, 320 Longwood Ave, Boston, MA 02115 USA.	harrison@crystal.harvard.edu		Modis, Yorgo/0000-0002-6084-0429				Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; Allison SL, 1999, J VIROL, V73, P5605, DOI 10.1128/JVI.73.7.5605-5612.1999; Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001; Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Baldwin CE, 2003, CURR MED CHEM, V10, P1633, DOI 10.2174/0929867033457124; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; Cuzzubbo AJ, 2001, CLIN DIAGN LAB IMMUN, V8, P1150, DOI 10.1128/CDLI.8.6.1150-1155.2001; Dutch RE, 2001, J VIROL, V75, P5363, DOI 10.1128/JVI.75.11.5363-5369.2001; Ferlenghi I, 2001, MOL CELL, V7, P593, DOI 10.1016/S1097-2765(01)00206-4; GAO GF, 1994, J GEN VIROL, V75, P609, DOI 10.1099/0022-1317-75-3-609; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; Ito H, 1999, J VIROL, V73, P8907, DOI 10.1128/JVI.73.10.8907-8912.1999; IVY J, 1997, Patent No. 6165477; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Kuzmin PI, 2001, P NATL ACAD SCI USA, V98, P7235, DOI 10.1073/pnas.121191898; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; LOBIGS M, 1990, VIROLOGY, V176, P587, DOI 10.1016/0042-6822(90)90029-Q; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Razinkov VI, 1999, BIOPHYS J, V77, P3144, DOI 10.1016/S0006-3495(99)77144-4; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Stiasny K, 1996, J VIROL, V70, P8142, DOI 10.1128/JVI.70.11.8142-8147.1996; Stiasny K, 2002, J VIROL, V76, P3784, DOI 10.1128/JVI.76.8.3784-3790.2002; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WIMLEY WC, 1992, BIOCHEMISTRY-US, V31, P12813, DOI 10.1021/bi00166a015; Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990	51	854	910	4	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					313	319		10.1038/nature02165	http://dx.doi.org/10.1038/nature02165			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737159				2022-12-28	WOS:000188266200031
J	Reilly, JJ; Jackson, DM; Montgomery, C; Kelly, LA; Slater, C; Grant, S; Paton, JY				Reilly, JJ; Jackson, DM; Montgomery, C; Kelly, LA; Slater, C; Grant, S; Paton, JY			Total energy expenditure and physical activity in young Scottish children: mixed longitudinal study	LANCET			English	Article							REPRESENTATIVE SAMPLE	Childhood obesity has been attributed to a decline in total energy expenditure (TEE). We measured TEE, physical activity, and sedentary behaviour in a representative sample of young children from Glasgow, UK, at age 3 years (n=78), and we did a follow-up study at age 5 years (n=72). Mean physical activity level (TEE/resting energy expenditure) was 1.56 (SD 0.39) at age 3 years and 1.61 (0.22) at age 5 years. Median time in sedentary behaviour was 79% of monitored hours at age 3 years (IQR 74-84) and 76% (71-80) at age 5 years. Median time spent in moderate to vigorous physical activity represented only 2% of monitored hours at age 3 years (IQR 1-4) and 4% at age 5 years (2-6). Modern British children establish a sedentary lifestyle at an early age.	Univ Glasgow, Royal Hosp Sick Children, Div Dev Med, Glasgow G3 8SJ, Lanark, Scotland; Rowett Res Inst, Div Energy Balance & Obes, Aberdeen, Scotland; Univ Glasgow, Fac Biol & Life Sci, Glasgow, Lanark, Scotland	University of Glasgow; University of Aberdeen; University of Glasgow	Reilly, JJ (corresponding author), Univ Glasgow, Royal Hosp Sick Children, Div Dev Med, Glasgow G3 8SJ, Lanark, Scotland.	jjr2y@clinmed.gla.ac.uk	Paton, James/B-9541-2008; Jackson, Diane/A-6194-2009					Jackson DM, 2003, OBES RES, V11, P420, DOI 10.1038/oby.2003.57; Puyau MR, 2002, OBES RES, V10, P150, DOI 10.1038/oby.2002.24; Reilly JJ, 1999, LANCET, V354, P1874, DOI 10.1016/S0140-6736(99)04555-9; Reilly JJ, 2003, OBES RES, V11, P1155, DOI 10.1038/oby.2003.158; Reilly JJ, 2001, BRIT J NUTR, V86, P601, DOI 10.1079/BJN2001449	5	278	287	1	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					211	212		10.1016/S0140-6736(03)15331-7	http://dx.doi.org/10.1016/S0140-6736(03)15331-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738795				2022-12-28	WOS:000188243900012
J	Rubin, HR; Fink, NE; Plantinga, LC; Sadler, JH; Kliger, AS; Powe, NR				Rubin, HR; Fink, NE; Plantinga, LC; Sadler, JH; Kliger, AS; Powe, NR			Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	33rd Annual Meeting American-Society-of-Nephrology	OCT 13-16, 2000	PHILADELPHIA, PENNSYLVANIA	Amer Soc Nephrol			STAGE RENAL-DISEASE; HEALTH SURVEY SF-36; MODALITY SELECTION; MORTALITY; OUTCOMES; QUALITY; QUESTIONNAIRE; NEPHROLOGISTS	Context In light of conflicting evidence of differential effects of dialysis modality on survival, patient experience becomes a more important consideration in choosing between hemodialysis and peritoneal dialysis. Objective To compare patient satisfaction with hemodialysis and peritoneal dialysis in a cohort of patients who have recently begun dialysis. Design and Setting Cross-sectional survey at enrollment in a prospective inception cohort study of patients who recently started dialysis at 37 dialysis centers participating in the Choices for Healthy Outcomes in Caring for End-stage Renal Disease (CHOICE) study, a national multicenter study of dialysis outcomes, from October 1995 to June 1998. Patients Of 736 enrolled incident dialysis patients, 656 (89%) returned a satisfaction questionnaire after an average of 7 weeks of dialysis. Main Outcome Measure Data collected from a patient-ad ministered questionnaire including 3 overall ratings and 20 items rating specific aspects of dialysis care. Results Patients receiving peritoneal dialysis were much more likely than those receiving hemodialysis to give excellent ratings of dialysis care overall (85% vs 56%, respectively; relative probability, 1.46 [95% confidence interval, 1.31-1.57]) and significantly more likely to give excellent ratings for each specific aspect of care rated. The 3 items with the greatest differences were in the domain of information provided (average of information items: peritoneal dialysis [69% excellent] vs hemodialysis [30% excellent]). The smallest differences were in ratings of accuracy of information from the nephrologist, response to pain, amount of fluid removed, and staff availability in an emergency. Adjustment for patient age, race, education, health status, marital status, employment status, distance from the center, and time since starting dialysis did not reduce the differences between peritoneal dialysis and hemodialysis patients. Conclusions After several weeks of initiating dialysis, patients receiving peritoneal dialysis rated their care higher than those receiving hemodialysis. These findings indicate that clinicians should give patients more information about the option of peritoneal dialysis.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Independent Dialysis Fdn, Baltimore, MD USA; Hosp St Raphael, Dept Med, New Haven, CT USA; Yale Univ, Dept Med, New Haven, CT 06520 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Hospital Saint Raphael; Yale University	Rubin, HR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1830 E Monument St,Room 8015, Baltimore, MD 21205 USA.	hrubin@jhmi.edu	Kliger, Alan/AAN-6653-2021		AHRQ HHS [HS08365] Funding Source: Medline; NIDDK NIH HHS [DK59616, DK07024] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007024, R01DK059616] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; Cooper B S, 1997, Adv Ren Replace Ther, V4, P332; Eggers PW, 2002, AM J KIDNEY DIS, V39, P796, DOI 10.1053/ajkd.2002.32000; Golper T, 2001, NEPHROL DIAL TRANSPL, V16, P20, DOI 10.1093/ndt/16.suppl_7.20; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Hirth R A, 1997, Adv Ren Replace Ther, V4, P314; King K, 2000, ADV RENAL REPLACE TH, V7, P261, DOI 10.1053/jarr.2000.8123; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; *MED PAYM ADV COMM, 2001, REP C MED PAYM POL, P128; Mendelssohn DC, 2001, AM J KIDNEY DIS, V37, P22, DOI 10.1053/ajkd.2001.20573; Murphy SW, 2000, KIDNEY INT, V57, P1720, DOI 10.1046/j.1523-1755.2000.00017.x; Murray B P, 2000, Manag Care Interface, V13, P55; NELSON EC, 1990, MED CARE, V28, pS18, DOI 10.1097/00005650-199009001-00006; Powe NR, 1996, SEMIN DIALYSIS, V9, P9, DOI 10.1111/j.1525-139X.1996.tb00890.x; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; Rubin HR, 1997, AM J KIDNEY DIS, V30, P793, DOI 10.1016/S0272-6386(97)90084-6; Steinman TI, 1997, J AM SOC NEPHROL, V8, P1618; *US REN DAT SYST, 2002, USRDS 2002 ANN DAT R; Valderrabano F, 2001, NEPHROL DIAL TRANSPL, V16, P61, DOI 10.1093/ndt/16.suppl_7.61; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wu AW, 2001, AM J KIDNEY DIS, V37, P11, DOI 10.1053/ajkd.2001.20571; Wuerth DB, 2000, AM J KIDNEY DIS, V35, P638, DOI 10.1016/S0272-6386(00)70010-2; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zimmerman DL, 2003, NEPHROL DIAL TRANSPL, V18, P305, DOI 10.1093/ndt/18.2.305	25	219	223	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					697	703		10.1001/jama.291.6.697	http://dx.doi.org/10.1001/jama.291.6.697			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871912	Bronze			2022-12-28	WOS:000188819200022
J	Dash, P				Dash, P			New providers in UK health care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NHS				Dash, P (corresponding author), 13 Churchill Rd, St Albans AL1 4HH, Herts, England.	pennydash@aol.com						DASH P, 2003, GUARDIAN        0429; *DEP HLTH, GROW CAP DIAGN TREAT; *DEP HLTH, 2000, NHS PLAN; *DEP HLTH, 2003, FAIR ALL PERS YOU; Department of Health, 2002, DEL NHS PLAN; Department of Health, 2002, REF NHS FIN FLOWS IN; Dixon J, 2004, BRIT MED J, V328, P223, DOI 10.1136/bmj.328.7433.223; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Lewis R, 2004, BMJ-BRIT MED J, V328, P220, DOI 10.1136/bmj.328.7433.220; MANGO PD, 2001, MCKINSEY Q, P2; TIMMINS N, 2003, FINANCIAL TIMES 1229; TOYNBEE P, 2003, GUARDIAN        1022	12	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					340	342		10.1136/bmj.328.7435.340	http://dx.doi.org/10.1136/bmj.328.7435.340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764502	Green Published			2022-12-28	WOS:000188926900030
J	Schmid, GP; Buve, A; Mugyenyi, P; Garnett, GP; Hayes, RJ; Williams, BG; Calleja, JG; De Cock, KM; Whitworth, JA; Kapiga, SH; Ghys, PD; Hankins, C; Zaba, B; Helmer, R; Boerma, JT				Schmid, GP; Buve, A; Mugyenyi, P; Garnett, GP; Hayes, RJ; Williams, BG; Calleja, JG; De Cock, KM; Whitworth, JA; Kapiga, SH; Ghys, PD; Hankins, C; Zaba, B; Helmer, R; Boerma, JT			Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE SETTINGS; SOUTH-WEST UGANDA; MOTHER-TO-CHILD; MALE CIRCUMCISION; RURAL-POPULATION; SEXUAL-BEHAVIOR; COTE-DIVOIRE; DRUG-USERS; PREVALENCE	During the past year, a group has argued that unsafe injections are a major if not the main mode of HIV-1 transmission in sub-Saharan Africa. We review the main arguments used to question the epidemiological interpretations on the lead role of unsafe sex in HIV-1 transmission, and conclude there is no compelling evidence that unsafe injections are a predominant mode of HIV-1 transmission in sub-Saharan Africa. Conversely, though there is a clear need to eliminate all unsafe injections, epidemiological evidence indicates that sexual transmission continues to be by far the major mode of spread of HIV-1 in the region. Increased efforts are needed to reduce sexual transmission of HIV-1.	WHO, Dept HIV AIDS, CH-1211 Geneva 27, Switzerland; Inst Trop Med, B-2000 Antwerp, Belgium; Joint Clin Res Ctr, Kampala, Uganda; Univ London Imperial Coll Sci Technol & Med, London, England; London Sch Hyg & Trop Med, London WC1, England; Ctr Dis Control & Prevent, Atlanta, GA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; UNAIDS, Geneva, Switzerland; Yale Univ, Sch Med, New Haven, CT USA	World Health Organization; Institute of Tropical Medicine (ITM); Joint Clinic Research Center - United Arab Emirates; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Centers for Disease Control & Prevention - USA; Harvard University; Harvard T.H. Chan School of Public Health; UNAIDS; Yale University	Schmid, GP (corresponding author), WHO, Dept HIV AIDS, CH-1211 Geneva 27, Switzerland.	schmidg@who.int	Garnett, Geoffrey P/A-9312-2008	Hayes, Richard/0000-0002-1729-9892; Williams, Brian/0000-0002-3174-4876; Kapiga, Saidi/0000-0003-1753-4060; Hankins, Catherine/0000-0002-1642-8592				Abdala N, 1999, J ACQ IMMUN DEF SYND, V20, P73, DOI 10.1097/00042560-199901010-00011; Abdala N, 2001, J ACQ IMMUN DEF SYND, V28, P487; Allen S, 2003, AIDS, V17, P733, DOI 10.1097/00002030-200303280-00012; [Anonymous], 2002, CAUSES DEATH S AFRIC; Auvert B, 2001, AIDS, V15, P885, DOI 10.1097/00002030-200105040-00009; Bird A, 1997, TRANSFUS SCI, V18, P161; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; Brody S, 2003, BJOG-INT J OBSTET GY, V110, P450, DOI [10.1016/S1470-0328(03)03704-2, 10.1046/j.1471-0528.2003.03004.x]; BULTERYS M, 1994, AIDS, V8, P1585, DOI 10.1097/00002030-199411000-00010; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P1; Clatts MC, 1999, J ACQ IMMUN DEF SYND, V22, P194; Dicko M, 2000, B WORLD HEALTH ORGAN, V78, P163; Dziekan G, 2003, B WORLD HEALTH ORGAN, V81, P277; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Fontanet AL, 1998, AIDS, V12, P315, DOI 10.1097/00002030-199803000-00010; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; Gerbase AC, 1998, SEX TRANSM INFECT, V74, pS12; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; Gisselquist D, 2003, INT J STD AIDS, V14, P148, DOI 10.1258/095646203762869151; Gisselquist D, 2002, INT J STD AIDS, V13, P657, DOI 10.1258/095646202760326390; Gissequist DP, 2002, INT J STD AIDS, V13, P152, DOI 10.1258/0956462021924820; Glynn JR, 2001, AIDS, V15, P2025, DOI 10.1097/00002030-200110190-00016; *GOV ZIMB MIN HLTH, 2002, REP ASS IMM INJ PRAC; Gregson S, 2002, LANCET, V359, P1896, DOI 10.1016/S0140-6736(02)08780-9; Gregson S, 2002, SEX TRANSM DIS, V29, P568, DOI 10.1097/00007435-200210000-00002; Gregson S, 2000, AIDS, V14, pS85; HAURI AM, IN PRESS INT J STD A; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P83; HOELSCHER M, 1994, AIDS, V8, P1609, DOI 10.1097/00002030-199411000-00014; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; KENGEYAKAYONDO JF, 1995, ANN TROP PAEDIATR, V15, P115, DOI 10.1080/02724936.1995.11747758; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; MacPhail C, 2002, INT J STD AIDS, V13, P331, DOI 10.1258/0956462021925162; MANN JM, 1986, JAMA-J AM MED ASSOC, V256, P721, DOI 10.1001/jama.256.6.721; MASTERS BMF, 1998, 12 WORLD AIDS C JUN; Mbulaiteye SM, 2002, LANCET, V360, P41, DOI 10.1016/S0140-6736(02)09331-5; Merlin M, 1988, Med Trop (Mars), V48, P381; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MINTZ M, 1995, AM J PUBLIC HEALTH, V85, P586; MOSES S, 1990, INT J EPIDEMIOL, V19, P693, DOI 10.1093/ije/19.3.693; Mulder DW, 1996, TROP MED INT HEALTH, V1, P81, DOI 10.1046/j.1365-3156.1996.d01-12.x; Mwaluko G, 2003, AIDS, V17, P2645, DOI 10.1097/00002030-200312050-00012; MYERS SS, 1993, AIDS, V7, P925, DOI 10.1097/00002030-199307000-00004; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; Quigley MA, 2000, J ACQ IMMUN DEF SYND, V23, P418, DOI 10.1097/00042560-200004150-00009; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rich JD, 1998, AIDS, V12, P2345, DOI 10.1097/00002030-199817000-00017; RWANDAN HIV, 1989, LANCET, V1, P941; *S AFR MIN HLTH, 2002, NAT HIV SYPH ANT SER; Shisana O, 2002, S AFRICAN NATL HIV P; Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739; TESFAYE F, 2003, 2 IAS C HIV PATH TRE; Uganda Bureau of Statistics (UBOS) ORC Macro, 2001, UG DEM HLTH SURV 200; VANBUEREN SH, 1992, 8 INT C AIDS JUL 19; Wadsworth J, 1996, J R STAT SOC A STAT, V159, P111, DOI 10.2307/2983472; WAWER MJ, 1994, BRIT MED J, V308, P171, DOI 10.1136/bmj.308.6922.171; Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018; *WHO, 2001, WHOBCT0310; Williams BG, 2001, PHILOS T ROY SOC B, V356, P1077, DOI 10.1098/rstb.2001.0896	62	116	116	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	2004	363	9407					482	488		10.1016/S0140-6736(04)15497-4	http://dx.doi.org/10.1016/S0140-6736(04)15497-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962531				2022-12-28	WOS:000188999500025
J	Sinha, DN; Gupta, PC; Pednekar, MS				Sinha, DN; Gupta, PC; Pednekar, MS			Use of tobacco products as dentifrice among adolescents in India: questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Tata Inst Fundamental Res, Bombay 400005, Maharashtra, India; Sch Prevent Oncol, Patna 800001, Bihar, India; Tata Mem Hosp, Epidemiol Res Ctr, Bombay 400012, Maharashtra, India	Tata Institute of Fundamental Research (TIFR); Tata Memorial Centre (TMC); Tata Memorial Hospital	Gupta, PC (corresponding author), Tata Inst Fundamental Res, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	pcgupta@tifr.res.in		Pednekar, Mangesh/0000-0001-6266-5356				BHONSLE RB, 1992, CONTROL TOBACCO RELA; Global Youth Tobacco Survey Collabor, 2003, J SCHOOL HEALTH, V73, P207; Simpson D, 1997, Tob Control, V6, P171; SINHA DN, IN PRESS INDIAN J CA; Yach D, 2002, TOB CONTROL, V11, P252, DOI 10.1136/tc.11.3.252	5	17	18	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					323	324		10.1136/bmj.328.7435.323	http://dx.doi.org/10.1136/bmj.328.7435.323			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764494	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000188926900021
J	Boots, M; Hudson, PJ; Sasaki, A				Boots, M; Hudson, PJ; Sasaki, A			Large shifts in pathogen virulence relate to host population structure	SCIENCE			English	Article							HEMORRHAGIC-DISEASE-VIRUS; EVOLUTION; EPIDEMIOLOGY; COEVOLUTION; PARASITES	Theory on the evolution of virulence generally predicts selection for an optimal level of virulence determined by trade-offs with transmission and/or recovery. Here we consider the evolution of pathogen virulence in hosts who acquire long-lived immunity and live in a spatially structured population. We show theoretically that large shifts in virulence may occur in pathogen populations as a result of a bistability in evolutionary dynamics caused by the local contact or social population structure of the host. This model provides an explanation for the rapid emergence of the highly virulent strains of rabbit hemorrhagic disease virus.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Penn State Univ, Dept Biol, Mueller Lab, University Pk, PA 16802 USA; Kyushu Univ, Math Biol Lab, Higashi Ku, Fukuoka 812, Japan	University of Sheffield; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Kyushu University	Boots, M (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	m.boots@sheffield.ac.uk	Hudson, Peter/AAB-8080-2020	Hudson, Peter/0000-0003-0468-3403				ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; Boots M, 1999, P ROY SOC B-BIOL SCI, V266, P1933, DOI 10.1098/rspb.1999.0869; Ellner SP, 2001, J THEOR BIOL, V210, P435, DOI 10.1006/jtbi.2001.2322; Haraguchi Y, 2000, J THEOR BIOL, V203, P85, DOI 10.1006/jtbi.1999.1065; LEVY E, 2003, NEW KILLER DIS; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; MOSS SJ, UNPUB; Moss SR, 2002, J GEN VIROL, V83, P2461, DOI 10.1099/0022-1317-83-10-2461; RAND DA, 1995, P ROY SOC B-BIOL SCI, V259, P55, DOI 10.1098/rspb.1995.0009; SCHROER R, 1995, IEEE AERO EL SYS MAG, V10, P3; White PJ, 2001, PHILOS T R SOC B, V356, P1087, DOI 10.1098/rstb.2001.0897	11	145	149	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	2004	303	5659					842	844		10.1126/science.1088542	http://dx.doi.org/10.1126/science.1088542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764881				2022-12-28	WOS:000188753800059
J	Quinlan, DJ; McQuillan, A; Eikelboom, JW				Quinlan, DJ; McQuillan, A; Eikelboom, JW			Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism - A meta-analysis of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; RECURRENT VENOUS THROMBOEMBOLISM; DAILY SUBCUTANEOUS DALTEPARIN; INITIAL TREATMENT; STANDARD HEPARIN; OUTPATIENT TREATMENT; LONG-TERM; HOME; PREVENTION; FRAGMIN	Background: Low-molecular-weight heparin has greatly simplified the management of deep venous thrombosis. However, for patients who present with pulmonary embolism, the role of low-molecular-weight heparin is uncertain and unfractionated heparin remains widely used. Purpose: To compare the efficacy and safety of fixed-dose subcutaneous low-molecular-weight heparin with that of close-adjusted intravenous unfractionated heparin to treat acute pulmonary embolism. Data Sources: The MEDLINE, EMBASE, and Cochrane Library databases were searched up to 1 August 2003. Additional data sources were manual searches of abstract proceedings and personal contact with investigators and pharmaceutical companies. Study Selection: Randomized trials comparing fixed-dose subcutaneous low-molecular-weight heparin with dose-adjusted intravenous unfractionated heparin for the treatment of nonmassive symptomatic pulmonary embolism or asymptomatic pulmonary embolism in the context of symptomatic deep venous thrombosis. Data Extraction: Two reviewers independently selected studies and extracted data on study design; quality; and clinical outcomes, including symptomatic venous thromboembolism, death, and major and minor bleeding. Odds ratios for individual outcomes were calculated for each trial and were pooled by using the Mantel-Haenszel method. Data Synthesis: Fourteen trials involving 2110 patients with pulmonary embolism met the inclusion criteria. Separate outcome data for patients with pulmonary embolism were not available from 2 trials (159 patients), leaving 12 trials for meta-analysis. Compared with unfractionated heparin, low-molecular-weight heparin was associated with a non-statistically significant decrease in recurrent symptomatic venous thromboembolism at the end of treatment (1.4% vs. 2.4%; odds ratio, 0.63 [95% Cl, 0.33 to 1.18]) and at 3 months (3.0% vs. 4.4%; odds ratio, 0.68 [Cl, 0.42 to 1.09]). Similar estimates were obtained for patients who presented with symptomatic pulmonary embolism (1.7% vs. 2.3%; odds ratio, 0.72 [Cl, 0.35 to 1.48]) or asymptomatic pulmonary embolism (1.2% vs. 3.2%; odds ratio, 0.53 [Cl, 0.15 to 1.88]). For major bleeding complications, the odds ratio favoring low-molecular-weight heparin (1.3% vs. 2.1%; odds ratio, 0.67 [Cl, 0.36 to 1.27]) was also not statistically significant. Conclusions: Fixed-dose low-molecular-weight heparin treatment appears to be as effective and safe as dose-adjusted intravenous unfractionated heparin for the initial treatment of nonmassive pulmonary embolism.	Royal Perth Hosp, Dept Haematol, Perth, WA 6001, Australia; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; Kings Coll Hosp London, London, England	Royal Perth Hospital; University of Western Australia; University of Western Australia; King's College Hospital NHS Foundation Trust; King's College Hospital	Eikelboom, JW (corresponding author), Royal Perth Hosp, Dept Haematol, Wellington St, Perth, WA 6001, Australia.	john.eikelboom@health.wa.gov.au	Eikelboom, John/AAG-6117-2019	Eikelboom, John/0000-0003-4126-1285				Agnelli G, 2002, ARCH INTERN MED, V162, P2537, DOI 10.1001/archinte.162.22.2537; ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; Beckman JA, 2003, THROMB HAEMOSTASIS, V89, P953, DOI 10.1055/s-0037-1613395; Beer JH, 2003, J THROMB HAEMOST, V1, P186, DOI 10.1046/j.1538-7836.2003.00005.x; Belcaro G, 1999, ANGIOLOGY, V50, P781; BRATT G, 1985, THROMB HAEMOSTASIS, V54, P813; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Campbell IA, 1998, THORAX, V53, P254; COLMAN RW, 2001, HEMOSTASIS THROMBOSI, P1153; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Dolovich LR, 2000, ARCH INTERN MED, V160, P181, DOI 10.1001/archinte.160.2.181; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eikelboom J, 2001, BRIT MED J, V322, P1192, DOI 10.1136/bmj.322.7296.1192; FAIVRE R, 1988, PRESSE MED, V17, P197; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; Findik S, 2002, RESPIRATION, V69, P440, DOI 10.1159/000064023; Goldhaber SZ, 1998, NEW ENGL J MED, V339, P93, DOI 10.1056/NEJM199807093390207; Gould MK, 1999, ANN INTERN MED, V130, P800, DOI 10.7326/0003-4819-130-10-199905180-00003; Gould MK, 1999, ANN INTERN MED, V130, P789, DOI 10.7326/0003-4819-130-10-199905180-00002; HAFELI R, 2001, SCHWEIZ RUNDSCH MED, V90, P1339; Harenberg J, 2000, THROMB HAEMOSTASIS, V83, P652; Hull RD, 2000, ARCH INTERN MED, V160, P229, DOI 10.1001/archinte.160.2.229; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; Kakkar VV, 2003, THROMB HAEMOSTASIS, V89, P674; Kirchmaier CM, 1998, INT ANGIOL, V17, P135; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Kovacs MJ, 2000, THROMB HAEMOSTASIS, V83, P209; Kovacs MJ, 2001, BLOOD, V98, p265A; KUIJER PMM, 1995, THROMB HAEMOSTASIS, V73, P974; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; Luomanmaki K, 1996, J INTERN MED, V240, P85, DOI 10.1046/j.1365-2796.1996.18845000.x; MANTEL N, 1959, J NATL CANCER I, V22, P719; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Meyer G, 1995, THROMB HAEMOSTASIS, V74, P1432; Moreno-Palomares J J, 2001, An Med Interna, V18, P364; Murin S, 2002, THROMB HAEMOSTASIS, V88, P407; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRANDONI P, 2001, THROMB HAEMOSTASIS, V86, P1646; Raschke R, 2003, ANN INTERN MED, V138, P720, DOI 10.7326/0003-4819-138-9-200305060-00008; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; tenCate JW, 1997, NEW ENGL J MED, V337, P657; THERY C, 1992, CIRCULATION, V85, P1380, DOI 10.1161/01.CIR.85.4.1380; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; VANDENBELT AG, 2003, COCHRANE LIB, P3; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; 1989, REV MED INTERNE, V10, P375	59	266	276	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					175	183		10.7326/0003-4819-140-3-200402030-00008	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757615				2022-12-28	WOS:000188704500003
J	Hajkova, P; Surani, MA				Hajkova, P; Surani, MA			Programming the X chromosome	SCIENCE			English	Editorial Material							ES CELLS; INACTIVATION; PLURIPOTENCY; METHYLATION; NANOG		Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England	University of Cambridge	Hajkova, P (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England.	as10021@molec.bio.cam.ac.uk		Hajkova, Petra/0000-0003-4145-1468; Surani, Azim/0000-0002-8640-4318				Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; John RM, 2000, CELL, V101, P585, DOI 10.1016/S0092-8674(00)80870-3; JOHNSON MH, 1981, CELL, V24, P71, DOI 10.1016/0092-8674(81)90502-X; Mak W, 2004, SCIENCE, V303, P666, DOI 10.1126/science.1092674; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; OKAMOTO I, 2003, SCIENCE         1211, DOI DOI 10.1126/SCIENCE.1092727; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574	13	11	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					633	634		10.1126/science.1094408	http://dx.doi.org/10.1126/science.1094408			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752149				2022-12-28	WOS:000188530800027
J	McIntosh, K; McAdam, AJ				McIntosh, K; McAdam, AJ			Human metapneumovirus - An important new respiratory virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	McIntosh, K (corresponding author), Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA.								0	24	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					431	433		10.1056/NEJMp038212	http://dx.doi.org/10.1056/NEJMp038212			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749447				2022-12-28	WOS:000188463900001
J	Rhoden, EL; Morgentaler, A				Rhoden, EL; Morgentaler, A			Medical progress - Risks of testosterone-replacement therapy and recommendations for monitoring	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROSTATE-SPECIFIC ANTIGEN; RANDOMIZED CONTROLLED-TRIAL; HORMONE-BINDING GLOBULIN; ESTROGEN PLUS PROGESTIN; SERUM-FREE TESTOSTERONE; CORONARY-HEART-DISEASE; HEALTHY OLDER MEN; HYPOGONADAL MEN; TRANSDERMAL TESTOSTERONE; AGING MALE		Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Morgentaler, A (corresponding author), 1 Brookline Pl,Suite 624, Brookline, MA 02445 USA.	amorgent@caregroup.harvard.edu						ANDERSON RA, 1995, THROMB HAEMOSTASIS, V74, P693; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; BARRETTCONNOR EL, 1995, DIABETES METAB, V21, P156; Basaria S, 1999, DRUG AGING, V15, P131, DOI 10.2165/00002512-199915020-00006; Bhasin S, 2003, J ANDROL, V24, P299; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P3, DOI 10.1210/jc.82.1.3; Bhasin S, 2001, J ANDROL, V22, P718; CARRASCO D, 1985, J HEPATOL, V1, P573, DOI 10.1016/S0168-8278(85)80001-5; CARTER HB, 1995, PROSTATE, V27, P25, DOI 10.1002/pros.2990270106; CARTER HB, 1995, UROLOGY, V45, P591, DOI 10.1016/S0090-4295(99)80049-1; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; Carvalhal GF, 1999, J UROLOGY, V161, P835, DOI 10.1016/S0022-5347(01)61785-3; Cherrier MM, 2001, NEUROLOGY, V57, P80, DOI 10.1212/WNL.57.1.80; Comhaire FH, 2000, EUR UROL, V38, P655, DOI 10.1159/000020358; Curran MJ, 1999, UROLOGY, V53, P423, DOI 10.1016/S0090-4295(98)00348-3; Dobs AS, 1999, J CLIN ENDOCR METAB, V84, P3469, DOI 10.1210/jc.84.10.3469; *END SOC, 2001, 2 ANN ANDR CONS M CH; *END SOC, 2002, ENDOCR REP, V2, P1; English KM, 2000, CIRCULATION, V102, P1906, DOI 10.1161/01.CIR.102.16.1906; English KM, 2000, EUR HEART J, V21, P890, DOI 10.1053/euhj.1999.1873; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gooren LJG, 1996, BRIT J UROL, V78, P763, DOI 10.1046/j.1464-410X.1996.05918.x; Gustafsson O, 1996, BRIT J UROL, V77, P433, DOI 10.1046/j.1464-410X.1996.89120.x; Gyllenborg J, 2001, METABOLISM, V50, P882, DOI 10.1053/meta.2001.24916; Hajjar RR, 1997, J CLIN ENDOCR METAB, V82, P3793, DOI 10.1210/jc.82.11.3793; Hak AE, 2002, J CLIN ENDOCR METAB, V87, P3632, DOI 10.1210/jc.87.8.3632; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Heikkila R, 1999, CANCER, V86, P312, DOI 10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.3.CO;2-Z; Hoffman MA, 2000, J UROLOGY, V163, P824, DOI 10.1016/S0022-5347(05)67812-3; Hsing AW, 2001, EPIDEMIOL REV, V23, P42, DOI 10.1093/oxfordjournals.epirev.a000795; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Kabakci G, 1999, CARDIOLOGY, V92, P221, DOI 10.1159/000006977; Kenny AM, 2001, J GERONTOL A-BIOL, V56, pM266, DOI 10.1093/gerona/56.5.M266; Kim YC, 1999, INT J IMPOT RES, V11, P343, DOI 10.1038/sj.ijir.3900446; Kouri EM, 1996, CLIN J SPORT MED, V6, P152, DOI 10.1097/00042752-199607000-00003; KRIEG M, 1993, J CLIN ENDOCR METAB, V77, P375, DOI 10.1210/jc.77.2.375; Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7; Kunelius P, 2002, J CLIN ENDOCR METAB, V87, P1467, DOI 10.1210/jc.87.4.1467; Loughlin KR, 1997, J UROLOGY, V157, P1845, DOI 10.1016/S0022-5347(01)64881-X; Madersbacher S, 2002, UROLOGY, V60, P869, DOI 10.1016/S0090-4295(02)01893-9; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marcelli M, 1999, J CLIN ENDOCR METAB, V84, P3463, DOI 10.1210/jc.84.10.3463; MATSUMOTO AM, 1985, CLIN ENDOCRINOL, V22, P713, DOI 10.1111/j.1365-2265.1985.tb00161.x; McNicholas TA, 2003, BJU INT, V91, P69, DOI 10.1046/j.1464-410X.2003.04016.x; Miller LR, 1998, J UROLOGY, V160, P449, DOI 10.1016/S0022-5347(01)62922-7; Moffat SD, 2002, J CLIN ENDOCR METAB, V87, P5001, DOI 10.1210/jc.2002-020419; Morgentaler A, 1996, JAMA-J AM MED ASSOC, V276, P1904, DOI 10.1001/jama.276.23.1904; Morley JE, 1997, METABOLISM, V46, P410, DOI 10.1016/S0026-0495(97)90057-3; Nieschlag E, 1998, J CLIN ENDOCRINOLOGY, V83, P3443; Pechersky AV, 2002, INT J ANDROL, V25, P119, DOI 10.1046/j.1365-2605.2002.00335.x; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SCHNEIDER BK, 1986, J APPL PHYSIOL, V61, P618, DOI 10.1152/jappl.1986.61.2.618; Schroder FH, 2003, NEW ENGL J MED, V349, P393, DOI 10.1056/NEJMe030073; Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661; Singh AB, 2002, J CLIN ENDOCR METAB, V87, P136, DOI 10.1210/jc.87.1.136; Slater S, 2000, DRUG AGING, V17, P431, DOI 10.2165/00002512-200017060-00001; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966; Snyder PJ, 2001, AM J MED, V111, P255, DOI 10.1016/S0002-9343(01)00813-0; Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670; Tangredi JF, 2001, ANN PHARMACOTHER, V35, P1205, DOI 10.1345/aph.1A020; Tenover JL, 1998, ENDOCRIN METAB CLIN, V27, P969, DOI 10.1016/S0889-8529(05)70050-5; Vermeulen A, 2001, J CLIN ENDOCR METAB, V86, P2380, DOI 10.1210/jc.86.6.2380; Viallard JF, 2000, BRIT J HAEMATOL, V110, P237, DOI 10.1046/j.1365-2141.2000.02072-3.x; Von Eckardstein S, 2002, J ANDROL, V23, P419; Wang C, 2000, J CLIN ENDOCR METAB, V85, P2839, DOI 10.1210/jc.85.8.2839; Webb CM, 1999, CIRCULATION, V100, P1690, DOI 10.1161/01.CIR.100.16.1690; WESTABY D, 1977, LANCET, V2, P261; Whitsel EA, 2001, AM J MED, V111, P261, DOI 10.1016/S0002-9343(01)00833-6; Zmuda JM, 1997, AM J EPIDEMIOL, V146, P609, DOI 10.1093/oxfordjournals.aje.a009326	71	495	517	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					482	492		10.1056/NEJMra022251	http://dx.doi.org/10.1056/NEJMra022251			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749457				2022-12-28	WOS:000188463900011
J	Sagrista-Sauleda, J; Angel, J; Sanchez, A; Permanyer-Miralda, G; Soler-Soler, J				Sagrista-Sauleda, J; Angel, J; Sanchez, A; Permanyer-Miralda, G; Soler-Soler, J			Effusive-constrictive pericarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPECTRUM	BACKGROUND: Effusive-constrictive pericarditis is an uncommon pericardial syndrome characterized by concomitant tamponade, caused by tense pericardial effusion, and constriction, caused by the visceral pericardium. We conducted a prospective study of its clinical evolution and management. METHODS: From 1986 through 2001, all patients with effusive-constrictive pericarditis were prospectively evaluated. Combined pericardiocentesis and cardiac catheterization were performed in all patients, and pericardiectomy was performed in those with persistent constriction. Follow-up ranged from 1 month to 15 years (median, 7 years). RESULTS: A total of 1184 patients with pericarditis were evaluated, 218 of whom had tamponade. Of these 218, 190 underwent combined pericardiocentesis and catheterization. Fifteen of these patients had effusive-constrictive pericarditis and were included in the study. All patients presented with clinical tamponade; however, concomitant constriction was recognized in only seven patients. At catheterization, all patients had elevated intrapericardial pressure (median, 12 mm Hg; interquartile range, 7 to 18) and elevated right atrial and end-diastolic right and left ventricular pressures. After pericardiocentesis, the intrapericardial pressure decreased (median value, -5 mm Hg; interquartile range, -5 to 0), whereas right atrial and end-diastolic right and left ventricular pressures, although slightly reduced, remained elevated, with a dip-plateau morphology. The causes were diverse, and death was mainly related to the underlying disease. Pericardiectomy was required in seven patients, all of whom had involvement of the visceral pericardium. Three patients had spontaneous resolution. CONCLUSIONS: Effusive-constrictive pericarditis is an uncommon pericardial syndrome that may be missed in some patients who present with tamponade. Although evolution to persistent constriction is frequent, idiopathic cases may resolve spontaneously. In our opinion, extensive epicardiectomy is the procedure of choice in patients requiring surgery.	Hosp Gen Univ Vall Hebron, Serv Cardiol, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Sagrista-Sauleda, J (corresponding author), Hosp Gen Univ Vall Hebron, Serv Cardiol, C-P Vall Hebron 119-129, Barcelona 08035, Spain.							BURCHELL H B, 1954, J Lancet, V74, P465; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; DCRUZ IA, 1991, SOUTHERN MED J, V84, P1375, DOI 10.1097/00007611-199111000-00022; DOIG JC, 1991, BRIT HEART J, V65, P296; FOWLER N, 1978, AM HEART J, V96, P533, DOI 10.1016/0002-8703(78)90168-0; HANCOCK EW, 1971, CIRCULATION, V43, P183, DOI 10.1161/01.CIR.43.2.183; HIRATA K, 1991, JPN CIRC J, V55, P154, DOI 10.1253/jcj.55.154; HUGOHAMMAN CT, 1994, PEDIATR INFECT DIS J, V13, P13, DOI 10.1097/00006454-199401000-00004; Ling LH, 1999, CIRCULATION, V100, P1380, DOI 10.1161/01.CIR.100.13.1380; Oudiz R, 1995, J Am Soc Echocardiogr, V8, P947, DOI 10.1016/S0894-7317(05)80024-0; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; SAGRISTASAULEDA J, 1987, AM J CARDIOL, V59, P961, DOI 10.1016/0002-9149(87)91134-9; SATOH T, 1993, BRIT HEART J, V69, P563; SOLERSOLER J, 1990, DEV CARDIOVASC MED, V108, P217; SPODICK DH, 1968, DIS CHEST, V54, P62, DOI 10.1378/chest.54.1.62; Tanaka Kimihiro, 2002, J Cardiol, V39, P267; Tsang TSM, 2003, AM J CARDIOL, V91, P704, DOI 10.1016/S0002-9149(02)03408-2; WALSH TJ, 1982, J THORAC CARDIOV SUR, V83, P126; Woods T, 1999, CLIN CARDIOL, V22, P316, DOI 10.1002/clc.4960220414	19	154	158	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					469	475		10.1056/NEJMoa035630	http://dx.doi.org/10.1056/NEJMoa035630			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749455				2022-12-28	WOS:000188463900009
J	Rabow, MW; Hauser, JM; Adams, J				Rabow, MW; Hauser, JM; Adams, J			Supporting family Caregivers at the end of life - "They don't know what they don't know"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERMINALLY-ILL PATIENTS; NURSING-HOME PLACEMENT; INTENSIVE-CARE UNIT; OF-LIFE; PALLIATIVE CARE; INFORMAL CAREGIVERS; ADVANCE DIRECTIVES; FUNCTIONAL DECLINE; ALZHEIMER-DISEASE; ELDERLY-PEOPLE	Even for patients receiving complex, intensive medical care for serious and life-threatening illness, family caregiving is typically at the core of what sustains patients at the end of life. The amorphous relationship between physicians and the families of patients at the end of life presents both challenges and opportunities for which physicians may be unprepared. Families play important roles in the practical and emotional aspects of patient care and in decision making at the end of life. At the same time, family members may carry significant burdens as a result of their work. Through the perspectives of the wife, daughter, and home care nurse of a patient who died from pancreatic cancer, we illustrate the range of family caregiver experiences and suggest potentially helpful physician interventions. We describe 5 burdens of family caregiving (time and logistics, physical tasks, financial costs, emotional burdens and mental health risks, and physical health risks) and review the responsibilities of physicians to family caregivers. Based on available evidence, we identify 5 areas of opportunity for physicians to be of service to family members caring for patients at the end of life, including promoting excellent communication with family, encouraging appropriate advance care planning and decision making, supporting home care, demonstrating empathy for family emotions and relationships, and attending to family grief and bereavement. In caring well for family caregivers at the end of life, physicians may not only improve the experiences of patients and family but also find greater sustenance and meaning in their own work.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Ctr Caregiver Training, San Francisco, CA USA; Northwestern Univ, Feinberg Sch Med, Dept Med,Buehler Ctr Aging, Palliat Care & Home Hospice Program, Chicago, IL 60611 USA	University of California System; University of California San Francisco; Northwestern University; Feinberg School of Medicine	Rabow, MW (corresponding author), Univ Calif San Francisco, Dept Med, 1701 Divisadero St,No 554, San Francisco, CA 94143 USA.	mrabow@medicine.ucsf.edu						ANDOLSEK KM, 1988, ARCH INTERN MED, V148, P2177, DOI 10.1001/archinte.148.10.2177; BASCOM PB, 1995, WESTERN J MED, V163, P292; BASS DM, 1991, GERONTOLOGIST, V31, P32, DOI 10.1093/geront/31.1.32; Bedell SE, 2001, NEW ENGL J MED, V344, P1162, DOI 10.1056/NEJM200104123441510; Benson J, 1996, BRIT MED J, V313, P729, DOI 10.1136/bmj.313.7059.729; Billings J A, 2001, J Palliat Med, V4, P361, DOI 10.1089/109662101753123986; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Cameron JI, 2002, CANCER-AM CANCER SOC, V94, P521, DOI 10.1002/cncr.10212; Cannuscio CC, 2002, AM J PUBLIC HEALTH, V92, P1305, DOI 10.2105/AJPH.92.8.1305; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Cochrane JJ, 1997, AM J PUBLIC HEALTH, V87, P2002, DOI 10.2105/AJPH.87.12.2002; COLLINS C, 1994, J AM GERIATR SOC, V42, P719, DOI 10.1111/j.1532-5415.1994.tb06530.x; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Covinsky KE, 2001, J GERONTOL A-BIOL, V56, pM707, DOI 10.1093/gerona/56.11.M707; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; Curtis JR, 2001, CRIT CARE MED, V29, pN26, DOI 10.1097/00003246-200102001-00006; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Desbiens NA, 2001, J GERONTOL A-BIOL, V56, pM231, DOI 10.1093/gerona/56.4.M231; Donelan K, 2002, HEALTH AFFAIR, V21, P222, DOI 10.1377/hlthaff.21.4.222; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; EMANUEL LL, 1995, J AM COLL CARDIOL, V25, P35, DOI 10.1016/0735-1097(94)00339-R; Falk S, 1997, BRIT MED J, V315, P1525, DOI 10.1136/bmj.315.7121.1525; Ferrell B R, 1999, Oncol Nurs Forum, V26, P1655; Field MJ, 1997, APPROACHING DEATH IM; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fried TR, 2003, ARCH INTERN MED, V163, P2073, DOI 10.1001/archinte.163.17.2073; Ganzini L, 2002, NEW ENGL J MED, V347, P582, DOI 10.1056/NEJMsa020562; Goldman L, 2001, AM J MED, V111, P36, DOI 10.1016/S0002-9343(01)00968-8; Haley W E, 2001, Hosp J, V15, P1, DOI 10.1300/J011v15n04_01; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; HARE J, 1992, ARCH INTERN MED, V152, P1049, DOI 10.1001/archinte.152.5.1049; Hayman JA, 2001, J CLIN ONCOL, V19, P3219, DOI 10.1200/JCO.2001.19.13.3219; Hebert R, 2003, J GERONTOL B-PSYCHOL, V58, pS58, DOI 10.1093/geronb/58.1.S58; Hickenbottom SL, 2002, NEUROLOGY, V58, P1754, DOI 10.1212/WNL.58.12.1754; Horowitz MJ, 1997, AM J PSYCHIAT, V154, P904; Hurley AC, 2002, JAMA-J AM MED ASSOC, V288, P2324, DOI 10.1001/jama.288.18.2324; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Karlawish JHT, 2001, J AM GERIATR SOC, V49, P1066, DOI 10.1046/j.1532-5415.2001.49210.x; Langa KM, 2002, J GERONTOL B-PSYCHOL, V57, pS177, DOI 10.1093/geronb/57.3.S177; Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x; LAWTON MP, 1989, GERONTOLOGIST, V29, P8, DOI 10.1093/geront/29.1.8; Levine C, 1999, ANN INTERN MED, V130, P148, DOI 10.7326/0003-4819-130-2-199901190-00010; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; LOEB JM, 1993, JAMA-J AM MED ASSOC, V269, P1282; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 2003, ANN INTERN MED, V138, P812, DOI 10.7326/0003-4819-138-10-200305200-00009; Main J, 2000, BRIT J GEN PRACT, V50, P863; Mant J, 2000, LANCET, V356, P808, DOI 10.1016/S0140-6736(00)02655-6; MARMAR CR, 1988, AM J PSYCHIAT, V145, P203; Matter CA, 2003, ACAD MED, V78, P793, DOI 10.1097/00001888-200308000-00009; McCallion P, 1999, J AM GERIATR SOC, V47, P203, DOI 10.1111/j.1532-5415.1999.tb04579.x; McConnell S, 1999, GENERATIONS, V23, P69; MetLife Mature Market Institute National Alliance for Caregiving & The National Center on Women and Aging, 1999, METL JUGGL ACT STUD; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MORGAN DL, 1989, GERONTOLOGIST, V29, P101, DOI 10.1093/geront/29.1.101; MORRIS BA, 1995, J FAM PRACTICE, V40, P41; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; Navaie-Waliser M, 2002, AM J PUBLIC HEALTH, V92, P409, DOI 10.2105/AJPH.92.3.409; *OFF CIV RIGHTS, SUMM HIPAA PRIV RUL; *OFF CIV RIGHTS WE, MED PRIV NAT STAND P; Oldenquist GW, 2001, CLEV CLIN J MED, V68, P433, DOI 10.3949/ccjm.68.5.433; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Prendergast TJ, 2002, JAMA-J AM MED ASSOC, V288, P2732, DOI 10.1001/jama.288.21.2732; Prigerson HG, 2001, JAMA-J AM MED ASSOC, V286, P1369, DOI 10.1001/jama.286.11.1369; PRIGERSON HG, 1994, PSYCHIAT RES, V51, P33, DOI 10.1016/0165-1781(94)90045-0; Quill TE, 2001, ANN INTERN MED, V135, P551, DOI 10.7326/0003-4819-135-7-200110020-00022; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2003, J PAIN SYMPTOM MANAG, V26, P1010, DOI 10.1016/j.jpainsymman.2003.03.002; Rabow MW, 1999, WESTERN J MED, V171, P260; REUBEN SH, 2001, VOICES BROKEN SYSTEM; Saunders C, 1989, TXB PAIN, P624; Schneider D S, 1996, Ann Clin Psychiatry, V8, P51, DOI 10.3109/10401239609148802; Schulz R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/jama.285.24.3123; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Shugarman LR, 2002, J AM GERIATR SOC, V50, P1079, DOI 10.1046/j.1532-5415.2002.50264.x; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; SILLIMAN RA, 1993, J AM GERIATR SOC, V41, P1039, DOI 10.1111/j.1532-5415.1993.tb06450.x; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Slutsman J, 2002, J AM GERIATR SOC, V50, P2077, DOI 10.1046/j.1532-5415.2002.50622.x; Smith MC, 1997, J AM GERIATR SOC, V45, P194, DOI 10.1111/j.1532-5415.1997.tb04506.x; Stein MD, 2000, AM J PUBLIC HEALTH, V90, P1138, DOI 10.2105/AJPH.90.7.1138; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; *US GEN ACC OFF, 1994, LONG TERM CAR DIV GR; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051; von Gunten Charles F, 2002, J Palliat Med, V5, P35, DOI 10.1089/10966210252784999; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yin T, 2002, NURS RES, V51, P199, DOI 10.1097/00006199-200205000-00009; Zarit SH, 1998, J GERONTOL B-PSYCHOL, V53, pS267, DOI 10.1093/geronb/53B.5.S267	98	282	291	3	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					483	491		10.1001/jama.291.4.483	http://dx.doi.org/10.1001/jama.291.4.483			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	767EF	14747506				2022-12-28	WOS:000188426700034
J	Bayram, N; van Wely, M; Kaaijk, EM; Bossuyt, PMM; van der Veen, F				Bayram, N; van Wely, M; Kaaijk, EM; Bossuyt, PMM; van der Veen, F			Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GONADOTROPIN THERAPY; WOMEN	Objective To compare the effectiveness of an electrocautery strategy with ovulation induction using recombinant follicle stimulating hormone in patients with clomiphene resistant polycystic ovary syndrome. Design Randomised controlled trial. Setting Secondary and tertiary hospitals in the Netherlands. Participants 168 patients with clomiphene citrate resistant polycystic ovary syndrome: 83 were allocated electrocautery and 85 were allocated recombinant follicle stimulating hormone. Intervention Laparoscopic electrocautery of the ovaries followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or induction of ovulation with recombinant follicle stimulating hormone. Main outcome measure Ongoing pregnancy within 12 months. Results The cumulative rate of ongoing pregnancy after recombinant follicle stimulating hormone was 67%. With only electrocautery it was 34%, which increased to 49% after clomiphene citrate was given. Subsequent recombinant follicle stimulating hormone increased the rate to 67% at 12 months (rate ratio 1.01, 95% confidence interval 0.81 to 1.24). No complications occurred from electrocautery with or without clomiphene citrate. Patients allocated to electrocautery had a significantly lower risk of multiple pregnancy (0.11, 0.01 to 0.86). Conclusion The ongoing pregnancy rate from ovulation induction with laparoscopic electrocautery followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or recombinant follicle stimulating hormone, seems equivalent to ovulation induction with recombinant follicle stimulating hormone, but the former procedure carries a lower risk of multiple pregnancy.	Acad Med Ctr, Ctr Reprod Med, Dept Obstet & Gynaecol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Bayram, N (corresponding author), Acad Med Ctr, Ctr Reprod Med, Dept Obstet & Gynaecol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	n.bayram@amc.uva.nl	van Wely, Madelon/GXV-1757-2022; Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; van Wely, Madelon/0000-0001-8263-213X				Abdel Gadir A, 1990, Clin Endocrinol (Oxf), V33, P585; ADAMS J, 1985, LANCET, V2, P1375; *AM FERT SOC, 1985, FERTIL STERIL, V43, P351; Balen A, 2002, HUM REPROD, V17, P2219, DOI 10.1093/humrep/17.9.2219; BAYRAM N, 2001, COCHRANE LIB; Christin-Maitre S, 2003, HUM REPROD, V18, P1626, DOI 10.1093/humrep/deg336; Cohen J, 2001, SEMIN REPROD MED, V19, P269, DOI 10.1055/s-2001-18046; DONESKY BW, 1995, FERTIL STERIL, V63, P439; Farquhar CM, 2002, FERTIL STERIL, V78, P404, DOI 10.1016/S0015-0282(02)03225-9; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; GJONNAESS H, 1984, FERTIL STERIL, V41, P20; GREENBLATT E, 1987, AM J OBSTET GYNECOL, V156, P279, DOI 10.1016/0002-9378(87)90268-7; HAMILTONFAIRLEY D, 1991, HUM REPROD, V6, P1095, DOI 10.1093/oxfordjournals.humrep.a137491; Homburg R, 1999, HUM REPROD UPDATE, V5, P493, DOI 10.1093/humupd/5.5.493; Homburg R, 2002, HUM REPROD, V17, P2495, DOI 10.1093/humrep/17.10.2495; Imani B, 1998, J CLIN ENDOCR METAB, V83, P2361, DOI 10.1210/jc.83.7.2361; Jacobs HS, 1998, BAILLIERE CLIN OB GY, V12, P565, DOI 10.1016/S0950-3552(98)80052-7; KAAIJK EM, 1995, LASER SURG MED, V16, P292, DOI 10.1002/lsm.1900160312; LAZOVIC G, 1998, FERTIL STERIL, V70, pS472; Patrick J., 1993, WHO MANUAL STANDARDI; vanSantbrink EJP, 1997, FERTIL STERIL, V67, P452, DOI 10.1016/S0015-0282(97)80068-4; Vegetti W, 1998, HUM REPROD, V13, P120; Vicino M, 2000, GYNECOL ENDOCRINOL, V14, P42, DOI 10.3109/09513590009167659	23	123	125	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					192	195		10.1136/bmj.328.7433.192	http://dx.doi.org/10.1136/bmj.328.7433.192			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739186	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188652200012
J	Lewis, R; Dixon, J				Lewis, R; Dixon, J			Rethinking management of chronic diseases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; HEALTH-CARE		Kings Fund, Hlth Policy, London W1G 0AN, England		Lewis, R (corresponding author), Kings Fund, Hlth Policy, London W1G 0AN, England.	rlewis@kingsfund.org.uk						Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; British Medical Association, 2003, INV GEN PRACT NEW GE; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Collins C, 1999, HEALTH POLICY, V47, P69, DOI 10.1016/S0168-8510(99)00003-2; *DEP HLTH, 2002, IMPR EXP REF NEX 3 Y; Department of Foreign Affairs and Trade, 2003, GOV RESP HLTH SEL CO, V11, P13; Department of Health, 1998, INF HLTH INF STRAT M; Department of Health, 2001, EXP PAT NEW APPR CHR; Department of Health, 2002, REF NHS FIN FLOWS IN; LEWIS R, 2003, FUTURE DIRECTIONS PR; *NAT COAL HLTH CAR, 2002, CUR SYST; *NHS CONF, 2003, GMS CONTR NEG FACT S; RICHARDSON T, 2001, PERSONAL MED SERVICE; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; *RW JOHNS FDN, CHRON CAR MOD; Smith PC, 2002, HEALTH AFFAIR, V21, P103, DOI 10.1377/hlthaff.21.3.103; Wagner E H, 1998, Eff Clin Pract, V1, P2; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64	19	75	77	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					220	222		10.1136/bmj.328.7433.220	http://dx.doi.org/10.1136/bmj.328.7433.220			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739194	Green Published			2022-12-28	WOS:000188652200024
J	Smith, JC; Siddique, H; Corrall, RM				Smith, JC; Siddique, H; Corrall, RM			Misinterpretation of serum cortisol in a patient with hyponatraemia	BRITISH MEDICAL JOURNAL			English	Review							ADRENAL INSUFFICIENCY; MANAGEMENT		Bristol Royal Infirm & Gen Hosp, Dept Endocrinol & Diabet, Bristol BS2 8HW, Avon, England; Bristol Royal Infirm & Gen Hosp, Dept Med, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; Bristol Royal Infirmary	Smith, JC (corresponding author), Bristol Royal Infirm & Gen Hosp, Dept Endocrinol & Diabet, Bristol BS2 8HW, Avon, England.	jamie.smith@virgin.net						Crook MA, 1999, ANN CLIN BIOCHEM, V36, P158, DOI 10.1177/000456329903600204; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Saeed BO, 2002, J CLIN PATHOL, V55, P893, DOI 10.1136/jcp.55.12.893; VERMES I, 1995, J CLIN ENDOCR METAB, V80, P1238, DOI 10.1210/jc.80.4.1238; VITA JA, 1985, AM J MED, V78, P461, DOI 10.1016/0002-9343(85)90339-0	6	18	19	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	2004	328	7433					215	216		10.1136/bmj.328.7433.215	http://dx.doi.org/10.1136/bmj.328.7433.215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739192	Green Published			2022-12-28	WOS:000188652200022
J	Flier, JS				Flier, JS			Obesity wars: Molecular progress confronts an expanding epidemic	CELL			English	Review							MELANIN-CONCENTRATING HORMONE; FATTY-ACID OXIDATION; CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; NEUROTROPHIC FACTOR; LEPTIN-RECEPTOR; INSULIN-RESISTANCE; NEUROPEPTIDE-Y; ENERGY-BALANCE; ADIPOSE-TISSUE	The worldwide prevalence of obesity is increasing at an alarming rate, with major adverse consequences for human health. This "obesity epidemic" is paralleled by a rapid and substantive increase in our understanding of molecular pathways and physiologic systems underlying the regulation of energy balance. While efforts to address the environmental factors that are responsible for the recent "epidemic" must continue, new molecular and physiologic insights into this system offer exciting possibilities for future development of successful therapies.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019					Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Billington C J, 1992, Curr Opin Neurobiol, V2, P847, DOI 10.1016/0959-4388(92)90144-A; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Borowsky B, 2002, NAT MED, V8, P825, DOI 10.1038/nm741; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Clement Karine, 2002, Am J Pharmacogenomics, V2, P177, DOI 10.2165/00129785-200202030-00003; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Dunn-Meynell AA, 2002, DIABETES, V51, P2056, DOI 10.2337/diabetes.51.7.2056; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; Fulton S, 2000, SCIENCE, V287, P125, DOI 10.1126/science.287.5450.125; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5; Hahm S, 2002, J NEUROSCI, V22, P6929; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Heisler LK, 2002, SCIENCE, V297, P609, DOI 10.1126/science.1072327; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Hileman SM, 2002, ENDOCRINOLOGY, V143, P775, DOI 10.1210/en.143.3.775; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kowalski TJ, 2001, DIABETES, V50, P425, DOI 10.2337/diabetes.50.2.425; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 2001, J CLIN INVEST, V107, P379, DOI 10.1172/JCI10660; Marks DL, 2001, CANCER RES, V61, P1432; Marsh DJ, 2002, P NATL ACAD SCI USA, V99, P3240, DOI 10.1073/pnas.052706899; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Mieda M, 2002, CURR OPIN NEUROBIOL, V12, P339, DOI 10.1016/S0959-4388(02)00331-8; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moran TH, 2000, NUTRITION, V16, P858, DOI 10.1016/S0899-9007(00)00419-6; Moran TH, 1998, AM J PHYSIOL-REG I, V274, pR618, DOI 10.1152/ajpregu.1998.274.3.R618; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Ridderstrale M, 2002, DIABETES, V51, P3554, DOI 10.2337/diabetes.51.12.3554; Rios M, 2001, MOL ENDOCRINOL, V15, P1748, DOI 10.1210/me.15.10.1748; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Segal-Lieberman G, 2003, P NATL ACAD SCI USA, V100, P10085, DOI 10.1073/pnas.1633636100; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Unger T, 1996, J HYPERTENS, V14, pS95; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wang ZW, 2000, BIOCHEM BIOPH RES CO, V277, P20, DOI 10.1006/bbrc.2000.3615; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wieland HA, 2000, EXPERT OPIN INV DRUG, V9, P1327, DOI 10.1517/13543784.9.6.1327; WOODS SC, 1985, AM J CLIN NUTR, V42, P1063, DOI 10.1093/ajcn/42.5.1063; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; Yamamoto H, 2002, J CLIN INVEST, V110, P43, DOI 10.1172/JCI200215595; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; Yoshimatsu K, 1999, DIABETES, V48, P2286, DOI 10.2337/diabetes.48.12.2286; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	122	882	933	0	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					337	350		10.1016/S0092-8674(03)01081-X	http://dx.doi.org/10.1016/S0092-8674(03)01081-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744442	Bronze			2022-12-28	WOS:000188541700021
J	Matsuo, H; Chevallier, J; Mayran, N; Le Blanc, I; Ferguson, C; Faure, J; Blanc, NS; Matile, S; Dubochet, J; Sadoul, R; Parton, RG; Vilbois, F; Gruenberg, J				Matsuo, H; Chevallier, J; Mayran, N; Le Blanc, I; Ferguson, C; Faure, J; Blanc, NS; Matile, S; Dubochet, J; Sadoul, R; Parton, RG; Vilbois, F; Gruenberg, J			Role of LBPA and Alix in multivesicular liposome formation and endosome organization	SCIENCE			English	Article							PROTEIN; APOPTOSIS; VESICLES; EXOSOMES; PATHWAY; ACID; CELL	What are the components that control the assembly of subcellular organelles in eukaryotic cells? Although membranes can clearly be distorted by cytosolic factors, very little is known about the intrinsic mechanisms that control the biogenesis, shape, and organization of organellar membranes. Here, we found that the unconventional phospholipid lysobisphosphatidic acid (LBPA) could induce the formation of multivesicular liposomes that resembled the multivesicular endosomes that exist where this lipid is found in vivo. This process depended on the same pH gradient that exists across endosome membranes in vivo and was selectively controlled by Alix. In turn, Alix regulated the organization of LBPA-containing endosomes in vivo.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Organ Chem, CH-1211 Geneva 4, Switzerland; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Grenoble 1, Hop A Michallon, Neurodegenerescence & Plast Inserm, F-38043 Grenoble 9, France; Univ Lausanne, Lab Anal Ultrastruct, CH-1015 Lausanne, Switzerland; Serono Pharmaceut Res Inst, CH-1228 Plan Les Ouates, Switzerland	University of Geneva; University of Geneva; University of Queensland; University of Queensland; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Lausanne	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.	jean.gruenberg@biochem.unige.ch	Parton, Robert G/C-5673-2009; Matile, Stefan/AFL-7826-2022; Fauré, julien/AAJ-1845-2020	Parton, Robert G/0000-0002-7494-5248; Matile, Stefan/0000-0002-8537-8349; Fauré, julien/0000-0002-3660-9809; SADOUL, Remy/0000-0002-4763-0320				Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chevallier J, 2000, ORG LETT, V2, P1859, DOI 10.1021/ol0059246; Cluett EB, 1997, MOL BIOL CELL, V8, P2233, DOI 10.1091/mbc.8.11.2233; Cluett EB, 1996, J CELL SCI, V109, P2121; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; Dubochet J, 2001, MICRON, V32, P91, DOI 10.1016/S0968-4328(00)00026-3; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Galve-de Rochemonteix B, 2000, ARTERIOSCL THROM VAS, V20, P563; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tedesco MM, 1999, BIOORGAN MED CHEM, V7, P1373, DOI 10.1016/S0968-0896(99)00076-0; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; WHITNEY JA, 1995, CELL, V83, P703	26	515	526	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					531	534		10.1126/science.1092425	http://dx.doi.org/10.1126/science.1092425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739459				2022-12-28	WOS:000188316400040
J	Pai, RA; Humayun, R; Schulberg, MT; Sengupta, A; Sun, JN; Watkins, JJ				Pai, RA; Humayun, R; Schulberg, MT; Sengupta, A; Sun, JN; Watkins, JJ			Mesoporous silicates prepared using preorganized templates in supercritical fluids	SCIENCE			English	Article							COPOLYMER THIN-FILMS; BLOCK-COPOLYMER; CARBON-DIOXIDE; MOLECULAR-SIEVES; PHASE-BEHAVIOR; NANOSTRUCTURES; MICROELECTRONICS; ALIGNMENT; SOLVENTS; ROUTE	Well-ordered mesoporous silicate films were prepared by infusion and selective condensation of silicon alkoxides within microphase-separated block copolymer templates dilated with supercritical carbon dioxide. Confinement of metal oxide deposition to specific subdomains of the pre-organized template yields high-fidelity, three-dimensional replication of the copolymer morphology, enabling the preparation of structures with multiscale order in a process that closely resembles biomineralization. Ordered mesoporous silicate films were synthesized with dielectric constants as low as 1.8 and excellent mechanical properties. The films survive the chemical-mechanical polishing step required for device manufacturing.	Univ Massachusetts, Dept Chem Engn, Amherst, MA 01003 USA; Novellus Syst Inc, San Jose, CA 95134 USA	University of Massachusetts System; University of Massachusetts Amherst	Watkins, JJ (corresponding author), Univ Massachusetts, Dept Chem Engn, Amherst, MA 01003 USA.	watkins@ecs.umass.edu		Watkins, James/0000-0001-8302-825X				Aksay IA, 1996, SCIENCE, V273, P892, DOI 10.1126/science.273.5277.892; BATES FS, 1994, FARADAY DISCUSS, V98, P7, DOI 10.1039/fd9949800007; Blackburn JM, 2001, SCIENCE, V294, P141, DOI 10.1126/science.1064148; Condo PD, 1996, IND ENG CHEM RES, V35, P1115, DOI 10.1021/ie950356x; DeSimone JM, 2002, SCIENCE, V297, P799, DOI 10.1126/science.1069622; Fan HY, 2000, NATURE, V405, P56, DOI 10.1038/35011026; Goldfarb DL, 2000, J VAC SCI TECHNOL B, V18, P3313, DOI 10.1116/1.1313582; Gupta RR, 2003, MACROMOLECULES, V36, P1295, DOI 10.1021/ma021557x; Hanley KJ, 2000, MACROMOLECULES, V33, P5918, DOI 10.1021/ma000318b; Huang E, 1998, NATURE, V395, P757, DOI 10.1038/27358; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lin ZQ, 2002, ADV MATER, V14, P1373, DOI 10.1002/1521-4095(20021002)14:19<1373::AID-ADMA1373>3.0.CO;2-F; Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699; Maex K, 2003, J APPL PHYS, V93, P8793, DOI 10.1063/1.1567460; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; Mansky P, 1998, MACROMOLECULES, V31, P4399, DOI 10.1021/ma980299u; Melosh NA, 1999, MACROMOLECULES, V32, P4332, DOI 10.1021/ma9817323; Namatsu H, 2002, J PHOTOPOLYM SCI TEC, V15, P381, DOI 10.2494/photopolymer.15.381; Segalman RA, 2001, ADV MATER, V13, P1152, DOI 10.1002/1521-4095(200108)13:15<1152::AID-ADMA1152>3.0.CO;2-5; Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242; Sundararajan N, 2000, CHEM MATER, V12, P41, DOI 10.1021/cm9902467; TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865; Thurn-Albrecht T, 2000, ADV MATER, V12, P787, DOI 10.1002/(SICI)1521-4095(200006)12:11<787::AID-ADMA787>3.0.CO;2-1; Tolbert SH, 1997, SCIENCE, V278, P264, DOI 10.1126/science.278.5336.264; Trau M, 1997, NATURE, V390, P674, DOI 10.1038/37764; Vogt BD, 2003, MACROMOLECULES, V36, P4029, DOI 10.1021/ma0300544; Weibel GL, 2003, MICROELECTRON ENG, V65, P145, DOI 10.1016/S0167-9317(02)00747-5; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	29	291	301	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					507	510		10.1126/science.1092627	http://dx.doi.org/10.1126/science.1092627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739454				2022-12-28	WOS:000188316400033
J	Mueller, C; Scholer, A; Laule-Kilian, K; Martina, B; Schindler, C; Buser, P; Pfisterer, M; Perruchoud, AP				Mueller, C; Scholer, A; Laule-Kilian, K; Martina, B; Schindler, C; Buser, P; Pfisterer, M; Perruchoud, AP			Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; VENTRICULAR SYSTOLIC DYSFUNCTION; COST-EFFECTIVENESS; EMERGENCY DIAGNOSIS; GENE-EXPRESSION; UTILITY; RECOMMENDATIONS; GUIDELINES; EPIDEMIC; DISEASE	Background: B-type natriuretic peptide levels are higher in patients with congestive heart failure than in patients with dyspnea from other causes. Methods: We conducted a prospective, randomized, controlled study of 452 patients who presented to the emergency department with acute dyspnea: 225 patients were randomly assigned to a diagnostic strategy involving the measurement of B-type natriuretic peptide levels with the use of a rapid bedside assay, and 227 were assessed in a standard manner. The time to discharge and the total cost of treatment were the primary end points. Results: Base-line demographic and clinical characteristics were well matched between the two groups. The use of B-type natriuretic peptide levels reduced the need for hospitalization and intensive care; 75 percent of patients in the B-type natriuretic peptide group were hospitalized, as compared with 85 percent of patients in the control group (P=0.008), and 15 percent of those in the B-type natriuretic peptide group required intensive care, as compared with 24 percent of those in the control group (P=0.01). The median time to discharge was 8.0 days in the B-type natriuretic peptide group and 11.0 days in the control group (P=0.001). The mean total cost of treatment was $5,410 (95 percent confidence interval, $4,516 to $6,304) in the B-type natriuretic peptide group, as compared with $7,264 (95 percent confidence interval, $6,301 to $8,227) in the control group (P=0.006). The respective 30-day mortality rates were 10 percent and 12 percent (P=0.45). Conclusions: Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide in the emergency department improved the evaluation and treatment of patients with acute dyspnea and thereby reduced the time to discharge and the total cost of treatment.	Univ Basel, Univ Hosp, Dept Internal Med, Med Div A, Basel, Switzerland; Univ Basel, Univ Hosp, Dept Lab Med, Basel, Switzerland; Univ Basel, Univ Hosp, Emergency Dept, Basel, Switzerland; Univ Basel, Univ Hosp, Inst Social & Prevent Med, Basel, Switzerland; Univ Basel, Univ Hosp, Div Cardiol, Basel, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel	Mueller, C (corresponding author), Univ Klin, Med Klin A, Petersgraben 4, CH-4031 Basel, Switzerland.	chmueller@uhbs.ch	Schindler, Christian/D-3472-2015; Müller, Christian/AAB-4783-2022	Müller, Christian/0000-0002-1120-6405				*AM HEART ASS, 2002, HEART DIS STROK STAT; Bales AC, 1997, POSTGRAD MED, V101, P44, DOI 10.3810/pgm.1997.01.141; Cabanes L, 2001, CHEST, V120, P2047, DOI 10.1378/chest.120.6.2047; Cheng V, 2001, J AM COLL CARDIOL, V37, P386, DOI 10.1016/S0735-1097(00)01157-8; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; Gillespie ND, 1997, BMJ-BRIT MED J, V314, P936, DOI 10.1136/bmj.314.7085.936; HAMA N, 1995, CIRCULATION, V92, P1558, DOI 10.1161/01.CIR.92.6.1558; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Incalzi RA, 2002, J INTERN MED, V252, P48, DOI 10.1046/j.1365-2796.2002.01005.x; Koglin J, 2001, J AM COLL CARDIOL, V38, P1934, DOI 10.1016/S0735-1097(01)01672-2; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; McCullough PA, 2003, AM J KIDNEY DIS, V41, P571, DOI 10.1053/ajkd.2003.50118; McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; Mueller C, 2002, SWISS MED WKLY, V132, P618; Nielsen OW, 2003, J AM COLL CARDIOL, V41, P113, DOI 10.1016/S0735-1097(02)02625-6; Redfield MM, 2002, NEW ENGL J MED, V347, P1442, DOI 10.1056/NEJMe020115; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Remme WJ, 2001, EUR HEART J, V22, P2217; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Wiese S, 2000, CIRCULATION, V102, P3074; WUERZ RC, 1992, ANN EMERG MED, V21, P669, DOI 10.1016/S0196-0644(05)82777-5; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195; Zile MR, 2001, CIRCULATION, V104, P779, DOI 10.1161/hc3201.094226	30	680	723	1	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					647	654		10.1056/NEJMoa031681	http://dx.doi.org/10.1056/NEJMoa031681			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960741				2022-12-28	WOS:000188869500005
J	Shih, WM; Quispe, JD; Joyce, GF				Shih, WM; Quispe, JD; Joyce, GF			A 1.7-kilobase single-stranded DNA that folds into a nanoscale octahedron	NATURE			English	Article							DOUBLE CROSSOVER MOLECULES; NUCLEIC-ACID JUNCTIONS; CONSTRUCTION; SPECIMENS; DESIGN; VIRUS; RNA	Molecular self-assembly offers a means of spontaneously forming complex and well-defined structures from simple components. The specific bonding between DNA base pairs has been used in this way to create DNA-based nanostructures and to direct the assembly of material on the subnanometre to micrometre scale(1,2). In principle, large-scale clonal production of suitable DNA sequences and the directed evolution of sequence lineages towards optimized behaviour(3) can be realized through exponential DNA amplification by polymerases. But known examples of three-dimensional geometric DNA objects(4-6) are not amenable to cloning because they contain topologies that prevent copying by polymerases(1,2,7). Here we report the design and synthesis of a 1,669-nucleotide, single-stranded DNA molecule that is readily amplified by polymerases and that, in the presence of five 40-mer synthetic oligodeoxynucleotides, folds into an octahedron structure by a simple denaturation-renaturation procedure. We use cryo-electron microscopy to show that the DNA strands fold successfully, with 12 struts or edges joined at six four-way junctions to form hollow octahedra approximately 22 nanometres in diameter. Because the base-pair sequence of individual struts is not repeated in a given octahedron(8,9), each strut is uniquely addressable by the appropriate sequence-specific DNA binder.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Shih, WM (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wmshih@scripps.edu						Carragher B, 2000, J STRUCT BIOL, V132, P33, DOI 10.1006/jsbi.2000.4314; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; DORENBECK A, 2000, THESIS U BOCHUM; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1975, ULTRAMICROSCOPY, V1, P159, DOI 10.1016/S0304-3991(75)80020-9; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; Li XJ, 1996, J AM CHEM SOC, V118, P6131, DOI 10.1021/ja960162o; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Sa-Ardyen P, 2003, BIOPHYS J, V84, P3829, DOI 10.1016/S0006-3495(03)75110-8; SEEMAN NC, 1991, DNA CELL BIOL, V10, P475, DOI 10.1089/dna.1991.10.475; SEEMAN NC, 1983, BIOPHYS J, V44, P201, DOI 10.1016/S0006-3495(83)84292-1; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; SEEMAN NC, 1990, J BIOMOL STRUCT DYN, V8, P573, DOI 10.1080/07391102.1990.10507829; Seeman NC, 1998, ANNU REV BIOPH BIOM, V27, P225, DOI 10.1146/annurev.biophys.27.1.225; STEMMER WP, 1995, GENE, V64, P49; Tang L, 2001, NAT STRUCT BIOL, V8, P77, DOI 10.1038/83089; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Zhang XP, 2002, J AM CHEM SOC, V124, P12940, DOI 10.1021/ja026973b; ZHANG YW, 1994, J AM CHEM SOC, V116, P1661, DOI 10.1021/ja00084a006; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	23	773	818	6	235	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 12	2004	427	6975					618	621		10.1038/nature02307	http://dx.doi.org/10.1038/nature02307			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961116				2022-12-28	WOS:000188875300036
J	Garde, V; Harper, D; Fairchok, MP				Garde, V; Harper, D; Fairchok, MP			Tertiary contact vaccinia in a breastfeeding infant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMALLPOX VACCINATION	On May 4, 2003, a US Army soldier received primary smallpox vaccination and experienced a primary uptake reaction at the inoculation site on days 6 through 8. The vaccinee reported observing all of the standard precautions to avoid household spread. In mid May, his breastfeeding wife developed vesicles on both areolas. On May 29, their infant daughter developed a papule on her philtrum. Contact vaccinia was confirmed by positive polymerase chain reaction and culture for vaccinia of both the maternal and infant lesions. This is the first documented case of inadvertent contact vaccinia transmission from a mother to her infant through direct skin-to-skin and skin-to-mucous membrane contact while breastfeeding. The mechanism of transfer from the vaccinee to the spouse is uncertain. This report demonstrates that breastfeeding infants living in close contact with smallpox vaccinees are at potential risk for contact vaccinia, even if the vaccinee is not the breastfeeding mother, and highlights the need for special precautions to prevent secondary transfer to breastfeeding mothers.	Madigan Army Med Ctr, Dept Pediat, Tacoma, WA 98431 USA	Madigan Army Medical Center	Fairchok, MP (corresponding author), Madigan Army Med Ctr, Dept Pediat, Tacoma, WA 98431 USA.	Mary.Fairchok@nw.amedd.army.mil						*CDCP, CDC REC SMALLP VACC; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P639; *CDCP, CLIN EV TOOLS SMALLP; *CDCP, SMALLP FACT SHEET PE; *CDCP, SMALLP FACT SHEET SM; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; Neff JM, 2002, JAMA-J AM MED ASSOC, V288, P1901, DOI 10.1001/jama.288.15.1901; NEFF JM, 1967, NEW ENGL J MED, V276, P1; Sepkowitz KA, 2003, NEW ENGL J MED, V348, P439, DOI 10.1056/NEJMra022500	9	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					725	727		10.1001/jama.291.6.725	http://dx.doi.org/10.1001/jama.291.6.725			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871916	Bronze			2022-12-28	WOS:000188819200026
J	Bhowmick, NA; Chytil, A; Plieth, D; Gorska, AE; Dumont, N; Shappell, S; Washington, MK; Neilson, EG; Moses, HL				Bhowmick, NA; Chytil, A; Plieth, D; Gorska, AE; Dumont, N; Shappell, S; Washington, MK; Neilson, EG; Moses, HL			TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; TISSUE FIBROSIS; TUMOR-CELLS; C-MYC; EXPRESSION; ORGANS; MICE	Stromal cells can have a significant impact on the carcinogenic process in adjacent epithelia. The role of transforming growth factor-beta (TGF-beta) signaling in such epithelial-mesenchymal interactions was determined by conditional inactivation of the TGF-beta type II receptor gene in mouse fibroblasts (Tgfbr2(fspKO)). The loss of TGF-beta responsiveness in fibroblasts resulted in intraepithelial neoplasia in prostate and invasive squamous cell carcinoma of the forestomach, both associated with an increased abundance of stromal cells. Activation of paracrine hepatocyte growth factor (HGF) signaling was identified as one possible mechanism for stimulation of epithelial proliferation. Thus, TGF-beta signaling in fibroblasts modulates the growth and oncogenic potential of adjacent epithelia in selected tissues.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA.	hal.moses@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	NATIONAL CANCER INSTITUTE [R01CA102162, P30CA068485, R01CA085492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046282] Funding Source: NIH RePORTER; NCI NIH HHS [CA102162, CA85492, CA68485] Funding Source: Medline; NIAMS NIH HHS [AR41943] Funding Source: Medline; NIDDK NIH HHS [DK46282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; COOPER M, 1977, CANCER RES, V37, P2544; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; HAYASHI N, 1991, CANCER RES, V51, P4924; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Iwano M, 2001, MOL THER, V3, P149, DOI 10.1006/mthe.2000.0251; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MILLAN FA, 1991, DEVELOPMENT, V111, P131; Nakamura T, 1997, CANCER RES, V57, P3305; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Sakurai H, 1997, AM J PHYSIOL-RENAL, V272, pF139, DOI 10.1152/ajprenal.1997.272.1.F139; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; Shima N, 1998, J CELL PHYSIOL, V177, P130, DOI 10.1002/(SICI)1097-4652(199810)177:1<130::AID-JCP14>3.3.CO;2-O; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Walter KA, 2002, MOL CELL BIOL, V22, P2703, DOI 10.1128/MCB.22.8.2703-2715.2002; Watanabe R, 2000, NTT REVIEW, V12, P65; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333	24	1087	1138	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					848	851		10.1126/science.1090922	http://dx.doi.org/10.1126/science.1090922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764882				2022-12-28	WOS:000188753800061
J	Parkman, R				Parkman, R			Getting a handle on graft-versus-host disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							T-CELLS		Childrens Hosp, Saban Res Inst, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Parkman, R (corresponding author), Childrens Hosp, Saban Res Inst, Los Angeles, CA 90027 USA.							Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Itoh M, 1999, J IMMUNOL, V162, P5317; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x	3	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					614	615		10.1056/NEJMcibr033175	http://dx.doi.org/10.1056/NEJMcibr033175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762191				2022-12-28	WOS:000188712800016
J	Tsiavaliaris, G; Fujita-Becker, S; Manstein, DJ				Tsiavaliaris, G; Fujita-Becker, S; Manstein, DJ			Molecular engineering of a backwards-moving myosin motor	NATURE			English	Article							NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; CHARGE CHANGES; ATOMIC MODEL; LIGHT-CHAIN; F-ACTIN; DOMAIN; DICTYOSTELIUM; COMPLEX; MOVE	All members of the diverse myosin superfamily have a highly conserved globular motor domain that contains the actin- and nucleotide-binding sites and produces force and movement(1,2). The light-chain-binding domain connects the motor domain to a variety of functionally specialized tail domains and amplifies small structural changes in the motor domain through rotation of a lever arm(3,4). Myosins move on polarized actin filaments either forwards to the barbed (1) or backwards to the pointed (2) end(5,6). Here, we describe the engineering of an artificial backwards-moving myosin from three pre-existing molecular building blocks. These blocks are: a forward-moving class I myosin motor domain, a directional inverter formed by a four-helix bundle segment of human guanylate-binding protein-1 and an artificial lever arm formed by two alpha-actinin repeats. Our results prove that reverse-direction movement of myosins can be achieved simply by rotating the direction of the lever arm 180degrees.	Hannover Med Sch, Inst Biophys Chem, OE 4350, D-30623 Hannover, Germany; Max Planck Inst Med Res, Biophys Abt, D-69120 Heidelberg, Germany	Hannover Medical School; Max Planck Society	Manstein, DJ (corresponding author), Hannover Med Sch, Inst Biophys Chem, OE 4350, Carl Neuberg Str 1, D-30623 Hannover, Germany.	manstein@bpc.mh-hannover.de	Manstein, Dietmar J./AAG-2640-2019; Manstein, Dietmar J. J/M-1034-2013	Manstein, Dietmar J./0000-0003-0763-0147; Manstein, Dietmar J. J/0000-0003-0763-0147				Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Furch M, 2000, BIOCHEMISTRY-US, V39, P11602, DOI 10.1021/bi000985x; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Kull FJ, 2002, J CELL SCI, V115, P15; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; Ponomarev MA, 2000, BIOCHEMISTRY-US, V39, P4527, DOI 10.1021/bi992420a; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; Ringler P, 2003, SCIENCE, V302, P106, DOI 10.1126/science.1088074; Ruff C, 2001, NAT STRUCT BIOL, V8, P226, DOI 10.1038/84962; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; Tsiavaliaris G, 2002, EMBO REP, V3, P1099, DOI 10.1093/embo-reports/kvf214; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Van Dijk J, 1999, EUR J BIOCHEM, V260, P672, DOI 10.1046/j.1432-1327.1999.00172.x; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835	30	89	89	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					558	561		10.1038/nature02303	http://dx.doi.org/10.1038/nature02303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765199				2022-12-28	WOS:000188721800045
J	LaRoche, SM; Helmers, SL				LaRoche, SM; Helmers, SL			The new antiepileptic drugs - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ADD-ON THERAPY; PLACEBO-CONTROLLED TRIAL; REFRACTORY PARTIAL EPILEPSY; DOSE-RANGING TRIAL; PROGRESSIVE MYOCLONUS EPILEPSY; CONTROLLED CLINICAL-TRIAL; COMPLEX PARTIAL SEIZURES; PARTIAL-ONSET SEIZURES; DOUBLE-BLIND; LAMOTRIGINE MONOTHERAPY	Context The past decade has brought many advances to the treatment of epilepsy, including many new pharmacological agents. Primary care physicians often care for patients with epilepsy and therefore should be familiar with the new options available. Objective To review data regarding the efficacy and tolerability of antiepileptic drugs introduced in the past decade. Data Sources A search of the Cochrane Central Register of Controlled Trials was performed to identify all published human and English -language randomized controlled trials evaluating the efficacy and tolerability of the antiepileptic drugs that have been approved for use in the United States since 1990. Additional reports evaluating pharmacokinetic properties were identified through a MEDLINE search as well as review of article bibliographies. Study Selection and Data Extraction Search terms included felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, and zonisamide. Studies were selected if efficacy and tolerability were reported as major outcome measures. Included studies (n =55) enrolled a minimum of 20 adult subjects and had a treatment period of at least 6 weeks. Data Synthesis Eight new antiepileptic drugs have been approved for use in the United States in the past decade. Each new antiepileptic drug is well tolerated and demonstrates statistically significant reductions in seizure frequency over baseline. No randomized controlled trials have compared the new antiepileptic drugs with each other or against the traditional antiepileptic drugs. Although there is no evidence to suggest that the newer medications are more efficacious, several studies have demonstrated broader spectrum of activity, fewer drug interactions, and overall better tolerability of the new agents. Conclusions New antiepileptic drugs offer many options in the treatment of epilepsy, each with unique mechanisms of action as well as adverse effect profiles. The new antiepileptic drugs are well tolerated with few adverse effects, minimal drug interactions, and a broad spectrum of activity.	Atlanta VA Med Ctr, Atlanta, GA USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; Emory University	LaRoche, SM (corresponding author), Emory Clin, Bldg A,1365 Clifton Rd, Atlanta, GA 30322 USA.	Suzette_LaRoche@emoryhealthcare.org						ANDREWS J, 1990, LANCET, V335, P1114; ANHUT H, 1994, EPILEPSIA, V35, P795, DOI 10.1111/j.1528-1157.1994.tb02513.x; Barcs G, 2000, EPILEPSIA, V41, P1597; Baulac M, 1998, SEIZURE-EUR J EPILEP, V7, P55, DOI 10.1016/S1059-1311(98)90009-7; BEGLEY CE, 1994, EPILEPSIA, V35, P1230, DOI 10.1111/j.1528-1157.1994.tb01794.x; Ben-Menachem E, 2000, EPILEPSIA, V41, P1276, DOI 10.1111/j.1528-1157.2000.tb04605.x; BenMenachem E, 1996, EPILEPSIA, V37, P539, DOI 10.1111/j.1528-1157.1996.tb00606.x; Beran RG, 1998, EPILEPSIA, V39, P1329, DOI 10.1111/j.1528-1157.1998.tb01332.x; Betts T, 2000, SEIZURE-EUR J EPILEP, V9, P80, DOI 10.1053/seiz.2000.0380; Beydoun A, 2000, NEUROLOGY, V54, P2245, DOI 10.1212/WNL.54.12.2245; Beydoun A, 2003, NEUROLOGY, V60, pS13, DOI 10.1212/WNL.60.11_suppl_4.S13; Beydoun A, 1997, NEUROLOGY, V49, P746, DOI 10.1212/WNL.49.3.746; Bill PA, 1997, EPILEPSY RES, V27, P195, DOI 10.1016/S0920-1211(97)00024-7; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; Biton V, 1999, NEUROLOGY, V52, P1330, DOI 10.1212/WNL.52.7.1330; Blume Warren T., 2001, Epilepsia, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x; Boas J, 1996, ACTA NEUROL SCAND, V94, P247, DOI 10.1111/j.1600-0404.1996.tb07060.x; BOPP BA, 1995, EPILEPSIA, V36, pS159; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; BRODIE MJ, 1995, EPILIPSIA, V36, P7; Cereghino JJ, 2000, NEUROLOGY, V55, P236, DOI 10.1212/WNL.55.2.236; Chadwick D, 1996, EPILEPSY RES, V25, P191, DOI 10.1016/S0920-1211(96)00020-4; Chadwick DW, 1998, NEUROLOGY, V51, P1282, DOI 10.1212/WNL.51.5.1282; Christe W, 1997, EPILEPSY RES, V26, P451, DOI 10.1016/S0920-1211(96)01013-3; DAM M, 1989, EPILEPSY RES, V3, P70; DeLorenzo RJ, 2000, EPILEPSIA, V41, pS40, DOI 10.1111/j.1528-1157.2000.tb06048.x; DESARRO G, 1994, EUR J PHARMACOL, V262, P11, DOI 10.1016/0014-2999(94)90022-1; Eckardt KM, 1998, EPILEPSIA, V39, P671, DOI 10.1111/j.1528-1157.1998.tb01438.x; Eriksson AS, 1997, THER DRUG MONIT, V19, P499, DOI 10.1097/00007691-199710000-00002; Fattore C, 1999, EPILEPSIA, V40, P783, DOI 10.1111/j.1528-1157.1999.tb00779.x; FAUGHT E, 1993, NEUROLOGY, V43, P688, DOI 10.1212/WNL.43.4.688; Faught E, 1996, NEUROLOGY, V46, P1684, DOI 10.1212/WNL.46.6.1684; Faught E, 2001, NEUROLOGY, V57, P1774, DOI 10.1212/WNL.57.10.1774; FITTON A, 1995, DRUGS, V50, P691, DOI 10.2165/00003495-199550040-00008; FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224; Gibbs JW, 2000, EPILEPSIA, V41, pS10; Gilliam F, 1998, NEUROLOGY, V51, P1018, DOI 10.1212/WNL.51.4.1018; Goodwin M, 2002, SEIZURE-EUR J EPILEP, V11, P519, DOI 10.1016/S1059-1311(02)00132-2; Guberman AH, 1999, EPILEPSIA, V40, P985, DOI 10.1111/j.1528-1157.1999.tb00807.x; GUSTAVSON LE, 1995, EPILEPSIA, V36, P605, DOI 10.1111/j.1528-1157.1995.tb02575.x; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HENRY TR, 1988, NEUROLOGY, V38, P928, DOI 10.1212/WNL.38.6.928; HOLDRICH T, 1992, EPILEPSIA S1, V32, P96; HOUTKOOPER MA, 1987, EPILEPSIA, V28, P693, DOI 10.1111/j.1528-1157.1987.tb03702.x; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; JENSEN PK, 1994, EPILEPSIA, V35, pS54, DOI 10.1111/j.1528-1157.1994.tb05969.x; Kalviainen R, 1998, EPILEPSY RES, V30, P31, DOI 10.1016/S0920-1211(97)00082-X; Kaufman DW, 1997, EPILEPSIA, V38, P1265, DOI 10.1111/j.1528-1157.1997.tb00062.x; KERANEN T, 1992, ACTA NEUROL SCAND, V86, P120, DOI 10.1111/j.1600-0404.1992.tb05051.x; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Klitgaard H, 2001, EPILEPSIA, V42, P13, DOI 10.1046/j.1528-1157.2001.0420s4013.x; Knake S, 1999, SEIZURE-EUR J EPILEP, V8, P314, DOI 10.1053/seiz.1999.0303; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Kyllerman M, 1998, EPILEPSY RES, V29, P109, DOI 10.1016/S0920-1211(97)00069-7; LEPPIK IE, 1993, EPILEPSY RES, V14, P165, DOI 10.1016/0920-1211(93)90021-X; Leppik IE, 1999, EPILEPSIA, V40, pS23, DOI 10.1111/j.1528-1157.1999.tb00916.x; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; LOISEAU P, 1990, EPILEPSY RES, V7, P136, DOI 10.1016/0920-1211(90)90099-H; MAGDALOU J, 1992, J PHARMACOL EXP THER, V260, P1166; Marson AG, 1996, BMJ-BRIT MED J, V313, P1169, DOI 10.1136/bmj.313.7066.1169; MATSUO F, 1993, NEUROLOGY, V43, P2284, DOI 10.1212/WNL.43.11.2284; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248; MCLEAN M, 2001, TREATMENT EPILEPSY, P915; MCLEAN MJ, 1994, EPILEPSIA, V35; Meador KJ, 1999, EPILEPSIA, V40, P1279, DOI 10.1111/j.1528-1157.1999.tb00858.x; *MED EC CO, 2002, PHYS DESK REF; MENGEL HB, 1994, J PHARM MED, V4, P141; MESSENHEIMER J, 1994, EPILEPSIA, V35, P113, DOI 10.1111/j.1528-1157.1994.tb02920.x; Mimaki T, 1998, THER DRUG MONIT, V20, P593, DOI 10.1097/00007691-199812000-00001; Morris GL, 1999, EPILEPSIA, V40, pS63, DOI 10.1111/j.1528-1157.1999.tb00921.x; Motte J, 1997, NEW ENGL J MED, V337, P1807, DOI 10.1056/NEJM199712183372504; Nieto-Barrera M, 2001, EPILEPSY RES, V46, P145, DOI 10.1016/S0920-1211(01)00271-6; OOMMEN K, 1993, NEUROLOGY, V43, P2292; Pellock J M, 1997, Semin Pediatr Neurol, V4, P9, DOI 10.1016/S1071-9091(97)80004-6; Pellock JM, 1997, EPILEPSIA, V38, P1261, DOI 10.1111/j.1528-1157.1997.tb00061.x; Perucca E, 2002, THER DRUG MONIT, V24, P74, DOI 10.1097/00007691-200202000-00013; Privitera M, 1996, NEUROLOGY, V46, P1678, DOI 10.1212/WNL.46.6.1678; Radtke RA, 2001, EPILEPSIA, V42, P24, DOI 10.1046/j.1528-1157.2001.0420s4024.x; RADULOVIC LL, 1994, EPILEPSIA, V35, P155, DOI 10.1111/j.1528-1157.1994.tb02926.x; REINIKAINEN KJ, 1987, EPILEPSY RES, V1, P284, DOI 10.1016/0920-1211(87)90003-9; RICHENS A, 1994, EPILEPSIA, V35, pS37, DOI 10.1111/j.1528-1157.1994.tb05965.x; Rosenfeld WE, 1997, EPILEPSIA, V38, P324, DOI 10.1111/j.1528-1157.1997.tb01124.x; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; Rzany B, 1999, LANCET, V353, P2190, DOI 10.1016/S0140-6736(98)05418-X; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; Sachdeo R, 2001, NEUROLOGY, V57, P864, DOI 10.1212/WNL.57.5.864; Sachdeo RC, 1997, ARCH NEUROL-CHICAGO, V54, P595, DOI 10.1001/archneur.1997.00550170069016; Sachdeo RC, 1997, EPILEPSIA, V38, P294, DOI 10.1111/j.1528-1157.1997.tb01120.x; Sachdeo RC, 1999, NEUROLOGY, V52, P1882, DOI 10.1212/WNL.52.9.1882; Sachdeo RC, 2002, EPILEPSIA, V43, P691, DOI 10.1046/j.1528-1157.2002.41701.x; SANDER JWAS, 1990, EPILEPSY RES, V6, P221, DOI 10.1016/0920-1211(90)90077-9; SCHAPEL GJ, 1993, J NEUROL NEUROSUR PS, V56, P448, DOI 10.1136/jnnp.56.5.448; SCHMIDT D, 1993, EPILEPSY RES, V15, P67, DOI 10.1016/0920-1211(93)90011-U; Sharief M, 1996, EPILEPSY RES, V25, P217, DOI 10.1016/S0920-1211(96)00029-0; Shorvon SD, 2000, EPILEPSIA, V41, P1179, DOI 10.1111/j.1528-1157.2000.tb00323.x; Shorvon SD, 1996, EPILEPSIA, V37, pS18, DOI 10.1111/j.1528-1157.1996.tb06029.x; Siegel H, 1999, EPILEPSY RES, V34, P91, DOI 10.1016/S0920-1211(98)00119-3; SIVENIUS J, 1991, EPILEPSIA, V32, P539, DOI 10.1111/j.1528-1157.1991.tb04689.x; SMITH D, 1993, EPILEPSIA, V34, P312, DOI 10.1111/j.1528-1157.1993.tb02417.x; SMITH MC, 1996, DIS MONTH, V42, P72; Stefani A, 1997, EPILEPSIA, V38, P959, DOI 10.1111/j.1528-1157.1997.tb01477.x; Steiner TJ, 1999, EPILEPSIA, V40, P601, DOI 10.1111/j.1528-1157.1999.tb05562.x; SUZDAK PD, 1995, EPILEPSIA, V36, P612, DOI 10.1111/j.1528-1157.1995.tb02576.x; SUZUKI S, 1992, EPILEPSY RES, V12, P21, DOI 10.1016/0920-1211(92)90087-A; Tassinari CA, 1996, EPILEPSIA, V37, P763, DOI 10.1111/j.1528-1157.1996.tb00649.x; Thapar AK, 1998, FAM PRACT, V15, P437, DOI 10.1093/fampra/15.5.437; THEODORE WH, 1991, EPILEPSIA, V32, P392, DOI 10.1111/j.1528-1157.1991.tb04668.x; Uthman BM, 1998, ARCH NEUROL-CHICAGO, V55, P56, DOI 10.1001/archneur.55.1.56; VANPARYS JAP, 1994, EPILEPSY RES, V19, P79, DOI 10.1016/0920-1211(94)90091-4; VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830; WASSERSTEIN AG, 1995, EPILEPSIA S3, V36, P153; White HS, 1997, EPILEPSY RES, V28, P167, DOI 10.1016/S0920-1211(97)00045-4; WHITE HS, 1992, EPILEPSIA, V33, P564, DOI 10.1111/j.1528-1157.1992.tb01711.x; Willmore LJ, 1997, NEUROLOGY, V48, pS39, DOI 10.1212/WNL.48.6_Suppl_8.S39; Wong ICK, 2000, DRUG SAFETY, V23, P35, DOI 10.2165/00002018-200023010-00003; Yen DJ, 2000, EPILEPSIA, V41, P1162, DOI 10.1111/j.1528-1157.2000.tb00321.x; YUEN AWC, 1992, BRIT J CLIN PHARMACO, V33, P511, DOI 10.1111/j.1365-2125.1992.tb04079.x; ZACCARA G, 1993, THER DRUG MONIT, V15, P39, DOI 10.1097/00007691-199302000-00007	118	175	187	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					605	614		10.1001/jama.291.5.605	http://dx.doi.org/10.1001/jama.291.5.605			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762040	Bronze			2022-12-28	WOS:000188650700026
J	Chan, AT; Giovannucci, EL; Schernhammer, ES; Colditz, GA; Hunter, DJ; Willett, WC; Fuchs, CS				Chan, AT; Giovannucci, EL; Schernhammer, ES; Colditz, GA; Hunter, DJ; Willett, WC; Fuchs, CS			A prospective study of aspirin use and the risk for colorectal adenoma	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Digestive Disease Week Meeting/104th Annual Meeting of the American-Gastroenterological-Association	MAY 17-22, 2003	ORLANDO, FL	Amer Gastroenterol Assoc			NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LONG-TERM USE; COST-EFFECTIVENESS ANALYSIS; COLON-CANCER CELLS; NF-KAPPA-B; LARGE-BOWEL; RANDOMIZED-TRIAL; UNITED-STATES; PHYSICAL-ACTIVITY; REDUCED RISK	Background: Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma. However, the effect of dose and duration of use, particularly in an average-risk population, is not well understood. Objective: To examine the influence of dose and duration of aspirin use in the primary prevention of colorectal adenoma. Design: Prospective cohort study. Setting: Nurses' Health Study. Participants: 27 077 women, 34 to 77 years of age, without a history of adenoma, cancer, inflammatory bowel disease, or familial polyposis, who underwent lower endoscopy between 1980 and 1998. Measurements: 1368 cases of confirmed distal colorectal adenoma were diagnosed between 1980 and 1998. Self-reported data on aspirin use were collected from biennial questionnaires. Results: After other risk factors for adenoma were adjusted, women who regularly used aspirin (greater than or equal to2 standard aspirin tablets/wk) had a multivariate relative risk for adenoma of 0.75 (95% Cl, 0.66 to 0.84) compared with nonregular users. Compared with women who denied any aspirin use, the multivariate relative risks for adenoma were 0.80 (Cl, 0.70 to 0.93) for women who used 0.5 to 1.5 standard tablets per week, 0.74 (Cl, 0.62 to 0.88) for those who used 2 to 5 tablets per week, 0.72 (Cl, 0.61 to 0.85) for those who used 6 to 14 tablets per week, and 0.49 (Cl, 0.36 to 0.65) for those who used more than 14 tablets per week (P<0.001 for trend). Similar dose-response relationships were found among regular short-term users (less than or equal to5 years; P<0.001) and long-term users (>5 years; P<0.001). In contrast, after adjustments were made for dose, increasing duration of aspirin use did not confer greater risk reduction (P>0.2). Conclusions: Regular, short-term use of aspirin is inversely associated with risk for colorectal adenoma. However, the greatest protective effect is evident at substantially higher doses (>14 tablets/wk) than those recommended for the prevention of cardiovascular disease. Before aspirin can be recommended for chemo-prevention in the general adult population, these results suggest the need for a more thorough evaluation of the risks and benefits of routine aspirin use at doses not previously considered.	Harvard Univ, Gastrointestinal Unit, Massachusetts Gen Hosp,Med Sch, Brigham & Womens Hosp,Dana Farber Canc Inst, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Chan, AT (corresponding author), Harvard Univ, Gastrointestinal Unit, Massachusetts Gen Hosp,Med Sch, Brigham & Womens Hosp,Dana Farber Canc Inst, 55 Fruit St,GRJ-722, Boston, MA 02114 USA.		Colditz, Graham/A-3963-2009; Schernhammer, Eva S/L-7898-2018; Chan, Andrew T/P-8293-2014	Colditz, Graham/0000-0002-7307-0291; Schernhammer, Eva S/0000-0002-4337-9415; Chan, Andrew T/0000-0001-7284-6767	NCI NIH HHS [CA 87969, CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIDDK NIH HHS [T32DK07191] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Baier M, 2000, CANCER EPIDEM BIOMAR, V9, P229; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4; Berg AO, 2002, ANN INTERN MED, V136, P157, DOI 10.7326/0003-4819-136-2-200201150-00015; Breuer-Katschinski B, 2000, DIGESTION, V61, P129, DOI 10.1159/000007745; Chan AT, 2003, CANCER CAUSE CONTROL, V14, P413, DOI 10.1023/A:1024986220526; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chau I, 2002, NEW ENGL J MED, V346, P1085, DOI 10.1056/NEJM200204043461412; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; Giovannucci E, 1996, CANCER CAUSE CONTROL, V7, P253, DOI 10.1007/BF00051301; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Imperiale TF, 2003, NEW ENGL J MED, V348, P879, DOI 10.1056/NEJMp030005; Iso H, 1999, STROKE, V30, P1764, DOI 10.1161/01.STR.30.9.1764; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Ladabaum U, 2001, ANN INTERN MED, V135, P769, DOI 10.7326/0003-4819-135-9-200111060-00007; LaVecchia C, 1997, BRIT J CANCER, V76, P675, DOI 10.1038/bjc.1997.444; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; Martin C, 2002, GASTROENTEROLOGY, V123, P1770, DOI 10.1053/gast.2002.37053; MARTINEZ ME, 1995, CANCER EPIDEM BIOMAR, V4, P703; NEUGUT AI, 1995, GASTROENTEROLOGY, V108, P402, DOI 10.1016/0016-5085(95)90066-7; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; Peleg II, 1996, DIGEST DIS SCI, V41, P1319, DOI 10.1007/BF02088554; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; REX DK, 1995, AM J GASTROENTEROL, V90, P353; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P376, DOI 10.1097/00001648-200007000-00003; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Ruffin MT, 1997, JNCI-J NATL CANCER I, V89, P1152, DOI 10.1093/jnci/89.15.1152; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sandler RS, 1998, GASTROENTEROLOGY, V114, P441, DOI 10.1016/S0016-5085(98)70526-8; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shureiqi I, 2000, CANCER RES, V60, P6846; SLATTERY J, 1995, GUT, V37, P509, DOI 10.1136/gut.37.4.509; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; Suleiman S, 2002, GASTROENTEROLOGY, V122, P78, DOI 10.1053/gast.2002.29689; Tangrea JA, 2003, CANCER CAUSE CONTROL, V14, P403, DOI 10.1023/A:1024990617158; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307	58	135	143	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					157	166		10.7326/0003-4819-140-3-200402030-00006	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	770BZ	14757613				2022-12-28	WOS:000188704500001
J	Thompson, S; Neal, S; Clark, V				Thompson, S; Neal, S; Clark, V			Clinical risk management in obstetrics: eclampsia drills	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE	Problem Infrequent presentation of patients with eclampsia, leading to staff inexperienced in the condition and untested emergency systems. Design "Fire drill" programme using on-site simulation of patients with eclampsia. Setting Tertiary referral obstetric unit. Key measures for improvement Successful implementation of measures to optimise management of eclampsia. Strategies for change Rapid activation of emergency team after one call, development and dissemination of evidence based protocol for eclampsia, strategically placed "eclampsia boxes," individual staff feedback and education. Effects of change Efficient and appropriate management of subsequent simulated patients. Lessons learnt On-site simulation can identify and correct potential deficiencies in the care of patients with eclampsia.	St George Hosp, Dept Anaesthet, Kogarah, NSW 2217, Australia; St Johns Hosp, Livingston EH54 6PP, Scotland; Royal Infirm Edinburgh NHS Trust, Edinburgh EH3 9YW, Midlothian, Scotland	St George Hospital; Royal Infirmary of Edinburgh; University of Edinburgh	Thompson, S (corresponding author), St George Hosp, Dept Anaesthet, Kogarah, NSW 2217, Australia.	sarahathompson@hotmail.com						BURKE C, 2003, CLIN RISK, V9, P103; CHOPRA V, 1994, BRIT J ANAESTH, V73, P293, DOI 10.1093/bja/73.3.293; Cro S, 2001, BR J MIDWIFERY, V9, P492; Department of Health, 2000, ORG MEM; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Duley L, 1996, BRIT J OBSTET GYNAEC, V103, P103, DOI 10.1111/j.1471-0528.1996.tb09657.x; Gaba DM, 1998, ANESTHESIOLOGY, V89, P8, DOI 10.1097/00000542-199807000-00005; *NHS LIT AUTH, 2003, CLIN NEGL SCHEM TRUS; Patel R M, 1998, Acad Med, V73, P593, DOI 10.1097/00001888-199805000-00060; *ROYAL COLL OBST G, 1999, WHY MOTH DIE; *ROYAL COLL OBST G, MAN ECL; *ROYAL COLL OBST G, 1999, TOW SAF CHILDB; SIBAI BM, 1990, AM J OBSTET GYNECOL, V163, P1049, DOI 10.1016/0002-9378(90)91123-T; Walpole R, 2002, CPD ANAESTHESIA, V4, P15	14	46	47	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					269	271		10.1136/bmj.328.7434.269	http://dx.doi.org/10.1136/bmj.328.7434.269			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14751898	Green Published			2022-12-28	WOS:000188786000023
J	Gibot, S; Cravoisy, A; Levy, B; Bene, MC; Faure, G; Bollaert, PE				Gibot, S; Cravoisy, A; Levy, B; Bene, MC; Faure, G; Bollaert, PE			Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; BRONCHOALVEOLAR LAVAGE; NOSOCOMIAL PNEUMONIA; CLINICAL JUDGMENT; ORGAN FAILURE; TREM-1; SEPSIS; SCORE; PROCALCITONIN; STRATEGIES	BACKGROUND: The diagnosis and treatment of bacterial pneumonia in patients who are receiving mechanical ventilation remain a difficult challenge. The triggering receptor expressed on myeloid cells (TREM-1) is a member of the immunoglobulin superfamily, and its expression on phagocytes is specifically up-regulated by microbial products. The presence of soluble TREM-1 (sTREM-1) in bronchoalveolar-lavage fluid from patients receiving mechanical ventilation may be an indicator of pneumonia. METHODS: We conducted a prospective study of 148 patients receiving mechanical ventilation in whom infectious pneumonia was suspected. A rapid immunoblot technique was used to measure sTREM-1 in bronchoalveolar-lavage fluid. Two independent intensivists who were unaware of the results of the sTREM-1 assay determined whether community-acquired pneumonia and ventilator-associated pneumonia were present or absent. RESULTS: The final diagnosis was community-acquired pneumonia in 38 patients, ventilator-associated pneumonia in 46 patients, and no pneumonia in 64 patients. The presence of sTREM-1 by itself was more accurate than any clinical findings or laboratory values in identifying the presence of bacterial or fungal pneumonia (likelihood ratio, 10.38; sensitivity, 98 percent; specificity, 90 percent). In multiple logistic-regression analysis, the presence of sTREM-1 was the strongest independent predictor of pneumonia (odds ratio, 41.5). CONCLUSIONS: In patients receiving mechanical ventilation, rapid detection of sTREM-1 in bronchoalveolar-lavage fluid may be useful in establishing or excluding the diagnosis of bacterial or fungal pneumonia.	Hop Cent, Serv Reanimat Med, F-54035 Nancy, France; Fac Med, Immunol Lab, Nancy, France	CHU de Nancy; Universite de Lorraine	Gibot, S (corresponding author), Hop Cent, Serv Reanimat Med, 29 Ave Marechal de Lattre de Tassigny, F-54035 Nancy, France.	s.gibot@chu-nancy.fr						Amyes SGB, 1998, CHEST, V113, p228S, DOI 10.1378/chest.113.3_Supplement.228S; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; Birmingham MC, 1997, PHARMACOECONOMICS, V12, P637, DOI 10.2165/00019053-199712060-00004; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bonten MJM, 1997, AM J RESP CRIT CARE, V156, P1105, DOI 10.1164/ajrccm.156.4.9610002; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Brunkhorst FM, 2002, CLIN MICROBIOL INFEC, V8, P93, DOI 10.1046/j.1469-0691.2002.00349.x; Campbell GD, 2000, CHEST, V117, p207S, DOI 10.1378/chest.117.4_suppl_2.207S; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Cohen J, 2001, LANCET, V358, P776, DOI 10.1016/S0140-6736(01)06007-X; Duflo F, 2002, ANESTHESIOLOGY, V96, P74, DOI 10.1097/00000542-200201000-00018; Fagon JY, 2000, ANN INTERN MED, V132, P621, DOI 10.7326/0003-4819-132-8-200004180-00004; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; FUKUSHIMA R, 1994, CRIT CARE MED, V22, P114, DOI 10.1097/00003246-199401000-00022; Helling TS, 1996, AM J SURG, V171, P570, DOI 10.1016/S0002-9610(96)00040-2; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; MEDURI GU, 1992, CHEST, V101, P500, DOI 10.1378/chest.101.2.500; Monton C, 1999, CRIT CARE MED, V27, P1745, DOI 10.1097/00003246-199909000-00008; Nathan C, 2001, NAT MED, V7, P530, DOI 10.1038/87846; PAPAZIAN L, 1995, AM J RESP CRIT CARE, V152, P1982, DOI 10.1164/ajrccm.152.6.8520766; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Wu CL, 2003, CRIT CARE MED, V31, P812, DOI 10.1097/01.CCM.0000054865.47068.58; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349	28	426	494	1	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					451	458		10.1056/NEJMoa031544	http://dx.doi.org/10.1056/NEJMoa031544			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749453				2022-12-28	WOS:000188463900007
J	Itoh, H; Takahashi, A; Adachi, K; Noji, H; Yasuda, R; Yoshida, M; Kinosita, K				Itoh, H; Takahashi, A; Adachi, K; Noji, H; Yasuda, R; Yoshida, M; Kinosita, K			Mechanically driven ATP synthesis by F-1-ATPase	NATURE			English	Article							MOLECULAR MOTOR; SYNTHASE; F1-ATPASE; DIMETHYLSULFOXIDE; RESOLUTION; NUCLEOTIDE; ROTATION; BINDING; ENERGY; MYOSIN	ATP, the main biological energy currency, is synthesized from ADP and inorganic phosphate by ATP synthase in an energy-requiring reaction(1-3). The F-1 portion of ATP synthase, also known as F-1-ATPase, functions as a rotary molecular motor: in vitro its gamma-subunit rotates(4) against the surrounding alpha(3)beta(3) subunits(5), hydrolysing ATP in three separate catalytic sites on the beta-subunits. It is widely believed that reverse rotation of the gamma-subunit, driven by proton flow through the associated F-o portion of ATP synthase, leads to ATP synthesis in biological systems(1-3,6,7). Here we present direct evidence for the chemical synthesis of ATP driven by mechanical energy. We attached a magnetic bead to the gamma-subunit of isolated F-1 on a glass surface, and rotated the bead using electrical magnets. Rotation in the appropriate direction resulted in the appearance of ATP in the medium as detected by the luciferase-luciferin reaction. This shows that a vectorial force ( torque) working at one particular point on a protein machine can influence a chemical reaction occurring in physically remote catalytic sites, driving the reaction far from equilibrium.	Hamamatsu Photon KK, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan; CREST, Creat & Applicat Soft Nanomachine Hyperfunct Mol, Tsukuba, Ibaraki 3002635, Japan; Hamamatsu Photon KK, Syst Div, Hamamatsu, Shizuoka 4313103, Japan; Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan; Univ Tokyo, Inst Ind Sci, Tokyo 1538505, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; ERATO ATP Syst, Yokohama, Kanagawa 2260026, Japan	Hamamatsu Photonics; Japan Science & Technology Agency (JST); Hamamatsu Photonics; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Tokyo; Cold Spring Harbor Laboratory; Japan Science & Technology Agency (JST)	Itoh, H (corresponding author), Hamamatsu Photon KK, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan.	hiritoh@hpk.trc-net.co.jp	Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; Hattori N, 2002, BIOSCI BIOTECH BIOCH, V66, P2587, DOI 10.1271/bbb.66.2587; Kinosita K, 2000, PHILOS T R SOC B, V355, P473, DOI 10.1098/rstb.2000.0589; MANNHERZ HG, 1974, EUR J BIOCHEM, V48, P287, DOI 10.1111/j.1432-1033.1974.tb03767.x; MCELROY WD, 1969, PHOTOCHEM PHOTOBIOL, V10, P153, DOI 10.1111/j.1751-1097.1969.tb05676.x; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OISHI N, 1994, BBA-BIOENERGETICS, V1185, P346, DOI 10.1016/0005-2728(94)90250-X; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; SAKAMOTO J, 1984, J BIOCHEM-TOKYO, V96, P483, DOI 10.1093/oxfordjournals.jbchem.a134860; Turina P, 2003, EMBO J, V22, P418, DOI 10.1093/emboj/cdg073; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; WOLCOTT RG, 1974, BIOCHEM BIOPH RES CO, V57, P709, DOI 10.1016/0006-291X(74)90604-4; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; YOSHIDA M, 1983, BIOCHEM BIOPH RES CO, V114, P907, DOI 10.1016/0006-291X(83)90646-0; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	22	394	411	5	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 29	2004	427	6973					465	468		10.1038/nature02212	http://dx.doi.org/10.1038/nature02212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749837				2022-12-28	WOS:000188470500049
J	Ohtomo, A; Hwang, HY				Ohtomo, A; Hwang, HY			A high-mobility electron gas at the LaAlO3/SrTiO3 heterointerface	NATURE			English	Article							SRTIO3; TITANATE	Polarity discontinuities at the interfaces between different crystalline materials (heterointerfaces) can lead to nontrivial local atomic and electronic structure, owing to the presence of dangling bonds and incomplete atomic coordinations(1-3). These discontinuities often arise in naturally layered oxide structures, such as the superconducting copper oxides and ferroelectric titanates, as well as in artificial thin film oxide heterostructures such as manganite tunnel junctions(4-6). If polarity discontinuities can be atomically controlled, unusual charge states that are inaccessible in bulk materials could be realized. Here we have examined a model interface between two insulating perovskite oxides - LaAlO3 and SrTiO3 - in which we control the termination layer at the interface on an atomic scale. In the simple ionic limit, this interface presents an extra half electron or hole per two-dimensional unit cell, depending on the structure of the interface. The hole-doped interface is found to be insulating, whereas the electron-doped interface is conducting, with extremely high carrier mobility exceeding 10,000 cm(2) V-1 s(-1). At low temperature, dramatic magnetoresistance oscillations periodic with the inverse magnetic field are observed, indicating quantum transport. These results present a broad opportunity to tailor low-dimensional charge states by atomically engineered oxide heteroepitaxy.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan; Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan; Univ Tokyo, Dept Adv Mat Sci, Chiba 2778651, Japan	Alcatel-Lucent; Lucent Technologies; AT&T; Tohoku University; Japan Science & Technology Agency (JST); University of Tokyo	Hwang, HY (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	hyhwang@k.u-tokyo.ac.jp	Ohtomo, Akira/C-4944-2008; Fonseca, James E/G-1018-2011; Hwang, Harold Y/I-6943-2012	Ohtomo, Akira/0000-0003-0300-4712; 				BARAFF GA, 1977, PHYS REV LETT, V38, P237, DOI 10.1103/PhysRevLett.38.237; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; Frank G, 2001, STUD EUROP JUDAISM, V1, P3; FREDERIKSE HP, 1967, PHYS REV, V158, P775, DOI 10.1103/PhysRev.158.775; HARRISON WA, 1978, PHYS REV B, V18, P4402, DOI 10.1103/PhysRevB.18.4402; HERRING C, 1960, J APPL PHYS, V31, P1939, DOI 10.1063/1.1735477; KAWASAKI M, 1994, SCIENCE, V266, P1540, DOI 10.1126/science.266.5190.1540; Kim DW, 1999, APPL PHYS LETT, V74, P2176, DOI 10.1063/1.123792; KROEMER H, 1987, J CRYST GROWTH, V81, P193, DOI 10.1016/0022-0248(87)90391-5; Landis D., 1996, HDB INTERCULTURAL TR, V2nd; Nishimura T, 1999, SURF SCI, V421, P273, DOI 10.1016/S0039-6028(98)00840-1; PIPPARD AB, 1989, MAGNETORESISTANCE ME, pCH6; Robinson P, 2002, NATURE, V418, P517, DOI 10.1038/nature00942; RUDDLESDEN SN, 1958, ACTA CRYSTALLOGR, V11, P54, DOI 10.1107/S0365110X58000128; RUDDLESDEN SN, 1957, ACTA CRYSTALLOGR, V10, P538, DOI 10.1107/S0365110X57001929; SAKUDO T, 1971, PHYS REV LETT, V26, P851, DOI 10.1103/PhysRevLett.26.851; TOKURA Y, 1993, PHYS REV LETT, V70, P2126, DOI 10.1103/PhysRevLett.70.2126; TOKURA YR, 2000, COLOSSAL MAGNETORESI, pCH9; TUFTE ON, 1967, PHYS REV, V155, P796, DOI 10.1103/PhysRev.155.796; Wang T, 1999, PHYS REV LETT, V82, P3304, DOI 10.1103/PhysRevLett.82.3304	22	3635	3680	62	1635	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					423	426		10.1038/nature02308	http://dx.doi.org/10.1038/nature02308			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749825				2022-12-28	WOS:000188470500037
J	Snyder, PJ				Snyder, PJ			Hypogonandism in elderly men - What to do until the evidence comes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania	Snyder, PJ (corresponding author), Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.							LIVERMAN CT, IN PRESS TESTOSTERON	1	81	89	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					440	442		10.1056/NEJMp038207	http://dx.doi.org/10.1056/NEJMp038207			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749451				2022-12-28	WOS:000188463900005
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Overcoming the false dichotomy of "curative" vs "palliative" care for late-stage HIV/AIDS - "Let me live the way I want to live, until I can't"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Selwyn PA, 2003, JAMA-J AM MED ASSOC, V290, P806, DOI 10.1001/jama.290.6.806	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					492	492		10.1001/jama.291.4.492	http://dx.doi.org/10.1001/jama.291.4.492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747507				2022-12-28	WOS:000188426700035
J	Ephrussi, A; St Johnston, D				Ephrussi, A; St Johnston, D			Seeing is believing: The bicoid morphogen gradient matures	CELL			English	Review							RNA LOCALIZATION SIGNAL; DORSAL-VENTRAL PATTERN; MATERNAL-EFFECT MUTANT; CAUDAL MESSENGER-RNA; DROSOPHILA EMBRYO; POSTERIOR DETERMINANT; ANTERIOR LOCALIZATION; ANTEROPOSTERIOR AXIS; DORSOVENTRAL PATTERN; MOLECULAR ANALYSIS	Although Cell has a long history of publishing some of the most significant advances in developmental biology, the back to back papers by Driever and Nusslein-Volhard on the role of the Bicoid gradient in patterning the Drosophila embryo stand out as the first molecular demonstration of two of the longest standing concepts of the field, namely localized cytoplasmic determinants and morphogen gradients. Here we discuss the impact of this ground-breaking work and review recent results on bicoid mRNA localization and the dual role of Bicoid as a transcription and translation factor.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	European Molecular Biology Laboratory (EMBL); University of Cambridge	Ephrussi, A (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	ephrussi@embl.de; ds139@mole.bio.cam.ac.uk	Ephrussi, Anne/AAG-4075-2020; St Johnston, Daniel/C-9568-2009; Ephrussi, Anne/ABD-4393-2021	Ephrussi, Anne/0000-0002-5061-4620; St Johnston, Daniel/0000-0001-5582-3301				AKAM M, 1987, DEVELOPMENT, V101, P1; Arn EA, 2003, DEV CELL, V4, P41, DOI 10.1016/S1534-5807(02)00397-0; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOVERI T, 2001, ZOOL JB ABT ANAT ONT, V14, P384; Cha BJ, 2001, CELL, V106, P35, DOI 10.1016/S0092-8674(01)00419-6; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CHILD CM, 1941, PATTERNS PROBELMS DE; Conklin E, 1905, BIOL BULL-US, V8, P205, DOI 10.2307/1535879; Conklin EG, 1905, J EXP ZOOL, V2, P145, DOI 10.1002/jez.1400020202; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Eldar A, 2003, DEV CELL, V5, P635, DOI 10.1016/S1534-5807(03)00292-2; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; Gao Q, 1998, DEVELOPMENT, V125, P4185; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Horstadius S., 1936, Pubblicazioni della Stazione Zoologica di Napoli, V14, P251; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; Macdonald PM, 1998, MOL CELL BIOL, V18, P3788, DOI 10.1128/MCB.18.7.3788; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Macdonald PM, 1997, RNA, V3, P1413; MacDougall N, 2003, DEV CELL, V4, P307, DOI 10.1016/S1534-5807(03)00058-3; Mancebo R, 2001, MOL CELL BIOL, V21, P3462, DOI 10.1128/MCB.21.10.3462-3471.2001; Martin SG, 2003, DEVELOPMENT, V130, P4201, DOI 10.1242/dev.00630; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nakamura A, 1996, SCIENCE, V274, P2075, DOI 10.1126/science.274.5295.2075; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Niessing D, 2000, MOL CELL, V5, P395, DOI 10.1016/S1097-2765(00)80434-7; Niessing D, 1999, EMBO J, V18, P1966, DOI 10.1093/emboj/18.7.1966; Niessing D, 2002, GENE DEV, V16, P2576, DOI 10.1101/gad.240002; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1977, ROUX ARCH DEV BIOL, V183, P249, DOI 10.1007/BF00867325; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SAUNDERS JW, 1972, ANN NY ACAD SCI, V193, P29, DOI 10.1111/j.1749-6632.1972.tb27821.x; Schnorrer F, 2002, DEV CELL, V3, P685, DOI 10.1016/S1534-5807(02)00301-5; SCHONORRER F, 2000, NAT CELL BIOL, V2, P185; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; Schroder R, 2003, NATURE, V422, P621, DOI 10.1038/nature01536; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; Stauber M, 1999, P NATL ACAD SCI USA, V96, P3786, DOI 10.1073/pnas.96.7.3786; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Surdej P, 1998, MOL CELL BIOL, V18, P2892, DOI 10.1128/MCB.18.5.2892; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TREISMAN J, 1989, CELL, V59, P553; Wagner C, 2001, J MOL BIOL, V313, P511, DOI 10.1006/jmbi.2001.5057; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wilson EB, 1904, J EXP ZOOL, V1, P1, DOI 10.1002/jez.1400010102; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0	104	128	136	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					143	152		10.1016/S0092-8674(04)00037-6	http://dx.doi.org/10.1016/S0092-8674(04)00037-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744427	Bronze			2022-12-28	WOS:000188541700006
J	Murray, AW				Murray, AW			Recycling the cell cycle: Cyclins revisited	CELL			English	Review							ANAPHASE-PROMOTING COMPLEX; SPINDLE ASSEMBLY CHECKPOINT; NUCLEAR-ENVELOPE BREAKDOWN; XENOPUS EGG EXTRACTS; CONTROL GENE CDC2+; S-PHASE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; BUDDING YEAST; MITOTIC REGULATOR	I discuss advances in the cell cycle in the 21 years since cyclin was discovered. The surprising redundancy amongst the classical cyclins (A, B, and E) and cyclin-dependent kinases (Cdk1 and Cdk2) show that the important differences between these proteins are when and where they are expressed rather than the proteins they phosphorylate. Although the broad principles of the cell cycle oscillator are widely accepted, we are surprisingly ignorant of its detailed mechanism. This is especially true of the anaphase promoting complex (APC), the machine that triggers chromosome segregation and the exit of mitosis by targeting securin and mitotic cyclins for destruction. I discuss how a cyclin/Cdk-based engine could have evolved to assume control of the cell cycle from other, older protein kinases.	Harvard Univ, Dept Mol & Cellular Biol, Biol Labs, Cambridge, MA 02138 USA	Harvard University	Murray, AW (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biol Labs, Cambridge, MA 02138 USA.	amurray@mcb.harvard.edu						Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; CLUTE P, 1995, DEV BIOL, V171, P273, DOI 10.1006/dbio.1995.1280; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Collas P, 1999, J CELL SCI, V112, P977; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; Dong XZ, 1997, GENE DEV, V11, P94, DOI 10.1101/gad.11.1.94; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Garrett S, 2001, MOL CELL BIOL, V21, P88, DOI 10.1128/MCB.21.1.88-99.2001; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Haase SB, 1999, NATURE, V401, P394, DOI 10.1038/43930; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jeffery DA, 2001, J MOL BIOL, V306, P997, DOI 10.1006/jmbi.2000.4417; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; Krylov DM, 2003, CURR BIOL, V13, P173, DOI 10.1016/S0960-9822(03)00008-3; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; Lehman DA, 1999, DEVELOPMENT, V126, P1793; Lenart P, 2003, J CELL BIOL, V160, P1055, DOI 10.1083/jcb.200211076; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Meyer CA, 2002, CURR BIOL, V12, P661, DOI 10.1016/S0960-9822(02)00770-4; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1991, COLD SPRING HARB SYM, V56, P399; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; ROBERTS JW, 1975, P NATL ACAD SCI USA, V72, P147, DOI 10.1073/pnas.72.1.147; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; SMITH LD, 1971, DEV BIOL, V25, P233; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998; Strausfeld UP, 1996, J CELL SCI, V109, P1555; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Surrey T, 2001, SCIENCE, V292, P1167, DOI 10.1126/science.1059758; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Terasaki M, 2003, MOL BIOL CELL, V14, P4685, DOI 10.1091/mbc.E03-04-0249; Terasaki M, 2001, MOL BIOL CELL, V12, P503, DOI 10.1091/mbc.12.2.503; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wilson E.B., 1906, CELL DEV INHERITANCE; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	113	850	877	1	125	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	2004	116	2					221	234		10.1016/S0092-8674(03)01080-8	http://dx.doi.org/10.1016/S0092-8674(03)01080-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744433	Bronze			2022-12-28	WOS:000188541700012
J	Halligan, SC; Gersh, BJ; Brown, RD; Rosales, AG; Munger, TM; Shen, WK; Hammill, SC; Friedman, PA				Halligan, SC; Gersh, BJ; Brown, RD; Rosales, AG; Munger, TM; Shen, WK; Hammill, SC; Friedman, PA			The natural history of lone atrial flutter	ANNALS OF INTERNAL MEDICINE			English	Article							FIBRILLATION	Background: The natural history of atrial flutter is not well defined. Objective: To report the risk for stroke, conversion to atrial fibrillation, and anticoagulation for lone atrial flutter. Design: Retrospective cohort analysis. Setting: A clinically based longitudinal study of inpatients and outpatients with atrial flutter. Patients: The authors compared the stroke rate in 59 patients with atrial flutter with rates in a sample in which age- and sex-specific ischemic cerebrovascular event rates were determined and in a sample of nonhypertensive patients with lone atrial fibrillation. The risk for developing atrial fibrillation after presenting with atrial flutter is also reported. Measurements: Electrocardiograms and clinical data were collected and reviewed for each study participant. Results: After adjustment for age and sex, patients with atrial flutter had a higher incidence of thromboembolic events than the sample control patients and patients with atrial fibrillation. Atrial fibrillation developed in 56% of patients with atrial flutter. Conclusions: Lone atrial flutter has a stroke risk at least as high as lone atrial fibrillation and carries a higher risk for subsequent development of atrial fibrillation than in the general population. Anticoagulation should be considered for all patients with atria[ flutter who are older than 65 years of age.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Friedman, PA (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Lavu, Madhav/A-9409-2013					[Anonymous], 2001, CIRCULATION, V104, P2118; BHANDARI AK, 1992, AM HEART J, V124, P381, DOI 10.1016/0002-8703(92)90601-Q; Biblo LA, 2001, AM J CARDIOL, V87, P346, DOI 10.1016/S0002-9149(00)01374-6; COSIO FG, 1993, AM J CARDIOL, V71, P705, DOI 10.1016/0002-9149(93)91014-9; Kopecky SL, 1999, ARCH INTERN MED, V159, P1118, DOI 10.1001/archinte.159.10.1118; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104	6	101	103	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					265	268		10.7326/0003-4819-140-4-200402170-00008	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970149				2022-12-28	WOS:000188970400004
J	Haig, E				Haig, E			A message from the gut	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Long Isl Internal Med Associates, Rockville Ctr, NY 11570 USA		Haig, E (corresponding author), Long Isl Internal Med Associates, Rockville Ctr, NY 11570 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					706	706		10.1056/NEJMicm030045	http://dx.doi.org/10.1056/NEJMicm030045			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960746				2022-12-28	WOS:000188869500011
J	Jablonski, D				Jablonski, D			Extinction: past and present	NATURE			English	Editorial Material							MASS EXTINCTIONS; LESSONS		Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Jablonski, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.							Erwin DH, 2001, P NATL ACAD SCI USA, V98, P5399, DOI 10.1073/pnas.091092698; Jablonski D, 2001, P NATL ACAD SCI USA, V98, P5393, DOI 10.1073/pnas.101092598; Purvis A, 2000, BIOESSAYS, V22, P1123, DOI 10.1002/1521-1878(200012)22:12<1123::AID-BIES10>3.0.CO;2-C	3	31	35	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 12	2004	427	6975					589	589		10.1038/427589a	http://dx.doi.org/10.1038/427589a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961099				2022-12-28	WOS:000188875300020
J	Petersen, KF; Dufour, S; Befroy, D; Garcia, R; Shulman, GI				Petersen, KF; Dufour, S; Befroy, D; Garcia, R; Shulman, GI			Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECEPTOR-GAMMA COACTIVATOR-1; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; FREE FATTY-ACIDS; TRIGLYCERIDE CONTENT; GLUCOSE-TOLERANCE; MUSCLE; OBESITY; SENSITIVITY; MECHANISM	Background: Insulin resistance appears to be the best predictor of the development of diabetes in the children of patients with type 2 diabetes, but the mechanism responsible is unknown. Methods: We performed hyperinsulinemic-euglycemic clamp studies in combination with infusions of [6,6-(sup 2)H(sub 2)]glucose in healthy, young, lean, insulin-resistant offspring of patients with type 2 diabetes and insulin-sensitive control subjects matched for age, height, weight, and physical activity to assess the sensitivity of liver and muscle to insulin. Proton ((sup 1)H) magnetic resonance spectroscopy studies were performed to measure intramyocellular lipid and intrahepatic triglyceride content. Rates of whole-body and subcutaneous fat lipolysis were assessed by measuring the rates of [(sup 2)H(sub 5)]glycerol turnover in combination with microdialysis measurements of glycerol release from subcutaneous fat. We performed (sup 31)P magnetic resonance spectroscopy studies to assess the rates of mitochondrial oxidative-phosphorylation activity in muscle. Results: The insulin-stimulated rate of glucose uptake by muscle was approximately 60 percent lower in the insulin-resistant subjects than in the insulin-sensitive control subjects (P<0.001) and was associated with an increase of approximately 80 percent in the intramyocellular lipid content (P=0.005). This increase in intramyocellular lipid content was most likely attributable to mitochondrial dysfunction, as reflected by a reduction of approximately 30 percent in mitochondrial phosphorylation (P=0.01 for the comparison with controls), since there were no significant differences in systemic or localized rates of lipolysis or plasma concentrations of tumor necrosis factor (alpha), interleukin-6, resistin, or adiponectin. Conclusions: These data support the hypothesis that insulin resistance in the skeletal muscle of insulin-resistant offspring of patients with type 2 diabetes is associated with dysregulation of intramyocellular fatty acid metabolism, possibly because of an inherited defect in mitochondrial oxidative phosphorylation.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Box 208020,300 Cedar St,S269 CAB, New Haven, CT 06510 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NCRR NIH HHS [M01 RR-00125, M01 RR000125] Funding Source: Medline; NIA NIH HHS [R01 AG023686-02, R01 AG023686-01A1, R01 AG-23686, R01 AG023686] Funding Source: Medline; NIDDK NIH HHS [R01 DK-49230, R01 DK049230, P30 DK045735, P30 DK-45735, K23 DK-02347, R01 DK-063192] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230, P30DK045735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023686] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DIAMOND MP, 1993, J REPROD MED, V38, P417; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Krssak M, 1999, DIABETOLOGIA, V42, P386; Lebon V, 2001, J CLIN INVEST, V108, P733, DOI 10.1172/JCI11775; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Luft R, 1993, Lakartidningen, V90, P2770; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; MEYER RA, 1985, AM J PHYSIOL, V248, pC279, DOI 10.1152/ajpcell.1985.248.3.C279; MILES J, 1983, J LIPID RES, V24, P96; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller YL, 2003, DIABETES, V52, P895, DOI 10.2337/diabetes.52.3.895; Nyholm B, 1997, DIABETES, V46, P1822, DOI 10.2337/diabetes.46.11.1822; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Perseghin G, 1997, DIABETES, V46, P1001, DOI 10.2337/diabetes.46.6.1001; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Petersen KF, 1998, DIABETES, V47, P381, DOI 10.2337/diabetes.47.3.381; Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014-2999(02)01430-9; VANDENBORNE K, 1995, AM J PHYSIOL-CELL PH, V268, pC869, DOI 10.1152/ajpcell.1995.268.4.C869; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	44	1362	1404	2	129	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					664	671		10.1056/NEJMoa031314	http://dx.doi.org/10.1056/NEJMoa031314			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960743	Green Accepted			2022-12-28	WOS:000188869500007
J	Winn, JN; Rusin, D; Kochanek, CS				Winn, JN; Rusin, D; Kochanek, CS			The central image of a gravitationally lensed quasar	NATURE			English	Article							MASS MODELS; QUINTUPLE QUASAR; RADIO; GALAXIES; CENTERS	A galaxy can act as a gravitational lens, producing multiple images of a background object. Theory predicts that there should be an odd number of images produced by the lens(1,2), but hitherto almost all lensed objects have two or four images. The missing 'central' images, which should be faint and appear near the centre of the lensing galaxy, have long been sought as probes of galactic cores too distant to resolve with ordinary observations(3-7). There are five candidates for central images, but in one case the third image is not necessarily the central one(8-10), and in the others the putative central images might be foreground sources(11-15). Here we report a secure identification of a central image, based on radio observations of one of the candidates(14). Lens models using the central image reveal that the massive black hole at the centre of the lensing galaxy has a mass of <2x10(8) solar masses (M-circle dot), and the galaxy's surface density at the location of the central image is >20,000 M-circle dot pc(-2); which is in agreement with expections based on observations of galaxies that are much closer to the Earth.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; Ohio State Univ, Dept Astron, Columbus, OH 43210 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Pennsylvania; University System of Ohio; Ohio State University	Winn, JN (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	jwinn@cfa.harvard.edu						Beckert T, 1996, ASTRON ASTROPHYS, V307, P450; BURKE WL, 1981, ASTROPHYS J, V244, pL1, DOI 10.1086/183466; CHEN GH, 1993, ASTRON J, V106, P1719, DOI 10.1086/116759; DYER CC, 1980, ASTROPHYS J, V238, pL67, DOI 10.1086/183260; Evans NW, 2002, ASTROPHYS J, V575, P68, DOI 10.1086/341214; Faber SM, 1997, ASTRON J, V114, P1771, DOI 10.1086/118606; Fassnacht CD, 1999, ASTRON J, V117, P658, DOI 10.1086/300724; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; GORENSTEIN MV, 1983, SCIENCE, V219, P54, DOI 10.1126/science.219.4580.54; Keeton CR, 2003, ASTROPHYS J, V590, P39, DOI 10.1086/374833; Lewis GF, 2002, MON NOT R ASTRON SOC, V334, pL7, DOI 10.1046/j.1365-8711.2002.05700.x; Lewis GF, 2002, MON NOT R ASTRON SOC, V330, pL15, DOI 10.1046/j.1365-8711.2002.05260.x; Mao S, 2001, MON NOT R ASTRON SOC, V323, P301, DOI 10.1046/j.1365-8711.2001.04143.x; MEZGER PG, 1967, ASTROPHYS J, V147, P471, DOI 10.1086/149030; Munoz JA, 2001, ASTROPHYS J, V558, P657, DOI 10.1086/322314; NARASIMHA D, 1986, NATURE, V321, P45, DOI 10.1038/321045a0; NARAYAN R, 1984, NATURE, V310, P112, DOI 10.1038/310112a0; Shepherd MC, 1997, ASTR SOC P, V125, P77; SUBRAMANIAN K, 1985, ASTROPHYS J, V289, P37, DOI 10.1086/162862; Taylor GB, 1996, ASTROPHYS J, V470, P394, DOI 10.1086/177874; Tremaine S, 2002, ASTROPHYS J, V574, P740, DOI 10.1086/341002; Walker RC, 2000, ASTROPHYS J, V530, P233, DOI 10.1086/308372; WALLINGTON S, 1993, ASTROPHYS J, V403, P517, DOI 10.1086/172222; Winn JN, 2003, ASTROPHYS J, V590, P26, DOI 10.1086/374832; Winn JN, 2003, ASTROPHYS J, V587, P80, DOI 10.1086/368150; Winn JN, 2002, ASTRON J, V123, P10, DOI 10.1086/338094	29	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					613	615		10.1038/nature02279	http://dx.doi.org/10.1038/nature02279			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961114	Green Submitted			2022-12-28	WOS:000188875300034
J	Gouin, E; Egile, C; Dehoux, P; Villiers, V; Adams, J; Gertler, F; Li, R; Cossart, P				Gouin, E; Egile, C; Dehoux, P; Villiers, V; Adams, J; Gertler, F; Li, R; Cossart, P			The RickA protein of Rickettsia conorii activates the Arp2/3 complex	NATURE			English	Article							MONOCYTOGENES ACTA PROTEIN; LISTERIA-MONOCYTOGENES; FIBROBLAST MOTILITY; WASP/SCAR PROTEINS; ENA/VASP PROTEINS; POLYMERIZATION; WASP; NUCLEATION; CORTACTIN; FILAMENTS	Actin polymerization, the main driving force for cell locomotion, is also used by the bacteria Listeria and Shigella and vaccinia virus for intracellular and intercellular movements(1,2). Seminal studies have shown the key function of the Arp2/3 complex in nucleating actin and generating a branched array of actin filaments during membrane extension and pathogen movement(3). Arp2/3 requires activation by proteins such as the WASP-family proteins or ActA of Listeria. We previously reported that actin tails of Rickettsia conorii, another intracellular bacterium, unlike those of Listeria, Shigella or vaccinia, are made of long unbranched actin filaments apparently devoid of Arp2/3 (ref. 4). Here we identify a R. conorii surface protein, RickA, that activates Arp2/3 in vitro, although less efficiently than ActA. In infected cells, Arp2/3 is detected on the rickettsial surface but not in actin tails. When expressed in mammalian cells and targeted to the membrane, RickA induces filopodia. Thus RickA-induced actin polymerization, by generating long actin filaments reminiscent of those present in filopodia, has potential as a tool for studying filopodia formation.	Inst Pasteur, Unite Interact Bacteries Cellules, F-75015 Paris, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Harvard University; Harvard Medical School; Cleveland Clinic Foundation; Massachusetts Institute of Technology (MIT)	Cossart, P (corresponding author), Inst Pasteur, Unite Interact Bacteries Cellules, 28 Rue Docteur Roux, F-75015 Paris, France.	pcossart@pasteur.fr	Adams, Josephine C/B-1121-2009	Adams, Josephine C/0000-0002-2225-4947				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; David V, 1998, J CELL SCI, V111, P2877; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Gouin E, 1999, J CELL SCI, V112, P1697; Hackstadt T, 1996, INFECT AGENT DIS, V5, P127; Kureishy N, 2002, BIOESSAYS, V24, P350, DOI 10.1002/bies.10070; Lamarche N, 1996, BIOCHEM J, V320, P129, DOI 10.1042/bj3200129; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Ogata H, 2001, SCIENCE, V293, P2093, DOI 10.1126/science.1061471; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Skoble J, 2001, J CELL BIOL, V155, P89, DOI 10.1083/jcb.200106061; TEYSSEIRE N, 1992, RES MICROBIOL, V143, P821, DOI 10.1016/0923-2508(92)90069-Z; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Van Kirk LS, 2000, INFECT IMMUN, V68, P4706, DOI 10.1128/IAI.68.8.4706-4713.2000; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; Vignjevic D, 2003, J CELL BIOL, V160, P951, DOI 10.1083/jcb.200208059; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8	29	195	201	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					457	461		10.1038/nature02318	http://dx.doi.org/10.1038/nature02318			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749835				2022-12-28	WOS:000188470500047
J	Mennink-Kersten, MASH; Klont, RR; Warris, A; Op den Camp, HJM; Verweij, PE				Mennink-Kersten, MASH; Klont, RR; Warris, A; Op den Camp, HJM; Verweij, PE			Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection	LANCET			English	Article							LINKED-IMMUNOSORBENT-ASSAY; INVASIVE ASPERGILLOSIS; CIRCULATING GALACTOMANNAN; PLATELIA(R) ASPERGILLUS; EARLY-DIAGNOSIS; INFANTS	A major difficulty with the detection of circulating galactomannan, a cell-wall polysaccharide released by Aspergillus sp during growth, in the serodiagnosis of invasive aspergillosis is the occurrence of false-positive ELISA results, especially in neonates and infants. On the basis of molecule similarity, we postulate that a lipotelchoic acid of Bifidobacterium sp can act as epitope for the monoclonal antibody used in the ELISA. The neonatal gut is heavily colonised with Bifidobacterium sp and these bacteria or their lipoteichoic acid might cause ELISA reactivity with serum after translocation because of immaturity of the intestinal mucosa. If our hypothesis is correct, we might find a method to discriminate between false-positive and true-positive ELISA results and thereby prevent unnecessary pre-emptive treatment of patients.	Univ Med Ctr Nijmegen, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Paediat, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands; Univ Nijmegen, Dept Microbiol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Mennink-Kersten, MASH (corresponding author), Univ Med Ctr Nijmegen, Dept Med Microbiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Warris, A./L-4745-2015; Warris, Adilia/F-4882-2010; Camp, Huub J.M. Op den/F-5114-2011; Verweij, P.E./H-8108-2014	Camp, Huub J.M. Op den/0000-0003-1990-9030; Verweij, P.E./0000-0002-8600-9860; Warris, Adilia/0000-0001-6586-3358				Ansorg R, 1997, MYCOSES, V40, P353, DOI 10.1111/j.1439-0507.1997.tb00249.x; Denning DW, 2000, LANCET, V355, P423, DOI 10.1016/S0140-6736(00)82003-6; Duffy LC, 2000, J NUTR, V130, p432S, DOI 10.1093/jn/130.2.432S; FISCHER W, 1987, EUR J BIOCHEM, V165, P639, DOI 10.1111/j.1432-1033.1987.tb11488.x; HUSBY S, 1985, SCAND J IMMUNOL, V22, P83, DOI 10.1111/j.1365-3083.1985.tb01862.x; IWASAKI H, 1990, J BACTERIOL, V172, P845, DOI 10.1128/jb.172.2.845-852.1990; LATGE JP, 1994, INFECT IMMUN, V62, P5424; Letscher-Bru V, 1998, J MYCOL MED, V8, P112; Locascio M, 2001, CAN J MICROBIOL, V47, P1048, DOI 10.1139/cjm-47-11-1048; Maertens J, 2002, J INFECT DIS, V186, P1297, DOI 10.1086/343804; Maertens J, 2001, BLOOD, V97, P1604, DOI 10.1182/blood.V97.6.1604; Naaber P, 2000, J MED MICROBIOL, V49, P431, DOI 10.1099/0022-1317-49-5-431; Requena T, 2002, APPL ENVIRON MICROB, V68, P2420, DOI 10.1128/AEM.68.5.2420-2427.2002; Rohrlich P, 1996, PEDIATR INFECT DIS J, V15, P232, DOI 10.1097/00006454-199603000-00011; Siemann M, 1998, MYCOSES, V41, P373, DOI 10.1111/j.1439-0507.1998.tb00356.x; STYNEN D, 1995, J CLIN MICROBIOL, V33, P497, DOI 10.1128/JCM.33.2.497-500.1995; STYNEN D, 1992, INFECT IMMUN, V60, P2237, DOI 10.1128/IAI.60.6.2237-2245.1992; Sulahian A, 2001, CANCER-AM CANCER SOC, V91, P311, DOI 10.1002/1097-0142(20010115)91:2<311::AID-CNCR1003>3.0.CO;2-3; Swanink CMA, 1997, J CLIN MICROBIOL, V35, P257, DOI 10.1128/JCM.35.1.257-260.1997; WARRIS A, 2001, 41 INT C ANT AG CHEM, P387	20	87	101	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					325	327		10.1016/S0140-6736(03)15393-7	http://dx.doi.org/10.1016/S0140-6736(03)15393-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751710				2022-12-28	WOS:000188361400028
J	Mallon, WT; Korn, D				Mallon, WT; Korn, D			Education - Bonus pay for research faculty	SCIENCE			English	Editorial Material							ACADEMIC MEDICAL-CENTERS		Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Mallon, WT (corresponding author), Assoc Amer Med Coll, Washington, DC 20037 USA.	wmallon@aamc.org		Mallon, William/0000-0003-0100-5893				AAUP, 1915, AAUP BULL, V1, P17; Bok D, 2003, U MARKETPLACE; *DEP HLTH HUM SERV, 2003, WORK PLAN FISC YEAR; Flannery T. P., 1996, PEOPLE PERFORMANCE P; Kennedy D, 1997, ACAD DUTY; KENNEDY RJ, 2003, MED RES LAW POLICY R, V2, P155; Korn D, 1996, ACAD MED, V71, P1033, DOI 10.1097/00001888-199610000-00008; Korn D, 1998, J SOC GYNECOL INVEST, V5, P227, DOI 10.1016/S1071-5576(98)00029-X; MANGAN K, 2003, CHRON HIGH ED, V50, pA18; ROBINSON L, 2003, AAMC DATA BOOK	10	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					476	477		10.1126/science.1094859	http://dx.doi.org/10.1126/science.1094859			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739444				2022-12-28	WOS:000188316400022
J	Hall, IP				Hall, IP			The beta-agonist controversy revisited	LANCET			English	Editorial Material							ASTHMA; RECEPTORS		Univ Nottingham Hosp, Queens Med Ctr, Div Therapeut & Mol Med, Nottingham NG7 2UH, England	University of Nottingham	Hall, IP (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Div Therapeut & Mol Med, Nottingham NG7 2UH, England.	ian.hall@nottingham.ac.uk		Hall, Ian/0000-0001-9933-3216				Beasley R, 1999, J ALLERGY CLIN IMMUN, V104, pS18, DOI 10.1016/S0091-6749(99)70270-8; Fenech A, 2002, BRIT J CLIN PHARMACO, V53, P3, DOI 10.1046/j.0306-5251.2001.01509.x; McGraw DW, 1999, J BIOL CHEM, V274, P32241, DOI 10.1074/jbc.274.45.32241; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; VATHENEN AS, 1998, LANCET, V351, P554	7	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					183	184		10.1016/S0140-6736(03)15369-X	http://dx.doi.org/10.1016/S0140-6736(03)15369-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738788				2022-12-28	WOS:000188243900005
J	Solforosi, L; Criado, JR; McGavern, DB; Wirz, S; Sanchez-Alavez, M; Sugama, S; DeGiorgio, LA; Volpe, BT; Wiseman, E; Abalos, G; Masliah, E; Gilden, D; Oldstone, MB; Conti, B; Williamson, RA				Solforosi, L; Criado, JR; McGavern, DB; Wirz, S; Sanchez-Alavez, M; Sugama, S; DeGiorgio, LA; Volpe, BT; Wiseman, E; Abalos, G; Masliah, E; Gilden, D; Oldstone, MB; Conti, B; Williamson, RA			Cross-linking cellular prion protein triggers neuronal apoptosis in vivo	SCIENCE			English	Article							DISEASE; ANTIBODIES; EXPRESSION	Neuronal death is a prominent, but poorly understood, pathological hallmark of prion disease. Notably, in the absence of the cellular prion protein (PrPC), the disease-associated isoform, PrPSc, appears not to be intrinsically neurotoxic, suggesting that PrPC itself may participate directly in the prion neurodegenerative cascade. Here, cross-linking PrPC in vivo with specific monoclonal antibodies was found to trigger rapid and extensive apoptosis in hippocampal and cerebellar neurons. These findings suggest that PrPC functions in the control of neuronal survival and provides a model to explore whether cross-linking of PrPC by oligomeric PrPSc can promote neuronal loss during prion infection.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Scripps Res Inst, Harold Dorris Neurol Res Ctr, La Jolla, CA 92037 USA; Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY 10605 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92037 USA; Univ Colorado, Dept Neurol, Denver, CO 80262 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Cornell University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Colorado System; University of Colorado Denver	Williamson, RA (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	anthony@scripps.edu	volpe, b/U-8409-2019; McGavern, Dorian/HCH-3601-2022	McGavern, Dorian/0000-0001-9568-545X; Volpe, Bruce/0000-0002-1098-1848; Conti, Bruno/0000-0002-9185-5201; Sanchez-Alavez, Manuel/0000-0002-8164-8452	NHLBI NIH HHS [HL63817] Funding Source: Medline; NIAID NIH HHS [AI09484] Funding Source: Medline; NIA NIH HHS [AG04342, AG00080] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BURTON DR, 1987, MOL GENETICS IMMUNOG; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Farkas I, 2003, J IMMUNOL, V170, P5764, DOI 10.4049/jimmunol.170.11.5764; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Yu JX, 2002, J NEUROIMMUNOL, V123, P91, DOI 10.1016/S0165-5728(01)00483-0	14	285	301	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1514	1516		10.1126/science.1094273	http://dx.doi.org/10.1126/science.1094273			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	14752167				2022-12-28	WOS:000220000100041
J	Wertz, IE; O'Rourke, KM; Zhang, ZM; Dornan, D; Arnott, D; Deshaies, RJ; Dixit, VM				Wertz, IE; O'Rourke, KM; Zhang, ZM; Dornan, D; Arnott, D; Deshaies, RJ; Dixit, VM			Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase	SCIENCE			English	Article							COP9 SIGNALOSOME; GENE-EXPRESSION; ARABIDOPSIS; PHOTOMORPHOGENESIS; DEGRADATION; PROTEIN-1; INTERACTS; MOTIF; SCF	Arabidopsis thaliana De-etiolated-1 (AtDET1) is a highly conserved protein, with orthologs in vertebrate and invertebrate organisms. AtDET1 negatively regulates photomorphogenesis, but its biochemical mechanism and function in other species are unknown. We report that human DET1 (hDET1) promotes ubiquitination and degradation of the proto-oncogenic transcription factor c-Jun by assembling a multisubunit ubiquitin ligase containing DNA Damage Binding Protein-1 (DDB1), cullin 4A (CUL4A), Regulator of Cullins-1 (ROC1), and constitutively photomorphogenic-1. Ablation of any subunit by RNA interference stabilized c-Jun and increased c-Jun-activated transcription. These findings characterize a c-Jun ubiquitin ligase and define a specific function for hDET1 in mammalian cells.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California Davis; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012; Deshaies, Raymond/B-8354-2014	dixit, vishva m/0000-0001-6983-0326; Deshaies, Raymond/0000-0002-3671-9354	NIGMS NIH HHS [GM065997] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065997] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Holm M, 2001, EMBO J, V20, P118, DOI 10.1093/emboj/20.1.118; Holm M, 2002, GENE DEV, V16, P1247, DOI 10.1101/gad.969702; Hu JP, 2002, SCIENCE, V297, P405, DOI 10.1126/science.1073633; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; Schroeder DF, 2002, CURR BIOL, V12, P1462, DOI 10.1016/S0960-9822(02)01106-5; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Torii KU, 1999, J BIOL CHEM, V274, P27674, DOI 10.1074/jbc.274.39.27674; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yi CL, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-30	25	292	304	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1371	1374		10.1126/science.1093549	http://dx.doi.org/10.1126/science.1093549			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14739464				2022-12-28	WOS:000189238600052
J	Kotchen, TA; Lindquist, T; Malik, K; Ehrenfeld, E				Kotchen, TA; Lindquist, T; Malik, K; Ehrenfeld, E			NIH peer review of grant applications for clinical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INSTITUTES-OF-HEALTH; PHYSICIAN-SCIENTISTS; CHALLENGES; INVESTIGATORS; CRISIS	Context Support of research to facilitate translation of scientific discoveries to the prevention and treatment of human disease is a high priority for the US National Institutes of Health (NIH). Nevertheless, a perception exists among clinical investigators that the NIH peer review process may discriminate against clinical research. Objective To describe recent trends and outcomes of peer review of grant applications to NIH requesting support for clinical research. Design and Setting Peer review outcomes of grant applications submitted to NIH by MDs were compared with those of non-MDs, and outcomes of applications involving inclusion of human subjects were compared with those not involving human subjects. Analyses were carried out using an inclusive definition of clinical research and after stratifying clinical research into specific categories. Main Outcome Measures Median priority scores and funding rates. Results Between 1997 and 2002, on average, 25.2% of total grant applications (ranging from 27 607 to 34 422 per year) were submitted by MDs, and 27.5% of awards (ranging from 8495 to 10769 awards per year) were made to MDs. Median priority scores (239.0 vs 250.0) and funding rates (31.4% vs 29.1%) reviewed in 2 grant cycles in 2002 were more favorable for MDs than for non-MDs (P<.001). However, median priority scores (254.0 vs 244.0) and funding rates (23.9% vs 28.1%) were less favorable (P<.001) for R01 applications for clinical research (n=7227 applications) than for nonclinical research (n=10209). This trend was most convincingly observed for clinical research categorized as mechanisms of disease (P=.006) or clinical trials and interventions (P=.001). Similar trends were observed for grant mechanisms other than R01. Concerns about safety and privacy of human subjects may have contributed to the less favorable outcomes of clinical research applications. Conclusion Although physicians compete favorably in the peer review process, review outcomes are modestly less favorable for grant applications for clinical research than for laboratory research.	NIH, Ctr Sci Review, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Kotchen, TA (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	tkotchen@mcw.edu						*ASS AM MED COLL, 2003, AAMC DAT BOOK STAT I; *ASS AM MED COLL A, 1990, BREAK SCI BOTT REP G; Campbell EG, 2001, JAMA-J AM MED ASSOC, V286, P800, DOI 10.1001/jama.286.7.800; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; HEALY B, 1988, NEW ENGL J MED, V319, P1058, DOI 10.1056/NEJM198810203191605; LANDIS JR, 1977, BIOMETRICS, V33, P150; Ley TJ, 2002, NEW ENGL J MED, V346, P368, DOI 10.1056/NEJM200201313460515; Miller ED, 2001, JAMA-J AM MED ASSOC, V286, P845, DOI 10.1001/jama.286.7.845; Nathan DG, 2000, NAT MED, V6, P1201, DOI 10.1038/81282; Nathan DG, 2002, NEW ENGL J MED, V346, P372, DOI 10.1056/NEJM200201313460516; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; Nathan DG, 2003, NEW ENGL J MED, V349, P1860, DOI 10.1056/NEJMsb035066; Nathan DG, 2002, JAMA-J AM MED ASSOC, V287, P2424, DOI 10.1001/jama.287.18.2424; Neilson EG, 2003, J CLIN INVEST, V111, P765, DOI 10.1172/JCI200318116; Rosenberg LE, 1999, J CLIN INVEST, V103, P1621, DOI 10.1172/JCI7304; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Shine KI, 1998, JAMA-J AM MED ASSOC, V280, P1442, DOI 10.1001/jama.280.16.1442; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Taylor AE, 2002, ACAD MED, V77, P824, DOI 10.1097/00001888-200208000-00015; Williams GH, 1997, JAMA-J AM MED ASSOC, V278, P227, DOI 10.1001/jama.278.3.227; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; Zemlo TR, 2000, FASEB J, V14, P221, DOI 10.1096/fasebj.14.2.221; Zheng Y, 2001, ACAD CHIN, P30; [No title captured]; [No title captured]	28	82	83	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					836	843		10.1001/jama.291.7.836	http://dx.doi.org/10.1001/jama.291.7.836			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970062	Bronze			2022-12-28	WOS:000189000400021
J	Jiang, R; Manson, JE; Meigs, JB; Ma, J; Rifai, N; Hu, FB				Jiang, R; Manson, JE; Meigs, JB; Ma, J; Rifai, N; Hu, FB			Body iron stores in relation to risk of type 2 diabetes in apparently healthy women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM FERRITIN; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; MELLITUS; HYPERINSULINEMIA; REPRODUCIBILITY; VALIDITY	Context Type 2 diabetes is a common manifestation of hemochromatosis, a disease of iron overload. However, it is not clear whether higher iron stores predict the development of type 2 diabetes in a healthy population. Objective To examine plasma ferritin concentration and the ratio of the concentrations of transferrin receptors to ferritin in relation to risk of type 2 diabetes. Design, Setting, and Participants Prospective nested case-control study within the Nurses' Health Study cohort. Of the 32826 women who provided blood samples during 1989-1990 and were free of diagnosed diabetes, cardiovascular disease, and cancer, 698 developed diabetes during 10 years of follow-up. The controls (n=716) were matched to cases on age, race, and fasting status; and on body mass index (BMI) for cases in the top BMI decile. Main Outcome Measure Incident cases of type 2 diabetes. Results Among cases, the mean (SD) concentration of ferritin was significantly higher (109 [1051 vs 71.5 [68.7] ng/mL for controls; P<.001 for difference) and the mean (SD) ratio of transferrin receptors to ferritin was significantly lower (102 [205] vs 141 [340], respectively; P=.01). In conditional logistic regression stratified on the matching factors and controlled for BMI and other diabetes risk factors, the multivariate relative risks [RRs] of incident type 2 diabetes across increasing quintiles of ferritin were 1.00, 1.09 (95% confidence interval [CI], 0.70-1.70),1.26 (95% Cl, 0.82-1.95),1.30 (95% Cl, 0.83-2.04), and 2.68 (95% Cl, 1.75-4.11) (P<.001 for trend). The RRs across increasing quintiles of transferrin receptors to ferritin ratio were 2.44 (95% Cl, 1.61-3.71), 1.00 (95% Cl, 0.64-1.56),1.13 (95% Cl, 0.73-1.74), 0.99 (95% Cl, 0.64-1.53), and 1.00 (P=.01 for trend). Further adjustment for an inflammatory marker (C-reactive protein) did not change the results appreciably. The associations persisted within strata defined by levels of BMI, menopausal status, alcohol consumption, and C-reactive protein. Conclusion Higher iron stores (reflected by an elevated ferritin concentration and a lower ratio of transferrin receptors to ferritin) are associated with an increased risk of type 2 diabetes in healthy women independent of known diabetes risk factors.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Prevent Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; Channing Labs, Boston, MA USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Childrens Hosp, Med Ctr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Jiang, R (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	rjiang@hsph.harvard.edu	Hu, Frank/C-1919-2013; Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657	NCI NIH HHS [CA78293, CA87969] Funding Source: Medline; NIDDK NIH HHS [DK58845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969, R29CA078293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Beard JL, 2001, J NUTR, V131, p568S, DOI 10.1093/jn/131.2.568S; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; CUTLER P, 1989, DIABETES, V38, P1207, DOI 10.2337/diabetes.38.10.1207; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62; Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS M, 1979, DIABETES, V28, P1039; Hernandez C, 2000, MED CLIN-BARCELONA, V115, P21, DOI 10.1016/S0025-7753(00)71450-3; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hughes K, 1998, ATHEROSCLEROSIS, V136, P25, DOI 10.1016/S0021-9150(97)00180-9; KAYE TB, 1993, J DIABETES COMPLICAT, V7, P246, DOI 10.1016/0891-6632(93)90008-5; Kim NH, 2000, YONSEI MED J, V41, P387, DOI 10.3349/ymj.2000.41.3.387; KNULMAN MW, 2003, AM J EPIDEMIOL, V158, P144; Ma J, 2002, CLIN CHEM, V48, P601; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; McCord JM, 1996, NUTR REV, V54, P85, DOI 10.1111/j.1753-4887.1996.tb03876.x; MERKEL PA, 1988, NEW ENGL J MED, V318, P809, DOI 10.1056/NEJM198803313181303; NIEDERAU C, 1984, DIABETOLOGIA, V26, P441; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; Salonen JT, 1998, BRIT MED J, V317, P727, DOI 10.1136/bmj.317.7160.727; Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLETT WC, 1998, MODERN EPIDEMIOLOGY, P623; Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; WOLFF SP, 1993, BRIT MED BULL, V49, P642, DOI 10.1093/oxfordjournals.bmb.a072637	31	424	444	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					711	717		10.1001/jama.291.6.711	http://dx.doi.org/10.1001/jama.291.6.711			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871914				2022-12-28	WOS:000188819200024
J	Hillmen, P; Hall, C; Marsh, JCW; Elebute, M; Bombara, MP; Petro, BE; Cullen, MJ; Richards, SJ; Rollins, SA; Mojcik, CF; Rother, RP				Hillmen, P; Hall, C; Marsh, JCW; Elebute, M; Bombara, MP; Petro, BE; Cullen, MJ; Richards, SJ; Rollins, SA; Mojcik, CF; Rother, RP			Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DECAY-ACCELERATING FACTOR; PIG-A GENE; MEMBRANE-PROTEIN; INAB PHENOTYPE; COMPLEMENT; DEFICIENCY; ERYTHROCYTES; SAFETY; ACTIVATION; ANTIBODIES	Background: Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement system. We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH. Methods: Eleven transfusion-dependent patients with PNH received infusions of eculizumab (600 mg) every week for four weeks, followed one week later by a 900-mg dose and then by 900 mg every other week through week 12. Clinical and biochemical indicators of hemolysis were measured throughout the trial. Results: Mean lactate dehydrogenase levels decreased from 3111 IU per liter before treatment to 594 IU per liter during treatment (P=0.002). The mean percentage of PNH type III erythrocytes increased from 36.7 percent of the total erythrocyte population to 59.2 percent (P=0.005). The mean and median transfusion rates decreased from 2.1 and 1.8 units per patient per month to 0.6 and 0.0 units per patient per month, respectively (P=0.003 for the comparison of the median rates). Episodes of hemoglobinuria were reduced by 96 percent (P<0.001), and measurements of the quality of life improved significantly. Conclusions: Eculizumab is safe and well tolerated in patients with PNH. This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.	Leeds Teaching Hosp Natl Hlth Sci Trust, Dept Haematol, Leeds, W Yorkshire, England; St George Hosp, Sch Med, Dept Haematol, London, England; Alexion Pharmaceut, Cheshire, CT USA	St Georges University London	Hillmen, P (corresponding author), Leeds Gen Infirm, Dept Haematol, Great George St, Leeds LS1 3EX, W Yorkshire, England.	peter.hillmen@panp-tr.northy.nhs.uk	Bidyuk, Petro/S-1161-2016	Richards, Stephen/0000-0002-8421-5353				BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; Colnot DR, 2003, CANCER IMMUNOL IMMUN, V52, P576, DOI 10.1007/s00262-003-0396-5; Corbin JD, 2002, UROLOGY, V60, P4, DOI 10.1016/S0090-4295(02)01686-2; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HOLGUIN MH, 1992, J IMMUNOL, V148, P498; MATIS LA, 1995, NAT MED, V1, P839, DOI 10.1038/nm0895-839; MERRY AH, 1989, BRIT J HAEMATOL, V73, P248, DOI 10.1111/j.1365-2141.1989.tb00260.x; MORGAN BP, 1992, BIOCHEM J, V282, P409, DOI 10.1042/bj2820409; MOTOYAMA N, 1992, EUR J IMMUNOL, V22, P2669, DOI 10.1002/eji.1830221029; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; OKADA N, 1990, CLIN EXP IMMUNOL, V80, P109; Przybelski RJ, 1996, CRIT CARE MED, V24, P1993, DOI 10.1097/00003246-199612000-00011; RICHARDS SJ, 2001, CLIN APPL IMMUNOL RE, V1, P315; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROSSE WF, 2000, HEMATOLOGY BASIC PRI, P331; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TELEN MJ, 1989, BLOOD, V74, P437; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707; YONEMURA Y, 1990, BRIT J HAEMATOL, V74, P108, DOI 10.1111/j.1365-2141.1990.tb02546.x	25	422	527	0	24	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					552	559		10.1056/NEJMoa031688	http://dx.doi.org/10.1056/NEJMoa031688			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762182				2022-12-28	WOS:000188712800006
J	Lundgren, JD; Phillips, AN				Lundgren, JD; Phillips, AN			Commentary: Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs	BRITISH MEDICAL JOURNAL			English	Editorial Material							COMBINATION THERAPY; INFECTION; REGIMENS; EFFICACY; TRIALS		Hvidovre Univ Hosp, Copenhagen HIV Programme, Sect 044, DK-2650 Hvidovre, Denmark; UCL Royal Free & Univ Coll, Royal Free Ctr HIV Med, Sch Med, London NW3 2PF, England; UCL Royal Free & Univ Coll, Dept Primary Care & Populat Sci, Sch Med, London NW3 2PF, England	University of Copenhagen; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Lundgren, JD (corresponding author), Hvidovre Univ Hosp, Copenhagen HIV Programme, Sect 044, DK-2650 Hvidovre, Denmark.	jdl@cphiv.dk	Lundgren, Jens/AAE-6876-2019; Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807; Lundgren, Jens/0000-0001-8901-7850				Kirk O, 2002, ANTIVIR THER, V7, P271; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6	5	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					253	253		10.1136/bmj.328.7434.253	http://dx.doi.org/10.1136/bmj.328.7434.253			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14751897	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188786000015
J	Ozanne, SE; Hales, CN				Ozanne, SE; Hales, CN			Lifespan - Catch-up growth and obesity in male mice	NATURE			English	Editorial Material							LONGEVITY; RATS		Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2QR, England	University of Cambridge	Ozanne, SE (corresponding author), Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2QR, England.	seo10@cam.ac.uk		Ozanne, Susan/0000-0001-8753-5144				Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Johnson PR, 1997, AM J CLIN NUTR, V66, P890, DOI 10.1093/ajcn/66.4.890; Petry CJ, 1997, CLIN SCI, V93, P147, DOI 10.1042/cs0930147; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682	6	427	432	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					411	412		10.1038/427411b	http://dx.doi.org/10.1038/427411b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749819				2022-12-28	WOS:000188470500031
J	Chinnery, PF; Cartlidge, NEF; Tennant, S; Birchall, D; Stenhouse, SAR				Chinnery, PF; Cartlidge, NEF; Tennant, S; Birchall, D; Stenhouse, SAR			Genetics in reverse	LANCET			English	Editorial Material							X PREMUTATION CARRIERS; FRAGILE-X		Univ Newcastle Upon Tyne, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Gen Hosp, Reg Neurosci Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle General Hospital	Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	P.F.Chinnery@ncl.ac.uk		Chinnery, Patrick/0000-0002-7065-6617				Brunberg JA, 2002, AM J NEURORADIOL, V23, P1757; Hagerman RJ, 2001, NEUROLOGY, V57, P127, DOI 10.1212/WNL.57.1.127; Jacquemont S, 2003, AM J HUM GENET, V72, P869, DOI 10.1086/374321; Murray A, 1996, HUM MOL GENET, V5, P727, DOI 10.1093/hmg/5.6.727; Steyaert J, 2003, AM J MED GENET A, V116A, P44, DOI 10.1002/ajmg.a.10821	5	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					290	290		10.1016/S0140-6736(03)15387-1	http://dx.doi.org/10.1016/S0140-6736(03)15387-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751702				2022-12-28	WOS:000188361400011
J	Ahn, CH; Rabe, KM; Triscone, JM				Ahn, CH; Rabe, KM; Triscone, JM			Ferroelectricity at the nanoscale: Local polarization in oxide thin films and heterostructures	SCIENCE			English	Review							EPITAXIAL BATIO3/SRTIO3 SUPERLATTICES; PHASE-TRANSITIONS; FORCE MICROSCOPY; ULTRATHIN FILMS; DATA-STORAGE; FIELD; 1ST-PRINCIPLES; SI; DYNAMICS; PBTIO3	Ferroelectric oxide materials have offered a tantalizing potential for applications since the discovery of ferroelectric perovskites more than 50 years ago. Their switchable electric polarization is ideal for use in devices for memory storage and integrated microelectronics, but progress has long been hampered by difficulties in materials processing. Recent breakthroughs in the synthesis of complex oxides have brought the field to an entirely new level, in which complex artificial oxide structures can be realized with an atomic-level precision comparable to that well known for semiconductor heterostructures. Not only can the necessary high-quality ferroelectric films now be grown for new device capabilities, but ferroelectrics can be combined with other functional oxides, such as high-temperature superconductors and magnetic oxides, to create multifunctional materials and devices. Moreover, the shrinking of the relevant lengths to the nanoscale produces new physical phenomena. Real-space characterization and manipulation of the structure and properties at atomic scales involves new kinds of local probes and a key role for first-principles theory.	Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA; Yale Univ, Dept Phys, New Haven, CT 06520 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Univ Geneva, Dept Condensed Matter Phys, CH-1211 Geneva 4, Switzerland	Yale University; Yale University; Rutgers State University New Brunswick; University of Geneva	Ahn, CH (corresponding author), Yale Univ, Dept Appl Phys, POB 208284, New Haven, CT 06520 USA.	charles.ahn@yale.edu; rabe@physics.rutgers.edu; jean-marc.triscon@physics.unige.ch						Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152; Ahn CH, 2003, NATURE, V424, P1015, DOI 10.1038/nature01878; Ahn CH, 1997, SCIENCE, V276, P1100, DOI 10.1126/science.276.5315.1100; Auciello O, 1998, PHYS TODAY, V51, P22, DOI 10.1063/1.882324; Bune AV, 1998, NATURE, V391, P874, DOI 10.1038/36069; Cho YS, 2002, APPL PHYS LETT, V81, P4401, DOI 10.1063/1.1526916; Christen HM, 1998, MAT SCI ENG B-SOLID, V56, P200, DOI 10.1016/S0921-5107(98)00237-2; COHEN RE, 1992, NATURE, V358, P136, DOI 10.1038/358136a0; Dawber M, 2003, J PHYS-CONDENS MAT, V15, pL393, DOI 10.1088/0953-8984/15/24/106; Eisenbeiser K, 2000, APPL PHYS LETT, V76, P1324, DOI 10.1063/1.126023; Eng LM, 1996, J VAC SCI TECHNOL B, V14, P1191, DOI 10.1116/1.588512; EOM CB, 1993, APPL PHYS LETT, V63, P2570, DOI 10.1063/1.110436; Ghosez P, 2000, APPL PHYS LETT, V76, P2767, DOI 10.1063/1.126469; Ghosez P, 1999, PHYS REV B, V60, P836, DOI 10.1103/PhysRevB.60.836; Grinberg I, 2002, NATURE, V419, P909, DOI 10.1038/nature01115; Gruverman A, 1997, APPL PHYS LETT, V71, P3492, DOI 10.1063/1.120369; GUTAKOVSKII AK, 1995, PHYS STATUS SOLIDI A, V150, P127, DOI 10.1002/pssa.2211500111; Hidaka T, 1996, APPL PHYS LETT, V68, P2358, DOI 10.1063/1.115857; Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]; Hong X, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.134415; Ishikawa K, 1996, JPN J APPL PHYS 1, V35, P5196, DOI 10.1143/JJAP.35.5196; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; KAWASAKI M, 1994, SCIENCE, V266, P1540, DOI 10.1126/science.266.5190.1540; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; KINGSMITH RD, 1994, PHYS REV B, V49, P5828, DOI 10.1103/PhysRevB.49.5828; Koster G, 1998, APPL PHYS LETT, V73, P2920, DOI 10.1063/1.122630; KUMAR A, IN PRESS FERROELECTR; Le Marrec F, 2000, PHYS REV B, V61, pR6447, DOI 10.1103/PhysRevB.61.R6447; Li SP, 1997, PHILOS MAG B, V76, P47, DOI 10.1080/01418639708241077; Lin A, 2001, APPL PHYS LETT, V78, P2034, DOI 10.1063/1.1358848; Lines M.E., 2001, PRINCIPLES APPL FERR; McKee RA, 1998, PHYS REV LETT, V81, P3014, DOI 10.1103/PhysRevLett.81.3014; MERZ WJ, 1954, PHYS REV, V95, P690, DOI 10.1103/PhysRev.95.690; Meyer B, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.104111; Meyer B, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.205426; Munkholm A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.016101; Nagarajan V, 2002, APPL PHYS LETT, V81, P4215, DOI 10.1063/1.1516857; Neaton JB, 2003, APPL PHYS LETT, V82, P1586, DOI 10.1063/1.1559651; Ogawa Y, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.217403; Ohtomo A, 2002, NATURE, V419, P378, DOI 10.1038/nature00977; Pertsev NA, 1998, PHYS REV LETT, V80, P1988, DOI 10.1103/PhysRevLett.80.1988; Pertsev NA, 1998, PHYS SOLID STATE+, V40, P2002, DOI 10.1134/1.1130703; RESTA R, 1994, REV MOD PHYS, V66, P899, DOI 10.1103/RevModPhys.66.899; Sai N, 2000, PHYS REV LETT, V84, P5636, DOI 10.1103/PhysRevLett.84.5636; SAURENBACH F, 1990, APPL PHYS LETT, V56, P1703, DOI 10.1063/1.103122; Schlom DG, 2001, MAT SCI ENG B-SOLID, V87, P282, DOI 10.1016/S0921-5107(01)00726-7; Scott J.F., 2000, FERROELECTRIC MEMORI; SCOTT JF, 2001, FERROELECTRICS, V260, P305; Sepliarsky M, 2002, J APPL PHYS, V91, P3165, DOI 10.1063/1.1435826; Shimuta T, 2002, J APPL PHYS, V91, P2290, DOI 10.1063/1.1434547; Sigman J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.097601; Streiffer SK, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067601; Szafraniak I, 2003, APPL PHYS LETT, V83, P2211, DOI 10.1063/1.1611258; Tiedke S, 2001, APPL PHYS LETT, V79, P3678, DOI 10.1063/1.1421638; TILLEY DR, 1984, SOLID STATE COMMUN, V49, P823, DOI 10.1016/0038-1098(84)90089-9; Tybell T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.097601; Tybell T, 1999, APPL PHYS LETT, V75, P856, DOI 10.1063/1.124536; Vettiger P, 2000, IBM J RES DEV, V44, P323, DOI 10.1147/rd.443.0323; Waghmare UV, 2003, FERROELECTRICS, V291, P187, DOI 10.1080/00150190390222682; Wang Y, 2002, APPL PHYS LETT, V80, P97, DOI 10.1063/1.1428413; Warusawithana MP, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.036802; YU R, 1995, PHYS REV LETT, V74, P4067, DOI 10.1103/PhysRevLett.74.4067; Yun WS, 2002, NANO LETT, V2, P447, DOI 10.1021/nl015702g; Zhou C, 1997, APPL PHYS LETT, V70, P598, DOI 10.1063/1.118285	64	753	773	25	722	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					488	491		10.1126/science.1092508	http://dx.doi.org/10.1126/science.1092508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739450				2022-12-28	WOS:000188316400028
J	Draganski, B; Gaser, C; Busch, V; Schuierer, G; Bogdahn, U; May, A				Draganski, B; Gaser, C; Busch, V; Schuierer, G; Bogdahn, U; May, A			Neuroplasticity: Changes in grey matter induced by training - Newly honed juggling skills show up as a transient feature on a brain-imaging scan	NATURE			English	Editorial Material							ADULT CORTEX		Univ Regensburg, Dept Neurol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Neuroradiol, D-93053 Regensburg, Germany; Univ Jena, Dept Psychiat, D-07740 Jena, Germany	University of Regensburg; University of Regensburg; Friedrich Schiller University of Jena	Draganski, B (corresponding author), Univ Regensburg, Dept Neurol, D-93053 Regensburg, Germany.	arne.may@klinik.uni-regensburg.de	Draganski, Bogdan/C-3096-2016; Gaser, Christian/F-5103-2010	Draganski, Bogdan/0000-0002-5159-5919; Gaser, Christian/0000-0002-9940-099X				Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bisley JW, 2000, CEREB CORTEX, V10, P1053, DOI 10.1093/cercor/10.11.1053; Draganski B, 2002, NAT MED, V8, P1186, DOI 10.1038/nm1102-1186; Good CD, 2002, NEUROIMAGE, V17, P29, DOI 10.1006/nimg.2002.1202; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Sereno MI, 2001, SCIENCE, V294, P1350, DOI 10.1126/science.1063695; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273	9	1489	1527	7	301	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					311	312		10.1038/427311a	http://dx.doi.org/10.1038/427311a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737157				2022-12-28	WOS:000188266200029
J	Dyson, F				Dyson, F			A meeting with Enrico Fermi - How one intuitive physicist rescued a team from fruitless research.	NATURE			English	Editorial Material									Inst Adv Study, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Dyson, F (corresponding author), Inst Adv Study, Einstein Dr, Princeton, NJ 08540 USA.								0	157	160	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					297	297		10.1038/427297a	http://dx.doi.org/10.1038/427297a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737148	Bronze			2022-12-28	WOS:000188266200022
J	Riley, T; Kilbreth, E				Riley, T; Kilbreth, E			Health coverage in the states - Maine's plan for universal access	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Governors Off Hlth Policy & Finance, Augusta, GA USA; Univ So Maine, Muskie Sch Publ Serv, Portland, ME 04103 USA	University of Maine System; University of Southern Maine	Riley, T (corresponding author), Governors Off Hlth Policy & Finance, Augusta, GA USA.								0	3	3	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					330	332		10.1056/NEJMp038226	http://dx.doi.org/10.1056/NEJMp038226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736924				2022-12-28	WOS:000188254800004
J	Spira, A; Ettinger, DS				Spira, A; Ettinger, DS			Drug therapy: Multidisciplinary management of lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PHASE-III TRIAL; PROPHYLACTIC CRANIAL IRRADIATION; SEQUENTIAL THORACIC RADIOTHERAPY; PROSPECTIVE RANDOMIZED-TRIAL; PACLITAXEL PLUS CARBOPLATIN; SUPERIOR SULCUS TUMORS; QUALITY-OF-LIFE; TERM-FOLLOW-UP; RADIATION-THERAPY; BRONCHOGENIC-CARCINOMA		Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Ettinger, DS (corresponding author), Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg,Rm G88,1650 Orlea, Baltimore, MD 21231 USA.	ettinda@jhmi.edu						AISNER J, 1983, CANCER TREAT REP, V67, P37; ALBERTI W, 1995, BRIT MED J, V311, P899; [Anonymous], 1995, Eur J Surg Oncol, V21, P69; Ardizzoni A, 1997, J CLIN ONCOL, V15, P2090, DOI 10.1200/JCO.1997.15.5.2090; Argiris A, 2001, CANCER J, V7, P437; ARITA T, 1995, THORAX, V50, P1267, DOI 10.1136/thx.50.12.1267; ARRIAGADA R, 1994, ANTICANCER RES, V14, P333; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; Attar S, 1998, ANN THORAC SURG, V66, P193, DOI 10.1016/S0003-4975(98)00374-9; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Barnes JB, 2002, AM J CLIN ONCOL-CANC, V25, P90, DOI 10.1097/00000421-200202000-00019; BLANKE C, 1995, J CLIN ONCOL, V13, P1425, DOI 10.1200/JCO.1995.13.6.1425; BLOOMER WD, 1975, NEW ENGL J MED, V293, P80, DOI 10.1056/NEJM197507102930206; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; Burdett S, 1998, LANCET, V352, P257; Carney DN, 2002, NEW ENGL J MED, V346, P126, DOI 10.1056/NEJM200201103460211; Choy H, 1998, J CLIN ONCOL, V16, P3316, DOI 10.1200/JCO.1998.16.10.3316; Choy H, 2002, P AN M AM SOC CLIN, V21, p291a; Cullen MH, 1999, J CLIN ONCOL, V17, P3188, DOI 10.1200/JCO.1999.17.10.3188; Curran WJ, 2003, P AN M AM SOC CLIN, V22, P621; DAUTZENBERG B, 1995, CANCER, V76, P779, DOI 10.1002/1097-0142(19950901)76:5<779::AID-CNCR2820760511>3.0.CO;2-O; Debevec M, 1996, LUNG CANCER, V14, P99, DOI 10.1016/0169-5002(95)00515-3; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; Depierre A., 2001, P AN M AM SOC CLIN, V20, p309a; Dillman RO, 1996, J NATL CANCER I, V88, P1210, DOI 10.1093/jnci/88.17.1210; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; Dy GK, 2002, J CLIN ONCOL, V20, P2881, DOI 10.1200/JCO.2002.11.145; ELLIS PA, 1995, BRIT J CANCER, V71, P366, DOI 10.1038/bjc.1995.74; Ettinger DS, 2002, ONCOLOGIST, V7, P226, DOI 10.1634/theoncologist.7-3-226; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354; Frasci G, 1999, J CLIN ONCOL, V17, P2316, DOI 10.1200/JCO.1999.17.8.2316; FUKUOKA M, 1991, J NATL CANCER I, V83, P855, DOI 10.1093/jnci/83.12.855; Fukuoka M, 2002, P AN M AM SOC CLIN, V21, p298a; Furuse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692; Gandhi S, 1999, ANN THORAC SURG, V68, P1778, DOI 10.1016/S0003-4975(99)01068-1; Gatzemeier U, 2000, J CLIN ONCOL, V18, P3390, DOI 10.1200/JCO.2000.18.19.3390; GEORGOULIAS V, 2002, P AN M AM SOC CLIN, V21, pA291; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; Helsing M, 1998, EUR J CANCER, V34, P1036, DOI 10.1016/S0959-8049(97)10122-8; Hirsch FR, 2001, CLIN CANCER RES, V7, P5; HOLMES EC, 1986, J CLIN ONCOL, V4, P710, DOI 10.1200/JCO.1986.4.5.710; Huisman C, 2000, J CLIN ONCOL, V18, P3722, DOI 10.1200/JCO.2000.18.21.3722; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Inoue M, 2000, ANN THORAC SURG, V70, P1615, DOI 10.1016/S0003-4975(00)01401-6; Inoue M, 2000, ANN THORAC SURG, V70, P1620, DOI 10.1016/S0003-4975(00)01910-X; JOHNSON DH, 2002, ANN ONCOL, V13, P127; Johnson ZA, 2001, XENOTRANSPLANTATION, V8, P9; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; Kelly K, 2000, CLIN CANCER RES, V6, P3474; KLASTERSKY J, 1990, J CLIN ONCOL, V8, P1556, DOI 10.1200/JCO.1990.8.9.1556; KOMAKI R, 1990, INT J RADIAT ONCOL, V19, P31, DOI 10.1016/0360-3016(90)90130-C; KOMAKI R, 1981, CANCER TREAT REP, V65, P811; Kosmidis P, 2002, J CLIN ONCOL, V20, P3578, DOI 10.1200/JCO.2002.12.112; KOSMIDIS PA, 1994, SEMIN ONCOL, V21, P23; LAD T, 1994, CHEST, V106, pS320, DOI 10.1378/chest.106.6.320S; LAD T, 1988, J CLIN ONCOL, V6, P9; Lafitte JJ, 1996, ANN THORAC SURG, V62, P830, DOI 10.1016/S0003-4975(96)00507-3; Langer CJ, 1997, SEMIN ONCOL, V24, P89; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; Lilenbaum RC, 2002, P AN M AM SOC CLIN, V21, p1a; MAGILLIGAN DJ, 1986, ANN THORAC SURG, V42, P360, DOI 10.1016/S0003-4975(10)60536-X; MARINO P, 1995, CANCER, V76, P593, DOI 10.1002/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO;2-N; Mavroudis D, 2001, ANN ONCOL, V12, P463, DOI 10.1023/A:1011131303391; MAYR NA, 1995, AM J NEURORADIOL, V16, P215; MCLOUD TC, 1992, RADIOLOGY, V182, P319, DOI 10.1148/radiology.182.2.1732943; MICHEL F, 1991, THORAX, V46, P469, DOI 10.1136/thx.46.7.469; MORTON RF, 1991, ANN INTERN MED, V115, P681, DOI 10.7326/0003-4819-115-9-681; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Mountain CF, 1997, CHEST, V111, P1718, DOI 10.1378/chest.111.6.1718; MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336; NIELL HB, 2002, P AN M AM SOC CLIN, V21, pA293; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; OHTA M, 1993, J THORAC CARDIOV SUR, V106, P703, DOI 10.1016/S0022-5223(19)33714-6; PASS HI, 1992, ANN THORAC SURG, V53, P992, DOI 10.1016/0003-4975(92)90373-C; PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802; PEREZ CA, 1986, INT J RADIAT ONCOL, V12, P539, DOI 10.1016/0360-3016(86)90061-1; PEREZ CA, 1986, INT J RADIAT ONCOL, V12, P2057; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; Pisters KMW, 2000, J THORAC CARDIOV SUR, V119, P429, DOI 10.1016/S0022-5223(00)70120-6; Pritchard RS, 1997, ANN INTERN MED, V126, P670, DOI 10.7326/0003-4819-125-9-199611010-00003; Pritchard RS, 1996, ANN INTERN MED, V125, P723, DOI 10.7326/0003-4819-125-9-199611010-00003; RAVIV G, 1990, J SURG ONCOL, V43, P123, DOI 10.1002/jso.2930430212; REYES L, 1990, J SURG ONCOL, V44, P32, DOI 10.1002/jso.2930440108; Rosell R, 1999, LUNG CANCER, V26, P7, DOI 10.1016/S0169-5002(99)00045-8; ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301; Rosell R, 2002, ANN ONCOL, V13, P1539, DOI 10.1093/annonc/mdf332; ROTH BJ, 1992, J CLIN ONCOL, V10, P282, DOI 10.1200/JCO.1992.10.2.282; Roth JA, 1998, LUNG CANCER-J IASLC, V21, P1, DOI 10.1016/S0169-5002(98)00046-4; ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; RUCKDESCHEL JC, 1985, J CLIN ONCOL, V3, P72, DOI 10.1200/JCO.1985.3.1.72; Rusch VW, 2001, J THORAC CARDIOV SUR, V121, P472, DOI 10.1067/mtc.2001.112465; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sederholm C, 2002, P AN M AM SOC CLIN, V21, p291a; SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Simon G, 2001, Chest Surg Clin N Am, V11, P165; SKARIN A, 1989, J SURG ONCOL, V40, P266, DOI 10.1002/jso.2930400413; Smith IE, 2001, J CLIN ONCOL, V19, P1336, DOI 10.1200/JCO.2001.19.5.1336; Socinski MA, 2002, J CLIN ONCOL, V20, P1335, DOI 10.1200/JCO.20.5.1335; SORESI E, 1988, SEMIN ONCOL, V15, P20; Stephens RJ, 1996, BRIT J CANCER, V74, P632, DOI 10.1038/bjc.1996.413; Tahara RW, 2000, AM J SURG, V180, P488, DOI 10.1016/S0002-9610(00)00509-2; Takada M, 2002, J CLIN ONCOL, V20, P3054, DOI 10.1200/JCO.2002.12.071; Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403; Van Zandwijk N, 2000, J CLIN ONCOL, V18, P2658, DOI 10.1200/JCO.2000.18.14.2658; von Pawel J, 2000, J CLIN ONCOL, V18, P1351, DOI 10.1200/JCO.2000.18.6.1351; Wada H, 1996, J CLIN ONCOL, V14, P1048, DOI 10.1200/JCO.1996.14.4.1048; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377; Weng E, 2000, AM J CLIN ONCOL-CANC, V23, P47, DOI 10.1097/00000421-200002000-00014; Wozniak AJ, 1998, J CLIN ONCOL, V16, P2459, DOI 10.1200/JCO.1998.16.7.2459; Wright CD, 2002, ANN THORAC SURG, V73, P1541, DOI 10.1016/S0003-4975(02)03471-9; Xu GC, 2000, CHINESE MED J-PEKING, V113, P617	123	697	739	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					379	392		10.1056/NEJMra035536	http://dx.doi.org/10.1056/NEJMra035536			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736930				2022-12-28	WOS:000188254800010
J	Verver, S; Warren, RM; Munch, Z; Richardson, M; van der Spuy, GD; Borgdorff, MW; Behr, MA; Beyers, N; van Helden, PD				Verver, S; Warren, RM; Munch, Z; Richardson, M; van der Spuy, GD; Borgdorff, MW; Behr, MA; Beyers, N; van Helden, PD			Proportion of tuberculosis transmission that takes place in households in a high-incidence area	LANCET			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; COMMUNITY	The prevalence of infection among household contacts of people with tuberculosis is high. This information frequently guides active case finding. We analysed DNA fingerprints of Mycobacterium tuberculosis from 765 tuberculosis patients in Ravensmead and Uitsig, adjacent suburbs of Cape Town, South Africa. In 129 households in which DNA fingerprints were available for more than one patient, we identified 313 patients, of whom 145 (46%) had a fingerprint pattern matching that of another member of the household. The proportion of transmission in the community that took place in the household was 19%, and therefore, in this high-incidence area, tuberculosis transmission occurs mainly outside the household.	Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa; Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, Dept Biochem Med, Cape Town, South Africa; KNCV TB Fdn, The Hague, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; McGill Univ, Ctr Hlth, Dept Med, Div Infect Dis, Montreal, PQ, Canada	Stellenbosch University; Stellenbosch University; KNCV Tuberculosis Foundation; University of Amsterdam; Academic Medical Center Amsterdam; McGill University	Verver, S (corresponding author), Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa.	ververs@kncvtbc.nl	van der Spuy, Gian/AAY-7701-2020; Münch, Zahn/D-5193-2016	van der Spuy, Gian/0000-0002-9067-5903; Münch, Zahn/0000-0003-0691-7920; Warren, Robin/0000-0001-5741-7358				Classen CN, 1999, THORAX, V54, P136, DOI 10.1136/thx.54.2.136; Lockman S, 2001, J CLIN MICROBIOL, V39, P1042, DOI 10.1128/JCM.39.3.1042-1047.2001; Murray M, 2002, EMERG INFECT DIS, V8, P363, DOI 10.3201/eid0804.000444; Richardson M, 2002, J CLIN MICROBIOL, V40, P2750, DOI 10.1128/JCM.40.8.2750-2754.2002; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Warren RM, 2002, J CLIN MICROBIOL, V40, P1277, DOI 10.1128/JCM.40.4.1277-1282.2002	6	213	217	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					212	214		10.1016/S0140-6736(03)15332-9	http://dx.doi.org/10.1016/S0140-6736(03)15332-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738796				2022-12-28	WOS:000188243900013
J	PETTIGREW, JD; WALLMAN, J; WILDSOET, CF				PETTIGREW, JD; WALLMAN, J; WILDSOET, CF			SACCADIC OSCILLATIONS FACILITATE OCULAR PERFUSION FROM THE AVIAN PECTEN	NATURE			English	Article									CUNY CITY COLL,DEPT BIOL,NEW YORK,NY 10031; QUEENSLAND UNIV TECHNOL,DEPT OPTOMETRY,BRISBANE 4001,AUSTRALIA	City University of New York (CUNY) System; City College of New York (CUNY); Queensland University of Technology (QUT)	PETTIGREW, JD (corresponding author), UNIV QUEENSLAND,VIS TOUCH & HEARING RES CTR,ST LUCIA,QLD 4067,AUSTRALIA.							Abelsdorff G., 1909, Archiv fuer Augenheilkunde Wiesbaden, V64; AMEMIYA T, 1982, GRAEF ARCH CLIN EXP, V219, P11, DOI 10.1007/BF02159972; BARLOW HB, 1972, NATURE-NEW BIOL, V236, P88, DOI 10.1038/newbio236088a0; BAWA SR, 1972, EXP EYE RES, V13, P92, DOI 10.1016/0014-4835(72)90129-7; BELL SM, 1975, PATHOLOGY, V7, P1; BRAEKEVELT CR, 1984, OPHTHALMOLOGICA, V189, P211, DOI 10.1159/000309412; DUKEELDER S, 1958, EYE EVOLUTION, V1, P362; LETELIER J C, 1987, Society for Neuroscience Abstracts, V13, P172; LETELIER J C, 1984, Society for Neuroscience Abstracts, V10, P912; Pettigrew J. D., 1978, ANIMAL MIGRATION NAV, P42; RAVIOLA E, 1967, AM J ANAT, V120, P427, DOI 10.1002/aja.1001200304; REYMOND L, 1985, VISION RES, V25, P1477, DOI 10.1016/0042-6989(85)90226-3; SEAMAN AR, 1973, EXPL EYE RES, V2, P163; TUCKER R, 1975, CELL TISSUE RES, V157, P457; WALLMAN J, 1985, J NEUROSCI, V5, P1418; WALLS GL, 1967, VERTEBRATE EYE ITS A, P648; WINGSTRAND KARL GEORG, 1965, BIOL SKR KONGELIGE DANSKE VIDENSKABERNES SELSK, V14, P1; [No title captured]	18	84	84	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1990	343	6256					362	363		10.1038/343362a0	http://dx.doi.org/10.1038/343362a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK918	14756148				2022-12-28	WOS:A1990CK91800059
J	Gomberg, J; Bodin, P; Larson, K; Dragert, H				Gomberg, J; Bodin, P; Larson, K; Dragert, H			Earthquake nucleation by transient deformations caused by the M=7.9 Denali, Alaska, earthquake	NATURE			English	Article							LANDERS; SEISMICITY; CALIFORNIA; MAGNITUDE	The permanent and dynamic (transient) stress changes inferred to trigger earthquakes are usually orders of magnitude smaller than the stresses relaxed by the earthquakes themselves, implying that triggering occurs on critically stressed faults(1-4). Triggered seismicity rate increases may therefore be most likely to occur in areas where loading rates are highest and elevated pore pressures, perhaps facilitated by high-temperature fluids, reduce frictional stresses and promote failure(5-7). Here we show that the 2002 magnitude M=7.9 Denali, Alaska, earthquake triggered widespread seismicity rate increases throughout British Columbia and into the western United States. Dynamic triggering by seismic waves should be enhanced in directions where rupture directivity focuses radiated energy, and we verify this using seismic and new high-sample GPS recordings of the Denali mainshock. These observations are comparable in scale only to the triggering caused by the 1992 M=7.4 Landers, California, earthquake(1), and demonstrate that Landers triggering did not reflect some peculiarity of the region or the earthquake. However, the rate increases triggered by the Denali earthquake occurred in areas not obviously tectonically active, implying that even in areas of low ambient stressing rates, faults may still be critically stressed and that dynamic triggering may be ubiquitous and unpredictable.	US Geol Survey, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA; Univ Memphis, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA; Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO 80309 USA; Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada	United States Department of the Interior; United States Geological Survey; University of Memphis; University of Colorado System; University of Colorado Boulder; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Gomberg, J (corresponding author), US Geol Survey, Ctr Earthquake Res & Informat, 3876 Cent Ave,Suite 2, Memphis, TN 38152 USA.	gomberg@usgs.gov	Larson, Kristine M/J-7623-2018	Larson, Kristine M/0000-0003-4666-8885				ANDERSON JG, 1994, B SEISMOL SOC AM, V84, P863; Belardinelli ME, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001779; Cocco M, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000138; Eberhart-Phillips D, 2003, SCIENCE, V300, P1113, DOI 10.1126/science.1082703; Fluck P, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002201; GALBRIELSE H, 1991, GEOLOGY CORDILLERAN, P13; Gomberg J, 2001, NATURE, V411, P462, DOI 10.1038/35078053; Gomberg J, 2000, J GEOPHYS RES-SOL EA, V105, P7857, DOI 10.1029/1999JB900438; Gomberg J, 1996, B SEISMOL SOC AM, V86, P212; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; Hough SE, 2003, B SEISMOL SOC AM, V93, P2212, DOI 10.1785/0120020055; Huc M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001645; Larson KM, 2003, SCIENCE, V300, P1421, DOI 10.1126/science.1084531; Miller MM, 2001, TECTONICS, V20, P161, DOI 10.1029/2000TC001224; Ozacar AA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017272; Riddihough R. P., 1991, GEOLOGY CORDILLERA G, V4, P435; Seeber L, 1998, J GEOPHYS RES-SOL EA, V103, P24505, DOI 10.1029/98JB01497; Streit JE, 2001, J GEOPHYS RES-SOL EA, V106, P2235, DOI 10.1029/2000JB900359; Sturtevant B, 1996, J GEOPHYS RES-SOL EA, V101, P25269, DOI 10.1029/96JB02654; Townend J, 2000, GEOLOGY, V28, P399, DOI 10.1130/0091-7613(2000)28<399:HFKTCS>2.0.CO;2	20	128	135	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					621	624		10.1038/nature02335	http://dx.doi.org/10.1038/nature02335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961117				2022-12-28	WOS:000188875300037
J	Llewelyn, CA; Hewitt, PE; Knight, RSG; Amar, K; Cousens, S; Mackenzie, J; Will, RG				Llewelyn, CA; Hewitt, PE; Knight, RSG; Amar, K; Cousens, S; Mackenzie, J; Will, RG			Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion	LANCET			English	Article							SPONGIFORM ENCEPHALOPATHY; PRION DISEASES; INFECTIVITY; DIAGNOSIS; PROTEIN; TISSUES; TONSIL	Background Variant Creutzfeldt-Jakob disease (vCJD) is a novel human prion disease caused by infection with the agent of bovine spongiform encephalopathy (BSE). Epidemiological evidence does not suggest that sporadic CJD is transmitted from person to person via blood transfusion, but this evidence may not apply to vCJD. We aimed to identify whether vCJD is transmissible through blood transfusion. Methods The national CJD surveillance unit reported all cases of probable or definite vCJD to the UK blood services, which searched for donation records at blood centres and hospitals. Information on named recipients and donors was provided to the surveillance unit to establish if any matches existed between recipients or donors and the database of cases of vCJD. Recipients were also flagged at the UK Office of National Statistics to establish date and cause of death. Findings 48 individuals were identified as having received a labile blood component from a total of 15 donors who later became vCJD cases and appeared on the surveillance unit's register. One of these recipients was identified as developing symptoms of vCJD 6.5 years after receiving a transfusion of red cells donated by an individual 3.5 years before the donor developed symptoms of vCJD. Interpretation Our findings raise the possibility that this infection was transfusion transmitted. Infection in the recipient could have been due to past dietary exposure to the BSE agent. However, the age of the patient was well beyond that of most vCJD cases, and the chance of observing a case of vCJD in a recipient in the absence of transfusion transmitted infection is about 1 in 15 000 to 1 in 30 000.	Western Gen Hosp, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Natl Blood Serv, Cambridge Ctr, Cambridge CB2 2PT, England; Natl Blood Serv, N London Ctr, London NW9 5BG, England; London Sch Hyg & Trop Med, London WC1 7HT, England	University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine	Will, RG (corresponding author), Western Gen Hosp, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	r.g.will@ed.ac.uk						Andrews NJ, 2003, LANCET, V361, P751, DOI 10.1016/S0140-6736(03)12632-3; Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x; Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; Bruce ME, 2001, LANCET, V358, P208, DOI 10.1016/S0140-6736(01)05411-3; Bruce ME, 1979, SLOW TRANSMISSIBLE D, V2, P71; CASACCIA P, 1989, ARCH VIROL, V108, P145, DOI 10.1007/BF01313752; Cervenakova L, 2003, TRANSFUSION, V43, P1687, DOI 10.1046/j.0041-1132.2003.00586.x; Collie DA, 2003, AM J NEURORADIOL, V24, P1560; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; Foster PR, 2000, TRANSFUS SCI, V22, P53, DOI 10.1016/S0955-3886(00)00011-4; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; Ironside JW, 2000, LANCET, V355, P1693, DOI 10.1016/S0140-6736(00)02243-1; Ironside JW, 2000, HISTOPATHOLOGY, V37, P1, DOI 10.1046/j.1365-2559.2000.00946.x; Kimberlin R. H., 1979, Slow transmissible diseases of the nervous system. Volume 2., P33; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Will RG, 2000, ANN NEUROL, V47, P575; Wilson K, 2000, BMJ-BRIT MED J, V321, P17, DOI 10.1136/bmj.321.7252.17	19	823	855	0	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					417	421		10.1016/S0140-6736(04)15486-X	http://dx.doi.org/10.1016/S0140-6736(04)15486-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962520				2022-12-28	WOS:000188999500007
J	Tong, AHY; Lesage, G; Bader, GD; Ding, HM; Xu, H; Xin, XF; Young, J; Berriz, GF; Brost, RL; Chang, M; Chen, YQ; Cheng, X; Chua, G; Friesen, H; Goldberg, DS; Haynes, J; Humphries, C; He, G; Hussein, S; Ke, LZ; Krogan, N; Li, ZJ; Levinson, JN; Lu, H; Menard, P; Munyana, C; Parsons, AB; Ryan, O; Tonikian, R; Roberts, T; Sdicu, AM; Shapiro, J; Sheikh, B; Suter, B; Wong, SL; Zhang, LV; Zhu, HW; Burd, CG; Munro, S; Sander, C; Rine, J; Greenblatt, J; Peter, M; Bretscher, A; Bell, G; Roth, FP; Brown, GW; Andrews, B; Bussey, H; Boone, C				Tong, AHY; Lesage, G; Bader, GD; Ding, HM; Xu, H; Xin, XF; Young, J; Berriz, GF; Brost, RL; Chang, M; Chen, YQ; Cheng, X; Chua, G; Friesen, H; Goldberg, DS; Haynes, J; Humphries, C; He, G; Hussein, S; Ke, LZ; Krogan, N; Li, ZJ; Levinson, JN; Lu, H; Menard, P; Munyana, C; Parsons, AB; Ryan, O; Tonikian, R; Roberts, T; Sdicu, AM; Shapiro, J; Sheikh, B; Suter, B; Wong, SL; Zhang, LV; Zhu, HW; Burd, CG; Munro, S; Sander, C; Rine, J; Greenblatt, J; Peter, M; Bretscher, A; Bell, G; Roth, FP; Brown, GW; Andrews, B; Bussey, H; Boone, C			Global mapping of the yeast genetic interaction network	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SMALL-WORLD; S-PHASE; BIOLOGY; DISEASE; COMPLEX	A genetic interaction network containing similar to1000 genes and similar to4000 interactions was mapped by crossing mutations in 132 different query genes into a set of similar to4700 viable gene yeast deletion mutants and scoring the double mutant progeny for fitness defects. Network connectivity was predictive of function because interactions often occurred among functionally related genes, and similar patterns of interactions tended to identify components of the same pathway. The genetic network exhibited dense local neighborhoods; therefore, the position of a gene on a partially mapped network is predictive of other genetic interactions. Because digenic interactions are common in yeast, similar networks may underlie the complex genetics associated with inherited phenotypes in other organisms.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland	University of Toronto; University of Toronto; McGill University; Memorial Sloan Kettering Cancer Center; University of Toronto; Cornell University; Harvard University; Harvard Medical School; University of California System; University of California Berkeley; University of Pennsylvania; MRC Laboratory Molecular Biology; Swiss Federal Institutes of Technology Domain; ETH Zurich	Andrews, B (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada.	brenda.andrews@utoronto.ca; howard.bussey@mcgill.ca; charlie.boone@utoronto.ca	Haynes, Jennifer/P-8565-2019; Sander, Chris/H-1452-2011; Chang, Michael/B-9279-2012; Bader, Gary/C-1176-2009; Xin, Xiaofeng/G-7736-2016; Roth, Frederick P/H-6308-2011; Shapiro, B. Jesse/U-9337-2019	Sander, Chris/0000-0001-6059-6270; Chang, Michael/0000-0002-1706-3337; Bader, Gary/0000-0003-0185-8861; Xin, Xiaofeng/0000-0002-2439-7183; Munro, Sean/0000-0001-6160-5773; Roberts, Tania/0000-0001-9518-3011; Shapiro, B. Jesse/0000-0001-6819-8699; Burd, Christopher/0000-0003-1831-8706; Peter, Matthias/0000-0002-2160-6824; Roth, Frederick/0000-0002-6628-649X; Menard, Patrice/0000-0001-8844-3727; Brown, Grant/0000-0002-9002-5003	NIGMS NIH HHS [GM39066, GM61221] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039066, R01GM061221] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Barabasi AL, 2003, SCI AM, V288, P60, DOI 10.1038/scientificamerican0503-60; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BERRIZ GF, IN PRESS BIOINFORMAT; DOLINSKI K, SACCHAROMYCES GENOME; Foss EJ, 2001, GENETICS, V157, P567; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Hariharan IK, 2003, NEW ENGL J MED, V348, P2457, DOI 10.1056/NEJMon023158; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Kamb A, 2003, J THEOR BIOL, V223, P205, DOI 10.1016/S0022-5193(03)00087-0; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Lee WL, 2003, J CELL BIOL, V160, P355, DOI 10.1083/jcb.200209022; MAYER M, IN PRESS MOL BIOL CE; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Phillips PC, 1998, GENETICS, V150, P449; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	25	1519	1573	0	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					808	813		10.1126/science.1091317	http://dx.doi.org/10.1126/science.1091317			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764870				2022-12-28	WOS:000188753800048
J	Erlinger, TP; Platz, EA; Rifai, N; Helzlsouer, KJ				Erlinger, TP; Platz, EA; Rifai, N; Helzlsouer, KJ			C-reactive protein and the risk of incident colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; RANDOMIZED-TRIAL; COLON-CANCER; MORTALITY; DISEASE; INFLAMMATION; SULINDAC; INTERLEUKIN-6; ASPIRIN; COUNT	Context Inflammation may play a role in the pathogenesis of colorectal cancer; however, epidemiological evidence supporting this hypothesis in average-risk persons is sparse. Objective To determine the risk of incident colon and rectal cancer associated with elevated baseline plasma concentrations of C-reactive protein (CRP). Design, Setting, and Participants Prospective, nested case-control study of a cohort of 22887 adults (>18 years and Washington County, Maryland, residents) enrolled between May and October 1989 and followed up through December 2000. A total of 172 colorectal cancer cases were identified through linkage with the Washington County and Maryland State Cancer registries. Up to 2 controls (n=342) were selected from the cohort for each case and matched by age, sex, race, and date of blood draw. Main Outcome Measure Odds ratio (OR) of incident colon and rectal cancer. Results Plasma CRP concentrations were higher among all colorectal cases combined than controls (median CRP, 2.44 vs 1.94 mg/L; P=.01). The highest concentration was found in persons who subsequently developed colon cancer vs matched controls (median CRP, 2.69 vs 1.97 mg/L; P<.001). Among rectal cancer cases, CRIP concentrations were not significantly different from controls (median CRP, 1.79 vs 1.81 mg/L; P=32). The risk of colon cancer was higher in persons in the highest vs lowest quartile of CRP (OR, 2.55; 95% confidence interval [CI], 1.34-4.88; P for trend =.002). in nonsmokers, the corresponding association was stronger (OR, 3.51; 95% Cl, 1.64-7.51; P for trend <.001). A 1 -SD increase in log CRP (1.02 mg/Q was associated with an increased risk of colon cancer after adjusting for potential confounders and excluding cases occurring within 2 years of baseline (OR, 1.35; 95% Cl, 1.05-1.74) or excluding those with late-stage colon cancer at the time of diagnosis (OR, 1.38; 95% Cl, 0.99-1.91). Conclusions Plasma CRP concentrations are elevated among persons who subsequently develop colon cancer. These data support the hypothesis that inflammation is a risk factor for the development of colon cancer in average-risk individuals.	Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Erlinger, TP (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Dept Med, 2024 E Monument,Suite 2-600, Baltimore, MD 21205 USA.	terlinge@jhmi.edu			NATIONAL CANCER INSTITUTE [U01CA086308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG018033] Funding Source: NIH RePORTER; NCI NIH HHS [IU01 CA86308] Funding Source: Medline; NIA NIH HHS [IU01 AG18033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DAS I, 1985, CLIN CHIM ACTA, V153, P9, DOI 10.1016/0009-8981(85)90133-0; FRIEDMAN GD, 1991, AM J EPIDEMIOL, V133, P376, DOI 10.1093/oxfordjournals.aje.a115891; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRIMM RH, 1985, JAMA-J AM MED ASSOC, V254, P1932, DOI 10.1001/jama.254.14.1932; Gussekloo J, 2000, ARTERIOSCL THROM VAS, V20, P1047, DOI 10.1161/01.ATV.20.4.1047; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; KO WF, 1994, J NATL CANCER I, V86, P1874, DOI 10.1093/jnci/86.24.1874; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LADENHEIM J, 1995, GASTROENTEROLOGY, V108, P1083, DOI 10.1016/0016-5085(95)90206-6; LEVIN B, 1992, CANCER-AM CANCER SOC, V70, P1313, DOI 10.1002/1097-0142(19920901)70:3+<1313::AID-CNCR2820701518>3.0.CO;2-B; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Okada F, 2000, LAB INVEST, V80, P1617, DOI 10.1038/labinvest.3780172; Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C; Rifai N, 1999, CLIN CHEM, V45, P2136; Rifai N, 2002, ANN INTERN MED, V136, P529, DOI 10.7326/0003-4819-136-7-200204020-00010; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Schneider MR, 2000, CANCER LETT, V151, P31, DOI 10.1016/S0304-3835(99)00401-2; SoRelle Ruth, 2002, Circulation, V105, pE9071, DOI 10.1161/hc0502.106411; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P2167, DOI 10.1161/01.ATV.17.10.2167; Yano K, 2001, ARTERIOSCL THROM VAS, V21, P1065, DOI 10.1161/01.ATV.21.6.1065	24	417	434	2	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					585	590		10.1001/jama.291.5.585	http://dx.doi.org/10.1001/jama.291.5.585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762037	Bronze			2022-12-28	WOS:000188650700023
J	Christensen, H; Griffiths, KM; Jorm, AF				Christensen, H; Griffiths, KM; Jorm, AF			Delivering interventions for depression by using the internet: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							COGNITIVE BIBLIOTHERAPY	Objective To evaluate the efficacy of two internet interventions for community-dwelling individuals with symptoms of depression-a psychoeducation website offering information about depression,and an interactive website offering cognitive behaviour therapy. Design Randomised controlled trial. Setting Internet users in the community, in Canberra, Australia. Participants 525 individuals with increased depressive symptoms recruited by survey and randomly allocated to a website offering information about depression (n = 166) or a cognitive behaviour therapy website (n = 182), or a control intervention using an attention placebo (n = 178). Main outcome measures Change in depression, dysfunctional thoughts; knowledge of medical, psychological, and lifestyle treatments; and knowledge of cognitive behaviour therapy Results Intention to treat analyses indicated that information about depression and interventions that used cognitive behaviour therapy and were delivered via the internet were more effective than a credible control intervention in reducing symptoms of depression in a community sample. For the intervention that delivered cognitive behaviour therapy the reduction in score on the depression scale of the Center for Epidemiologic Studies was 3.2 (95% confidence interval 0.9 to 5.4). For the "depression literacy" site (BluePages), the reduction was 3.0 (95% confidence interval 0.6 to 5.2). Cognitive behaviour therapy (MoodGYM) reduced dysfunctional thinking and increased knowledge of cognitive behaviour therapy. Depression literacy (BluePages) significantly improved participants' understanding of effective evidence based treatments for depression (P < 0.05). Conclusions Both cognitive behaviour therapy and psychoeducation delivered via the internet are effective in reducing symptoms of depression.	Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia	Australian National University	Christensen, H (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia.	Helen.Christensen@anu.edu.au	Griffiths, Kathleen/A-9872-2012; Christensen, Helen/F-5053-2012; Jorm, Anthony F/B-5555-2009; Young, Alexander/A-1523-2009	Christensen, Helen/0000-0003-0435-2065; Jorm, Anthony F/0000-0002-1424-4116; Young, Alexander/0000-0002-9367-9213				Ackerson J, 1998, J CONSULT CLIN PSYCH, V66, P685, DOI 10.1037/0022-006X.66.4.685; Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-842X.2001.tb00310.x; Andrews GA, 1999, UNMET NEED PSYCHIAT; Bebbington PE, 2000, PSYCHOL MED, V30, P1369, DOI 10.1017/S0033291799002974; Christensen H, 2002, MED J AUSTRALIA, V177, pS122; Christensen H, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.1.e3; Clarke G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.3.e14; Cuijpers P, 1997, J BEHAV THER EXP PSY, V28, P139, DOI 10.1016/S0005-7916(97)00005-0; DORWICK C, 2000, BRIT MED J, V321, P1; HOLLON SD, 1980, COGNITIVE THER RES, V4, P383, DOI 10.1007/BF01178214; Jacob KS, 2002, INT J SOC PSYCHIATR, V48, P139, DOI 10.1177/002076402128783190; Jacobs MK, 2001, PROF PSYCHOL-RES PR, V32, P92, DOI 10.1037/0735-7028.32.1.92; JAMISON C, 1995, J CONSULT CLIN PSYCH, V63, P644, DOI 10.1037/0022-006X.63.4.644; Jorm AF, 2002, MED J AUSTRALIA, V176, pS84; Kaltenthaler E, 2002, Health Technol Assess, V6, P1; Kenardy J, 2003, BEHAV COGN PSYCHOTH, V31, P279, DOI 10.1017/S1352465803003047; Kessler RC, 2001, HEALTH SERV RES, V36, P987; Proudfoot J, 2003, PSYCHOL MED, V33, P217, DOI 10.1017/S0033291702007225; Randolf LS, 1977, APPL PSYCH MEAS, V1, P385; Richards Jeffrey C., 2002, Cognitive Behaviour Therapy, V31, P41, DOI 10.1080/16506070252823652	20	578	591	6	118	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					265	268A		10.1136/bmj.37945.566632.EE	http://dx.doi.org/10.1136/bmj.37945.566632.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771LC	14742346	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188786000022
J	Stevens, W; Kaye, S; Corrah, T				Stevens, W; Kaye, S; Corrah, T			Antiretroviral therapy in Africa	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESISTANCE MUTATIONS; DRUG-RESISTANCE; HIV; ADHERENCE; FAILURE		MRC Labs, Banjul, Gambia	MRC Laboratory Molecular Biology	Stevens, W (corresponding author), MRC Labs, POB 273, Banjul, Gambia.	wstevens@mrc.gm						Ansah EK, 2001, TROP MED INT HEALTH, V6, P496, DOI 10.1046/j.1365-3156.2001.00740.x; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Burger DM, 1998, ANTIVIR THER, V3, P215; Harrigan PR, 2002, ANTIMICROB AGENTS CH, V46, P909, DOI 10.1128/AAC.46.3.909-912.2002; Karmochkine M, 2000, ANTIVIR RES, V47, P179, DOI 10.1016/S0166-3542(00)00110-8; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; Moulding TS, 2002, INT J TUBERC LUNG D, V6, P313; O'Boyle SJ, 2002, INT J TUBERC LUNG D, V6, P307; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; Quinones-Mateu ME, 2002, DRUG RESIST UPDATE, V5, P224, DOI 10.1016/S1368-7646(02)00123-1; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *WHO, 2002, WHO REP 2002 GLOB TU; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	19	49	51	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	2004	328	7434					280	282		10.1136/bmj.328.7434.280	http://dx.doi.org/10.1136/bmj.328.7434.280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14751902	Green Published			2022-12-28	WOS:000188786000027
J	Baughn, AD; Malamy, MH				Baughn, AD; Malamy, MH			The strict anaerobe Bacteroides fragilis grows in and benefits from nanomolar concentrations of oxygen	NATURE			English	Article							RESPIRATION; OXIDATION; REDUCTION; EVOLUTION; PROTEIN	Strict anaerobes cannot grow in the presence of greater than 5 muM dissolved oxygen(1). Despite this growth inhibition, many strict anaerobes of the Bacteroides class of eubacteria can survive in oxygenated environments until the partial pressure of O-2 (P-O2) is sufficiently reduced. For example, the periodontal pathogens Porphyromonas gingivalis and Tannerella forsythensis colonize subgingival plaques of mammals, whereas several other Bacteroides species colonize the gastrointestinal tract of animals. It has been suggested that pre-colonization of these sites by facultative anaerobes is essential for reduction of the P-O2 and subsequent colonization by strict anaerobes(2). However, this model is inconsistent with the observation that Bacteroides fragilis can colonize the colon in the absence of facultative anaerobes(3). Thus, this strict anaerobe may have a role in reduction of the environmental P-O2. Although some strictly anaerobic bacteria can consume oxygen through an integral membrane electron transport system(4), the physiological role of this system has not been established in these organisms. Here we demonstrate that B. fragilis encodes a cytochrome bd oxidase that is essential for O-2 consumption and is required, under some conditions, for the stimulation of growth in the presence of nanomolar concentrations of O-2. Furthermore, our data suggest that this property is conserved in many other organisms that have been described as strict anaerobes.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts University	Malamy, MH (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.malamy@tufts.edu	Baughn, Anthony/ABB-7881-2020	Baughn, Anthony/0000-0003-1188-4238				Baughn AD, 2002, P NATL ACAD SCI USA, V99, P4662, DOI 10.1073/pnas.052710199; BAUGHN AD, 2003, MICROBIOLOGY, V149, P1503; Bocchetta M, 2000, J MOL EVOL, V50, P366, DOI 10.1007/s002399910040; BORNSIDE GH, 1976, P SOC EXP BIOL MED, V151, P437; CASTRESANA J, 1995, TRENDS BIOCHEM SCI, V20, P443, DOI 10.1016/S0968-0004(00)89098-2; Catling DC, 2001, SCIENCE, V293, P839, DOI 10.1126/science.1061976; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cypionka H, 2000, ANNU REV MICROBIOL, V54, P827, DOI 10.1146/annurev.micro.54.1.827; Di Giulio M, 2003, J THEOR BIOL, V221, P425, DOI 10.1006/jtbi.2003.3197; Duwat P, 2001, J BACTERIOL, V183, P4509, DOI 10.1128/JB.183.15.4509-4516.2001; Engelkirk P.G., 1992, PRINCIPLES PRACTICE; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; LEVITT MD, 1970, NEW ENGL J MED, V282, P1039, DOI 10.1056/NEJM197004302821814; MACY J, 1975, J BACTERIOL, V123, P436, DOI 10.1128/JB.123.2.436-442.1975; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; SCHMALFUSS H, 1925, BERICHTE DTSCH CHEM, V52, P71; Swofford D.L., 2002, PHYLOGENETIC ANAL US; TALLY FP, 1982, J BACTERIOL, V151, P686, DOI 10.1128/JB.151.2.686-691.1982; Towe Kenneth M, 2002, Science, V295, P1419; WEISBURG WG, 1985, J BACTERIOL, V164, P230, DOI 10.1128/JB.164.1.230-236.1985	22	195	203	6	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					441	444		10.1038/nature02285	http://dx.doi.org/10.1038/nature02285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749831				2022-12-28	WOS:000188470500043
J	Selje, N; Simon, M; Brinkhoff, T				Selje, N; Simon, M; Brinkhoff, T			A newly discovered Roseobacter cluster in temperate and polar oceans	NATURE			English	Article							16S RIBOSOMAL-RNA; MARINE BACTERIOPLANKTON; COMMUNITY COMPOSITION; SAR11 CLUSTER; DIVERSITY; BACTERIA; IDENTIFICATION; GENES	Bacterioplankton phylotypes of alpha-Proteobacteria have been detected in various marine regions, but systematic biogeographical studies of their global distribution are missing. alpha-Proteobacteria comprise one of the largest fractions of heterotrophic marine bacteria(1,2) and include two clades, SAR11 and Roseobacter, which account for 26 and 16% of 16S ribosomal RNA gene clones retrieved from marine bacterioplankton(3). The SAR11 clade attracted much interest because related 16S rRNA gene clones were among the first groups of marine bacteria to be identified by cultivation-independent approaches(4) and appear to dominate subtropical surface bacterioplankton communities(5). Here we report on the global distribution of a newly discovered cluster affiliated to the Roseobacter clade, comprising only as-yet-uncultured phylotypes. Bacteria of this cluster occur from temperate to polar regions with highest abundance in the Southern Ocean, but not in tropical and subtropical regions. Between the south Atlantic subtropical front and Antarctica, we detected two distinct phylotypes, one north and one south of the polar front, indicating that two adjacent but different oceanic provinces allow the persistence of distinct but closely related phylotypes. These results suggest that the global distribution of major marine bacterioplankton components is related to oceanic water masses and controlled by their environmental and biogeochemical properties.	Carl von Ossietzky Univ Oldenburg, Inst Chem & Biol Marine Environm, D-26111 Oldenburg, Germany	Carl von Ossietzky Universitat Oldenburg	Simon, M (corresponding author), Carl von Ossietzky Univ Oldenburg, Inst Chem & Biol Marine Environm, POB 2503, D-26111 Oldenburg, Germany.	m.simon@icbm.de						Bano N, 2002, APPL ENVIRON MICROB, V68, P505, DOI 10.1128/AEM.68.2.505-518.2002; Beja O, 2002, NATURE, V415, P630, DOI 10.1038/415630a; Cottrell MT, 2000, APPL ENVIRON MICROB, V66, P5116, DOI 10.1128/AEM.66.12.5116-5122.2000; Field KG, 1997, APPL ENVIRON MICROB, V63, P63, DOI 10.1128/AEM.63.1.63-70.1997; Fuchs BM, 2000, APPL ENVIRON MICROB, V66, P3603, DOI 10.1128/AEM.66.8.3603-3607.2000; Fuchs BM, 2000, ENVIRON MICROBIOL, V2, P191, DOI 10.1046/j.1462-2920.2000.00092.x; Garcia-Martinez J, 2000, MOL ECOL, V9, P935, DOI 10.1046/j.1365-294x.2000.00953.x; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; Giovannoni SJ., 2000, MICROBIAL ECOLOGY OC, P47; Glockner FO, 1999, APPL ENVIRON MICROB, V65, P3721; Glockner FO, 1996, SYST APPL MICROBIOL, V19, P403; Gonzalez JM, 1997, APPL ENVIRON MICROB, V63, P4237; Gonzalez JM, 2000, APPL ENVIRON MICROB, V66, P4237, DOI 10.1128/AEM.66.10.4237-4246.2000; Gosink JJ, 1997, SYST APPL MICROBIOL, V20, P356, DOI 10.1016/S0723-2020(97)80003-3; Hagstrom A, 2002, APPL ENVIRON MICROB, V68, P3628, DOI 10.1128/AEM.68.7.3628-3633.2002; Kirchman DL, 2002, FEMS MICROBIOL ECOL, V39, P91, DOI 10.1111/j.1574-6941.2002.tb00910.x; Kolber ZS, 2001, SCIENCE, V292, P2492, DOI 10.1126/science.1059707; LONGHURST A, 1998, ECOLOGICAL GEOGRAPHY, P339; Morris RM, 2002, NATURE, V420, P806, DOI 10.1038/nature01240; MUYZER G, 1995, ARCH MICROBIOL, V164, P165, DOI 10.1007/BF02529967; Muyzer G., 1998, MOL MICROBIAL ECOLOG, P1; Rappe MS, 1997, LIMNOL OCEANOGR, V42, P811, DOI 10.4319/lo.1997.42.5.0811; SCHUT F, 1993, APPL ENVIRON MICROB, V59, P2150, DOI 10.1128/AEM.59.7.2150-2160.1993; Selje N, 2003, AQUAT MICROB ECOL, V30, P221, DOI 10.3354/ame030221; Staley JT, 1999, ANNU REV MICROBIOL, V53, P189, DOI 10.1146/annurev.micro.53.1.189; Ward BB, 2002, APPL ENVIRON MICROB, V68, P4153, DOI 10.1128/AEM.68.8.4153-4157.2002; Zubkov MV, 2001, ENVIRON MICROBIOL, V3, P304, DOI 10.1046/j.1462-2920.2001.00196.x; [No title captured]	28	212	221	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					445	448		10.1038/nature02272	http://dx.doi.org/10.1038/nature02272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749832				2022-12-28	WOS:000188470500044
J	Jacquemont, S; Hagerman, RJ; Leehey, MA; Hall, DA; Levine, RA; Brunberg, JA; Zhang, L; Jardini, T; Gane, LW; Harris, SW; Herman, K; Grigsby, J; Greco, CM; Berry-Kravis, E; Tassone, F; Hagerman, PJ				Jacquemont, S; Hagerman, RJ; Leehey, MA; Hall, DA; Levine, RA; Brunberg, JA; Zhang, L; Jardini, T; Gane, LW; Harris, SW; Herman, K; Grigsby, J; Greco, CM; Berry-Kravis, E; Tassone, F; Hagerman, PJ			Penetrance of the fragile X - Associated tremor/ataxia syndrome in a premutation carrier population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE RATING-SCALE; ESSENTIAL TREMOR; PARKINSONS-DISEASE; CGG REPEAT; FEMALE CARRIERS; COPIAH COUNTY; PREVALENCE; ALLELES; ATAXIA; CEREBELLAR	Context Premutation expansions (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene are frequent in the general population, with estimated prevalences of 1 per 259 females and 1 per 813 males. Several articles have recently described the presence of late-onset neurological symptoms in male carriers of premutation (FMR1) alleles. The main clinical features described in this newly identified syndrome are cerebellar ataxia and intention tremor. Additional documented symptoms include short-term memory loss, executive functional deficits, cognitive decline, parkinsonism, peripheral neuropathy, lower-limb proximal muscle weakness, and autonomic dysfunction. Objective To study the penetrance of the fragile X-associated tremor/ataxia syndrome (FXTAS) among premutation carriers. Design, Setting, and Participants Family-based study of 192 individuals (premutation carriers and controls) whose families belong to the Northern or Southern California Fragile X Associations. Data were collected (March 2002-April 2003) through a survey and a standardized neurological examination, which was videotaped and subsequently scored in a blinded fashion. Main Outcome Measures Penetrance of intention tremor and ataxia among adult carriers (aged greater than or equal to50 years) of premutation expansions of the FMR1 gene. Results Data from the survey of 192 individuals demonstrated an age-related penetrance of the combination of reported intention tremor and gait ataxia in male carriers (17%, 38%, 47%, and 75% [lower-bound estimates] for participants aged 50-59, 60-69, 70-79, and greater than or equal to80 years, respectively). The male carrier group had an age-adjusted 13-fold increased risk (95% confidence interval, 3.9-25.4; P=.003) of combined intention tremor and gait ataxia when compared with male controls. The clinical examination data from 93 individuals demonstrated that male carriers experienced more difficulties on each of 3 standardized neurological rating scales compared with controls (P<.05). Female carrier scores were also higher than those of female controls (P<.05) on 2 of the 3 neurological rating scales, but no participant was identified with probable or definite FXTAS. Conclusions The study demonstrates that older male carriers of premutation alleles of the FMR1 gene are at high risk of developing FXTAS. Since male premutation carriers are relatively common in the general population, older men with ataxia and intention tremor should be screened for the FMR1 mutation, especially if these signs are accompanied by parkinsonism, autonomic dysfunction, or cognitive decline, regardless of family history.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Univ Calif Davis, Med Ctr, MIND Inst, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Neurol, Sacramento, CA 95817 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; San Diego State Univ, Dept Math & Stat, San Diego, CA 92182 USA; Univ Calif Davis, Sch Med, Dept Radiol, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Pathol, Davis, CA 95616 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pediat, Chicago, IL 60612 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; California State University System; San Diego State University; University of California System; University of California Davis; University of California System; University of California Davis; Rush University	Hagerman, PJ (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, 1 Shields Ave, Davis, CA 95616 USA.	pjhagerman@ucdavis.edu	Jacquemont, Sebastien/AAS-5060-2021	Jacquemont, Sebastien/0000-0001-6838-8767	NICHD NIH HHS [HD 36071] Funding Source: Medline; NINDS NIH HHS [R01 NS044299, NS 43532] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD036071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043532, R01NS044299] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Allingham-Hawkins SJ, 1999, AM J MED GENET, V83, P322, DOI 10.1002/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-B; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Berry-Kravis E, 2003, ANN NEUROL, V53, P616, DOI 10.1002/ana.10522; BHARUCHA NE, 1988, ARCH NEUROL-CHICAGO, V45, P907, DOI 10.1001/archneur.1988.00520320105023; Brunberg JA, 2002, AM J NEURORADIOL, V23, P1757; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; Dombrowski C, 2002, HUM MOL GENET, V11, P371, DOI 10.1093/hmg/11.4.371; DORN MB, 1994, J AM ACAD CHILD PSY, V33, P256, DOI 10.1097/00004583-199402000-00015; Fahn S., 1987, RECENT DEV PARKINSON, P153; FAHN S, 1998, PARKINSONS DIS MOVEM, P225; Franke P, 1998, PSYCHIAT RES, V80, P113, DOI 10.1016/S0165-1781(98)00055-9; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Greco CM, 2002, BRAIN, V125, P1760, DOI 10.1093/brain/awf184; HAERER AF, 1982, ARCH NEUROL-CHICAGO, V39, P750, DOI 10.1001/archneur.1982.00510240012003; Hagerman Paul J., 2003, Neurology, V60, pA469; Hagerman R.J., 2002, FRAGILE X SYNDROME D; Hagerman Randi J., 2003, Neurology, V60, pA331; Hagerman RJ, 2001, NEUROLOGY, V57, P127, DOI 10.1212/WNL.57.1.127; HO SC, 1989, NEUROLOGY, V39, P1314, DOI 10.1212/WNL.39.10.1314; HOLM S, 1979, SCAND J STAT, V6, P65; Jacquemont S, 2003, AM J HUM GENET, V72, P869, DOI 10.1086/374321; Johnston C, 2001, AM J MED GENET, V103, P314, DOI 10.1002/ajmg.1561; Kis B, 2002, NEUROLOGY, V58, P1820, DOI 10.1212/WNL.58.12.1820; Leehey MA, 2002, MOVEMENT DISORD, V17, pS351; Leehey MA, 2003, ARCH NEUROL-CHICAGO, V60, P117, DOI 10.1001/archneur.60.1.117; Loesch DZ, 2002, J DEV BEHAV PEDIATR, V23, P416, DOI 10.1097/00004703-200212000-00004; Louis ED, 2000, MOVEMENT DISORD, V15, P516, DOI 10.1002/1531-8257(200005)15:3<516::AID-MDS1015>3.0.CO;2-J; LOUIS ED, 1995, ARCH NEUROL-CHICAGO, V52, P1201, DOI 10.1001/archneur.1995.00540360079019; Louis ED, 1999, ARCH NEUROL-CHICAGO, V56, P841, DOI 10.1001/archneur.56.7.841; Macpherson J, 2003, HUM GENET, V112, P619, DOI 10.1007/s00439-003-0939-z; Murray A, 1997, HUM MOL GENET, V6, P173, DOI 10.1093/hmg/6.2.173; Nolin SL, 2003, AM J HUM GENET, V72, P454, DOI 10.1086/367713; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RAJPUT AH, 1984, J NEUROL NEUROSUR PS, V47, P466, DOI 10.1136/jnnp.47.5.466; REISS AL, 1993, AM J HUM GENET, V52, P884; Riddle JE, 1998, AM J MENT RETARD, V102, P590; ROUSSEAU F, 1995, AM J HUM GENET, V57, P1006; SCHOENBERG BS, 1985, NEUROLOGY, V35, P841, DOI 10.1212/WNL.35.6.841; Schrag A, 2000, BRIT MED J, V321, P21, DOI 10.1136/bmj.321.7252.21; Schrag A, 1999, LANCET, V354, P1771, DOI 10.1016/S0140-6736(99)04137-9; SCHWARTZ CE, 1994, AM J MED GENET, V51, P400, DOI 10.1002/ajmg.1320510419; SINGER C, 1994, MOVEMENT DISORD, V9, P193, DOI 10.1002/mds.870090212; Sobesky WE, 1996, AM J MED GENET, V64, P340, DOI 10.1002/(SICI)1096-8628(19960809)64:2<340::AID-AJMG21>3.3.CO;2-K; Stebbins GT, 1999, MOVEMENT DISORD, V14, P585, DOI 10.1002/1531-8257(199907)14:4<585::AID-MDS1006>3.0.CO;2-3; Stebbins GT, 1998, MOVEMENT DISORD, V13, P633, DOI 10.1002/mds.870130404; TANDBERG E, 1995, MOVEMENT DISORD, V10, P541, DOI 10.1002/mds.870100503; Tassone F, 1999, AM J MED GENET, V84, P250, DOI 10.1002/(SICI)1096-8628(19990528)84:3<250::AID-AJMG17>3.3.CO;2-W; TASSONE F, 2002, 8 INT FRAG X C JUL 1; TAYLOR AK, 1994, JAMA-J AM MED ASSOC, V271, P507, DOI 10.1001/jama.271.7.507; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Willemsen R, 2003, HUM MOL GENET, V12, P949, DOI 10.1093/hmg/ddg114; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zhang Lin, 2003, Neurology, V60, pA470	55	454	464	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					460	469		10.1001/jama.291.4.460	http://dx.doi.org/10.1001/jama.291.4.460			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	767EF	14747503	Bronze			2022-12-28	WOS:000188426700031
J	van Koningsveld, R; Schmitz, PIM; van der Meche, FGA; Visser, LH; Meulstee, J; van Doorn, PA				van Koningsveld, R; Schmitz, PIM; van der Meche, FGA; Visser, LH; Meulstee, J; van Doorn, PA		Dutch GBS Study Grp	Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial	LANCET			English	Article							INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; PLASMA-EXCHANGE; PREDNISOLONE	Background Despite available treatment with intravenous immunoglobulin (lVlg), morbidity and mortality are considerable in patients with Guillain-Barn syndrome (GBS). Our aim was to assess whether methylprednisolone, when taken with IVIg, improves outcome when compared with lVIg alone. Methods We did a double-blind, placebo-controlled, multicentre, randomised study, to which we enrolled patients who were unable to walk independently and who had been treated within 14 days after onset of weakness with lVlg (0.4 g/kg bodyweight per day) for 5 days. We assigned 233 individuals to receive either intravenous methylprednisolone (500 mg per day; n=116) or placebo (n=117) for 5 days within 48 h of administration of first dose of IVIg. Because age is an important prognostic factor, we split treatment groups into two age-groups-ie, younger than age 50 years, or 50 years and older. Our primary outcome was an improvement from baseline in GBS disability score of one or more grades 4 weeks after randomisation. Analysis was by intention to treat. Findings We analysed 225 patients. GBS disability scores increased by one grade or more in 68%, (76 of 112) of, patients in the methylprednisolone, group and in 56% (63 of 113) of controls (odds ratio [OR] 1.68, 95% Cl 0.97-2.88; p=0.06). After adjustment for age and degree of disability at entry, treatment OR was 1.89 (95% Cl 1.07-3.35; p=0.03). Side-effects did not differ greatly between groups. Interpretation We noted no significant difference between treatment with methylprednisolone and lVIg and Wig alone. Because of the relevance of prognostic factors and the limited side-effects of methylprednisolone, the potential importance of combination treatment with the drug and Wig, however, warrants further investigation.	Erasmus MC, Dept Neurol, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Stat, NL-3000 DR Rotterdam, Netherlands; St Elizabeth Hosp, Tilburg, Netherlands; Canisius Wilhelmina Hosp, Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Elisabeth-TweeSteden Ziekenhuis (ETZ); Canisius-Wilhelmina Hospital	van Koningsveld, R (corresponding author), Erasmus MC, Dept Neurol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	r.vankoningsveld@erasmusmc.nl						[Anonymous], 1994, Ann Neurol, V35, P749; [Anonymous], 1993, Lancet, V341, P586; [Anonymous], 1976, AIDS INVESTIGATION P; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; Berciano J, 1998, LANCET, V351, P754, DOI 10.1016/S0140-6736(05)78528-7; Berciano J, 1997, MUSCLE NERVE, V20, P846; DEJAGER AEJ, 1991, J NEUROL SCI, V104, P151, DOI 10.1016/0022-510X(91)90304-P; DYCK PJ, 1982, ANN NEUROL, V11, P136, DOI 10.1002/ana.410110205; Fletcher DD, 2000, NEUROLOGY, V54, P2311, DOI 10.1212/WNL.54.12.2311; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758; Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; Hughes RAC, 1997, LANCET, V349, P225; HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2; Hughes RAC, 2003, COCHRANE LIB; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; MCKHANN, 1985, NEUROLOGY, V35, P1096; MCKHANN GM, 1988, ANN NEUROL, V23, P347, DOI 10.1002/ana.410230406; Merkies ISJ, 1999, NEUROLOGY, V53, P1648, DOI 10.1212/WNL.53.8.1648; RAPHAEL JC, 1987, ANN NEUROL, V22, P753; Rees JH, 1998, J NEUROL NEUROSUR PS, V64, P74, DOI 10.1136/jnnp.64.1.74; ROPPER AH, 1991, GUILLAINBARRE SYNDRO; Van Koningsveld R, 2000, NEUROLOGY, V54, P620, DOI 10.1212/WNL.54.3.620; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Visser LH, 1996, NEUROLOGY, V47, P668, DOI 10.1212/WNL.47.3.668	26	229	234	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					192	196		10.1016/S0140-6736(03)15324-X	http://dx.doi.org/10.1016/S0140-6736(03)15324-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738791	Green Submitted			2022-12-28	WOS:000188243900008
J	Little, P; Dorward, M; Warner, G; Moore, M; Stephens, K; Senior, J; Kendrick, T				Little, P; Dorward, M; Warner, G; Moore, M; Stephens, K; Senior, J; Kendrick, T			Randomised controlled trial of effect of leaflets to empower patients in consultations in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HAMPSHIRE DEPRESSION PROJECT; GENERAL-PRACTICE; IMPROVE COMMUNICATION; PATIENTS EXPECTATIONS; DOCTORS PERCEPTIONS; CLINICAL-PRACTICE; QUESTIONNAIRE; OUTCOMES; ATTITUDES; EDUCATION	Objective To assess the impact of leaflets encouraging patients to raise concerns and to discuss symptoms or other health related issues in the consultation. Design Randomised controlled trial. Setting Five UK general practices in three settings. Participants 635 consecutive patients, aged 16-80 years, randomised to receive a general leaflet, a depression leaflet, both, or neither. Main outcomes Mean item score on the medical interview satisfaction scale, consultation time, prescribing, referral, and investigation. Results The general leaflet increased patient satisfaction and was more effective with shorter consultations (leaflet 0.64,95% confidence interval 0.19 to 1.08; time 0.3 1, 0.0 to 0.06; interaction between both - 0.045, - 0.08 to -0.009), with similar results for subscales related to the different aspects of communication. Thus for a 10 minute consultation the leaflet increased satisfaction by 7% (seven centile points) and for a five minute consultation by 14%. The leaflet overall caused a small non-significant increase in consultation time (0.36 minutes, - 0.54 to 1.26). Although there was no change in prescribing or referral, a general leaflet increased the numbers of investigations (odds ratio 1.43, 1.00 to 2.05), which persisted when controlling for the major potential confounders of perceived medical need and patient preference (1.87, 1. 10 to 3.19). Most of excess investigations were not thought strongly needed by the doctor or the patient. The depression leaflet had no significant effect on any outcome. Conclusions Encouraging patients to raise issues and to discuss symptoms and other health related issues in the consultation improves their satisfaction and perceptions of communication, particularly in short consultations. Doctors do, however, need to elicit expectations to prevent needless investigations.	Univ Southampton, Community Clin Sci Div, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England; Nightingale Surg, Romsey SO51 7QN, Hants, England; Three Swans Surg, Salisbury SP1 1DX, Wilts, England	University of Southampton	Little, P (corresponding author), Univ Southampton, Community Clin Sci Div, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England.	psl3@soton.ac.uk	Moore, Michael/C-3447-2011; Kendrick, Tony/H-8558-2014	Moore, Michael/0000-0002-5127-4509; Kendrick, Tony/0000-0003-1618-9381; Little, Paul/0000-0003-3664-1873				Albertson G, 2002, AM J MANAG CARE, V8, P375; Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Britten N, 1997, BRIT MED J, V315, P1506, DOI 10.1136/bmj.315.7121.1506; BUTOW PN, 1994, ANN ONCOL, V5, P199, DOI 10.1093/oxfordjournals.annonc.a058793; Carmin CN, 1998, INT J PSYCHIAT MED, V28, P293, DOI 10.2190/4UVD-H84A-KXY4-QHMK; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Coulter A, 2002, BMJ-BRIT MED J, V324, P648, DOI 10.1136/bmj.324.7338.648; DOWRICK C, 1995, BMJ-BRIT MED J, V311, P1274, DOI 10.1136/bmj.311.7015.1274; Fleissig A, 1999, PATIENT EDUC COUNS, V38, P69, DOI 10.1016/S0738-3991(98)00124-4; FREDERIKSON LG, 1995, PATIENT EDUC COUNS, V25, P51, DOI 10.1016/0738-3991(94)00696-J; FREELING P, 1985, BMJ-BRIT MED J, V290, P1880, DOI 10.1136/bmj.290.6485.1880; Hornberger J, 1997, J GEN INTERN MED, V12, P597, DOI 10.1046/j.1525-1497.1997.07119.x; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; Kendrick T, 2000, BMJ-BRIT MED J, V320, P200, DOI 10.1136/bmj.320.7229.200; Kendrick T, 2001, BRIT J GEN PRACT, V51, P911; Little P, 2004, BMJ-BRIT MED J, V328, P444, DOI 10.1136/bmj.38013.644086.7C; Little P, 2001, BRIT MED J, V323, P908, DOI 10.1136/bmj.323.7318.908; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; McCann S, 1996, PATIENT EDUC COUNS, V27, P227, DOI 10.1016/0738-3991(95)00830-6; MIDDLETON J, 1994, BRIT J GEN PRACT, V44, P309; Moore RG, 1997, BRIT J GEN PRACT, V47, P587; Office of Population Censuses and Surveys, 1994, MORB STAT GEN PRACT; Ostler K, 2001, BRIT J PSYCHIAT, V178, P12, DOI 10.1192/bjp.178.1.12; Paterson C, 1996, BRIT MED J, V312, P1016; Pill R, 2001, BRIT MED BULL, V57, P207, DOI 10.1093/bmb/57.1.207; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; TABAK E, 1998, PATIENT ED COUNSEL, V12, P37; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; THOMPSON SC, 1990, HEALTH PSYCHOL, V9, P390, DOI 10.1037/0278-6133.9.4.390; WILKIN D, 1992, MEASURES NEED OUTCOM; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	66	67	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					441	444		10.1136/bmj.37999.716157.44	http://dx.doi.org/10.1136/bmj.37999.716157.44			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14966078	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000189161000021
J	Levine, RJ; Maynard, SE; Qian, C; Lim, KH; England, LJ; Yu, KF; Schisterman, EF; Thadhani, R; Sachs, BP; Epstein, FH; Sibai, BM; Sukhatme, VP; Karumanchi, SA				Levine, RJ; Maynard, SE; Qian, C; Lim, KH; England, LJ; Yu, KF; Schisterman, EF; Thadhani, R; Sachs, BP; Epstein, FH; Sibai, BM; Sukhatme, VP; Karumanchi, SA			Circulating angiogenic factors and the risk of preeclampsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED-TRIAL; FACTOR RECEPTOR; SERUM LEVELS; 2ND-TRIMESTER; BEVACIZUMAB; EXPRESSION; CALCIUM; CANCER	Background: The cause of preeclampsia remains unclear. Limited data suggest that excess circulating soluble fms-like tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), may have a pathogenic role. Methods: We performed a nested case-control study within the Calcium for Preeclampsia Prevention trial, which involved healthy nulliparous women. Each woman with preeclampsia was matched to one normotensive control. A total of 120 pairs of women were randomly chosen. Serum concentrations of angiogenic factors (total sFlt-1, free PlGF, and free VEGF) were measured throughout pregnancy; there were a total of 655 serum specimens. The data were analyzed cross-sectionally within intervals of gestational age and according to the time before the onset of preeclampsia. Results: During the last two months of pregnancy in the normotensive controls, the level of sFlt-1 increased and the level of PlGF decreased. These changes occurred earlier and were more pronounced in the women in whom preeclampsia later developed. The sFlt-1 level increased beginning approximately five weeks before the onset of preeclampsia. At the onset of clinical disease, the mean serum level in the women with preeclampsia was 4382 pg per milliliter, as compared with 1643 pg per milliliter in controls with fetuses of similar gestational age (P<0.001). The PlGF levels were significantly lower in the women who later had preeclampsia than in the controls beginning at 13 to 16 weeks of gestation (mean, 90 pg per milliliter vs. 142 pg per milliliter, P=0.01), with the greatest difference occurring during the weeks before the onset of preeclampsia, coincident with the increase in the sFlt-1 level. Alterations in the levels of sFlt-1 and free PlGF were greater in women with an earlier onset of preeclampsia and in women in whom preeclampsia was associated with a small-for-gestational-age infant. Conclusions: Increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia.	NICHHD, Div Epidemiol Stat & Prevent Res, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Allied Technol Grp, Rockville, MD USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Obstet, Boston, MA 02114 USA; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University System of Ohio; University of Cincinnati	Levine, RJ (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, Dept Hlth & Human Serv, Bldg 6100,Rm 7B03, Bethesda, MD 20892 USA.	levinerj@mail.nih.gov; sananth@bidmc.harvard.edu	Sukhatme, Vikas/W-2776-2019; Karumanchi, Subbian Ananth/AAI-1694-2021	Schisterman, Enrique/0000-0003-3757-641X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000864, Z01HD000373, Z01HD000864] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Cockell AP, 1997, BRIT J OBSTET GYNAEC, V104, P235, DOI 10.1111/j.1471-0528.1997.tb11052.x; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Holzgreve W, 1998, OBSTET GYNECOL, V91, P669, DOI 10.1016/S0029-7844(98)00068-4; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Koga K, 2003, J CLIN ENDOCR METAB, V88, P2348, DOI 10.1210/jc.2002-021942; Levine RJ, 1996, CONTROL CLIN TRIALS, V17, P442, DOI 10.1016/S0197-2456(96)00106-7; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Polliotti BM, 2003, OBSTET GYNECOL, V101, P1266, DOI 10.1016/S0029-7844(03)00338-7; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Strevens H, 2003, BJOG-INT J OBSTET GY, V110, P831, DOI 10.1111/j.1471-0528.2003.02162.x; Su YN, 2001, OBSTET GYNECOL, V97, P898, DOI 10.1016/S0029-7844(01)01341-2; Taylor RN, 2003, AM J OBSTET GYNECOL, V188, P177, DOI 10.1067/mob.2003.111; THADHANI R, IN PRESS J CLIN ENDO; Tidwell SC, 2001, AM J OBSTET GYNECOL, V184, P1267, DOI 10.1067/mob.2001.113129; Tjoa ML, 2001, OBSTET GYNECOL, V98, P600, DOI 10.1016/S0029-7844(01)01497-1; Torry DS, 1998, AM J OBSTET GYNECOL, V179, P1539, DOI 10.1016/S0002-9378(98)70021-3; Torry DS, 2003, J SOC GYNECOL INVEST, V10, P178, DOI 10.1016/S1071-5576(03)00048-0; Tsatsaris V, 2003, J CLIN ENDOCR METAB, V88, P5555, DOI 10.1210/jc.2003-030528; Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; ZHANG J, 1995, OBSTET GYNECOL, V86, P200, DOI 10.1016/0029-7844(95)00142-E; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	25	2555	2706	8	112	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					672	683		10.1056/NEJMoa031884	http://dx.doi.org/10.1056/NEJMoa031884			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14764923				2022-12-28	WOS:000188869500008
J	Pisharody, SN; Jones, RR				Pisharody, SN; Jones, RR			Probing two-electron dynamics of an atom	SCIENCE			English	Article							DOUBLY-EXCITED-STATES; RYDBERG STATES; HELIUM ATOM; QUANTUM-THEORY; SYSTEMS; BA	Coherent short-pulse laser excitation has been used to control the approximate energy and relative proximity of two valence electrons within the same alkaline-earth atom, thereby providing insight into the dynamical evolution of a three-body Coulomb system. Our time-domain experiments enable direct experimental study of the electron dynamics at the classical limit of a two-electron atom. As an example, we look at the mechanism of autoionization for one two-electron configuration class and find that the doubly excited atom decays through a single violent electron-electron collision rather than a gradual exchange of energy between the electrons.	Univ Virginia, Dept Phys, Charlottesville, VA 22904 USA	University of Virginia	Jones, RR (corresponding author), Univ Virginia, Dept Phys, 382 McCormick Rd, Charlottesville, VA 22904 USA.	rrj3c@virginia.edu						BLOOMFIELD LA, 1984, PHYS REV LETT, V53, P2234, DOI 10.1103/PhysRevLett.53.2234; Bohr N, 1913, PHILOS MAG, V26, P476, DOI 10.1080/14786441308634993; Bromage J, 1999, PHYS REV LETT, V83, P4963, DOI 10.1103/PhysRevLett.83.4963; EBERHARDT W, 1988, PHYS REV A, V38, P3808, DOI 10.1103/PhysRevA.38.3808; FEAGIN JM, 1988, PHYS REV A, V37, P4599, DOI 10.1103/PhysRevA.37.4599; HANDKE G, 1993, PHYSICA A, V197, P113, DOI 10.1016/0378-4371(93)90461-C; Huang W, 1999, PHYS REV A, V59, P2744, DOI 10.1103/PhysRevA.59.2744; Jones RR, 1997, ADV ATOM MOL OPT PHY, V38, P1; Kalinski M, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032503; Langmuir I, 1921, PHYS REV, V17, P339, DOI 10.1103/PhysRev.17.339; LEOPOLD JG, 1980, J PHYS B-AT MOL OPT, V13, P1037, DOI 10.1088/0022-3700/13/6/012; RICHTER K, 1990, J PHYS B-AT MOL OPT, V23, pL197, DOI 10.1088/0953-4075/23/11/002; RICHTER K, 1993, PHYS REV A, V48, P4182, DOI 10.1103/PhysRevA.48.4182; RICHTER K, 1991, PHYS REV LETT, V66, P149, DOI 10.1103/PhysRevLett.66.149; Tanner G, 2000, REV MOD PHYS, V72, P497, DOI 10.1103/RevModPhys.72.497; TENWOLDE A, 1988, PHYS REV LETT, V61, P2099, DOI 10.1103/PhysRevLett.61.2099; Van Vleck JH, 1922, PHILOS MAG, V44, P842, DOI 10.1080/14786441208562559; WATANABE S, 1986, PHYS REV A, V34, P823, DOI 10.1103/PhysRevA.34.823; Weinacht TC, 1999, NATURE, V397, P233, DOI 10.1038/16654; West JA, 1998, PHYS REV A, V58, P186, DOI 10.1103/PhysRevA.58.186	24	44	47	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					813	815		10.1126/science.1092220	http://dx.doi.org/10.1126/science.1092220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764871				2022-12-28	WOS:000188753800049
J	Chopra, SS; Sotile, WM; Sotile, MO				Chopra, SS; Sotile, WM; Sotile, MO			Physician burnout	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JOB-SATISFACTION; STRESS; MANAGEMENT; PREVENTION; RESIDENTS; CARE		Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Vanderbilt University; Wake Forest University; Tulane University	Chopra, SS (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.							Gabbe SG, 2002, AM J OBSTET GYNECOL, V186, P601, DOI 10.1067/mob.2002.122391; Grunfeld E, 2000, CAN MED ASSOC J, V163, P166; KELLER KL, 1989, ANN EMERG MED, V18, P42; Lloyd S, 1994, J Emerg Med, V12, P559; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; MCCUE JD, 1991, ARCH INTERN MED, V151, P2273, DOI 10.1001/archinte.151.11.2273; Michels PJ, 2003, ACAD MED, V78, P69, DOI 10.1097/00001888-200301000-00013; Mirvis D M, 1999, J Health Hum Serv Adm, V21, P390; Mirvis DM, 1999, J HEALTHC MANAG, V44, P353, DOI 10.1097/00115514-199909000-00007; RAFFERTY JP, 1986, J CLIN PSYCHOL, V42, P488, DOI 10.1002/1097-4679(198605)42:3<488::AID-JCLP2270420315>3.0.CO;2-S; Schaufeli W.B., 1996, MASLACH BURNOUT INVE, V3rd, P22; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Thommasen HV, 2001, CAN FAM PHYSICIAN, V47, P737	13	75	78	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					633	633		10.1001/jama.291.5.633	http://dx.doi.org/10.1001/jama.291.5.633			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762045				2022-12-28	WOS:000188650700031
J	Shinoda-Tagawa, T; Leonard, R; Pontikas, J; McDonough, JE; Allen, D; Dreyer, PI				Shinoda-Tagawa, T; Leonard, R; Pontikas, J; McDonough, JE; Allen, D; Dreyer, PI			Resident-to-resident violent incidents in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AGGRESSIVE-BEHAVIOR; PSYCHOSIS; VICTIMS	Context Little is known about nursing home residents' injuries that are inflicted by other residents. Objective To assess risk factors for violent injury to nursing home residents by other residents. Design, Setting, and Subjects. Case-control study using data from the Massachusetts Department of Public Health's Complaint and Incident Reporting System and from Minimum Data Set assessments for Massachusetts nursing home residents. Cases had an injury sustained from an incident with another nursing home resident between January 1, 2000, and December 31, 2000, which left visible evidence Oe, fracture, dislocation, bruise or hematoma, laceration, and reddened area) (median age, 81 years). Controls were randomly selected from all residents who had a Minimum Data Set assessment completed in 2000 (n = 101429) and no injury report (median age, 83 years). A total of 1994 controls were included in the analyses. Main Outcome Measures Injury type and risk of being injured by resident-to-resident aggressive physical behaviors based on the specific characteristics of the injured resident. Results During the first incident, 294 residents sustained fractures (n=39), dislocations (n=6), bruises or hematomas (n=105), lacerations (n=113), and reddened areas (n=31). Injured residents (cases) were more likely to be cognitively impaired, exhibit symptoms of wandering, be verbally abusive, and have socially inappropriate behavior than the controls. Residents who were classified as needing extensive assistance (adjusted odds ratio [AOR], 0.3; 95% confidence interval [CI], 0.2-0.6) and being severely dependent (AOR, 0.12; 95% Cl, 0.05-0.27) had a significant reduction in being injured. Residents in an Alzheimer disease unit were almost 3 times as likely to be injured than those living in other units (AOR, 3.2; 95% Cl, 1.4-7.5). Conclusions Injured residents were more likely, perhaps unknowingly, to "put themselves in harm's way," be verbally aggressive, and be cognitively impaired. Interventions to prevent these incidents should focus on the behavior of the injured persons.	Yale Univ, Sch Med, Div Geriatr, Dept Internal Med, New Haven, CT 06504 USA; Hlth Care All, Boston, MA USA; Massachusetts Dept Publ Hlth, Div Hlth Care Qual, Boston, MA USA; Harvard Injury Control Res Ctr, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Yale University; Massachusetts Department of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Leonard, R (corresponding author), Yale Univ, Sch Med, Div Geriatr, Dept Internal Med, 17B Tompkins,20 York St, New Haven, CT 06504 USA.	Ralph.Leonard@yale.edu						Brodaty H, 2001, INT J GERIATR PSYCH, V16, P504, DOI 10.1002/gps.382; BURSTON GR, 1975, BRIT MED J, V3, P592, DOI 10.1136/bmj.3.5983.592-a; Covington H, 2001, Holist Nurs Pract, V15, P59; *EX OFF ELD AFF, NURS HOM OMB PROGR; Feldt K S, 1998, J Gerontol Nurs, V24, P14; *GEN ACC OFF, 2002, 02312 GAO PUBL; *GEN ACC OFF, 2002, 02448T GAO PUBL; *GEN ACC OFF, 1999, HEHS9989 GAO PUBL; Gray MJ, 2002, J ANXIETY DISORD, V16, P299, DOI 10.1016/S0887-6185(02)00101-9; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; *I MED, 1990, MED STRAT QUAL ASS, V1; Ikegami N., 2002, MEASURING IMPROVING; Institute of Medicine, 2001, CROSSING QUALITY CHA; Institute of Medicine, 2001, IMPR QUAL LONG TERM; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; Kolanowski A M, 1999, J Neurosci Nurs, V31, P278; Lam LCW, 1997, INT J GERIATR PSYCH, V12, P678, DOI 10.1002/(SICI)1099-1166(199706)12:6<678::AID-GPS610>3.0.CO;2-R; Lang AJ, 2002, DEPRESS ANXIETY, V16, P77, DOI 10.1002/da.10062; LOHR KN, 1990, MED STRATEGY QUALITY, V1; Lou MF, 2001, SCAND J CARING SCI, V15, P165, DOI 10.1046/j.1471-6712.2001.00021.x; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Morris JN., 2003, VALIDATION LONG TERM; NELSON HW, 1995, GERONTOLOGIST, V35, P509, DOI 10.1093/geront/35.4.509; Nishith P, 2002, BIOL PSYCHIAT, V51, P867, DOI 10.1016/S0006-3223(01)01346-4; PILLEMER K, 1989, GERONTOLOGIST, V29, P314, DOI 10.1093/geront/29.3.314; Price J. D., 2000, COCHRANE DB SYST REV, V4; Rapoport MJ, 2001, INT J GERIATR PSYCH, V16, P123, DOI 10.1002/1099-1166(200102)16:2<123::AID-GPS260>3.3.CO;2-T; Ray WA, 1997, JAMA-J AM MED ASSOC, V278, P557, DOI 10.1001/jama.278.7.557; RUDMAN D, 1993, HOSP COMMUNITY PSYCH, V44, P571; RUDMAN D, 1994, J GEN INTERN MED, V9, P261, DOI 10.1007/BF02599652; Ryden MB, 1999, ARCH PSYCHIAT NURS, V13, P170, DOI 10.1016/S0883-9417(99)80003-X; Schnelle JF, 1996, J AM GERIATR SOC, V44, P507, DOI 10.1111/j.1532-5415.1996.tb01434.x; Shah A, 2000, INT PSYCHOGERIATR, V12, P145, DOI 10.1017/S1041610200006281; TATARA T, 1990, ELDERLY ABUSE US ISS; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1207, DOI 10.1111/j.1532-5415.1995.tb07395.x; Wooldridge J.M., 2000, INTRO ECONOMETRICS M	38	84	84	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					591	598		10.1001/jama.291.5.591	http://dx.doi.org/10.1001/jama.291.5.591			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	769LC	14762038	Bronze			2022-12-28	WOS:000188650700024
J	Zheng, H; Wang, J; Lofland, SE; Ma, Z; Mohaddes-Ardabili, L; Zhao, T; Salamanca-Riba, L; Shinde, SR; Ogale, SB; Bai, F; Viehland, D; Jia, Y; Schlom, DG; Wuttig, M; Roytburd, A; Ramesh, R				Zheng, H; Wang, J; Lofland, SE; Ma, Z; Mohaddes-Ardabili, L; Zhao, T; Salamanca-Riba, L; Shinde, SR; Ogale, SB; Bai, F; Viehland, D; Jia, Y; Schlom, DG; Wuttig, M; Roytburd, A; Ramesh, R			Multiferroic BaTiO3-CoFe2O4 nanostructures	SCIENCE			English	Article							COMPOSITES	We report on the coupling between ferroelectric and magnetic order parameters in a nanostructured BaTiO3-CoFe2O4 ferroelectromagnet. This facilitates the interconversion of energies stored in electric and magnetic fields and plays an important role in many devices, including transducers, field sensors, etc. Such nanostructures were deposited on single-crystal SrTiO3 (001) substrates by pulsed laser deposition from a single Ba-Ti-Co-Fe-oxide target. The films are epitaxial in-plane as well as out-of-plane with self-assembled hexagonal arrays of CoFe2O4 nanopillars embedded in a BaTiO3 matrix. The CoFe2O4 nanopillars have uniform size and average spacing of 20 to 30 nanometers. Temperature-dependent magnetic measurements illustrate the coupling between the two order parameters, which is manifested as a change in magnetization at the ferroelectric Curie temperature. Thermodynamic analyses show that the magnetoelectric coupling in such a nanostructure can be understood on the basis of the strong elastic interactions between the two phases.	Univ Maryland, Dept Mat Sci & Engn, College Pk, MD 20742 USA; Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Rowan Univ, Dept Phys, Glassboro, NJ 08028 USA; Virginia Tech, Dept Mat Sci & Engn, Blacksburg, VA 24061 USA; Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Rowan University; Virginia Polytechnic Institute & State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zheng, H (corresponding author), Univ Maryland, Dept Mat Sci & Engn, College Pk, MD 20742 USA.		WANG, Junling/B-3596-2009; Bai, Feiming/K-5762-2013; Ramesh, Ramamoorthy/ABI-4883-2020; Salamanca-Riba, Lourdes G/B-3785-2009; Wuttig, Manfred/A-8763-2012; Schlom, Darrell G/J-2412-2013; Lofland, Samuel E/A-2595-2008	WANG, Junling/0000-0003-3663-7081; Salamanca-Riba, Lourdes G/0000-0001-8155-6403; Schlom, Darrell G/0000-0003-2493-6113; Bai, Feiming/0000-0002-9431-4013; Zheng, Haimei/0000-0003-3813-4170; Lofland, Samuel/0000-0002-1024-5103				Bichurin MI, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.134404; Bozorth R.M., 1993, FERROMAGNETISM; Folen V J, 1970, LANDOLTBORNSTEIN 4B, V3, P366; Hill NA, 2002, ANNU REV MATER RES, V32, P1, DOI 10.1146/annurev.matsci.32.101901.152309; Khachaturyan A.G., 1993, THEORY STRUCTURAL TR; LEFKI K, 1994, J APPL PHYS, V76, P1764, DOI 10.1063/1.357693; Moshnyaga V, 2003, NAT MATER, V2, P247, DOI 10.1038/nmat859; NEWNHAM RE, 1990, J APPL CRYSTALLOGR, V23, P447, DOI 10.1107/S0021889890006471; ROITBURD AL, 1976, PHYS STATUS SOLIDI A, V37, P329, DOI 10.1002/pssa.2210370141; Roytburd AL, 1998, J APPL PHYS, V83, P228, DOI 10.1063/1.366677; Ryu J, 2002, J ELECTROCERAM, V8, P107, DOI 10.1023/A:1020599728432; Smolenskii G. A., 1982, Soviet Physics - Uspekhi, V25, P475, DOI 10.1070/PU1982v025n07ABEH004570; VANDENBOOMGAARD J, 1976, FERROELECTRICS, V14, P727, DOI 10.1080/00150197608236711; VANSUCHTELEN J, 1972, PHILIPS RES REP, V27, P28; Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615	15	1883	1929	46	1330	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					661	663		10.1126/science.1094207	http://dx.doi.org/10.1126/science.1094207			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752158				2022-12-28	WOS:000188530800037
J	Karam, JA; Baker, LA				Karam, JA; Baker, LA			True hermaphroditism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Karam, JA (corresponding author), Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					393	393		10.1056/NEJMicm030685	http://dx.doi.org/10.1056/NEJMicm030685			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736931				2022-12-28	WOS:000188254800011
J	Steinbrook, R				Steinbrook, R			Financial conflicts of interest and the NIH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Blumenthal D, 2003, NEW ENGL J MED, V349, P2452, DOI 10.1056/NEJMhpr035460; Willman David, 2003, Los Angeles Times, pA32; ZERHOUNI EA, 2003, COMMUNICATION   1223	3	28	29	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					327	330		10.1056/NEJMp038247	http://dx.doi.org/10.1056/NEJMp038247			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736923				2022-12-28	WOS:000188254800003
J	Pathan, N; Hemingway, CA; Alizadeh, AA; Stephens, AC; Boldrick, JC; Oragui, EE; McCabe, C; Welch, SB; Whitney, A; O'Gara, P; Nadel, S; Relman, DA; Harding, SE; Levin, M				Pathan, N; Hemingway, CA; Alizadeh, AA; Stephens, AC; Boldrick, JC; Oragui, EE; McCabe, C; Welch, SB; Whitney, A; O'Gara, P; Nadel, S; Relman, DA; Harding, SE; Levin, M			Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock	LANCET			English	Article							ADHESION MOLECULE EXPRESSION; INCREASING PROTEIN RBPI(21); NITRIC-OXIDE; PROINFLAMMATORY CYTOKINES; NEISSERIA-MENINGITIDIS; DEPRESSANT FACTOR; PLASMA-LEVELS; IN-VITRO; CHILDREN; SEVERITY	Background Myocardial failure has a central role in the complex pathophysiology of septic shock and contributes to organ failure and death. During the sepsis-induced inflammatory process, specific factors are released that depress myocardial contractile function. We aimed to identify these mediators of myocardial depression in meningococcal septic shock. Methods We combined gene-expression profiling with protein and cellular methods to identify a serum factor causing cardiac dysfunction in meningococcal septic shock. We identified genes that were significantly upregulated in blood after exposure to meningococci. We then selected for further analysis those genes whose protein products had properties of a myocardial depressant factor-specifically a 12-25 kDa heat-stable protein that is released into serum shortly after onset of meningococcal infection. Findings We identified 174 significantly upregulated genes in meningococcus-infected blood: six encoded proteins that were of the predicted size and had characteristics of a myocardial depressant factor. Of these, interleukin 6 caused significant myocardial depression in vitro. Removal of interleukin 6 from serum samples of patients with meningococcaemia and from supernatants of inflammatory cells stimulated by meningococci in vitro abolished the negative inotropic activity. Furthermore, concentrations in serum of interleukin 6 strongly predicted degree of myocardial dysfunction and severity of disease in children with meningococcal septic shock. Interpretation Interleukin 6 is a mediator of myocardial depression in meningococcal disease. This cytokine and its downstream mediators could be a target for future treatment strategies.	Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, London, England; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Imperial College London; Imperial College London; Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Pathan, N (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, 2nd Floor,Med Sch Bldg, London W2 1PG, England.	n.pathan@imperial.ac.uk	Alizadeh, Ash A/C-5594-2009	Alizadeh, Ash A/0000-0002-5153-5625; Relman, David A./0000-0001-8331-1354; Levin, Michael/0000-0003-2767-6919; Harding, Sian/0000-0002-3651-6354; Pathan, Nazima/0000-0001-7656-9453				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BENNASSAYAG C, 1984, EUR J CLIN INVEST, V14, P288; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chan B, 1996, BIOTHERAPY, V9, P221, DOI 10.1007/BF02620735; EISEN M, MICROARRAYS ORG SOFT; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296; Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007; HAZELZET JA, 1994, INTENS CARE MED, V20, P371, DOI 10.1007/BF01720912; Hazelzet JA, 1996, THROMB HAEMOSTASIS, V76, P932; Heyderman RS, 1999, J INFECT DIS, V179, P1288, DOI 10.1086/314706; Hovels-Gurich HH, 2002, J THORAC CARDIOV SUR, V124, P811, DOI 10.1067/mtc.2002.122308; KINUGAWA K, 1994, CIRC RES, V75, P285, DOI 10.1161/01.RES.75.2.285; Klein NJ, 1996, J INFECT DIS, V173, P172, DOI 10.1093/infdis/173.1.172; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; LIU CL, DATA PROCESSING TIME; MERCIER JC, 1988, CRIT CARE MED, V16, P27, DOI 10.1097/00003246-198801000-00006; PARRILLO JE, 1985, J CLIN INVEST, V76, P1539, DOI 10.1172/JCI112135; Pathan N, 2002, CRIT CARE MED, V30, P2191, DOI 10.1097/00003246-200210000-00003; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; SAGHER U, 1986, CIRC SHOCK, V19, P319; Sugishita K, 1999, J MOL CELL CARDIOL, V31, P1457, DOI 10.1006/jmcc.1999.0989; THALINGE.AR, 1971, P SOC EXP BIOL MED, V136, P354; VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; STANFORD MICROARRAY	28	214	237	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					203	209		10.1016/S0140-6736(03)15326-3	http://dx.doi.org/10.1016/S0140-6736(03)15326-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738793	Green Submitted			2022-12-28	WOS:000188243900010
J	Nateri, AS; Riera-Sans, L; Da Costa, C; Behrens, A				Nateri, AS; Riera-Sans, L; Da Costa, C; Behrens, A			The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling	SCIENCE			English	Article							F-BOX PROTEIN; C-JUN; CYCLIN-E; MICE LACKING; PHOSPHORYLATION; SYSTEM; GENE; SEL-10; SCF	Jun N-terminal kinases (JNKs) are essential for neuronal microtubule assembly and apoptosis. Phosphorylation of the activating protein 1 (AP1) transcription factor c-Jun, at multiple sites within its transactivation domain, is required for JNK-induced neurotoxicity. We report that in neurons the stability of c-Jun is regulated by the E3 ligase SCFFbw7, which ubiquitinates phosphorylated c-Jun and facilitates c-Jun degradation. Fbw7 depletion resulted in accumulation of phosphorylated c-Jun, stimulation of AP1 activity, and neuronal apoptosis. SCFFbw7 therefore antagonizes the apoptotic c-Jun-dependent effector arm of JNK signaling, allowing neurons to tolerate potentially neurotoxic JNK activity.	Canc Res UK, Mammalian Genet Lab, London Res Inst, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Behrens, A (corresponding author), Canc Res UK, Mammalian Genet Lab, London Res Inst, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.	axel.behrens@cancer.org.uk		Behrens, Axel/0000-0002-1557-1143; Shams Nateri, Abdolrahman/0000-0002-6422-6813; Da Costa, Clive/0000-0002-0435-6747				Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Maruyama S, 2001, GENOMICS, V78, P214, DOI 10.1006/geno.2001.6658; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Spruck CH, 2002, CANCER RES, V62, P4535; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	22	301	313	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1374	1378		10.1126/science.1092880	http://dx.doi.org/10.1126/science.1092880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14739463				2022-12-28	WOS:000189238600053
J	Wilson, JF				Wilson, JF			The promise of disease proteomics: Faster detection, diagnosis, and drug development	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PATTERNS; CANCER; SERUM					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Liotta LA, 2003, NATURE, V425, P905, DOI 10.1038/425905a; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; PETRICOIN EF, 2003, AM ASS CANC RES ABST, V4573; Service RF, 2003, SCIENCE, V302, P1316, DOI 10.1126/science.302.5649.1316; 2001, TECHNOLOGY REV  1004	7	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					317	319		10.7326/0003-4819-140-4-200402170-00036	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00036			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970168				2022-12-28	WOS:000188970400026
J	Bernasconi, G; Ashman, TL; Birkhead, TR; Bishop, JDD; Grossniklaus, U; Kubli, E; Marshall, DL; Schmid, B; Skogsmyr, I; Snook, RR; Taylor, D; Till-Bottraud, I; Ward, PI; Zeh, DW; Hellriegel, B				Bernasconi, G; Ashman, TL; Birkhead, TR; Bishop, JDD; Grossniklaus, U; Kubli, E; Marshall, DL; Schmid, B; Skogsmyr, I; Snook, RR; Taylor, D; Till-Bottraud, I; Ward, PI; Zeh, DW; Hellriegel, B			Evolutionary ecology of the prezygotic stage	SCIENCE			English	Review							SPERM COMPETITION GAMES; CRYPTIC FEMALE CHOICE; POLLEN PERFORMANCE; SEXUAL SELECTION; CONFLICT; PLANTS; FERTILIZATION; STRATEGIES; MORPHOLOGY; POLYANDRY	The life cycles of sexually reproducing animals and flowering plants begin with male and female gametes and their fusion to form a zygote. Selection at this earliest stage is crucial for offspring quality and raises similar evolutionary issues, yet zoology and botany use dissimilar approaches. There are striking parallels in the role of prezygotic competition for sexual selection on males, cryptic female choice, sexual conflict, and against selfish genetic elements and genetic incompatibility. In both groups, understanding the evolution of sex-specific and reproductive traits will require an appreciation of the effects of prezygotic competition on fitness.	Univ Zurich, Inst Environm Sci, CH-8057 Zurich, Switzerland; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Univ Plymouth, Sch Biol Sci, Plymouth PL4 8AA, Devon, England; Marine Biol Assoc UK, Plymouth PL1 2PB, Devon, England; Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Lund Univ, Dept Theoret Ecol, S-22362 Lund, Sweden; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA; Univ Grenoble 1, Lab Ecol Alpine, F-38041 Grenoble, France; Univ Zurich, Museum Zool, CH-8057 Zurich, Switzerland; Univ Nevada, Dept Biol, Reno, NV 89557 USA; Tech Univ Munich, Inst Med Stat & Epidemiol, D-81675 Munich, Germany	University of Zurich; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sheffield; University of Plymouth; Marine Biological Association United Kingdom; University of Zurich; University of Zurich; University of New Mexico; Lund University; University of Virginia; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Savoie; University of Zurich; Nevada System of Higher Education (NSHE); University of Nevada Reno; Technical University of Munich	Bernasconi, G (corresponding author), Univ Zurich, Inst Environm Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	bernasco@uwinst.unizh.ch	Schmid, Bernhard/C-8625-2009; Grossniklaus, Ueli/E-9995-2016; Grossniklaus, Ueli/A-2736-2012; Snook, Rhonda/D-7291-2016	Schmid, Bernhard/0000-0002-8430-3214; Grossniklaus, Ueli/0000-0002-0522-8974; Bernasconi, Giorgina/0000-0003-1042-1784; Snook, Rhonda/0000-0003-1852-1448				Arnqvist G, 2000, P NATL ACAD SCI USA, V97, P10460, DOI 10.1073/pnas.97.19.10460; Arthur KM, 2003, GENETICS, V165, P2137; ASHMAN TL, 1994, NATURE, V371, P788, DOI 10.1038/371788a0; ASHMAN TL, UNPUB; Barrett SCH, 2003, PHILOS T R SOC B, V358, P991, DOI 10.1098/rstb.2003.1301; Becker JD, 2003, PLANT PHYSIOL, V133, P713, DOI 10.1104/pp.103.028241; Bernasconi G, 2004, PERSPECT PLANT ECOL, V6, P149, DOI 10.1078/1433-8319-00075; Bernasconi G, 2003, OIKOS, V102, P217, DOI 10.1034/j.1600-0706.2003.12598.x; BERTIN RI, 1988, AM J BOT, V75, P1140, DOI 10.2307/2444097; Birkhead TR, 2002, NAT REV GENET, V3, P262, DOI 10.1038/nrg774; Birkhead TR, 1998, SPERM COMPETITION SE; Bishop JDD, 1996, P ROY SOC B-BIOL SCI, V263, P369, DOI 10.1098/rspb.1996.0057; BOWERS KAW, 1975, AM J BOT, V62, P633, DOI 10.2307/2441943; CARRE D, 1991, DEV BIOL, V147, P381, DOI 10.1016/0012-1606(91)90296-F; Chapman T, 2003, P NATL ACAD SCI USA, V100, P9923, DOI 10.1073/pnas.1631635100; Clark AG, 1998, GENETICS, V149, P1487; DAJOZ I, 1991, SCIENCE, V253, P66, DOI 10.1126/science.253.5015.66; DELPH LF, 1998, SPERM COMPETITION SE; Edvardsson M, 2000, P ROY SOC B-BIOL SCI, V267, P559, DOI 10.1098/rspb.2000.1037; Foerster K, 2003, NATURE, V425, P714, DOI 10.1038/nature01969; HAIG D, 1995, J EVOLUTION BIOL, V8, P265, DOI 10.1046/j.1420-9101.1995.8030265.x; Hellriegel B, 2000, ANIM BEHAV, V59, P311, DOI 10.1006/anbe.1999.1308; Hellriegel B, 1998, J THEOR BIOL, V190, P179, DOI 10.1006/jtbi.1997.0546; Herrero M, 1996, SEX PLANT REPROD, V9, P343, DOI 10.1007/BF02441953; Honys D, 2003, PLANT PHYSIOL, V132, P640, DOI 10.1104/pp.103.020925; Huck N, 2003, DEVELOPMENT, V130, P2149, DOI 10.1242/dev.00458; Hughes RN, 2003, P NATL ACAD SCI USA, V100, P10326, DOI 10.1073/pnas.1334011100; Hughes RN, 2002, P NATL ACAD SCI USA, V99, P14884, DOI 10.1073/pnas.162339699; KELLER L, 1995, TRENDS ECOL EVOL, V10, P355, DOI 10.1016/S0169-5347(00)89133-8; Liu HF, 2003, P NATL ACAD SCI USA, V100, P9929, DOI 10.1073/pnas.1631700100; Lord EM, 2003, J EXP BOT, V54, P47, DOI 10.1093/jxb/54.380.47; Marshall DL, 1998, AM J BOT, V85, P1389, DOI 10.2307/2446397; Meiklejohn CD, 2003, P NATL ACAD SCI USA, V100, P9894, DOI 10.1073/pnas.1630690100; Moller AP., 1998, SPERM COMPETITION SE; Moore H, 2002, NATURE, V418, P174, DOI 10.1038/nature00832; MULCAHY DL, 1979, SCIENCE, V206, P20, DOI 10.1126/science.206.4414.20; Nasrallah JB, 2002, SCIENCE, V296, P305, DOI 10.1126/science.296.5566.305; Page DR, 2002, NAT REV GENET, V3, P124, DOI 10.1038/nrg730; PARKER GA, 1990, P ROY SOC B-BIOL SCI, V242, P120, DOI 10.1098/rspb.1990.0114; PARKER GA, 1993, P ROY SOC B-BIOL SCI, V253, P255, DOI 10.1098/rspb.1993.0111; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; Pizzari T, 2003, EVOLUTION, V57, P1223, DOI 10.1111/j.0014-3820.2003.tb00331.x; QUELLER DC, 1987, SEXUAL SELECTION TES; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Rotman N, 2003, CURR BIOL, V13, P432, DOI 10.1016/S0960-9822(03)00093-9; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; Skogsmyr I, 2002, BIOL REV, V77, P537, DOI 10.1017/S1464793102005973; SNOW AA, 1993, ANNU REV ECOL SYST, V24, P331, DOI 10.1146/annurev.es.24.110193.001555; Stearns S., 1987, EVOLUTION SEX ITS CO; Stephenson AG, 2003, PHILOS T R SOC B, V358, P1009, DOI 10.1098/rstb.2003.1290; Swallow JG, 2002, BIOL REV, V77, P153, DOI 10.1017/S1464793101005851; Taylor DR, 1999, EVOLUTION, V53, P1028, DOI 10.1111/j.1558-5646.1999.tb04518.x; TILLBOTTRAUD I, 1994, AM NAT, V144, P395, DOI 10.1086/285683; Tregenza T, 2002, NATURE, V415, P71, DOI 10.1038/415071a; Vielle-Calzada JP, 2000, NATURE, V404, P91, DOI 10.1038/35003595; Walbot V, 2003, NAT REV GENET, V4, P369, DOI 10.1038/nrg1064; Ward PI, 2000, EVOLUTION, V54, P1680, DOI 10.1111/j.0014-3820.2000.tb00712.x; WEDEKIND C, 1994, PHILOS T R SOC B, V346, P303, DOI 10.1098/rstb.1994.0147; Wilkinson GS, 2001, P ROY SOC B-BIOL SCI, V268, P2559, DOI 10.1098/rspb.2001.1831; Willson M.F., 1983, MATE CHOICE PLANTS T; Wilson N, 1997, P ROY SOC B-BIOL SCI, V264, P1491, DOI 10.1098/rspb.1997.0206; Wolf JB, 2003, P NATL ACAD SCI USA, V100, P4655, DOI 10.1073/pnas.0635741100; Zeh JA, 1997, P ROY SOC B-BIOL SCI, V264, P69, DOI 10.1098/rspb.1997.0010; Zeh JA, 1996, P ROY SOC B-BIOL SCI, V263, P1711, DOI 10.1098/rspb.1996.0250; Zeh JA, 2001, ANIM BEHAV, V61, P1051, DOI 10.1006/anbe.2000.1705; Zeh JA, 1998, P NATL ACAD SCI USA, V95, P13732, DOI 10.1073/pnas.95.23.13732	67	135	139	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					971	975		10.1126/science.1092180	http://dx.doi.org/10.1126/science.1092180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963320	Green Submitted			2022-12-28	WOS:000188918000034
J	Weitz, DA				Weitz, DA			Packing in the spheres	SCIENCE			English	Editorial Material							RANDOM CLOSE PACKING		Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Weitz, DA (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	weitz@deas.harvard.edu						BERNAL JD, 1960, NATURE, V188, P910, DOI 10.1038/188910a0; Donev A, 2004, SCIENCE, V303, P990, DOI 10.1126/science.1093010; Nowak ER, 1998, PHYS REV E, V57, P1971, DOI 10.1103/PhysRevE.57.1971; O'Hern CS, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.011306; O'Hern CS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.075507; ONODA GY, 1990, PHYS REV LETT, V64, P2727, DOI 10.1103/PhysRevLett.64.2727; SCOTT GD, 1962, NATURE, V194, P956, DOI 10.1038/194956a0; Torquato S, 2000, PHYS REV LETT, V84, P2064, DOI 10.1103/PhysRevLett.84.2064	8	121	131	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	2004	303	5660					968	969		10.1126/science.1094581	http://dx.doi.org/10.1126/science.1094581			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963318				2022-12-28	WOS:000188918000032
J	Mecsas, J; Franklin, G; Kuziel, WA; Brubaker, RR; Falkow, S; Mosier, DE				Mecsas, J; Franklin, G; Kuziel, WA; Brubaker, RR; Falkow, S; Mosier, DE			CCR5 mutation and plague protection	NATURE			English	Editorial Material							RESISTANCE ALLELE; HIV-1 CORECEPTOR; INFECTION; PROGRESSION; ORIGIN; MICE; AIDS		Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA	Stanford University; Scripps Research Institute; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Michigan State University	Mecsas, J (corresponding author), Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	dmosier@scripps.edu						BUTLER T, 1989, T ROY SOC TROP MED H, V83, P458, DOI 10.1016/0035-9203(89)90246-0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Galvani AP, 2003, P NATL ACAD SCI USA, V100, P15276, DOI 10.1073/pnas.2435085100; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Huffnagle GB, 1999, J IMMUNOL, V163, P4642; Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Sato N, 1999, J IMMUNOL, V163, P5519; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Zhou YH, 1998, J IMMUNOL, V160, P4018	11	70	73	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					606	606		10.1038/427606a	http://dx.doi.org/10.1038/427606a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961112	Bronze			2022-12-28	WOS:000188875300032
J	Lynch, HT; Coronel, SM; Okimoto, R; Hampel, H; Sweet, K; Lynch, JF; Barrows, A; Wijnen, J; van der Klift, H; Franken, P; Wagner, A; Fodde, R; de la Chapelle, A				Lynch, HT; Coronel, SM; Okimoto, R; Hampel, H; Sweet, K; Lynch, JF; Barrows, A; Wijnen, J; van der Klift, H; Franken, P; Wagner, A; Fodde, R; de la Chapelle, A			A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLON-CANCER; FAMILIES; POPULATION; HNPCC; INDIVIDUALS; FREQUENCY; CARCINOMA; ORIGIN; BRCA1; RISK	Context Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is caused by mutations in the mismatch repair genes and confers an extraordinarily high risk of colorectal, endometrial, and other cancers. However, while carriers of these mutations should be identified, counseled, and offered clinical surveillance, at present the mutations are not tested for in mutation analyses. Objective To describe the prevalence of a large genomic deletion encompassing exons 1 to 6 of the MSH2 gene that is widespread in the US population as a result of a founder effect. Design, Setting, and Patients Ongoing genealogical, and historical study conducted to assess the origin and spread of an MSH2 mutation previously identified in 9 apparently unrelated families with putative HNPCC and living in widely different geographic locations in the United States. Main Outcome Measures Classification of family members as carriers or noncarriers of the MSH2 mutation; spread of the mutation across the continental United States. Results To date, 566 family members of the 9 probands have been identified to be at risk and counseled; 137 of these have been tested, and 61 carry the founder mutation. Three families have been genealogically shown to descend from a German immigrant family that arrived and first settled in Pennsylvania in the early 1700s. Movements of branches of the family from Pennsylvania through North Carolina, Alabama, Kentucky, Missouri, Iowa, Nebraska, Utah, Texas, and California have been documented, and carriers of the mutation have already been diagnosed in 14 states. In contrast, the deletion was not found among 407 European and Australian families with HNPCC. Conclusion The postulated high frequency and continent-wide geographic distribution of a cancer-predisposing founder mutation of the MSH2 gene in a large, outbred (as opposed to genetically isolated) population, and the ease with which the mutation can be detected, suggest that the routine testing of individuals at risk for HNPCC in the United States should include an assay for this mutation until more is learned about its occurrence.	Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Leiden Univ, Sylvius Lab, Dept Human Genet, Leiden, Netherlands; Erasmus Univ, Med Ctr, Dept Clin Genet, Rotterdam, Netherlands	Creighton University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	Lynch, HT (corresponding author), Creighton Univ, Sch Med, Dept Prevent Med, 2500 Calif Plaza, Omaha, NE 68178 USA.	htlynch@creighton.edu	Sweet, Kevin/E-4172-2011; Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324	NATIONAL CANCER INSTITUTE [U01CA067941, R01CA067941, P30CA016058, U01CA086389] Funding Source: NIH RePORTER; NCI NIH HHS [CA67941, CA16058, 1U01 CA86389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Burn J, 1998, P NUTR SOC, V57, P183, DOI 10.1079/PNS19980030; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Desai DC, 2000, J MED GENET, V37, P646, DOI 10.1136/jmg.37.9.646; Foulkes WD, 2002, AM J HUM GENET, V71, P1395, DOI 10.1086/345075; FROGGATT NJ, 1995, LANCET, V345, P727, DOI 10.1016/S0140-6736(95)90900-1; Froggatt NJ, 1999, J MED GENET, V36, P97; GOODMAN RM, 1979, GENETIC DIS ASHKENAZ; Hutter P, 1996, J MED GENET, V33, P636, DOI 10.1136/jmg.33.8.636; *INT AG RES CANC, GLOB 2000 CANC INC P; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; Lynch HT, 1999, J MED GENET, V36, P801; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MCKUSICK VA, 1964, B JOHNS HOPKINS HOSP, V115, P203; Moisio AL, 1996, AM J HUM GENET, V59, P1243; Nakagawa H, 2002, CANCER RES, V62, P4579; Nakagawa Hidewaki, 2003, Hum Mutat, V22, P258, DOI 10.1002/humu.9171; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Reyes CM, 2002, CANCER, V95, P1848, DOI 10.1002/cncr.10910; RISINGER JI, 1993, CANCER RES, V53, P5100; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Vogelstein B., 1998, GENETIC BASIS HUMAN; Wagner A, 2003, AM J HUM GENET, V72, P1088, DOI 10.1086/373963; Wagner A, 2002, GENE CHROMOSOME CANC, V35, P49, DOI 10.1002/gcc.10094; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659	36	66	67	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					718	724		10.1001/jama.291.6.718	http://dx.doi.org/10.1001/jama.291.6.718			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871915	hybrid			2022-12-28	WOS:000188819200025
J	Guan, JL				Guan, JL			Integrins, Rafts, Rac, and Rho	SCIENCE			English	Editorial Material							MEMBRANE; ADHESION		Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu						Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Ghosh PK, 2002, NAT CELL BIOL, V4, P894, DOI 10.1038/ncb873; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052	14	67	69	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					773	774		10.1126/science.1094376	http://dx.doi.org/10.1126/science.1094376			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764856				2022-12-28	WOS:000188753800034
J	Kang, TM; Hilgemann, DW				Kang, TM; Hilgemann, DW			Multiple transport modes of the cardiac Na+/Ca2+ exchanger	NATURE			English	Article							SODIUM-CALCIUM EXCHANGE; PIG VENTRICULAR MYOCYTES; NA+-CA2+ EXCHANGE; MEMBRANE PATCHES; GUINEA-PIG; DYNAMIC PROPERTIES; STEADY-STATE; STOICHIOMETRY; ION; TRANSLOCATION	The cardiac Na+/Ca2+ exchanger(1) (NCX1; ref. 2) is a bi-directional Ca2+ transporter that contributes to the electrical activity of the heart(3,4). When, and if, Ca2+ is exported or imported depends on the Na+/Ca2+ exchange ratio(5). Whereas a ratio of 3:1 (Na+:Ca2+) has been indicated by Ca2+ flux equilibrium studies(6), a ratio closer to 4:1 has been indicated by exchange current reversal potentials(7,8). Here we show, using an ion-selective electrode technique(9) to quantify ion fluxes in giant patches(10), that ion flux ratios are approximately 3.2 for maximal transport in either direction. With Na+ and Ca2+ on both sides of the membrane, net current and Ca2+ flux can reverse at different membrane potentials, and inward current can be generated in the absence of cytoplasmic Ca2+, but not Na+. We propose that NCX1 can transport not only 1 Ca2+ or 3 Na+ ions, but also 1 Ca2+ with 1 Na+ ion at a low rate. Therefore, in addition to the major 3:1 transport mode, import of 1 Na+ with 1 Ca2+ defines a Na+-conducting mode that exports 1 Ca2+, and an electroneutral Ca2+ influx mode that exports 3 Na+. The two minor transport modes can potentially determine resting free Ca2+ and background inward current in heart.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Ctr Mol Med,Dept Physiol, Suwon 440746, South Korea	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Samsung; Sungkyunkwan University (SKKU)	Hilgemann, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	donald.hilgemann@utsouthwestern.edu		Kang, Tong Mook/0000-0001-7404-9382				CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; DeFelice LJ, 1998, METHOD ENZYMOL, V296, P578; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; Hilgemann DW, 1996, BIOPHYS J, V71, P759, DOI 10.1016/S0006-3495(96)79275-5; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; Hinata M, 2002, J PHYSIOL-LONDON, V545, P453, DOI 10.1113/jphysiol.2002.025866; Kang TM, 2002, ANN NY ACAD SCI, V976, P142; Kang TM, 2003, J GEN PHYSIOL, V121, P325, DOI 10.1085/jgp.200208777; Kappl M, 1996, BIOPHYS J, V71, P2473, DOI 10.1016/S0006-3495(96)79441-9; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; LYTTON J, 2002, P 4 INT C; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; NOBLE D, 1984, J PHYSIOL-LONDON, V353, P1; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REEVES JP, 1983, J BIOL CHEM, V258, P3178; REUTER H, 1968, J PHYSIOL-LONDON, V195, P451, DOI 10.1113/jphysiol.1968.sp008467; Robinson R.A., 2002, ELECTROLYTE SOLUTION; SMITH PJS, 1995, NATURE, V378, P645, DOI 10.1038/378645a0; Wang E, 2001, BIOPHYS J, V81, P3275, DOI 10.1016/S0006-3495(01)75961-9	29	118	126	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					544	548		10.1038/nature02271	http://dx.doi.org/10.1038/nature02271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765196				2022-12-28	WOS:000188721800042
J	Levine, C; Faden, R; Grady, C; Hammerschmidt, D; Eckenwiler, L; Sugarman, J				Levine, C; Faden, R; Grady, C; Hammerschmidt, D; Eckenwiler, L; Sugarman, J		Consortium Examine Clin Res Ethics	"Special scrutiny": A targeted form of research protocol review	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PERINATAL TRANSMISSION; PARKINSONS-DISEASE; CLINICAL-RESEARCH; SMALLPOX VACCINE; PLACEBO-CONTROLS; TRIALS; SURGERY; ETHICS; DEATH; VOLUNTEER	Research participants require ongoing protection of the kind already established in law and regulation. However, "special scrutiny" for certain types of research is also needed. Three criteria for special scrutiny are 1) research that involves initial experiences of translating new scientific advances into humans, especially when the intervention is novel, irreversible, or both; 2) research with a known or credible risk for significant harm (death or serious disability are the clearest examples) to research participants as a consequence of the experimental intervention and with no potential for offsetting direct medical benefit; or 3) research with a protocol that raises ethical questions about research design or implementation for which there is no consensus. Special scrutiny recognizes that not all research protocols are equally ethically challenging and aims to provide appropriate protection for all research participants.	Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Baltimore, MD 21205 USA; United Hosp Fund, New York, NY USA; NIH, Bethesda, MD 20892 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Duke Univ, Med Ctr, Durham, NC 27706 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; University of Minnesota System; University of Minnesota Twin Cities; Duke University	Sugarman, J (corresponding author), Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Hampton House 351,624 N Broadway, Baltimore, MD 21205 USA.			Sugarman, Jeremy/0000-0001-7022-8332				Abramson JS, 2002, PEDIATRICS, V110, P841; Al-Khatib SM, 2001, SCIENCE, V292, P2013, DOI 10.1126/science.1057783; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Baltimore RS, 2003, CURR OPIN INFECT DIS, V16, P237, DOI 10.1097/00001432-200306000-00009; Carpenter WT, 1998, ARCH GEN PSYCHIAT, V55, P283; Chapman LE, 2003, CURR TOP MICROBIOL, V278, P23; Check E, 2002, NATURE, V420, P110, DOI 10.1038/420110b; Clark PA, 2002, J LAW MED ETHICS, V30, P58, DOI 10.1111/j.1748-720X.2002.tb00720.x; Cottington EM, 2002, ARTERIOSCL THROM VAS, V22, P1046, DOI 10.1161/01.ATV.0000020400.25088.A7; Day RO, 1998, MED J AUSTRALIA, V168, P449, DOI 10.5694/j.1326-5377.1998.tb139026.x; Dowling RD, 2003, ANN THORAC SURG, V75, pS93, DOI 10.1016/S0003-4975(03)00484-3; Fins JJ, 1997, ARCH GEN PSYCHIAT, V54, P415; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; Goldberg Debbie, 2002, Washington Post, pA3; Jenks S, 2000, J NATL CANCER I, V92, P98, DOI 10.1093/jnci/92.2.98; Karim SSA, 1998, AM J PUBLIC HEALTH, V88, P564, DOI 10.2105/AJPH.88.4.564; King NMP, 2002, J LAW MED ETHICS, V30, P381, DOI 10.1111/j.1748-720X.2002.tb00407.x; Levine C, 1998, HASTINGS CENT REP, V28, P43, DOI 10.2307/3528269; Levinsky NG, 2002, NEW ENGL J MED, V347, P759, DOI 10.1056/NEJMsb020853; London AJ, 2002, STAT METHODS MED RES, V11, P413, DOI 10.1191/0962280202sm300ra; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Lyerly AD, 2001, OBSTET GYNECOL, V98, P689, DOI 10.1016/S0029-7844(01)01513-7; National Bioethics Advisory Commission, 1998, RES INV PERS MENT DI; *NEW YORK STAT DEP, 2003, SAF HLTH RES SUBJ PR; *NEW YORK STAT DEP, 2003, CAS REP DEATH U ROCH; OBYRNE PM, 1985, J ALLERGY CLIN IMMUN, V76, P97, DOI 10.1016/0091-6749(85)90810-3; *PRES ADV COMM HUM, 1996, FIN REP ADV COMM HUM, P439; Rosen AC, 2002, BRAIN COGNITION, V50, P469, DOI 10.1016/S0278-2626(02)00535-3; Samuels Louis E., 2003, Cardiology Clinics, V21, P115, DOI 10.1016/S0733-8651(02)00141-8; Savulescu J, 2002, J MED ETHICS, V28, P3, DOI 10.1136/jme.28.1.3; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Steinbrook R, 2002, NEW ENGL J MED, V346, P716, DOI 10.1056/NEJM200202283460924; Sutherland Fraser W H, 2003, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V6, P152; Sykes M, 2003, XENOTRANSPLANTATION, V10, P194, DOI 10.1034/j.1399-3089.2003.00067.x; Weijer C, 2002, J LAW MED ETHICS, V30, P69, DOI 10.1111/j.1748-720X.2002.tb00721.x; 1996, FED REG, V61, P51531	36	21	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2004	140	3					220	223		10.7326/0003-4819-140-3-200402030-00013	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770BZ	14757620				2022-12-28	WOS:000188704500008
J	Zheng, Y; Mellem, JE; Brockie, PJ; Madsen, DM; Maricq, AV				Zheng, Y; Mellem, JE; Brockie, PJ; Madsen, DM; Maricq, AV			SOL-1 is a CUB-domain protein required for GLR-1 glutamate receptor function in C-elegans	NATURE			English	Article							CAENORHABDITIS-ELEGANS; SEMAPHORIN-III; MUTATION; SUBUNIT; NEURONS; GENE; NEUROPILIN; CHANNEL; SYSTEM; MODULE	Ionotropic glutamate receptors (iGluRs) mediate most excitatory synaptic signalling between neurons. Binding of the neurotransmitter glutamate causes a conformational change in these receptors that gates open a transmembrane pore through which ions can pass. The gating of iGluRs is crucially dependent on a conserved amino acid that was first identified in the 'lurcher' ataxic mouse(1). Through a screen for modifiers of iGluR function in a transgenic strain of Caenorhabditis elegans expressing a GLR-1 subunit containing the lurcher mutation, we identify suppressor of lurcher (sol-1). This gene encodes a transmembrane protein that is predicted to contain four extracellular beta-barrel-forming domains known as CUB domains(2,3). SOL-1 and GLR-1 are colocalized at the cell surface and can be coimmunoprecipitated. By recording from neurons expressing GLR-1, we show that SOL-1 is an accessory protein that is selectively required for glutamate-gated currents. We propose that SOL-1 participates in the gating of non-NMDA (N-methyl-D-aspartate) iGluRs, thereby providing a previously unknown mechanism of regulation for this important class of neurotransmitter receptor.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Maricq, AV (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	maricq@biology.utah.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson P, 1995, METHOD CELL BIOL, V48, P31; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brockie PJ, 2001, NEURON, V31, P617, DOI 10.1016/S0896-6273(01)00394-4; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; Chelur DS, 2002, NATURE, V420, P669, DOI 10.1038/nature01205; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; Dingledine R, 1999, PHARMACOL REV, V51, P7; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hilliard MA, 2002, CURR BIOL, V12, P730, DOI 10.1016/S0960-9822(02)00813-8; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; Mellem JE, 2002, NEURON, V36, P933, DOI 10.1016/S0896-6273(02)01088-7; Michishita M, 2003, BIOCHEM BIOPH RES CO, V306, P680, DOI 10.1016/S0006-291X(03)01035-0; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Stohr H, 2002, GENE, V286, P223, DOI 10.1016/S0378-1119(02)00438-9; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Zheng Y, 1999, NEURON, V24, P347, DOI 10.1016/S0896-6273(00)80849-1; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	28	105	113	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					451	457		10.1038/nature02244	http://dx.doi.org/10.1038/nature02244			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749834				2022-12-28	WOS:000188470500046
J	Miglioretti, DL; Rutter, CM; Geller, BM; Cutter, G; Barlow, WE; Rosenberg, R; Weaver, DL; Taplin, SH; Ballard-Barbash, R; Carney, PA; Yankaskas, BC; Kerlikowske, K				Miglioretti, DL; Rutter, CM; Geller, BM; Cutter, G; Barlow, WE; Rosenberg, R; Weaver, DL; Taplin, SH; Ballard-Barbash, R; Carney, PA; Yankaskas, BC; Kerlikowske, K			Effect of breast augmentation on the accuracy of mammography and cancer characteristics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCREENING MAMMOGRAPHY; UNITED-STATES; IMPLANTS; WOMEN; MAMMAPLASTY; DIAGNOSIS; SURVIVAL; PERFORMANCE; PROGNOSIS; DENSITY	Context Breast augmentation is not associated with an increased risk of breast cancer; however, implants may interfere with the detection of breast cancer thereby delaying cancer diagnosis in women with augmentation. Objective To determine whether mammography accuracy and tumor characteristics are different for women with and without augmentation. Design, Setting, and Participants A prospective cohort of 137 women with augmentation and 685 women without augmentation diagnosed with breast cancer between January 1, 1995, and October 15, 2002, matched (1:5) by age, race/ethnicity, previous mammography screening, and mammography registry, and 10533 women with augmentation and 974915 women without augmentation and without breast cancer among 7 mammography registries in Denver, Colo; Lebanon, NH; Albuquerque, NM; Chapel Hill, NC; San Francisco, Calif; Seattle, Wash; and Burlington, Vt. Main Outcome Measures Comparison between women with and without augmentation of mammography performance measures and cancer characteristics, including invasive carcinoma or ductal carcinoma in situ, tumor stage, nodal status, size, grade, and estrogen-receptor status. Results Among asymptomatic women, the sensitivity of screening mammography based on the final assessment was lower in women with breast augmentation vs women without (45.0% [95% confidence interval {CI}, 29.3%-61.5%] vs 66.8% [95% CI, 60.4%-72.8%]; P=.008), and specificity was slightly higher in women with augmentation (97.7% [95% CI, 97.4%-98.0%] vs 96.7% [95% CI, 96.6%-96.7%]; P<.001). Among symptomatic women, both sensitivity and specificity were lower for women with augmentation compared with women without but these differences were not significant. Tumors were of similar stage, size, estrogen-receptor status, and nodal status but tended to be lower grade (P=.052) for women with breast augmentation vs without. Conclusions Breast augmentation decreases the sensitivity of screening mammography among asymptomatic women but does not increase the false-positive rate. Despite the lower accuracy of mammography in women with augmentation, the prognostic characteristics of tumors are not influenced by augmentation.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Canc Res & Biostat, Seattle, WA USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Univ Nevada, Sch Med, Ctr Res Design & Stat Methods, Appl Res Facil, Reno, NV 89557 USA; Univ New Mexico, Hlth Sci Ctr, Dept Radiol, Albuquerque, NM 87131 USA; NCI, Appl Res Program, Dept Canc Control & Populat Sci, Bethesda, MD 20892 USA; Dartmouth Coll Sch Med, Dept Community & Family Med, Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH USA; Univ N Carolina, Dept Radiol, Chapel Hill, NC USA; Univ Calif San Francisco, Dept Vet Affairs, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med & Epidemiol & Biostat, San Francisco, CA 94143 USA	Group Health Cooperative; University of Washington; University of Washington Seattle; Cancer Research & Biostatistics; University of Vermont; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of New Mexico; University of New Mexico's Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dartmouth College; Norris Cotton Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miglioretti, DL (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	miglioretti.d@ghc.org	Cutter, Gary/AAY-5392-2021; Rutter, Carolyn/AAZ-3677-2021	Cutter, Gary/0000-0002-8455-980X; 	NATIONAL CANCER INSTITUTE [U01CA070013, U01CA063736, U01CA086076, U01CA070040, U01CA086082, U01CA063731, U01CA069976, U01CA063740] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA63740, U01CA69976, U01CA86082, U01CA70013, U01CA70040, U01CA63736, U01CA63731, U01CA86076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM SOC PLAST SURG, 2002 QUICK FACTS COS; BallardBarbash R, 1997, AM J ROENTGENOL, V169, P1001, DOI 10.2214/ajr.169.4.9308451; BIRDSELL DC, 1993, PLAST RECONSTR SURG, V92, P795, DOI 10.1097/00006534-199392050-00003; BRIGHT RA, 1993, J LONG-TERM EFF MED, V3, P81; Brinton LA, 2000, CANCER CAUSE CONTROL, V11, P819, DOI 10.1023/A:1008941110816; Brinton LA, 1996, PLAST RECONSTR SURG, V97, P269, DOI 10.1097/00006534-199602000-00001; CAHAN AC, 1995, ANN SURG ONCOL, V2, P121, DOI 10.1007/BF02303626; CARLSON GW, 1993, PLAST RECONSTR SURG, V91, P837, DOI 10.1097/00006534-199304001-00014; Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008; CLARK CP, 1993, CANCER, V72, P2170, DOI 10.1002/1097-0142(19931001)72:7<2170::AID-CNCR2820720717>3.0.CO;2-1; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; Deapen D, 2000, PLAST RECONSTR SURG, V105, P535, DOI 10.1097/00006534-200002000-00009; Deapen DM, 1997, PLAST RECONSTR SURG, V99, P1346, DOI 10.1097/00006534-199704001-00022; DORSI CJ, 1998, AM COLL RADIOLOGY AC; DOUGLAS KP, 1991, SOUTH MED J, V84, P49, DOI 10.1097/00007611-199101000-00013; EKLUND GW, 1988, AM J ROENTGENOL, V151, P469, DOI 10.2214/ajr.151.3.469; EKLUND GW, 1992, RADIOL CLIN N AM, V30, P21; Ernster VL, 2002, J NATL CANCER I, V94, P1546; FAJARDO LL, 1995, RADIOLOGY, V194, P859, DOI 10.1148/radiology.194.3.7862991; Garbers S, 1998, PLAST RECONSTR SURG, V101, P695, DOI 10.1097/00006534-199803000-00016; GUMUCIO CA, 1989, PLAST RECONSTR SURG, V84, P772, DOI 10.1097/00006534-198911000-00008; HANDEL N, 1992, JAMA-J AM MED ASSOC, V268, P1913, DOI 10.1001/jama.268.14.1913; HAYES H, 1988, PLAST RECONSTR SURG, V82, P1, DOI 10.1097/00006534-198882010-00001; Holmich LR, 2003, BRIT J CANCER, V88, P832, DOI 10.1038/sj.bjc.6600819; Hoshaw SJ, 2001, PLAST RECONSTR SURG, V107, P1393, DOI 10.1097/00006534-200105000-00012; Kerlikowske K, 2000, ANN INTERN MED, V133, P855, DOI 10.7326/0003-4819-133-11-200012050-00009; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; LEIBMAN AJ, 1990, RADIOLOGY, V174, P195, DOI 10.1148/radiology.174.1.2152981; MOGELVANG LC, 1995, PLAST RECONSTR SURG, V95, P935, DOI 10.1097/00006534-199504000-00036; Muzaffar AR, 2002, PLAST RECONSTR SURG, V109, P742, DOI 10.1097/00006534-200202000-00049; Rosenberg RD, 2000, ACAD RADIOL, V7, P1058, DOI 10.1016/S1076-6332(00)80057-4; SCHIRBER S, 1993, SOUTHERN MED J, V86, P263, DOI 10.1097/00007611-199303000-00001; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P635, DOI 10.1016/S0959-8049(05)80115-7; SILVERSTEIN MJ, 1990, PLAST RECONSTR SURG, V86, P1126, DOI 10.1097/00006534-199012000-00014; Skinner KA, 2001, ANN SURG ONCOL, V8, P138; Swan J, 2003, CANCER, V97, P1528, DOI 10.1002/cncr.11208; 1997, AJCC CANC STAGING MA, P171	37	99	102	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					442	450		10.1001/jama.291.4.442	http://dx.doi.org/10.1001/jama.291.4.442			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747501	Bronze			2022-12-28	WOS:000188426700029
J	Gao, RS; Popp, PJ; Fahey, DW; Marcy, TP; Herman, RL; Weinstock, EM; Baumgardner, DG; Garrett, TJ; Rosenlof, KH; Thompson, TL; Bui, PT; Ridley, BA; Wofsy, SC; Toon, OB; Tolbert, MA; Karcher, B; Peter, T; Hudson, PK; Weinheimer, AJ; Heymsfield, AJ				Gao, RS; Popp, PJ; Fahey, DW; Marcy, TP; Herman, RL; Weinstock, EM; Baumgardner, DG; Garrett, TJ; Rosenlof, KH; Thompson, TL; Bui, PT; Ridley, BA; Wofsy, SC; Toon, OB; Tolbert, MA; Karcher, B; Peter, T; Hudson, PK; Weinheimer, AJ; Heymsfield, AJ			Evidence that nitric acid increases relative humidity in low-temperature cirrus clouds	SCIENCE			English	Article							IN-SITU MEASUREMENTS; ICE CRYSTALS; FREEZING RESISTANCE; UPPER TROPOSPHERE; VAPOR GROWTH; HNO3; ADSORPTION; MECHANISM; MODEL; MICROPHYSICS	In situ measurements of the relative humidity with respect to ice (RHi) and of nitric acid (HNO3) were made in both natural and contrail cirrus clouds in the upper troposphere. At temperatures lower than 202 kelvin, RHi values show a sharp increase to average values of over 130% in both cloud types. These enhanced RHi values are attributed to the presence of a new class of HNO3-containing ice particles (Delta-ice). We propose that surface HNO3 molecules prevent the ice/vapor system from reaching equilibrium by a mechanism similar to that of freezing point depression by antifreeze proteins. Delta-ice represents a new link between global climate and natural and anthropogenic nitrogen oxide emissions. Including Delta-ice in climate models will alter simulated cirrus properties and the distribution of upper tropospheric water vapor.	NOAA, Aeron Lab, Boulder, CO 80305 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Univ Colorado, Program Atmospher & Ocean Sci, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; NASA, Jet Prop Lab, Pasadena, CA 91109 USA; Harvard Univ, Atmospher Res Project, Cambridge, MA 02138 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Nacl Autonoma Mexico, Ctr Ciencias Atmosfera, Mexico City 04510, DF, Mexico; Univ Utah, Dept Meteorol, Salt Lake City, UT 84112 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Natl Ctr Atmospher Res, Div Atmospher Chem, Boulder, CO 80307 USA; Deutsch Zentrum Luft & Raumfahrt, Inst Phys Atmosphare, Wessling, Germany; ETH, Lab Atmospharenphys, CH-8093 Zurich, Switzerland	National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Harvard University; Harvard University; Universidad Nacional Autonoma de Mexico; Utah System of Higher Education; University of Utah; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Center Atmospheric Research (NCAR) - USA; Helmholtz Association; German Aerospace Centre (DLR); Swiss Federal Institutes of Technology Domain; ETH Zurich	Gao, RS (corresponding author), NOAA, Aeron Lab, Boulder, CO 80305 USA.	rgao@al.noaa.gov	Herman, Robert L./AAK-1986-2020; Kärcher, Bernd/D-5325-2014; Rosenlof, Karen H/B-5652-2008; Peter, Thomas/B-2529-2018; Heymsfield, Andrew J/E-7340-2011; Herman, Robert/H-9389-2012; Fahey, David W/G-4499-2013; Gao, Ru-Shan/H-7455-2013	Herman, Robert L./0000-0001-7063-6424; Kärcher, Bernd/0000-0003-0278-4980; Rosenlof, Karen H/0000-0002-0903-8270; Peter, Thomas/0000-0002-7218-7156; Heymsfield, Andrew J/0000-0003-4107-7533; Herman, Robert/0000-0001-7063-6424; Fahey, David W/0000-0003-1720-0634; Gao, Ru-Shan/0000-0001-6985-1637				Abbatt JPD, 1997, GEOPHYS RES LETT, V24, P1479, DOI 10.1029/97GL01403; [Anonymous], 2001, CLIMATE CHANGE 2001; Arora OP, 1999, GEOPHYS RES LETT, V26, P3621, DOI 10.1029/1999GL010881; Baehr J, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016935; Baker MB, 1997, SCIENCE, V276, P1072, DOI 10.1126/science.276.5315.1072; Barone SB, 1997, J PHYS CHEM A, V101, P8643, DOI 10.1021/jp971107k; Biermann UM, 1998, GEOPHYS RES LETT, V25, P3939, DOI 10.1029/1998GL900040; CHEN JP, 1994, J ATMOS SCI, V51, P1206, DOI 10.1175/1520-0469(1994)051<1206:TTBFTP>2.0.CO;2; DANIELSEN EF, 1982, GEOPHYS RES LETT, V9, P605, DOI 10.1029/GL009i006p00605; Delval C, 2003, ATMOS CHEM PHYS, V3, P1131, DOI 10.5194/acp-3-1131-2003; DEVRIES AL, 1969, SCIENCE, V163, P1073, DOI 10.1126/science.163.3871.1073; Djikaev YS, 2003, J CHEM PHYS, V118, P6572, DOI 10.1063/1.1559034; Domine F, 1996, GEOPHYS RES LETT, V23, P3627, DOI 10.1029/96GL03290; GAO RS, UNPUB; HANSON D, 1988, GEOPHYS RES LETT, V15, P855, DOI 10.1029/GL015i008p00855; HANSON DR, 1991, J GEOPHYS RES-ATMOS, V96, P5081, DOI 10.1029/90JD02613; HANSON DR, 1992, GEOPHYS RES LETT, V19, P2063, DOI 10.1029/92GL02182; Harries JE, 1996, Q J ROY METEOR SOC, V122, P799, DOI 10.1002/qj.49712253202; Heymsfield AJ, 1998, GEOPHYS RES LETT, V25, P1335, DOI 10.1029/98GL00189; Heymsfield AJ, 1995, J ATMOS SCI, V52, P4302, DOI 10.1175/1520-0469(1995)052<4302:RHATIO>2.0.CO;2; Hudson PK, 2002, J PHYS CHEM A, V106, P9874, DOI 10.1021/jp020508j; *IPCC, 1997, SPEC REP AV GLOB ATM; IRIBARNE JV, 1990, ATMOS ENVIRON A-GEN, V24, P383, DOI 10.1016/0960-1686(90)90118-7; Jaegle L, 1998, GEOPHYS RES LETT, V25, P1705, DOI 10.1029/97GL03591; Jensen EJ, 1998, J GEOPHYS RES-ATMOS, V103, P31557, DOI 10.1029/98JD02594; Jensen EJ, 1998, GEOPHYS RES LETT, V25, P1371, DOI 10.1029/97GL03592; Jensen EJ, 2001, J GEOPHYS RES-ATMOS, V106, P17253, DOI 10.1029/2000JD900526; *JPL, 2003, JPL PUBL, V225; Khvorostyanov VI, 1998, J ATMOS SCI, V55, P1822, DOI 10.1175/1520-0469(1998)055<1822:CCSUEM>2.0.CO;2; KLEY D, 2000, 113 SPARC WORLD MET; Kondo Y, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016539; Lawrence MG, 1998, TELLUS B, V50, P263, DOI 10.1034/j.1600-0889.1998.t01-2-00005.x; LEU MT, 1988, GEOPHYS RES LETT, V15, P17, DOI 10.1029/GL015i001p00017; Meilinger SK, 1999, GEOPHYS RES LETT, V26, P2207, DOI 10.1029/1999GL900423; MIDDLEBROOK AM, 1992, GEOPHYS RES LETT, V19, P2417, DOI 10.1029/92GL02635; Murphy DM, 1998, SCIENCE, V282, P1664, DOI 10.1126/science.282.5394.1664; Nelson JT, 1996, J GEOPHYS RES-ATMOS, V101, P7033, DOI 10.1029/95JD03162; Nenes A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015295; Neuman JA, 2001, ATMOS ENVIRON, V35, P5789, DOI 10.1016/S1352-2310(01)00354-5; NEUSTAEDTER J, 1987, J CRYST GROWTH, V85, P422, DOI 10.1016/0022-0248(87)90472-6; Ovarlez J, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014440; PETER T, UNPUB; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sangwal K, 1996, PROG CRYST GROWTH CH, V32, P3, DOI 10.1016/0960-8974(96)00008-3; SCHAEFER VJ, 1949, CHEM REV, V44, P291, DOI 10.1021/cr60138a004; Sommerfeld RA, 1998, GEOPHYS RES LETT, V25, P935, DOI 10.1029/98GL00413; STEPHENS GL, 1991, J GEOPHYS RES-ATMOS, V96, P15311, DOI 10.1029/91JD00973; STEPHENS GL, 2002, CIRRUS, pCH20; Tabazadeh A, 1998, GEOPHYS RES LETT, V25, P1379, DOI 10.1029/97GL03585; Tabazadeh A, 1999, GEOPHYS RES LETT, V26, P2211, DOI 10.1029/1999GL900501; Talbot RW, 1997, J GEOPHYS RES-ATMOS, V102, P28303, DOI 10.1029/96JD02975; Talbot RW, 1999, GEOPHYS RES LETT, V26, P3057, DOI 10.1029/1999GL900589; Tyndale J, 1861, PHILOS T ROYAL SOC L, V151, P1; VeintemillasVerdaguer S, 1996, PROG CRYST GROWTH CH, V32, P75, DOI 10.1016/0960-8974(96)00005-8; Vomel H, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000707; Warshawsky MS, 1999, GEOPHYS RES LETT, V26, P823, DOI 10.1029/1999GL900120; Weinheimer AJ, 1998, GEOPHYS RES LETT, V25, P1725, DOI 10.1029/97GL02957; Wood SE, 2001, J GEOPHYS RES-ATMOS, V106, P4845, DOI 10.1029/2000JD900338; WORSNOP DR, 1993, SCIENCE, V259, P71, DOI 10.1126/science.259.5091.71; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Young K., 1993, MICROPHYSICAL PROCES; Zondlo MA, 1997, GEOPHYS RES LETT, V24, P1391, DOI 10.1029/97GL01287	62	94	94	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					516	520		10.1126/science.1091255	http://dx.doi.org/10.1126/science.1091255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739457				2022-12-28	WOS:000188316400036
J	Pickart, CM				Pickart, CM			Back to the future with ubiquitin	CELL			English	Review							TEMPERATURE-SENSITIVE MUTANT; PROTEIN-QUALITY CONTROL; CELL-CYCLE; PROTEASOME PATHWAY; ACTIVATING ENZYME; STRUCTURAL BASIS; PLASMA-MEMBRANE; DNA-REPAIR; HIF-ALPHA; DEGRADATION	Two papers published in 1984 by the Varshavsky laboratory revealed that the ubiquitin/proteasome pathway is the principal system for degradation of short-lived proteins in mammalian cells, setting the stage for future demonstrations of this pathway's many regulatory roles. This perspective discusses the impact of those papers and highlights some of the subsequent insights that have led to our current appreciation of the breadth of ubiquitin-mediated signaling.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pickart, CM (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.	cpickart@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060372] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984] Funding Source: Medline; NIGMS NIH HHS [GM60372] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; AYUSAWA D, 1992, CELL STRUCT FUNCT, V17, P113, DOI 10.1247/csf.17.113; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fersht A., 1984, ENZYME STRUCTURE MEC; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gregory RC, 2003, SEMIN CANCER BIOL, V13, P77, DOI 10.1016/S1044-579X(02)00102-5; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; HOUGH R, 1986, J BIOL CHEM, V261, P2391; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MARUNOUCHI T, 1980, BIOCHEM BIOPH RES CO, V95, P126, DOI 10.1016/0006-291X(80)90713-5; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; MITA S, 1980, EXP CELL RES, V126, P407, DOI 10.1016/0014-4827(80)90280-3; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nalepa G, 2003, CANCER TREAT REV, V29, P49, DOI 10.1016/S0305-7372(03)00083-5; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwartz AL, 1999, ANNU REV MED, V50, P57; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Semple CAM, 2003, GENOME RES, V13, P1389, DOI 10.1101/gr.980303; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; SIMPSON MV, 1953, J BIOL CHEM, V201, P143; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Wu PY, 2003, EMBO J, V22, P5241, DOI 10.1093/emboj/cdg501; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	107	560	602	1	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					181	190		10.1016/S0092-8674(03)01074-2	http://dx.doi.org/10.1016/S0092-8674(03)01074-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744430	Bronze			2022-12-28	WOS:000188541700009
J	Jerome, KR; Corey, L				Jerome, KR; Corey, L			The danger within	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CELLS		Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Jerome, KR (corresponding author), Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.							Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991	2	19	21	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					411	412		10.1056/NEJMcibr032455	http://dx.doi.org/10.1056/NEJMcibr032455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736935				2022-12-28	WOS:000188254800016
J	Little, P; Dorward, M; Warner, G; Stephens, K; Senior, J; Moore, M				Little, P; Dorward, M; Warner, G; Stephens, K; Senior, J; Moore, M			Importance of patient pressure and perceived pressure and perceived medical need for investigations, referral, and prescribing in primary care: nested observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE CONSULTATIONS; PATIENTS EXPECTATIONS; DOCTORS PERCEPTIONS; RANDOMIZED-TRIAL; DECISION; STRATEGIES; AGENDAS	Objective To assess how pressures from patients on doctors in the consultation contribute to referral and investigation. Design Observational study nested within a. randomised controlled trial. Setting Five general practices in three settings in the United Kingdom. Participants 847 consecutive patients, aged 16-80 years. Main outcomes measures Patient preferences and doctors' perception of patient pressure and medical need. Results Perceived medical need was the strongest independent predictor of all behaviours and confounded all other predictors. The doctors thought, however, there was no or only a slight indication for medical need among a significant minority of those who were examined (89/580,15%), received a prescription (74/394, 19%), or were referred (27/125, 22%) and almost half of those investigated (99/216, 46%). After controlling for patient preference, medical need, and clustering by doctor, doctors' perceptions of patient pressure were strongly associated with prescribing (adjusted odds ratio 2.87,95% confidence interval 1.16 to 7.08) and even more strongly associated with examination (4.38,1.24 to 15.5), referral (10.72, 2.08 to 55.3), and investigation (3.18, 1.31 to 7.70). In all cases, doctors' perception of. patient pressure was a stronger predictor than patients' preferences. Controlling for randomisation group, mean consultation time, or patient variables did not alter estimates or inferences. Conclusions Doctors' behaviour in the consultation is most strongly associated with perceived medical need of the patient, which strongly confounds other predictors. However, a significant minority of examining, prescribing, and referral, and almost half of investigations, are still thought by the doctor to be slightly needed or not needed at all, and perceived patient pressure is a strong independent predictor of all doctor behaviours. To limit unnecessary resource use and iatrogenesis, when management decisions are not thought to be medically needed, doctors need to directly ask patients about their expectations.	Univ Southampton, Aldermoor Hlth Ctr, Community Clin Sci Div, Southampton SO16 5ST, Hants, England; Nightingale Surg, Romsey SO51 7QN, Hants, England; Three Swans Surg, Salisbury SP1 1DX, Wilts, England	University of Southampton	Little, P (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Community Clin Sci Div, Southampton SO16 5ST, Hants, England.	psl3@soton.ac.uk	Moore, Michael/C-3447-2011	Moore, Michael/0000-0002-5127-4509; Little, Paul/0000-0003-3664-1873				Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; BRADLEY CP, 1992, BRIT J GEN PRACT, V42, P454; Britten N, 1997, BRIT MED J, V315, P1506, DOI 10.1136/bmj.315.7121.1506; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; Illich I, 1995, BRIT MED J, V311, P1652, DOI 10.1136/bmj.311.7021.1652; Illich Ivan, 1975, MED NEMESIS; Jewell D, 2000, BRIT J OBSTET GYNAEC, V107, P1237, DOI 10.1111/j.1471-0528.2000.tb11613.x; Jones MI, 2001, BMJ-BRIT MED J, V323, P378, DOI 10.1136/bmj.323.7309.378; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Little P, 1998, FAM PRACT, V15, P264, DOI 10.1093/fampra/15.3.264; LITTLE P, 2004, BMJ-BRIT MED J, P441; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Office of Population Censuses and Surveys, 1994, MORB STAT GEN PRACT; Paterson C, 1996, BRIT MED J, V312, P1016; Scott A, 1996, SOC SCI MED, V42, P35, DOI 10.1016/0277-9536(95)00063-1; Sharpe V.A., 1998, MED HARM HIST CONCEP; Stevenson FA, 1999, FAM PRACT, V16, P255, DOI 10.1093/fampra/16.3.255; WILKIN D, 1992, MEASURES NEED OUTCOM	22	207	212	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					444	446A		10.1136/bmj.38013.644086.7C	http://dx.doi.org/10.1136/bmj.38013.644086.7C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14966079	Bronze, Green Published			2022-12-28	WOS:000189161000022
J	Smith, G; Bartlett, A; King, M				Smith, G; Bartlett, A; King, M			Treatments of homosexuality in Britain since the 1950s - an oral history: the experience of patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To investigate the circumstances since the 1950s in which people who were attracted to members of the same sex received treatments to change their sexual orientation, the referral pathway and the process of therapy, and its aftermath. Design A nationwide study based on qualitative interviews. Participants 29 people who had received treatments to change their sexual orientation in the United Kingdom and two relatives of former patients. Results Most participants had been distressed by their attraction to their own sex and people in whom they confided thought they needed treatment. Although some participants chose to undergo treatments instead of imprisonment or were encouraged through some form of medical coercion, most were responding to complex personal and social pressures that discouraged any expression of their sexuality. While many participants found happiness in same sex relationships after their treatment, most were left feeling emotionally distressed to some degree. Conclusion The definition of same sex attraction as an illness and the development of treatments to eradicate such attraction have had a negative long term impact on individuals.	UCL Royal Free & Univ Coll Sch Med, London NW3 2PF, England; St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England	University of London; University College London; St Georges University London	King, M (corresponding author), UCL Royal Free & Univ Coll Sch Med, Royal Free Campus, London NW3 2PF, England.	m.king@rfc.ucl.ac.uk	bartlett, annie/I-6651-2013; King, Michael B/D-7477-2011	bartlett, annie/0000-0002-5498-7141; King, Michael B/0000-0003-4715-7171				Bartlett A, 2001, BRIT J PSYCHIAT, V179, P545, DOI 10.1192/bjp.179.6.545; Davenport-Hines R., 1990, SEX DEATH PUNISHMENT; Foucault Michel, 1981, HIST SEXUALITY, VI; Hall Lesley, 2000, SEX GENDER SOCIAL CH; King M, 2004, BMJ-BRIT MED J, V328, P429, DOI 10.1136/bmj.37984.496725.EE; King M, 1999, BRIT J PSYCHIAT, V175, P106, DOI 10.1192/bjp.175.2.106; PORTER R, 1994, FACTS LIFE CREATION; Porter R., 1997, GREATEST BENEFIT MAN; Smith G, 2004, BMJ-BRIT MED J, V328, P427, DOI 10.1136/bmj.37984.442419.EE; Weeks J., 1990, COMING OUT HOMOSEXUA	10	56	58	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					427	429		10.1136/bmj.37984.442419.EE	http://dx.doi.org/10.1136/bmj.37984.442419.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14751920	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000189161000014
J	Kelly, KA				Kelly, KA			Wind data: A promise in peril	SCIENCE			English	Editorial Material									Univ Washington, Appl Phys Lab, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kelly, KA (corresponding author), Univ Washington, Appl Phys Lab, Seattle, WA 98195 USA.							Chelton DB, 2004, SCIENCE, V303, P978, DOI 10.1126/science.1091901; DONELAN MA, 1987, J GEOPHYS RES-OCEANS, V92, P4971, DOI 10.1029/JC092iC05p04971; Freilich MH, 1999, J GEOPHYS RES-OCEANS, V104, P11231, DOI 10.1029/1998JC900091; FREILICH MH, 1986, J PHYS OCEANOGR, V16, P741, DOI 10.1175/1520-0485(1986)016<0741:WSOPWM>2.0.CO;2; Halpern D, 1988, J CLIMATE, V1, P1251, DOI 10.1175/1520-0442(1988)001<1251:MSWOAF>2.0.CO;2; Kelly K. J., UNPUB; Kelly KA, 2001, GEOPHYS RES LETT, V28, P2469, DOI 10.1029/2000GL012610; Yueh SH, 1999, IEEE T GEOSCI REMOTE, V37, P949, DOI 10.1109/36.752213	8	10	10	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	2004	303	5660					962	963		10.1126/science.1094584	http://dx.doi.org/10.1126/science.1094584			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963314				2022-12-28	WOS:000188918000028
J	Rustom, A; Saffrich, R; Markovic, I; Walther, P; Gerdes, HH				Rustom, A; Saffrich, R; Markovic, I; Walther, P; Gerdes, HH			Nanotubular highways for intercellular organelle transport	SCIENCE			English	Article							MOVEMENT; VESICLE; CELL	Cell-to-cell communication is a crucial prerequisite for the development and maintenance of multicellular organisms. To date, diverse mechanisms of intercellular exchange of information have been documented, including chemical synapses, gap junctions, and plasmodesmata. Here, we describe highly sensitive nanotubular structures formed de novo between cells that create complex networks. These structures facilitate the selective transfer of membrane vesicles and organelles but seem to impede the flow of small molecules. Accordingly, we propose a novel biological principle of cell-to-cell interaction based on membrane continuity and intercellular transfer of organelles.	Heidelberg Univ, Inst Neurobiol, Interdisciplinary Ctr Neurosci IZN, D-69120 Heidelberg, Germany; Heidelberg Univ, Otto Meyerhoff Zentrum, D-69120 Heidelberg, Germany; Univ Belgrade, Fac Med, Inst Biochem, YU-11000 Belgrade, Serbia; Univ Ulm, Electron Microscopy Facil, D-89069 Ulm, Germany; Univ Bergen, Inst Biochem & Mol Biol, N-5009 Bergen, Norway	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Belgrade; Ulm University; University of Bergen	Gerdes, HH (corresponding author), Heidelberg Univ, Inst Neurobiol, Interdisciplinary Ctr Neurosci IZN, INF 364, D-69120 Heidelberg, Germany.	Hans-Hermann.Gerdes@ibmb.uib.no	Markovic, Ivanka/AAJ-1243-2020	Saffrich, Rainer/0000-0002-0547-4550; Markovic, Ivanka/0000-0002-7961-3752				Denzer K, 2000, J CELL SCI, V113, P3365; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Karlsson A, 2001, NATURE, V409, P150, DOI 10.1038/35051656; KUFFLER DP, 1990, J COMP NEUROL, V302, P729, DOI 10.1002/cne.903020405; Lucas WJ, 2001, NAT REV MOL CELL BIO, V2, P849, DOI 10.1038/35099096; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nakajima K, 2001, NATURE, V413, P307, DOI 10.1038/35095061; PASTAN IH, 1981, SCIENCE, V214, P504, DOI 10.1126/science.6170111; Pelham RJ, 2001, NAT CELL BIOL, V3, P235, DOI 10.1038/35060020; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Scott G, 2002, J CELL SCI, V115, P1441	16	1207	1248	8	215	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1007	1010		10.1126/science.1093133	http://dx.doi.org/10.1126/science.1093133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963329				2022-12-28	WOS:000188918000044
J	Ojha, RP; Lemieux, PA; Dixon, PK; Liu, AJ; Durian, DJ				Ojha, RP; Lemieux, PA; Dixon, PK; Liu, AJ; Durian, DJ			Statistical mechanics of a gas-fluidized particle	NATURE			English	Article							GRANULAR MATTER; DYNAMICS; VORTEX; GLASS; TEMPERATURE; MODEL	Characterization of the microscopic fluctuations in systems that are far from equilibrium is crucial for understanding the macroscopic response. One approach is to use an 'effective temperature'-such a quantity has been invoked for chaotic fluids(1,2), spin glasses(3,4), glasses(5,6) and colloids(7,8), as well as non-thermal systems such as flowing granular materials(9-14) and foams(15). We therefore ask to what extent the concept of effective temperature is valid. Here we investigate this question experimentally in a simple system consisting of a sphere placed on a fine screen in an upward flow of gas; the sphere rolls because of the turbulence it generates in the gas stream. In contrast to many-particle systems, in which it is difficult to measure and predict fluctuations, our system has no particle-particle interactions and its dynamics can be captured fully by video imaging. Surprisingly, we find that the sphere behaves exactly like a harmonically bound brownian particle. The random driving force and frequency-dependent drag satisfy the fluctuation-dissipation relation, a cornerstone of statistical mechanics. The statistical mechanics of near-equilibrium systems is therefore unexpectedly useful for studying at least some classes of systems that are driven far from equilibrium.	Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Durian, DJ (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.	durian@physics.ucla.edu	Liu, Andrea J/K-3968-2017; Durian, Douglas J./D-7013-2012; Liu, Andrea/GYD-4759-2022	Liu, Andrea J/0000-0002-2295-2729; Durian, Douglas J./0000-0003-3240-2381; Liu, Andrea/0000-0002-2295-2729				ACHENBACH E, 1974, J FLUID MECH, V62, P209, DOI 10.1017/S0022112074000644; Baxter GW, 2003, NATURE, V425, P680, DOI 10.1038/425680a; Bellon L, 2001, EUROPHYS LETT, V53, P511, DOI 10.1209/epl/i2001-00182-9; Berthier L, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.095702; CUGLIANDOLO LF, 1993, PHYS REV LETT, V71, P173, DOI 10.1103/PhysRevLett.71.173; D'Anna G, 2003, NATURE, V424, P909, DOI 10.1038/nature01867; DURAN J, 2000, SANDS POWDERS GRAINS; Egolf DA, 2000, SCIENCE, V287, P101, DOI 10.1126/science.287.5450.101; Feitosa K, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.198301; Geldart D., 1986, GAS FLUIDIZATION TEC; Herisson D, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.257202; HOHENBERG PC, 1989, PHYSICA D, V37, P109, DOI 10.1016/0167-2789(89)90121-8; IPPOLITO I, 1995, PHYS REV E, V52, P2072, DOI 10.1103/PhysRevE.52.2072; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; Kubo R., 1991, STAT PHYS; Lemieux PA, 2000, PHYS REV LETT, V85, P4273, DOI 10.1103/PhysRevLett.85.4273; Leweke T, 2001, J FLUID STRUCT, V15, P377; Losert W, 2000, PHYS REV LETT, V85, P1428, DOI 10.1103/PhysRevLett.85.1428; Makse HA, 2002, NATURE, V415, P614, DOI 10.1038/415614a; Mueth DM, 2000, NATURE, V406, P385, DOI 10.1038/35019032; Olafsen JS, 1998, PHYS REV LETT, V81, P4369, DOI 10.1103/PhysRevLett.81.4369; Ono IK, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.095703; POULIGNY B, 1990, PHYS REV B, V42, P988, DOI 10.1103/PhysRevB.42.988; Prentis JJ, 2000, AM J PHYS, V68, P1073, DOI 10.1119/1.1315604; Reydellet G, 2000, EUROPHYS LETT, V51, P27, DOI 10.1209/epl/i2000-00333-0; Segre PN, 2001, NATURE, V409, P594, DOI 10.1038/35054518; Suryanarayana GK, 2000, EXP FLUIDS, V29, P582, DOI 10.1007/s003480000126	28	127	132	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					521	523		10.1038/nature02294	http://dx.doi.org/10.1038/nature02294			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765189				2022-12-28	WOS:000188721800035
J	Jarvis, MJ				Jarvis, MJ			ABC of smoking cessation - Why people smoke	BRITISH MEDICAL JOURNAL			English	Review									UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Jarvis, MJ (corresponding author), UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.		Jarvis, Martin J/B-1034-2008	Jarvis, Martin J/0000-0001-9238-8038				BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity, 2001, GUID DOC US IN VITR; Jarvis MJ, 1997, PROG RESPIR RES, V28, P151; Saks M, 2021, REPORT ROYAL COLL PO, DOI [10.1111/add.14502, DOI 10.1111/ADD.14502]	4	143	151	0	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					277	279		10.1136/bmj.328.7434.277	http://dx.doi.org/10.1136/bmj.328.7434.277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14751901	Green Published			2022-12-28	WOS:000188786000026
J	Lapointe, C; Hultgren, A; Silevitch, DM; Felton, EJ; Reich, DH; Leheny, RL				Lapointe, C; Hultgren, A; Silevitch, DM; Felton, EJ; Reich, DH; Leheny, RL			Elastic torque and the levitation of metal wires by a nematic liquid crystal	SCIENCE			English	Article							COLLOIDAL INTERACTIONS; COEFFICIENTS; DEFECTS; FORCES	Anisotropic particles suspended in a nematic liquid crystal disturb the alignment of the liquid crystal molecules and experience small forces that depend on the particles' orientation. We have measured these forces using magnetic nanowires. The torque on a wire and its orientation-dependent repulsion from a. at surface are quantitatively consistent with theoretical predictions based on the elastic properties of the liquid crystal. These forces can also be used to manipulate submicrometer-scale particles. We show that controlled spatial variations in the liquid crystal's alignment convert the torque on a wire to a translational force that levitates the wire to a specified height.	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Lapointe, C (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.		Lapointe, Clayton/G-7455-2011; Lapointe, Clayton/E-3609-2013					Alouges F, 1999, J PHYS A-MATH GEN, V32, P1177, DOI 10.1088/0305-4470/32/7/008; Andrienko D, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041702; Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t; Bowden N, 1997, SCIENCE, V276, P233, DOI 10.1126/science.276.5310.233; Bracic AB, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.011708; BROCHARD F, 1970, J PHYS-PARIS, V31, P691, DOI 10.1051/jphys:01970003107069100; CHMIELEWSKI AG, 1986, MOL CRYST LIQ CRYST, V132, P339, DOI 10.1080/00268948608079552; de Gennes P. G., 1993, PHYS LIQUID CRYSTALS; Fukuda J, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.051711; Hultgren A, 2003, J APPL PHYS, V93, P7554, DOI 10.1063/1.1556204; Loudet JC, 2000, NATURE, V407, P611, DOI 10.1038/35036539; Loudet JC, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.165503; Lubensky TC, 1998, PHYS REV E, V57, P610, DOI 10.1103/PhysRevE.57.610; MacKintosh FC, 1999, CURR OPIN COLLOID IN, V4, P300, DOI 10.1016/S1359-0294(99)90010-9; MADHUSUDANA NV, 1982, MOL CRYST LIQ CRYST, V89, P249, DOI 10.1080/00268948208074481; Mondain-Monval O, 1999, EUR PHYS J B, V12, P167, DOI 10.1007/s100510050992; MORKVED TL, 1994, APPL PHYS LETT, V64, P422, DOI 10.1063/1.111118; Poulin P, 1997, SCIENCE, V275, P1770, DOI 10.1126/science.275.5307.1770; Poulin P, 1997, PHYS REV LETT, V79, P4862, DOI 10.1103/PhysRevLett.79.4862; Shin K, 2002, NANO LETT, V2, P933, DOI 10.1021/nl0256560; Tanase M, 2001, NANO LETT, V1, P155, DOI 10.1021/nl005532s; Tasinkevych M, 2002, EUR PHYS J E, V9, P341, DOI 10.1140/epje/i2002-10087-y; Thompson RB, 2001, SCIENCE, V292, P2469, DOI 10.1126/science.1060585; TIRADO MM, 1979, J CHEM PHYS, V71, P2581, DOI 10.1063/1.438613	24	106	112	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					652	655		10.1126/science.1092608	http://dx.doi.org/10.1126/science.1092608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752155				2022-12-28	WOS:000188530800034
J	Marx, D				Marx, D			Throwing tetrahedral dice	SCIENCE			English	Editorial Material							DENSITY-FUNCTIONAL THEORY; LIQUID WATER; MOLECULAR-DYNAMICS; SPECTROSCOPY; SIMULATION; INTERFACE; IONS		Ruhr Univ Bochum, Lehrstuhl Theoret Chem, D-44780 Bochum, Germany	Ruhr University Bochum	Marx, D (corresponding author), Ruhr Univ Bochum, Lehrstuhl Theoret Chem, D-44780 Bochum, Germany.	dominik.marx@theochem.ruhr-uni-bochum.de						Benjamin I, 1996, CHEM REV, V96, P1449, DOI 10.1021/cr950230+; Chen B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.215503; DU Q, 1994, SCIENCE, V264, P826, DOI 10.1126/science.264.5160.826; DU Q, 1993, PHYS REV LETT, V70, P2313, DOI 10.1103/PhysRevLett.70.2313; Geiger A., COMMUNICATION; Head-Gordon T, 2002, CHEM REV, V102, P2651, DOI 10.1021/cr0006831; HUTTER J, 1995, CPMD; Jungwirth P, 2002, J PHYS CHEM B, V106, P6361, DOI 10.1021/jp020242g; Kirchner B, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.215901; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; Kuo IFW, 2004, SCIENCE, V303, P658, DOI 10.1126/science.1092787; LAASONEN K, 1993, J CHEM PHYS, V99, P9080, DOI 10.1063/1.465574; Marx D., 2000, MODERN METHODS ALGOR, P301; Omta AW, 2003, SCIENCE, V301, P347, DOI 10.1126/science.1084801; Richmond GL, 2002, CHEM REV, V102, P2693, DOI 10.1021/cr0006876; ROUSSEAU R, IN PRESS BIOPHYS J; Schwegler E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.265501; Soper AK, 2000, CHEM PHYS, V258, P121, DOI 10.1016/S0301-0104(00)00179-8; Sprik M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957; TOLAN M, COMMUNICATION; Wilson KR, 2002, J CHEM PHYS, V117, P7738, DOI 10.1063/1.1508364; Wilson KR, 2002, J PHYS-CONDENS MAT, V14, pL221, DOI 10.1088/0953-8984/14/8/107; Wilson KR, 2001, J PHYS CHEM B, V105, P3346, DOI 10.1021/jp010132u	24	49	49	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	2004	303	5658					634	636		10.1126/science.1094001	http://dx.doi.org/10.1126/science.1094001			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752150				2022-12-28	WOS:000188530800028
J	Paulsson, J				Paulsson, J			Summing up the noise in gene networks	NATURE			English	Article							TRANSCRIPTIONAL REGULATION; ESCHERICHIA-COLI; STOCHASTIC-MODEL; FLUCTUATIONS; REPLICATION; SENSITIVITY; MECHANISMS; EXPRESSION; CELLS	Ransom fluctuations in genetic networks are inevitable as chemical reactions are probabilistic and many genes, RNAs and proteins are present in low numbers per cell. Such 'noise' affects all life processes and has recently been measured using green protein (GFP). Two studies show that negative feedback suppresses noise, and three others identify the sources of in gene expression. Here I critically analyse these studies and present a simple equation that unifies and extends both the and biological perspectives.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Cambridge, Ctr Math Sci, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England	Princeton University; University of Cambridge	Paulsson, J (corresponding author), Princeton Univ, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	J.Paulsson@damtp.cam.ac.uk						Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; BERG OG, 1995, J THEOR BIOL, V173, P307, DOI 10.1006/jtbi.1995.0064; Berg OG, 2000, BIOPHYS J, V79, P1228, DOI 10.1016/S0006-3495(00)76377-6; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Chattoraj DK, 2000, MOL MICROBIOL, V37, P467, DOI 10.1046/j.1365-2958.2000.01986.x; DOGTEROM M, 1993, PHYS REV LETT, V70, P1347, DOI 10.1103/PhysRevLett.70.1347; Elf J, 2003, GENOME RES, V13, P2475, DOI 10.1101/gr.1196503; Elf J, 2003, BIOPHYS J, V84, P154, DOI 10.1016/S0006-3495(03)74839-5; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Howard M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.128102; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KEIZER K, 1987, STAT THERMODYNAMICS; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Lobner-Olesen A, 1999, EMBO J, V18, P1712, DOI 10.1093/emboj/18.6.1712; MALONEY PC, 1973, J MOL BIOL, V73, P77, DOI 10.1016/0022-2836(73)90160-5; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; NOVICK A, 1957, P NATL ACAD SCI USA, V43, P553, DOI 10.1073/pnas.43.7.553; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2000, P NATL ACAD SCI USA, V97, P7148, DOI 10.1073/pnas.110057697; Paulsson J, 2002, GENETICS, V161, P1373; Paulsson J, 2001, Q REV BIOPHYS, V34, P1, DOI 10.1017/S0033583501003663; PECCOUD J, 1995, THEOR POPUL BIOL, V48, P222, DOI 10.1006/tpbi.1995.1027; RIGNEY DR, 1977, J THEOR BIOL, V69, P761, DOI 10.1016/0022-5193(77)90381-2; Sasai M, 2003, P NATL ACAD SCI USA, V100, P2374, DOI 10.1073/pnas.2627987100; SAVAGEAU MA, 1974, NATURE, V252, P546, DOI 10.1038/252546a0; SAVAGEAU MA, 1971, NATURE, V229, P542, DOI 10.1038/229542a0; SAVAGEAU MA, 1976, BIOCH SYSTEMS ANAL; Schroedinger E., 1944, WHAT IS LIFE; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; SINGH UN, 1969, J THEOR BIOL, V25, P444, DOI 10.1016/S0022-5193(69)80032-9; Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; VANKAMPER NG, 1992, STOCHASTIC PROCESSES; Vilar JMG, 2002, P NATL ACAD SCI USA, V99, P5988, DOI 10.1073/pnas.092133899; Westerhoff H., 1987, THERMODYNAMICS CONTR; Xie XS, 2002, J CHEM PHYS, V117, P11024, DOI 10.1063/1.1521159; Zwanzig R., 2001, NONEQUILIBRIUM STAT	38	950	966	3	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					415	418		10.1038/nature02257	http://dx.doi.org/10.1038/nature02257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749823				2022-12-28	WOS:000188470500035
J	Burridge, K; Wennerberg, K				Burridge, K; Wennerberg, K			Rho and Rac take center stage	CELL			English	Review							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; ADP-RIBOSYLATION FACTOR; ACTIN STRESS FIBERS; RAC1-INTERACTING PROTEIN; STRUCTURAL MIMICRY; CELL-ADHESION; P115 RHOGEF; CROSS-TALK; KINASE-C	Many features of cell behavior are regulated by Rho family GTPases, but the most profound effects of these proteins are on the actin cytoskeleton and it was these that first drew attention to this family of signaling proteins. Focusing on Rho and Rac, we will discuss how their effectors regulate the actin cytoskeleton. We will describe how the activity of Rho proteins is regulated downstream from growth factor receptors and cell adhesion molecules by guanine nucleotide exchange factors and GTPase activating proteins. Additionally, we will discuss how there is signaling crosstalk between family members and how various bacterial pathogens have developed strategies to manipulate Rho protein activity so as to enhance their own survival.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Burridge, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	keith_burridge@med.unc.edu	Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220				Adnane J, 2002, J BIOL CHEM, V277, P8500, DOI 10.1074/jbc.M104367200; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Bliska JB, 2000, TRENDS MICROBIOL, V8, P205, DOI 10.1016/S0966-842X(00)01738-8; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chardin P, 2003, CURR BIOL, V13, pR702, DOI 10.1016/j.cub.2003.08.042; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cherfils J, 2001, FEBS LETT, V507, P280, DOI 10.1016/S0014-5793(01)02970-2; CHLANG SH, 2002, J BIOL CHEM, V277, P13067; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Du W, 1999, MOL CELL BIOL, V19, P1831; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fransson A, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Gampel A, 2002, BIOCHEM J, V366, P393, DOI 10.1042/BJ20020844; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Prieto-Sanchez RM, 2003, J BIOL CHEM, V278, P37916, DOI 10.1074/jbc.M301437200; Radhakrishna H, 1999, J CELL SCI, V112, P855; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wang L, 2003, J BIOL CHEM, V278, P44617, DOI 10.1074/jbc.M308929200; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wherlock M, 2002, J CELL SCI, V115, P239; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	121	1452	1528	0	141	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					167	179		10.1016/S0092-8674(04)00003-0	http://dx.doi.org/10.1016/S0092-8674(04)00003-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744429	Green Submitted, Bronze			2022-12-28	WOS:000188541700008
J	Lee, MCS; Schekman, R				Lee, MCS; Schekman, R			Cell biology - BAR domains go on a bender	SCIENCE			English	Editorial Material							CURVATURE; ENDOCYTOSIS; DYNAMIN; COAT		Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	schekman@uclink4.berkeley.edu		Lee, Marcus/0000-0002-4973-0915				ANTONNY B, COMMUNICATION; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Farsad K, 2003, CURR OPIN CELL BIOL, V15, P372, DOI 10.1016/S0955-0674(03)00073-5; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Ryan TA, 2003, P NATL ACAD SCI USA, V100, P2171, DOI 10.1073/pnas.0530260100; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x	12	29	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					479	480		10.1126/science.1094231	http://dx.doi.org/10.1126/science.1094231			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739445				2022-12-28	WOS:000188316400023
J	Liu, ZY; Moore, PH; Ma, H; Ackerman, CM; Ragiba, M; Yu, QY; Pearl, HM; Kim, MS; Charlton, JW; Stiles, JI; Zee, FT; Paterson, AH; Ming, R				Liu, ZY; Moore, PH; Ma, H; Ackerman, CM; Ragiba, M; Yu, QY; Pearl, HM; Kim, MS; Charlton, JW; Stiles, JI; Zee, FT; Paterson, AH; Ming, R			A primitive Y chromosome in papaya marks incipient sex chromosome evolution	NATURE			English	Article							GENOME; SEQUENCES; SILENE; GENE	Many diverse systems for sex determination have evolved in plants and animals(1-3). One involves physically distinct ( heteromorphic) sex chromosomes ( X and Y, or Z and W) that are homozygous in one sex ( usually female) and heterozygous in the other ( usually male). Sex chromosome evolution is thought to involve suppression of recombination around the sex determination genes, rendering permanently heterozygous a chromosomal region that may then accumulate deleterious recessive mutations by Muller's ratchet, and fix deleterious mutations by hitchhiking as nearby favourable mutations are selected on the Y chromosome(4,5). Over time, these processes may cause the Y chromosome to degenerate and to diverge from the X chromosome over much of its length; for example, only 5% of the human Y chromosome still shows X - Y recombination(6). Here we show that papaya contains a primitive Y chromosome, with a male-specific region that accounts for only about 10% of the chromosome but has undergone severe recombination suppression and DNA sequence degeneration. This finding provides direct evidence for the origin of sex chromosomes from autosomes.	Hawaii Agr Res Ctr, Aiea, HI 96701 USA; ARS, USDA, Pacific Basin Agr Res Ctr, Hilo, HI 96720 USA; Univ Hawaii, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA; Integrated Coffee Technol Inc, Waialua, HI 96791 USA; Univ Georgia, Plant Genome Mapping Lab, Athens, GA 30602 USA	United States Department of Agriculture (USDA); University of Hawaii System; University System of Georgia; University of Georgia	Ming, R (corresponding author), Hawaii Agr Res Ctr, Aiea, HI 96701 USA.	rming@harc-hspa.com	; Yu, Qingyi/E-8899-2019	Liu liu, Zhiyong zhi yong/0000-0002-6958-5233; Yu, Qingyi/0000-0001-5393-5764				Bachtrog D, 2003, NAT GENET, V34, P215, DOI 10.1038/ng1164; CHARLESWORTH B, 1978, AM NAT, V112, P975, DOI 10.1086/283342; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; Charlesworth D, 2002, HEREDITY, V88, P94, DOI 10.1038/sj.hdy.6800016; CHIU CT, 2000, STUDY SEX INHERITANC; Deputy JC, 2002, THEOR APPL GENET, V106, P107, DOI 10.1007/s00122-002-0995-0; Filatov DA, 2000, NATURE, V404, P388, DOI 10.1038/35006057; HOFMEYR J D J, 1967, Agronomia Tropical (Maracay), V17, P345; HOFMEYR J. D. J., 1938, Science Bulletin. Department of Agriculture and Forestry, Union of South Africa, V187; HOROVITZ S, 1967, AGRONOMIA TROPICAL, V17, P353; Iwase M, 2003, P NATL ACAD SCI USA, V100, P5258, DOI 10.1073/pnas.0635848100; Lahn BT, 1999, SCIENCE, V286, P964, DOI 10.1126/science.286.5441.964; Lengerova M, 2003, GENETICS, V165, P935; MA H, IN PRESS GENETICS; Ming R, 2001, THEOR APPL GENET, V102, P892, DOI 10.1007/s001220000448; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; OHNO S, 1967, SEX CHROMOSOME SEX L; Okada S, 2001, P NATL ACAD SCI USA, V98, P9454, DOI 10.1073/pnas.171304798; RICE WR, 1987, GENETICS, V116, P161; Siroky J, 2001, CHROMOSOME RES, V9, P387, DOI 10.1023/A:1016783501674; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Sondur SN, 1996, THEOR APPL GENET, V93, P547, DOI 10.1007/BF00417946; Storey, 1941, HAWAII AGR EXPT STAT, V87, P5; Storey W. B., 1976, Evolution of crop plants., P21; STOREY WB, 1953, J HERED, V44, P70, DOI 10.1093/oxfordjournals.jhered.a106358; STOREY WB, 1938, AM SOC HORT SCI P, V35, P83; TANKSLEY SD, 1988, P 18 STADL GEN S NEW, P157; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; WHITE MJD, 1973, INSECT REPROD, P57; Yang ZN, 2000, GENOME, V43, P412	30	280	314	3	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					348	352		10.1038/nature02228	http://dx.doi.org/10.1038/nature02228			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737167				2022-12-28	WOS:000188266200040
J	Khaw, KT; Reeve, J; Luben, R; Bingham, S; Welch, A; Wareham, N; Oakes, S; Day, N				Khaw, KT; Reeve, J; Luben, R; Bingham, S; Welch, A; Wareham, N; Oakes, S; Day, N			Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study	LANCET			English	Article							BONE-MINERAL DENSITY; OSTEOPOROTIC FRACTURES; POSTMENOPAUSAL WOMEN; ELDERLY WOMEN; VERTEBRAL FRACTURE; TRIAL; MORTALITY; OUTCOMES; COHORT	Background A quarter of fractures needing admission happen in men, but few data are available that show the value of bone measures for prediction of fracture risk in men. We aimed to assess quantitative ultrasound of the calcaneum and fracture incidence in a prospective observational population study. Methods Calcaneum broadband ultrasound attenuation (BUA) was measured in men and women in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) between 1997 and 2000. Incident fractures were ascertained by hospital record linkage. Findings In 14 824 men and women aged 42-82 years, during mean follow-up of 1.9 years (SD 0.7), there were 121 incident fractures that needed admission, including 31 hip fractures. Men and women in the lowest 10% of the calcaneum BUA distribution had a relative risk of fracture of 4.44 (95% Cl 2.24-8.89, p<0.0001) compared with those in the upper 30% of the distribution. A fall of about 1 SD in BUA (20 db/MHz) was associated with a relative risk of fracture of 1.95 (95% Cl :1.50-2.52, p<0.0001), independent of age, sex, weight, height, cigarette smoking habit, and past history of fracture. BUA predicted fractures with consistent magnitude in subgroups stratified by sex, age 65 years or older and younger than 65 years, smoking habit, past history of fracture, and hip and non-hip fractures separately. The sex difference in fracture risk was largely accounted for by differences in BUA. Interpretation Quantitative calcaneum ultrasound predicts total and hip fracture risk in men and women in a continuous relation. The challenge now is to identify interventions to improve bone health in the whole population.	Univ Cambridge, Sch Clin Med, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England; MRC, Dunn Human Nutr Unit, Cambridge, England	University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Khaw, KT (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Clin Gerontol Unit, Box 251, Cambridge CB2 2QQ, England.	kk101@medschl.cam.ac.uk	Khaw, Kay-Tee/AAZ-3209-2021; Reeve, Jonathan/C-7551-2012; Luben, Robert N/H-5519-2015; Welch, Ailsa Ann/A-4850-2008	Reeve, Jonathan/0000-0002-4364-2682; Luben, Robert N/0000-0002-5088-6343; Welch, Ailsa Ann/0000-0002-6702-3704				BLACK DM, 1992, J BONE MINER RES, V7, P633; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BOYCE WJ, 1985, LANCET, V1, P150; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Day N, 1999, BRIT J CANCER, V80, P95; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300; Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224; Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140-6736(95)11456-4; Jakes RW, 2001, BMJ-BRIT MED J, V322, P140, DOI 10.1136/bmj.322.7279.140; KHAW KT, 1992, BRIT MED J, V305, P273, DOI 10.1136/bmj.305.6848.273; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; Khaw KT, 1999, BRIT MED J, V319, P1350, DOI 10.1136/bmj.319.7221.1350; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Miller Paul D, 2002, J Clin Densitom, V5 Suppl, pS39, DOI 10.1385/JCD:5:3S:S39; *NAT OST FDN, 1998, OSTEOPOROS INT S4, V8, pS1; *NAT OST SOC, POS STAT US QUANT UL; Nguyen TV, 1996, AM J EPIDEMIOL, V144, P255, DOI 10.1093/oxfordjournals.aje.a008920; O'Neill TW, 2002, J BONE MINER RES, V17, P2214, DOI 10.1359/jbmr.2002.17.12.2214; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; *UK DEP HLTH, HOSP IN PAT DAT HOSP; WELCH A, IN PRESS OSTEOPOROS; World Health Organization, 1994, ASS FRACT RISK APPL	30	224	230	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					197	202		10.1016/S0140-6736(03)15325-1	http://dx.doi.org/10.1016/S0140-6736(03)15325-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738792				2022-12-28	WOS:000188243900009
J	Sack, DA; Sack, RB; Nair, GB; Siddique, AK				Sack, DA; Sack, RB; Nair, GB; Siddique, AK			Cholera	LANCET			English	Review							TOXIGENIC VIBRIO-CHOLERAE; MANNOSE-SENSITIVE HEMAGGLUTININ; VACCINE CVD 103-HGR; PHAGE TYPING SCHEME; O139 SYNONYM BENGAL; ABO BLOOD-GROUPS; BIOTYPE EL-TOR; ASIATIC CHOLERA; GENE CASSETTES; FLUOROQUINOLONE RESISTANCE	Intestinal infection with Vibrio cholerae results in the loss of large volumes of watery stool, leading to severe and rapidly progressing dehydration and shock. Without adequate and appropriate rehydration therapy, severe cholera kills' about half of affected individuals. Cholera toxin, a potent stimulator of adenylate cyclase, causes the intestine to secrete watery fluid rich in sodium, bicarbonate, and potassium, in volumes far exceeding the intestinal absorptive capacity. Cholera has spread from the Indian subcontinent where it is endemic to involve nearly the whole world seven times during the past 185 years. V cholerae serogroup 01, biotype El Tor, has moved from Asia to cause pandemic disease in Africa and South America during the past 35 years. A new serogroup, 0139, appeared in south Asia in 1992, has become endemic there, and threatens to start the next pandemic. Research on case management of cholera led to the development of rehydration therapy for dehydrating diarrhoea in general, including the proper use of intravenous and oral rehydration solutions. Appropriate case management has reduced deaths from diarrhoea[ disease by an estimated 3 million per year compared with 20 years ago. Vaccination was thought to have no role for cholera, but new oral vaccines are showing great promise.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Dhaka 1000, Bangladesh; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sack, DA (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, GPO Box 128, Dhaka 1000, Bangladesh.	dsack@icddrb.org			NIAID NIH HHS [R01 AI39129, R01 AI039129] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039129] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT MJ, 1993, LANCET, V342, P387, DOI 10.1016/0140-6736(93)92811-7; ALDOVA E, 1968, J INFECT DIS, V118, P25, DOI 10.1093/infdis/118.1.25; [Anonymous], 1971, BMJ-BRIT MED J, V3, P266; AZURIN JC, 1967, B WORLD HEALTH ORGAN, V37, P745; BAINE WB, 1974, LANCET, V2, P1370; Baranwal S, 2002, ANTIMICROB AGENTS CH, V46, P2676, DOI 10.1128/AAC.46.8.2676-2678.2002; BARUA D, 1977, ANN HUM BIOL, V4, P489, DOI 10.1080/03014467700002481; BARUA D, 1972, P ROY SOC MED, V65, P423, DOI 10.1177/003591577206500501; BARUA D, 1974, CHOLERA; BENENSON A. S., 1964, BULL WORLD HEALTH ORGAN, V30, P827; BERCHE P, 1994, J INFECT DIS, V170, P701, DOI 10.1093/infdis/170.3.701; BIK EM, 1995, EMBO J, V14, P209, DOI 10.1002/j.1460-2075.1995.tb06993.x; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; Broza M, 2001, NATURE, V412, P40, DOI 10.1038/35083691; BUTLER T, 1989, T ROY SOC TROP MED H, V83, P839, DOI 10.1016/0035-9203(89)90348-9; CAMERON DN, 1994, J CLIN MICROBIOL, V32, P1685, DOI 10.1128/JCM.32.7.1685-1690.1994; CARPENTER CC, 1966, B JOHNS HOPKINS HOSP, V118, P174; Chakrabarti AK, 2000, J CLIN MICROBIOL, V38, P44; CHATTOPADHYAY DJ, 1993, J CLIN MICROBIOL, V31, P1579, DOI 10.1128/JCM.31.6.1579-1585.1993; CHEN F, 1991, EPIDEMIOL INFECT, V107, P225, DOI 10.1017/S0950268800048846; Chiavelli DA, 2001, APPL ENVIRON MICROB, V67, P3220, DOI 10.1128/AEM.67.7.3220-3225.2001; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1989, J INFECT DIS, V159, P770, DOI 10.1093/infdis/159.4.770; Cohen MB, 2002, INFECT IMMUN, V70, P1965, DOI 10.1128/IAI.70.4.1965-1970.2002; Colwell R R, 2000, J Infect Chemother, V6, P121, DOI 10.1007/PL00012151; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; COLWELL RR, 1977, SCIENCE, V198, P394, DOI 10.1126/science.910135; Comstock LE, 1996, MOL MICROBIOL, V19, P815, DOI 10.1046/j.1365-2958.1996.407928.x; COMSTOCK LE, 1995, INFECT IMMUN, V63, P317, DOI 10.1128/IAI.63.1.317-323.1995; CVJETANOVIC B, 1972, NATURE, V239, P137, DOI 10.1038/239137a0; DAKIN WPH, 1974, MED J AUSTRALIA, V2, P487, DOI 10.5694/j.1326-5377.1974.tb70935.x; DE SN, 1959, NATURE, V183, P1533, DOI 10.1038/1831533a0; DUFFY J, 1971, B NEW YORK ACAD MED, V47, P1152; Dumontier S, 1998, FEMS MICROBIOL LETT, V164, P91, DOI 10.1016/S0378-1097(98)00201-8; DUTTA NK, 1959, J BACTERIOL, V78, P594, DOI 10.1128/JB.78.4.594-595.1959; Faruque SM, 1998, INFECT IMMUN, V66, P5819, DOI 10.1128/IAI.66.12.5819-5825.1998; Faruque SM, 1998, INFECT IMMUN, V66, P3752, DOI 10.1128/IAI.66.8.3752-3757.1998; Faruque SM, 1997, J CLIN MICROBIOL, V35, P624, DOI 10.1128/JCM.35.3.624-630.1997; Faruque SM, 2003, EMERG INFECT DIS, V9, P1116; FARUQUE SM, 1995, J CLIN MICROBIOL, V33, P2833, DOI 10.1128/JCM.33.11.2833-2838.1995; Faruque SM, 2000, J INFECT DIS, V182, P1161, DOI 10.1086/315807; FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242; FIELD M, 1972, J CLIN INVEST, V51, P796, DOI 10.1172/JCI106874; FINKELSTEIN RA, 1969, J EXP MED, V130, P185, DOI 10.1084/jem.130.1.185; FRANZON VL, 1993, INFECT IMMUN, V61, P3032, DOI 10.1128/IAI.61.7.3032-3037.1993; Garg P, 2001, ANTIMICROB AGENTS CH, V45, P1605, DOI 10.1128/AAC.45.5.1605-1606.2001; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; GLASS RI, 1980, J INFECT DIS, V142, P939, DOI 10.1093/infdis/142.6.939; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; Gunnlaugsson G, 1998, EPIDEMIOL INFECT, V120, P7, DOI 10.1017/S0950268897008170; HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x; HASAN JAK, 1994, J CLIN MICROBIOL, V32, P249, DOI 10.1128/JCM.32.1.249-252.1994; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HISATSUNE K, 1993, BIOCHEM BIOPH RES CO, V196, P1309, DOI 10.1006/bbrc.1993.2395; Hochhut B, 2001, ANTIMICROB AGENTS CH, V45, P2991, DOI 10.1128/AAC.45.11.2991-3000.2001; HOLMGREN J, 1989, VACCINE, V7, P94, DOI 10.1016/0264-410X(89)90042-X; HOLMGREN J, 1971, ACTA PATHOLOG MICROB, VB 79, P448; HOLMGREN J, 1973, Scandinavian Journal of Infectious Diseases, V5, P77, DOI 10.3109/inf.1973.5.issue-1.15; HORNICK RB, 1971, B NEW YORK ACAD MED, V47, P1181; HUGHES JM, 1982, B WORLD HEALTH ORGAN, V60, P395; HUGHES KJ, 1994, GENE, V148, P97, DOI 10.1016/0378-1119(94)90240-2; HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983; ISLAM MS, 1994, J DIARRHOEAL DIS RES, V12, P245; ISLAM S, 1990, J TROP MED HYG, V93, P133; JOHNSON JA, 1994, INFECT IMMUN, V62, P2108, DOI 10.1128/IAI.62.5.2108-2110.1994; JONSON G, 1994, MOL MICROBIOL, V13, P109, DOI 10.1111/j.1365-2958.1994.tb00406.x; Kabir I, 1996, J DIARRHOEAL DIS RES, V14, P243; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; Karaolis DKR, 1998, P NATL ACAD SCI USA, V95, P3134, DOI 10.1073/pnas.95.6.3134; KHAN M, 1980, J TROP MED HYG, V83, P35; Khan P K, 1969, Int Surg, V51, P138; Khan WA, 1996, LANCET, V348, P296, DOI 10.1016/S0140-6736(96)01180-4; Khan WA, 2002, LANCET, V360, P1722, DOI 10.1016/S0140-6736(02)11680-1; Kirn TJ, 2000, MOL MICROBIOL, V35, P896, DOI 10.1046/j.1365-2958.2000.01764.x; Ko WC, 1998, CLIN INFECT DIS, V27, P774, DOI 10.1086/514947; KOCH R, 1894, BMJ-BRIT MED J, V2, P453; Kovach ME, 1996, MICROBIOL-SGM, V142, P2165, DOI 10.1099/13500872-142-8-2165; KUSTNER HGV, 1981, S AFR MED J, V60, P87; Lazar S, 1998, INFECT IMMUN, V66, P394, DOI 10.1128/IAI.66.1.394-397.1998; Legros D, 1999, B WORLD HEALTH ORGAN, V77, P837; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; LINDENBA.J, 1967, B WORLD HEALTH ORGAN, V36, P871; LONNROTH I, 1973, J GEN MICROBIOL, V76, P417, DOI 10.1099/00221287-76-2-417; Manning PA, 1997, GENE, V192, P63, DOI 10.1016/S0378-1119(97)00036-X; MCCARTHY SA, 1994, APPL ENVIRON MICROB, V60, P2597, DOI 10.1128/AEM.60.7.2597-2601.1994; Mead GH., 1936, SOCIAL PSYCHOL SELEC; Mekalanos JJ, 1997, FEMS IMMUNOL MED MIC, V18, P241, DOI 10.1016/S0928-8244(97)00054-0; MHALU FS, 1979, LANCET, V1, P345; MOLLA AM, 1981, J PEDIATR-US, V98, P835, DOI 10.1016/S0022-3476(81)80863-3; MOLLA AM, 1982, LANCET, V1, P1317; MOMEN H, 1985, T ROY SOC TROP MED H, V79, P773, DOI 10.1016/0035-9203(85)90113-0; MORRIS JG, 1990, J CLIN INVEST, V85, P697, DOI 10.1172/JCI114494; MOSLEY WH, 1972, B WORLD HEALTH ORGAN, V47, P229; Mukhopadhyay AK, 1998, ANTIMICROB AGENTS CH, V42, P206, DOI 10.1128/AAC.42.1.206; NAIR GB, 1988, APPL ENVIRON MICROB, V54, P3180, DOI 10.1128/AEM.54.12.3180-3182.1988; PARSOT C, 1990, P NATL ACAD SCI USA, V87, P9898, DOI 10.1073/pnas.87.24.9898; PARSOT C, 1991, P NATL ACAD SCI USA, V88, P1641, DOI 10.1073/pnas.88.5.1641; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; PETERSON KM, 1988, INFECT IMMUN, V56, P2822, DOI 10.1128/IAI.56.11.2822-2829.1988; Pollitzer R, 1959, CHOLERA CHAPTER WORL; POPOVIC T, 1993, J CLIN MICROBIOL, V31, P2474, DOI 10.1128/JCM.31.9.2474-2482.1993; QADRI F, 1995, J CLIN MICROBIOL, V33, P732, DOI 10.1128/JCM.33.3.732-734.1995; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; Recchia GD, 1995, MICROBIOL-UK, V141, P3015, DOI 10.1099/13500872-141-12-3015; Reidl J, 2002, FEMS MICROBIOL REV, V26, P125, DOI 10.1111/j.1574-6976.2002.tb00605.x; Richie E, 2000, VACCINE, V18, P2399, DOI 10.1016/S0264-410X(00)00006-2; RIES AA, 1992, J INFECT DIS, V166, P1429, DOI 10.1093/infdis/166.6.1429; Rosenberg Charles E, 1987, CHOLERA YEARS US 183; Sack D.A., 2001, ANTIMICROBIAL RESIST; Sack DA, 1998, INFECT IMMUN, V66, P1968, DOI 10.1128/IAI.66.5.1968-1972.1998; SACK DA, 1978, ANTIMICROB AGENTS CH, V14, P462, DOI 10.1128/AAC.14.3.462; Sack DA, 1997, J INFECT DIS, V176, P201, DOI 10.1086/514025; SACK GH, 1972, B WORLD HEALTH ORGAN, V47, P31; SACK RB, 1979, NEW ENGL J MED, V300, P1107, DOI 10.1056/NEJM197905103001910; Sack RB, 2003, J INFECT DIS, V187, P96, DOI 10.1086/345865; SALLES CA, 1991, T ROY SOC TROP MED H, V85, P544, DOI 10.1016/0035-9203(91)90251-S; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; SENGUPTA DK, 1992, INFECT IMMUN, V60, P4848, DOI 10.1128/IAI.60.11.4848-4855.1992; Shapiro RL, 1999, AM J TROP MED HYG, V60, P271, DOI 10.4269/ajtmh.1999.60.271; SIDDIQUE AK, 1992, J DIARRHOEAL DIS RES, V10, P79; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; SPEELMAN P, 1986, GASTROENTEROLOGY, V91, P1164, DOI 10.1016/S0016-5085(86)80012-9; SPRINZ H, 1962, AM J CLIN PATHOL, V38, P43; STROEHER UH, 1995, P NATL ACAD SCI USA, V92, P10374, DOI 10.1073/pnas.92.22.10374; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; Tacket CO, 1997, AM J TROP MED HYG, V56, P533, DOI 10.4269/ajtmh.1997.56.533; TACKET CO, 1995, J INFECT DIS, V172, P883, DOI 10.1093/infdis/172.3.883; Tacket CO, 1999, INFECT IMMUN, V67, P6341; TANAMAL STW, 1959, AM J TROP MED HYG, V8, P72, DOI 10.4269/ajtmh.1959.8.72; TAUXE RV, 1995, EMERG INFECT DIS, V1, P141, DOI 10.3201/eid0104.950408; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Thungapathra M, 2002, ANTIMICROB AGENTS CH, V46, P2948, DOI 10.1128/AAC.46.9.2948-2955.2002; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; Trucksis M, 1998, P NATL ACAD SCI USA, V95, P14464, DOI 10.1073/pnas.95.24.14464; Trucksis M, 2000, AM J PHYSIOL-CELL PH, V279, pC567, DOI 10.1152/ajpcell.2000.279.3.C567; VANHEYNINGEN WE, 1971, J INFECT DIS, V124, P415, DOI 10.1093/infdis/124.4.415; WACHSMUTH IK, 1993, J INFECT DIS, V167, P621, DOI 10.1093/infdis/167.3.621; Waldor MK, 1997, MOL MICROBIOL, V24, P917, DOI 10.1046/j.1365-2958.1997.3911758.x; Waldor MK, 1996, J BACTERIOL, V178, P4157, DOI 10.1128/jb.178.14.4157-4165.1996; WALDOR MK, 1994, J INFECT DIS, V170, P278, DOI 10.1093/infdis/170.2.278; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Watnick PI, 2001, MOL MICROBIOL, V39, P223, DOI 10.1046/j.1365-2958.2001.02195.x; WEIL O, 1992, REV EPIDEMIOL SANTE, V40, P145; *WHO GLOB TASK FOR, 1993, GUID CHOL CONTR; Yamai S, 1997, Kansenshogaku Zasshi, V71, P1037; Yamasaki S, 1999, GENE, V237, P321, DOI 10.1016/S0378-1119(99)00344-3; Zaman K, 2001, ACTA PAEDIATR, V90, P505, DOI 10.1080/080352501750197629	150	744	776	4	189	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					223	233		10.1016/S0140-6736(03)15328-7	http://dx.doi.org/10.1016/S0140-6736(03)15328-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738797				2022-12-28	WOS:000188243900023
J	Chan, SC; Lo, CY				Chan, SC; Lo, CY			Meckel's diverticulum in action	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hong Kong, Med Ctr, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan, SC (corresponding author), Univ Hong Kong, Med Ctr, Hong Kong, Hong Kong, Peoples R China.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					E7	E7		10.1056/ENEJMicm010421	http://dx.doi.org/10.1056/ENEJMicm010421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973202				2022-12-28	WOS:000189006400010
J	Vazquez, M; LaRussa, PS; Gershon, AA; Niccolai, LM; Muehlenbein, CE; Steinberg, SP; Shapiro, ED				Vazquez, M; LaRussa, PS; Gershon, AA; Niccolai, LM; Muehlenbein, CE; Steinberg, SP; Shapiro, ED			Effectiveness over time of varicella vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN	Context Reports of outbreaks of varicella in highly immunized groups have increased concern about the effectiveness of varicella vaccine. Objective To assess whether the effectiveness of varicella vaccine is affected either by time since vaccination or by age at the time of vaccination. Design Case-control study conducted from March 1997 through June 2003. Setting Twenty different group practices in southern Connecticut. Participants Case subjects, identified by active surveillance of all practices, consisted of 339 eligible children 13 months or older who were clinically diagnosed as having chickenpox and who also had a polymerase chain reaction (PCR) test result that was positive for varicella-zoster virus DNA. For each case subject, 2 controls were selected, matched by both age and pediatric practice. Main Outcome Measures The effectiveness of the vaccine, especially the effects of time since vaccination and age at the time of vaccination, adjusted for possible confounders. Results Although the adjusted overall effectiveness of the vaccine was 87% (95% confidence interval, 81%-91%; P<.001), there was a substantial difference in the vaccine's effectiveness in the first year after vaccination (97%) and in years 2 to 8 after vaccination (84%, P=.003). The vaccine's effectiveness in year 1 was substantially lower if the vaccine was administered at younger than 15 months (73%) than if it was administered at 15 months or older (99%, P=.01), although the difference in effectiveness overall for children immunized at younger than 15 months was not statistically significantly different than for those immunized at 15 months or older (81% vs 88%, P=.17). Most cases of chickenpox in vaccinees were mild. Conclusions Although varicella vaccine is effective, its effectiveness decreases significantly after 1 year, although most cases of breakthrough disease are mild. If administered at younger than 15 months, the vaccine's effectiveness was lower in the first year after vaccination, but the difference in effectiveness was not statistically significant for subsequent years.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale Univ, Sch Med, Childrens Clin Res Ctr, New Haven, CT USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA	Yale University; Yale University; Yale University; Columbia University	Shapiro, ED (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.	Eugene.Shapiro@Yale.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001703, R01AI024021, R01AI041608] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR06022] Funding Source: Medline; NIAID NIH HHS [R01-AI41608, R01-AI 24021, K24-AI01703] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON JH, 2001, COMPUTER PROGRAMS EP, P113; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P884; CORNFIELD J, 1951, J NATL CANCER I, V11, P1269; Galil K, 2002, J INFECT DIS, V186, P102, DOI 10.1086/341089; Galil K, 2002, NEW ENGL J MED, V347, P1909, DOI 10.1056/NEJMoa021662; Gershon AA, 2002, NEW ENGL J MED, V347, P1962, DOI 10.1056/NEJMe020138; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; LARUSSA P, 1992, J VIROL, V66, P1016, DOI 10.1128/JVI.66.2.1016-1020.1992; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; *SAS I INC, 1999, SAS ONL VERS 8; Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; Vazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302; Verstraeten T, 2003, PEDIATRICS, V112, pE98, DOI 10.1542/peds.112.2.e98; WATSON B, 1995, CLIN INFECT DIS, V20, P316, DOI 10.1093/clinids/20.2.316; 2003, MMWR MORB MORTAL WKL, V52, P545	17	175	187	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2004	291	7					851	855		10.1001/jama.291.7.851	http://dx.doi.org/10.1001/jama.291.7.851			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TF	14970064				2022-12-28	WOS:000189000400023
J	Raithatha, N; Smith, RD				Raithatha, N; Smith, RD			Paying for statins	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; PRIMARY PREVENTION; CHOLESTEROL; RISK		Univ E Anglia, Ctr Hlth, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Hlth Econ & Eth Grp, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Raithatha, N (corresponding author), Univ E Anglia, Ctr Hlth, Norwich NR4 7TJ, Norfolk, England.	N.Raithatha@uea.ac.uk		Smith, Richard/0000-0003-3837-6559				Beattie J, 1998, J RISK UNCERTAINTY, V17, P5, DOI 10.1023/A:1007711416843; *BRIT MED ASS ROYA, 2003, BRIT NAT FORM, P128; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; *DEP HLTH, 2003, FAIR ALL PERS YOU CH; *DEP HLTH, 2000, NAT SERV FRAM CORN H; Department of Health, 1999, SAV LIV OUR HLTH NAT; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Haq IU, 2001, HEART, V86, P289, DOI 10.1136/heart.86.3.289; Hulley SB, 2000, BRIT MED J, V321, P971, DOI 10.1136/bmj.321.7267.971; Jackson R, 2000, BMJ-BRIT MED J, V320, P659, DOI 10.1136/bmj.320.7236.659; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Marks D, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [10.3310/hta4290, DOI 10.3310/HTA4290]; Pickin DM, 1999, HEART, V82, P325, DOI 10.1136/hrt.82.3.325; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; Rawls J., 1972, SOCIAL JUSTICE LIBER; TIMMINS N, 2001, FINANCIAL TIMES 0810	16	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					400	402		10.1136/bmj.328.7436.400	http://dx.doi.org/10.1136/bmj.328.7436.400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962879	Green Accepted, Green Published			2022-12-28	WOS:000189031300032
J	Matsumoto, K; Tanaka, K				Matsumoto, K; Tanaka, K			Conflict and cognitive control	SCIENCE			English	Editorial Material							ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; SELECTION; CELLS		RIKEN, Brain Sci Inst, Cognit Brain Mapping Lab, Wako, Saitama 3510198, Japan	RIKEN	Matsumoto, K (corresponding author), RIKEN, Brain Sci Inst, Cognit Brain Mapping Lab, Wako, Saitama 3510198, Japan.	matsumot@riken.jp	Tanaka, Keiji/N-5917-2015	Tanaka, Keiji/0000-0002-1910-3427; Matsumoto, Kenji/0000-0003-0883-4280				Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Duncan J, 2001, NAT REV NEUROSCI, V2, P820, DOI 10.1038/35097575; Funahashi S, 2001, NEUROSCI RES, V39, P147, DOI 10.1016/S0168-0102(00)00224-8; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Matsumoto K, 2003, SCIENCE, V301, P229, DOI 10.1126/science.1084204; Procyk E, 2000, NAT NEUROSCI, V3, P502, DOI 10.1038/74880; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; Wang Y, 2001, NEUROSCI RES, V39, P39, DOI 10.1016/S0168-0102(00)00198-X	11	96	104	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	2004	303	5660					969	970		10.1126/science.1094733	http://dx.doi.org/10.1126/science.1094733			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	773JJ	14963319				2022-12-28	WOS:000188918000033
J	Boutros, M; Kiger, AA; Armknecht, S; Kerr, K; Hild, M; Koch, B; Haas, SA; Paro, R; Perrimon, N				Boutros, M; Kiger, AA; Armknecht, S; Kerr, K; Hild, M; Koch, B; Haas, SA; Paro, R; Perrimon, N		Heidelberg Fly Array Consortium	Genome-wide RNAi analysis of growth and viability in Drosophila cells	SCIENCE			English	Article							IDENTIFICATION; INTERFERENCE; PROTEIN; GENES	A crucial aim upon completion of whole genome sequences is the functional analysis of all predicted genes. We have applied a high-throughput RNA-interference (RNAi) screen of 19,470 double-stranded (ds) RNAs in cultured cells to characterize the function of nearly all (91%) predicted Drosophila genes in cell growth and viability. We found 438 dsRNAs that identified essential genes, among which 80% lacked mutant alleles. A quantitative assay of cell number was applied to identify genes of known and uncharacterized functions. In particular, we demonstrate a role for the homolog of a mammalian acute myeloid leukemia gene (AML1) in cell survival. Such a systematic screen for cell phenotypes, such as cell viability, can thus be effective in characterizing functionally related genes on a genome-wide scale.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Ruprecht Karls University Heidelberg; Max Planck Society	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	perrimon@rascal.med.harvard.edu	Boutros, Michael/C-3566-2008	Boutros, Michael/0000-0002-9458-817X; Perrimon, Norbert/0000-0001-7542-472X; Haas, Stefan/0000-0003-3418-3688	NIGMS NIH HHS [R01 GM078176] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078176] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; Frank LH, 1996, DEVELOPMENT, V122, P1343; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hild M, 2004, GENOME BIOL, V5; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; MISRA S, 2002, GENOME BIOL, V3, P83, DOI [DOI 10.1186/GB-2002-3-12-RESEARCH0083, 10.1186/gb-2002-3-12-research0083]; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Yanagawa S, 1998, J BIOL CHEM, V273, P32353, DOI 10.1074/jbc.273.48.32353	21	562	614	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					832	835		10.1126/science.1091266	http://dx.doi.org/10.1126/science.1091266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764878				2022-12-28	WOS:000188753800056
J	Pan, XP; Shao, M; Kulkarni, SR				Pan, XP; Shao, M; Kulkarni, SR			A distance of 133-137 parsecs to the Pleiades star cluster	NATURE			English	Article							PALOMAR TESTBED INTERFEROMETER; III STELLAR INTERFEROMETER; SPECTROSCOPIC BINARIES; LUNAR OCCULTATIONS; PARALLAXES; ORBIT	Nearby ' open' clusters of stars ( those that are not gravitationally bound) have played a crucial role in the development of stellar astronomy because, as a consequence of the stars having a common age, they provide excellent natural laboratories to test theoretical stellar models. Clusters also play a fundamental part in determining distance scales. The satellite Hipparcos(1) surprisingly found that an extensively studied open cluster - the Pleiades ( also known as the Seven Sisters) - had a distance of D = 118 +/- 4 pc ( refs 2, 3), about ten per cent smaller than the accepted value(4-6). The discrepancy generated a spirited debate because the implication(7) was that either current stellar models were incorrect by a surprising amount or Hipparcos was giving incorrect distances. Here we report the orbital parameters of the bright double star Atlas in the Pleiades, using long- baseline optical/ infrared interferometry. From the data we derive a firm lower bound of D > 127 pc, with the most likely range being 133 < D < 137 pc. Our result reaffirms the fidelity of current stellar models.	CALTECH, Opt Observ 105 24, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kulkarni, SR (corresponding author), CALTECH, Opt Observ 105 24, Pasadena, CA 91125 USA.	srk@anju.caltech.edu						ABT HA, 1965, ASTROPHYS J, V142, P1604, DOI 10.1086/148440; Castellani V, 2002, MON NOT R ASTRON SOC, V334, P193, DOI 10.1046/j.1365-8711.2002.05508.x; Colavita MM, 1999, ASTROPHYS J, V510, P505, DOI 10.1086/306579; DEVEGT C, 1976, ASTRON ASTROPHYS, V48, P245; Gatewood G, 2000, ASTROPHYS J, V533, P938, DOI 10.1086/308679; GIANNUZZI MA, 1995, ASTRON ASTROPHYS, V293, P360; HUMMEL CA, 1993, ASTRON J, V106, P2486, DOI 10.1086/116816; Lane BF, 2003, ASTRON J, V125, P1623, DOI 10.1086/367793; MCGRAW JT, 1974, ASTRON J, V79, P1299, DOI 10.1086/111677; Mermilliod JC, 1997, ESA SP PUBL, V402, P643; MERMILLIOD JC, 1992, ASTRON ASTROPHYS, V265, P513; MEYER C, 1995, ASTRON ASTROPHYS SUP, V110, P107; MEYNET G, 1993, ASTRON ASTROPHYS SUP, V98, P477; Narayanan VK, 1999, ASTROPHYS J, V523, P328, DOI 10.1086/307716; Paczynski B, 2003, ACTA ASTRONOM, V53, P209; PAN XP, 1990, ASTROPHYS J, V356, P641, DOI 10.1086/168870; PEARCE JA, 1971, PUBL ASTRON SOC PAC, V83, P493, DOI 10.1086/129161; Pinfield DJ, 1998, MON NOT R ASTRON SOC, V299, P955, DOI 10.1046/j.1365-8711.1998.01754.x; Pinsonneault MH, 1998, ASTROPHYS J, V504, P170, DOI 10.1086/306077; Raboud D, 1998, ASTRON ASTROPHYS, V329, P101; RICHICHI A, 1994, ASTRON ASTROPHYS, V286, P829; SHAO M, 1988, ASTRON ASTROPHYS, V193, P357; SHAO M, 1992, ANNU REV ASTRON ASTR, V30, P457; Torres G., 2003, IBVS, V5402, P1; VANLEEUWEN F, 1997, ESA, P689; Ventura P, 1998, ASTRON ASTROPHYS, V334, P953; [No title captured]	27	69	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					326	328		10.1038/nature02296	http://dx.doi.org/10.1038/nature02296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737161				2022-12-28	WOS:000188266200033
J	Wells, S; Mullin, B; Norton, R; Langley, J; Connor, J; Lay-Yee, R; Jackson, R				Wells, S; Mullin, B; Norton, R; Langley, J; Connor, J; Lay-Yee, R; Jackson, R			Motorcycle rider conspicuity and crash related injury: case-control study	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGIC FEATURES; COLLISION INJURIES; LAWS; RISK	Objective To investigate whether the risk of motorcycle crash related injuries is associated with the conspicuity of the driver or vehicle. Design Population based case-control study. Setting Auckland region of New Zealand from February 1993 to February 1996. Participants 463 motorcycle drivers (cases) involved in crashes leading to hospital treatment or death; 1233 motorcycle drivers (controls) recruited from randomly selected roadside survey sites. Main outcome measures Estimates of relative risk of motorcycle crash related injury and population attributable risk associated with conspicuity measures, including the use of reflective or fluorescent clothing, headlight operation, and colour of helmet, clothing, and motorcycle. Results Crash related injuries occurred mainly in urban zones with 50 km/h speed limit (66%), during the day (63%), and in fine weather (72%). After adjustment for potential confounders, drivers wearing any reflective or fluorescent clothing had a 37% lower risk (multivariate odds ratio 0.63, 95% confidence interval 0.42 to 0.94) than other drivers. Compared with wearing a black helmet, use of a white helmet was associated with a 24% lower risk (multivariate odds ratio 0.76, 0.57 to 0.99). Self reported light coloured helmet versus dark coloured helmet was associated with a 19% lower risk. Three quarters of motorcycle riders had their headlight turned on during the day, and this was associated with a 27% lower risk (multivariate odds ratio 0.73, 0.53 to 1.00). No association occurred between risk and the frontal colour of drivers' clothing or motorcycle. If these odds ratios are unconfounded, the population attributable risks are 33% for wearing no reflective or fluorescent clothing, 18% for a non-white helmet, 11% for a dark coloured helmet, and 7% for no daytime headlight operation. Conclusions Low conspicuity may increase the risk of motorcycle crash related injury. Increasing the use of reflective or fluorescent clothing, white or light coloured helmets, and daytime headlights are simple, cheap interventions that could considerably reduce motorcycle crash related injury and death.	Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand; Univ Auckland, Sch Populat Hlth, Ctr Hlth Serv & Policy Res, Auckland 1, New Zealand; Univ Sydney, Inst Int Hlth, Sydney, NSW 2006, Australia; Univ Otago, Injury Prevent Res Unit, Otago, New Zealand	University of Auckland; University of Auckland; University of Sydney; University of Otago	Wells, S (corresponding author), Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Private Bag 92019,Graften Rd, Auckland 1, New Zealand.	s.wells@auckland.ac.nz		Jackson, Rod/0000-0001-5914-6934; Connor, Jennie/0000-0002-3209-8693				[Anonymous], 1980, INT CLASS DIS; Bijleveld F.D., 1997, EFFECTIVENESS DAYTIM; Bragg B. W, 1980, INT MOT SAF C WASH, V3, P1131; Hurt H, 1981, 805862 DOT HS NAT HI; Hurt H.H., 1981, MOTORCYCLE ACCIDENT, V2; Janoff M., 1971, HIGHWAY RES REC, V377, P53; KRAUS JF, 1976, ACCIDENT ANAL PREV, V8, P247, DOI 10.1016/0001-4575(76)90010-5; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P74, DOI 10.1093/oxfordjournals.aje.a112136; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; *LAND TRANSP SAF A, 1991, NZ HOUS TRAV SURV; Langley J, 2000, ACCIDENT ANAL PREV, V32, P659, DOI 10.1016/S0001-4575(99)00101-3; MULLER A, 1982, AM J PUBLIC HEALTH, V72, P1136, DOI 10.2105/AJPH.72.10.1136; MULLER A, 1984, ACCIDENT ANAL PREV, V16, P1, DOI 10.1016/0001-4575(84)90002-2; Mullin B, 2000, Inj Prev, V6, P32, DOI 10.1136/ip.6.1.32; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Radin Umar R.S., 1995, J TRAFFIC MED, V23, P17; ROBERTSON LS, 1976, LAW SOC REV, V10, P467, DOI 10.2307/3053144; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; UMAR RSR, 1996, ACCIDENT ANAL PREV, V28, P325; Vaughan R. G, 1977, MOTORCYCLE CRASHES L; WILLIAMS MJ, 1979, ACCIDENT ANAL PREV, V11, P209, DOI 10.1016/0001-4575(79)90005-8; ZADOR PL, 1985, AM J PUBLIC HEALTH, V75, P543, DOI 10.2105/AJPH.75.5.543	25	94	96	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 10	2004	328	7444					857	860A		10.1136/bmj.37984.574757.EE	http://dx.doi.org/10.1136/bmj.37984.574757.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	812XE	14742349	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000220871400013
J	Richards, M; Shipley, B; Fuhrer, R; Wadsworth, MEJ				Richards, M; Shipley, B; Fuhrer, R; Wadsworth, MEJ			Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AGE	Objective To examine die association between cognitive ability in childhood and mid-life cognitive decline in the normal population. Design Longitudinal, population based, birth cohort study. Participants 2058 men and women born in 1946. Main study measures Ability in childhood measured by AH4 and test of verbal comprehension at age 15 years. Ability in adulthood measured by the national adult reading test (NART) at age 53 years. Outcome measures were decline in memory (word list learning) and speed and concentration (timed visual search) from age 43 to 53 years. Results Ability in childhood was significantly and negatively associated with decline in memory (beta = 0.09, P = 0.005, for men; 0.10, P < 0.001, for women) and search speed (beta = 0.13, P < 0.001, for men; 0.08, P = 0.0 1, for women), independent of educational attainment, occupational social class, and a range of health indicators. The adult reading test was also significantly and negatively associated with decline in these outcomes (for memory beta = 0.21, P < 0.001, for men; 0.17, P < 0.001, for women; and for search speed beta = - 0.05 for men; 0.10, P = 0.008 for women) independent of educational attainment, social class, and childhood ability. Conclusions Ability in childhood can protect against cognitive decline in mid-life and beyond. Results for the adult reading test indicate that the protective effect of ability may also be acquired in adulthood.	UCL, MRC, Natl Survey Hlth & Dev, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3A 1A2, Canada	University of London; University College London; McGill University	Richards, M (corresponding author), UCL, MRC, Natl Survey Hlth & Dev, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	m.richards@ucl.ac.uk		Richards, Marcus/0000-0001-9191-2192				Berger A, 2001, BMJ-BRIT MED J, V322, P203, DOI 10.1136/bmj.322.7280.203; Deary IJ, 1998, INTELLIGENCE, V26, P357, DOI 10.1016/S0160-2896(99)00005-7; Douglas James W.B, 1964, HOME SCH; Heim AW, 1970, AH4 GROUP TEST INTEL; MORITZ DJ, 1995, AM J EPIDEMIOL, V141, P41, DOI 10.1093/oxfordjournals.aje.a117344; Nelson H., 1991, NATL ADULT READING T; Pigeon DA, 1968, ALL OUR FUTURE; Plomin R, 1999, NATURE, V402, pC25, DOI 10.1038/35011520; RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055; Rabbitt P, 2003, BRIT J PSYCHOL, V94, P63, DOI 10.1348/000712603762842101; Richards M, 2003, AM J PUBLIC HEALTH, V93, P994, DOI 10.2105/AJPH.93.6.994; Richards M, 2003, SOC SCI MED, V56, P785, DOI 10.1016/S0277-9536(02)00075-8; RUTTER M, 1985, J CHILD PSYCHOL PSYC, V26, P683, DOI 10.1111/j.1469-7610.1985.tb00584.x; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schmand B, 1997, PSYCHOL MED, V27, P1337, DOI 10.1017/S0033291797005461; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; Wadsworth MEJ, 2003, SOC SCI MED, V57, P2193, DOI 10.1016/S0277-9536(03)00083-2; WADSWORTH MEJ, IN PRESS SOC SCI MED; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Whalley LJ, 2001, BRIT MED J, V322, P819, DOI 10.1136/bmj.322.7290.819	21	122	123	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2004	328	7439					552	554B		10.1136/bmj.37972.513819.EE	http://dx.doi.org/10.1136/bmj.37972.513819.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	801JI	14761906	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220091800018
J	Sande, MA; Ronald, AR				Sande, MA; Ronald, AR			Update in infectious diseases	ANNALS OF INTERNAL MEDICINE			English	Review									Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Sande, MA (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Internal Med, 4C104 SOM,30 N 1900 E, Salt Lake City, UT 84132 USA.	merle.sande@hsc.utah.edu		Ronald, Allan/0000-0002-5746-3490				Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367	2	3	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					290	295		10.7326/0003-4819-140-4-200402170-00011	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970152				2022-12-28	WOS:000188970400007
J	Curran, LM; Trigg, SN; McDonald, AK; Astiani, D; Hardiono, YM; Siregar, P; Caniago, I; Kasischke, E				Curran, LM; Trigg, SN; McDonald, AK; Astiani, D; Hardiono, YM; Siregar, P; Caniago, I; Kasischke, E			Lowland forest loss in protected areas of Indonesian Borneo	SCIENCE			English	Article							DEFORESTATION; SCALE; PARKS	The ecology of Bornean rainforests is driven by El Nino-induced droughts that trigger synchronous fruiting among trees and bursts of faunal reproduction that sustain vertebrate populations. However, many of these species- and carbon-rich ecosystems have been destroyed by logging and conversion, which increasingly threaten protected areas. Our satellite, Geographic Information System, and field-based analyses show that from 1985 to 2001, Kalimantan's protected lowland forests declined by more than 56% (>29,000 square kilometers). Even uninhabited frontier parks are logged to supply international markets. "Protected" forests have become increasingly isolated and deforested and their buffer zones degraded. Preserving the ecological integrity of Kalimantan's rainforests requires immediate transnational management.	Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; Univ Maryland, Dept Geog, College Pk, MD 20742 USA; Univ Tanjungpura, Dept Forestry, Pontianak 780011, W Kalimantan, Indonesia; Jalan Abdurrachman Saleh, Pontianak 78124, W Kalimantan, Indonesia	Yale University; University System of Maryland; University of Maryland College Park; Universitas Tanjungpura	Curran, LM (corresponding author), Yale Univ, Sch Forestry & Environm Studies, 205 Prospect St, New Haven, CT 06511 USA.	lisa.curran@yale.edu		Dwi, Astiani/0000-0002-1341-9201				Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; Barr C., 2002, WHICH WAY FORWARD PE, P191; Blundell Arthur G., 1996, Tropical Biodiversity, V3, P251; Brook BW, 2003, NATURE, V424, P420, DOI 10.1038/nature01795; Bruner AG, 2001, SCIENCE, V291, P125, DOI 10.1126/science.291.5501.125; BUDIARTO T, 2003, INVESTIGASI AKTIVITA; Curran LM, 2000, ECOL MONOGR, V70, P129, DOI 10.1890/0012-9615(2000)070[0129:ETOTSS]2.0.CO;2; Curran LM, 2000, ECOL MONOGR, V70, P101, DOI 10.1890/0012-9615(2000)070[0101:VRTSVI]2.0.CO;2; Curran LM, 1999, SCIENCE, V286, P2184, DOI 10.1126/science.286.5447.2184; Gascon C, 2000, SCIENCE, V288, P1356, DOI 10.1126/science.288.5470.1356; HOLMES D, 2002, DEFORESTATION INDONE; *ITTO, 1996, ANN REV ASS WORLD TR; JOHNSON AM, UNPUB; Laidlaw RK, 2000, CONSERV BIOL, V14, P1639, DOI 10.1046/j.1523-1739.2000.99073.x; Laman Timothy G., 1996, Tropical Biodiversity, V3, P281; Lambert F.R., 2002, Forktail, V18, P127; LAWRENCE DC, 1995, CONSERV BIOL, V9, P76, DOI 10.1046/j.1523-1739.1995.09010076.x; Leighton M., 1983, TROPICAL RAIN FOREST, P181; MacKinnon K., 1996, ECOLOGY KALIMANTAN, V3; Nepstad D, 2002, SCIENCE, V295, P629, DOI 10.1126/science.1067053; Nepstad D, 2001, FOREST ECOL MANAG, V154, P395, DOI 10.1016/S0378-1127(01)00511-4; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; NEPSTAD DC, UNPUB; ROSS ML, 2000, TIMBER BOOMS I BREAK; Sanchez-Azofeifa GA, 2003, BIOL CONSERV, V109, P123, DOI 10.1016/S0006-3207(02)00145-3; Schwartzman S, 2000, CONSERV BIOL, V14, P1351, DOI 10.1046/j.1523-1739.2000.99329.x; Siegert F, 2001, NATURE, V414, P437, DOI 10.1038/35106547; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; WONG ST, 1997, THESIS U MONTANA MIS	29	513	544	5	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1000	1003		10.1126/science.1091714	http://dx.doi.org/10.1126/science.1091714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963327				2022-12-28	WOS:000188918000042
J	Brown-Saltzman, K; Diamant, A; Fineberg, IC; Gritsch, HA; Keane, M; Korenman, S; Lewis, M; Morgan, M; Rothenberg, L; Tymchuk, A; Weiss, F; Weiss, I; Wenger, N; Wiley, F; Archie, C; Bazzano, A; Billet, B; Conolly, M; Cunningham, M; Dee, V; Dorff, RE; Gelberg, L; Gershfield, D; Gitlin, M; Kious, B; Kuchta, K; Lippsett, J; McCoy, B; Marsh, C; Martinez, J; Robins, RN; Peckman, S; Rosenfeld, K; Schnell, K; Skinner, L; Winnick, RK; Yarlott, S; Danovitch, G; Wilkinson, A; Pham, PTT; Rosenthal, JT; Sanford, A; Kendrick, E				Brown-Saltzman, K; Diamant, A; Fineberg, IC; Gritsch, HA; Keane, M; Korenman, S; Lewis, M; Morgan, M; Rothenberg, L; Tymchuk, A; Weiss, F; Weiss, I; Wenger, N; Wiley, F; Archie, C; Bazzano, A; Billet, B; Conolly, M; Cunningham, M; Dee, V; Dorff, RE; Gelberg, L; Gershfield, D; Gitlin, M; Kious, B; Kuchta, K; Lippsett, J; McCoy, B; Marsh, C; Martinez, J; Robins, RN; Peckman, S; Rosenfeld, K; Schnell, K; Skinner, L; Winnick, RK; Yarlott, S; Danovitch, G; Wilkinson, A; Pham, PTT; Rosenthal, JT; Sanford, A; Kendrick, E		UCLA Med Ctr Ethics Comm; UCLA Renal Transpl Program	Surrogate consent for living related organ donation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							KIDNEY DONATION; BRAIN-DEATH; DONOR		Univ Calif Los Angeles, Healthcare Eth Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Wenger, N (corresponding author), Univ Calif Los Angeles, Healthcare Eth Ctr, 924 Westwood Blvd,Suite 900, Los Angeles, CA 90024 USA.	nwenger@mednet.ucla.edu						Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Beasley CL, 1997, AM J KIDNEY DIS, V30, P549, DOI 10.1016/S0272-6386(97)90315-2; Boulware LE, 2002, AM J TRANSPLANT, V2, P186, DOI 10.1034/j.1600-6143.2002.020211.x; Cheyette C, 2000, Boston Coll Law Rev, V41, P465; Delmonico FL, 2002, AM J TRANSPLANT, V2, P333, DOI 10.1034/j.1600-6143.2002.20407.x; DePalma J A, 1996, Crit Care Nurs Q, V19, P1; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; HARMON L, 1990, YALE LAW J, V100, P1, DOI 10.2307/796763; Morley MT, 2002, YALE LAW J, V111, P1215, DOI 10.2307/797621; Parker M, 2002, CRIT CARE, V6, P399; Rosendale J D, 2001, Clin Transpl, P87; Schlessinger S, 2002, AM J MED SCI, V324, P232, DOI 10.1097/00000441-200210000-00011	12	5	5	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					728	731						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871917				2022-12-28	WOS:000188819200027
J	Coull, AJ; Lovett, JK; Rothwell, PM				Coull, AJ; Lovett, JK; Rothwell, PM		Oxford Vasc Study	Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OXFORDSHIRE; MANAGEMENT; COUNCIL	Objective To estimate the very early stroke risk after a transient ischaemic attack (TIA) or minor stroke and thereby inform the planning of effective stroke prevention services. Design Population based prospective cohort study of patients with TIA, or stroke. Setting Nine general practices in Oxfordshire, England, from April 2002 to April 2003. Participants All patients who had a TIA (n=87) or minor stroke (n=87) during the study period and who presented to medical attention. Main outcome measures Risk of recurrent stroke at seven days, one month, and three months after TIAs and minor strokes. Results The estimated risk of recurrent stroke was 8.0% (95% confidence interval 2.3% to 13.7%) at seven days, 11.5% (4.8% to 18.2%) at one month, and 17.3% (9.3% to 25.3%) at three months after a TIA. The risks at these three time periods after a minor stroke were 11.5% (4.8% to 11.2%),15.0% (7.5% to 22.5% and 18.5% (10.3% to 26.7%). Conclusions The early risks of stroke after a TIA or minor stroke are much higher than commonly quoted. More research is needed to determine whether these risks can be reduced by more rapid instigation of preventive treatment.	Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England	Radcliffe Infirmary	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; Department of Health, 2001, NAT SERV FRAM OLD PE; Evenson KR, 2001, NEUROEPIDEMIOLOGY, V20, P65, DOI 10.1159/000054763; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Gubitz G, 1999, CEREBROVASC DIS, V9, P210, DOI 10.1159/000015957; Gubitz G, 2000, BMJ-BRIT MED J, V321, P1455, DOI 10.1136/bmj.321.7274.1455; HANKEY GJ, 1993, BRIT MED J, V306, P1107, DOI 10.1136/bmj.306.6885.1107; Hankey GJ, 1996, CEREBROVASC DIS, V6, P26, DOI 10.1159/000108068; *INT WORK PART STR, 2000, NAT CLIN GUID STRO; Johnston SC, 1999, EUR NEUROL, V42, P105, DOI 10.1159/000069419; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Lovett JK, 2003, STROKE, V34, pE138, DOI 10.1161/01.STR.0000080935.01264.91; *N I NEUR DIS STRO, 1997, P NAT S RAP ID TREAT; ROTHWELL PM, 2004, IN PRESS LANCET; Schulz UGR, 2003, STROKE, V34, P2050, DOI 10.1161/01.STR.0000079818.08343.8C; *SCOTT INT GUID NE, 1997, SIGN GUID MAN PAT ST; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Warlow CP., 2001, STROKE PRACTICAL GUI; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991	22	566	602	2	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					326	328		10.1136/bmj.37991.635266.44	http://dx.doi.org/10.1136/bmj.37991.635266.44			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14744823	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188926900023
J	Hallani, H; Eslick, GD; Cox, M; Wyatt, JM; Lee, CH				Hallani, H; Eslick, GD; Cox, M; Wyatt, JM; Lee, CH			Chest pain: ? cause	LANCET			English	Editorial Material							CYSTS		Nepean Hosp, Dept Cardiol, Penrith, NSW 2751, Australia; Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia; Nepean Hosp, Dept Surg, Penrith, NSW 2751, Australia; Nepean Hosp, Dept Pathol, Penrith, NSW 2751, Australia; Liverpool Hosp, Dept Cardiol, Liverpool, Merseyside, England	Nepean Hospital; University of Sydney; Nepean Hospital; University of Sydney; Nepean Hospital; University of Sydney; Nepean Hospital; University of Sydney	Lee, CH (corresponding author), Nepean Hosp, Dept Cardiol, Penrith, NSW 2751, Australia.	drchoonlee@bigpond.com						CARTMILL JA, 1989, AUST NZ J SURG, V59, P253, DOI 10.1111/j.1445-2197.1989.tb01510.x; Cioffi U, 1998, CHEST, V113, P1492, DOI 10.1378/chest.113.6.1492; CREECH O, 1954, J THORAC SURG, V28, P64; Kennebeck GA, 1999, ANN THORAC SURG, V67, P1789, DOI 10.1016/S0003-4975(99)00340-9; WYSS H, 1970, VIRCHOWS ARCH PATH A, V51, P143	5	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					452	452		10.1016/S0140-6736(04)15492-5	http://dx.doi.org/10.1016/S0140-6736(04)15492-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962526				2022-12-28	WOS:000188999500012
J	Infante, PF; Newman, LS				Infante, PF; Newman, LS			Beryllium exposure and chronic beryllium disease	LANCET			English	Editorial Material							MACHINING PLANT; SENSITIZATION; SARCOIDOSIS; WORKERS		George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20037 USA; Natl Jewish Med & Res Ctr, Div Environm & Occupat Hlth Sci, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	George Washington University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Infante, PF (corresponding author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20037 USA.	pinfante@starpower.net		Infante, Peter/0000-0001-5350-0154				Department of Labor Semiannual Agenda of Regulations, 2000, FED REGISTER, V65, P74120; Fireman E, 2003, SARCOIDOSIS VASC DIF, V20, P144; HARDY HL, 1946, J IND HYG TOXICOL, V28, P197; Henneberger PK, 2001, INT ARCH OCC ENV HEA, V74, P167, DOI 10.1007/s004200100237; IARC (International Agency for Research on Cancer), 1993, IARC MON EV CARC RIS, V58, P41; Kelleher PC, 2001, J OCCUP ENVIRON MED, V43, P238, DOI 10.1097/00043764-200103000-00012; KREISS K, 1993, AM REV RESPIR DIS, V148, P985, DOI 10.1164/ajrccm/148.4_Pt_1.985; Kreiss K, 1997, OCCUP ENVIRON MED, V54, P605, DOI 10.1136/oem.54.8.605; KREISS K, 1993, J OCCUP ENVIRON MED, V35, P267; KREISS K, 1996, AM J IND MED, V30, P6; MROZ MM, 1991, J ALLERGY CLIN IMMUN, V88, P54, DOI 10.1016/0091-6749(91)90300-D; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Newman LS, 2001, J OCCUP ENVIRON MED, V43, P231, DOI 10.1097/00043764-200103000-00011; *OCC SAF HLTH ADM, 1975, FED REGISTER, V40, P48814; Richards B., 1978, WASH POST, pA1; RICHARDS B, 1978, WASHINGTON POST 0914, pA20; 1949, PROD ENG         SEP, P155; 1951, LANCET, V1, P1358	18	56	60	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	2004	363	9407					415	416		10.1016/S0140-6736(04)15523-2	http://dx.doi.org/10.1016/S0140-6736(04)15523-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962519				2022-12-28	WOS:000188999500006
J	Dong, CJ; Huang, FL; Deng, H; Schaffrath, C; Spencer, JB; O'Hagan, D; Naismith, JH				Dong, CJ; Huang, FL; Deng, H; Schaffrath, C; Spencer, JB; O'Hagan, D; Naismith, JH			Crystal structure and mechanism of a bacterial fluorinating enzyme	NATURE			English	Article							STREPTOMYCES-CATTLEYA; BIOSYNTHESIS; DATABASE; MOLECULES; CHEMISTRY; FAMILIES; PROGRAMS; MODELS; BONDS; ACID	Fluorine is the thirteenth most abundant element in the earth's crust, but fluoride concentrations in surface water are low and fluorinated metabolites are extremely rare(1,2). The fluoride ion is a potent nucleophile in its desolvated state, but is tightly hydrated in water and effectively inert. Low availability and a lack of chemical reactivity have largely excluded fluoride from biochemistry: in particular, fluorine's high redox potential precludes the haloperoxidase-type mechanism(3,4) used in the metabolic incorporation of chloride and bromide ions. But fluorinated chemicals are growing in industrial importance, with applications in pharmaceuticals, agrochemicals and materials products(5-7). Reactive fluorination reagents requiring specialist process technologies are needed in industry and, although biological catalysts for these processes are highly sought after, only one enzyme that can convert fluoride to organic fluorine has been described(8). Streptomyces cattleya can form carbon-fluorine bonds(9) and must therefore have evolved an enzyme able to overcome the chemical challenges of using aqueous fluoride. Here we report the sequence and three-dimensional structure of the first native fluorination enzyme, 5'-fluoro-5'-deoxyadenosine synthase, from this organism. Both substrate and products have been observed bound to the enzyme, enabling us to propose a nucleophilic substitution mechanism for this biological fluorination reaction.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England	University of St Andrews; University of Cambridge	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	naismith@st-andrews.ac.uk	Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012; Deng, Hai/AAE-1758-2020	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Deng, Hai/0000-0002-0047-0622; O'Hagan, David/0000-0002-0510-5552	Biotechnology and Biological Sciences Research Council [BBS/B/04579] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Boutselakis H, 2003, NUCLEIC ACIDS RES, V31, P458, DOI 10.1093/nar/gkg065; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; DONG C, 2003, ACTA CRYSTALLOGR D, V60, P760; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dunitz JD, 1997, CHEM-EUR J, V3, P89, DOI 10.1002/chem.19970030115; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; Howard JAK, 1996, TETRAHEDRON, V52, P12613, DOI 10.1016/0040-4020(96)00749-1; Hutchinson J, 1997, TOP CURR CHEM, V193, P1; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; Littlechild J, 1999, CURR OPIN CHEM BIOL, V3, P28, DOI 10.1016/S1367-5931(99)80006-4; MANN J, 1987, CHEM SOC REV, V16, P381, DOI 10.1039/cs9871600381; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; O'Hagan D, 2002, NATURE, V416, P279, DOI 10.1038/416279a; O'Hagan D, 1999, J FLUORINE CHEM, V100, P127, DOI 10.1016/S0022-1139(99)00201-8; O'Hagan D, 2003, J AM CHEM SOC, V125, P379, DOI 10.1021/ja026654k; SANADA M, 1986, J ANTIBIOT, V39, P259, DOI 10.7164/antibiotics.39.259; Sandford G, 2000, PHILOS T R SOC A, V358, P455, DOI 10.1098/rsta.2000.0541; Schaffrath C, 2003, FEBS LETT, V547, P111, DOI 10.1016/S0014-5793(03)00688-4; Schaffrath C, 2002, ANGEW CHEM INT EDIT, V41, P3913, DOI 10.1002/1521-3773(20021018)41:20<3913::AID-ANIE3913>3.0.CO;2-E; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; vanPee KH, 1996, ANNU REV MICROBIOL, V50, P375, DOI 10.1146/annurev.micro.50.1.375; Xu XH, 2003, J NAT PROD, V66, P285, DOI 10.1021/np020034f; Zechel DL, 2001, J AM CHEM SOC, V123, P4350, DOI 10.1021/ja005855q	31	235	243	8	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					561	565		10.1038/nature02280	http://dx.doi.org/10.1038/nature02280			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765200				2022-12-28	WOS:000188721800046
J	Levine, SR; Brey, RL; Tilley, BC; Thompson, JLP; Sacco, RL; Sciacca, RR; Murphy, A; Lu, YM; Costigan, TM; Rhine, C; Levin, B; Triplett, DA; Mohr, JP				Levine, SR; Brey, RL; Tilley, BC; Thompson, JLP; Sacco, RL; Sciacca, RR; Murphy, A; Lu, YM; Costigan, TM; Rhine, C; Levin, B; Triplett, DA; Mohr, JP		APASS Investigators	Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTICARDIOLIPIN ANTIBODIES; LUPUS ANTICOAGULANTS; MYOCARDIAL-INFARCTION; RECURRENT THROMBOSIS; WORKSHOP; ASSOCIATION; PREVENTION; MORTALITY; STATEMENT; WARFARIN	Context The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. Objective To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke. <LF>Design, Setting, and Participants The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study WARSS), a randomized double-blind trial (N =2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory. Main Outcome Measure Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized). Results Of the 1770 APASS patients, 720 (41 %)were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [Cl], 0.75-1.31; P=.94), or aspirin (RR, 0.94; 95% Cl, 0.70-1.28; P=.71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment X aPL interaction (P= 91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% Cl, 0.97-1.92; P=.07). Classification and regression tree analyses did not identify a specific LA test or aCL isotype or titer that was associated with increased risk of thrombo-occlusive event. Conclusions The presence of aPL (either LA or aCL) among patients with ischemic stroke does not predict either increased risk for subsequent vascular occlusive events over 2 years or a differential response to aspirin or warfarin therapy. Routine screening for aPL in patients with ischemic stroke does not appear warranted.	Mt Sinai Sch Med, Dept Neurol, Stroke Program, New York, NY 10029 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA; Columbia Univ, Mailman Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10027 USA; Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX USA; Ball Mem Hosp, Dept Pathol, Muncie, IN 47303 USA	Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio; Medical University of South Carolina; Columbia University; Columbia University; University of Texas System; University of Texas Health San Antonio; Indiana University System	Levine, SR (corresponding author), Mt Sinai Sch Med, Dept Neurol, Stroke Program, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	steven.levine@mssm.edu	Mohr, J/AAO-9694-2020; Sacco, Ralph/Y-9278-2019		NINDS NIH HHS [1R01 NS 28371, 1K24 NS 43992, 1R01 NS 30896] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030896, K24NS043992, R01NS028371] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1597; Brey RL, 2002, STROKE, V33, P2396, DOI 10.1161/01.STR.0000031927.25510.D1; BREY RL, 1994, AM J CLIN PATHOL, V102, P586, DOI 10.1093/ajcp/102.5.586; Brey RL, 2001, STROKE, V32, P1701, DOI 10.1161/01.STR.32.8.1701; Cabral AR, 1996, AM J MED, V101, P472, DOI 10.1016/S0002-9343(96)00254-9; Crowther MA, 2003, NEW ENGL J MED, V349, P1133, DOI 10.1056/NEJMoa035241; Galli M, 2000, THROMB HAEMOSTASIS, V84, P1012; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; GORELICK PB, 2002, PREVENTION STROKE; HARRIS EN, 1994, AM J CLIN PATHOL, V101, P616, DOI 10.1093/ajcp/101.5.616; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; Hojnik M, 1996, CIRCULATION, V93, P1579, DOI 10.1161/01.CIR.93.8.1579; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KITTNER S, 1993, NEUROLOGY, V43, P2069; Kittner S, 1997, NEUROLOGY, V48, P91; KrnicBarrie S, 1997, ARCH INTERN MED, V157, P2101, DOI 10.1001/archinte.157.18.2101; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; Lockshin MD, 1997, JAMA-J AM MED ASSOC, V277, P1549, DOI 10.1001/jama.277.19.1549; Metz LM, 1998, CAN J NEUROL SCI, V25, P64, DOI 10.1017/S0317167100033515; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Mohr JP, 1997, CEREBROVASC DIS, V7, P100; MUIR KW, 1994, LANCET, V344, P452, DOI 10.1016/S0140-6736(94)91775-2; NENCINI P, 1992, STROKE, V23, P189, DOI 10.1161/01.STR.23.2.189; Petty GW, 1998, NEUROLOGY, V50, P208, DOI 10.1212/WNL.50.1.208; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; Roubey RAS, 1997, LANCET, V350, P1491, DOI 10.1016/S0140-6736(05)63936-0; Ruiz-Irastorza G, 2002, ARCH INTERN MED, V162, P1164, DOI 10.1001/archinte.162.10.1164; Sanmarco M, 1997, J LAB CLIN MED, V129, P499, DOI 10.1016/S0022-2143(97)90004-4; SLETNES KE, 1992, LANCET, V339, P451, DOI 10.1016/0140-6736(92)91057-F; STEINBERG D, 1995, MART TREE STRUCTURED; Tanne D, 2002, NEUROEPIDEMIOLOGY, V21, P93, DOI 10.1159/000048623; Tripodi A, 2003, CLIN CHEM, V49, P1608, DOI 10.1373/49.10.1608; Tuhrim S, 1999, NEUROLOGY, V53, P1523, DOI 10.1212/WNL.53.7.1523; Tuhrim S, 1999, STROKE, V30, P1561, DOI 10.1161/01.STR.30.8.1561; Wilson W A, 2001, Lupus, V10, P457, DOI 10.1191/096120301678415999; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991	40	299	309	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					576	584						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762036	Bronze			2022-12-28	WOS:000188650700022
J	Toole, JF; Malinow, MR; Chambless, LE; Spence, JD; Pettigrew, LC; Howard, VJ; Sides, EG; Wang, CH; Stampfer, M				Toole, JF; Malinow, MR; Chambless, LE; Spence, JD; Pettigrew, LC; Howard, VJ; Sides, EG; Wang, CH; Stampfer, M			Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death - The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERIAL OCCLUSIVE DISEASE; INDEPENDENT RISK FACTOR; PLASMA HOMOCYST(E)INE; FOLIC-ACID; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE; HEART-DISEASE; HYPERHOMOCYSTEINEMIA; ATHEROSCLEROSIS	Context In observational studies, elevated plasma total homocysteine levels have been positively associated with ischemic stroke risk. However the utility of homocysteine-lowering therapy to reduce that risk has not been confirmed by randomized trials. Objective To determine whether high doses of folic acid, pyridoxine (vitamin B-6), and cobalamin (vitamin B-12), given to lower total homocysteine levels, reduce the risk of recurrent stroke over a 2-year period compared with low doses of these vitamins. Design Double-blind randomized controlled trial (September 1996-May 2003). Setting and Participants 3680 adults with nondisabling cerebral infarction at 56 university-affiliated hospitals, community hospitals, private neurology practices, and Veterans Affairs medical centers across the United States, Canada, and Scotland. Interventions All participants received best medical and surgical care plus a daily multivitamin containing the US Food and Drug Administration's reference daily intakes of other vitamins; patients were randomly assigned to receive once-daily doses of the high-dose formulation (n=1827), containing 25 mg of pyridoxine, 0.4 mg of cobalamin, and 2.5 mg of folic acid; or the low-dose formulation (n = 1853), containing 200 mug of pyridoxine, 6 mug of cobalamin, and 20 mug of folic acid. Main Outcome Measures Recurrent cerebral infarction (primary outcome); coronary heart disease (CHID) events and death (secondary outcomes). Results Mean reduction of total homocysteine was 2 mumol/L greater in the high-dose group than in the low-dose group, but there was no treatment effect on any end point. The unadjusted risk ratio for any stroke, CHID event, or death was 1.0 (95% confidence interval [CI], 0.8-1.1), with chances of an event within 2 years of 18.0% in the high-dose group and 18.6% in the low-dose group. The risk of ischemic stroke within 2 years was 9.2% for the high-dose and 8.8% for the low-dose groups (risk ratio, 1.0; 95% Cl, 0.8-1.3) (P = .80 by log-rank test of the primary hypothesis of difference in ischemic stroke between treatment groups). There was a persistent and graded association between baseline total homocysteine level and outcomes. A 3-mumol/L lower total homocysteine level was associated with a 10% lower risk of stroke (P = .05), a 26% lower risk of CHD events (P < .001), and a 16% lower risk of death (P = .001) in the low-dose group and a nonsignificantly lower risk in the high-dose group by 2% for stroke, 7% for CHID events, and 7% for death. Conclusions In this trial, moderate reduction of total homocysteine after nondisabling cerebral infarction had no effect on vascular outcomes during the 2 years of follow-up. However, the consistent findings of an association of total homocysteine with vascular risk suggests that further exploration of the hypothesis is warranted and longer trials in different populations with elevated total homocysteine may be necessary.	Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Ctr Stroke Res, Winston Salem, NC 27157 USA; Oregon Natl Primate Res Ctr, Lab Cardiovasc Dis, Beaverton, OR USA; Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA; Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, London, ON N6A 5C1, Canada; Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Lexington, KY 40536 USA; Univ Alabama, Dept Epidemiol & Int Hlth, Birmingham, AL USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Wake Forest University; Wake Forest Baptist Medical Center; Oregon Health & Science University; Oregon National Primate Research Center; University of North Carolina; University of North Carolina Chapel Hill; Western University (University of Western Ontario); University of Kentucky; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard T.H. Chan School of Public Health	Sides, EG (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Ctr Stroke Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.	esides@wfubmc.edu	Spence, J. David/K-6396-2013	Spence, J. David/0000-0001-7478-1098	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034447] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS34447] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baker F, 2002, CIRCULATION, V106, P741; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; Boysen G, 2003, STROKE, V34, P1258, DOI 10.1161/01.STR.0000069017.78624.37; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; BRATTSTROM L, 1992, EUR J CLIN INVEST, V22, P214, DOI 10.1111/j.1365-2362.1992.tb01829.x; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; Chambers JC, 1999, CIRCULATION, V99, P1156, DOI 10.1161/01.CIR.99.9.1156; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DOlhaberriague L, 1996, STROKE, V27, P2331, DOI 10.1161/01.STR.27.12.2331; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GERRITSEN T, 1962, BIOCHEM BIOPH RES CO, V9, P493, DOI 10.1016/0006-291X(62)90114-6; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HALPERIN M, 1982, CONTROL CLIN TRIALS, V3, P311, DOI 10.1016/0197-2456(82)90022-8; Howard VJ, 2002, STROKE, V33, P473, DOI 10.1161/hs0202.103069; *I MED FOOD NUTR B, 1988, DIET REF UBT TGUAN R; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; LEERINK CB, 1994, THROMB RES, V74, P219, DOI 10.1016/0049-3848(94)90110-4; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1990, CORONARY ARTERY DIS, V1, P215, DOI 10.1097/00019501-199003000-00010; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MUDD SH, 1995, NEW ENGL J MED, V333, P325; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; PIANTADOSI S, 1977, CLIN TRIALS METHODOL; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; SMOLIN LA, 1988, ANAL BIOCHEM, V168, P374, DOI 10.1016/0003-2697(88)90332-6; Spence JD, 2001, NEUROEPIDEMIOLOGY, V20, P16, DOI 10.1159/000054753; Stamler JS, 1996, NUTR REV, V54, P1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; VANDENBERG M, 1995, EUR J CLIN INVEST, V25, P176; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Yoo JH, 1998, STROKE, V29, P2478, DOI 10.1161/01.STR.29.12.2478; 1999, HOSP PAYER INT CLASS	43	1005	1060	2	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					565	575		10.1001/jama.291.5.565	http://dx.doi.org/10.1001/jama.291.5.565			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762035	Bronze			2022-12-28	WOS:000188650700021
J	Busari, JO; Weggelaar, NM				Busari, JO; Weggelaar, NM			How to investigate and manage the child who is slow to speak	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LANGUAGE; DISORDERS	Delay in speech and language development is the most common developmental disorder in children aged 3 to 16 years. The prevalence of this disorder ranges from 1% to 32% in the normal population and is influenced by factors such as the age of the child at presentation and the test method used in diagnosis.(1-2) A high rate of comorbidity (up to 50%) is known to exist between psychiatric disorders such as autism and disorders of speech and language development.(3) Despite the prevalence and reported risks of comorbidity, however, about 60% of cases of speech and language delay tend to resolve spontaneously in children aged under 3 years.(1) Children who are slow to speak form a particular category of patients with speech and language developmental disorders and often present clinicians with a dilemma-whether to conduct further investigations or just wait and see. This is because a delay in speaking could be either a normal (and temporary) stage in the child's development or the initial symptom of a psychiatric, neurological, or behavioural problem. As a result, the timely diagnosis, choice of therapy, and an individualised approach to the child with a speech and language delay become imperative as these interventions may prevent subsequent psychological or psychiatric problems later in life. We provide here an update of the current literature on speech and language development in children. Using a real patient encounter, we illustrate how a child with a delay in language development is presented to the clinician. We also propose a guideline that can be used to investigate and manage children with speech or language delays.	Boven IJ Hosp, Dept Paediat, NL-1030 BD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Busari, JO (corresponding author), Boven IJ Hosp, Dept Paediat, Statenjachtstr 1, NL-1030 BD Amsterdam, Netherlands.	Ojay33@hotmail.com	Busari, Jamiu/C-9425-2018; Busari, JO/AAI-1935-2020	Busari, Jamiu/0000-0002-8616-5564; 				Beitchman JH, 1998, J AM ACAD CHILD PSY, V37, P1117; BERMAN S, 1996, PEDIAT DECISION MAKI, P40; CANTWEL DP, 1991, PSYCHIAT DEV DISORDE; Chevrie-Muller C, 2000, Acta Otorhinolaryngol Belg, V54, P419; COPLAN J, 1990, PEDIATRICS, V86, P963; Cronin VS, 2002, J CHILD LANG, V29, P189, DOI 10.1017/S0305000901004998; CROSLEY CJ, 1999, PEDIAT NEUROLOGY PRI, P568; FENSON L, 1994, MONOGR SOC RES CHILD, V59, pR5; GILLBERG C, 1998, DIS NERVOUS SYSTEM C, P850; LAW J, 1998, HLTH TECHNOL ASSESS, V2; Toppelberg CO, 2000, J AM ACAD CHILD PSY, V39, P143, DOI 10.1097/00004583-200002000-00011; Wetherby AM, 2002, J SPEECH LANG HEAR R, V45, P1202, DOI 10.1044/1092-4388(2002/097)	12	9	13	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	2004	328	7434					272	276		10.1136/bmj.328.7434.272	http://dx.doi.org/10.1136/bmj.328.7434.272			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771LC	14751899	Green Published			2022-12-28	WOS:000188786000024
J	Thomson, H; Hoskins, R; Petticrew, M; Ogilvie, D; Craig, N; Quinn, T; Lindsay, G				Thomson, H; Hoskins, R; Petticrew, M; Ogilvie, D; Craig, N; Quinn, T; Lindsay, G			Evaluating the health effects of social interventions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXPERIMENTATION; EQUIPOISE; ETHICS		MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, Nursing & Midwifery Sch, Glasgow, Lanark, Scotland; Univ Glasgow, Div Community Based Sci, Glasgow G12 8QQ, Lanark, Scotland; Easterhouse Money Advice Ctr, Glasgow, Lanark, Scotland; Glasgow Caledonian Univ, Sch Nursing Midwifery & Community Hlth, Glasgow G4 0BA, Lanark, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of Glasgow; Glasgow Caledonian University	Thomson, H (corresponding author), MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	hilary@msoc.mrc.gla.ac.uk	Ogilvie, David/B-2444-2012; Petticrew, Mark/AAY-6274-2021	Ogilvie, David/0000-0002-0270-4672				Acheson D., 1998, INDEPENDENT INQUIRY; Black N, 1996, BRIT MED J, V312, P1215; CAMPBELL DT, 1969, AM PSYCHOL, V24, P409, DOI 10.1037/h0027982; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Connor J, 1999, J EPIDEMIOL COMMUN H, V53, P725, DOI 10.1136/jech.53.11.725; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; EXWORTHY M, 2003, TACKLING HLTH INEQUA; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freemantle N, 1998, J EPIDEMIOL COMMUN H, V52, P75, DOI 10.1136/jech.52.2.75; Hoskins RAJ, 2002, PUBLIC HEALTH, V116, P214, DOI 10.1038/sj.ph.1900848; Lilford RJ, 2003, BRIT MED J, V326, P980, DOI 10.1136/bmj.326.7396.980; Macintyre S, 2000, J EPIDEMIOL COMMUN H, V54, P802, DOI 10.1136/jech.54.11.802; Macintyre S, 2001, BRIT MED J, V322, P222, DOI 10.1136/bmj.322.7280.222; Millward L, 2001, PUBLIC HLTH INTERVEN; Oakley A, 1998, BRIT MED J, V317, P1239, DOI 10.1136/bmj.317.7167.1239; Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119; Shaw M, 1999, WIDENING GAP HLTH IN; Silverman WA, 2001, BMJ-BRIT MED J, V323, P1467, DOI 10.1136/bmj.323.7327.1467; Wolff N, 2001, J Health Serv Res Policy, V6, P123, DOI 10.1258/1355819011927224	19	61	64	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	2004	328	7434					282	285		10.1136/bmj.328.7434.282	http://dx.doi.org/10.1136/bmj.328.7434.282			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771LC	14751903	Green Accepted, Green Published			2022-12-28	WOS:000188786000028
J	Ottino, JM				Ottino, JM			Engineering complex systems	NATURE			English	Editorial Material									Northwestern Univ, Robert R McCormick Sch Engn & Appl Sci, Evanston, IL 60208 USA	Northwestern University	Ottino, JM (corresponding author), Northwestern Univ, Robert R McCormick Sch Engn & Appl Sci, Evanston, IL 60208 USA.		Ottino, Julio/B-6682-2009					Ball P., 2004, CRITICAL MASS; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540	3	184	188	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 29	2004	427	6973					399	399		10.1038/427399a	http://dx.doi.org/10.1038/427399a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749808	Bronze			2022-12-28	WOS:000188470500022
J	Shah, S; Whittle, A; Wilfond, B; Gensler, G; Wendler, D				Shah, S; Whittle, A; Wilfond, B; Gensler, G; Wendler, D			How do institutional review boards apply the federal risk and benefit standards for pediatric research?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN	Context Federal regulations allow children in the United States to be enrolled in clinical research only when the institutional review board (IRB) determines that the risks are minimal or a minor increase over minimal, or that the research offers a prospect of direct benefit. Despite this reliance on IRBs, no data exist on how IRBs apply the risk and benefit categories for pediatric research. Objective To determine how IRB chairpersons apply the federal risk and benefit categories for pediatric research. Design, Setting, and Participants Telephone survey, conducted between May and August 2002 of 188 randomly selected chairpersons of IRBs in the Unites States. The survey consisted of 21 questions to assess the application of federal risk standards to research procedures, whether certain interventions offer a prospect of direct benefit to participating children, and the extent to which IRBs use the federal definition of minimal risk when categorizing the risks of research procedures in children. Main Outcome Measures Responses regarding categorization of the risk level and direct benefits of pediatric research procedures. Results A single blood draw was the only procedure categorized as minimal risk by a majority (152 or 81%) of the 188 respondents. An electromyogram was categorized as minimal or a minor increase over minimal risk by 100 (53%) and as more than a minor increase over minimal risk by 77 (41%). Allergy skin testing was categorized as minimal risk by 43 IRB chairpersons (23%), a minor increase over minimal risk by 81 (43%), and more than a minor increase over minimal risk by 51 (27%). Regarding benefits, 113 chairpersons (60%) considered added psychological counseling to be a direct benefit, while participant payment was considered a direct benefit by 10% (n = 19). Conclusions Application of the federal risk and benefit categories for pediatric research by IRB chairpersons is variable and sometimes contradicted by the available data on risks and the regulations themselves. To protect children from excessive risks while allowing appropriate research, IRB chairpersons need guidance on applying the federal risk and benefit categories and also need data on the risks children face in daily life and during routine physical or psychological tests.	NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA; NIH, Human Genome Res Inst, Bethesda, MD 20892 USA; Emmes Corp, Bethesda, MD USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Emmes Corporation	Wendler, D (corresponding author), NIH, Dept Clin Bioeth, Bldg 10,Room 1C118,10 Ctr Dr, Bethesda, MD 20892 USA.	dwendler@nih.gov		Shah, Seema/0000-0001-7726-1186	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000145, Z01HG200326] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL010516] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); CLINICAL CENTER		Ackerman Terrence F, 1980, Bioethics Q, V2, P94, DOI 10.1007/BF00915263; *AM AC PED, GUID ETH COND STUD E; BARTHOLOME W, 1977, APPENDIX REPORT RECO, V3, P1; Brock D. W., 1994, CHILDREN RES SUBJECT, P81; BUNKER JP, 1973, NEW ENGL J MED, V289, P1249, DOI 10.1056/NEJM197312062892313; *CTR DRUG EV RES U, 1989, US DEP HHS PUBL; *FDA, PED EXCL PROV JAN 20; *FDA CTR DRUG EV R, PED DRUG DEV; *FOR CHILD FAM STA, 2001, AM CHILDR KEY NAT IN; FREEDMAN B, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562813; Glantz LH, 1998, AM J LAW MED, V24, P213; JANOFSKY J, 1981, J PEDIATR-US, V98, P842, DOI 10.1016/S0022-3476(81)80865-7; King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x; Kopelman LM, 2000, J MED PHILOS, V25, P745; National Bioethics Advisory Commission, ETH POL ISS RES INV; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ I; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; 2003, NIH POLICY GUIDELINE	19	200	202	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					476	482		10.1001/jama.291.4.476	http://dx.doi.org/10.1001/jama.291.4.476			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747505				2022-12-28	WOS:000188426700033
J	Fallowfield, L; Jenkins, V				Fallowfield, L; Jenkins, V			Communicating sad, bad, and difficult news in medicine	LANCET			English	Review							CANCER-PATIENTS; HEALTH-PROFESSIONALS; PATIENTS PERCEPTIONS; PATIENTS PERSPECTIVE; TRAINING MODEL; ORGAN DONATION; LUNG-CANCER; BREAKING; SKILLS; CARE	In every medical specialty bad, sad, and difficult information must be given to patients and their families. An insensitive approach increases the distress of recipients of bad news, may exert a lasting impact on their ability to adapt and adjust, and can lead to anger and an increased risk of litigation. Many doctors also find these interactions stressful, and in the absence of much effective training they may adopt inappropriate ways of delivering bad news and coping with the emotional fall-out. Recognition of these difficulties has led to many initiatives, ranging from increased communication skills training to the development of guidelines and protocols. We review some of the research on the impact that giving sad, bad, and difficult news has on doctors and patients, and assess whether interventions are helping. We focus mainly on difficulties encountered involving parents in an obstetric or paediatric setting, people in acute trauma situations such as accident and emergency departments, and patients with cancer.	Canc Res UK Psychosocial Oncol Grp, Brighton, E Sussex, England; Univ Sussex, Sussex Med Sch, Falmer BN1 9QG, England	Cancer Research UK; University of Sussex; University of Sussex	Fallowfield, L (corresponding author), Canc Res UK Psychosocial Oncol Grp, Brighton, E Sussex, England.	lesley@sussex.ac.uk		Fallowfield, Lesley/0000-0003-0577-4518				Ablon J, 2000, AM J MED GENET, V93, P136, DOI 10.1002/1096-8628(20000717)93:2<136::AID-AJMG11>3.0.CO;2-L; Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302; Baile W F, 1997, J Cancer Educ, V12, P166; Baile WF, 2002, J CLIN ONCOL, V20, P2189, DOI 10.1200/JCO.2002.08.004; Baile WF, 1999, CANCER-AM CANCER SOC, V86, P887, DOI 10.1002/(SICI)1097-0142(19990901)86:5<887::AID-CNCR27>3.0.CO;2-X; Baird G, 2000, ARCH DIS CHILD, V83, P475, DOI 10.1136/adc.83.6.475; Barnett MM, 2002, J ROY SOC MED, V95, P343, DOI 10.1258/jrsm.95.7.343; BRISTOL ROYAL INFIRMARY, 2001, LEARN BRIST REP PUBL; BUCKMAN R, 1984, BRIT MED J, V288, P1597, DOI 10.1136/bmj.288.6430.1597; Butow PN, 1995, J PALLIATIVE CARE, V11, P34, DOI 10.1177/082585979501100407; Cegala DJ, 2002, MED EDUC, V36, P1004, DOI 10.1046/j.1365-2923.2002.01331.x; Chan A, 1997, J PALLIAT CARE, V13, P29, DOI 10.1177/082585979701300305; Chapman K, 2003, PSYCHO-ONCOLOGY, V12, P557, DOI 10.1002/pon.673; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Cushing AM, 1995, MED EDUC, V29, P430, DOI 10.1111/j.1365-2923.1995.tb02867.x; Davies R, 2003, CHILD CARE HLTH DEV, V29, P77, DOI 10.1046/j.1365-2214.2003.00316.x; De Valck C, 2001, PSYCHO-ONCOLOGY, V10, P398, DOI 10.1002/pon.520; DIAMOND JC, 1998, BECAUSE COWARDS GET; Dosanjh S, 2001, MED EDUC, V35, P197, DOI 10.1046/j.1365-2923.2001.00766.x; DUNN SM, 1993, J CLIN ONCOL, V11, P989, DOI 10.1200/JCO.1993.11.5.989; Fallowfield L, 1999, EUR J CANCER, V35, P1592, DOI 10.1016/S0959-8049(99)00212-9; Fallowfield L, 2003, BRIT J CANCER, V89, P1445, DOI 10.1038/sj.bjc.6601309; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; FALLOWFIELD L, 1993, LANCET, V341, P476, DOI 10.1016/0140-6736(93)90219-7; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; FALLOWFIELD LJ, 1994, AM J GASTROENTEROL, V89, P473; Farrell M, 2001, J ADV NURS, V36, P765, DOI 10.1046/j.1365-2648.2001.02042.x; FAULKNER A, 1995, MED EDUC, V29, P303, DOI 10.1111/j.1365-2923.1995.tb02853.x; FELLOWES D, 2003, COCHRANE LIB; FINLAY I, 1991, BRIT MED J, V302, P1524, DOI 10.1136/bmj.302.6791.1524; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; Friedrichsen MJ, 2000, SUPPORT CARE CANCER, V8, P472; Friedrichsen MJ, 2002, PALLIATIVE MED, V16, P323, DOI 10.1191/0269216302pm543oa; Garg A, 1997, CAN MED ASSOC J, V156, P1159; GARWICK AW, 1995, ARCH PEDIAT ADOL MED, V149, P991, DOI 10.1001/archpedi.1995.02170220057008; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; Girgis A, 1999, BEHAV MED, V25, P69, DOI 10.1080/08964289909595739; Grassi L, 2000, SUPPORT CARE CANCER, V8, P40; Greenberg LW, 1999, PEDIATRICS, V103, P1210, DOI 10.1542/peds.103.6.1210; Hammond I, 1999, CAN ASSOC RADIOL J, V50, P233; Jan MMS, 2002, CAN J NEUROL SCI, V29, P78, DOI 10.1017/S0317167100001773; Jenkins V, 2002, J CLIN ONCOL, V20, P765, DOI 10.1200/JCO.20.3.765; Jenkins VA, 2001, QUAL HEALTH CARE, V10, P70, DOI 10.1136/qhc.10.2.70; Jurkovich GJ, 2000, J TRAUMA, V48, P865, DOI 10.1097/00005373-200005000-00009; Kim MK, 1999, LARYNGOSCOPE, V109, P1064, DOI 10.1097/00005537-199907000-00010; Kirwan JM, 2003, BRIT J CANCER, V88, P839, DOI 10.1038/sj.bjc.6600816; Klein S, 2000, EUR J CANCER, V36, P273; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Libert Y, 2001, B CANCER, V88, P1167; Lipkin M, 1985, MED INTERVIEW CLIN C, P422; Maguire P, 1998, EUR J SURG ONCOL, V24, P188, DOI 10.1016/S0748-7983(98)92929-8; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Morton J, 2000, ANAESTH INTENS CARE, V28, P184, DOI 10.1177/0310057X0002800210; Newton JT, 1999, BRIT DENT J, V186, P278, DOI 10.1038/sj.bdj.4800087a; Orlander JD, 2002, J GEN INTERN MED, V17, P825, DOI 10.1046/j.1525-1497.2002.10915.x; Parker PA, 2001, J CLIN ONCOL, V19, P2049, DOI 10.1200/JCO.2001.19.7.2049; Parle M, 1997, SOC SCI MED, V44, P231, DOI 10.1016/S0277-9536(96)00148-7; PEARSON IY, 1995, ANAESTH INTENS CARE, V23, P68, DOI 10.1177/0310057X9502300113; PEARSON IY, 1995, ANAESTH INTENS CARE, V23, P88, DOI 10.1177/0310057X9502300116; Poulson J, 1998, NEW ENGL J MED, V338, P1844, DOI 10.1056/NEJM199806183382512; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; Ptacek JT, 2001, J CLIN ONCOL, V19, P4160, DOI 10.1200/JCO.2001.19.21.4160; Ptacek JT, 2001, J BEHAV MED, V24, P205, DOI 10.1023/A:1010766732373; Ptacek JT, 1999, SUPPORT CARE CANCER, V7, P113, DOI 10.1007/s005200050240; Quirt CF, 1997, LUNG CANCER-J IASLC, V18, P1, DOI 10.1016/S0169-5002(97)00048-2; Rabow MW, 1999, WESTERN J MED, V171, P260; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; RAMRAYKA, 2002, GUARDIAN LONDON 1120, P5; Rosenbaum ME, 2002, TEACH LEARN MED, V14, P144, DOI 10.1207/S15328015TLM1403_2; Schofield PE, 2001, ANN ONCOL, V12, P365, DOI 10.1023/A:1011100524076; SCOPE, 2003, RIGHT START TEMPL GO, P8; *SCOPE, 1999, RIGHT START, P33; SHARP MC, 1992, J PEDIATR-US, V121, P539, DOI 10.1016/S0022-3476(05)81141-2; Smith GB, 2002, RESUSCITATION, V52, P281, DOI 10.1016/S0300-9572(01)00477-4; STRAUSS RP, 1995, PEDIATRICS, V96, P82; Ungar L, 2002, PATIENT EDUC COUNS, V48, P63, DOI 10.1016/S0738-3991(02)00088-5; Vaidya VU, 1999, ARCH PEDIAT ADOL MED, V153, P419; Vandekieft GK, 2001, AM FAM PHYSICIAN, V64, P1975; Vetto J T, 1999, J Cancer Educ, V14, P13; Yardley SJ, 2001, PALLIATIVE MED, V15, P379, DOI 10.1191/026921601680419429	80	583	613	0	117	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					312	319		10.1016/S0140-6736(03)15392-5	http://dx.doi.org/10.1016/S0140-6736(03)15392-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766FQ	14751707				2022-12-28	WOS:000188361400025
J	Klein, GL; Chen, TC; Holick, MF; Langman, CB; Price, H; Celis, MM; Herndon, DN				Klein, GL; Chen, TC; Holick, MF; Langman, CB; Price, H; Celis, MM; Herndon, DN			Synthesis of vitamin D in skin after burns	LANCET			English	Article							CHILDREN; INJURY	Severe burn injury is associated with vitamin D deficiency, low bone turnover, and abnormalities in calcium homoeostasis. Patients do not routinely receive vitamin D supplementation and sun exposure is currently not controlled. By analysis of skin biopsy samples for vitamin D3 precursors after exposure to ultraviolet B light we found that the conversion of 7-dehydrocholesterol to previtamin D3 was reduced in children a mean of 14 months after the burn. Low serum 25-hydroxyvitamin D concentrations were also found. We conclude that vitamin D supplementation is necessary after burn injury.	Univ Texas, Med Branch, Dept Paediat, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77550 USA; Shriners Burns Hosp, Galveston, TX USA; Boston Univ, Med Ctr, Dept Med, Boston, MA USA; Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Chicago, IL 60614 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Boston University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Klein, GL (corresponding author), Univ Texas, Med Branch, Childrens Hosp, 301 Univ Blvd, Galveston, TX 77555 USA.	gklein@utmb.edu	Klein, Gordon Leslie/A-7221-2009; Herndon, David/AAC-3354-2020	Klein, Gordon Leslie/0000-0002-3011-4186; Holick, Michael/0000-0001-6023-9062; Chen, Tai/0000-0002-5704-5694	NIGMS NIH HHS [1 P50 GM 60338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM060338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Klein GL, 2002, J TRAUMA, V52, P346, DOI 10.1097/00005373-200202000-00022; KLEIN GL, 1995, BONE, V17, P455, DOI 10.1016/8756-3282(95)00279-1; MATSUOKA LY, 1987, J CLIN ENDOCR METAB, V64, P1165, DOI 10.1210/jcem-64-6-1165; MCLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536; Murphey ED, 2000, CRIT CARE MED, V28, P3885, DOI 10.1097/00003246-200012000-00024	5	54	61	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	2004	363	9405					291	292		10.1016/S0140-6736(03)15388-3	http://dx.doi.org/10.1016/S0140-6736(03)15388-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751703				2022-12-28	WOS:000188361400012
J	Le Chevalier, T; Arriagada, R; Le Pechoux, C; Grunenwald, D; Dunant, A; Pignon, JP; Tarayre, M; Abratt, R; Arriagada, R; Bergman, B; Gralla, R; Grunenwald, D; Le Chevalier, T; Orlowski, T; Papadakis, E; Pinel, MIS; Araujo, C; Della Torre, H; de Solchaga, MM; Abdi, E; Blum, R; Ball, D; Basser, R; De Boer, R; Bishop, J; Brigham, B; Davis, S; Fox, D; Richardson, G; Wyld, D; Pirker, R; Humblet, Y; Delaunois, L; Van Meerbeeck, JP; Germonpre, P; Vansteenkiste, J; Nackaerts, K; Pinel, MIS; Vauthier, G; Younes, RN; Arriagada, R; Baeza, R; Carvajal, P; Kleinman, S; Orlandi, L; Castro, C; Godoy, J; Kosatova, K; Gaafar, R; Azarian, R; Benichou, M; Boudoux, L; Boyer, G; Chirat, E; Chomy, F; Coetmeur, D; Couderc, LJ; Coudert, B; Crequit, J; David, P; Delaval, P; Dohollou, N; Foucher, P; Gonzalez, G; Jeanfaivre, T; Joveniaux, A; Kanoui, AA; Le Chevalier, T; Le Pechoux, C; Baldeyrou, P; Debrosse, D; Girard, P; Grunenwald, D; Ruffie, P; Leclerc, P; Milleron, B; Monnet, I; Monnot, H; Morere, JF; Naman, H; Dides, S; Noel, JP; Otto, J; Ozanne, F; Ozenne, G; Parent, F; Peureux, M; Picon, B; Pujol, JL; Quoix, E; Rabut, H; Riviere, A; Gervais, R; Icard, P; Rixe, O; Deplanque, G; Sevin, D; Spaeth, D; Tourani, JM; Toussaint, C; Tuchais, C; Vannetzel, JM; VArflet, F; Virally, J; Zaegel, M; Zalcman, G; Livatorwski, A; Eberhardt, W; Alexopoulos, C; Apostolopoulou, F; Bachlitzanakis, N; Bellenis, I; Christaki, P; Dosios, T; Georgoulias, V; Iliadis, K; Kardamakis, D; Konstantinou, M; Kotsovoulou, V; Pouliou, M; Michalopoulou, P; Papadakis, E; Agelidou, A; Zarogoulidis, K; Gottfried, M; Kovner, F; Agostara, B; Ascoli, M; Brigandi, A; Cigolari, S; Colucci, G; De Braud, F; Dirosa, T; Giglio, A; Maiorino, A; Masotti, A; Rusca, M; Ogawara, M; Osada, H; Park, K; Jackevicius, A; Smickoska, S; El Gueddari, BE; Aaesebo, U; Desales, R; Furman, M; Kozlowski, M; Laudansk, J; Grodzki, T; Orlowski, T; Chabowski, M; Pluzanska, A; Gaspar, L; Ciuleanu, T; Baumohl, J; Cerna, M; Bitenc, M; Abratt, R; Chasen, M; Alberola, V; Azagra, P; Garcia, PB; CArdenal, F; Curto, CP; Salinas, J; Serrate, RS; Bergman, B; Andersson, L; Hero, U; Mansson, T; Martinsson, JE; Hillerdal, G; Agrenius, V; Sederholm, C; Arvidsson, I; Ydreborg, SO; Thaning, L; Sjogren, A; Jonsson, P; Grip, H; Singer, J; Lundgren, R; Brodin, O; Andejani, D; Branden, E; Lamberg, K; Riska, H; Egli, E; Joss, R; Martinelli, G; Roth, A; Stahel, R; Stupp, R; El Kamel, A; Gralla, R; Cole, JT; Jahanzeb, M; Wiznitzer, I; Masters, GA; Radosavljevic, G; Babiker, A; Green, M; Osterlind, K; Taube, A; Wedel, H				Le Chevalier, T; Arriagada, R; Le Pechoux, C; Grunenwald, D; Dunant, A; Pignon, JP; Tarayre, M; Abratt, R; Arriagada, R; Bergman, B; Gralla, R; Grunenwald, D; Le Chevalier, T; Orlowski, T; Papadakis, E; Pinel, MIS; Araujo, C; Della Torre, H; de Solchaga, MM; Abdi, E; Blum, R; Ball, D; Basser, R; De Boer, R; Bishop, J; Brigham, B; Davis, S; Fox, D; Richardson, G; Wyld, D; Pirker, R; Humblet, Y; Delaunois, L; Van Meerbeeck, JP; Germonpre, P; Vansteenkiste, J; Nackaerts, K; Pinel, MIS; Vauthier, G; Younes, RN; Arriagada, R; Baeza, R; Carvajal, P; Kleinman, S; Orlandi, L; Castro, C; Godoy, J; Kosatova, K; Gaafar, R; Azarian, R; Benichou, M; Boudoux, L; Boyer, G; Chirat, E; Chomy, F; Coetmeur, D; Couderc, LJ; Coudert, B; Crequit, J; David, P; Delaval, P; Dohollou, N; Foucher, P; Gonzalez, G; Jeanfaivre, T; Joveniaux, A; Kanoui, AA; Le Chevalier, T; Le Pechoux, C; Baldeyrou, P; Debrosse, D; Girard, P; Grunenwald, D; Ruffie, P; Leclerc, P; Milleron, B; Monnet, I; Monnot, H; Morere, JF; Naman, H; Dides, S; Noel, JP; Otto, J; Ozanne, F; Ozenne, G; Parent, F; Peureux, M; Picon, B; Pujol, JL; Quoix, E; Rabut, H; Riviere, A; Gervais, R; Icard, P; Rixe, O; Deplanque, G; Sevin, D; Spaeth, D; Tourani, JM; Toussaint, C; Tuchais, C; Vannetzel, JM; VArflet, F; Virally, J; Zaegel, M; Zalcman, G; Livatorwski, A; Eberhardt, W; Alexopoulos, C; Apostolopoulou, F; Bachlitzanakis, N; Bellenis, I; Christaki, P; Dosios, T; Georgoulias, V; Iliadis, K; Kardamakis, D; Konstantinou, M; Kotsovoulou, V; Pouliou, M; Michalopoulou, P; Papadakis, E; Agelidou, A; Zarogoulidis, K; Gottfried, M; Kovner, F; Agostara, B; Ascoli, M; Brigandi, A; Cigolari, S; Colucci, G; De Braud, F; Dirosa, T; Giglio, A; Maiorino, A; Masotti, A; Rusca, M; Ogawara, M; Osada, H; Park, K; Jackevicius, A; Smickoska, S; El Gueddari, BE; Aaesebo, U; Desales, R; Furman, M; Kozlowski, M; Laudansk, J; Grodzki, T; Orlowski, T; Chabowski, M; Pluzanska, A; Gaspar, L; Ciuleanu, T; Baumohl, J; Cerna, M; Bitenc, M; Abratt, R; Chasen, M; Alberola, V; Azagra, P; Garcia, PB; CArdenal, F; Curto, CP; Salinas, J; Serrate, RS; Bergman, B; Andersson, L; Hero, U; Mansson, T; Martinsson, JE; Hillerdal, G; Agrenius, V; Sederholm, C; Arvidsson, I; Ydreborg, SO; Thaning, L; Sjogren, A; Jonsson, P; Grip, H; Singer, J; Lundgren, R; Brodin, O; Andejani, D; Branden, E; Lamberg, K; Riska, H; Egli, E; Joss, R; Martinelli, G; Roth, A; Stahel, R; Stupp, R; El Kamel, A; Gralla, R; Cole, JT; Jahanzeb, M; Wiznitzer, I; Masters, GA; Radosavljevic, G; Babiker, A; Green, M; Osterlind, K; Taube, A; Wedel, H		Int Adjuvant Lung Canc Trial Colla	Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE-II; PREOPERATIVE CHEMOTHERAPY; TRIALS	BACKGROUND: On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer. METHODS: We randomly assigned patients either to three or four cycles of cisplatin-based chemotherapy or to observation. Before randomization, each center determined the pathological stages to include, its policy for chemotherapy (the dose of cisplatin and the drug to be combined with cisplatin), and its postoperative radiotherapy policy. The main end point was overall survival. RESULTS: A total of 1867 patients underwent randomization; 36.5 percent had pathological stage I disease, 24.2 percent stage II, and 39.3 percent stage III. The drug allocated with cisplatin was etoposide in 56.5 percent of patients, vinorelbine in 26.8 percent, vinblastine in 11.0 percent, and vindesine in 5.8 percent. Of the 932 patients assigned to chemotherapy, 73.8 percent received at least 240 mg of cisplatin per square meter of body-surface area. The median duration of follow-up was 56 months. Patients assigned to chemotherapy had a significantly higher survival rate than those assigned to observation (44.5 percent vs. 40.4 percent at five years [469 deaths vs. 504]; hazard ratio for death, 0.86; 95 percent confidence interval, 0.76 to 0.98; P<0.03). Patients assigned to chemotherapy also had a significantly higher disease-free survival rate than those assigned to observation (39.4 percent vs. 34.3 percent at five years [518 events vs. 577]; hazard ratio, 0.83; 95 percent confidence interval, 0.74 to 0.94; P<0.003). There were no significant interactions with prespecified factors. Seven patients (0.8 percent) died of chemotherapy-induced toxic effects. CONCLUSIONS: Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer.	Inst Radiomed, Santiago, Chile; Sahlgrenska Hosp, Gothenburg, Sweden; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Inst Gustave Roussy, Dept Biostat & Epidemiol, IALT Secretariat, F-94805 Villejuif, France	Sahlgrenska University Hospital; KU Leuven; University Hospital Leuven; UNICANCER; Gustave Roussy	Le Chevalier, T (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, IALT Secretariat, Rue Camille Desmoulins, F-94805 Villejuif, France.		Ciuleanu, Tudor-Eliade/ABH-8452-2020; Stupp, Roger/L-3303-2019; Chabowski, Mariusz/H-9847-2019; ZALCMAN, Gérard/L-7809-2015; ZALCMAN, Gerard/M-8113-2019; Vansteenkiste, Johan F/B-8191-2014; Cole, John/A-5803-2011; van Meerbeeck, Jan/ABA-5109-2020; Wyld, David K/B-8893-2015; Nackaerts, Kristiaan/B-6596-2015; ICARD, Philippe/K-6510-2015; Ciuleanu, Tudor Eliade/C-3996-2011	Chabowski, Mariusz/0000-0002-9232-4525; ZALCMAN, Gérard/0000-0002-0343-9575; Vansteenkiste, Johan F/0000-0002-6721-2775; Wyld, David K/0000-0001-9523-4333; Arriagada, Rodrigo/0000-0002-3134-1735; PIGNON, Jean-Pierre/0000-0003-2047-1582				ALBERTI W, 1995, BRIT MED J, V311, P899; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, Lancet, V339, P1; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Burdett S, 1998, LANCET, V352, P257; COX DR, 1972, J R STAT SOC B, V34, P187; Depierre A, 2001, CANCER TREAT REV, V27, P119, DOI 10.1053/ctrv.2001.0218; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; Ferlay J, 2001, GLOBOCAN 2000 CANC I; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; KATO H, 2003, P AN M AM SOC CLIN, V22, P621; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; LABIANCA R, 1995, LANCET, V345, P939; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; Peto R, 1994, MORTALITY SMOKING DE; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rea D, 1998, BRIT MED J, V316, P1518, DOI 10.1136/bmj.316.7143.1518; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Trimbos JB, 2003, JNCI-J NATL CANCER I, V95, P105; Wartelle M., 1983, Proceedings of the Second International Workshop on Statistical Database Management, P124	23	1757	1857	5	113	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					351	360		10.1056/nejmoa031644	http://dx.doi.org/10.1056/nejmoa031644			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736927				2022-12-28	WOS:000188254800007
J	Reed, KD; Melski, JW; Graham, MB; Regnery, RL; Sotir, MJ; Wegner, MV; Kazmierczak, JJ; Stratman, EJ; Li, Y; Fairley, JA; Swain, GR; Olson, VA; Sargent, EK; Kehl, SC; Frace, MA; Kline, R; Foldy, SL; Davis, JP; Damon, IK				Reed, KD; Melski, JW; Graham, MB; Regnery, RL; Sotir, MJ; Wegner, MV; Kazmierczak, JJ; Stratman, EJ; Li, Y; Fairley, JA; Swain, GR; Olson, VA; Sargent, EK; Kehl, SC; Frace, MA; Kline, R; Foldy, SL; Davis, JP; Damon, IK			The detection of monkeypox in humans in the Western Hemisphere	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; REEMERGENCE; CONGO	BACKGROUND: During May and June 2003, an outbreak of febrile illness with vesiculopustular eruptions occurred among persons in the midwestern United States who had had contact with ill pet prairie dogs obtained through a common distributor. Zoonotic transmission of a bacterial or viral pathogen was suspected. METHODS: We reviewed medical records, conducted interviews and examinations, and collected blood and tissue samples for analysis from 11 patients and one prairie dog. Histopathological and electron-microscopical examinations, microbiologic cultures, and molecular assays were performed to identify the etiologic agent. RESULTS: The initial Wisconsin cases evaluated in this outbreak occurred in five males and six females ranging in age from 3 to 43 years. All patients reported having direct contact with ill prairie dogs before experiencing a febrile illness with skin eruptions. We found immunohistochemical or ultrastructural evidence of poxvirus infection in skin-lesion tissue from four patients. Monkeypox virus was recovered in cell cultures of seven samples from patients and from the prairie dog. The virus was identified by detection of monkeypox-specific DNA sequences in tissues or isolates from six patients and the prairie dog. Epidemiologic investigation suggested that the prairie dogs had been exposed to at least one species of rodent recently imported into the United States from West Africa. CONCLUSIONS: Our investigation documents the isolation and identification of monkeypox virus from humans in the Western Hemisphere. Infection of humans was associated with direct contact with ill prairie dogs that were being kept or sold as pets.	Marshfield Clin Res Fdn, Clin Res Ctr, Marshfield, WI 54449 USA; Marshfield Clin Fdn Med Res & Educ, Dept Pathol, Marshfield, WI USA; Marshfield Clin Fdn Med Res & Educ, Dept Dermatol, Marshfield, WI USA; Med Coll Wisconsin, Div Infect Dis, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Family & Community Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; City Milwaukee Hlth Dept, Milwaukee, WI USA; Ctr Dis Control & Prevent, Poxvirus Sect, Off Director, Div Viral & Rickettsial Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Intelligence Serv, Atlanta, GA USA; Wisconsin Div Publ Hlth, Bur Communicable Dis, Madison, WI USA	Marshfield Clinic; Marshfield Clinic; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Reed, KD (corresponding author), Marshfield Clin Res Fdn, Clin Res Ctr, 1000 N Oak, Marshfield, WI 54449 USA.	reed.kurt@mcrf.mfldclin.edu		Fairley, Janet/0000-0002-8203-0486				Breman JG, 2000, EMERGING INFECTIONS 4, P45; *CDCP, 2003, UPD MULT OUTBR MONK; *CDCP, 2003, MONK REP CAS US DAT; *CDCP, 2003, INT GUID COLL DIAGN; *CDCP, 2003, INT GUID STAT LOC GO; DOANE FW, 1987, ELECT MICROSCOPY DIA, P87; ESPOSITO JJ, 1985, VIROLOGY, V143, P230, DOI 10.1016/0042-6822(85)90111-4; Hazelton PR, 2003, EMERG INFECT DIS, V9, P294, DOI 10.3201/eid0903.020327; Heymann DL, 1998, BRIT MED BULL, V54, P693, DOI 10.1093/oxfordjournals.bmb.a011720; Hutin YJF, 2001, EMERG INFECT DIS, V7, P434; Ibrahim MS, 2003, J CLIN MICROBIOL, V41, P3835, DOI 10.1128/JCM.41.8.3835-3839.2003; JEZEK Z, 1986, J INFECT DIS, V154, P551, DOI 10.1093/infdis/154.4.551; JEZEK Z, 1987, AM J EPIDEMIOL, V126, P1082, DOI 10.1093/oxfordjournals.aje.a114747; JEZEK Z, 1988, TROP GEOGR MED, V40, P73; JEZEK Z, 1987, J TROP MED HYG, V90, P31; KHODAKEVICH L, 1986, LANCET, V1, P98; KHODAKEVICH L, 1987, TROP GEOGR MED, V39, P115; LANDYL ID, 1972, B WORLD HEALTH ORGAN, V46, P593; Meyer H, 2002, J CLIN MICROBIOL, V40, P2919, DOI 10.1128/JCM.40.8.2919-2921.2002; Meyer H, 1997, J VIROL METHODS, V64, P217, DOI 10.1016/S0166-0934(96)02155-6; Meyer H, 1998, METH MOLEC MED, V12, P199; Mukinda VBK, 1997, LANCET, V349, P1449, DOI 10.1016/S0140-6736(05)63725-7; Pattyn SR, 2000, REV SCI TECH OIE, V19, P92, DOI 10.20506/rst.19.1.1207; ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995; *STAT IL EX DEP, 2003, EX ORD RESP ORTH OUT; *WI DEP HLTH FAM S, 2003, EM ORD; Zaucha GM, 2001, LAB INVEST, V81, P1581, DOI 10.1038/labinvest.3780373; 2003, RESTRICTIONS AFRICAN; 2003, MMWR MORB MORTAL WKL, V52, P537	29	444	472	13	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					342	350		10.1056/NEJMoa032299	http://dx.doi.org/10.1056/NEJMoa032299			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736926				2022-12-28	WOS:000188254800006
J	Attaran, A; Barnes, KI; Curtis, C; d'Alessandro, U; Fanello, CI; Galinski, MR; Kokwaro, G; Looareesuwan, S; Makanga, M; Mutabingwa, TK; Talisuna, A; Trape, JF; Watkins, WM				Attaran, A; Barnes, KI; Curtis, C; d'Alessandro, U; Fanello, CI; Galinski, MR; Kokwaro, G; Looareesuwan, S; Makanga, M; Mutabingwa, TK; Talisuna, A; Trape, JF; Watkins, WM			WHO, the Global Fund, and medical malpractice in malaria treatment	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA; CHLOROQUINE RESISTANCE; ARTESUNATE; HEALTH; ARTEMETHER; MORTALITY; EFFICACY; THERAPY; AFRICA; IMPACT		Royal Inst Int Affairs, London, England; Univ Cape Town, Div Pharmacol, ZA-7700 Rondebosch, South Africa; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Malaria Fdn Int, Atlanta, GA USA; Univ Nairobi, Fac Pharm, Nairobi, Kenya; Mahidol Univ, Fac Trop Med, Bangkok, Thailand; Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Nairobi, Kenya; EANMAT, Tanga, Tanzania; Minist Hlth, Epidemiol Surveillance Div, Kampala, Uganda; Inst Rech & Dev, Dakar, Senegal; Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England	University of Cape Town; University of London; London School of Hygiene & Tropical Medicine; Institute of Tropical Medicine (ITM); University of Nairobi; Mahidol University; Kenya Medical Research Institute; Institut de Recherche pour le Developpement (IRD); University of Liverpool	Attaran, A (corresponding author), Royal Inst Int Affairs, London, England.	aattaran@riia.org	Fanello, Caterina/AAT-9679-2021; D'Alessandro, Umberto/D-3457-2015	Fanello, Caterina/0000-0003-1932-9562; D'Alessandro, Umberto/0000-0001-6341-5009				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; [Anonymous], 2000, LANCET, V356, P521; *GFATM, SERV TECHN REV PAN A; *GFATM TECHN REV P, UG REV FORM; *GLOB FUND, 2003, UNICEF COP OCT 20; *GLOB FUND, FRAM DOC GLOB FUND F; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Hien TT, 2004, LANCET, V363, P18, DOI 10.1016/S0140-6736(03)15163-X; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; Kshirsagar NA, 2000, AM J TROP MED HYG, V62, P402, DOI 10.4269/ajtmh.2000.62.402; Marquino W, 2003, AM J TROP MED HYG, V68, P608, DOI 10.4269/ajtmh.2003.68.608; MCINTOSH HM, 2003, COCHRANE LIB; MCNEIL DG, 2002, NY TIMES        0528; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; PREMJI Z, 2003, AM SOC TROP MED HYG; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860, DOI 10.1046/j.1360-2276.2003.01114.x; *ROLL BACK MAL PAR, 2003, SCAL UP SUST IMP ROL; TALISUNA AO, IN PRESS CLIN MICROB; Tjitra E, 2001, AM J TROP MED HYG, V65, P309, DOI 10.4269/ajtmh.2001.65.309; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; van Agtmael MA, 1999, TRENDS PHARMACOL SCI, V20, P199, DOI 10.1016/S0165-6147(99)01302-4; van Vugt M, 2000, T ROY SOC TROP MED H, V94, P545, DOI 10.1016/S0035-9203(00)90082-8; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; *WHO, 2003, WHOCDSMAL20031095; *WHO, POS WHOS ROLL BACK M; *WHO, 2001, WHO TECHN CONS 4 5 A; *WHO, 2001, WHO INF CONS NOV 13; *WHO, 2003, 2003313 WHOCDSTB; *WHO, 2003, 182003 WHO; *WHO UNICEF, 2003, WHOCDSMAL20031093; World Health Organization, 2003, SCAL ANT THER RES LT; Yamey G, 2000, BRIT MED J, V321, P787, DOI 10.1136/bmj.321.7264.787; Yamey G, 2003, BRIT MED J, V327, P1188, DOI 10.1136/bmj.327.7425.1188; *ZAMB NAT MAL CONT, 2003, UNPUB IN VIV EFF STU; Zucker JR, 2003, AM J TROP MED HYG, V68, P386, DOI 10.4269/ajtmh.2003.68.386	38	165	168	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					237	240		10.1016/S0140-6736(03)15330-5	http://dx.doi.org/10.1016/S0140-6736(03)15330-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738799				2022-12-28	WOS:000188243900025
J	Vershinin, M; Misra, S; Ono, S; Abe, Y; Ando, Y; Yazdani, A				Vershinin, M; Misra, S; Ono, S; Abe, Y; Ando, Y; Yazdani, A			Local ordering in the pseudogap state of the high-T-c superconductor Bi2Sr2CaCu2O8+delta	SCIENCE			English	Article							QUASI-PARTICLE STATES; STRIPE PHASES; VORTEX CORES; GAP; FLUCTUATIONS; COHERENCE	We report atomic-scale characterization of the pseudogap state in a high-T-c superconductor, Bi2Sr2CaCu2O8+delta. The electronic states at low energies within the pseudogap exhibit spatial modulations having an energy-independent incommensurate periodicity. These patterns, which are oriented along the copper-oxygen bond directions, appear to be a consequence of an electronic ordering phenomenon, the observation of which correlates with the pseudogap in the density of electronic states. Our results provide a stringent test for various ordering scenarios in the cuprates, which have been central in the debate on the nature of the pseudogap and the complex electronic phase diagram of these compounds.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; Cent Res Inst Elect Power Ind, Tokyo 2018511, Japan	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Central Research Institute of Electric Power Industry - Japan	Yazdani, A (corresponding author), Stanford Univ, Geballe Lab Adv Mat, Stanford, CA 94305 USA.	ayazdani@uiuc.edu	Ando, Yoichi/B-8163-2013; Ono, Shimpei/D-2918-2017	Ando, Yoichi/0000-0002-3553-3355; Vershinin, Michael/0000-0002-8207-1376; Ono, Shimpei/0000-0003-1514-8879; Yazdani, Ali/0000-0003-4996-8904; Ando, Yukio/0000-0001-7115-9105				BYERS JM, 1993, PHYS REV LETT, V71, P3363, DOI 10.1103/PhysRevLett.71.3363; CAPRIOTTI L, 2003, PHYS REV B, V68, P45120; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Chen HD, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137004; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; Corson J, 1999, NATURE, V398, P221, DOI 10.1038/18402; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Hoffman JE, 2002, SCIENCE, V297, P1148, DOI 10.1126/science.1072640; Howald C, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014533; Lake B, 1999, NATURE, V400, P43, DOI 10.1038/21840; McElroy K, 2003, NATURE, V422, P592, DOI 10.1038/nature01496; Norman MR, 1998, NATURE, V392, P157, DOI 10.1038/32366; Norman MR, 1998, PHYS REV B, V57, pR11093, DOI 10.1103/PhysRevB.57.R11093; NORMAN MR, 1995, PHYS REV B, V52, P615, DOI 10.1103/PhysRevB.52.615; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Pereg-Barnea T, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.180506; Polkovnikov A, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.220509; Renner C, 1998, PHYS REV LETT, V80, P3606, DOI 10.1103/PhysRevLett.80.3606; Tallon JL, 2001, PHYSICA C, V349, P53, DOI 10.1016/S0921-4534(00)01524-0; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; Vojta M, 1999, PHYS REV LETT, V83, P3916, DOI 10.1103/PhysRevLett.83.3916; Wang QH, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.020511; Wen XG, 1996, PHYS REV LETT, V76, P503, DOI 10.1103/PhysRevLett.76.503; Xu ZA, 2000, NATURE, V406, P486, DOI 10.1038/35020016; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089	30	433	433	1	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					1995	1998		10.1126/science.1093384	http://dx.doi.org/10.1126/science.1093384			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	14963336	Green Submitted			2022-12-28	WOS:000220429800035
J	Marston, AL; Tham, WH; Shah, H; Amon, A				Marston, AL; Tham, WH; Shah, H; Amon, A			A genome-wide screen identifies genes required for centromeric cohesion	SCIENCE			English	Article							SISTER-CHROMATID COHESION; MEI-S332	During meiosis, two chromosome segregation phases follow a single round of DNA replication. We identified factors required to establish this specialized cell cycle by examining meiotic chromosome segregation in a collection of yeast strains lacking all nonessential genes. This analysis revealed Sgo1, Chl4, and Iml3 to be important for retaining centromeric cohesin until the onset of anaphase II. Consistent with this role, Sgo1 localizes to centromeric regions but dissociates at the onset of anaphase II. The screen described here provides a comprehensive analysis of the genes required for the meiotic cell cycle and identifies three factors important for the stepwise loss of sister chromatid cohesion.	MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Amon, A (corresponding author), MIT, Howard Hughes Med Inst, Ctr Canc Res, E17-233,40 Ames St, Cambridge, MA 02139 USA.	angelika@mit.edu	Tham, Wai-Hong/P-6474-2019; Tham, Wai-Hong/L-3173-2018	Tham, Wai-Hong/0000-0001-7950-8699; Tham, Wai-Hong/0000-0001-7950-8699; Amon, Angelika/0000-0001-9837-0314; Marston, Adele/0000-0002-3596-9407	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062207] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62207] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KERREBROCK AW, 1992, GENETICS, V130, P827; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; MARSTON A, UNPUB; Marston AL, 2003, DEV CELL, V4, P711, DOI 10.1016/S1534-5807(03)00130-8; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; Mythreye K, 2003, J CELL BIOL, V160, P833, DOI 10.1083/jcb.200211116; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Pot I, 2003, MOL BIOL CELL, V14, P460, DOI 10.1091/mbc.E02-08-0517; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8	18	214	221	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1367	1370		10.1126/science.1094220	http://dx.doi.org/10.1126/science.1094220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14752166				2022-12-28	WOS:000189238600051
J	Anastos, K; Barron, Y; Cohen, MH; Greenblatt, RM; Minkoff, H; Levine, A; Young, M; Gange, SJ				Anastos, K; Barron, Y; Cohen, MH; Greenblatt, RM; Minkoff, H; Levine, A; Young, M; Gange, SJ			The prognostic importance of changes in CD4(+) cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; VIRAL LOAD; INTERAGENCY HIV; MORTALITY; INFECTION; COHORT; AIDS	Background: The prognostic value of CD4(+) cell counts and HIV-1 RNA levels attained after the initiation of highly active antiretroviral therapy (HAART) compared with before the initiation of HAART has not been well defined. Objective: To determine the prognostic value for clinical outcomes of CD4(+) cell counts and HIV-1 RNA levels attained after initiating therapy. Design: Prospective cohort study. Setting: Women's Interagency HIV Study. Patients: 1132 participants in the Women's Interagency HIV Study. Measurements: HIV-1 RNA level, CD4(+) cell counts, AIDS-defining illness, and death. Results: In multivariate analyses with a median follow-up of 3.9 years, women with CD4(+) cell counts of less than 0.200 x 10(9) cells/L compared with women with CD4(+) cell counts of greater than 0.350 x 109 cells/L after HAART initiation had a relative hazard of death from all causes of 2.66 (95% CI, 1.42 to 4.99) and a relative hazard of death from AIDS of 47.61 (CI, 5.69 to 398.40). The relative hazard of all-cause death was 3.44 (CI, 1.67 to 7.09) in women with RNA levels of more than 10 000 copies/mL compared with women with attained RNA levels of less than 80 copies/mL. The relative hazard of AIDS-related or all-cause death did not increase for women with post-HAART CD4(+) cell counts between 0.200 and 0.350 x 10(9) cells/L compared with women with CD4(+) cell counts of greater than 0.350 X 10(9) cells/L. Also, the relative hazard did not increase in women with post-HAART HIV-1 RNA levels between 80 and 10000 copies/mL compared with women with post-HAART HIV-1 RNA levels of less than 80 copies/mL. Of the laboratory markers, only the post-HAART CD4(+) cell count and HIV-1 RNA level were predictive of new AIDS-defining illness. Conclusion: Post-HAART laboratory markers predicted death and new AIDS-defining illness. Pre-HAART CD4(+) cell count and HIV-1 RNA level were not predictive of clinical outcomes if adjusted for values attained after HAART initiation, suggesting that even advanced immune suppression can be overcome with HAART that results in CD4(+) cell counts of greater than 0.200 x 10(9) cells/L and RNA levels of less than 10 000 copies/mL.	Montefiore Med Ctr, Bronx, NY 10467 USA; Lincoln Med & Mental Hlth Ctr, Bronx, NY 10451 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Cook Cty Hosp, Chicago, IL 60612 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Univ So Calif, Los Angeles, CA USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; John H Stroger Junior Hospital Cook County; University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Southern California; Georgetown University	Anastos, K (corresponding author), Womens Interagcy HIV Study, 3311 Bainbridge Ave,2nd Floor, Bronx, NY 10467 USA.	kanastos@verizon.net	Gange, Stephen/AGY-5004-2022	Gange, Stephen/0000-0001-7842-512X	NCRR NIH HHS [M01-RR-00071, M01-RR00083, M01-RR-00079] Funding Source: Medline; NIAID NIH HHS [U01-AI-31834, U01-AI-42590, U01-AI-35004, U01-AI-34994, U01-AI-34993, U01-AI-34989] Funding Source: Medline; NICHD NIH HHS [U01-HD-32632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD032632] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079, M01RR000071, M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI042590, U01AI035004, U01AI031834, U01AI034994, U01AI034993, U01AI034989] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahdieh L, 2000, AM J EPIDEMIOL, V152, P923, DOI 10.1093/aje/152.10.923; Anastos K, 2002, ARCH INTERN MED, V162, P1973, DOI 10.1001/archinte.162.17.1973; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Chiasson MA, 1999, J ACQ IMMUN DEF SYND, V21, P59, DOI 10.1097/00126334-199905010-00008; Cook JA, 2002, AM J PUBLIC HEALTH, V92, P82, DOI 10.2105/AJPH.92.1.82; Cox D. R., 1984, ANAL SURVIVAL DATA; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Erb P, 2000, ARCH INTERN MED, V160, P1134, DOI 10.1001/archinte.160.8.1134; Gange SJ, 2002, J EPIDEMIOL COMMUN H, V56, P153, DOI 10.1136/jech.56.2.153; Ghani AC, 2001, J ACQ IMMUN DEF SYND, V28, P226, DOI 10.1097/00042560-200111010-00004; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Jacobson LP, 2002, AM J EPIDEMIOL, V155, P760, DOI 10.1093/aje/155.8.760; Kirstein LM, 2002, J ACQ IMMUN DEF SYND, V29, P495, DOI 10.1097/00126334-200204150-00010; Lew J, 1998, J CLIN MICROBIOL, V36, P1471, DOI 10.1128/JCM.36.6.1471-1479.1998; Lewden C, 2002, J INFECT DIS, V186, P710, DOI 10.1086/342047; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; *US DOE, 1999, HUM GENOME NEWS, V10, P1	22	57	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					256	264		10.7326/0003-4819-140-4-200402170-00007	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970148				2022-12-28	WOS:000188970400003
J	Chipuk, JE; Kuwana, T; Bouchier-Hayes, L; Droin, NM; Newmeyer, D; Schuler, M; Green, DR				Chipuk, JE; Kuwana, T; Bouchier-Hayes, L; Droin, NM; Newmeyer, D; Schuler, M; Green, DR			Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis	SCIENCE			English	Article							CYTOCHROME-C RELEASE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; CASPASE ACTIVATION; BCL-2; DEATH; PUMA; ABSENCE	The tumor suppressor p53 exerts its anti-neoplastic activity primarily through the induction of apoptosis. We found that cytosolic localization of endogenous wild-type or trans-activation-deficient p53 was necessary and sufficient for apoptosis. p53 directly activated the proapoptotic Bcl-2 protein Bax in the absence of other proteins to permeabilize mitochondria and engage the apoptotic program. p53 also released both proapoptotic multidomain proteins and BH3-only proteins [Proapoptotic Bcl-2 family proteins that share only the third Bcl-2 homology domain (BH3)] that were sequestered by Bcl-xL. The transcription-independent activation of Bax by p53 occurred with similar kinetics and concentrations to those produced by activated Bid. We propose that when p53 accumulates in the cytosol, it can function analogously to the BH3-only subset of proapoptotic Bcl-2 proteins to activate Bax and trigger apoptosis.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Mainz, Dept Med 3, D-55101 Mainz, Germany	La Jolla Institute for Immunology; Johannes Gutenberg University of Mainz	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	doug@liai.org	Bouchier-Hayes, Lisa/T-9491-2019; Droin, Nathalie M/Y-5506-2018; Green, Douglas R/N-8083-2018	Bouchier-Hayes, Lisa/0000-0003-3886-5977; Droin, Nathalie M/0000-0002-6099-5324; Green, Douglas R/0000-0002-7332-1417; Chipuk, Jerry Edward/0000-0002-1337-842X	NIAID NIH HHS [AI40646, AI47891] Funding Source: Medline; NIGMS NIH HHS [GM52735] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047891, R01AI040646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052735, R01GM052735] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHIPUK JE, UNPUB; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Vater CA, 1996, ONCOGENE, V13, P739; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	30	1562	1651	9	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1010	1014		10.1126/science.1092734	http://dx.doi.org/10.1126/science.1092734			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963330				2022-12-28	WOS:000188918000045
J	Kerns, JG; Cohen, JD; MacDonald, AW; Cho, RY; Stenger, VA; Carter, CS				Kerns, JG; Cohen, JD; MacDonald, AW; Cho, RY; Stenger, VA; Carter, CS			Anterior Cingulate conflict monitoring and adjustments in control	SCIENCE			English	Article							PREFRONTAL CORTEX; ERROR-DETECTION; BEHAVIOR	Conflict monitoring by the anterior cingulate cortex (ACC) has been posited to signal a need for greater cognitive control, producing neural and behavioral adjustments. However, the very occurrence of behavioral adjustments after conflict has been questioned, along with suggestions that there is no direct evidence of ACC conflict-related activity predicting subsequent neural or behavioral adjustments in control. Using the Stroop color-naming task and controlling for repetition effects, we demonstrate that ACC conflict-related activity predicts both greater prefrontal cortex activity and adjustments in behavior, supporting a role of ACC conflict monitoring in the engagement of cognitive control.	Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Missouri, Dept Psychol Sci, Columbia, MO 65211 USA; Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15213 USA; Univ Calif Davis, Dept Psychiat, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Psychol, Sacramento, CA 95817 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Missouri System; University of Missouri Columbia; Princeton University; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Davis; University of California System; University of California Davis	Carter, CS (corresponding author), Univ Pittsburgh, Dept Psychiat, 3811 Ohara St, Pittsburgh, PA 15213 USA.	cameron.carter@ucdmc.ucdavis.edu	Cho, Raymond/P-3028-2014; MacDonald, Angus/M-9855-2016	Cho, Raymond/0000-0003-1331-1409; MacDonald, Angus/0000-0003-4588-931X				Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Carter CS, 2000, P NATL ACAD SCI USA, V97, P1944, DOI 10.1073/pnas.97.4.1944; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; LAMING D, 1979, ACTA PSYCHOL, V43, P381, DOI 10.1016/0001-6918(79)90032-5; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; NORMAN DA, 1986, CONSCIOUSNESS SELF R, V4, pCH1; POSNER MI, 1998, ATTENTIVE BRAIN, pCH17; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rosenthal R., 1991, METAANALYTIC PROCEDU, DOI [10.2307/1175262, DOI 10.2307/1175262]; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837	23	2185	2241	5	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1023	1026		10.1126/science.1089910	http://dx.doi.org/10.1126/science.1089910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963333				2022-12-28	WOS:000188918000049
J	Samba, E; Nkrumah, F; Leke, R				Samba, E; Nkrumah, F; Leke, R			Getting polio eradication back on track in Nigeria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									WHO, Off Africa, Brazzaville, Rep Congo; Univ Ghana, Sch Med, Noguchi Mem Inst Med Res, Legon, Ghana; Univ Yaounde, Fac Med, Dept Immunol & Microbiol, Yaounde, Cameroon	World Health Organization; University of Ghana; University of Yaounde I	Samba, E (corresponding author), WHO, Off Africa, Brazzaville, Rep Congo.							Kapp D, 2003, LANCET, V362, P1631, DOI 10.1016/S0140-6736(03)14826-X; 2003, WKLY EPIDEMIOL REC, V78, P210	2	26	26	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					645	+		10.1056/NEJMp038210	http://dx.doi.org/10.1056/NEJMp038210			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960740				2022-12-28	WOS:000188869500004
J	Taylor, R				Taylor, R			Causation of type 2 diabetes - The Gordian knot unravels	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INSULIN-RESISTANCE; DYSFUNCTION		Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK	Taylor, R (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.			Taylor, Roy/0000-0001-6273-0170				Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889	5	37	40	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					639	641		10.1056/NEJMp038239	http://dx.doi.org/10.1056/NEJMp038239			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960738				2022-12-28	WOS:000188869500001
J	Lyeo, HK; Khajetoorians, AA; Shi, L; Pipe, KP; Ram, RJ; Shakouri, A; Shih, CK				Lyeo, HK; Khajetoorians, AA; Shi, L; Pipe, KP; Ram, RJ; Shakouri, A; Shih, CK			Profiling the thermoelectric power of semiconductor junctions with nanometer resolution	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; THERMOPOWER; FIGURE; MERIT	We have probed the local thermoelectric power of semiconductor nanostructures with the use of ultrahigh-vacuum scanning thermoelectric microscopy. When applied to a p-n junction, this method reveals that the thermoelectric power changes its sign abruptly within 2 nanometers across the junction. Because thermoelectric power correlates with electronic structure, we can pro. le with nanometer spatial resolution the thermoelectric power, band structures, and carrier concentrations of semiconductor junctions that constitute the building blocks of thermoelectric, electronic, and optoelectronic devices.	Univ Texas, Dept Mech Engn, Austin, TX 78712 USA; Univ Texas, Dept Phys, Austin, TX 78712 USA; Univ Texas, Ctr Nano & Mol Sci & Technol, Austin, TX 78712 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA; Univ Calif Santa Cruz, Dept Elect Engn, Santa Cruz, CA 95064 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Massachusetts Institute of Technology (MIT); University of California System; University of California Santa Cruz	Shi, L (corresponding author), Univ Texas, Dept Mech Engn, Austin, TX 78712 USA.	lishi@mail.utexas.edu; shih@physics.utexas.edu	Khajetoorians, Alexander A/F-9698-2015; Shi, Li/C-8123-2013	Shi, Li/0000-0002-5401-6839				BRESSE JF, 1988, J APPL PHYS, V64, P98, DOI 10.1063/1.341225; De Wolf P, 2000, J VAC SCI TECHNOL B, V18, P361, DOI 10.1116/1.591198; DiSalvo FJ, 1999, SCIENCE, V285, P703, DOI 10.1126/science.285.5428.703; EDWARDS H, 1999, WILEY ENCY ELECT ELE, V22, P80; Harman TC, 2002, SCIENCE, V297, P2229, DOI 10.1126/science.1072886; HICKS LD, 1993, PHYS REV B, V47, P12727, DOI 10.1103/PhysRevB.47.12727; HICKS LD, 1993, PHYS REV B, V47, P16631, DOI 10.1103/PhysRevB.47.16631; Jager ND, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.165307; Mahan G, 1997, PHYS TODAY, V50, P42, DOI 10.1063/1.881752; Pipe KP, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.125316; POLER JC, 1995, LANGMUIR, V11, P2689, DOI 10.1021/la00007a058; SHKLYAREVSKII OI, 1986, PHYS REV LETT, V57, P1374, DOI 10.1103/PhysRevLett.57.1374; Smit GDJ, 2002, APPL PHYS LETT, V81, P3852, DOI 10.1063/1.1521251; SMITH AR, 1994, J VAC SCI TECHNOL B, V12, P2610, DOI 10.1116/1.587218; TRZCINSKI R, 1986, PHYS REV LETT, V56, P1086, DOI 10.1103/PhysRevLett.56.1086; VATERLAUS A, 1993, J VAC SCI TECHNOL B, V11, P1502, DOI 10.1116/1.586959; VENHATASUBRAMAN.R, 2001, NATURE, V413, P597; WEBER L, 1992, PHYS REV B, V46, P9511, DOI 10.1103/PhysRevB.46.9511; WILLIAMS CC, 1990, NATURE, V344, P317, DOI 10.1038/344317a0	19	147	160	4	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					816	818		10.1126/science.1091600	http://dx.doi.org/10.1126/science.1091600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764872				2022-12-28	WOS:000188753800050
J	Kang, JX; Wang, JD; Wu, L; Kang, ZB				Kang, JX; Wang, JD; Wu, L; Kang, ZB			Transgenic mice - Fat-1 mice convert n-6 to n-3 fatty acids	NATURE			English	Editorial Material							EXPRESSION; DESATURASE		Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kang, JX (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.	kang.jing@mgh.harvard.edu						Kang ZB, 2001, P NATL ACAD SCI USA, V98, P4050, DOI 10.1073/pnas.061040198; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Simopoulos AP, 2003, WORLD REV NUTR DIET, V92, P1; SIMOPOULOS AP, 1998, WORLD REV NUTR DIET, V83; Spychalla JP, 1997, P NATL ACAD SCI USA, V94, P1142, DOI 10.1073/pnas.94.4.1142	7	434	470	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					504	504		10.1038/427504a	http://dx.doi.org/10.1038/427504a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765186	Bronze			2022-12-28	WOS:000188721800031
J	Nowak, MA				Nowak, MA			Prisoners of the dilemma - When mathematics and biology met on a mountain.	NATURE			English	Editorial Material									Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA	Harvard University	Nowak, MA (corresponding author), Harvard Univ, Program Evolutionary Dynam, 1 Brattle Sq, Cambridge, MA 02138 USA.		Nowak, Martin A/A-6977-2008						0	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 5	2004	427	6974					491	491		10.1038/427491a	http://dx.doi.org/10.1038/427491a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765175				2022-12-28	WOS:000188721800022
J	Upperman, JS; Barksdale, EM				Upperman, JS; Barksdale, EM			Congenital lymphedema	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Upperman, JS (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					E5	E5		10.1056/ENEJMicm010514	http://dx.doi.org/10.1056/ENEJMicm010514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762199				2022-12-28	WOS:000188712800012
J	Worley, P; Esterman, A; Prideaux, D				Worley, P; Esterman, A; Prideaux, D			Cohort study of examination performance of undergraduate medical students learning in community settings	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CURRICULUM; CARE	Objectives To determine whether moving clinical medical education out of the tertiary hospital into a community setting compromises academic standards. Design Cohort study. Setting Flinders University four year graduate entry medical course. In their third year, students are able to choose to study at the tertiary teaching hospital in Adelaide, in rural general practices, or at Royal Darwin Hospital, a regional secondary referral hospital. Participants All 371 medical students who did their year 3 study from 1998-2002. Main outcome measures Mean student examination score (%) at the end of year 3. Results The unadjusted mean year 3 scores at each location differed significantly (P < 0.001); the mean score was 65.2 (SE = 0.43) for Adelaide students, 68.2 (0.83) for Darwin students, and 69.3 (0.97) for students on the rural programme. Mean year 2 scores were similar for each location. Post hoc tests of means adjusted for sex, age, year 2 score, and cohort year showed that the rural and Darwin groups had a significantly improved score in year 3 compared with the Adelaide group (adjusted mean difference = 3.08, 95% confidence inter-vat 1.25 to 4.90, P < 0.001 for rural group; 1.91, 0.47 to 3.36, P = 0.001 for Darwin group). Conclusions These findings show that the concern that student academic performance in the tertiary hospital would be better than that of students in the regional hospital and community settings is not justified. This challenges the orthodoxy of a tertiary hospital education being die gold standard for undergraduate medical students.	Flinders Univ S Australia, Rural Clin Sch, Adelaide, SA 5001, Australia; Flinders Univ S Australia, Dept Gen Practice, Adelaide, SA 5001, Australia; Flinders Univ S Australia, Dept Med Educ, Adelaide, SA 5001, Australia	Flinders University South Australia; Flinders University South Australia; Flinders University South Australia	Worley, P (corresponding author), Flinders Univ S Australia, Rural Clin Sch, GPO Box 2100, Adelaide, SA 5001, Australia.	paul.worley@flinders.edu.au	Esterman, Adrian J/D-1042-2009	Prideaux, David/0000-0001-6695-2723; Esterman, Adrian/0000-0001-7324-9171				Finucane P, 2001, MED EDUC, V35, P56, DOI 10.1046/j.1365-2923.2001.00830.x; IRBY DM, 1995, ACAD MED, V70, P898, DOI 10.1097/00001888-199510000-00014; Murray E, 1997, BRIT MED J, V315, P920; Oswald N, 2001, MED EDUC, V35, P782, DOI 10.1046/j.1365-2923.2001.00981.x; Prideaux D, 2002, BRIT MED J, V324, P126, DOI 10.1136/bmj.324.7330.126; Worley P, 2000, MED EDUC, V34, P558, DOI 10.1046/j.1365-2923.2000.00668.x; 1989, LANCET, V1, P702	7	169	171	1	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	2004	328	7433					207	209		10.1136/bmj.328.7433.207	http://dx.doi.org/10.1136/bmj.328.7433.207			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739189	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188652200017
J	Reed, RR				Reed, RR			After the holy grail: Establishing a molecular basis for mammalian olfaction	CELL			English	Review							ODORANT RECEPTOR EXPRESSION; FUNCTIONAL EXPRESSION; SENSORY MAP; SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; GENOMIC ANALYSIS; TOPOGRAPHIC MAP; GENE-EXPRESSION; XENOPUS-LAEVIS; GATED CHANNEL	The quest to identify mammalian odorant receptors was a triumph of molecular biology. The characterization of these molecules has provided extraordinary insight into the strategy used by one neuronal system to organize sensory structures and code complex information. The odorant receptor genes have also served as powerful tools in understanding genomic organization and gene regulation.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet,Dept Neurosci, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Reed, RR (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet,Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	rreed@jhmi.edu						AMOORE JE, 1967, NATURE, V214, P1095, DOI 10.1038/2141095a0; Araneda RC, 2000, NAT NEUROSCI, V3, P1248, DOI 10.1038/81774; Aungst JL, 2003, NATURE, V426, P623, DOI 10.1038/nature02185; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; Belluscio L, 2001, J NEUROSCI, V21, P2113, DOI 10.1523/JNEUROSCI.21-06-02113.2001; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BOEKHOFF I, 1990, CELL SIGNAL, V2, P49, DOI 10.1016/0898-6568(90)90032-6; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Cutforth T, 2003, CELL, V114, P311, DOI 10.1016/S0092-8674(03)00568-3; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; Fox AN, 2001, P NATL ACAD SCI USA, V98, P14693, DOI 10.1073/pnas.261432998; Freitag J, 1995, NEURON, V15, P1383, DOI 10.1016/0896-6273(95)90016-0; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; GRIFF IC, 1995, CELL, V83, P407, DOI 10.1016/0092-8674(95)90118-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LANCET D, 1993, P NATL ACAD SCI USA, V90, P3715, DOI 10.1073/pnas.90.8.3715; Lane RP, 2002, GENOME RES, V12, P81, DOI 10.1101/gr.197901; Lane RP, 2001, P NATL ACAD SCI USA, V98, P7390, DOI 10.1073/pnas.131215398; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LEWCOCK JL, 2004, IN PRESS PNAS; LOWE G, 1989, P NATL ACAD SCI USA, V86, P5641, DOI 10.1073/pnas.86.14.5641; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Mefford HC, 2002, NAT REV GENET, V3, P91, DOI 10.1038/nrg727; Meister M, 2001, J NEUROSCI, V21, P1351; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; Niimura Y, 2003, P NATL ACAD SCI USA, V100, P12235, DOI 10.1073/pnas.1635157100; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; Qasba P, 1998, J NEUROSCI, V18, P227; Reed RR, 2000, NAT NEUROSCI, V3, P638, DOI 10.1038/76584; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; Strotmann J, 1996, CELL TISSUE RES, V284, P347, DOI 10.1007/s004410050595; Strotmann J, 2000, J NEUROSCI, V20, P6927, DOI 10.1523/JNEUROSCI.20-18-06927.2000; THOMAS L, 1983, NY TIMES, P1; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Treloar HB, 2002, J NEUROSCI, V22, P2469, DOI 10.1523/JNEUROSCI.22-07-02469.2002; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; WYSOCKI CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4899, DOI 10.1073/pnas.81.15.4899; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; Zhao HQ, 2001, CELL, V104, P651, DOI 10.1016/S0092-8674(02)01107-8; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X; Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506	65	49	50	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	2004	116	2					329	336		10.1016/S0092-8674(04)00047-9	http://dx.doi.org/10.1016/S0092-8674(04)00047-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	768KG	14744441	Bronze			2022-12-28	WOS:000188541700020
J	Dickens, AF; Gelinas, Y; Masiello, CA; Wakeham, S; Hedges, JI				Dickens, AF; Gelinas, Y; Masiello, CA; Wakeham, S; Hedges, JI			Reburial of fossil organic carbon in marine sediments	NATURE			English	Article							BLACK CARBON; MATTER PRESERVATION; VARIABILITY; DEGRADATION; SEA	Marine sediments act as the ultimate sink for organic carbon, sequestering otherwise rapidly cycling carbon for geologic time-scales(1,2). Sedimentary organic carbon burial appears to be controlled by oxygen exposure time in situ(3,4), and much research has focused on understanding the mechanisms of preservation of organic carbon(5). In this context, combustion- derived black carbon has received attention as a form of refractory organic carbon that may be preferentially preserved in soils(6,7) and sediments(8,9). However, little is understood about the environmental roles, transport and distribution of black carbon. Here we apply isotopic analyses to graphitic black carbon samples isolated from pre- industrial marine and terrestrial sediments. We find that this material is terrestrially derived and almost entirely depleted of radiocarbon, suggesting that it is graphite weathered from rocks, rather than a combustion product. The widespread presence of fossil graphitic black carbon in sediments has therefore probably led to significant overestimates of burial of combustion-derived black carbon in marine sediments. It could be responsible for biasing radiocarbon dating of sedimentary organic carbon, and also reveals a closed loop in the carbon cycle. Depending on its susceptibility to oxidation, this recycled carbon may be locked away from the biologically mediated carbon cycle for many geologic cycles.	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada; CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Calif Santa Barbara, Dept Geog, Santa Barbara, CA 93106 USA; Skidaway Inst Oceanog, Savannah, GA 31411 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Concordia University - Canada; California Institute of Technology; University of California System; University of California Santa Barbara; University System of Georgia; University of Georgia; Skidaway Institute of Oceanography	Dickens, AF (corresponding author), Univ Washington, Sch Oceanog, Box 355351, Seattle, WA 98195 USA.	dickensa@u.washington.edu	Gélinas, Yves/K-4019-2013; Masiello, Caroline/A-2653-2011	Gélinas, Yves/0000-0001-5751-8378; Masiello, Caroline/0000-0003-2102-6229; Dickens, Angela/0000-0001-8433-5913				BERNER RA, 1989, PALAEOGEOGR PALAEOCL, V75, P97, DOI DOI 10.1016/0031-0182(89)90186-7; Blair NE, 2003, GEOCHIM COSMOCHIM AC, V67, P63, DOI 10.1016/S0016-7037(02)01043-8; CARPENTER R, 1987, GEOCHIM COSMOCHIM AC, V51, P1897, DOI 10.1016/0016-7037(87)90181-5; DRUFFEL ERM, 1984, EARTH PLANET SC LETT, V71, P205, DOI 10.1016/0012-821X(84)90087-6; Eglinton TI, 1997, SCIENCE, V277, P796, DOI 10.1126/science.277.5327.796; Eglinton TI, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000269; Gelinas Y, 2001, ENVIRON SCI TECHNOL, V35, P3519, DOI 10.1021/es010504c; Goldberg E.D., 1985, BLACK CARBON ENV PRO; Hartnett HE, 1998, NATURE, V391, P572, DOI 10.1038/35351; Hedges JI, 2000, ORG GEOCHEM, V31, P945, DOI 10.1016/S0146-6380(00)00096-6; Hedges JI, 1999, AM J SCI, V299, P529, DOI 10.2475/ajs.299.7-9.529; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; HERRING JR, 1985, CARBON CYCLE ATMOSPH, P419; Jahnke RA, 1996, GLOBAL BIOGEOCHEM CY, V10, P71, DOI 10.1029/95GB03525; Masiello CA, 1998, SCIENCE, V280, P1911, DOI 10.1126/science.280.5371.1911; Middelburg JJ, 1999, MAR CHEM, V65, P245, DOI 10.1016/S0304-4203(99)00005-5; Petsch ST, 2000, ORG GEOCHEM, V31, P475, DOI 10.1016/S0146-6380(00)00014-0; Petsch ST, 2001, GEOCHIM COSMOCHIM AC, V65, P1867, DOI 10.1016/S0016-7037(01)00572-5; PRAHL FG, 1984, ESTUAR COAST SHELF S, V18, P703, DOI 10.1016/0272-7714(84)90040-4; SACKETT WM, 1974, SCIENCE, V185, P1045, DOI 10.1126/science.185.4156.1045; Schidlowski M, 2001, PRECAMBRIAN RES, V106, P117, DOI 10.1016/S0301-9268(00)00128-5; Schmidt MWI, 1999, EUR J SOIL SCI, V50, P351, DOI 10.1046/j.1365-2389.1999.00236.x; Schmidt MWI, 2000, GLOBAL BIOGEOCHEM CY, V14, P777, DOI 10.1029/1999GB001208; Skjemstad JO, 1999, COMMUN SOIL SCI PLAN, V30, P2283, DOI 10.1080/00103629909370372; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Suman D.O., 1997, NATO ASI SERIES GLOB, P271, DOI [10.1007/978-3-642-59171-6_12, DOI 10.1007/978-3-642-59171-6_12]; VOGEL JS, 1987, RADIOCARBON, V29, P323; Wakeham SG, 1997, GEOCHIM COSMOCHIM AC, V61, P5363, DOI 10.1016/S0016-7037(97)00312-8; WAKEHAM SG, IN PRESS ENV SCI TEC; WEIS PL, 1981, GEOCHIM COSMOCHIM AC, V45, P2325, DOI 10.1016/0016-7037(81)90086-7	30	202	244	5	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					336	339		10.1038/nature02299	http://dx.doi.org/10.1038/nature02299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737163				2022-12-28	WOS:000188266200036
J	Koreny, M; Riedmuller, E; Nikfardjam, M; Siostrzonek, P; Mullner, M				Koreny, M; Riedmuller, E; Nikfardjam, M; Siostrzonek, P; Mullner, M			Arterial puncture closing devices compared with standard manual compression after cardiac catheterization - Systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							VASCULAR HEMOSTASIS DEVICE; SUTURE-MEDIATED CLOSURE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED-TRIAL; FEMORAL ACCESS; DIAGNOSTIC ANGIOGRAPHY; COLLAGEN; COMPLICATIONS; SITE; SAFETY	Context Arterial puncture closing devices (APCDs) were developed to replace standard compression at the puncture site and to shorten bed rest following percutaneous coronary intervention. Objective. To assess the safety and efficacy of APCDs (Angioseal, Vasoseal, Duett, Perclose, Techstar, Prostar) compared with standard manual compression in patients undergoing coronary angiography or percutaneous vascular interventions. Data Sources A systematic literature search of MEDLINE (1966-January 2003), EMBASE (1989-January 2003), PASCAL (1996-January 2003), BIOSIS (1990-January. 2003), and CINHAL (1982-January 2003) databases and the Cochrane Central Register of Controlled Trial for relevant articles in any language. Study Selection Included randomized controlled trials reporting vascular complications at the puncture site (hematoma, bleeding, arteriovenous fistula, pseudoaneurysm) and efficacy (time to hemostasis, time to ambulation, time to discharge from hospital). Data Extraction Two reviewers abstracted the data independently and in duplicate. Disagreements were resolved by discussion among at least 3 reviewers. The most important criteria were adequacy of allocation concealment, whether the analysis was according to the intention-to-treat principle, and if person assessing the outcome was blinded to intervention group. Random-effects models were used to pool the data. Data Synthesis Thirty trials met the selection criteria and included up to 4000 patients. When comparing any APCD with standard compression, the relative risk (RR) of groin hematoma was 1.14 (95% confidence interval [CI], 0.86-1.51; P=35); bleeding, 1.48 (95% Cl, 0.88-2.48; P=.14); developing an arteriovenous fistula, 0.83 (95% CI, 0.23-2.94; P=.77); and developing a pseudoaneurysm at the puncture site, 1.19 (95% Cl, 0.75-1.88; P=.46) Time to hemostasis was shorter in the group with APCD compared with standard compression (mean difference, 17 minutes; range, 14-19 minutes), but there was a high degree of heterogeneity among studies. Only 2 studies explicitly reported allocation concealment, blinded outcome assessment, and intention-to-treat analysis. When limiting analyses to only trials that used explicit intention-to-treat approaches, APCDs were associated with a higher risk of hematoma (RR, 1.89; 95% Cl, 1.13-3.15) and a higher risk of pseudoaneurysm (RR, 5.40; 95% Cl, 1.21-24.5). Conclusions Based on this meta-analysis of 30 randomized trials, many of poor methodological quality, there is only marginal evidence that APCDs are effective and there is reason for concern that these devices may increase the risk of hematoma and pseudoaneurysm.	Univ Vienna, Vienna Gen Hosp, Dept Emergency Med, Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Internal Med 2, Div Cardiol, Vienna, Austria; KH Barmherzige Schwestern, Dept Internal Med, Linz, Austria	University of Vienna; University of Vienna	Mullner, M (corresponding author), Med Univ Wien, Univ Klin Notfallmed, Allgemeines Krankenhaus Wien, Wahringer Gurtel 18-20-6D, Vienna, Austria.	marcus.muellner@univie.ac.at						*ACC, ACC NAT CARD DAT REG; Applegate RJ, 2002, J AM COLL CARDIOL, V40, P78, DOI 10.1016/S0735-1097(02)01924-1; Baim DS, 2000, AM J CARDIOL, V85, P864, DOI 10.1016/S0002-9149(99)00882-6; Bos JJ, 1996, J VASC INTERV RADIOL, V7, P479, DOI 10.1016/S1051-0443(96)70788-1; Brachmann J, 1998, AM J CARDIOL, V81, P1502, DOI 10.1016/S0002-9149(98)00221-5; BROWN CL, 1997, CIRCULATION S, V96, P618; CAMENZIND E, 1994, J AM COLL CARDIOL, V24, P655, DOI 10.1016/0735-1097(94)90011-6; Chevalier B, 2000, EUR HEART J, V21, P642; Chevalier B, 1999, CIRCULATION, V100, P447; CONDON JV, 1995, CIRCULATION, V92, P2867; COPE G, 1994, AUST NZ J MED, V24, P650; Dangas G, 2001, J AM COLL CARDIOL, V38, P638, DOI 10.1016/S0735-1097(01)01449-8; DESWART H, 1994, J AM COLL CARDIOL, pA355; Doneux P, 2001, EUR HEART J, V22, P216; DOUGLAS JJ, 2001, HURSTS HEART MANUAL, P327; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; el Amine S, 1999, ARCH MAL COEUR VAISS, V92, P1447; Ellis SG, 2002, AM HEART J, V143, P612, DOI 10.1067/mhj.2002.121464; Gerckens U, 1999, AM J CARDIOL, V83, P1658, DOI 10.1016/S0002-9149(99)00174-5; GIBBS HH, 1993, AUST NZ J MED, V23, P628; Gwechenberger M, 1997, ANGIOLOGY, V48, P121, DOI 10.1177/000331979704800204; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; KUSSMAUL WG, 1995, J AM COLL CARDIOL, V25, P1685, DOI 10.1016/0735-1097(95)00101-9; Landis Dawn, 1997, European Heart Journal, V18, P232; Magosaki N, 1999, J Cardiol, V34, P131; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Murray CR, 1996, CIRCULATION, V94, P2192; NASSER TK, 1995, CLIN CARDIOL, V18, P609, DOI 10.1002/clc.4960181105; Noguchi T, 2000, EUR J VASC ENDOVASC, V19, P451, DOI 10.1053/ejvs.1999.1071; OMOIGUI NA, 1995, J AM COLL CARDIOL, V26, P922, DOI 10.1016/0735-1097(95)00263-4; Resnic FS, 2001, AM J CARDIOL, V88, P493, DOI 10.1016/S0002-9149(01)01725-8; Rickli H, 2002, CATHETER CARDIO INTE, V57, P297, DOI 10.1002/ccd.10294; SANBORN TA, 1993, J AM COLL CARDIOL, V22, P1273, DOI 10.1016/0735-1097(93)90529-A; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Seidelin PH, 1997, J INTERV CARDIOL, V10, P409, DOI 10.1111/j.1540-8183.1997.tb00065.x; SIEVERT H, 1999, Z KARDIOLOGIE S2, V88, P108; Silber S, 1998, CATHETER CARDIO DIAG, V43, P421, DOI 10.1002/(SICI)1097-0304(199804)43:4<421::AID-CCD13>3.0.CO;2-M; Silber S, 1998, AM HEART J, V135, P152, DOI 10.1016/S0002-8703(98)70356-4; SLAUGHTER PMP, 1995, CATHETER CARDIO DIAG, V34, P210, DOI 10.1002/ccd.1810340106; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; Tron C., 1998, European Heart Journal, V19, P392; VONHOCH F, 1995, EUR HEART J, V16, P640, DOI 10.1093/oxfordjournals.eurheartj.a060967; WAKSMAN R, 1995, AM J CARDIOL, V75, P886, DOI 10.1016/S0002-9149(99)80681-X; Ward SR, 1998, AM J CARDIOL, V81, P569, DOI 10.1016/S0002-9149(97)00970-3; Zhang Z, 2001, AM HEART J, V142, P982, DOI 10.1067/mhj.2001.118742	45	407	430	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					350	357		10.1001/jama.291.3.350	http://dx.doi.org/10.1001/jama.291.3.350			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734598				2022-12-28	WOS:000188243100035
J	Minelli, C; Abrams, KR; Sutton, AJ; Cooper, NJ				Minelli, C; Abrams, KR; Sutton, AJ; Cooper, NJ			Benefits and harms associated with hormone replacement therapy: clinical decision analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; ESTROGEN PLUS PROGESTIN; CORONARY-ARTERY DISEASE; UP HERS-II; POSTMENOPAUSAL WOMEN; ESTROGEN/PROGESTIN REPLACEMENT; BREAST-CANCER; COST-EFFECTIVENESS; ATRIAL-FIBRILLATION; RANDOMIZED TRIALS	Objective To evaluate harms and benefits associated with use of combined hormone replacement therapy (HRT) for five years in women with different baseline risks for breast cancer. Design Probabilistic clinical decision analysis. Setting Hypothetical population of white UK women aged 50 years with different baseline risks for breast cancer. Main outcome measure Gain or loss in quality adjusted life years (QALYs). Results Women free of menopausal symptoms showed a net harm from HRT use, which increased for increasing baseline risk of breast cancer. Those with a baseline risk of 1.2% would expect a loss in QALYs of 0.4 months (-0.03 QALYs, 95% credibility interval -0.05 to -0.01). The main analysis showed HRT to be on average beneficial in women with symptoms, with benefit decreasing with increasing baseline risk of breast cancer. The results were sensitive to the assumed value of quality of life with menopausal symptoms, therefore a contour plot was developed to show the probability of net harm for a range of different values and baseline risks. Conclusions HRT for primary prevention of chronic diseases in women without menopausal symptoms is unjustified. Perceived quality of life in women with symptoms should be taken into account when deciding on HRT. Thus, a decision analysis tailored to an individual woman is more appropriate in clinical practice than a population based approach.	Univ Leicester, Dept Hlth Sci, Ctr Biostat & Genet Epidemiol, Leicester LE1 6TP, Leics, England	University of Leicester	Abrams, KR (corresponding author), Univ Leicester, Dept Hlth Sci, Ctr Biostat & Genet Epidemiol, Leicester LE1 6TP, Leics, England.	keith.abrams@le.ac.uk	Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567; Sutton, Alexander/0000-0002-8934-9940				Armstrong K, 2001, OBSTET GYNECOL, V98, P996, DOI 10.1016/S0029-7844(01)01624-6; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Col NF, 1999, ARCH INTERN MED, V159, P1458, DOI 10.1001/archinte.159.13.1458; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Daly E, 1996, MATURITAS, V23, P247, DOI 10.1016/0378-5122(95)00978-7; DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gallus S, 2002, INT J CANCER, V99, P762, DOI 10.1002/ijc.10411; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; Gold MR, 1996, COST EFFECTIVENESS H; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hill DA, 2000, AM J OBSTET GYNECOL, V183, P1456, DOI 10.1067/mob.2000.108081; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; HOGERVORST E, 2004, COCHRANE LIB; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; LETHABY A, 2004, COCHRANE LIB; MacLennan A, 2004, COCHRANE LIB; *MED HEALTHC PROD, REG AG US HORM REPL; *MED HEALTHC PROD, US HORM REPL THER PR; Melsop KA, 2003, AM HEART J, V145, P36, DOI 10.1067/mhj.2003.37; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Neymark N, 1998, EUR J CANCER, V34, P1317, DOI 10.1016/S0959-8049(98)00074-4; *OFF NAT STAT, 2001, SOC TRENDS, V31, pCH7; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, DOI DOI 10.1002/0470092602; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Sturdee DW, 2000, BRIT J OBSTET GYNAEC, V107, P1392, DOI 10.1111/j.1471-0528.2000.tb11654.x; SUTTON AJ, 2004, 0401 U LEIC DEP HLTH; Tengs TO, 2000, MED CARE, V38, P583, DOI 10.1097/00005650-200006000-00004; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Uhler ML, 2000, MENOPAUSE, V7, P162, DOI 10.1097/00042192-200007030-00006; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; White C, 2002, BRIT MED J, V325, P987, DOI 10.1136/bmj.325.7371.987; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x; Zethraeus N, 1999, INT J TECHNOL ASSESS, V15, P352, DOI 10.1017/S0266462399015275	55	36	38	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					371	375		10.1136/bmj.328.7436.371	http://dx.doi.org/10.1136/bmj.328.7436.371			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962874	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000189031300017
J	Pack, A; Shelley, JMG; Palme, H				Pack, A; Shelley, JMG; Palme, H			Chondrules with peculiar REE patterns: Implications for solar nebular condensation at high C/O	SCIENCE			English	Article							ALUMINUM-RICH INCLUSIONS; UNEQUILIBRATED ENSTATITE CHONDRITES; RARE-EARTH ELEMENTS; FRACTIONATION; CHEMISTRY; MINERALOGY; ORIGIN	Rare earth element (REE) data from two ordinary chondrite chondrules show distinct negative chondrite-normalized concentration anomalies of samarium, europium, and ytterbium. The peculiar patterns may be the result of REE gas/solid fractionation at an oxygen fugacity lower than has been assumed for the canonical solar nebula. We suggest that the two ordinary chondrite chondrules acquired the fractionated REE patterns by incorporation of highly reduced, ultrarefractory condensates in their precursors. This interpretation implies that high-temperature condensation processes occurred in nebular environments with a strong deficit in oxygen, such as regions with an enhanced carbon/oxygen ratio.	Univ Cologne, Inst Mineral & Geochem, D-50674 Cologne, Germany; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; CNRS, Ctr Rech Petrog & Geochim, F-54501 Vandoeuvre Les Nancy, France	University of Cologne; Australian National University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Pack, A (corresponding author), Univ Cologne, Inst Mineral & Geochem, Zulpicher Str 49B, D-50674 Cologne, Germany.	apack@crpg.cnrs-nancy.fr		Pack, Andreas/0000-0002-2618-2768				ALEXANDER CMO, 1994, GEOCHIM COSMOCHIM AC, V58, P3451, DOI 10.1016/0016-7037(94)90098-1; Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; [Anonymous], 1983, RARE EARTH ELEMENT G; Boynton W. V., 1980, LUNAR PLANET SCI, V11, P103; BOYNTON WV, 1975, GEOCHIM COSMOCHIM AC, V39, P569, DOI 10.1016/0016-7037(75)90003-4; CROZAZ G, 1995, GEOCHIM COSMOCHIM AC, V59, P3817, DOI 10.1016/0016-7037(95)00268-5; DAVIS AM, 1979, GEOCHIM COSMOCHIM AC, V43, P1611, DOI 10.1016/0016-7037(79)90181-9; Ebel DS, 2000, GEOCHIM COSMOCHIM AC, V64, P339, DOI 10.1016/S0016-7037(99)00284-7; El Goresy A, 2002, GEOCHIM COSMOCHIM AC, V66, P1459, DOI 10.1016/S0016-7037(01)00854-7; Fagan TJ, 2000, METEORIT PLANET SCI, V35, P771, DOI 10.1111/j.1945-5100.2000.tb01461.x; Grossman JN, 2002, METEORIT PLANET SCI, V37, P49, DOI 10.1111/j.1945-5100.2002.tb00795.x; GROSSMAN L, 1988, NATURE, V334, P14; Guan YB, 2000, SCIENCE, V289, P1330, DOI 10.1126/science.289.5483.1330; Hsu WB, 1998, GEOCHIM COSMOCHIM AC, V62, P1993, DOI 10.1016/S0016-7037(98)00124-0; Jones R. H., 2000, Protostars and planets 4, P927; Krot A. N., 2000, Protostars and planets 4, P1019; KURAT G, 1984, EARTH PLANET SC LETT, V68, P43, DOI 10.1016/0012-821X(84)90139-0; LARIMER JW, 1979, GEOCHIM COSMOCHIM AC, V43, P1455, DOI 10.1016/0016-7037(79)90140-6; Lodders K, 2003, ASTROPHYS J, V591, P1220, DOI 10.1086/375492; LODDERS K, 1993, EARTH PLANET SC LETT, V117, P125, DOI 10.1016/0012-821X(93)90122-P; Mason B., 1977, SMITHSON CONTRIB EAR, V19, P84; MCPHERSON GJ, 1988, METEORITES EARLY SOL, P746; MISAWA K, 1988, GEOCHIM COSMOCHIM AC, V52, P1699, DOI 10.1016/0016-7037(88)90238-4; MISAWA K, 1988, NATURE, V334, P47, DOI 10.1038/334047a0; Nakamura N., 1993, PRIMITIVE SOLAR NEBU, P409; Nakano H, 2003, ASTROPHYS J, V592, P1252, DOI 10.1086/375856; PACK A, IN PRESS GEOCHIM COS; PALME H, 1982, EARTH PLANET SC LETT, V61, P1, DOI 10.1016/0012-821X(82)90032-2; Simon SB, 2002, METEORIT PLANET SCI, V37, P533, DOI 10.1111/j.1945-5100.2002.tb00837.x; Varela ME, 2002, GEOCHIM COSMOCHIM AC, V66, P1663, DOI 10.1016/S0016-7037(01)00871-7	31	36	36	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	2004	303	5660					997	1000		10.1126/science.1092906	http://dx.doi.org/10.1126/science.1092906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963326				2022-12-28	WOS:000188918000041
J	Solomon, CG; Seely, EW				Solomon, CG; Seely, EW			Preeclampsia - Searching for the cause	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PREVENT PREECLAMPSIA		Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Solomon, CG (corresponding author), Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA.							Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189	3	69	73	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					641	642		10.1056/NEJMp038241	http://dx.doi.org/10.1056/NEJMp038241			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14764924				2022-12-28	WOS:000188869500002
J	Seddon, JM; Gensler, G; Milton, RC; Klein, ML; Rifai, N				Seddon, JM; Gensler, G; Milton, RC; Klein, ML; Rifai, N			Association between C-reactive protein and age-related macular degeneration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; DIETARY-FAT; EYE DISEASE; VITAMIN-C; INFLAMMATION; PROGRESSION; MODEL; AREDS	Context C-reactive protein (CRP) is a systemic inflammatory marker associated with risk for cardiovascular disease (CVD). Some risk factors for CVD are associated with age-related macular degeneration (AMD), but the association between CRP and AMD is unknown. Objective To test the hypothesis that elevated CRP levels are associated with an increased risk for AMD. Design, Setting, and Participants A total of 930 (91%) of 1026 participants at 2 centers in the Age-Related Eye Disease Study (AREDS), a multicenter randomized trial of antioxidant vitamins and minerals, were enrolled in this case-control study. There were 183 individuals without any maculopathy, 200 with mild maculopathy, 325 with intermediate disease, and 222 with advanced AMD (geographic atrophy or neovascular AMD). The AMD status was assessed by standardized grading of fundus photographs, and stored fasting blood specimens drawn between January 1996 and April 1997 were analyzed for high-sensitivity CRP levels. Main Outcome Measure Association between CRP and AMD. Results The CRP levels were significantly higher among participants with advanced AMD (case patients) than among those with no AMD (controls; median values, 3.4 vs 2.7 mg/L; P=.02). After adjustment for age, sex, and other variables, including smoking and body mass index, CRP levels were significantly associated with the presence of intermediate and advanced stages of AMD. The odds ratio (OR) for the highest vs the lowest quartile of CRP was 1.65 (95% confidence interval [0], 1.07-2.55; P for trend =.02). The OR for CRP values at or above the 90th percentile (10.6 mg/L) was 1.92 (95% Cl, 1.20-3.06), and the OR for CRP values at or above the mean plus 2 SDs (16.8 mg/L) was 2.03 (95% Cl, 1.03-4.00). A trend for an increased risk for intermediate and advanced AMD with higher levels of CRP was seen for smokers (OR, 2.16; 95% Cl, 1.33-3.49) and those who never smoked (OR, 2.03; 95% Cl, 1.19-3.46) with the highest level of CRP. Conclusion Our results suggest that elevated CRP level is an independent risk factor for AMD and may implicate the role of inflammation in the pathogenesis of AMD.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Epidemiol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; EMMES Corp, Rockville, MD USA; Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard T.H. Chan School of Public Health; Emmes Corporation; Oregon Health & Science University; Harvard University; Boston Children's Hospital; Harvard Medical School	Seddon, JM (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.	Johanna_Seddon@meei.harvard.edu			NEI NIH HHS [R01EY13982, N01EY02117, N01EY02126] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013982, N01EY002117, N01EY002126] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Cho E, 2001, AM J CLIN NUTR, V73, P209; Hawkins B, 2001, OCULAR HISTOPLASMOSI, V2, P1687; Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8; McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353; Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728; Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701	21	330	347	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					704	710		10.1001/jama.291.6.704	http://dx.doi.org/10.1001/jama.291.6.704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871913	Bronze			2022-12-28	WOS:000188819200023
J	Buchbinder, R; Jolley, D				Buchbinder, R; Jolley, D			Population based intervention to change back pain beliefs: three year follow up population survey	BRITISH MEDICAL JOURNAL			English	Article									Cabrini Hosp, Dept Clin Epidemiol, Malvern, Vic 3144, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Malvern, Vic 3144, Australia; Deakin Univ, Sch Hlth Sci, Burwood, Vic 3125, Australia	Cabrini Health; Monash University; Deakin University	Buchbinder, R (corresponding author), Cabrini Hosp, Dept Clin Epidemiol, Suite 41,Cabrini Med Ctr,183 Wattletree Rd, Malvern, Vic 3144, Australia.	rachelle.buchbinder@med.monash.edu.au	Buchbinder, Rachelle/G-2952-2011	Buchbinder, Rachelle/0000-0002-0597-0933				Buchbinder R, 2001, BRIT MED J, V322, P1516, DOI 10.1136/bmj.322.7301.1516; Buchbinder R, 2001, SPINE, V26, P2535, DOI 10.1097/00007632-200112010-00005; Buchbinder R, 2003, PREVENTING MANAGING; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Symonds TL, 1995, SPINE, V20, P2738, DOI 10.1097/00007632-199512150-00016	5	85	88	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2004	328	7435					321	321		10.1136/bmj.328.7435.321	http://dx.doi.org/10.1136/bmj.328.7435.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764492	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188926900019
J	Majumdar, A				Majumdar, A			Thermoelectricity in semiconductor nanostructures	SCIENCE			English	Editorial Material							DEVICES; FIGURE; MERIT		Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Majumdar, A (corresponding author), Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.	majumdar@me.berkeley.edu		Majumdar, Arunava/0000-0003-4226-9705				Cahill DG, 2003, J APPL PHYS, V93, P793, DOI 10.1063/1.1524305; DiSalvo FJ, 1999, SCIENCE, V285, P703, DOI 10.1126/science.285.5428.703; Harman TC, 2002, SCIENCE, V297, P2229, DOI 10.1126/science.1072886; HICKS LD, 1993, PHYS REV B, V47, P12727, DOI 10.1103/PhysRevB.47.12727; HICKS LD, 1993, PHYS REV B, V47, P16631, DOI 10.1103/PhysRevB.47.16631; Hsu KF, 2004, SCIENCE, V303, P818, DOI 10.1126/science.1092963; Li DY, 2003, APPL PHYS LETT, V83, P3186, DOI 10.1063/1.1619221; Lyeo HK, 2004, SCIENCE, V303, P816, DOI 10.1126/science.1091600; Mahan G, 1997, PHYS TODAY, V50, P42, DOI 10.1063/1.881752; Venkatasubramanian R, 2001, NATURE, V413, P597, DOI 10.1038/35098012	10	820	859	14	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	2004	303	5659					777	778		10.1126/science.1093164	http://dx.doi.org/10.1126/science.1093164			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764859				2022-12-28	WOS:000188753800037
J	Jauhar, S				Jauhar, S			Retrospective - The artificial heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU Med Ctr, New York, NY 10016 USA	New York University	Jauhar, S (corresponding author), NYU Med Ctr, New York, NY 10016 USA.							DEVRIES WC, 1984, NEW ENGL J MED, V310, P273, DOI 10.1056/NEJM198402023100501	1	6	6	1	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					542	544		10.1056/NEJMp038244	http://dx.doi.org/10.1056/NEJMp038244			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762180				2022-12-28	WOS:000188712800004
J	Mason, N; Biercuk, MJ; Marcus, CM				Mason, N; Biercuk, MJ; Marcus, CM			Local gate control of a carbon nanotube double quantum dot	SCIENCE			English	Article							ELECTRON-TRANSPORT; COULOMB-BLOCKADE; DEFECTS; CONDUCTANCE; COMPUTATION; SPECTRUM; STATES; WIRES	We have measured carbon nanotube quantum dots with multiple electrostatic gates and used the resulting enhanced control to investigate a nanotube double quantum dot. Transport measurements reveal honeycomb charge stability diagrams as a function of two nearly independent gate voltages. The device can be tuned from weak to strong interdot tunnel-coupling regimes, and the transparency of the leads can be controlled independently. We extract values of energy-level spacings, capacitances, and interaction energies for this system. This ability to control electron interactions in the quantum regime in a molecular conductor is important for applications such as quantum computation.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University	Mason, N (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	nmason@fas.harvard.edu; marcus@harvard.edu	Marcus, Charles M./M-4526-2014; Biercuk, Michael J/B-4768-2010	Marcus, Charles M./0000-0003-2420-4692; Biercuk, Michael J/0000-0002-4371-2580				BIERCUK MJ, 2003, IN PRESS NANO L 1119; Bockrath M, 2001, SCIENCE, V291, P283, DOI 10.1126/science.291.5502.283; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Chico L, 1996, PHYS REV B, V54, P2600, DOI 10.1103/PhysRevB.54.2600; Choi HJ, 2000, PHYS REV LETT, V84, P2917, DOI 10.1103/PhysRevLett.84.2917; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; DiVincenzo DP, 2000, NATURE, V408, P339, DOI 10.1038/35042541; Fujisawa T, 1998, SCIENCE, V282, P932, DOI 10.1126/science.282.5390.932; Hone J, 2000, SCIENCE, V289, P1730, DOI 10.1126/science.289.5485.1730; Ishibashi K, 2001, APPL PHYS LETT, V79, P1864, DOI 10.1063/1.1403295; Kaminski A, 1999, PHYS REV B, V59, P9798, DOI 10.1103/PhysRevB.59.9798; Kong J, 2000, APPL PHYS LETT, V77, P3977, DOI 10.1063/1.1331088; Kostyrko T, 1999, PHYS REV B, V59, P3241, DOI 10.1103/PhysRevB.59.3241; KOUWENHOVEN LP, 1997, MESOSCOPIC ELECT TRA; Lefebvre J, 1999, APPL PHYS LETT, V75, P3014, DOI 10.1063/1.125218; Livermore C, 1996, SCIENCE, V274, P1332, DOI 10.1126/science.274.5291.1332; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Matveev KA, 1996, PHYS REV B, V54, P5637, DOI 10.1103/PhysRevB.54.5637; Odom TW, 2000, J PHYS CHEM B, V104, P2794, DOI 10.1021/jp993592k; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; van der Wiel WG, 2003, REV MOD PHYS, V75, P1, DOI 10.1103/RevModPhys.75.1; VANDERVAART NC, 1995, PHYS REV LETT, V74, P4702, DOI 10.1103/PhysRevLett.74.4702; Vavro J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.065503; Wind SJ, 2002, APPL PHYS LETT, V80, P3817, DOI 10.1063/1.1480877; YU DVA, 1992, SINGLE CHARGE TUNNEL	25	169	170	4	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					655	658		10.1126/science.1093605	http://dx.doi.org/10.1126/science.1093605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752156				2022-12-28	WOS:000188530800035
J	Nittler, LR				Nittler, LR			Nuclear fossils in stardust	SCIENCE			English	Editorial Material							SILICON-CARBIDE GRAINS; METEORITES; ZIRCONIUM; BARIUM; STARS		Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	Carnegie Institution for Science	Nittler, LR (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.	lrn@dtm.ciw.edu						ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; Lugaro M, 2003, ASTROPHYS J, V593, P486, DOI 10.1086/376442; MERRILL PW, 1952, SCIENCE, V115, P484; Nicolussi GK, 1997, SCIENCE, V277, P1281, DOI 10.1126/science.277.5330.1281; Nittler LR, 2003, EARTH PLANET SC LETT, V209, P259, DOI 10.1016/S0012-821X(02)01153-6; Savina MR, 2004, SCIENCE, V303, P649, DOI 10.1126/science.3030649; Savina MR, 2003, GEOCHIM COSMOCHIM AC, V67, P3201, DOI 10.1016/S0016-7037(03)00083-8; Treffers R., 1974, Astrophysical Journal, V188, P545, DOI 10.1086/152746; Zinner E, 2003, SCIENCE, V300, P265, DOI 10.1126/science.1080300	10	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	2004	303	5658					636	637		10.1126/science.1091478	http://dx.doi.org/10.1126/science.1091478			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14752151				2022-12-28	WOS:000188530800029
J	Napolitano, LM				Napolitano, LM			Retroperitoneal sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Napolitano, LM (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					493	493		10.1056/NEJMicm960317	http://dx.doi.org/10.1056/NEJMicm960317			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749458				2022-12-28	WOS:000188463900012
J	Frey, SE; Belshe, RB				Frey, SE; Belshe, RB			Poxvirus zoonoses - Putting pocks into context	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Louis Univ, Div Infect Dis & Immunol, St Louis, MO 63103 USA	Saint Louis University	Frey, SE (corresponding author), St Louis Univ, Div Infect Dis & Immunol, St Louis, MO 63103 USA.								0	19	20	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					324	327		10.1056/NEJMp038208	http://dx.doi.org/10.1056/NEJMp038208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736922				2022-12-28	WOS:000188254800002
J	Ferreira, KN; Iverson, TM; Maghlaoui, K; Barber, J; Iwata, S				Ferreira, KN; Iverson, TM; Maghlaoui, K; Barber, J; Iwata, S			Architecture of the photosynthetic oxygen-evolving center	SCIENCE			English	Article							WATER-OXIDIZING COMPLEX; AMINO-ACID-RESIDUES; SITE-DIRECTED MUTAGENESIS; PRIMARY CHARGE SEPARATION; PRIMARY ELECTRON-DONOR; II REACTION-CENTER; PHOTOSYSTEM-II; BETA-CAROTENE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION	Photosynthesis uses light energy to drive the oxidation of water at an oxygen-evolving catalytic site within photosystem II ( PSII). We report the structure of PSII of the cyanobacterium Thermosynechococcus elongatus at 3.5 angstrom resolution. We have assigned most of the amino acid residues of this 650-kilodalton dimeric multisubunit complex and refined the structure to reveal its molecular architecture. Consequently, we are able to describe details of the binding sites for cofactors and propose a structure of the oxygen-evolving center (OEC). The data strongly suggest that the OEC contains a cubane-like Mn3CaO4 cluster linked to a fourth Mn by a mono-mu-oxo bridge. The details of the surrounding coordination sphere of the metal cluster and the implications for a possible oxygen-evolving mechanism are discussed.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; ERATO, Japan Sci & Technol Corp, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England	Imperial College London; Japan Science & Technology Agency (JST); Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England.	j.barber@imperial.ac.uk; s.iwata@imperial.ac.uk			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM068304] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM068304, F32 GM068304-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; [Anonymous], 1996, ADV PHOTOSYNTH; Baranov SV, 2000, BIOCHEMISTRY-US, V39, P6060, DOI 10.1021/bi992682c; Barber J, 2003, Q REV BIOPHYS, V36, P71, DOI 10.1017/S0033583502003839; Barber J, 2001, J PHOTOCH PHOTOBIO A, V142, P97, DOI 10.1016/S1010-6030(01)00503-2; Barter LMC, 2003, P NATL ACAD SCI USA, V100, P946, DOI 10.1073/pnas.0136891100; Carrell TG, 2002, J BIOL INORG CHEM, V7, P2, DOI 10.1007/s00775-001-0305-3; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; de Weerd FL, 2002, BIOPHYS J, V82, P1586, DOI 10.1016/S0006-3495(02)75510-0; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Dekker JP, 2000, PHOTOSYNTH RES, V63, P195, DOI 10.1023/A:1006468024245; DEPAULA JC, 1986, J AM CHEM SOC, V108, P4002, DOI 10.1021/ja00274a025; Diner BA, 2002, ANNU REV PLANT BIOL, V53, P551, DOI 10.1146/annurev.arplant.53.100301.135238; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Diner BA, 1991, CURR OPIN STRUC BIOL, V1, P546, DOI 10.1016/S0959-440X(05)80076-4; DURRANT JR, 1995, P NATL ACAD SCI USA, V92, P4798, DOI 10.1073/pnas.92.11.4798; Faller P, 2001, P NATL ACAD SCI USA, V98, P14368, DOI 10.1073/pnas.251382598; Faller P, 2001, BIOCHEMISTRY-US, V40, P6431, DOI 10.1021/bi0026021; Fromme P, 2002, PHILOS T R SOC B, V357, P1337, DOI 10.1098/rstb.2002.1143; GOVINDJEE, 1993, PHOTOSYNTHETIC REACT, V1, P357; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; Haumann M, 1999, BBA-BIOENERGETICS, V1411, P86, DOI 10.1016/S0005-2728(99)00042-0; Hienerwadel R, 1995, BIOCHEMISTRY-US, V34, P16288, DOI 10.1021/bi00050a008; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Knoepfle N, 1999, BIOCHEMISTRY-US, V38, P1582, DOI 10.1021/bi9821418; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; OETTMEIER W, 1992, TOPICS PHOTOSYNTHESI, V11, P349; Pecoraro VL, 1998, PURE APPL CHEM, V70, P925, DOI 10.1351/pac199870040925; Peloquin JM, 2001, BBA-BIOENERGETICS, V1503, P96, DOI 10.1016/S0005-2728(00)00219-X; Rappaport F, 2002, BIOCHEMISTRY-US, V41, P8518, DOI 10.1021/bi025725p; Robblee JH, 2001, BBA-BIOENERGETICS, V1503, P7, DOI 10.1016/S0005-2728(00)00217-6; Rosenberg C, 1999, BIOCHEMISTRY-US, V38, P15994, DOI 10.1021/bi991326r; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Siegbahn PEM, 2002, CURR OPIN CHEM BIOL, V6, P227, DOI 10.1016/S1367-5931(02)00312-5; Siegbahn PEM, 1999, J AM CHEM SOC, V121, P117, DOI 10.1021/ja982290d; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; TELFER A, 1991, BIOCHIM BIOPHYS ACTA, V1060, P106, DOI 10.1016/S0005-2728(05)80125-2; TELFER A, 1994, BIOCHEMISTRY-US, V33, P14469, DOI 10.1021/bi00252a013; Tommos C, 2000, BBA-BIOENERGETICS, V1458, P199, DOI 10.1016/S0005-2728(00)00069-4; Tracewell CA, 2003, BIOCHEMISTRY-US, V42, P9127, DOI 10.1021/bi0345844; Tracewell CA, 2001, ARCH BIOCHEM BIOPHYS, V385, P61, DOI 10.1006/abbi.2000.2150; Tracewell CA, 2001, BIOCHEMISTRY-US, V40, P193, DOI 10.1021/bi001992o; VINCENT JB, 1987, INORG CHIM ACTA, V136, P41; Vrettos JS, 2001, BBA-BIOENERGETICS, V1503, P229, DOI 10.1016/S0005-2728(00)00214-0; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	50	2749	2837	20	976	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1831	1838		10.1126/science.1093087	http://dx.doi.org/10.1126/science.1093087			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	14764885				2022-12-28	WOS:000220281600046
J	He, JF; Peng, GW; Min, J; Yu, DW; Liang, WJ; Zhang, SY; Xu, RH; Zheng, HY; Wu, XW; Xu, J; Wang, ZH; Fang, L; Zhang, X; Li, H; Yan, XG; Lu, JH; Hu, ZH; Huang, JC; Wan, ZY; Hou, JL; Lin, JY; Song, HD; Wang, SY; Zhou, XJ; Zhang, GW; Gu, BW; Zheng, HJ; Zhang, XL; He, M; Zheng, K; Wang, BF; Fu, G; Wang, XN; Chen, SJ; Chen, Z; Hao, P; Tang, H; Ren, SX; Zhong, Y; Guo, ZM; Liu, Q; Miao, YG; Kong, XY; He, WZ; Li, YX; Wu, CI; Zhao, GP; Chiu, RWK; Chim, SSC; Tong, YK; Chan, PKS; Tam, JS; Lo, YMD				He, JF; Peng, GW; Min, J; Yu, DW; Liang, WJ; Zhang, SY; Xu, RH; Zheng, HY; Wu, XW; Xu, J; Wang, ZH; Fang, L; Zhang, X; Li, H; Yan, XG; Lu, JH; Hu, ZH; Huang, JC; Wan, ZY; Hou, JL; Lin, JY; Song, HD; Wang, SY; Zhou, XJ; Zhang, GW; Gu, BW; Zheng, HJ; Zhang, XL; He, M; Zheng, K; Wang, BF; Fu, G; Wang, XN; Chen, SJ; Chen, Z; Hao, P; Tang, H; Ren, SX; Zhong, Y; Guo, ZM; Liu, Q; Miao, YG; Kong, XY; He, WZ; Li, YX; Wu, CI; Zhao, GP; Chiu, RWK; Chim, SSC; Tong, YK; Chan, PKS; Tam, JS; Lo, YMD		Chinese SARS Mol Epidemiology	Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China	SCIENCE			English	Article							ACUTE-RESPIRATORY-SYNDROME; GENOME SEQUENCE; AMOY GARDENS; OUTBREAK; VIRUS; IDENTIFICATION; VIRULENCE; MUTATION; HISTORY; RATES	Sixty-one SARS coronavirus genomic sequences derived from the early, middle, and late phases of the severe acute respiratory syndrome ( SARS) epidemic were analyzed together with two viral sequences from palm civets. Genotypes characteristic of each phase were discovered, and the earliest genotypes were similar to the animal SARS-like coronaviruses. Major deletions were observed in the Orf8 region of the genome, both at the start and the end of the epidemic. The neutral mutation rate of the viral genome was constant but the amino acid substitution rate of the coding sequences slowed during the course of the epidemic. The spike protein showed the strongest initial responses to positive selection pressures, followed by subsequent purifying selection and eventual stabilization.	Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, State Key Lab Med Genom Pole Sino Francais Rech S, Shanghai 200025, Peoples R China; Guangdong Ctr Dis Control & Prevent, Guangzhou 510300, Guangdong, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China; Chinese Acad Sci, Inst Zool, Beijing 100080, Peoples R China; Guangzhou Ctr Dis Control & Prevent, Guangzhou 510080, Guangdong, Peoples R China; Guangzhou Inst Resp Dis, Guangzhou 510120, Guangdong, Peoples R China; First Med Univ, Nanfang Hosp, Dept Infect Dis & Mol Immunol, Guangzhou 510515, Guangdong, Peoples R China; Chinese Acad Sci, Wuhan Inst Virol, Wuhan 430071, Hubei, Peoples R China; Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Hlth Sci Ctr, Inst Plant Physiol & Eocl,Bioinformat Ctr, Shanghai 200031, Peoples R China; Shanghai Ctr Bioinformat Technol, Shanghai 200235, Peoples R China; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China	Shanghai Jiao Tong University; Sun Yat Sen University; Chinese Academy of Sciences; Institute of Zoology, CAS; Southern Medical University - China; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chicago; Fudan University; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Zhao, GP (corresponding author), Chinese Natl Human Genome Ctr Shanghai, 250 Bi Bo Rd,Zhang Jiang High Tech Pk, Shanghai 201203, Peoples R China.	gpzhao@ibs.ac.cn	Hu, Zhihong/AAS-2215-2020; Chim, Stephen SC/O-6271-2016; Song, Huai-Dong/G-8961-2011; Chan, Paul KS/J-9360-2013; Lo, Yuk Ming Dennis/D-4468-2011; Zhang, Shuyi/B-5117-2011	Hu, Zhihong/0000-0002-1560-0928; Chim, Stephen SC/0000-0002-2152-7050; Chan, Paul KS/0000-0002-6360-4608; Lo, Yuk Ming Dennis/0000-0001-8746-0293; Hao, Pei/0000-0002-1498-7059; Zhao, Guo-Ping/0000-0002-7621-6620				Brown EG, 2001, P NATL ACAD SCI USA, V98, P6883, DOI 10.1073/pnas.111165798; Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P241; Chim SSC, 2003, LANCET, V362, P1807, DOI 10.1016/S0140-6736(03)14901-X; Chiu RWK, 2003, NEW ENGL J MED, V349, P1875, DOI 10.1056/NEJM200311063491923; Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Ewald PW, 1998, J URBAN HEALTH, V75, P480, DOI 10.1007/BF02427686; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; LAI MMC, 2001, FIELDS VIROLOGY, pCH35; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; LI WH, 1988, MOL BIOL EVOL, V5, P313; Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599; Rest JS, 2003, INFECT GENET EVOL, V3, P219, DOI 10.1016/j.meegid.2003.08.001; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Tsui SKW, 2003, NEW ENGL J MED, V349, P187, DOI 10.1056/NEJM200307103490216; Vogel G, 2003, SCIENCE, V300, P1062; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	26	434	464	8	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1666	1669		10.1126/science.1092002	http://dx.doi.org/10.1126/science.1092002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	14752165				2022-12-28	WOS:000220151400043
J	Coleman, T				Coleman, T			ABC of smoking cessation - Use of simple advice and behavioural support	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Nottingham Hosp, Queens Med Ctr, Div Primary Care, Sch Community Hlth Sci, Nottingham NG7 2UH, England	University of Nottingham	Coleman, T (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Div Primary Care, Sch Community Hlth Sci, Nottingham NG7 2UH, England.			Coleman, Tim/0000-0002-7303-4805				LANCASTER T, 2003, COCHRANE DB SYST REV; LANCASTER T, 2003, COCHRANE DATABASE SY; STEAD LF, 2003, COCHRANE DATABASE SY; Stead LF, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000165.PUB3; Stead LF, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002850	5	48	51	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					397	399		10.1136/bmj.328.7436.397	http://dx.doi.org/10.1136/bmj.328.7436.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962878	Green Published			2022-12-28	WOS:000189031300031
J	Mallik, R; Carter, BC; Lex, SA; King, SJ; Gross, SP				Mallik, R; Carter, BC; Lex, SA; King, SJ; Gross, SP			Cytoplasmic dynein functions as a gear in response to load	NATURE			English	Article							HEAVY-CHAIN; OPTICAL TRAPS; KINESIN; ATP; FORCE; MOVEMENTS; DYNACTIN; PROTEIN; MYOSIN	Cytoskeletal molecular motors belonging to the kinesin and dynein families transport cargos (for example, messenger RNA, endosomes, virus) on polymerized linear structures called microtubules in the cel(l)1. These 'nanomachines' use energy obtained from ATP hydrolysis to generate force(2), and move in a step-like manner on microtubules. Dynein(3-5) has a complex and fundamentally different structure from other motor families. Thus, understanding dynein's force generation can yield new insight into the architecture and function of nanomachines. Here, we use an optical trap(6) to quantify motion of polystyrene beads driven along microtubules by single cytoplasmic dynein motors. Under no load, dynein moves predominantly with a mixture of 24-nm and 32-nm steps. When moving against load applied by an optical trap, dynein can decrease step size to 8 nm and produce force up to 1.1 pN. This correlation between step size and force production is consistent with a molecular gear mechanism. The ability to take smaller but more powerful strokes under load-that is, to shift gears-depends on the availability of ATP. We propose a model whereby the gear is downshifted through load-induced binding of ATP at secondary sites in the dynein head.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92612 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of California System; University of California Irvine; University of Missouri System; University of Missouri Kansas City	Gross, SP (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92612 USA.	sgross@uci.edu		mallik, roop/0000-0001-6820-6556				Asai DJ, 2001, TRENDS CELL BIOL, V11, P196, DOI 10.1016/S0962-8924(01)01970-5; Bingham JB, 1998, METHOD ENZYMOL, V298, P171, DOI 10.1016/S0076-6879(98)98017-X; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; Gross SP, 2000, J CELL BIOL, V148, P945, DOI 10.1083/jcb.148.5.945; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirakawa E, 2000, P NATL ACAD SCI USA, V97, P2533, DOI 10.1073/pnas.050585297; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 2000, J CELL SCI, V113, P2521; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; Neuwald AF, 1999, GENOME RES, V9, P27; Rice SE, 2003, METHOD ENZYMOL, V361, P112; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; Silvanovich A, 2003, MOL BIOL CELL, V14, P1355, DOI 10.1091/mbc.E02-10-0675; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P171; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	30	386	391	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					649	652		10.1038/nature02293	http://dx.doi.org/10.1038/nature02293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773AJ	14961123				2022-12-28	WOS:000188875300045
J	Wang, TJ; Larson, MG; Levy, D; Benjamin, EJ; Leip, EP; Omland, T; Wolf, PA; Vasan, RS				Wang, TJ; Larson, MG; Levy, D; Benjamin, EJ; Leip, EP; Omland, T; Wolf, PA; Vasan, RS			Plasma natriuretic peptide levels and the risk of cardiovascular events and death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; ATRIAL-FIBRILLATION; DIASTOLIC DYSFUNCTION; MYOCARDIAL-INFARCTION; SYSTOLIC DYSFUNCTION; PROGNOSTIC VALUE; MORTALITY; DISEASE; PREDICTION	Background: The natriuretic peptides are counterregulatory hormones involved in volume homeostasis and cardiovascular remodeling. The prognostic significance of plasma natriuretic peptide levels in apparently asymptomatic persons has not been established. Methods: We prospectively studied 3346 persons without heart failure. Using proportional-hazards regression, we examined the relations of plasma B-type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any cause, a first major cardiovascular event, heart failure, atrial fibrillation, stroke or transient ischemic attack, and coronary heart disease. Results: During a mean follow-up of 5.2 years, 119 participants died and 79 had a first cardiovascular event. After adjustment for cardiovascular risk factors, each increment of 1 SD in log B-type natriuretic peptide levels was associated with a 27 percent increase in the risk of death (P=0.009), a 28 percent increase in the risk of a first cardiovascular event (P=0.03), a 77 percent increase in the risk of heart failure (P<0.001), a 66 percent increase in the risk of atrial fibrillation (P<0.001), and a 53 percent increase in the risk of stroke or transient ischemic attack (P=0.002). Peptide levels were not significantly associated with the risk of coronary heart disease events. B-type natriuretic peptide values above the 80th percentile (20.0 pg per milliliter for men and 23.3 pg per milliliter for women) were associated with multivariable-adjusted hazard ratios of 1.62 for death (P=0.02), 1.76 for a first major cardiovascular event (P=0.03), 1.91 for atrial fibrillation (P=0.02), 1.99 for stroke or transient ischemic attack (P=0.02), and 3.07 for heart failure (P=0.002). Similar results were obtained for N-terminal pro-atrial natriuretic peptide. Conclusions: In this community-based sample, plasma natriuretic peptide levels predicted the risk of death and cardiovascular events after adjustment for traditional risk factors. Excess risk was apparent at natriuretic peptide levels well below current thresholds used to diagnose heart failure.	Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA; Boston Med Ctr, Cardiol Sect, Boston, MA USA; Boston Med Ctr, Dept Neurol, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Akershus Hosp, Dept Med, Oslo, Norway	Framingham Heart Study; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston Medical Center; Boston Medical Center; Boston University; University of Oslo	Vasan, RS (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave,2, Framingham, MA 01702 USA.	vasan@fram.nhlbi.nih.gov	Levy, Daniel/ABF-6873-2021; Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABB-2752-2021; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Larson, Martin/0000-0002-9631-1254; Benjamin, Emelia/0000-0003-4076-2336; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL074077, K24HL004334] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-25195, K23-HL074077-01, K24-HL-04334] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Berger R, 2002, CIRCULATION, V105, P2392, DOI 10.1161/01.CIR.0000016642.15031.34; Brunner F, 2001, CARDIOVASC RES, V51, P577, DOI 10.1016/S0008-6363(01)00283-8; COX DR, 1972, J R STAT SOC B, V34, P187; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; DAVIS KM, 1992, JAMA-J AM MED ASSOC, V267, P2625, DOI 10.1001/jama.267.19.2625; DAVIS KM, 1993, JAMA-J AM MED ASSOC, V269, P991; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; Goetze JP, 2003, FASEB J, V17, P1105, DOI 10.1096/fj.02-0796fje; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Herring N, 2001, AM J PHYSIOL-HEART C, V281, pH2318, DOI 10.1152/ajpheart.2001.281.6.H2318; James SK, 2003, CIRCULATION, V108, P275, DOI 10.1161/01.CIR.0000079170.10579.DC; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1987, NIH PUBLICATION NAT; Kannell WB, 1999, ARCH INTERN MED, V159, P1197, DOI 10.1001/archinte.159.11.1197; Knight EL, 1998, J AM GERIATR SOC, V46, P453, DOI 10.1111/j.1532-5415.1998.tb02465.x; Kohno M, 1997, CIRC RES, V81, P585, DOI 10.1161/01.RES.81.4.585; Kook H, 2003, AM J PHYSIOL-HEART C, V284, pH1388, DOI 10.1152/ajpheart.00414.2002; Levin ER, 1998, NEW ENGL J MED, V339, P321; Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; McDonagh TA, 2001, HEART, V86, P21, DOI 10.1136/heart.86.1.21; Molkentin JD, 2003, J CLIN INVEST, V111, P1275, DOI 10.1172/JCI200318389; Morrow DA, 2003, J AM COLL CARDIOL, V41, P1264, DOI 10.1016/S0735-1097(03)00168-2; Morrow DA, 2003, J AM COLL CARDIOL, V41, P1853, DOI 10.1016/S0735-1097(03)00571-0; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Richards AM, 2003, CIRCULATION, V107, P2786, DOI 10.1161/01.CIR.0000070953.76250.B9; Rossi A, 2000, J AM COLL CARDIOL, V35, P1256, DOI 10.1016/S0735-1097(00)00515-5; Rubattu S, 1999, CIRCULATION, V100, P1722, DOI 10.1161/01.CIR.100.16.1722; Rubattu S, 1999, CIRC RES, V85, P900; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; *SAS I INC, 1997, SAS STAT SOFTW CHANG, P871; Schirmer H, 1999, EUR HEART J, V20, P1439, DOI 10.1053/euhj.1999.1830; Struthers AD, 2002, LANCET, V359, P1430, DOI 10.1016/S0140-6736(02)08358-7; Ueda R, 2003, AM J MED, V114, P266, DOI 10.1016/S0002-9343(02)01525-5; van den Berg MP, 2002, EUR J HEART FAIL, V4, P255, DOI 10.1016/S1388-9842(01)00232-X; Vasan RS, 2002, JAMA-J AM MED ASSOC, V288, P1252, DOI 10.1001/jama.288.10.1252; Wallen T, 1997, J INTERN MED, V241, P269, DOI 10.1046/j.1365-2796.1997.128149000.x; Wang TJ, 2003, ANN INTERN MED, V138, P907, DOI 10.7326/0003-4819-138-11-200306030-00012; Wang TJ, 2002, AM J CARDIOL, V90, P254, DOI 10.1016/S0002-9149(02)02464-5; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988	45	1142	1200	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					655	663		10.1056/NEJMoa031994	http://dx.doi.org/10.1056/NEJMoa031994			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960742				2022-12-28	WOS:000188869500006
J	Stroud, CR				Stroud, CR			Pas de deux for atomic electrons	SCIENCE			English	Editorial Material							CLASSICAL LIMIT		Univ Rochester, Inst Opt, Rochester, NY 14627 USA; Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA	University of Rochester; University of Rochester	Stroud, CR (corresponding author), Univ Rochester, Inst Opt, Rochester, NY 14627 USA.	stroud@optics.rochester.edu						Born M., 1936, ATOMIC PHYS; Chen X, 1998, PHYS REV LETT, V81, P5772, DOI 10.1103/PhysRevLett.81.5772; Gutzwiller MC, 1998, REV MOD PHYS, V70, P589, DOI 10.1103/RevModPhys.70.589; Kamta GL, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.053418; Moshammer R, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.035401; NAUENBERG M, 1994, SCI AM, V270, P44, DOI 10.1038/scientificamerican0694-44; Noordam LD, 1997, J MOD OPTIC, V44, P2515, DOI 10.1080/095003497152645; Panfili R, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.113001; PARKER J, 1986, PHYS REV LETT, V56, P716, DOI 10.1103/PhysRevLett.56.716; Parker JS, 2000, J PHYS B-AT MOL OPT, V33, pL239, DOI 10.1088/0953-4075/33/7/101; Pisharody SN, 2004, SCIENCE, V303, P813, DOI 10.1126/science.1092220; Rangan C, 2002, J MOD OPTIC, V49, P2339, DOI 10.1080/0950034021000011365; Tanner G, 2000, REV MOD PHYS, V72, P497, DOI 10.1103/RevModPhys.72.497; TENWOLDE A, 1988, PHYS REV LETT, V61, P2099, DOI 10.1103/PhysRevLett.61.2099; Van Vllck JH, 1928, P NATL ACAD SCI USA, V14, P178; WANG X, 1992, PHYS REV A, V46, P4347, DOI 10.1103/PhysRevA.46.4347; West JA, 1998, PHYS REV A, V58, P186, DOI 10.1103/PhysRevA.58.186; Wintgen D, 1992, CHAOS, V2, P19, DOI 10.1063/1.165920	18	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					778	779		10.1126/science.1093908	http://dx.doi.org/10.1126/science.1093908			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14764860	Green Submitted			2022-12-28	WOS:000188753800038
J	Chen, S; Howard, O				Chen, S; Howard, O			Parvovirus B19 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hartford Hosp, Hartford, CT 06102 USA; Charlotte Hungerford Hosp, Torrington, CT 06790 USA	Hartford Hospital	Chen, S (corresponding author), Hartford Hosp, Hartford, CT 06102 USA.								0	4	5	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					598	598		10.1056/NEJMicm010759	http://dx.doi.org/10.1056/NEJMicm010759			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762187				2022-12-28	WOS:000188712800011
J	Schwartz, RS				Schwartz, RS			Black mornings, yellow sunsets - A day with paroxysmal nocturnal hemoglobinuria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	5	5	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					537	538		10.1056/NEJMp038223	http://dx.doi.org/10.1056/NEJMp038223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762178				2022-12-28	WOS:000188712800002
J	Stone, MB; Bernstein, DP; Barry, R; Pelc, MD; Tsui, YK; Schiffer, P				Stone, MB; Bernstein, DP; Barry, R; Pelc, MD; Tsui, YK; Schiffer, P			Stress propagation: Getting to the bottom of a granular medium - A surprising resistance would be put up by sand grains hiding a buried treasure chest.	NATURE			English	Editorial Material							FLUCTUATIONS; DRAG		Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Stone, MB (corresponding author), Penn State Univ, Dept Phys, University Pk, PA 16802 USA.	schiffer@phys.psu.edu	Stone, Matthew/G-3275-2011; Schiffer, Peter/F-3227-2011	Stone, Matthew/0000-0001-7884-9715; Tsui, Yee Kin/0000-0003-1759-0951; Schiffer, Peter/0000-0002-6430-6549				Albert R, 1999, PHYS REV LETT, V82, P205, DOI 10.1103/PhysRevLett.82.205; BOUCHAUD JP, 1995, J PHYS I, V5, P639, DOI 10.1051/jp1:1995157; Da Silva M, 2000, NATURE, V406, P708, DOI 10.1038/35021023; Geng JF, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.035506; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; LIU CH, 1995, SCIENCE, V269, P513, DOI 10.1126/science.269.5223.513; MURGGENHURG NW, 2002, PHYS REV E, V66, DOI UNSP 031304-031312; O'Hern CS, 2001, PHYS REV LETT, V86, P111, DOI 10.1103/PhysRevLett.86.111; PETERSON RW, 1991, CALIBRATION CHAMBER, P315; Reydellet G, 2001, PHYS REV LETT, V86, P3308, DOI 10.1103/PhysRevLett.86.3308; Vanel L, 1999, EUR PHYS J B, V11, P525, DOI 10.1007/s100510050965; VERGELES M, 1995, PHYS REV LETT, V75, P232, DOI 10.1103/PhysRevLett.75.232; Yu HS, 1998, J GEOTECH GEOENVIRON, V124, P140, DOI 10.1061/(ASCE)1090-0241(1998)124:2(140)	13	56	61	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 5	2004	427	6974					503	504		10.1038/427503a	http://dx.doi.org/10.1038/427503a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765185				2022-12-28	WOS:000188721800030
J	Robinson, GE				Robinson, GE			Career satisfaction in female physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN PHYSICIANS; HEALTH; GENDER		Univ Toronto, Toronto, ON, Canada	University of Toronto	Robinson, GE (corresponding author), Univ Toronto, Toronto, ON, Canada.							*AM MED ASS, 1997, WOM MED DAT SOURC; Carr PL, 1998, ANN INTERN MED, V129, P532, DOI 10.7326/0003-4819-129-7-199810010-00004; Chiu C, 1998, SEX ROLES, V38, P521, DOI 10.1023/A:1018722208646; Corbie-Smith G, 2000, J NATL MED ASSOC, V92, P472; Frank E, 1999, ARCH INTERN MED, V159, P1417, DOI 10.1001/archinte.159.13.1417; Frank E, 1999, ACAD MED, V74, P553, DOI 10.1097/00001888-199905000-00025; Linzer Mark, 2002, J Am Med Womens Assoc (1972), V57, P191; McMurray JE, 2000, J GEN INTERN MED, V15, P372, DOI 10.1111/j.1525-1497.2000.im9908009.x; PHELAN J, 1994, SOC PSYCHOL QUART, V57, P95, DOI 10.2307/2786704	9	26	27	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2004	291	5					635	635		10.1001/jama.291.5.635	http://dx.doi.org/10.1001/jama.291.5.635			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LC	14762047				2022-12-28	WOS:000188650700033
J	Poremba, A; Malloy, M; Saunders, RC; Carson, RE; Herscovitch, P; Mishkin, M				Poremba, A; Malloy, M; Saunders, RC; Carson, RE; Herscovitch, P; Mishkin, M			Species-specific calls evoke asymmetric activity in the monkey's temporal poles	NATURE			English	Article							AUDITORY-CORTEX; VOCALIZATIONS; REPRESENTATION; PERCEPTION; MARMOSET; BRAIN	It has often been proposed that the vocal calls of monkeys are precursors of human speech, in part because they provide critical information to other members of the species who rely on them for survival and social interactions(1,2). Both behavioural and lesion studies suggest that monkeys, like humans, use the auditory system of the left hemisphere preferentially to process vocalizations(3,4). To investigate the pattern of neural activity that might underlie this particular form of functional asymmetry in monkeys, we measured local cerebral metabolic activity while the animals listened passively to species-specific calls compared with a variety of other classes of sound. Within the superior temporal gyrus, significantly greater metabolic activity occurred on the left side than on the right, only in the region of the temporal pole and only in response to monkey calls. This functional asymmetry was absent when these regions were separated by forebrain commissurotomy, suggesting that the perception of vocalizations elicits concurrent interhemispheric interactions that focus the auditory processing within a specialized area of one hemisphere.	Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA; NIMH, Neuropsychol Lab, NIH, Bethesda, MD 20892 USA; NIH, PET Dept, Ctr Clin, Bethesda, MD 20892 USA	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Poremba, A (corresponding author), Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA.	amy-poremba@uiowa.edu	Carson, Richard E/H-3250-2011	Carson, Richard E/0000-0002-9338-7966				Cheney D. L., 1990, MONKEYS SEE WORLD IN; EHRET G, 1987, NATURE, V325, P249, DOI 10.1038/325249a0; FERBERT A, 1992, J PHYSIOL-LONDON, V453, P525, DOI 10.1113/jphysiol.1992.sp019243; George I, 2002, CR BIOL, V325, P197, DOI 10.1016/S1631-0691(02)01430-0; Ghazanfar AA, 2001, CURR OPIN NEUROBIOL, V11, P712, DOI 10.1016/S0959-4388(01)00274-4; GLASS I, 1983, HEARING RES, V9, P27, DOI 10.1016/0378-5955(83)90131-4; Hauser MD, 1998, ANIM BEHAV, V55, P1647, DOI 10.1006/anbe.1997.0712; HAUSER MD, 1994, P NATL ACAD SCI USA, V91, P3946, DOI 10.1073/pnas.91.9.3946; HEFFNER HE, 1984, SCIENCE, V226, P75, DOI 10.1126/science.6474192; KEPPEL G, 1982, DESIGN ANAL RES HDB, pCH8; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; Netz J, 1999, EEG CL N SU, P137; Otten LJ, 2002, NAT NEUROSCI, V5, P1339, DOI 10.1038/nn967; PETERSEN MR, 1978, SCIENCE, V202, P324, DOI 10.1126/science.99817; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; Poremba A, 2003, SCIENCE, V299, P568, DOI 10.1126/science.1078900; PRELL CG, 2002, ANIM BEHAV, V63, P47; Rauschecker JP, 2000, P NATL ACAD SCI USA, V97, P11800, DOI 10.1073/pnas.97.22.11800; Snowdon CT., 1982, PRIMATE COMMUNICATIO; Sokoloff L, 1996, DEV NEUROSCI-BASEL, V18, P343, DOI 10.1159/000111427; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685; Wang XQ, 2001, J NEUROPHYSIOL, V86, P2616, DOI 10.1152/jn.2001.86.5.2616; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Yeterian EH, 1998, J COMP NEUROL, V399, P384	24	223	225	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	2004	427	6973					448	451		10.1038/nature02268	http://dx.doi.org/10.1038/nature02268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	767UF	14749833				2022-12-28	WOS:000188470500045
J	Dixon, J; Lewis, R; Rosen, R; Finlayson, B; Gray, D				Dixon, J; Lewis, R; Rosen, R; Finlayson, B; Gray, D			Can the NHS learn from US managed care organisations?	BRITISH MEDICAL JOURNAL			English	Article							KAISER-PERMANENTE; CHRONIC ILLNESS; UNITED-STATES; PHYSICIAN		Kings Fund, Hlth Policy, London W1G 0AN, England		Dixon, J (corresponding author), Kings Fund, Hlth Policy, London W1G 0AN, England.	jdixon@kingsfund.org.uk						*AUD COMM, 2002, INT SERV OLD PEOPL B, P24; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Budetti PP, 2002, HEALTH AFFAIR, V21, P203, DOI 10.1377/hlthaff.21.1.203; Casalino L, 2003, MILBANK Q, V81, P331, DOI 10.1111/1468-0009.t01-2-00056; *DEP HLTH, 2002, NAT SERV FRAM DIAB; *DEP HLTH, 2002, NHS PERF RAT IND JUL; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Department of Health, 1998, INF HLTH INF STRAT M; Druss BG, 2002, HEALTH AFFAIR, V21, P105, DOI 10.1377/hlthaff.21.4.105; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; HAGGAR T, 2003, HLTH SERVICES J  AUG; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; *KINGS FUND, 2004, MAN CHRON DIS LESS 5; Lewis R, 2004, BMJ-BRIT MED J, V328, P220, DOI 10.1136/bmj.328.7433.220; LISK SF, 2000, EFFECTIVE CLIN PRACT; *NAT COMM QUAL ASS, HLTH PLAN EMPL DAT I; *NHS MOD AG, CHRON DIS MAN; RICHARDSON T, 2001, PERSONAL MED SERVICE; SEHKRI N, 2000, B WORLD HEALTH ORGAN, V78, P6; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; 2002, BMJ, V324, P1332	22	21	22	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	2004	328	7433					223	225		10.1136/bmj.328.7433.223	http://dx.doi.org/10.1136/bmj.328.7433.223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14739195	Green Published			2022-12-28	WOS:000188652200025
J	Green, M				Green, M			Motherhood - a potential killer	LANCET			English	Editorial Material												marinagr@iafrica.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	2004	363	9405					311	311		10.1016/S0140-6736(03)15391-3	http://dx.doi.org/10.1016/S0140-6736(03)15391-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766FQ	14751706				2022-12-28	WOS:000188361400024
J	Riggs, TL				Riggs, TL			Research and development costs for drugs	LANCET			English	Editorial Material									US Bur Census, Ctr Econ Studies, Chicago Census Res Data Ctr, Chicago, IL 60604 USA		Riggs, TL (corresponding author), US Bur Census, Ctr Econ Studies, Chicago Census Res Data Ctr, Chicago, IL 60604 USA.	tlriggs@frbchi.org						DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Kolata Gina, 2003, NY TIMES        0928, P11; *NAT SCI FDN DIV S, 2003, 03318 NSF DIV SCI RE; US Congress Office of Technology Assessment, 1993, OTAH522 US C	4	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					184	184		10.1016/S0140-6736(03)15370-6	http://dx.doi.org/10.1016/S0140-6736(03)15370-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738789				2022-12-28	WOS:000188243900006
J	Webster, RG				Webster, RG			Wet markets - a continuing source of severe acute respiratory syndrome and influenza?	LANCET			English	Review							LIVE-BIRD MARKETS; AVIAN INFLUENZA; A VIRUSES; HONG-KONG; TRANSMISSION; GENE		St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, RG (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, 332 N Lauderdale St, Memphis, TN 38105 USA.	robert.webster@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA021765, CA-21765] Funding Source: Medline; NIAID NIH HHS [N01AI95357, AI95357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; Enserink M, 2003, SCIENCE, V302, P213; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; *INT SOC INF DIS, 2003, PROMED MAIL     1213; Ismael NF, 2000, DEV ARID REG RES SER, V1, P45; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Knipe D, 2001, FIELDS VIROLOGY, P1187; Lai M.M.C., 2001, FIELDS VIROLOGY, P1163; Liu M, 2003, VIROLOGY, V305, P267, DOI 10.1006/viro.2002.1762; Makarova NV, 2003, VIROLOGY, V310, P8, DOI 10.1016/S0042-6822(03)00094-1; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; Perez DR, 2003, J VIROL, V77, P3148, DOI 10.1128/JVI.77.5.3148-3156.2003; Senior K, 2003, LANCET INFECT DIS, V3, P679, DOI 10.1016/S1473-3099(03)00815-6; Senne DA, 2003, AVIAN DIS, V47, P898, DOI 10.1637/0005-2086-47.s3.898; SENNE DA, 1992, P 3 INT S AV INFL RI; Shortridge K F, 1992, Semin Respir Infect, V7, P11; Sims LD, 2003, AVIAN DIS, V47, P832, DOI 10.1637/0005-2086-47.s3.832; Trock SC, 2003, AVIAN DIS, V47, P1111, DOI 10.1637/0005-2086-47.s3.1111; van Kolfschooten F, 2003, LANCET, V361, P1444, DOI 10.1016/S0140-6736(03)13156-X; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; *WHO, 2003, WHO DIS ALERT   0219	24	243	256	1	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					234	236		10.1016/S0140-6736(03)15329-9	http://dx.doi.org/10.1016/S0140-6736(03)15329-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738798	Green Published, Bronze			2022-12-28	WOS:000188243900024
J	Hwang, WS; Ryu, YJ; Park, JH; Park, ES; Lee, EG; Koo, JM; Jeon, HY; Lee, BC; Kang, SK; Kim, SJ; Ahn, C; Hwang, JH; Park, KY; Cibelli, JB; Moon, SY				Hwang, WS; Ryu, YJ; Park, JH; Park, ES; Lee, EG; Koo, JM; Jeon, HY; Lee, BC; Kang, SK; Kim, SJ; Ahn, C; Hwang, JH; Park, KY; Cibelli, JB; Moon, SY			RETRACTED: Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst (Retracted Article. See vol 311, pg 335, 2006)	SCIENCE			English	Article; Retracted Publication							NUCLEAR TRANSFER; CULTURE-MEDIUM; IN-VITRO; MOUSE; DIFFERENTIATION; CLONING; FETAL	Somatic cell nuclear transfer (SCNT) technology has recently been used to generate animals with a common genetic composition. In this study, we report the derivation of a pluripotent embryonic stem (ES) cell line (SCNT-hES-1) from a cloned human blastocyst. The SCNT-hES-1 cells displayed typical ES cell morphology and cell surface markers and were capable of differentiating into embryoid bodies in vitro and of forming teratomas in vivo containing cell derivatives from all three embryonic germ layers in severe combined immunodeficient mice. After continuous proliferation for more than 70 passages, SCNT-hES-1 cells maintained normal karyotypes and were genetically identical to the somatic nuclear donor cells. Although we cannot completely exclude the possibility that the cells had a parthenogenetic origin, imprinting analyses support a SCNT origin of the derived human ES cells.	Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; MizMedi Hosp, Med Res Ctr, Seoul, South Korea; Gachon Med Sch, Inchon 417840, South Korea; Seoul Natl Univ, Coll Med, Seoul 110744, South Korea; Hanyang Univ, Sch Med, Seoul 471701, South Korea; Sunchon Natl Univ, Coll Nat Sci, Sunchon 540742, South Korea; Michigan State Univ, Dept Anim Sci Physiol, E Lansing, MI 48824 USA	Seoul National University (SNU); Seoul National University (SNU); Gachon University; Seoul National University (SNU); Hanyang University; Sunchon National University; Michigan State University	Hwang, WS (corresponding author), Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea.	hwangws@snu.ac.kr; shmoon@plaza.snu.ac.kr	Ahn, Curie/J-5527-2012					Barnett DK, 1996, MOL REPROD DEV, V43, P105, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;105::AID-MRD13&gt;3.0.CO;2-4; Choi YH, 2002, THERIOGENOLOGY, V58, P1187, DOI 10.1016/S0093-691X(02)00946-9; Cibelli J.B., 2001, J REGEN MED, V2, P25, DOI [10.1089/152489001753262168, DOI 10.1089/152489001753262168]; Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642; Gardner DK, 2002, J REPROD IMMUNOL, V55, P85, DOI 10.1016/S0165-0378(01)00136-X; Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399; Hyun S, 2003, BIOL REPROD, V69, P1060, DOI 10.1095/biolreprod.102.014886; JOHN SR, 2002, TRENDS BIOTECHNOL, V20, P417; KAUFMAN MH, 1973, NATURE, V242, P475, DOI 10.1038/242475a0; Kawase E, 2000, GENESIS, V28, P156, DOI 10.1002/1526-968X(200011/12)28:3/4<156::AID-GENE100>3.3.CO;2-K; KUHHOLZER B, 2004, BIOL REPROD, V64, P1635; Kwun J, 2003, MOL REPROD DEV, V65, P167, DOI 10.1002/mrd.10309; LANGENDONCKT A, 2001, FERTIL STERIL, V76, P1023; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Lanzendorf SE, 2001, FERTIL STERIL, V76, P132, DOI 10.1016/S0015-0282(01)01825-8; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5; Nakagawa K, 2001, ZYGOTE, V9, P83, DOI 10.1017/S0967199401001083; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Shu YM, 2002, FERTIL STERIL, V78, pS286, DOI 10.1016/S0015-0282(02)03934-1; Simerly C, 2003, SCIENCE, V300, P297, DOI 10.1126/science.1082091; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vrana KE, 2003, P NATL ACAD SCI USA, V100, P11911, DOI 10.1073/pnas.2034195100; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	28	462	525	0	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	2004	303	5664					1669	1674		10.1126/science.1094515	http://dx.doi.org/10.1126/science.1094515			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	14963337				2022-12-28	WOS:000220151400044
J	Fergusson, D; Glass, KC; Waring, D; Shapiro, S				Fergusson, D; Glass, KC; Waring, D; Shapiro, S			Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; OMEGA-3-FATTY-ACIDS; PREVENTION; VOLUNTEERS; DISORDER; SYMPTOMS; EFFICACY; ANXIETY	Objective To examine the reporting and success of double blinding in a sample of randomised, placebo controlled trials from leading general medicine and psychiatry journals. Methods Identification of placebo controlled, randomised controlled trials from prespecified general medical and psychiatric journals indexed on Medline between I January 1998 and I October 200 1, from which a random sample of 200 randomised clinical trials was chosen, of which 191 trials were evaluated. Results Only seven of the 97 (7%) general medicine trials provided evidence on the success of blinding, with five reporting that the success of blinding was imperfect In trials from psychiatric journals, the success of blinding was reported in eight of the 94 trials, with four reporting that the blinding was imperfect. Overall, only four of the 191 (2%) trials assessed blinding in the participants and either the outcome assessors or the investigators. Conclusions The current lack of reporting on the success of blinding provides little evidence that success of blinding is maintained in placebo controlled trials. Trialists and editors should make a concerted effort to incorporate, report, and publish such information and its potential effect on study results.	Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON K1H 8L6, Canada; McGill Univ, Dept Human Genet & Pediat, Montreal, PQ, Canada; McGill Univ, Dept Biomed Eth, Montreal, PQ, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Univ Toronto, Fac Law, Res Eth & Regulat Grp, Toronto, ON M5S 1A1, Canada	University of Ottawa; Ottawa Hospital Research Institute; McGill University; McGill University; McGill University; University of Toronto	Fergusson, D (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Program, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.	dafergusson@ohri.ca		Fergusson, Dean/0000-0002-3389-2485				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; Ben-Zion IZ, 1999, AM J PSYCHIAT, V156, P1635, DOI 10.1176/ajp.156.10.1635; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; Devereaux PJ, 2001, JAMA-J AM MED ASSOC, V285, P2000, DOI 10.1001/jama.285.15.2000; Heresco-Levy U, 1999, ARCH GEN PSYCHIAT, V56, P29, DOI 10.1001/archpsyc.56.1.29; Himle JA, 1999, AM J PSYCHIAT, V156, P1237; Rowe PC, 2001, JAMA-J AM MED ASSOC, V285, P52, DOI 10.1001/jama.285.1.52; Sackeim HA, 2001, JAMA-J AM MED ASSOC, V285, P1299, DOI 10.1001/jama.285.10.1299; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; Sandler RS, 1999, ANN INTERN MED, V130, P253, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00002; Schneier FR, 1998, BRIT J PSYCHIAT, V172, P70, DOI 10.1192/bjp.172.1.70; Schulz KF, 2002, ANN INTERN MED, V136, P254, DOI 10.7326/0003-4819-136-3-200202050-00022; Schulz KF, 1996, BRIT MED J, V312, P742; SHEINER LB, 1995, CLIN PHARMACOL THER, V57, P6, DOI 10.1016/0009-9236(95)90260-0; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407; von Schacky C, 1999, ANN INTERN MED, V130, P554, DOI 10.7326/0003-4819-130-7-199904060-00003; Warner J, 2001, BRIT J PSYCHIAT, V178, P36, DOI 10.1192/bjp.178.1.36; Wisner KL, 2001, J CLIN PSYCHIAT, V62, P82, DOI 10.4088/JCP.v62n0202; Young SA, 1998, J CLIN PSYCHIAT, V59, P76, DOI 10.4088/JCP.v59n0206	21	161	165	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					432	434		10.1136/bmj.37952.631667.EE	http://dx.doi.org/10.1136/bmj.37952.631667.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14761905	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000189161000016
J	Gendo, K; Larson, EB				Gendo, K; Larson, EB			Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis	ANNALS OF INTERNAL MEDICINE			English	Article							SKIN-PRICK TESTS; HAY-FEVER; PERENNIAL RHINITIS; IN-VITRO; EFFICACY; ASTHMA; IGE; PARAMETERS; HISTORY; IMMUNOTHERAPY	Allergic rhinitis is an increasingly common disease, with a prevalence of at least 10% to 25% in the United States. Diagnostic allergy tests, such as skin tests and in vitro tests, can assist clinicians in determining whether nasal symptoms are allergic in origin. In addition, safe and effective medications are available to treat allergic rhinitis. The initial strategy should be to determine whether patients should undergo diagnostic testing or receive empirical treatment. This paper reviews the test characteristics of the history, skin tests, and in vitro tests in diagnosing allergic rhinitis from the perspective of decision thresholds. A combination of pertinent medical history features in a practice with a high baseline prevalence of allergic rhinitis justifies the common practice of empirical treatment since allergy medication has minimal toxicity and side effects. The situation is more complex when the patient needs a diagnostic test, because reported sensitivities and specificities of skin tests and in vitro tests vary widely. As a result, it is difficult to calculate the post-test probability of allergic rhinitis with any confidence. The decision to initiate diagnostic testing must rely on clinical judgment to select patients who would benefit most from determining their allergic status while minimizing unnecessary testing and medications. Diagnosing allergy to a specific antigen allows patients to avoid the allergen and makes them candidates for allergen immunotherapy, which can decrease the need for medications.	Univ Washington, Grp Hlth Cooperat, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, NW Asthma & Allergy Ctr, Seattle, WA 98101 USA	Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Larson, EB (corresponding author), Univ Washington, Grp Hlth Cooperat, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.							Annesi-Maesano I, 2002, ALLERGY, V57, P107, DOI 10.1034/j.1398-9995.2002.1o3170.x; BENT S, 1998, EVIDENCE BASED MED F, P59; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; BROOKS GD, 2002, PATTERSONS ALLERGIC, P81; Charpin D, 1996, ALLERGY, V51, P293, DOI 10.1111/j.1398-9995.1996.tb00088.x; CLARKE PS, 1987, ANN ALLERGY, V59, P25; Crobach MJJS, 1998, SCAND J PRIM HEALTH, V16, P30; Day J, 1998, J ALLERGY CLIN IMMUN, V102, P902, DOI 10.1016/S0091-6749(98)70326-4; Demoly P, 2002, ALLERGY, V57, P546, DOI 10.1034/j.1398-9995.2002.t01-1-13370.x; Demoly P., 1998, ALLERGY PRINCIPLES P, V5th ed., P430; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; Escudero A I, 1993, Allergol Immunopathol (Madr), V21, P153; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; GO AS, 1998, EVIDENCE BASED MED F, P11; GORDIS L, 2000, ASSESSING VALIDITY R; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; Hamilton RG, 2003, J ALLERGY CLIN IMMUN, V111, P1414, DOI 10.1067/mai.2003.1520; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; Joko H, 2002, AM J RHINOL, V16, P11, DOI 10.1177/194589240201600103; Kauppi P, 1998, RESP MED, V92, P1281, DOI 10.1016/S0954-6111(98)90229-3; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Li JTC, 2000, ANN ALLERG ASTHMA IM, V85, P382, DOI 10.1016/S1081-1206(10)62550-1; LIN MS, 1993, ANN ALLERGY, V71, P557; LINDBERG S, 1993, ALLERGY, V48, P602, DOI 10.1111/j.1398-9995.1993.tb00756.x; Malm L, 2000, RHINOLOGY, V38, P1; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; Meltzer EO, 1999, ANN ALLERG ASTHMA IM, V83, P455, DOI 10.1016/S1081-1206(10)62851-7; MELVOLD RW, 2002, PATTERSONS ALLERGIC, P1; NALEBUFF D J, 1984, Rhinology (Utrecht), V22, P11; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1314; Ownby DR, 2000, CURR CLIN PRACT, P29; PETERSSON G, 1986, ALLERGY, V41, P398, DOI 10.1111/j.1398-9995.1986.tb00319.x; PLEBANI M, 1995, ANN ALLERG ASTHMA IM, V74, P23; RICKETTI AJ, 2002, PATTERSONS ALLERGIC, P159; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; SOLOMON WR, 2002, PATTERSONS ALLERGIC, P131; Szeinbach SL, 2001, ANN ALLERG ASTHMA IM, V86, P373, DOI 10.1016/S1081-1206(10)62481-7; TEN RM, 1995, MAYO CLIN PROC, V70, P783, DOI 10.4065/70.8.783; TRIPATHI A, 2002, PATTERSONS ALLERGIC, P145; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; Williams PB, 2001, ANN ALLERG ASTHMA IM, V86, P196, DOI 10.1016/S1081-1206(10)62691-9; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; Wuthrich B, 1998, SCHWEIZ MED WSCHR, V128, P139; ZEISS CR, 2002, PATTERSONS ALLERGIC, P43	55	67	74	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					278	289		10.7326/0003-4819-140-4-200402170-00010	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970151				2022-12-28	WOS:000188970400006
J	Lin, L; Spoor, MS; Gerth, AJ; Brody, SL; Peng, SL				Lin, L; Spoor, MS; Gerth, AJ; Brody, SL; Peng, SL			Modulation of Th1 activation and inflammation by the NF-kappa B repressor Foxj1	SCIENCE			English	Article							T-CELL; TRANSCRIPTION FACTORS; EXPRESSION; INDUCTION; REGULATOR; FAMILY; FOXP3; ALPHA; MICE	Forkhead transcription factors play key roles in the regulation of immune responses. Here, we identify a role for one member of this family, Foxj1, in the regulation of T cell activation and autoreactivity. Foxj1 deficiency resulted in multiorgan systemic inflammation, exaggerated Th1 cytokine production, and T cell proliferation in autologous mixed lymphocyte reactions. Foxj1 suppressed NF-kappaB transcription activity in vitro, and Foxj1-deficient T cells possessed increased NF-kappaB activity in vivo, correlating with the ability of Foxj1 to regulate IkappaB proteins, particularly IkappaBbeta. Thus, Foxj1 likely modulates inflammatory reactions and prevents autoimmunity by antagonizing proinflammatory transcriptional activities. These results suggest a potentially general role for forkhead genes in the enforcement of lymphocyte quiescence.	Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Peng, SL (corresponding author), Washington Univ, Sch Med, Div Rheumatol, 660 S Euclid Ave, St Louis, MO 63110 USA.	speng@im.wustl.edu	Peng, Stanford/S-6723-2019	Peng, Stanford/0000-0001-7445-2542	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063988, R01HL056244, R29HL056244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001803, R01AI057471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56244, HL63988] Funding Source: Medline; NIAID NIH HHS [AI057471, AI01803] Funding Source: Medline; NIDDK NIH HHS [DK52574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brody SL, 2000, AM J RESP CELL MOL, V23, P45, DOI 10.1165/ajrcmb.23.1.4070; Burgos P, 2000, J RHEUMATOL, V27, P116; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Corn RA, 2003, J IMMUNOL, V171, P1816, DOI 10.4049/jimmunol.171.4.1816; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Kaestner KH, 2000, GENE DEV, V14, P142; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN LL, UNPUB; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Vallabhapurapu S, 2001, EUR J IMMUNOL, V31, P2612, DOI 10.1002/1521-4141(200109)31:9<2612::AID-IMMU2612>3.0.CO;2-C	22	112	123	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1017	1020		10.1126/science.1093889	http://dx.doi.org/10.1126/science.1093889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14963332				2022-12-28	WOS:000188918000047
J	Carter, BS; Rabinov, JD; Pfannl, R; Schwamm, LH; Black-Schaffer, RM; Chapman, P				Carter, BS; Rabinov, JD; Pfannl, R; Schwamm, LH; Black-Schaffer, RM; Chapman, P			A man with slurred speech and left hemiparesis - Stroke involving the right middle cerebral artery, with the malignant middle-cerebral-artery edema syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTRAARTERIAL THROMBOLYSIS; ISCHEMIC-STROKE; DECOMPRESSIVE SURGERY; CT ANGIOGRAPHY; PROACT II; HEMICRANIECTOMY; PREDICTION; INFARCTION; VOLUME		Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurosurg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Carter, BS (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.		Black-Schaffer, Randie/AAY-4671-2021					Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Baird AE, 1997, ANN NEUROL, V41, P581, DOI 10.1002/ana.410410506; BOUNDS JV, 1981, STROKE, V12, P474, DOI 10.1161/01.STR.12.4.474; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; Christou I, 2001, INT ANGIOL, V20, P208; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Ezzeddine MA, 2002, STROKE, V33, P959, DOI 10.1161/hs0402.105388; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Kase CS, 2001, NEUROLOGY, V57, P1603, DOI 10.1212/WNL.57.9.1603; Leonhardt G, 2002, J NEUROL, V249, P1433, DOI 10.1007/s00415-002-0875-1; Lev MH, 2001, J COMPUT ASSIST TOMO, V25, P520, DOI 10.1097/00004728-200107000-00003; Lev MH, 2001, STROKE, V32, P2021, DOI 10.1161/hs0901.095680; Linfante I, 2002, STROKE, V33, P2066, DOI 10.1161/01.STR.0000021001.18101.A5; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Nesbit GM, 1996, J NEUROSURG, V84, P387, DOI 10.3171/jns.1996.84.3.0387; Oppenheim C, 2000, STROKE, V31, P2175, DOI 10.1161/01.STR.31.9.2175; Patel SC, 2001, JAMA-J AM MED ASSOC, V286, P2830, DOI 10.1001/jama.286.22.2830; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; SACKETT DL, 1986, CHEST, V89, pS2, DOI 10.1378/chest.89.2_Supplement.2S; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492; SPEARMAN MP, 1995, AM J NEURORADIOL, V16, P1791; Walz B, 2002, J NEUROL, V249, P1183, DOI 10.1007/s00415-002-0798-x; Wardlaw JM, 2001, NEUROLOGY, V57, pS69, DOI 10.1212/WNL.57.suppl_2.S69; Wu O, 2001, STROKE, V32, P933, DOI 10.1161/01.STR.32.4.933; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	30	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2004	350	7					707	716		10.1056/NEJMcpc030037	http://dx.doi.org/10.1056/NEJMcpc030037			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772YB	14960747				2022-12-28	WOS:000188869500013
J	Wendler, D; Emanuel, E				Wendler, D; Emanuel, E			Assessing the ethical and practical wisdom of surrogate consent for living organ donation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERSISTENT VEGETATIVE STATE; SUBSTITUTED JUDGMENTS; ADVANCE DIRECTIVES; ATTITUDES; DONORS; CARE; PREFERENCES; ACCURACY; DEATH		NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Wendler, D (corresponding author), NIH, Dept Clin Bioeth, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	dwendler@nih.gov						Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Arnold Robert M., 1993, Kennedy Institute of Ethics Journal, V3, P263; ARRAS JD, 1988, JAMA-J AM MED ASSOC, V259, P2284, DOI 10.1001/jama.259.15.2284; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Buchanan AE, 1998, DECIDING OTHERS ETHI; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Coppolino M, 2001, CHEST, V119, P603, DOI 10.1378/chest.119.2.603; Delmonico FL, 2002, NEW ENGL J MED, V346, P2002, DOI 10.1056/NEJMsb013216; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Gross MD, 1998, ARCH INTERN MED, V158, P363, DOI 10.1001/archinte.158.4.363; JENNETT B, 2002, VEGETATIVE STATE MED, P33; Keenan SP, 2002, J CRIT CARE, V17, P29, DOI 10.1053/jcrc.2002.33036; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koppelman ER, 2003, AM J BIOETHICS, V3, P1, DOI 10.1162/152651603321611782; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Loewy EH, 1998, ARCH INTERN MED, V158, P321, DOI 10.1001/archinte.158.4.321; ROBBINS RA, 1990, DEATH STUD, V14, P219, DOI 10.1080/07481189008252363; Robertson JA, 1999, HASTINGS CENT REP, V29, P6, DOI 10.2307/3527865; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Sheehy E, 2003, NEW ENGL J MED, V349, P667, DOI 10.1056/NEJMsa021271; Silverman HJ, 1996, AM J RESP CRIT CARE, V154, P582, DOI 10.1164/ajrccm.154.3.8810590; Siminoff LA, 2003, AM J BIOETHICS, V3, P30, DOI 10.1162/152651603321611926; Siminoff LA, 2001, CLIN TRANSPLANT, V15, P39, DOI 10.1034/j.1399-0012.2001.150107.x; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; SULMASY DP, 1994, AM J MED, V96, P432, DOI 10.1016/0002-9343(94)90170-8; Ubel PA, 2000, HEALTH AFFAIR, V19, P206, DOI 10.1377/hlthaff.19.5.206; UHLMANN RF, 1988, J GERONTOL, V43, P115, DOI DOI 10.1093/GERONJ/43.5.M115; Wendler D, 2002, AM J PSYCHIAT, V159, P585, DOI 10.1176/appi.ajp.159.4.585; Youngner SJ, 2001, J MED PHILOS, V26, P527, DOI 10.1076/jmep.26.5.527.3002; 2003, WEEK            0718, P4	32	3	3	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					732	735		10.1001/jama.291.6.732	http://dx.doi.org/10.1001/jama.291.6.732			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AY	14871918				2022-12-28	WOS:000188819200028
J	Chambers, M; Colthart, I; McKinstry, B				Chambers, M; Colthart, I; McKinstry, B			Scottish general practitioners' willingness to take part in a post-retirement retention scheme: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									NHS Educ Scotland, Lister Postgrad Inst, Edinburgh EH8 9DR, Midlothian, Scotland	NHS Education for Scotland; University of Edinburgh	Chambers, M (corresponding author), NHS Educ Scotland, Lister Postgrad Inst, Edinburgh EH8 9DR, Midlothian, Scotland.	margaret.chambers@nes.scot.nhs.uk		McKinstry, Brian/0000-0001-9581-0468				LUCE A, 2001, PRED EARL RET GEN PR; *NHS ED SCOTL, 2001, GP RET SCHEM SCOTL; *NHS SCOTL INF STA, 2003, WORKF STAT; *SCOTT GEN PRACT C, 2001, REAL RHET SURV VIEWS; Young R, 1999, BRIT J GEN PRACT, V49, P829	5	8	8	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2004	328	7435					329	329		10.1136/bmj.328.7435.329	http://dx.doi.org/10.1136/bmj.328.7435.329			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14764496	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188926900024
J	Fukuzawa, R; Breslow, NE; Morison, IM; Dwyer, P; Kusafuka, T; Kobayashi, Y; Becroft, DM; Beckwith, JB; Perlman, EJ; Reeve, AE				Fukuzawa, R; Breslow, NE; Morison, IM; Dwyer, P; Kusafuka, T; Kobayashi, Y; Becroft, DM; Beckwith, JB; Perlman, EJ; Reeve, AE			Epigenetic differences between Wilms' tumours in white and east-Asian children	LANCET			English	Article							BECKWITH-WIEDEMANN-SYNDROME; FACTOR-II GENE; CHILDHOOD-CANCER; H19 LOCUS; RELAXATION; HETEROZYGOSITY; METHYLATION; DISRUPTION; LESIONS; REGION	Background Variations in the international incidence of Wilms' tumour might be due to genetic factors. The maternal insulin-like growth factor 2 gene (IGF2) is imprinted in normal tissues, whereas in some Wilms' tumours and other tumour types the imprint is lost, leading to biallelic transcription of IGF2. We investigated whether the difference in incidence of Wilms' tumour between children of east-Asian descent and white children is due to variations in proportion of tumours with loss of IGF2 imprinting (IGF2 LOI). Methods We assessed IGF2 LOI by use of an Apal polymorphism in IGF2 exon 9 or quantitative PCR measuring DNA methylation of the H19 and KvDMR1 alleles. The frequencies of perilobar nephrogenic rests associated with Wilms' tumour were assessed histologically in Japanese children and children of white and east-Asian descent. Findings IGF2 LOI was present in Wilms' tumours from predominantly white children from New Zealand (13 of 41 tumours) but absent in tumours from Japanese children (0 of 21 tumours; difference in proportions 0.32, 95% CI 0.07-0.52). Frequency of perilobar nephrogenic rests accompanying tumours from white American children (1192 of 5002, 24%) was significantly higher than in Japanese (one of 56, 1%, difference in proportions 0.22, 95% CI 0.14-0.25) and east-Asian American children (seven of 92, 8%, 0.16, 0.09-0.21). Interpretation Wilms' tumours in the east-Asian population rarely arise from the IGF2 LOI mechanism frequently noted in white patients. Our findings that IGF2 LOI and perilobar nephrogenic rests associated with this mechanism arise at low frequency in Japanese and east-Asian American children lend support to this conclusion. Variation in frequency of this epigenetic mechanism provides one explanation for the difference in incidence of Wilms' tumour between populations.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Osaka Univ, Grad Sch Med, Dept Paediat Surg, Osaka, Japan; Osaka City Gen Hosp, Dept Pathol, Osaka, Japan; Univ Auckland, Natl Womens Hosp, Dept Obstet & Gynecol, Auckland 1, New Zealand; Northwestern Univ, Childrens Mem Med Ctr, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	University of Otago; University of Washington; University of Washington Seattle; Osaka University; Osaka City General Hospital; University of Auckland; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Reeve, AE (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.	a.reeve@otago.ac.nz	Morison, Ian M/A-1236-2008	Morison, Ian M/0000-0003-3616-0025; Perlman, Elizabeth/0000-0001-6853-6221; Dwyer, Patrick/0000-0002-3689-9201	NATIONAL CANCER INSTITUTE [R01CA054498, U10CA042326] Funding Source: NIH RePORTER; NCI NIH HHS [CA054498, R01 CA054498, CA042326] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKWITH J B, 1990, Pediatric Pathology, V10, P1; Beckwith JB, 1998, AM J MED GENET, V79, P268, DOI 10.1002/(SICI)1096-8628(19981002)79:4<268::AID-AJMG7>3.0.CO;2-I; Becroft DMO, 1998, PEDIATR DEVEL PATHOL, V1, P200, DOI 10.1007/s100249900027; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; BRESLOW NE, 2002, UKCCSG M BIOL CHILDH; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; DANGIO GJ, 1981, CANCER-AM CANCER SOC, V47, P2302, DOI 10.1002/1097-0142(19810501)47:9<2302::AID-CNCR2820470933>3.0.CO;2-K; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; GOODMAN MT, 1989, CANCER, V64, P1758, DOI 10.1002/1097-0142(19891015)64:8<1758::AID-CNCR2820640834>3.0.CO;2-5; KOBAYASHI Y, 1995, SHOUNI GEKA BYOURIGA; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEISENRING WM, 1994, CANCER RES, V54, P4680; Mishra K, 1998, CANCER, V83, P2228; Morison IM, 1998, MOL MED TODAY, V4, P110, DOI 10.1016/S1357-4310(97)01197-0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Nakadate H, 2001, INT J CANCER, V94, P396, DOI 10.1002/ijc.1475; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SANTNER TJ, 1980, J AM STAT ASSOC, V75, P386, DOI 10.2307/2287464; Scelfo RAM, 2002, ONCOGENE, V21, P2564, DOI 10.1038/sj.onc.1205336; Silverman BW, 1986, DENSITY ESTIMATION S, P45; STILLER CA, 1991, BRIT J CANCER, V64, P543, DOI 10.1038/bjc.1991.347; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Weksberg R, 2001, HUM MOL GENET, V10, P2989, DOI 10.1093/hmg/10.26.2989	30	58	63	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					446	451		10.1016/S0140-6736(04)15491-3	http://dx.doi.org/10.1016/S0140-6736(04)15491-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962525				2022-12-28	WOS:000188999500011
J	Mukherjee, JS; Rich, ML; Socci, AR; Joseph, JK; Viru, FA; Shin, SS; Furin, JJ; Becerra, MC; Barry, DJ; Kim, JY; Bayona, J; Farmer, P; Fawzi, MCS; Seung, KJ				Mukherjee, JS; Rich, ML; Socci, AR; Joseph, JK; Viru, FA; Shin, SS; Furin, JJ; Becerra, MC; Barry, DJ; Kim, JY; Bayona, J; Farmer, P; Fawzi, MCS; Seung, KJ			Programmes and principles in treatment of multidrug-resistant tuberculosis	LANCET			English	Review							EARLY BACTERICIDAL ACTIVITY; COMMUNITY-BASED THERAPY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; IN-VITRO; MURINE TUBERCULOSIS; CLAVULANIC ACID; SYNERGISTIC ACTIVITIES; CONTAINING REGIMENS; HUMAN MACROPHAGES	Multidrug-resistant tuberculosis (MDR-TB) presents an increasing threat to global tuberculosis control. Many crucial management issues in MDR-TB treatment remain unanswered. We reviewed the existing scientific research on MDR-TB treatment, which consists entirely of retrospective cohort studies. Although direct comparisons of these studies are impossible, some insights can be gained: MDR-TB can and should be addressed therapeutically in resource-poor settings; starting of treatment early is crucial; aggressive treatment regimens and high-end dosing are recommended given the lower potency of second-line antituberculosis drugs; and strategies to improve treatment adherence, such as directly observed therapy, should be used. Opportunities to treat MDR-TB in developing countries are now possible through the Global Fund to Fight AIDS, TB, and Malaria, and the Green Light Committee for Access to Second-line Antituberculosis Drugs. As treatment of MDR-TB becomes increasingly available in resource-poor areas, where it is needed most, further clinical and operational research is urgently needed to guide clinicians in the management of this disease.	Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02115 USA; Partners Hlth, Boston, MA USA; Socios Salud, Lima, Peru	Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Mukherjee, JS (corresponding author), Harvard Univ, Sch Med, Dept Social Med, Program Infect Dis & Social Change, 641 Huntington Ave, Boston, MA 02115 USA.	jmukherjee@pih.org						Avendano M, 2000, Can Respir J, V7, P383; Bastian I, 2000, MULTIDRUG RESISTANT; Becerra MC, 2000, INT J TUBERC LUNG D, V4, P108; BLASER J, 1995, THER DRUG MONIT, V17, P133, DOI 10.1097/00007691-199504000-00005; *BRIT MED RES COUN, 1960, TUBERCLE, V41, P399; Brooks JV, 1999, ANTIMICROB AGENTS CH, V43, P1285, DOI 10.1128/AAC.43.5.1285; CAVALIERI SJ, 1995, ANTIMICROB AGENTS CH, V39, P1542, DOI 10.1128/AAC.39.7.1542; Chambers HF, 1998, CLIN INFECT DIS, V26, P874, DOI 10.1086/513945; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; CYNAMON MH, 1983, ANTIMICROB AGENTS CH, V24, P429, DOI 10.1128/AAC.24.3.429; Dhillon J, 1998, INT J TUBERC LUNG D, V2, P736; Donald PR, 2001, SCAND J INFECT DIS, V33, P466, DOI 10.1080/00365540152029954; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; FELTEN MK, 1987, S AFR MED J, V72, P578; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Friedman LN, 2001, TUBERCULOSIS CURRENT, V2nd; Furin JJ, 2001, INT J TUBERC LUNG D, V5, P648; GANGADHARAM PRJ, 1987, AM REV RESPIR DIS, V136, P329, DOI 10.1164/ajrccm/136.2.329; Geerligs WA, 2000, INT J TUBERC LUNG D, V4, P758; GIRLING DJ, 1992, TUBERCLE LUNG DIS, V73, P59; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Gupta D K, 1977, J Indian Med Assoc, V68, P25; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; HARDING SM, 1994, TUBERCULOSIS, P69; Harvard Medical School and Open Society Institute, 1999, GLOB IMP DRUG RES TU; HEIFETS L, 1989, ANTIMICROB AGENTS CH, V33, P1298, DOI 10.1128/AAC.33.8.1298; HEIFETS LB, 1990, TUBERCLE, V71, P287, DOI 10.1016/0041-3879(90)90043-8; Hoffner SE, 1997, J ANTIMICROB CHEMOTH, V40, P885, DOI 10.1093/jac/40.6.885; JAGANNATH C, 1995, AM J RESP CRIT CARE, V151, P1083; JAJU M, 1983, HUM GENET, V64, P42, DOI 10.1007/BF00289477; Ji BH, 1998, ANTIMICROB AGENTS CH, V42, P2066, DOI 10.1128/AAC.42.8.2066; JINDANI A, 1980, AM REV RESPIR DIS, V121, P939; JOSEPH S, 1964, Tubercle, V45, P354, DOI 10.1016/S0041-3879(64)80049-0; Kennedy N, 1996, CLIN INFECT DIS, V22, P827, DOI 10.1093/clinids/22.5.827; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; Kim HJ, 2001, INT J TUBERC LUNG D, V5, P1129; KLEMENS SP, 1993, ANTIMICROB AGENTS CH, V37, P2344, DOI 10.1128/AAC.37.11.2344; KOHNO S, 1992, CHEST, V102, P1815, DOI 10.1378/chest.102.6.1815; LUNAHERRERA J, 1995, ANTIMICROB AGENTS CH, V39, P2692, DOI 10.1128/AAC.39.12.2692; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mor N, 1997, ANTIMICROB AGENTS CH, V41, P2035, DOI 10.1128/AAC.41.9.2035; MOULDING TS, 1981, AM REV RESPIR DIS, V123, P262; NADLER JP, 1991, CHEST, V99, P1025, DOI 10.1378/chest.99.4.1025; Narita M, 2001, CHEST, V120, P343, DOI 10.1378/chest.120.2.343; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Paramasivan CN, 1998, INDIAN J MED RES, V108, P115; Park MM, 1996, AM J RESP CRIT CARE, V153, P317, DOI 10.1164/ajrccm.153.1.8542137; Park SK, 1998, INT J TUBERC LUNG D, V2, P877; PELOQUIN CA, 1993, MED CLIN N AM, V77, P1253, DOI 10.1016/S0025-7125(16)30191-2; Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001; Rastogi N, 1996, CURR MICROBIOL, V33, P167, DOI 10.1007/s002849900095; RASTOGI N, 1991, ANTIMICROB AGENTS CH, V35, P1993; Reddy VM, 1996, ANTIMICROB AGENTS CH, V40, P633, DOI 10.1128/AAC.40.3.633; SANDERS WE, 1982, TUBERCLE, V63, P201; Schmidt L. H., 1959, B INT UNION TUBERC, V30, P316; SIRGEL FA, 1993, J ANTIMICROB CHEMOTH, V32, P867, DOI 10.1093/jac/32.6.867; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; TRUFFOTPERNOT C, 1995, ANTIMICROB AGENTS CH, V39, P2827, DOI 10.1128/AAC.39.12.2827; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; Viskum K, 1997, INT J TUBERC LUNG D, V1, P299; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; WHO, 1997, MID IMP US ANT FOOD; WHO, 2000, PUBL WHO; Yew WW, 2000, CHEST, V117, P744, DOI 10.1378/chest.118.3.744; 1968, TUBERCLE, V49, P243	72	272	294	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	2004	363	9407					474	481		10.1016/S0140-6736(04)15496-2	http://dx.doi.org/10.1016/S0140-6736(04)15496-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962530				2022-12-28	WOS:000188999500024
J	Hilliard, AA; Weinberger, SE; Tierney, LM; Midthun, DE; Saint, S				Hilliard, AA; Weinberger, SE; Tierney, LM; Midthun, DE; Saint, S			Occam's razor versus Saint's Triad	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Mayo Clinic; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of Michigan System; University of Michigan	Saint, S (corresponding author), Box 0429,300 NIB,Room 7E08, Ann Arbor, MI 48109 USA.	saint@umich.edu	Saint, Sanjay/AAF-5126-2019		AHRQ HHS [P20-HS11540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Drachman DA, 2000, ANN INTERN MED, V132, P403, DOI 10.7326/0003-4819-132-5-200003070-00010; FIRKIN BG, 1996, DICT MED EPONYMS, P354; Miller WT, 1998, SEMIN ROENTGENOL, V33, P213, DOI 10.1016/S0037-198X(98)80001-1; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Steinbrook R, 1998, NEW ENGL J MED, V338, P1541, DOI 10.1056/NEJM199805213382111	5	54	57	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					599	603		10.1056/NEJMcps031794	http://dx.doi.org/10.1056/NEJMcps031794			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762188				2022-12-28	WOS:000188712800013
J	Shin, C; Feng, Y; Manley, JL				Shin, C; Feng, Y; Manley, JL			Dephosphorylated SRp38 acts as a splicing repressor in response to heat shock	NATURE			English	Article							HELA-CELLS; NUCLEAR RIBONUCLEOPROTEINS; PROTEIN-PROTEIN; SR PROTEINS; ASF/SF2; STRESS; PHOSPHORYLATION; INACTIVATION; RECOGNITION; INHIBITION	The cellular response to stresses such as heat shock involves changes in gene expression(1). It is well known that the splicing of messenger RNA precursors is generally repressed on heat shock(2,3), but the factors responsible have not been identified(4-8). SRp38 is an SR protein splicing factor(9,10) that functions as a general repressor of splicing. It is activated by dephosphorylation and required for splicing repression in M-phase cells(11). Here we show that SRp38 is also dephosphorylated on heat shock and that this dephosphorylation correlates with splicing inhibition. Notably, depletion of SRp38 from heat-shocked cell extracts derepresses splicing, and adding back dephosphorylated SRp38 specifically restores inhibition. We further show that dephosphorylated SRp38 interacts with a U1 small nuclear ribonucleoprotein particle (snRNP) protein, and that this interaction interferes with 5'-splice-site recognition by the U1 snRNP. Finally, SRp38-deficient DT40 cells show an altered cell-cycle profile consistent with a mitotic defect; they are also temperature sensitive and defective in recovery after heat shock. SRp38 thus plays a crucial role in cell survival under stress conditions by inhibiting the splicing machinery.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jlm2@columbia.edu		Manley, James/0000-0002-8341-1459				ARRIGO AP, 1981, MOL GEN GENET, V184, P73, DOI 10.1007/BF00271198; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; Bond U, 2000, INT J BIOCHEM CELL B, V32, P643, DOI 10.1016/S1357-2725(00)00008-X; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Dubois MF, 1999, NUCLEIC ACIDS RES, V27, P1338, DOI 10.1093/nar/27.5.1338; Fukagawa T, 2001, NUCLEIC ACIDS RES, V29, P3796, DOI 10.1093/nar/29.18.3796; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Labourier E, 1999, GENE DEV, V13, P740, DOI 10.1101/gad.13.6.740; Mahe D, 1997, J BIOL CHEM, V272, P1827, DOI 10.1074/jbc.272.3.1827; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Nakai A, 2001, EMBO J, V20, P2885, DOI 10.1093/emboj/20.11.2885; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; SHUKLA RR, 1990, J BIOL CHEM, V265, P20377; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X	25	169	179	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					553	558		10.1038/nature02288	http://dx.doi.org/10.1038/nature02288			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14765198				2022-12-28	WOS:000188721800044
J	Yock, T; Schaefer, PW; Hoch, BL; Friedmann, AM; Tarbell, NJ; Rosenberg, AE; Harris, NL				Yock, T; Schaefer, PW; Hoch, BL; Friedmann, AM; Tarbell, NJ; Rosenberg, AE; Harris, NL			A nine-month-old boy with an orbital rhabdomyosarcoma - Rhabdomyosarcoma of the orbit.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTERGROUP RHABDOMYOSARCOMA; RADIATION-THERAPY; PROTON-BEAMS; GENE FUSIONS; STUDY-II; TUMORS; CHEMOTHERAPY; RADIOTHERAPY; ONCOLOGY; CHILDREN		Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Serv Pediat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Yock, T (corresponding author), Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Serv Pediat, Boston, MA 02114 USA.		Schaefer, Pamela/AAA-1323-2019					CASSADY JR, 1968, RADIOLOGY, V91, P116, DOI 10.1148/91.1.116; CRIST W, 1995, J CLIN ONCOL, V13, P610, DOI 10.1200/JCO.1995.13.3.610; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; HEYN R, 1986, CANCER-AM CANCER SOC, V57, P1738, DOI 10.1002/1097-0142(19860501)57:9<1738::AID-CNCR2820570905>3.0.CO;2-3; HEYN R, 1993, J CLIN ONCOL, V11, P262, DOI 10.1200/JCO.1993.11.2.262; Hill DA, 2002, AM J SURG PATHOL, V26, P965, DOI 10.1097/00000478-200208000-00001; Hug EB, 2002, INT J RADIAT ONCOL, V52, P1017, DOI 10.1016/S0360-3016(01)02725-0; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Loeffler JS, 1997, SEMIN ONCOL, V24, P686; MAURER HM, 1993, CANCER-AM CANCER SOC, V71, P1904, DOI 10.1002/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X; MAURER HM, 1988, CANCER-AM CANCER SOC, V61, P209, DOI 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L; Miralbell R, 2002, INT J RADIAT ONCOL, V54, P824, DOI 10.1016/S0360-3016(02)02982-6; Noel G, 2003, MED PEDIATR ONCOL, V40, P309, DOI 10.1002/mpo.10283; Notis CM, 1995, OPHTHALMIC GENET, V16, P159, DOI 10.3109/13816819509057857; Oberlin O, 2001, J CLIN ONCOL, V19, P197, DOI 10.1200/JCO.2001.19.1.197; RAJU MR, 1995, INT J RADIAT BIOL, V67, P237, DOI 10.1080/09553009514550301; ROUSSEAU P, 1994, J CLIN ONCOL, V12, P516, DOI 10.1200/JCO.1994.12.3.516; Sagerman R H, 1968, Trans Am Acad Ophthalmol Otolaryngol, V72, P849; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; SPIRO IJ, 2001, CANC PRINCIPLES PRAC, V2, P3229; STOBBE GD, 1950, CANCER, V3, P826, DOI 10.1002/1097-0142(1950)3:5<826::AID-CNCR2820030508>3.0.CO;2-X; SUIT H, 1982, INT J RADIAT ONCOL, V8, P2199, DOI 10.1016/0360-3016(82)90570-3; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; Weiss SW, 2001, SOFT TISSUE TUMORS, P785; WHARAM M, 1987, OPHTHALMOLOGY, V94, P251; Wharam MD, 1997, INT J RADIAT ONCOL, V38, P797, DOI 10.1016/S0360-3016(97)00120-X; WILBUR JR, 1974, CANCER CHEMOTH REP 1, V58, P281; [No title captured]	28	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					494	502		10.1056/NEJMcpc030036	http://dx.doi.org/10.1056/NEJMcpc030036			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749459				2022-12-28	WOS:000188463900014
J	Liu, YM; Coresh, J; Eustace, JA; Longenecker, JC; Jaar, B; Fink, NE; Tracy, RP; Powe, NR; Klag, MJ				Liu, YM; Coresh, J; Eustace, JA; Longenecker, JC; Jaar, B; Fink, NE; Tracy, RP; Powe, NR; Klag, MJ			Association between cholesterol level and mortality in - Role of inflammation dialysis patients and malnutrition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; SERUM TOTAL CHOLESTEROL; ACUTE-PHASE RESPONSE; CARDIOVASCULAR-DISEASE; HEART; RISK; INTERLEUKIN-6; CORONARY; DEATH; MEN	Context Total cholesterol level is inversely associated with mortality in dialysis patients, a group at high risk of cardiovascular disease (CVD). This paradox may be explained by systemic inflammation and/or malnutrition, which are associated with lower cholesterol levels and higher mortality. Objective To determine the relationship between cholesterol level and outcome in patients undergoing dialysis, accounting for inflammation and malnutrition. Design, Setting, and Participants Prospective study of 823 patients enrolled from October 1995 to June 1998 who recently initiated dialysis, from 79 clinics, classified by absence or presence of inflammation and/or malnutrition (defined as serum albumin levels <3.6 mg/dL, C-reactive protein >= 10 mg/L, or interleukin 6 >= 3.09 pg/mL). Main Outcome Measures All-cause and cardiovascular disease mortality. Results During a median follow-up of 2.4 years, 324 deaths (159 CVD deaths), 153 renal transplantations, and 10 losses to follow-up occurred. Average serum cholesterol level was lower in the presence of inflammation/malnutrition than in its absence. In a Cox model adjusted for age, race, and sex, a 40-mg/dL (1.0-mmol/L) increment in baseline total serum cholesterol level was associated with a decreased risk of all-cause mortality overall (relative hazard [RH], 0.92; 95% confidence interval [CI], 0.87-0.98) and in the presence of inflammation/malnutrition (RH, 0.89; CI, 0.84-0.95). In contrast, serum cholesterol level was associated with an increased risk in the absence of inflammation/malnutrition (RH, 1.32; 95% CI, 1.07-1.63). For CVD mortality, an inverse trend was not statistically significant in the presence of inflammation/malnutrition, and a positive association was evident in the absence of inflammation/malnutrition (RH, 1.41; 95% CI, 1.04-1.89). Further adjustment for traditional CVD risk factors, dialysis modality, comorbidity, and inflammatory markers attenuated the inverse association but strengthened the positive association. Conclusions The inverse association of total cholesterol level with mortality in dialysis patients is likely due to the cholesterol-lowering effect of systemic inflammation and malnutrition, not to a protective effect of high cholesterol concentrations. These findings support treatment of hypercholesterolemia in this population.	Johns Hopkins Univ, Baltimore, MD 21205 USA; Kuwait Univ, Kuwait, Kuwait; Univ Vermont, Burlington, VT USA	Johns Hopkins University; Kuwait University; University of Vermont	Coresh, J (corresponding author), Johns Hopkins Univ, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.	coresh@jhu.edu	Jaar, Bernard/B-1917-2009	Jaar, Bernard/0000-0003-1210-7115; Longenecker, Joseph/0000-0001-9471-5661	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058329, R01HL046696, R01HL062985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK002922, K24DK002856, T32DK007732, R01DK059616, K24DK002643] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00052] Funding Source: Medline; NHLBI NIH HHS [HL 58329, HL 46696, R01-HL-62985, KO8-HL-03896] Funding Source: Medline; NIDDK NIH HHS [T32 DK07732, K23DK02922, R01-DK-59616, K24-DK-02856, K24-DK-02643] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Attman PO, 1996, NEPHROL DIAL TRANSPL, V11, P63; Baigent C, 2000, NEPHROL DIAL TRANSPL, V15, P1118, DOI 10.1093/ndt/15.8.1118; Behar S, 1997, EUR HEART J, V18, P52, DOI 10.1093/oxfordjournals.eurheartj.a015117; Bologa RM, 1998, AM J KIDNEY DIS, V32, P107, DOI 10.1053/ajkd.1998.v32.pm9669431; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Coresh J, 1998, J Am Soc Nephrol, V9, pS24; Cullen P, 1997, CIRCULATION, V96, P2128; deFilippi C, 2003, JAMA-J AM MED ASSOC, V290, P353, DOI 10.1001/jama.290.3.353; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; GREENBERG AS, 1992, CANCER RES, V52, P4113; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Horwich TB, 2002, J CARD FAIL, V8, P216, DOI 10.1054/jcaf.2002.126519a; IRIBARREN C, 1995, JAMA-J AM MED ASSOC, V273, P1926, DOI 10.1001/jama.273.24.1926; Iseki K, 2002, KIDNEY INT, V61, P1887, DOI 10.1046/j.1523-1755.2002.00324.x; Kaysen GA, 2000, KIDNEY INT, V58, P346, DOI 10.1046/j.1523-1755.2000.00172.x; Kaysen GA, 2002, BLOOD PURIFICAT, V20, P70, DOI 10.1159/000046988; Kaysen GA, 2001, J AM SOC NEPHROL, V12, P1549, DOI 10.1681/ASN.V1271549; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Lowrie E G, 1998, Am J Kidney Dis, V32, pS105, DOI 10.1016/S0272-6386(98)70172-6; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; National Kidney Foundation, 2003, AM J KIDNEY DIS S, V41, pS22; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; *NHANES III, CDCP WEB SIT; Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059; NISHIZAWA Y, 2000, KIDNEY INT S84, V63, P117; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; Rocco MV, 2002, AM J KIDNEY DIS, V39, P146, DOI 10.1053/ajkd.2002.29905; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SAMMALKORPI KT, 1990, ANN MED, V22, P397, DOI 10.3109/07853899009147277; Schatz IJ, 2001, LANCET, V358, P351, DOI 10.1016/S0140-6736(01)05553-2; Seliger SL, 2002, KIDNEY INT, V61, P297, DOI 10.1046/j.1523-1755.2002.00109.x; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Stenvinkel P, 2002, KIDNEY INT, V61, pS103, DOI 10.1046/j.1523-1755.61.s80.19.x; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; *US REN DAT SYST, 1999, AM J KIDNEY DIS S, V34, pS87; US Renal Data System, 1999, USRDS 1999 ANN DAT R; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326	41	531	555	4	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					451	459		10.1001/jama.291.4.451	http://dx.doi.org/10.1001/jama.291.4.451			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747502	Bronze			2022-12-28	WOS:000188426700030
J	Moody, DB; Young, DC; Cheng, TY; Rosat, JP; Roura-mir, C; O'Connor, PB; Zajonc, DM; Walz, A; Miller, MJ; Levery, SB; Wilson, IA; Costello, CE; Brenner, MB				Moody, DB; Young, DC; Cheng, TY; Rosat, JP; Roura-mir, C; O'Connor, PB; Zajonc, DM; Walz, A; Miller, MJ; Levery, SB; Wilson, IA; Costello, CE; Brenner, MB			T cell activation by lipopeptide antigens	SCIENCE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; CRYSTAL-STRUCTURE; IRON ACQUISITION; LYMPHOCYTES-T; RECOGNITION; INFECTION; ANGSTROM; COMPLEX; CD1; RECEPTOR	Unlike major histocompatibility proteins, which bind peptides, CD1 proteins display lipid antigens to T cells. Here, we report that CD1a presents a family of previously unknown lipopeptides from Mycobacterium tuberculosis, named didehydroxymycobactins because of their structural relation to mycobactin siderophores. T cell activation was mediated by the alphabeta T cell receptors and was specific for structure of the acyl and peptidic components of these antigens. These studies identify a means of intracellular pathogen detection and identify lipopeptides as a biochemical class of antigens for T cells, which, like conventional peptides, have a potential for marked structural diversity.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Boston Univ, Sch Med, Mass Spectrometry Resource, Boston, MA 02115 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ New Hampshire, Dept Chem, Durham, NH 03834 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; University of Notre Dame; University System Of New Hampshire; University of New Hampshire; Scripps Research Institute; Scripps Research Institute	Moody, DB (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg Room 514,1 Jimmy Fund Way, Boston, MA 02115 USA.	bmoody@rics.bwh.harvard.edu	OConnor, Peter/C-2117-2009; Roura-Mir, Carme/D-4538-2013	OConnor, Peter/0000-0002-6588-6274; Roura-Mir, Carme/0000-0003-0514-337X; Costello, Catherine/0000-0003-1594-5122	NCI NIH HHS [CA58896] Funding Source: Medline; NCRR NIH HHS [P41-RR10888, P20 RR16459, S10-RR10493] Funding Source: Medline; NIAID NIH HHS [AI30988, AI50216] Funding Source: Medline; NIAMS NIH HHS [AR48632] Funding Source: Medline; NIGMS NIH HHS [GM25845, GM62116] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016459, S10RR010493, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI050216, R01AI030988, R01AI050216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, R01GM025845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; De Voss JJ, 1999, J BACTERIOL, V181, P4443, DOI 10.1128/JB.181.15.4443-4451.1999; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; Dussurget O, 1999, J BACTERIOL, V181, P3402, DOI 10.1128/JB.181.11.3402-3408.1999; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; Grant EP, 1999, J EXP MED, V189, P195, DOI 10.1084/jem.189.1.195; Honey K, 2002, NAT IMMUNOL, V3, P1069, DOI 10.1038/ni844; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Moody DB, 2002, NAT IMMUNOL, V3, P435, DOI 10.1038/ni780; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; MOODY DC, UNPUB; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; Rosat JP, 1999, J IMMUNOL, V162, P366; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; SNOW GA, 1970, BACTERIOL REV, V34, P99, DOI 10.1128/MMBR.34.2.99-125.1970; Stenger S, 1998, J IMMUNOL, V161, P3582; Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684; Tsukamoto M, 1997, J ANTIBIOT, V50, P815, DOI 10.7164/antibiotics.50.815; Vergne AF, 2000, NAT PROD REP, V17, P99, DOI 10.1039/a809397k; Vincent MS, 2002, NAT IMMUNOL, V3, P1163, DOI 10.1038/ni851; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	35	209	216	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	2004	303	5657					527	531		10.1126/science.1089353	http://dx.doi.org/10.1126/science.1089353			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739458				2022-12-28	WOS:000188316400039
J	Matloubian, M; Lo, CG; Cinamon, G; Lesneski, MJ; Xu, Y; Brinkmann, V; Allende, ML; Proia, RL; Cyster, JG				Matloubian, M; Lo, CG; Cinamon, G; Lesneski, MJ; Xu, Y; Brinkmann, V; Allende, ML; Proia, RL; Cyster, JG			Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1	NATURE			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTORS; THYMOCYTE EMIGRATION; SPHINGOSINE-1-PHOSPHATE; MATURATION; FTY720; IMMUNOSUPPRESSANT; RESPONSIVENESS; KINASE	Adaptive immunity depends on T- cell exit from the thymus and T and B cells travelling between secondary lymphoid organs to survey for antigens. After activation in lymphoid organs, T cells must again return to circulation to reach sites of infection; however, the mechanisms regulating lymphoid organ exit are unknown. An immunosuppressant drug, FTY720, inhibits lymphocyte emigration from lymphoid organs, and phosphorylated FTY720 binds and activates four of the five known sphingosine-1-phosphate ( S1P) receptors(1-4). However, the role of S1P receptors in normal immune cell trafficking is unclear. Here we show that in mice whose haematopoietic cells lack a single S1P receptor ( S1P(1); also known as Edg1) there are no T cells in the periphery because mature T cells are unable to exit the thymus. Although B cells are present in peripheral lymphoid organs, they are severely deficient in blood and lymph. Adoptive cell transfer experiments establish an intrinsic requirement for S1P(1) in T and B cells for lymphoid organ egress. Furthermore, S1P(1)- dependent chemotactic responsiveness is strongly upregulated in T- cell development before exit from the thymus, whereas S1P(1) is downregulated during peripheral lymphocyte activation, and this is associated with retention in lymphoid organs. We find that FTY720 treatment downregulates S1P(1), creating a temporary pharmacological S1P(1)- null state in lymphocytes, providing an explanation for the mechanism of FTY720- induced lymphocyte sequestration. These findings establish that S1P(1) is essential for lymphocyte recirculation and that it regulates egress from both thymus and peripheral lymphoid organs.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cyster, JG (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.	cyster@itsa.ucsf.edu	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Caligan TB, 2000, ANAL BIOCHEM, V281, P36, DOI 10.1006/abio.2000.4555; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Chiba K, 1998, J IMMUNOL, V160, P5037; Chu P, 2003, J BIOL, V2, P211; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graessley W. W, 1974, ADV POLYM SCI, V16, P1; HALL JG, 1965, BRIT J EXP PATHOL, V46, P450; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Idzko M, 2002, FASEB J, V16, P625, DOI 10.1096/fj.01-0625fje; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; LUCAS B, 1994, J IMMUNOL, V153, P53; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; PARROTT DMV, 1971, CLIN EXP IMMUNOL, V8, P663; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; SPRENT J, 1971, CELL IMMUNOL, V2, P171, DOI 10.1016/0008-8749(71)90036-0; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O	24	1937	2030	3	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	2004	427	6972					355	360		10.1038/nature02284	http://dx.doi.org/10.1038/nature02284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14737169				2022-12-28	WOS:000188266200042
J	Cummings, P; Rivara, FP				Cummings, P; Rivara, FP			Car occupant death according to the restraint use of other occupants - A matched cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAXIMUM-LIKELIHOOD METHODS; SEAT PASSENGERS; INJURIES; CRASHES	Context A car occupant could be killed if struck by another occupant who was catapulted forward, backward, or sideways in a crash. Objective To estimate the association between death of a car occupant (the target) and restraint use by other occupants. Design Matched-pair cohort study comparing the outcomes of 2 target occupants in the same passenger car that crashed. Setting United States traffic crashes in 1988-2000, using data from the Fatality Analysis Reporting System. Subjects Target pairs, at least 1 of whom died: 61834 front-seat pairs, 5278 rear-seat pairs, and 21127 pairs on the left or right side. Main Outcome Measures Adjusted risk ratio (RR) for death within 30 days of a crash. Results The risk of death was greater for a restrained front target occupant in front of an unrestrained occupant compared with a restrained front target in front of a restrained occupant (adjusted RR, 1.20 95% confidence interval [CI], 1.10-1.31). For a restrained rear target occupant behind an unrestrained occupant compared with a restrained rear target occupant behind a restrained occupant, the adjusted RR was 1.22 (95% Cl, 1.10-1.36). For a restrained side target occupant sitting next to an unrestrained occupant compared with a restrained side target occupant sitting next to a restrained occupant, the adjusted RR was 1.15 (95% Cl, 1.08-1.22). Among unrestrained target occupants, the adjusted RRs were, for front targets, 1.04 95% Cl, 0.97-1.12), rear targets, 1.22 (95% Cl, 1.10-1.36), and side targets, 0.85 (95% Cl, 0.80-0.92). Conclusion Persons who wish to reduce their risk of death in a crash should wear their own restraint and should ask others in the same car to use their restraints.	Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cummings, P (corresponding author), 250 Grandview Dr, Bishop, CA 93514 USA.	peterc@u.washington.edu			ODCDC CDC HHS [R49/CCR002570, R49/CCR019477-01] Funding Source: Medline	ODCDC CDC HHS		CAMERON AC, 1998, REGRESSION ANAL COUN, P282; Cummings P, 2002, INJ PREV, V8, P338, DOI 10.1136/ip.8.4.338; Cummings P, 2003, EPIDEMIOL REV, V25, P43, DOI 10.1093/epirev/mxg002; Cummings P, 2003, ACCIDENT ANAL PREV, V35, P131, DOI 10.1016/S0001-4575(01)00108-7; Efron B., 1993, INTRO BOOTSTRAP, P168; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P217, DOI 10.1016/0001-4575(86)90006-0; GOURIEROUX C, 1984, ECONOMETRICA, V52, P681, DOI 10.2307/1913471; GOURIEROUX C, 1984, ECONOMETRICA, V52, P701, DOI 10.2307/1913472; Greenlands S, 1994, APPL STAT-J ROY ST C, V43, P223; HARDIN J, 2001, GEN LINEAR MODELS EX, P196; *HIGHW LOSS DAT I, 2001, VIND 2001 COMP PROGR; Ichikawa M, 2002, LANCET, V359, P43, DOI 10.1016/S0140-6736(02)07279-3; LLOYD CJ, 1999, STAT ANAL CATEGORICA, P84; LONG JS, 1997, REGRESSION MODELS CA, P87; LOWENHIELM P, 1984, Z RECHTSMED, V92, P199; MACKAY GM, 1992, ACCIDENT ANAL PREV, V24, P307, DOI 10.1016/0001-4575(92)90007-6; PARK S, 1987, INFLUENCE REAR SEAT; ROBERTS AK, 1983, EFFECTS REAR SEAT PA; Rothman K. J., 1998, MODERN EPIDEMIOLOGY, P147; *STAT CORP, 2003, STAT STAT SOFTW COMP; WOOLDRIDGE JM, 2002, ECONOMETRIC ANAL CRO, P646; [No title captured]	22	29	31	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					343	349		10.1001/jama.291.3.343	http://dx.doi.org/10.1001/jama.291.3.343			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734597	Bronze			2022-12-28	WOS:000188243100034
J	Carpenter, RG; Irgens, LM; Blair, PS; England, PD; Fleming, P; Huber, J; Jorch, G; Schreuder, P				Carpenter, RG; Irgens, LM; Blair, PS; England, PD; Fleming, P; Huber, J; Jorch, G; Schreuder, P			Sudden unexplained infant death in 20 regions in Europe: case control study	LANCET			English	Article							SLEEPING POSITION; COT DEATH; RISK; SMOKING	Background After striking changes in rates of sudden unexplained infant death (SIDS) around 1990, four large case-control studies were set up to re-examine the epidemiology of this syndrome. The European Concerted Action on SIDS (ECAS) investigation was planned to bring together data from these and new studies to give an overview of risk factors for the syndrome in Europe. Methods We undertook case-control studies in 20 regions. Data for more than 60 variables were extracted from anonymised records of 745 SIDS cases and 2411 live controls. Logistic regression was used to calculate odds ratios (ORs) for every factor in isolation, and to construct multivariate models. Findings Principal risk factors were largely independent. Multivariately significant ORs showed little evidence of intercentre heterogeneity apart from four outliers, which were eliminated. Highly significant risks were associated with prone sleeping (OR 13.1 [95% Cl 8.51-20-2]) and with turning from the side to the prone position (45.4 [23.4-87.9]). About 48% of cases were attributable to sleeping in the side or prone position. If the mother smoked, significant risks were associated with bed-sharing, especially during the first weeks of life (at 2 weeks 27.0 [13.3-54.9]). This OR was partly attributable to mother's consumption of alcohol. Mother's alcohol consumption was significant only when baby bed-shared all night (OR increased by 1.66 [1.16-2.38] per drink). For mothers who did not smoke during pregnancy, OR for bed-sharing was very small (at 2 weeks 2.4 [1.2-4.6]) and only significant during the first 8 weeks of life. About 16% of cases were attributable to bed-sharing and roughly 36% to the baby sleeping in a separate room. Interpretation Avoidable risk factors such as those associated with inappropriate infants' sleeping position, type of bedding used, and sleeping arrangements strongly suggest a basis for further substantial reductions in SIDS incidence rates.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Med Stat Unit, London WC1E 7HT, England; Univ Bergen, Med Birth Registry Norway, N-5020 Bergen, Norway; Royal Hosp Sick Children, Inst Child Hlth, Bristol BS2 8BJ, Avon, England; Univ Hosp Children & Youth, Utrecht, Netherlands; Univ Magdeburg, Clin Gen Pediat & Neonatol, D-39106 Magdeburg, Germany	University of London; London School of Hygiene & Tropical Medicine; University of Bergen; Bristol Royal Hospital For Children; University of Bristol; Wilhelmina Kinderziekenhuis; Otto von Guericke University	Carpenter, RG (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Med Stat Unit, Keppel St, London WC1E 7HT, England.	bob.carpenter@lshtm.ac.uk	Fleming, Peter J/A-9081-2010; Blair, Peter S/C-1213-2009	Fleming, Peter J/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087; Aryayev, Mykola/0000-0003-3181-7518				Ball HL, 2003, BIRTH-ISS PERINAT C, V30, P181, DOI 10.1046/j.1523-536X.2003.00243.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; Blair PS, 1999, BRIT MED J, V319, P1457, DOI 10.1136/bmj.319.7223.1457; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; De Jonge G., 2002, WIEGENDOOD ERVARINGE; *DEP HLTH, 1993, SLEEP POS INF COT DE; ENGELBERTS AC, 1991, COT DEATH NETHERLAND; FINDEISEN M, 1995, PREV SUDD INF DEATH; Fleming P., 2000, SUDDEN UNEXPECTED DE; Golding J, 1997, PAEDIATR PERINAT EP, V11, P67, DOI 10.1046/j.1365-3016.1997.d01-12.x; GREGERSEN M, 1994, SUDDEN INFANT DEATH, P50; Guntheroth WG, 2001, PEDIATRICS, V107, P693, DOI 10.1542/peds.107.4.693; GUNTHEROTH WG, 1995, CRIB DEATH SUDDEN IN; Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508; JACKSON D, 1989, 3 BED WHY YOU SHOULD; KRAUS HF, 1994, SUDDEN INFANT DEATH, P81; L'Hoir MP, 1998, EUR J PEDIATR, V157, P681, DOI 10.1007/s004310050911; Li DK, 2003, AM J EPIDEMIOL, V157, P446, DOI 10.1093/aje/kwf226; Meadow R, 1999, ARCH DIS CHILD, V80, P7, DOI 10.1136/adc.80.1.7; Mehanni M, 1999, IRISH MED J, V92, P266; Mitchell EA, 1999, ARCH PEDIAT ADOL MED, V153, P1136, DOI 10.1001/archpedi.153.11.1136; MITCHELL EA, 1992, J PAEDIAT CHILD H S1, V28, P3; *NAT INF DEATH REG, 1999, ANN REP 1994 1998; *NAT SUDD INF DEAT, 1994 REP; NAUJOKS M, 1995, PREV SUDD INF DEATH; *NORD COUNC MIN, 1997, TEMANORD, P600; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; SHAPIRO S, 1998, ENCY BIOSTATISTICS, V1, P313; Sullivan FM, 2001, PAEDIATR PERINAT EP, V15, P144; TAYLOR EM, 1982, ARCH DIS CHILD, V57, P668, DOI 10.1136/adc.57.9.668; *UNICEF, 2002, FACTS LIF FIL BREAST; *US CONS PROD SAF, 1999, REC REV PREV INF DEA; Vege A., 1995, P67; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; 1997, BMH1CT931207, P65	35	287	303	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	2004	363	9404					185	191		10.1016/S0140-6736(03)15323-8	http://dx.doi.org/10.1016/S0140-6736(03)15323-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	14738790				2022-12-28	WOS:000188243900007
J	Hill, J				Hill, J			Physical activity and obesity	LANCET			English	Editorial Material									Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hill, J (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, 4200 E 9th Ave, Denver, CO 80262 USA.	james.hill@uchsc.edu						Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Peters J C, 2002, Obes Rev, V3, P69, DOI 10.1046/j.1467-789X.2002.00059.x; Saris W H M, 2003, Obes Rev, V4, P101, DOI 10.1046/j.1467-789X.2003.00101.x; AM MOVE	4	30	31	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					182	182		10.1016/S0140-6736(03)15368-8	http://dx.doi.org/10.1016/S0140-6736(03)15368-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	15194273				2022-12-28	WOS:000188243900004
